PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	KIRWAN, JR; BYRON, M; DIEPPE, P; EASTMOND, C; HALSEY, J; HICKLING, P; HOLLINGWORTH, P; JACOBY, R; KIRK, A; MORAN, C; REID, D; SWANNELL, T; YATES, D; COOPER, C; GEORGE, E; FORBES, D; JESSOP, J; WATT, I				KIRWAN, JR; BYRON, M; DIEPPE, P; EASTMOND, C; HALSEY, J; HICKLING, P; HOLLINGWORTH, P; JACOBY, R; KIRK, A; MORAN, C; REID, D; SWANNELL, T; YATES, D; COOPER, C; GEORGE, E; FORBES, D; JESSOP, J; WATT, I			THE EFFECT OF GLUCOCORTICOIDS ON JOINT DESTRUCTION IN RHEUMATOID-ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; PROGRESSION; THERAPY; DAMAGE; DRUGS; GOLD	Background. Oral glucocorticoids are widely used to treat patients with rheumatoid arthritis, but their effect on joint destruction, as assessed radiologically, is uncertain. Methods. We conducted a randomized, double-blind trial comparing oral prednisolone (7.5 mg daily for two years) with placebo in 128 adults with active rheumatoid arthritis of less than two years' duration. Except for systemic corticosteroids, other treatments could be prescribed, The primary outcome variables were the progression of damage as seen on radiographs of the hand after one and two years, as measured by the Larsen index, and the appearance of erosions in hands that had no erosions at base line. The radiographs were viewed jointly by a radiologist and a rheumatologist who were unaware of the treatment assignment and the time point at which the films were obtained. Results. The statistical analysis of radiologically detected changes was based on 106 patients for whom there were films obtained at base line and two years later. After two years, the Larsen scores increased by a mean of 0.72 unit in the prednisolone group, indicating very little change, and by 5.37 units in the placebo group, indicating substantial joint destruction (P=0.004). Of the 212 hands of these patients, 147 (69.3 percent) had no erosions at the start of the study, At two years, 15 of the 68 such hands in the prednisolone group (22.1 percent) and 36 of the 79 such hands in the placebo group (45.6 percent) had acquired erosions (difference, 23.5 percentage points; 95 percent confidence interval, 5.9 to 40.7; P=0.007), The patients in the prednisolone group had greater reductions than the patients in the placebo group in scores on an articular index and for pain and disability at 3 months; for pain at 6 months; and for disability at 6, 12, and 15 months (all P<0.05), There was no difference between groups in standardized scores for the acute-phase response. The adverse events were typical of those encountered with antirheumatoid drugs. Conclusions. In patients with early, active rheumatoid arthritis, prednisolone (7.5 mg daily) given for two years in addition to other treatments substantially reduced the rate of radiologically detected progression of disease.	STOKE MANDEVILLE HOSP,AYLESBURY HP21 8AL,BUCKS,ENGLAND; CITY HOSP,ABERDEEN,SCOTLAND; LANCASTER MOOR HOSP,LANCASTER,ENGLAND; MT GOULD HOSP,PLYMOUTH,DEVON,ENGLAND; SOUTHMEAD GEN HOSP,BRISTOL,AVON,ENGLAND; PRINCESS ELIZABETH HOSP,EXETER,DEVON,ENGLAND; AMERSHAM HOSP,AMERSHAM,BUCKS,ENGLAND; CHRISTCHURCH HOSP,CHRISTCHURCH,NEW ZEALAND; CITY HOSP,NOTTINGHAM NG5 1PB,ENGLAND; TAUNTON & SOMERSET HOSP,TAUNTON,SOMERSET,ENGLAND	Southmead Hospital; Christchurch Hospital New Zealand; University of Nottingham	KIRWAN, JR (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND.							[Anonymous], 1960, Ann Rheum Dis, V19, P331; [Anonymous], 1959, ANN RHEUM DIS, V18, P173; ARMITAGE P, 1971, STATISTICAL METHODS; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BERNTSEN CA, 1961, ANN INTERN MED, V54, P938, DOI 10.7326/0003-4819-54-5-938; BROOKS PM, 1990, BAILLIERE CLIN RHEUM, V4, P405; BYRON MA, 1985, BRIT J RHEUMATOL, V24, P164; BYRON MA, 1986, ANN RHEUM DIS, V45, P171, DOI 10.1136/ard.45.2.171; COOPER C, 1990, BAILLIERE CLIN RHEUM, V4, P305, DOI 10.1016/S0950-3579(05)80023-8; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIESEN WT, 1985, ANN RHEUM DIS, V44, P372, DOI 10.1136/ard.44.6.372; HARRIS ED, 1983, J RHEUMATOL, V10, P713; IANNUZZI L, 1983, NEW ENGL J MED, V309, P1023, DOI 10.1056/NEJM198310273091704; KIRWAN JR, 1986, BRIT J RHEUMATOL, V25, P206; KIRWAN JR, 1983, CLIN RHEUM DIS, V9, P581; KIRWAN JR, 1994, J RHEUMATOL, V21, P6; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415; LUUKKAINEN R, 1977, SCAND J RHEUMATOL, V6, P189, DOI 10.3109/03009747709095448; MILLION R, 1984, LANCET, V1, P812; SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002-9343(94)90131-7; SCOTT DL, 1985, RHEUMATOL INT, V5, P193, DOI 10.1007/BF00541335; SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21; THOMPSON PW, 1987, ARTHRITIS RHEUM, V30, P618, DOI 10.1002/art.1780300603; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; West HF, 1967, ABSTR WORLD MED, V41, P401	25	671	692	0	17	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					142	146		10.1056/NEJM199507203330302	http://dx.doi.org/10.1056/NEJM199507203330302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791815				2022-12-28	WOS:A1995RK91700002
J	BUCHWALD, D; UMALI, P; UMALI, J; KITH, P; PEARLMAN, T; KOMAROFF, AL				BUCHWALD, D; UMALI, P; UMALI, J; KITH, P; PEARLMAN, T; KOMAROFF, AL			CHRONIC FATIGUE AND THE CHRONIC-FATIGUE-SYNDROME - PREVALENCE IN A PACIFIC-NORTHWEST HEALTH-CARE SYSTEM	ANNALS OF INTERNAL MEDICINE			English	Article						FATIGUE; FATIGUE SYNDROME, CHRONIC; HEALTH STATUS INDICATORS; LYMPHADENITIS; PSYCHOPHYSIOLOGICAL DISORDERS	GENERAL-PRACTICE; FOLLOW-UP; SYMPTOMS; EPIDEMIOLOGY; DEFINITION; POPULATION	Objectives: To investigate the point prevalence of the chronic fatigue syndrome and unexplained debilitating chronic fatigue in a community-based sample of persons and to describe demographic, clinical, and psychosocial differences among those with the chronic fatigue syndrome, those with chronic fatigue, and healthy controls. Design: Prospective cohort study. Setting: A health maintenance organization in Seattle, Washington. Participants: A random sample of 4000 members of the health maintenance organization was surveyed by mail for the presence of chronic fatigue. Measurements: Persons with chronic fatigue were evaluated using a questionnaire that requested information about medical history and fatigue and related symptoms; validated measures of functional status and psychological distress; a physical examination; and standardized blood tests. A structured psychiatric interview was done in persons who appeared to meet the original Centers for Disease Control and Prevention (CDC) criteria for the chronic fatigue syndrome. Participants completed self-report measures at 12 and 24 months. Those with chronic fatigue were reevaluated in person 1 year after study enrollment. Results. 3066 (77%) of the 4000 members surveyed responded. Chronic fatigue was reported by 590 persons (19%). Of these, 388 (66%) had a medical or psychiatric condition that could account for the fatigue. Of the 74 persons (37%) with chronic fatigue who were enrolled in the study, only 3 met the CDC criteria for the chronic fatigue syndrome. The remaining 71 persons were designated as having chronic fatigue alone. Seventy-four healthy, age- and sex-matched controls who were drawn from the same sample but who denied having chronic fatigue were also studied. Demographic characteristics were similar in persons with the chronic fatigue syndrome, persons with chronic fatigue atone, and controls. Those with the chronic fatigue syndrome or chronic fatigue alone had more frequent cervical and axillary adenopathy, poorer functional status, and greater psychological distress than controls. Women and minorities were not overrepresented among cases with chronic fatigue. Conclusions: Using different assumptions about the likelihood that persons who did not participate in the study had the chronic fatigue syndrome, the estimated crude point prevalence of the syndrome in this community ranged from 75 to 267 cases per 100 000 persons. The point prevalence of chronic fatigue alone was strikingly higher; it ranged from 1775 to 6321 cases per 100 000 persons.	HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	BUCHWALD, D (corresponding author), UNIV WASHINGTON, HARBORVIEW MED CTR, 325 9TH AVE ZA-60, SEATTLE, WA 98104 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI032246, R01AI026788, R01AI027314] Funding Source: NIH RePORTER; NIAID NIH HHS [UO1 AI32246, R01 AI27314, R01 AI26788] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATES DW, 1993, ARCH INTERN MED, V153, P2759, DOI 10.1001/archinte.153.24.2759; BUCHWALD D, 1987, JAMA-J AM MED ASSOC, V257, P2303, DOI 10.1001/jama.257.17.2303; CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CHEN MK, 1986, PREV MED, V15, P74, DOI 10.1016/0091-7435(86)90037-X; CLARK MR, 1995, AM J MED, V98, P187, DOI 10.1016/S0002-9343(99)80403-3; DAVID A, 1990, BMJ-BRIT MED J, V301, P1199, DOI 10.1136/bmj.301.6762.1199; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GOLD D, 1990, JAMA-J AM MED ASSOC, V264, P48, DOI 10.1001/jama.264.1.48; Gore, 1987, HLTH LIFESTYLE SURVE; GUNN WJ, 1993, CIBA F SYMP, V173, P83; HAMMOND EC, 1964, AM J PUBLIC HEALTH N, V54, P11, DOI 10.2105/AJPH.54.1.11; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; HOYEN DO, 1991, BRIT J GEN PRACT, V41, P324; HOYEN DO, 1988, SCOT MED J, V33, P368, DOI 10.1177/003693308803300607; JERRETT WA, 1981, PRACTITIONER, V225, P731; KELLNER R, 1973, AM J PSYCHIAT, V130, P102, DOI 10.1176/ajp.130.1.102; KROENKE K, 1988, JAMA-J AM MED ASSOC, V260, P929, DOI 10.1001/jama.260.7.929; KROENKE K, 1990, ARCH INTERN MED, V150, P1685, DOI 10.1001/archinte.150.8.1685; LLOYD AR, 1990, MED J AUSTRALIA, V153, P522, DOI 10.5694/j.1326-5377.1990.tb126191.x; MATTHEWS DA, 1990, CLIN RES, V38, pA699; MCDONALD E, 1993, PSYCHOL MED, V23, P987, DOI 10.1017/S0033291700026453; MORRISON JD, 1980, J FAM PRACTICE, V10, P795; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; PRICE RK, 1992, PUBLIC HEALTH REP, V107, P514; REIDENBERG MM, 1968, NEW ENGL J MED, V279, P678, DOI 10.1056/NEJM196809262791304; Robins L.N., 1985, DIAGNOSTIC INTERVIEW; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; SHARPE M, 1992, BRIT MED J, V305, P147, DOI 10.1136/bmj.305.6846.147; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; TARNOPOLSKY A, 1980, PSYCHOL MED, V10, P683, DOI 10.1017/S0033291700054982; VALDINI AF, 1988, J FAM PRACTICE, V26, P33; 1987, DIAGNOSTIC STATISTIC	34	173	177	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					81	88		10.7326/0003-4819-123-2-199507150-00001	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM435	7778839				2022-12-28	WOS:A1995RM43500001
J	RICHEDWARDS, JW; MANSON, JE; HENNEKENS, CH; BURING, JE				RICHEDWARDS, JW; MANSON, JE; HENNEKENS, CH; BURING, JE			MEDICAL PROGRESS - THE PRIMARY PREVENTION OF CORONARY HEART-DISEASE IN WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DENSITY LIPOPROTEIN CHOLESTEROL; ACUTE MYOCARDIAL-INFARCTION; VITAMIN-E CONSUMPTION; BODY-FAT DISTRIBUTION; HIGH BLOOD-PRESSURE; 12 YEAR FOLLOW; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; RISK-FACTORS; POSTMENOPAUSAL WOMEN		BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health					NHLBI NIH HHS [HL-34595, HL-07575] Funding Source: Medline; NIDDK NIH HHS [DK-36798] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AMERY A, 1986, LANCET, V2, P589; ANASTOS K, 1991, ANN INTERN MED, V115, P287, DOI 10.7326/0003-4819-115-4-287; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; BARRETTCONNOR E, 1989, ANN INTERN MED, V111, P783, DOI 10.7326/0003-4819-111-10-783; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; BARRETTCONNOR E, 1987, CORONARY HEART DISEA, P117; BERLIN JA, 1990, AM J EPIDEMIOL, V132, P612, DOI 10.1093/oxfordjournals.aje.a115704; BIERENBAUM ML, 1973, LANCET, V1, P1404; BJORNTORP P, 1985, ANN INTERN MED, V103, P994, DOI 10.7326/0003-4819-103-6-994; BLAIR D, 1984, AM J EPIDEMIOL, V119, P526, DOI 10.1093/oxfordjournals.aje.a113770; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BRUNNER D, 1974, J CHRON DIS, V27, P217, DOI 10.1016/0021-9681(74)90047-2; BURR ML, 1989, LANCET, V2, P757; BUSH TL, 1988, CLIN CHEM, V34, pB60; BUSH TL, 1987, MENOPAUSE PHYSL PHAR, P187; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CROFT P, 1989, BRIT MED J, V298, P165, DOI 10.1136/bmj.298.6667.165; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FROOM J, 1991, J CLIN EPIDEMIOL, V44, P1127, DOI 10.1016/0895-4356(91)90144-X; GAZIANO J M, 1992, Journal of the American College of Cardiology, V19, p377A; GAZIANO JM, 1990, CIRCULATION, V82, P201; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; HAFFNER SM, 1991, INT J OBESITY, V15, P471; HAMMOND EC, 1975, BMJ-BRIT MED J, V2, P269, DOI 10.1136/bmj.2.5965.269; HARLAN LC, 1987, AM J EPIDEMIOL, V126, P674, DOI 10.1093/oxfordjournals.aje.a114707; HARTZ AJ, 1983, PREV MED, V12, P351, DOI 10.1016/0091-7435(83)90244-X; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; HELLER RF, 1978, BRIT MED J, V1, P472, DOI 10.1136/bmj.1.6111.472; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1994, NEW ENGL J MED, V330, P1080, DOI 10.1056/NEJM199404143301510; HENNEKENS CH, 1979, BR J FAM PLANN, V5, P66; HIGGINS M, 1989, INT J EPIDEMIOL, V18, pS58; HIGGINS M, 1987, CORONARY HEART DISEA, P83; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; Hughes EC, 1972, OBSTET GYNECOLOGIC T, P422; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JOHNSON JL, 1986, AM J EPIDEMIOL, V123, P209, DOI 10.1093/oxfordjournals.aje.a114230; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; KANNEL WB, 1987, AM HEART J, V114, P413, DOI 10.1016/0002-8703(87)90511-4; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KANNEL WB, 1981, FRONTIERS HYPERTENSI, P17; KAPLAN NM, 1989, ARCH INTERN MED, V149, P1514, DOI 10.1001/archinte.149.7.1514; KAYE SA, 1990, INT J OBESITY, V14, P583; KEANEY JF, 1993, P NATL ACAD SCI USA, V90, P11880, DOI 10.1073/pnas.90.24.11880; KEIL JE, 1987, CORONARY HEART DISEA, P90; KLATSKY AL, 1974, ANN INTERN MED, V81, P294, DOI 10.7326/0003-4819-81-3-294; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LANDOLFI R, 1984, BLOOD, V64, P679; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; LAPIDUS L, 1986, BRIT HEART J, V55, P295, DOI 10.1136/hrt.55.3.295; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LAUG WE, 1983, JAMA-J AM MED ASSOC, V250, P772, DOI 10.1001/jama.250.6.772; LEREN P, 1970, CIRCULATION, V42, P935, DOI 10.1161/01.CIR.42.5.935; LEVY RI, 1984, CIRCULATION, V69, P325, DOI 10.1161/01.CIR.69.2.325; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LIVSHITS G, 1989, AM J CARDIOL, V63, P676, DOI 10.1016/0002-9149(89)90250-6; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAGNUS K, 1979, AM J EPIDEMIOL, V110, P724, DOI 10.1093/oxfordjournals.aje.a112853; MANN JI, 1975, BMJ-BRIT MED J, V2, P241, DOI 10.1136/bmj.2.5965.241; MANN JI, 1976, BRIT J PREV SOC MED, V30, P94; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MANSON JE, 1991, CIRCULATION S2, V84, P546; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Mestman J., 1988, GESTATIONAL DIABETES, P191; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; MORENO GT, 1993, CORONARY ARTERY DIS, V4, P580, DOI 10.1097/00019501-199307000-00002; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; OSULLIVAN JB, 1984, CARBOHYD METABOL, P174; OWENS JF, 1992, CIRCULATION, V85, P1265, DOI 10.1161/01.CIR.85.4.1265; OWENS JF, 1990, PREV MED, V19, P147, DOI 10.1016/0091-7435(90)90016-D; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PALMER JR, 1989, NEW ENGL J MED, V320, P1569, DOI 10.1056/NEJM198906153202401; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; READER R, 1984, CIRCULATION, V69, P668; REICHLEY KB, 1987, AM J EPIDEMIOL, V125, P373, DOI 10.1093/oxfordjournals.aje.a114544; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RODIN J, 1990, INT J OBESITY, V14, P303; ROSENBERG L, 1990, NEW ENGL J MED, V322, P213, DOI 10.1056/NEJM199001253220401; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; ROSENBERG L, 1983, JAMA-J AM MED ASSOC, V250, P2801; ROSENHAMER G, 1980, ATHEROSCLEROSIS, V37, P129, DOI 10.1016/0021-9150(80)90100-8; Rothman K, 1986, MODERN EPIDEMIOLOGY, P14; RUDERMAN NB, 1984, PROG CARDIOVASC DIS, V26, P373, DOI 10.1016/0033-0620(84)90011-2; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SALTZBERG S, 1988, MED CLIN N AM, V72, P523, DOI 10.1016/S0025-7125(16)30781-7; SCRAGG R, 1987, AM J EPIDEMIOL, V126, P77, DOI 10.1093/oxfordjournals.aje.a114664; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHEKELLE RB, 1974, STROKE, V5, P71, DOI 10.1161/01.STR.5.1.71; SIGURDSSON JA, 1984, ACTA MED SCAND, V215, P313; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STAMPFER MJ, 1990, AM J OBSTET GYNECOL, V163, P285, DOI 10.1016/0002-9378(90)90569-S; STAMPFER MJ, 1990, ANN NY ACAD SCI, V592, P193; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STAMPFER MJ, 1987, CORONARY HEART DISEA, P112; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STOLLEY PD, 1980, AM J EPIDEMIOL, V112, P217, DOI 10.1093/oxfordjournals.aje.a112987; STOWERS JM, 1984, CARBOHYD METABOL, P181; THORNTON J, 1983, LANCET, V2, P819; Thorogood M., 1993, PHARMACOEPIDEMIOL DR, V2, P3; TYROLER HA, 1971, ARCH INTERN MED, V128, P907, DOI 10.1001/archinte.128.6.907; WARD WK, 1985, DIABETES, V34, P861, DOI 10.2337/diabetes.34.9.861; WENGER NK, 1992, JAMA-J AM MED ASSOC, V268, P1460, DOI 10.1001/jama.268.11.1460; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703; 1992, JAMA-J AM MED ASSOC, V267, P2330; 1984, HYPERTENSION S1, V6, P198; 1971, BRIT MED J, V790, P775; 1971, BRIT MED J, V79, P767; 1992, J MYOCARDIAL ISCHEMI, V4, P30; [No title captured]; 1989, DHHS CDC898411 PUBL; 1989, GUIDE CLIN PREVENTIV, P258; 1993, DHHS PHS931101 NAT C; 1980, BLOOD PRESSURE STUDY; 1992, 1993 HEART STROKE FA; 1974, BRIT MED J, V1, P440	148	271	276	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1758	1766		10.1056/NEJM199506293322607	http://dx.doi.org/10.1056/NEJM199506293322607			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760894				2022-12-28	WOS:A1995RE66700007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ONE-DAY COURSE ON CLINICAL-TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-28	WOS:A1995RE35400007
J	KICKBUSCH, I				KICKBUSCH, I			WORLD-HEALTH-ORGANIZATION - CHANGE AND PROGRESS	BRITISH MEDICAL JOURNAL			English	Article											KICKBUSCH, I (corresponding author), WHO,CH-1211 GENEVA 27,SWITZERLAND.							KING T, 1994, TOBACCO INT     1202, P1; PEABODY JW, 1995, SOC SCI MED, V40, P731, DOI 10.1016/0277-9536(94)00300-I; SMITH R, 1995, BRIT MED J, V310, P543, DOI 10.1136/bmj.310.6979.543; TOLTISON RD, 1993, DECLINE WHO	4	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1518	1520		10.1136/bmj.310.6993.1518	http://dx.doi.org/10.1136/bmj.310.6993.1518			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RD285	7787603	Green Published			2022-12-28	WOS:A1995RD28500028
J	WINKLER, J; SUHR, ST; GAGE, FH; THAL, LJ; FISHER, LJ				WINKLER, J; SUHR, ST; GAGE, FH; THAL, LJ; FISHER, LJ			ESSENTIAL ROLE OF NEOCORTICAL ACETYLCHOLINE IN SPATIAL MEMORY	NATURE			English	Article							NUCLEUS BASALIS MAGNOCELLULARIS; EXCITOTOXIC LESIONS; CHOLINERGIC SYSTEM; SENILE DEMENTIA; IBOTENIC ACID; FOREBRAIN; RATS; NEURONS; ACETYLTRANSFERASE; PHYSOSTIGMINE	THE cholinergic system plays a crucial role in learning and memory. Lesions of cholinergic nuclei(1-4), pharmacological manipulations of cholinergic systems(5-8), intracerebral transplantation of fetal tissue(9-11) and anatomical changes in cholinergic pathways during ageing(12-14) have all been correlated with altered cognitive behaviour. However, it has not been proved that regional acetylcholine is causally required for learning and memory. Here we describe how we achieved a permanent and selective impairment of learning and memory by damaging the nucleus basalis magnocellularis, a nucleus that provides the major cholinergic innervation of the neocortex(15,16), in adult rats. To test the hypothesis that acetylcholine is essential for restoration of cognitive function, we implanted genetically modified cells that produce acetylcholine(17) into denervated neocortical target regions. After grafting, rats with increased neocortical acetylcholine levels showed a significant improvement in a spatial navigation task. Acetylcholine is thus not only necessary for learning and memory, as previously argued, but its presence within the neocortex is also sufficient to ameliorate learning deficits and restore memory following damage to the nucleus basalis.	UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; VET AFFAIRS MED CTR,DEPT NEUROL,SAN DIEGO,CA 92161	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ALKON DL, 1991, BRAIN RES REV, V16, P193, DOI 10.1016/0165-0173(91)90005-S; ARENDT T, 1989, NEUROSCIENCE, V33, P435, DOI 10.1016/0306-4522(89)90397-7; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOEGMAN RJ, 1992, NEUROSCIENCE, V51, P129, DOI 10.1016/0306-4522(92)90477-J; CONNOR DJ, 1991, BRAIN RES, V555, P84, DOI 10.1016/0006-8993(91)90863-Q; DECKER MW, 1991, SYNAPSE, V7, P151, DOI 10.1002/syn.890070209; DEKKER AJAM, 1991, NEUROSCI BIOBEHAV R, V15, P299, DOI 10.1016/S0149-7634(05)80008-9; DUNNETT SB, 1985, NEUROSCIENCE, V16, P787, DOI 10.1016/0306-4522(85)90094-6; DUNNETT SB, 1991, TRENDS NEUROSCI, V14, P494, DOI 10.1016/0166-2236(91)90061-X; FIBIGER HC, 1982, BRAIN RES REV, V4, P327, DOI 10.1016/0165-0173(82)90011-X; FISHER LJ, 1993, J NEUROCHEM, V61, P1323, DOI 10.1111/j.1471-4159.1993.tb13625.x; FREED WJ, 1990, EXP NEUROL, V110, P139, DOI 10.1016/0014-4886(90)90026-O; GAGE FH, 1986, J NEUROSCI, V6, P2837; GAGE FH, 1991, NEURON, V6, P1, DOI 10.1016/0896-6273(91)90116-H; GIROD R, IN PRESS J NEUROSCI; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; MANDEL RJ, 1988, PSYCHOPHARMACOLOGY, V96, P421, DOI 10.1007/BF00216074; MANDEL RJ, 1989, BEHAV BRAIN RES, V31, P221, DOI 10.1016/0166-4328(89)90004-1; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; MUIR JL, 1993, BEHAV BRAIN RES, V57, P123, DOI 10.1016/0166-4328(93)90128-D; MURRAY CL, 1985, NEUROSCIENCE, V14, P1025, DOI 10.1016/0306-4522(85)90273-8; NILSSON OG, 1987, EXP BRAIN RES, V67, P195, DOI 10.1007/BF00269466; PAGE KJ, 1991, NEUROSCIENCE, V43, P457, DOI 10.1016/0306-4522(91)90308-B; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; TAKAHASHI JS, 1994, SCIENCE, V264, P1724, DOI 10.1126/science.8209253; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341	29	247	256	0	17	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					484	487		10.1038/375484a0	http://dx.doi.org/10.1038/375484a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777056				2022-12-28	WOS:A1995RC18800047
J	GUR, RC; GUR, RE				GUR, RC; GUR, RE			HYPOFRONTALITY IN SCHIZOPHRENIA - RIP	LANCET			English	Editorial Material							CEREBRAL BLOOD-FLOW; BRAIN-FUNCTION; TOMOGRAPHY				GUR, RC (corresponding author), UNIV PENN,DEPT PSYCHIAT,NEUROPSYCHIAT PROGRAM,PHILADELPHIA,PA 19104, USA.		Gur, Ruben/K-1999-2019	Gur, Ruben/0000-0002-9657-1996				ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P943; EBMEIER KP, 1995, J NEUROL NEUROSUR PS, V58, P452, DOI 10.1136/jnnp.58.4.452; FRANZEN G, 1975, J PSYCHIAT RES, V12, P199, DOI 10.1016/0022-3956(75)90027-8; GUR RC, 1992, ARCH GEN PSYCHIAT, V49, P409; GUR RE, 1987, ARCH GEN PSYCHIAT, V44, P126; GUR RE, 1985, ARCH GEN PSYCHIAT, V42, P329; GUR RE, 1994, BIOL PSYCHIAT, V35, P3, DOI 10.1016/0006-3223(94)91160-6; GUR RE, IN PRESS ARCH GEN PS; SIEGEL BV, 1993, AM J PSYCHIAT, V150, P1325; WARACH S, 1992, J CEREBR BLOOD F MET, V12, P546, DOI 10.1038/jcbfm.1992.78; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WOLKIN A, 1988, AM J PSYCHIAT, V145, P251	12	80	81	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1383	1384		10.1016/S0140-6736(95)92591-0	http://dx.doi.org/10.1016/S0140-6736(95)92591-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB441	7760605				2022-12-28	WOS:A1995RB44100003
J	KOCH, WJ; ROCKMAN, HA; SAMAMA, P; HAMILTON, RA; BOND, RA; MILANO, CA; LEFKOWITZ, RJ				KOCH, WJ; ROCKMAN, HA; SAMAMA, P; HAMILTON, RA; BOND, RA; MILANO, CA; LEFKOWITZ, RJ			CARDIAC-FUNCTION IN MICE OVEREXPRESSING THE BETA-ADRENERGIC-RECEPTOR KINASE OR A BETA-ARK INHIBITOR	SCIENCE			English	Article							BETA-2-ADRENERGIC RECEPTORS; GAMMA-SUBUNITS; G-PROTEINS; BINDING; DESENSITIZATION; PATHWAYS; LIGAND; HEART	Transgenic mice were created with cardiac-specific overexpression of the beta-adrenergic receptor kinase-1 (beta ARK1) or a beta ARK inhibitor. Animals overexpressing beta ARK1 demonstrated attenuation of isoproterenol-stimulated left ventricular contractility in vivo, dampening of myocardial adenylyl cyclase activity, and reduced functional coupling of beta-adrenergic receptors. Conversely, mice expressing the beta ARK inhibitor displayed enhanced cardiac contractility in vivo with or without isoproterenol. These animals demonstrate the important role of beta ARK in modulating in vivo myocardial function. Because increased amounts of beta ARK1 and diminished cardiac beta-adrenergic responsiveness characterize heart failure, these animals may provide experimental models to study the role of beta ARK in heart disease.	DUKE UNIV,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,DEPT SURG,DURHAM,NC 27710; UNIV HOUSTON,DEPT PHARMACOL & PHARMACEUT SCI,HOUSTON,TX 77204	Duke University; Howard Hughes Medical Institute; Duke University; University of Houston System; University of Houston	KOCH, WJ (corresponding author), DUKE UNIV,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710, USA.		Lefkowitz, Robert/AAW-2649-2021		NATIONAL CANCER INSTITUTE [F32CA009350] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NCI NIH HHS [5F32-CA09350] Funding Source: Medline; NHLBI NIH HHS [HL-16037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOEKHOFF I, 1994, J BIOL CHEM, V269, P37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISTOW MR, 1985, J MOL CELL CARDIOL, V17, P41, DOI 10.1016/0022-2828(85)90007-0; BRISTOW MR, 1990, CIRCULATION, V82, P12; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1993, PHARMACOL THERAPEUT, V60, P405, DOI 10.1016/0163-7258(93)90030-H; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELEAN A, 1980, J BIOL CHEM, V255, P7106; FREEDMAN NJ, UNPUB; GREEN SA, 1992, MOL PHARMACOL, V41, P889; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INGLESE J, 1992, NATURE, V359, P149; KENT RS, 1980, MOL PHARMACOL, V17, P14; KOCH W, UNPUB; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; ROCKMAN HA, UNPUB; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454	30	620	643	0	12	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1350	1353		10.1126/science.7761854	http://dx.doi.org/10.1126/science.7761854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761854				2022-12-28	WOS:A1995RB19800039
J	REES, J; PRICE, J				REES, J; PRICE, J			ABC OF ASTHMA - CHRONIC ASTHMA - GENERAL-MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1400	1401		10.1136/bmj.310.6991.1400	http://dx.doi.org/10.1136/bmj.310.6991.1400			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787551	Green Published			2022-12-28	WOS:A1995RB00500036
J	WIRTZ, E; CLAYTON, C				WIRTZ, E; CLAYTON, C			INDUCIBLE GENE-EXPRESSION IN TRYPANOSOMES MEDIATED BY A PROKARYOTIC REPRESSOR	SCIENCE			English	Article							RNA-POLYMERASE-I; AMANITIN-RESISTANT TRANSCRIPTION; TN10-ENCODED TET-REPRESSOR; PROTEIN-CODING GENES; COLI LAC REPRESSOR; CAMV 35S PROMOTER; REPETITIVE PROTEIN; HOMOLOGOUS RECOMBINATION; DISCONTINUOUS TRANSCRIPTION; DEVELOPMENTAL REGULATION	An inducible expression system was developed for the protozoan parasite Trypanosoma brucei. Transgenic trypanosomes expressing the tetracycline repressor of Escherichia coli exhibited inducer (tetracycline)-dependent expression of chromosomally integrated reporter genes under the control of a procyclic acidic repetitive protein (PARP) promoter bearing a fet operator. Reporter expression could be controlled over a range of four orders of magnitude in response to tetracycline concentration, a degree of regulation that exceeds those exhibited by other eukaryotic repression-based systems. The tet repressor-controlled PARP promoter should be a valuable tool for the study of trypanosome biochemistry, pathogenicity, and cell and molecular biology.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Clayton, Christine/K-7700-2019	Clayton, Christine/0000-0002-6384-0731				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; ALTSCHMIED L, 1988, EMBO J, V7, P4011, DOI 10.1002/j.1460-2075.1988.tb03290.x; ANZ L, 1994, MOL CELL BIOL, V14, P5804; Beverley S. M., 1993, PROTOCOLS MOL PARASI, P333; BEVERLEY SM, UNPUB; BONIN A, 1994, THESIS U HEIDELBERG; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BROWN SD, 1992, MOL CELL BIOL, V12, P2644, DOI 10.1128/MCB.12.6.2644; CHUNG HM, 1992, PARASITOL TODAY, V8, P414, DOI 10.1016/0169-4758(92)90194-7; CHUNG HMM, 1993, MOL CELL BIOL, V13, P3734, DOI 10.1128/MCB.13.6.3734; CLAYTON CE, 1990, MOL CELL BIOL, V10, P3036, DOI 10.1128/MCB.10.6.3036; CLAYTON CE, 1992, PROGR NUCLEIC ACID R, P37; DINGERMANN T, 1992, EMBO J, V11, P1487, DOI 10.1002/j.1460-2075.1992.tb05193.x; DINGERMANN T, 1992, MOL CELL BIOL, V12, P4038, DOI 10.1128/MCB.12.9.4038; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; EID JE, 1991, GENE DEV, V5, P2024, DOI 10.1101/gad.5.11.2024; FIGGE J, 1988, CELL, V52, P713, DOI 10.1016/0092-8674(88)90409-6; FLASPOHLER J, UNPUB; GATZ C, 1991, MOL GEN GENET, V227, P229, DOI 10.1007/BF00259675; GATZ C, 1988, P NATL ACAD SCI USA, V85, P1394, DOI 10.1073/pnas.85.5.1394; GATZ C, 1992, PLANT J, V2, P397, DOI 10.1046/j.1365-313X.1992.t01-37-00999.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HAMM B, 1990, MOL BIOCHEM PARASIT, V40, P13, DOI 10.1016/0166-6851(90)90075-W; HEINS L, 1992, MOL GEN GENET, V232, P328, DOI 10.1007/BF00280013; Hillen W., 1989, TOPICS MOL STRUCTURA, V10, P143; HU MCT, 1991, GENE, V99, P141, DOI 10.1016/0378-1119(91)90120-Z; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; HUG M, 1993, MOL BIOCHEM PARASIT, V61, P87, DOI 10.1016/0166-6851(93)90161-P; KONIG E, 1989, NUCLEIC ACIDS RES, V17, P8727, DOI 10.1093/nar/17.21.8727; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LEE MGS, 1991, GENE, V105, P255, DOI 10.1016/0378-1119(91)90159-9; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; NILSEN TW, 1994, SCIENCE, V264, P1868, DOI 10.1126/science.7912006; PAYS E, 1990, EMBO J, V9, P3145, DOI 10.1002/j.1460-2075.1990.tb07512.x; PAYS E, 1992, SOC GENERL MICROBIOL, V50, P127; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1992, NUCLEIC ACIDS RES, V20, P303, DOI 10.1093/nar/20.2.303; RUDENKO G, 1990, MOL CELL BIOL, V10, P3492, DOI 10.1128/MCB.10.7.3492; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; RUDENKO G, 1989, EMBO J, V8, P4259, DOI 10.1002/j.1460-2075.1989.tb08611.x; SHERMAN DR, 1991, EMBO J, V10, P3379, DOI 10.1002/j.1460-2075.1991.tb04902.x; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; VANDERPLOEG LHT, 1986, CELL, V47, P479, DOI 10.1016/0092-8674(86)90608-2; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; WIRTZ E, 1994, NUCLEIC ACIDS RES, V22, P3887, DOI 10.1093/nar/22.19.3887; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P5153, DOI 10.1093/nar/19.19.5153; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	54	195	201	0	16	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1179	1183		10.1126/science.7761835	http://dx.doi.org/10.1126/science.7761835			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761835				2022-12-28	WOS:A1995RA60400038
J	CRAIR, MC; MALENKA, RC				CRAIR, MC; MALENKA, RC			A CRITICAL PERIOD FOR LONG-TERM POTENTIATION AT THALAMOCORTICAL SYNAPSES	NATURE			English	Article							DEPENDENT SYNAPTIC PLASTICITY; NMDA RECEPTOR CHANNEL; VISUAL-CORTEX; SOMATOSENSORY CORTEX; BARREL CORTEX; MECHANISMS; TRANSMISSION; RESPONSES; PATTERNS; CURRENTS	IN mammalian development, the refinement of topographical projections from the thalamus to the cortex is thought to arise through an activity-dependent process in which thalamic axons compete for cortical targets(1,2). In support of this view, if activity is altered during a critical period in early development, normal connectivity is disrupted(1,2). It has been proposed that synaptic connections are strengthened during development by correlated pre- and postsynaptic activity(3,4), and a likely mechanism for this process would be N-methyl-D-aspartate (NMDA) receptor-dependent long-term potentiation (LTP)(5,6). However, the evidence that LTP is involved in normal development remains inconclusive. We have examined LTP in the thalamocortical synapses that form whisker barrels in rat somatosensory cortex (S1). We report here that the period during which LTP can be induced matches closely the critical period during which the barrels can be modified by sensory perturbations. Moreover, the loss of susceptibility to LTP with age is accompanied by a decrease in NMDA receptor-mediated synaptic currents. These findings provide compelling evidence that LTP is important for the development of cortical circuitry.	UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	CRAIR, MC (corresponding author), UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA.							AGMON A, 1992, J NEUROPHYSIOL, V68, P345, DOI 10.1152/jn.1992.68.1.345; AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; Bear M F, 1993, Curr Opin Neurobiol, V3, P197, DOI 10.1016/0959-4388(93)90210-P; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; FOX K, 1992, J NEUROSCI, V12, P1826; FOX K, 1993, TRENDS NEUROSCI, V16, P116, DOI 10.1016/0166-2236(93)90136-A; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HEBB DO, 1949, ORG BEHAVIOR; HESTRIN S, 1992, NATURE, V357, P686, DOI 10.1038/357686a0; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; KILLACKEY HP, 1975, BRAIN RES, V86, P469, DOI 10.1016/0006-8993(75)90897-5; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOONEY R, 1993, NEURON, V10, P815, DOI 10.1016/0896-6273(93)90198-Z; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X	29	578	589	0	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					325	328		10.1038/375325a0	http://dx.doi.org/10.1038/375325a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753197				2022-12-28	WOS:A1995RA03000053
J	SERENO, MI; DALE, AM; REPPAS, JB; KWONG, KK; BELLIVEAU, JW; BRADY, TJ; ROSEN, BR; TOOTELL, RBH				SERENO, MI; DALE, AM; REPPAS, JB; KWONG, KK; BELLIVEAU, JW; BRADY, TJ; ROSEN, BR; TOOTELL, RBH			BORDERS OF MULTIPLE VISUAL AREAS IN HUMANS REVEALED BY FUNCTIONAL MAGNETIC-RESONANCE-IMAGING	SCIENCE			English	Article							POSITRON-EMISSION TOMOGRAPHY; HUMAN STRIATE CORTEX; HUMAN BRAIN; RETINOTOPIC ORGANIZATION; CORTICAL AREAS; MACAQUE MONKEY; TOPOGRAPHY; MRI; REPRESENTATION; CONNECTIONS	The borders of human visual areas V1, V2, VP, V3, and V4 were precisely and noninvasively determined. Functional magnetic resonance images were recorded during phase-encoded retinal stimulation. This volume data set was then sampled with a cortical surface reconstruction, making it possible to calculate the local visual field sign (mirror image Versus non-mirror image representation). This method automatically and objectively outlines area borders because adjacent areas often have the opposite field sign. Cortical magnification factor curves for striate and extrastriate cortical areas were determined, which showed that human visual areas have a greater emphasis on the center-of-gaze than their counterparts in monkeys. Retinotopically organized visual areas in humans extend anteriorly to overlap several areas previously shown to be activated by written words.	UNIV OSLO,DEPT NEUROPHYSIOL,N-0316 OSLO,NORWAY; HARVARD MIT DIV HLTH SCI & TECHNOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,NUCL MAGNET RESONANCE CTR,BOSTON,MA 02129	University of Oslo; Harvard University; Harvard University; Massachusetts General Hospital	SERENO, MI (corresponding author), UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093, USA.		Dale, Anders M/A-5180-2010; Sereno, Martin I/F-7657-2012	Sereno, Martin I/0000-0002-7598-7829; Kwong, Kenneth K./0000-0001-5056-2173	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022614] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047035] Funding Source: NIH RePORTER; NEI NIH HHS [EY07980] Funding Source: Medline; NICHD NIH HHS [NICHD22614] Funding Source: Medline; NIMH NIH HHS [MH47035] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAKER JR, 1993, P SOC MAG RESON MED, V12, P1400; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BOUSSAOUD D, 1991, J COMP NEUROL, V306, P554, DOI 10.1002/cne.903060403; Carman G.J., 1990, THESIS CALTECH; CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103; CUSICK CG, 1984, J COMP NEUROL, V230, P311, DOI 10.1002/cne.902300302; DACEY DM, 1993, J NEUROSCI, V13, P5334, DOI 10.1523/JNEUROSCI.13-12-05334.1993; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DESIMONE R, 1986, J COMP NEUROL, V248, P164, DOI 10.1002/cne.902480203; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; ENGEL SA, 1994, NATURE, V369, P525, DOI 10.1038/369525a0; FELLEMAN D J, 1986, Society for Neuroscience Abstracts, V12, P1182; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FOSTER KH, 1985, J PHYSIOL-LONDON, V365, P331, DOI 10.1113/jphysiol.1985.sp015776; FOX PT, 1987, J NEUROSCI, V7, P913; GATTASS R, 1988, J NEUROSCI, V8, P1831; HORTON JC, 1991, ARCH OPHTHALMOL-CHIC, V109, P816, DOI 10.1001/archopht.1991.01080060080030; Jouandet M L, 1989, J Cogn Neurosci, V1, P88, DOI 10.1162/jocn.1989.1.1.88; Kaas JH, 1991, NEUROANATOMY VISUAL, P302; KRUBITZER LA, 1990, VISUAL NEUROSCI, V5, P165, DOI 10.1017/S0952523800000213; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; NEUENSCHWANDER S, 1994, J COMP NEUROL, V340, P65, DOI 10.1002/cne.903400106; NEWSOME WT, 1986, J COMP NEUROL, V252, P129; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; OLAVARRIA J, 1985, J NEUROSCI METH, V15, P191, DOI 10.1016/0165-0270(85)90098-6; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; ROSA MGP, 1993, VISUAL NEUROSCI, V10, P827, DOI 10.1017/S0952523800006064; SCHNEIDER W, 1993, NATURE, V365, P150, DOI 10.1038/365150a0; Schwartz E.L., 1990, COMPUTATIONAL NEUROS, P295; Schwartz Eric L., 1994, Cerebral Cortex, V10, P359; Sereno Martin I., 1991, P160; SERENO MI, 1994, CEREB CORTEX, V4, P601, DOI 10.1093/cercor/4.6.601; SERENO MI, IN PRESS CEREB CORTE; TOLHURST DJ, 1988, HUM NEUROBIOL, V6, P247; TOOTELL RB, 1981, SCIENCE, V214, P813, DOI 10.1126/science.7292014; TOOTELL RBH, 1982, SCIENCE, V218, P902, DOI 10.1126/science.7134981; TOOTELL RBH, 1985, J NEUROSCI, V5, P2786; TOOTELL RBH, 1995, CEREB CORTEX, V5, P39, DOI 10.1093/cercor/5.1.39; TOOTELL RBH, IN PRESS J NEUROSCI; VANESSEN DC, 1984, VISION RES, V24, P429, DOI 10.1016/0042-6989(84)90041-5; VANESSEN DC, 1980, J COMP NEUROL, V191, P255, DOI 10.1002/cne.901910208; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; VANESSEN DC, 1978, J PHYSIOL-LONDON, V277, P193; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; WISMER GL, 1988, J COMPUT ASSIST TOMO, V12, P259, DOI 10.1097/00004728-198803000-00014; ZEKI S, 1991, J NEUROSCI, V11, P641	49	1925	1952	6	126	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					889	893		10.1126/science.7754376	http://dx.doi.org/10.1126/science.7754376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754376				2022-12-28	WOS:A1995QX85000043
J	FERGUSON, AE; GIBSON, NA; AITCHISON, TC; PATON, JY				FERGUSON, AE; GIBSON, NA; AITCHISON, TC; PATON, JY			MEASURED BRONCHODILATOR USE IN PRESCHOOL-CHILDREN WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							MEDICATION	Objective-To investigate how parents use bronchodilator treatment for relief of symptoms when treating their asthmatic preschool children. Design-A commercial electromechanical timer device was attached to a large volume spacer to record the time and date of each use of inhaled bronchodilator over two months. The recorded time and dates were compared with symptoms noted in an asthma diary card. Setting-Large paediatric teaching hospital in Glasgow. Subjects-29 preschool children with moderately severe asthma attending a specialist paediatric asthma clinic. Main outcome measures-Inhaler use measured by the timer device; symptoms and inhaler use recorded by parents in a daily asthma diary. Results-Satisfactory data were obtained in 22 of the 29 children; the median number of study days was 53 (range 18-77). Asthmatic symptoms were recorded on a median of 30 (3-77) days. Bronchodilator was used on a median of 19 (2-73) days, or on 63% (7-100%) of days when symptoms occurred. The median number of puffs used in a day was 1 (range 0-100) and was significantly related to symptom severity in only 14 of the 22 children. In only two of the 22 children was bronchodilator given more frequently than four hourly, and only five children ever used more than 12 puffs a day. Conclusions-The frequency of parental administration of bronchodilator treatment was variable and not closely related to the parent's record of symptom severity. Parents often recorded symptoms in their children but did not treat them.	UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow	FERGUSON, AE (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT CHILD HLTH,GLASGOW G3 8SJ,LANARK,SCOTLAND.							[Anonymous], 1993, THORAX, V48, pS1; ARCHER LNJ, 1985, ARCH DIS CHILD, V60, P473, DOI 10.1136/adc.60.5.473; BOSLEY CM, 1994, EUR RESPIR J, V7, P504, DOI 10.1183/09031936.94.07030504; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332, DOI 10.1136/adc.67.3.332; GLEESON JGA, 1988, BRIT J DIS CHEST, V82, P172, DOI 10.1016/0007-0971(88)90039-3; Lenny W, 1994, EUR RESPIR REV, V4, P49; RAND CS, 1992, AM REV RESPIR DIS, V146, P1559, DOI 10.1164/ajrccm/146.6.1559; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SEARS MR, 1990, LANCET, V336, P1391, DOI 10.1016/0140-6736(90)93098-A; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8	10	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1161	1164		10.1136/bmj.310.6988.1161	http://dx.doi.org/10.1136/bmj.310.6988.1161			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767149	Green Published			2022-12-28	WOS:A1995QX56600019
J	CANNEGIETER, SC; ROSENDAAL, FR; WINTZEN, AR; VANDERMEER, FJM; VANDENBROUCKE, JP; BRIET, E				CANNEGIETER, SC; ROSENDAAL, FR; WINTZEN, AR; VANDERMEER, FJM; VANDENBROUCKE, JP; BRIET, E			OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH MECHANICAL HEART-VALVES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; COMPLICATIONS; REPLACEMENT; PROSTHESIS; INTENSITY; WARFARIN	Background. The optimal intensity of oral anticoagulant therapy for patients with mechanical heart valves (i.e., the level at which thromboembolic complications are effectively prevented without excessive bleeding) is not known. We attempted to determine the optimal intensity by calculating the incidence of both complications at different levels of anticoagulation. Methods. Data were collected on all patients with mechanical heart valves who have been seen at four regional Dutch anticoagulation clinics since 1985. The primary outcome events were episodes of thromboembolism or major bleeding, The intensity-specific incidence of each type of event was calculated as the number of events that occurred at a certain intensity of anticoagulation (expressed in terms of the international normalized ratio [INR]) divided by the number of patient-years during which the INR was at this level in the total patient population. Results. A total of 1608 patients were followed during 6475 patient-years. Cerebral embolism occurred in 43 patients (0.68 per 100 patient-years) and peripheral en embolism in 2 (0.03 per 100 patient-years). Intracranial and spinal bleeding occurred in 36 patients (0.57 per 100 patient-years) and major extracranial bleeding in 128 (2.1 per 100 patient-years). The optimal intensity of anticoagulation, at which the incidence of both complications was lowest, was achieved when the INR was between 2.5 and 4.9. Conclusions. The intensity of anticoagulant therapy for patients with prosthetic heart valves is optimal when the INR is between 2.5 and 4.9. To achieve this level of anticoagulation, a target INR of 3.0 to 4.0 is recommended.	UNIV LEIDEN HOSP,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS; UNIV LEIDEN HOSP,DEPT NEUROL,2300 RC LEIDEN,NETHERLANDS; LEIDEN ANTICOAGULAT CLIN,LEIDEN,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	CANNEGIETER, SC (corresponding author), UNIV LEIDEN HOSP,DEPT HEMATOL,HEMOSTASIS & THROMBOSIS RES CTR,BLDG 1,C2-R,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020; Rosendaal, Frits/Q-3842-2017; Cannegieter, Suzanne/W-3696-2019	Vandenbroucke, Jan/0000-0001-5668-6716; Rosendaal, Frits/0000-0003-2558-7496; Cannegieter, Suzanne/0000-0003-4707-2303				ALTMAN R, 1991, J THORAC CARDIOV SUR, V101, P427; CANNEGIETER SC, 1994, CIRCULATION, V89, P635, DOI 10.1161/01.CIR.89.2.635; DISESA VJ, 1989, ANN THORAC SURG, V48, P280, DOI 10.1016/0003-4975(89)90089-1; DUXBURY BM, 1986, ACTA HAEMATOL-BASEL, V76, P65, DOI 10.1159/000206023; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; KENT DL, 1992, MED DECIS MAKING, V12, P132, DOI 10.1177/0272989X9201200206; KRATZ JM, 1993, ANN THORAC SURG, V56, P462, DOI 10.1016/0003-4975(93)90880-Q; NAIR CK, 1990, AM J CARDIOL, V65, P217, DOI 10.1016/0002-9149(90)90088-I; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; STEIN PD, 1992, CHEST, V102, pS445, DOI 10.1378/chest.102.4_Supplement.445S; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; VANDENBESSELAAR AMHP, 1988, AM J CLIN PATHOL, V90, P685, DOI 10.1093/ajcp/90.6.685; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WIEGMAN H, 1977, COMPUT PROG BIOMED, V7, P71, DOI 10.1016/0010-468X(77)90014-9; WILSON DB, 1991, CHEST, V100, P1553, DOI 10.1378/chest.100.6.1553; 1985, THROMB HAEMOSTASIS, V53, P155	20	723	742	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					11	17		10.1056/NEJM199507063330103	http://dx.doi.org/10.1056/NEJM199507063330103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776988				2022-12-28	WOS:A1995RG73500003
J	BELLARY, S; SCHIANO, T; HARTMAN, G; BLACK, M				BELLARY, S; SCHIANO, T; HARTMAN, G; BLACK, M			CHRONIC HEPATITIS WITH COMBINED FEATURES OF AUTOIMMUNE CHRONIC HEPATITIS AND CHRONIC HEPATITIS-C - FAVORABLE RESPONSE TO PREDNISONE AND AZATHIOPRINE	ANNALS OF INTERNAL MEDICINE			English	Note							CHRONIC ACTIVE HEPATITIS; ALPHA-INTERFERON; VIRUS-INFECTION; LIVER-DISEASE; ANTIBODY		TEMPLE UNIV HOSP & MED SCH, DEPT GASTROENTEROL, LIVER UNIT, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								BLACK M, 1992, ANN INTERN MED, V116, P86, DOI 10.7326/0003-4819-116-1-86; DONAHUE D, 1993, HEPATOLOGY, V18, pA84; FONG TL, 1994, GASTROENTEROLOGY, V107, P196, DOI 10.1016/0016-5085(94)90077-9; FRIED MW, 1993, DIGEST DIS SCI, V38, P631, DOI 10.1007/BF01316792; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; LUNEL F, 1992, HEPATOLOGY, V16, P630, DOI 10.1002/hep.1840160304; MAGRIN S, 1994, HEPATOLOGY, V19, P273; MAGRIN S, 1991, J HEPATOL, V13, P364, DOI 10.1016/0168-8278(91)90082-M; MERICAN I, 1993, Q J MED, V86, P119; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; MITCHEL LS, 1993, AM J GASTROENTEROL, V88, P1027; NISHIGUCHI S, 1992, ANN INTERN MED, V116, P21, DOI 10.7326/0003-4819-116-1-21; NISHIOKA M, 1993, FALK SYMP, V70, P193; PAPO T, 1992, ANN INTERN MED, V116, P51, DOI 10.7326/0003-4819-116-1-51; SHINDO M, 1992, GASTROENTEROLOGY, V102, P1406; ULRICH PP, 1990, J CLIN INVEST, V86, P1609, DOI 10.1172/JCI114882	17	46	46	2	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					32	34		10.7326/0003-4819-123-1-199507010-00004	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00004			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762911				2022-12-28	WOS:A1995RE66500005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TOLL-FREE NUMBER FOR LOCATING CERTIFIED MAMMOGRAPHY FACILITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, JAMA-J AM MED ASSOC, V271, P179	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-28	WOS:A1995RE35400006
J	COHEN, J; STEWART, I				COHEN, J; STEWART, I			BEYOND ALL REASONABLE DNA	LANCET			English	Editorial Material									UNIV WARWICK,INTERDISCIPLINARY MATH RES PROGRAMME,COVENTRY,W MIDLANDS,ENGLAND	University of Warwick	COHEN, J (corresponding author), UNIV WARWICK,CTR ECOSYST ANAL & MANAGEMENT,COVENTRY,W MIDLANDS,ENGLAND.							BALDING DJ, 1994, NATURE, V368, P285, DOI 10.1038/368285a0; DEBENHAM PG, 1994, BER J BIOMED SCI, V51, P87; GILL P, 1995, NATURE, V375, P352, DOI 10.1038/375352d0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; Matthews R., 1995, B I MATH APPL, V31, P3; ROEDER K, 1994, STAT SCI, V9, P222, DOI 10.1214/ss/1177010488	6	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1586	1588		10.1016/S0140-6736(95)90109-4	http://dx.doi.org/10.1016/S0140-6736(95)90109-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783531				2022-12-28	WOS:A1995RE67000002
J	VIRGO, KS; VERNAVA, AM; LONGO, WE; MCKIRGAN, LW; JOHNSON, FE				VIRGO, KS; VERNAVA, AM; LONGO, WE; MCKIRGAN, LW; JOHNSON, FE			COST OF PATIENT FOLLOW-UP AFTER POTENTIALLY CURATIVE COLORECTAL-CANCER TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTOPERATIVE SURVEILLANCE; CARCINOMA; COLON; RESECTION; SURGERY; RECTUM; RECURRENCE; MUTATIONS	Objective.- To estimate the cost of follow-up among colorectal cancer patients treated with curative intent based on the broad spectrum of surveillance strategies suggested in the literature. Design.- Economic analysis of the costs associated with 11 separate surveillance strategies. Charge data were obtained from the Part B Medicare Annual Data file and the Hospital Outpatient Bill file. Setting.- Ambulatory care. Main Outcome Measures.- Medicare-allowed charges and an actual-charge proxy for 5 years of follow-up after treatment for colorectal cancer patients on a nationwide basis. Results.- Medicare-allowed charges varied widely for the 5 years of posttreatment follow-up from a low of $561 to a high of $16 492. When Medicare-allowed charges were converted to a proxy for actual charges using a conversion ratio of 1.62, the range was $910 to $26 717, a 28-fold difference in charges. Conclusions.- Charges vary extensively across follow-up strategies, with no indication that higher-cost strategies increase survival or quality of life.	DEPT VET AFFAIRS MED CTR, SURG SERV, ST LOUIS, MO USA		VIRGO, KS (corresponding author), ST LOUIS UNIV, HLTH SCI CTR, DEPT SURG, 3635 VISTA AVE, POB 15250, ST LOUIS, MO 63110 USA.		Virgo, Katherine S/AAG-3188-2021	Virgo, Katherine S/0000-0002-2069-0585				Adloff M, 1989, Chirurgie, V115, P228; ANDERSON C, 1994, SCIENCE, V263, P1080, DOI 10.1126/science.8108722; BEART RW, 1983, MAYO CLIN PROC, V58, P361; BERNSTAM VA, 1992, HDB GENE LEVEL DIAGN; BRUINVELS DJ, 1994, ANN SURG, V219, P174, DOI 10.1097/00000658-199402000-00009; BUHLER H, 1984, CANCER, V54, P791, DOI 10.1002/1097-0142(19840901)54:5<791::AID-CNCR2820540502>3.0.CO;2-R; BUIE WD, 1993, GASTROINTEST ENDOSC, V3, P691; CALI RL, 1993, DIS COLON RECTUM, V36, P388, DOI 10.1007/BF02053945; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEVENEY KE, 1984, AM J SURG, V148, P717, DOI 10.1016/0002-9610(84)90423-9; FISCHER DS, 1983, FOLLOW UP CANCER HDB, P4; FISCHER DS, 1992, FOLLOW UP CANCER HDB, P34; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GALANDIUK S, 1992, SURG GYNECOL OBSTET, V174, P27; JUHL G, 1990, WORLD J SURG, V14, P255, DOI 10.1007/BF01664886; KELLY CJ, 1992, CANCER-AM CANCER SOC, V70, P1397, DOI 10.1002/1097-0142(19920901)70:3+<1397::AID-CNCR2820701531>3.0.CO;2-A; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; Makela J, 1992, Surg Oncol, V1, P157, DOI 10.1016/0960-7404(92)90029-K; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NAVA HR, 1982, CANCER, V49, P1043, DOI 10.1002/1097-0142(19820301)49:5<1043::AID-CNCR2820490533>3.0.CO;2-Y; OVASKA J, 1990, AM J SURG, V159, P593, DOI 10.1016/S0002-9610(06)80074-7; OVASKA J, 1990, GASTROENTEROLOGY, V99, P1849; OVASKA JT, 1989, SCAND J GASTROENTERO, V24, P416, DOI 10.3109/00365528909093068; ROBERTS PJ, 1988, SCAND J GASTROENTERO, V23, P50, DOI 10.3109/00365528809096956; ROCKLIN MS, 1990, AM SURGEON, V56, P22; SAFI F, 1993, CANCER DETECT PREV, V17, P417; SANDLER RS, 1984, CANCER, V53, P193, DOI 10.1002/1097-0142(19840101)53:1<193::AID-CNCR2820530134>3.0.CO;2-V; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STEELE G, 1991, WORLD J SURG, V15, P583, DOI 10.1007/BF01789202; STEELE G, 1986, COLORECTAL CANCER; SUGARBAKER PH, 1987, SURGERY, V102, P79; TORNQVIST A, 1982, BRIT J SURG, V69, P725, DOI 10.1002/bjs.1800691213; VERNAVA AM, 1994, DIS COLON RECTUM, V37, P573, DOI 10.1007/BF02050993; VIRGO KS, IN PRESS ANN SURG ON; 1992, DIS COLON RECTUM, V35, P389; 1994, JAMA-J AM MED ASSOC, V271, P1587; 1960, CONSUMER PRICE INDEX	37	121	123	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1837	1841		10.1001/jama.273.23.1837	http://dx.doi.org/10.1001/jama.273.23.1837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776499				2022-12-28	WOS:A1995RD11600025
J	KELLEY, RL; SOLOVYEVA, I; LYMAN, LM; RICHMAN, R; SOLOVYEV, V; KURODA, MI				KELLEY, RL; SOLOVYEVA, I; LYMAN, LM; RICHMAN, R; SOLOVYEV, V; KURODA, MI			EXPRESSION OF MSL-2 CAUSES ASSEMBLY OF DOSAGE COMPENSATION REGULATORS ON THE X-CHROMOSOMES AND FEMALE LETHALITY IN DROSOPHILA	CELL			English	Article							SEX-SPECIFIC LETHALS; GENE-PRODUCT; SPLICE-SITE; SEQUENCE SIMILARITY; MELANOGASTER; PROTEIN; RNA; MUTATIONS; BINDING; TRANSCRIPTION	Male-specific lethal-2 (msl-2) is a RING finger protein that is required for X chromosome dosage compensation in Drosophila males. Consistent with the formation of a dosage compensation protein complex, msl-2 colocalizes with the other MSL proteins on the male X chromosome and coimmunoprecipitates with msl-1 from male larval extracts. Ectopic expression of msl-2 in females results in the appearance of the other MSL dosage compensation regulators on the female X chromosomes and decreased female viability. We suggest that msl-2 RNA is the primary target of Sxl regulation in the dosage compensation pathway and present a speculative model for the regulation of two distinct modes of dosage compensation by Sxl.			KELLEY, RL (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOWARD HUGHES MED INST,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Solovyev, Victor/C-4614-2013	Solovyev, Victor/0000-0001-8885-493X	NIGMS NIH HHS [GM45744] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045744, R37GM045744] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BENZ WK, 1988, GENETICS, V118, P461; BERNSTEIN M, 1994, GENETICS, V136, P1051; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BOPP D, 1991, GENE DEV, V5, P403, DOI 10.1101/gad.5.3.403; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; CLINE TW, 1978, GENETICS, V90, P683; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; CLINE TW, 1983, DEV BIOL, V95, P260, DOI 10.1016/0012-1606(83)90027-1; CRONMILLER C, 1994, MOL GENETICS SEX DET, P172; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GERGEN JP, 1987, GENETICS, V117, P477; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; HIEBERT JC, 1994, GENETICS, V136, P913; HILFIKER A, 1994, EMBO J, V15, P3542; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KARPEN GH, 1988, GENE DEV, V2, P1745, DOI 10.1101/gad.2.12b.1745; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; OKUNO T, 1984, JPN J GENET, V59, P237, DOI 10.1266/jjg.59.237; PALMER MJ, 1993, GENETICS, V134, P545; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; Paro R, 1993, CURR OPIN CELL BIOL, V5, P999, DOI 10.1016/0955-0674(93)90084-4; SAKAMOTO H, 1992, NUCLEIC ACIDS RES, V20, P5533, DOI 10.1093/nar/20.21.5533; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SAMUELS ME, 1991, MOL CELL BIOL, V11, P3584, DOI 10.1128/MCB.11.7.3584; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SKRIPSKY T, 1982, DEV BIOL, V94, P153, DOI 10.1016/0012-1606(82)90078-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STRATHMANN M, 1991, P NATL ACAD SCI USA, V88, P1247, DOI 10.1073/pnas.88.4.1247; SWEDER KS, 1993, SCIENCE, V262, P439, DOI 10.1126/science.8211165; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; UENOYAMA T, 1984, JPN J GENET, V59, P335, DOI 10.1266/jjg.59.335; UENOYAMA T, 1982, GENETICS, V102, P233; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XIAO H, 1989, MOL CELL BIOL, V9, P1746, DOI 10.1128/MCB.9.4.1746; ZHOU S, 1995, IN PRESS EMBO J	53	253	259	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					867	877		10.1016/0092-8674(95)90007-1	http://dx.doi.org/10.1016/0092-8674(95)90007-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781064	Bronze			2022-12-28	WOS:A1995RD76800008
J	COMPSTON, JE; COOPER, C; KANIS, JA				COMPSTON, JE; COOPER, C; KANIS, JA			BONE DENSITOMETRY IN CLINICAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							X-RAY ABSORPTIOMETERS; LUNAR-DPX; OSTEOPOROSIS; FRACTURES; WOMEN; PREDICTION; DENSITY; RISK; MASS; SITES		SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; UNIV SHEFFIELD,SCH MED,DEPT HUMAN METAB & CLIN BIOCHEM,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND	University of Southampton; University of Sheffield	COMPSTON, JE (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND.							[Anonymous], 1994, WHO TECH REP SER, V843; BHAMBHANI M, 1992, ANN RHEUM DIS, V51, P1069, DOI 10.1136/ard.51.9.1069; COMPSTON JE, 1992, CLIN ENDOCRINOL, V36, P223, DOI 10.1111/j.1365-2265.1992.tb01435.x; Consensus Development Conference, 1993, AM J MED, V94, P646; COOPER C, 1992, BRIT MED J, V304, P793, DOI 10.1136/bmj.304.6830.793; COOPER C, 1993, CLIN RHEUMATOL, V7, P459; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DONALDSON LJ, 1990, J EPIDEMIOL COMMUN H, V44, P241, DOI 10.1136/jech.44.3.241; GARDSELL P, 1991, CALCIFIED TISSUE INT, V49, P90, DOI 10.1007/BF02565127; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JOHNSTON C C J, 1989, Journal of Bone and Mineral Research, V4, P1; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; LASKEY MA, 1991, BRIT J RADIOL, V64, P1023, DOI 10.1259/0007-1285-64-767-1023; LASKEY MA, 1992, BRIT J RADIOL, V65, P1124, DOI 10.1259/0007-1285-65-780-1124; LAW MR, 1991, BMJ-BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453; MAZESS R, 1989, CALCIFIED TISSUE INT, V44, P228, DOI 10.1007/BF02556569; MAZESS RB, 1988, J BONE MINER RES, V3, P13; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; NEVITT MC, 1994, OSTEOPOROSIS INT, V4, P325, DOI 10.1007/BF01622192; NORDIN BEC, 1994, MED J AUSTRALIA, V160, P517, DOI 10.5694/j.1326-5377.1994.tb138321.x; REID IR, 1991, J CLIN ENDOCR METAB, V72, P1372, DOI 10.1210/jcem-72-6-1372; RIBOT C, 1992, CLIN ENDOCRINOL, V36, P225, DOI 10.1111/j.1365-2265.1992.tb01436.x; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; WASNICH RD, 1994, OSTEOPOROSIS INT, V4, P1, DOI 10.1007/BF02352253; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2	29	128	130	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1507	1510		10.1136/bmj.310.6993.1507	http://dx.doi.org/10.1136/bmj.310.6993.1507			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787600	Green Published			2022-12-28	WOS:A1995RD28500025
J	EDGAR, M				EDGAR, M			TACKLING RUGBY INJURIES	LANCET			English	Editorial Material							CERVICAL-SPINE; FOOTBALL; EMERGENCY; ACCIDENT				EDGAR, M (corresponding author), MIDDLESEX HOSP,LONDON,ENGLAND.							Addley K, 1988, Br J Sports Med, V22, P22; BARRY HC, 1988, BRIT MED J, V296, P149; Bedford P J, 1984, Br J Sports Med, V18, P116; BIER I, 1991, BRIT MED J, V303, P1552; GARRAWAY WM, 1991, BRIT MED J, V303, P1082, DOI 10.1136/bmj.303.6810.1082; GIBBS N, 1993, AM J SPORT MED, V21, P696, DOI 10.1177/036354659302100510; HORAN FT, 1984, J BONE JOINT SURG BR, V66, P470, DOI 10.1302/0301-620X.66B4.6746675; MCCOY GF, 1984, J BONE JOINT SURG BR, V66, P500, DOI 10.1302/0301-620X.66B4.6746681; NOAKES T, 1995, BRIT MED J, V310, P1345, DOI 10.1136/bmj.310.6991.1345; RYAN JM, 1992, IRISH MED J, V85, P72; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Silver J R, 1992, Br J Sports Med, V26, P253; SILVER JR, 1984, BRIT MED J, V288, P37, DOI 10.1136/bmj.288.6410.37; SILVER JR, 1994, PARAPLEGIA, V32, P442, DOI 10.1038/sc.1994.71; Sparks J P, 1981, Br J Sports Med, V15, P30; WATTERS DAK, 1984, ARCH EMERG MED, V1, P105	16	13	13	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1452	1453		10.1016/S0140-6736(95)91031-X	http://dx.doi.org/10.1016/S0140-6736(95)91031-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769897				2022-12-28	WOS:A1995RC18900003
J	ZUCKERMAN, AJ				ZUCKERMAN, AJ			THE NEW GB HEPATITIS VIRUSES	LANCET			English	Editorial Material											ZUCKERMAN, AJ (corresponding author), ROYAL FREE HOSP,SCH MED,WHO,COLLABORATING CTR REFERENCE & RES VIRAL DIS,LONDON,ENGLAND.							DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; PARKS WP, 1969, J INFECT DIS, V120, P539, DOI 10.1093/infdis/120.5.539; SCHLAUDER GG, 1995, J MED VIROL, V46, P81, DOI 10.1002/jmv.1890460117; SIMONS JN, IN PRESS P NATL ACAD	5	51	58	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1453	1454		10.1016/S0140-6736(95)91032-8	http://dx.doi.org/10.1016/S0140-6736(95)91032-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769898				2022-12-28	WOS:A1995RC18900004
J	BOHEN, SP; KRALLI, A; YAMAMOTO, KR				BOHEN, SP; KRALLI, A; YAMAMOTO, KR			HOLDEM AND FOLDEM - CHAPERONES AND SIGNAL-TRANSDUCTION	SCIENCE			English	Editorial Material							HEAT-SHOCK PROTEIN; RECEPTOR; BINDING		UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BOHEN, SP (corresponding author), NCI,BIOCHEM LAB,BETHESDA,MD 20892, USA.							ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	16	179	182	1	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1303	1304		10.1126/science.7761850	http://dx.doi.org/10.1126/science.7761850			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761850				2022-12-28	WOS:A1995RB19800026
J	GROTE, E; HAO, JC; BENNETT, MK; KELLY, RB				GROTE, E; HAO, JC; BENNETT, MK; KELLY, RB			A TARGETING SIGNAL IN VAMP REGULATING TRANSPORT TO SYNAPTIC VESICLES	CELL			English	Article							MEMBRANE-PROTEIN; RAT-BRAIN; SYNAPTOPHYSIN; FUSION; SYNAPTOBREVIN; GENES; BIOGENESIS; RECEPTORS; TETANUS; PATHWAY	VAMP is a synaptic vesicle membrane protein required for fusion. Synaptic vesicle targeting was measured for mutants of an epitope-tagged form of VAMP in transfected PC12 cells. A signal within a predicted amphipathic alpha helix is essential for targeting to synaptic vesicles. Cellubrevin, a nonneural VAMP homolog, contains this signal and is also targeted to synaptic vesicles. Amino acid substitutions within the synaptic vesicle targeting signal either enhance or inhibit sorting of VAMP to synaptic vesicles, but do not affect the ability of VAMP to form complexes with syntaxin and SNAP-25.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	GROTE, E (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.				NIDDK NIH HHS [DK33937, DK09878] Funding Source: Medline; NIGMS NIH HHS [GM51313] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009878, R01DK033937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051313] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HERMAN GA, 1994, P NATL ACAD SCI USA, V91, P12750, DOI 10.1073/pnas.91.26.12750; HOLTZMAN E, 1971, SCIENCE, V173, P733, DOI 10.1126/science.173.3998.733; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; JAHN R, 1993, J NEUROCHEM, V61, P12, DOI 10.1111/j.1471-4159.1993.tb03533.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MULLER SR, 1990, DNA CELL BIOL, V9, P221, DOI 10.1089/dna.1990.9.221; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TRIMBLE WS, 1993, J PHYSL, V87, P10; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WIEDENMANN B, 1988, FEBS LETT, V240, P71, DOI 10.1016/0014-5793(88)80342-9; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	36	139	139	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					581	589		10.1016/0092-8674(95)90079-9	http://dx.doi.org/10.1016/0092-8674(95)90079-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758112	Bronze			2022-12-28	WOS:A1995QZ71000015
J	KELLER, HR; MAGGIORINI, M; BARTSCH, P; OELZ, O				KELLER, HR; MAGGIORINI, M; BARTSCH, P; OELZ, O			SIMULATED DESCENT V DEXAMETHASONE IN TREATMENT OF ACUTE MOUNTAIN-SICKNESS - A RANDOMIZED TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH-ALTITUDE ILLNESS	Objective-Evaluation and comparison of the therapeutic efficacy of a portable hyperbaric chamber and dexamethasone in the treatment of acute mountain sickness. Design-Randomised trial during the summer mountaineering season. Setting-High altitude research laboratory in the Capanna Regina Margherita at 4559m above sea level (Alps Valais). Subjects-31 climbers with symptoms of acute mountain sickness randomly assigned to different treatments. Interventions-One hour of treatment in the hyperbaric chamber at a pressure of 193 mbar or oral administration of 8mg dexamethasone initially, followed by 4mg after 6 hours. Main outcome measures-Symptoms of acute mountain sickness (Lake Louise score, clinical score, and AMS-C score) before one and about 11 hours after beginning the different methods of treatment. Permitted intake of mild analgesics before treatment and in the follow up period. Results-After one hour of treatment compression with 193 mbar caused a significantly greater relief of symptoms of acute mountain sickness than dexamethasone (Lake Louise score: mean (SD) -4.6 (1.9) v -2.5 (1.8); clinical score: -4.0 (1.2) v -1.5 (1.4); AMS-C score: -1.24 (0.51) v -0.54 (0.59)). In contrast after about 11 hours subjects treated with dexamethasone suffered from significantly less severe acute mountain sickness than subjects treated with the hyperbaric chamber (-7.0 (3.6) v -1.6 (3.0); -4.1 (1.9) v -1.0 (1.5); -1.78 (0.73) v -0.75 (0.82) respectively). Intake of analgesics was similar in both groups. Conclusion-Both methods were efficient in treatment of acute mountain sickness. One hour of compression with 193 mbar in the hyperbaric chamber, corresponding to a descent of 2250 m, led to short term improvement but had no long term beneficial effect. On the other hand, treatment with dexamethasone in an oral dose of 8mg initially followed by 4mg every 6 hours resulted in a longer term clinical improvement. For optimal efficacy the two methods should be combined if descent or evacuation is not possible.	STADTSPITAL TRIEMLI, DEPT MED, MED KLIN, CH-8063 ZURICH, SWITZERLAND; UNIV HEIDELBERG, MED CLIN, HEIDELBERG, GERMANY; UNIV ZURICH HOSP, DEPT MED, CH-8091 ZURICH, SWITZERLAND; UNIV ZURICH, ZURICH, SWITZERLAND	Triemli Hospital; Ruprecht Karls University Heidelberg; University of Zurich; University Zurich Hospital; University of Zurich				Maggiorini, Marco/0000-0001-8180-2117				[Anonymous], 1981, LANCET, V1, P180; BARTSCH P, 1992, SCHWEIZ MED WSCHR, V122, P307; BARTSCH P, 1990, LANCET, V336, P772, DOI 10.1016/0140-6736(90)93240-P; BARTSCH P, 1993, BRIT MED J, V306, P1098, DOI 10.1136/bmj.306.6885.1098; Bartsch P., 1990, HYPOXIA ADAPTATIONS, P241; BURKI NK, 1992, CHEST, V101, P736, DOI 10.1378/chest.101.3.736; FERRAZZINI G, 1987, BRIT MED J, V294, P1380, DOI 10.1136/bmj.294.6584.1380; FORWAND SA, 1968, NEW ENGL J MED, V279, P839, DOI 10.1056/NEJM196810172791601; GAMOW RI, 1990, J WILDERNESS MED, V1, P165, DOI 10.1580/0953-9859-1.3.165; HACKETT PH, 1981, RESP PHYSIOL, V46, P383, DOI 10.1016/0034-5687(81)90133-X; HACKETT PH, 1988, AVIAT SPACE ENVIR MD, V59, P950; HARRY JP, 1992, INT J SPORTS MED, V13, P83; HOUSTON CS, 1975, LANCET, V2, P758; JOHNSON TS, 1984, NEW ENGL J MED, V310, P683, DOI 10.1056/NEJM198403153101103; JOHNSON TS, 1988, NEW ENGL J MED, V319, P841, DOI 10.1056/NEJM198809293191306; KING SJ, 1990, J WILDERNESS MED, V1, P193, DOI 10.1580/0953-9859-1.3.193; MAGGIORINI M, 1990, BRIT MED J, V301, P853, DOI 10.1136/bmj.301.6756.853; ROCK PB, 1989, CHEST, V95, P568, DOI 10.1378/chest.95.3.568; SAMPSON JB, 1983, AVIAT SPACE ENVIR MD, V54, P1063; STAMPER DA, 1980, AVIAT SPACE ENVIR MD, V51, P379; Sutton J., 1992, HYPOXIA MOUNTAIN MED, P327	21	34	35	2	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	1995	310	6989					1232	1235		10.1136/bmj.310.6989.1232	http://dx.doi.org/10.1136/bmj.310.6989.1232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767194	Green Published			2022-12-28	WOS:A1995QY87700018
J	FEANY, MB; QUINN, WG				FEANY, MB; QUINN, WG			A NEUROPEPTIDE GENE DEFINED BY THE DROSOPHILA MEMORY MUTANT AMNESIAC	SCIENCE			English	Article							STIMULATES ADENYLATE-CYCLASE; SUBSTANCE-P-LIKE; IMMUNOREACTIVE NEURONS; MOLECULAR-CLONING; INITIATION CODON; LEARNING MUTANT; CDNA CLONES; MELANOGASTER; RUTABAGA; DUNCE	Mutations in genes required for associative learning and memory in Drosophila exist, but isolation of the genes has been difficult because most are defined by a single, chemically induced allele. Here, a simplified genetic screen was used to identify candidate genes involved in learning and memory. Second site suppressors of the dunce (dnc) female sterility phenotype were isolated with the use of transposon mutagenesis. One suppressor mutation that was recovered mapped in the amnesiac (amn) gene. Cloning of the locus revealed that amn encodes a previously uncharacterized neuropeptide gene. Thus, with the cloning of amn, specific neuropeptides are implicated in the memory process.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	FEANY, MB (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E25-618,CAMBRIDGE,MA 02139, USA.			Feany, Mel/0000-0003-0315-7970				ACEVESPINA EO, 1983, COLD SPRING HARB SYM, V48, P831, DOI 10.1101/SQB.1983.048.01.086; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BELLEN HJ, 1987, DEV BIOL, V121, P432, DOI 10.1016/0012-1606(87)90180-1; BELLEN HJ, 1992, GENE DEV, V6, P2125, DOI 10.1101/gad.6.11.2125; BELLEN HJ, 1988, ROUX ARCH DEV BIOL, V197, P258, DOI 10.1007/BF00380019; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; DUDAI Y, 1984, NEUROSCI LETT, V47, P119, DOI 10.1016/0304-3940(84)90416-6; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; ENGLES WR, 1985, FOCUS, V8, P6; FEANY MB, 1990, P NATL ACAD SCI USA, V87, P2795, DOI 10.1073/pnas.87.7.2795; FEANY MB, UNPUB; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; HAMILTON BA, 1991, NUCLEIC ACIDS RES, V19, P1951, DOI 10.1093/nar/19.8.1951; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HEINKOFF S, 1987, METHOD ENZYMOL, V154, P156; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; LEE CS, 1987, GENETICS, V116, P55; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; LUNDQUIST T, 1990, J COMP NEUROL, V294, P161, DOI 10.1002/cne.902940202; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; NASSEL DR, 1990, BRAIN RES, V507, P225, DOI 10.1016/0006-8993(90)90276-H; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; OGI K, 1990, BIOCHEM BIOPH RES CO, V173, P1271, DOI 10.1016/S0006-291X(05)80924-6; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; QIU YH, 1991, J MOL BIOL, V222, P553, DOI 10.1016/0022-2836(91)90496-S; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGIHARA H, 1990, J BIOL CHEM, V265, P21714; TULLY T, 1986, J NEUROGENET, V3, P33, DOI 10.3109/01677068609106893; TULLY T, 1990, COLD SH Q B, V55, P203; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7	39	227	232	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					869	873		10.1126/science.7754370	http://dx.doi.org/10.1126/science.7754370			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754370				2022-12-28	WOS:A1995QX85000037
J	BERGMANN, OJ; ELLERMANNERIKSEN, S; MOGENSEN, SC; ELLEGAARD, J				BERGMANN, OJ; ELLERMANNERIKSEN, S; MOGENSEN, SC; ELLEGAARD, J			ACYCLOVIR GIVEN AS PROPHYLAXIS AGAINST ORAL ULCERS IN ACUTE MYELOID-LEUKEMIA - RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HERPES-SIMPLEX VIRUS; IMMUNOCOMPROMISED PATIENTS; HEMATOLOGIC MALIGNANCIES; MARROW TRANSPLANTATION; INFECTIONS; LEUKEMIA; ADULTS	Objectives-To evaluate (a) the prophylactic effect of the antiherpetic drug acyclovir on oral ulcers in patients with acute myeloid leukaemia receiving remission induction chemotherapy and thus (b), indirectly, the role of herpes simplex virus in the aetiology of these ulcers. Design-Randomised, double blind, placebo controlled trial. Subjects-74 herpes simplex virus seropositive patients aged 18-84. Thirty seven patients received acyclovir (800 mg by mouth daily) and 37 placebo. The patients were examined daily for 28 days. Main outcome measures-Occurrence of herpes labialis, intraoral ulcers, and acute necrotising ulcerative gingivitis. Results-The two populations were comparable in age, sex, type of antineoplastic treatment, and history of herpes labialis. Acute oral infections occurred in 25 of the acyclovir treated patients and 36 of the placebo treated patients (relative risk 0.69 (95% confidence interval 0.55 to 0.87)). This difference was due to a reduction in the incidence of herpes labialis (one case versus eight cases; relative risk 0.13 (0.02 to 0.95)), intraoral ulcers excluding the soft palate (one case versus 13 cases; relative risk 0.08 (0.01 to 0.56)), and acute necrotising ulcerative gingivitis (one case versus eight cases; relative risk 0.13 (0.02 to 0.95)). However, ulcers on the soft palate were diagnosed with similar frequency in the two groups. Isolation of herpes simplex virus type 1 in saliva was reduced from 15 cases in the placebo group to one case in the acyclovir group (relative risk 0.07 (0.01 to 0.48)). Conclusion-Intraoral ulcers excluding the soft palate are most often due to infection with herpes simplex virus, whereas ulcers on the soft palate have a non-herpetic aetiology. The findings suggest that acute necrotising ulcerative gingivitis may also be due to herpes simplex virus. Prophylaxis with acyclovir should be considered for patients with acute myeloid leukaemia during remission induction therapy.	AARHUS UNIV, DEPT MED MICROBIOL & IMMUNOL, AARHUS, DENMARK	Aarhus University	BERGMANN, OJ (corresponding author), AARHUS UNIV HOSP, AMTSSYGEHUSET, DEPT MED & HAEMATOL, DK-8000 AARHUS, DENMARK.							AXELL T, 1976, ODONTOLOGISK REV S36, V27; BERGMANN OJ, 1988, J CLIN MICROBIOL, V26, P2105, DOI 10.1128/JCM.26.10.2105-2109.1988; BERGMANN OJ, 1991, SCAND J INFECT DIS, V23, P355, DOI 10.3109/00365549109024323; BERGMANN OJ, 1992, DAN MED BULL, V39, P15; BERGMANN OJ, 1990, EUR J CLIN MICROBIOL, V9, P184, DOI 10.1007/BF01963835; BERGMANN OJ, 1989, EUR J CLIN MICROBIOL, V8, P207, DOI 10.1007/BF01965262; BERGMANN OJ, 1992, J CLIN PERIODONTOL, V19, P169, DOI 10.1111/j.1600-051X.1992.tb00634.x; GLUCKMAN E, 1983, LANCET, V2, P706; HANN IM, 1983, BMJ-BRIT MED J, V287, P384, DOI 10.1136/bmj.287.6389.384; JOHNSEN HE, 1989, DAN MED BULL, V36, P189; JOHNSON BD, 1986, J PERIODONTOL, V57, P141, DOI 10.1902/jop.1986.57.3.141; LONNQVIST B, 1993, SUPPORT CARE CANCER, V1, P139, DOI 10.1007/BF00366060; LUNDGREN G, 1985, SCAND J INFECT DIS, P137; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; PINDBORG JJ, 1951, ODONTOL TIDSKR, V59, P405; ROEDPETE.B, 1969, ACTA ODONTOL SCAND, V27, P681, DOI 10.3109/00016356909026317; SARAL R, 1983, ANN INTERN MED, V99, P773, DOI 10.7326/0003-4819-99-6-773; Siegel S., 1988, NONPARAMETRIC STAT B; WADE JC, 1984, ANN INTERN MED, V100, P823, DOI 10.7326/0003-4819-100-6-823	19	33	34	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 6	1995	310	6988					1169	1172		10.1136/bmj.310.6988.1169	http://dx.doi.org/10.1136/bmj.310.6988.1169			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767151	Green Published			2022-12-28	WOS:A1995QX56600022
J	SIMPSON, J				SIMPSON, J			MANAGEMENT FOR DOCTORS .1. DOCTORS AND MANAGEMENT - WHY BOTHER	BRITISH MEDICAL JOURNAL			English	Article											SIMPSON, J (corresponding author), BARNES HOSP,BRITISH ASSOC MED MANAGERS,CHEADLE SK8 2NY,CHESHIRE,ENGLAND.							DRUCKER P, 1986, EFFECTIVE EXECUTIVE, P138; HANDY C, 1985, AGE UNREASON, P106; MINTZBERG H, 1988, CONCEPTS CONTEXTS CA, P638; PETERS T, 1986, PASSION EXCELLENCE, P263; 1983, REPORT; 1993, MANAGING CLIN SERVIC	6	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 3	1994	309	6967					1505	1508		10.1136/bmj.309.6967.1505	http://dx.doi.org/10.1136/bmj.309.6967.1505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW053	7755707	Green Published			2022-12-28	WOS:A1994PW05300039
J	VICHINSKY, EP; HABERKERN, CH; NEUMAYR, L; EARLES, AN; BLACK, D; KOSHY, M; PEGELOW, C; ABBOUD, M; OHENEFREMPONG, K; IYER, RV; NAGEL, R; JOHNSON, R; SEARS, D; WONG, M; PARKE, J; BRAY, G; HURST, D; KOBLENZ, L; VICHINSKY, E; DEALARCON, P; GROSSI, M; WALDRON, P; WALTERS, M; RUSSO, C; MURPHY, S; SMITH, H; WOODS, G; GUARINI, L; HURLET, A; PIOMELLI, S; KINNEY, T; PHILLIPS, G; DAESCHNER, C; HOLBROOK, T; BUCHANAN, I; ECKMAN, J; CLASTER, S; HUME, H; OLIVERI, N; BELLEVUE, R; MANKAD, V; WANG, W; MILNER, P; JACKSON, S; BENJAMIN, L; BESTAK, M; RADEL, E; BARUCHEL, S; ESSENTINE, D; BLEI, F; EMBURY, S; MENTZER, W; GILLETTE, P; MILLER, S; RAO, S; GROVER, R; RAMIREZ, G; WETHERS, D; GLADER, B; JENNINGS, W; RUCKNAGEL, D; KALINYAK, K; LANE, P; TALISCHY, N; IYER, R; STEINBERG, M; COOPER, H; ORRINGER, E; MANKAD, V; YANG, Y; JOHNSON, C; POWARS, D				VICHINSKY, EP; HABERKERN, CH; NEUMAYR, L; EARLES, AN; BLACK, D; KOSHY, M; PEGELOW, C; ABBOUD, M; OHENEFREMPONG, K; IYER, RV; NAGEL, R; JOHNSON, R; SEARS, D; WONG, M; PARKE, J; BRAY, G; HURST, D; KOBLENZ, L; VICHINSKY, E; DEALARCON, P; GROSSI, M; WALDRON, P; WALTERS, M; RUSSO, C; MURPHY, S; SMITH, H; WOODS, G; GUARINI, L; HURLET, A; PIOMELLI, S; KINNEY, T; PHILLIPS, G; DAESCHNER, C; HOLBROOK, T; BUCHANAN, I; ECKMAN, J; CLASTER, S; HUME, H; OLIVERI, N; BELLEVUE, R; MANKAD, V; WANG, W; MILNER, P; JACKSON, S; BENJAMIN, L; BESTAK, M; RADEL, E; BARUCHEL, S; ESSENTINE, D; BLEI, F; EMBURY, S; MENTZER, W; GILLETTE, P; MILLER, S; RAO, S; GROVER, R; RAMIREZ, G; WETHERS, D; GLADER, B; JENNINGS, W; RUCKNAGEL, D; KALINYAK, K; LANE, P; TALISCHY, N; IYER, R; STEINBERG, M; COOPER, H; ORRINGER, E; MANKAD, V; YANG, Y; JOHNSON, C; POWARS, D			A COMPARISON OF CONSERVATIVE AND AGGRESSIVE TRANSFUSION REGIMENS IN THE PERIOPERATIVE MANAGEMENT OF SICKLE-CELL DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTOPERATIVE PULMONARY COMPLICATIONS; BLOOD-TRANSFUSION; ELECTIVE CHOLECYSTECTOMY; INCENTIVE SPIROMETRY; GENERAL-ANESTHESIA; ABDOMINAL-SURGERY; RISK-FACTORS; ANEMIA; CHILDREN; THERAPY	Background. Preoperative transfusions are frequently given to prevent perioperative morbidity in patients with sickle cell anemia. There is no consensus, however, on the best regimen of transfusions for this purpose. Methods. We conducted a multicenter study to compare the rates of perioperative complications among patients randomly assigned to receive either an aggressive transfusion regimen designed to decrease the hemoglobin S level to less than 30 percent (group 1) or a conservative regimen designed to increase the hemoglobin level to 10 g per deciliter (group 2). Results. Patients undergoing a total of 604 operations were randomly assigned to group 1 or group 2. The severity of the disease, compliance with the protocol, and the types of operations were similar in the two groups. The preoperative hemoglobin level was 11 g per deciliter in group 1 and 10.6 g per deciliter in group 2. The preoperative value for hemoglobin S was 31 percent in group 1 and 59 percent in group 2. The most frequent operations were cholecystectomies (232), head and neck surgery (156), and orthopedic surgery (72). With the exception of transfusion-related complications, which occurred in 14 percent of the operations in group 1 and in 7 percent of those in group 2, the frequency of serious complications was similar in the two groups (31 percent in group 1 and 35 percent in group 2). The acute chest syndrome developed in 10 percent of both groups and resulted in two deaths in group 1. A history of pulmonary disease and a higher risk associated with surgery were significant predictors of the acute chest syndrome. Conclusions. A conservative transfusion regimen was as effective as an aggressive regimen in preventing perioperative complications in patients with sickle cell anemia, and the conservative approach resulted in only half as many transfusion-associated complications.	UNIV WASHINGTON, DEPT ANESTHESIA, SEATTLE, WA USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; CHILDRENS HOSP & MED CTR, SEATTLE, WA 98105 USA; UNIV CALIF SAN FRANCISCO, PREVENT SCI GRP, SAN FRANCISCO, CA USA; UNIV ILLINOIS, DEPT MED, CHICAGO, IL USA; UNIV MIAMI, DEPT PEDIAT, MIAMI, FL 33152 USA; MED UNIV S CAROLINA, DEPT PEDIAT, CHARLESTON, SC 29425 USA; CHILDRENS HOSP, DEPT HEMATOL, PHILADELPHIA, PA USA; UNIV MISSISSIPPI, DEPT PEDIAT HEMATOL, JACKSON, MS USA; ALBERT EINSTEIN COLL MED, BRONX, NY 10467 USA; ALTA BATES COMMUNITY HOSP, BERKELEY, CA USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; BRONX LEBANON HOSP CTR, BRONX, NY USA; CAROLINAS MED CTR, CHARLOTTE, NC 28203 USA; CHILDRENS HOSP, NATL MED CTR, WASHINGTON, DC 20010 USA; CHILDRENS HOSP BUFFALO, BUFFALO, NY USA; CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP, SEATTLE, WA USA; CHILDRENS MEM HOSP, CHICAGO, IL 60614 USA; CHILDRENS MERCY HOSP, KANSAS CITY, MO 64108 USA; COLUMBIA PRESBYTERIAN MED CTR, NEW YORK, NY 10032 USA; DUKE UNIV, MED CTR, DURHAM, NC USA; E CAROLINA UNIV, GREENVILLE, NC 27834 USA; EMORY UNIV, ATLANTA, GA 30322 USA; HIGHLAND HOSP, OAKLAND, CA USA; HOP ST JUSTINE, MONTREAL, PQ H3T 1C5, CANADA; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; INTERFAITH MED CTR, BROOKLYN, NY USA; LEBONHEUR CHILDRENS HOSP & MED CTR, MEMPHIS, TN USA; MED COLL GEORGIA, AUGUSTA, GA 30912 USA; MONTEFIORE HOSP, BRONX, NY USA; MONTREAL CHILDRENS HOSP, MONTREAL, PQ H3H 1P3, CANADA; NYU, MED CTR, NEW YORK, NY 10016 USA; SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA; SUNY HLTH SCI CTR, BROOKLYN, NY 11203 USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY 10025 USA; STANFORD UNIV, CHILDRENS HOSP, STANFORD, CA USA; TRUMAN MED CTR, KANSAS CITY, MO USA; UNIV CINCINNATI, CINCINNATI, OH USA; UNIV COLORADO, DENVER, CO 80202 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; UNIV SO ALABAMA, MOBILE, AL 36688 USA; UNIV SO CALIF, MED CTR, LOS ANGELES, CA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of California System; University of California San Francisco; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Miami; Medical University of South Carolina; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Mississippi; Yeshiva University; Albert Einstein College of Medicine; Baylor College of Medicine; BronxCare Health System; Carolinas Medical Center; Children's National Health System; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Seattle Children's Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Children's Mercy Hospital; Columbia University; NewYork-Presbyterian Hospital; Duke University; University of North Carolina; East Carolina University; Emory University; Universite de Montreal; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University System of Georgia; Augusta University; McGill University; New York University; San Francisco General Hospital Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Mount Sinai St. Luke's; Mount Sinai West; Children's Hospital Los Angeles; Stanford University; University System of Ohio; University of Cincinnati; University of Colorado System; University of Colorado Denver; University of North Carolina; University of North Carolina Chapel Hill; University of South Alabama; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California	VICHINSKY, EP (corresponding author), CHILDRENS HOSP OAKLAND, DEPT HEMATOL ONCOL, 747 52ND ST, OAKLAND, CA 94609 USA.		Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579	NHLBI NIH HHS [HL-20985] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACURIO MT, 1992, J BONE JOINT SURG BR, V74, P367, DOI 10.1302/0301-620X.74B3.1587879; AMBRUSO DR, 1987, TRANSFUSION, V27, P94, DOI 10.1046/j.1537-2995.1987.27187121485.x; ANDERSON R, 1963, ARCH INTERN MED, V111, P286, DOI 10.1001/archinte.1963.03620270012003; BERTRAM RA, 1985, UROLOGY, V26, P229, DOI 10.1016/0090-4295(85)90115-3; BHATTACHARYYA N, 1993, J PEDIATR SURG, V28, P72, DOI 10.1016/S0022-3468(05)80359-8; BOND LR, 1987, BRIT MED J, V295, P234, DOI 10.1136/bmj.295.6592.234; BRODY JI, 1970, ANN INTERN MED, V72, P327, DOI 10.7326/0003-4819-72-3-327; BROWNE RA, 1965, BRIT J ANAESTH, V37, P181, DOI 10.1093/bja/37.3.181; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; CELLI BR, 1984, AM REV RESPIR DIS, V130, P12; CHARACHE S, 1983, AM J MED, V74, P757, DOI 10.1016/0002-9343(83)91063-X; CHARACHE S, 1992, MANAGEMENT THERAPY S, P25; CHARACHE S, 1992, MANAGEMENT THERAPY S, P49; CLARKE HJ, 1989, J BONE JOINT SURG BR, V71, P465, DOI 10.1302/0301-620X.71B3.2722941; COHEN AR, 1992, BLOOD, V79, P1657; COHEN DE, 1989, MAR M AM AC PED ORL, P16; COHEN MM, 1988, JAMA-J AM MED ASSOC, V260, P2859, DOI 10.1001/jama.260.19.2859; COHEN MM, 1988, J CLIN EPIDEMIOL, V41, P83, DOI 10.1016/0895-4356(88)90012-1; COKER NJ, 1982, ARCH OTOLARYNGOL, V108, P574; CUNNINGHAM FG, 1983, OBSTET GYNECOL, V62, P419; DERKAY CS, 1991, SOUTHERN MED J, V84, P205, DOI 10.1097/00007611-199102000-00013; ENGBERG G, 1988, ACTA ANAESTH SCAND, V32, P1, DOI 10.1111/j.1399-6576.1988.tb02676.x; Fliess JL, 1986, DESIGN ANAL CLIN EXP; FULLERTON MW, 1981, J PEDIATR SURG, V16, P297, DOI 10.1016/S0022-3468(81)80683-5; GILBERTSON AA, 1965, BRIT J ANAESTH, V37, P614, DOI 10.1093/bja/37.8.614; GRACEY DR, 1979, CHEST, V76, P123, DOI 10.1378/chest.76.2.123; GRIFFIN TC, 1993, J PEDIATR SURG, V28, P681, DOI 10.1016/0022-3468(93)90031-F; GROSS ML, 1993, AM SURGEON, V59, P261; HEWITT PE, 1988, BRIT J HAEMATOL, V69, P541, DOI 10.1111/j.1365-2141.1988.tb02412.x; HOLZMANN L, 1969, ANESTH ANAL CURR RES, V48, P566; HOMI J, 1979, BMJ-BRIT MED J, V1, P1599, DOI 10.1136/bmj.1.6178.1599; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JACKSON CV, 1988, ARCH INTERN MED, V148, P2120, DOI 10.1001/archinte.148.10.2120; JAN K, 1982, TRANSFUSION, V22, P17, DOI 10.1046/j.1537-2995.1982.22182154208.x; JANIK J, 1980, J PEDIATR SURG, V15, P117, DOI 10.1016/S0022-3468(80)80001-7; JAYR C, 1988, SURGERY, V104, P57; KINNEY TR, 1990, J PEDIATR-US, V117, P194, DOI 10.1016/S0022-3476(05)80529-3; KOSHY M, 1988, NEW ENGL J MED, V319, P1447, DOI 10.1056/NEJM198812013192204; KOSHY M, 1993, 18TH NAT SICKL CELL, pA46; LAGARDE MC, 1978, J PEDIATR SURG, V13, P605, DOI 10.1016/S0022-3468(78)80101-8; LANZKOWSKY P, 1978, AM J DIS CHILD, V132, P1206, DOI 10.1001/archpedi.1978.02120370058013; Lessin L S, 1978, Prog Clin Biol Res, V20, P123; LUBAN NLC, 1984, ADV ANESTHESIA, P289; MALLOUH AA, 1988, AM J DIS CHILD, V142, P178, DOI 10.1001/archpedi.1988.02150020080034; MILLER DM, 1980, BLOOD, V56, P1127; MILLER ST, 1989, ANN NY ACAD SCI, V565, P435, DOI 10.1111/j.1749-6632.1989.tb24216.x; MILLER ST, 1992, J PEDIATR-US, V120, P54, DOI 10.1016/S0022-3476(05)80597-9; MILNER PF, 1991, NEW ENGL J MED, V325, P1476, DOI 10.1056/NEJM199111213252104; MORRISON JC, 1978, AM J OBSTET GYNECOL, V132, P59, DOI 10.1016/0002-9378(78)90799-8; MURPHY JR, 1976, J LAB CLIN MED, V87, P475; ODUNTAN SA, 1971, BRIT J ANAESTH, V43, P1159, DOI 10.1093/bja/43.12.1159; ODURO KA, 1972, BRIT MED J, V4, P596, DOI 10.1136/bmj.4.5840.596; ODURO KA, 1969, ANAESTHESIA, V24, P307, DOI 10.1111/j.1365-2044.1969.tb02869.x; PEARSON HA, 1970, NEW ENGL J MED, V283, P334, DOI 10.1056/NEJM197008132830703; PEGELOW CH, 1995, J PEDIATR-US, V126, P896, DOI 10.1016/S0022-3476(95)70204-0; PFLUG AE, 1974, ANESTHESIOLOGY, V41, P8, DOI 10.1097/00000542-197407000-00003; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; RICKSTEN SE, 1986, CHEST, V89, P774, DOI 10.1378/chest.89.6.774; ROSENBAU.JM, 1965, ARCHIV OTOLARYNGOL, V82, P307; ROUKEMA JA, 1988, ARCH SURG-CHICAGO, V123, P30; RUTLEDGE R, 1986, SOUTHERN MED J, V79, P28, DOI 10.1097/00007611-198601000-00009; SCHMALZER EA, 1987, TRANSFUSION, V27, P228, DOI 10.1046/j.1537-2995.1987.27387235626.x; SCHUBERT TT, 1986, GASTROENTEROLOGY, V90, P2013, DOI 10.1016/0016-5085(86)90276-3; Scott-Conner Carol E. H., 1994, P809; SEARLE JF, 1973, ANAESTHESIA, V28, P48, DOI 10.1111/j.1365-2044.1973.tb00284.x; SHAPIRO ND, 1955, ANESTHESIOLOGY, V16, P771, DOI 10.1097/00000542-195509000-00017; SOLANKI DL, 1979, AM J MED SCI, V277, P319, DOI 10.1097/00000441-197905000-00011; SPENCE AA, 1971, BRIT J ANAESTH, V43, P144, DOI 10.1093/bja/43.2.144; SPIGELMAN A, 1972, ARCH SURG-CHICAGO, V104, P761; STEIN M, 1970, J AMER MED ASSOC, V211, P787, DOI 10.1001/jama.211.5.787; STEPHENS CG, 1980, ARCH INTERN MED, V140, P648, DOI 10.1001/archinte.140.5.648; STOCK MC, 1985, CHEST, V87, P151, DOI 10.1378/chest.87.2.151; STRANDBERG A, 1986, ACTA ANAESTH SCAND, V30, P154, DOI 10.1111/j.1399-6576.1986.tb02387.x; STYLES LA, 1994, J PEDIATR-US, V125, P909, DOI 10.1016/S0022-3476(05)82006-2; SUTTON JP, 1992, SICKLE CELL DISEASE, P364; TAGGE EP, 1994, J PEDIATR SURG, V29, P209, DOI 10.1016/0022-3468(94)90320-4; TAHHAN HR, 1994, TRANSFUSION, V34, P562, DOI 10.1046/j.1537-2995.1994.34794330008.x; TIRET L, 1986, CAN J ANAESTH, V33, P336, DOI 10.1007/BF03010747; TISI GM, 1979, AM REV RESPIR DIS, V119, P293; TISI GM, 1987, MED CLIN N AM, V71, P399, DOI 10.1016/S0025-7125(16)30848-3; Vichinsky Elliott, 1994, P781; VICHINSKY EP, 1991, SEMIN HEMATOL, V28, P220; VICHINSKY EP, 1990, NEW ENGL J MED, V322, P1617, DOI 10.1056/NEJM199006073222301; VODINH J, 1989, SURGERY, V105, P360; WALKER RH, 1990, TECHNICAL MANUAL, P269; WARE R, 1988, ANN SURG, V208, P17, DOI 10.1097/00000658-198807000-00003; WARE RE, 1992, J PEDIATR-US, V120, P58, DOI 10.1016/S0022-3476(05)80598-0; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1994, BLOOD S1, V84, pA219	90	381	390	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					206	213		10.1056/NEJM199507273330402	http://dx.doi.org/10.1056/NEJM199507273330402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791837				2022-12-28	WOS:A1995RK42300002
J	YOKOKAWA, K; MANKUS, R; SAKLAYEN, MG; KOHNO, M; YASUNARI, K; MINAMI, M; KANO, H; HORIO, T; TAKEDA, T; MANDEL, AK				YOKOKAWA, K; MANKUS, R; SAKLAYEN, MG; KOHNO, M; YASUNARI, K; MINAMI, M; KANO, H; HORIO, T; TAKEDA, T; MANDEL, AK			INCREASED NITRIC-OXIDE PRODUCTION IN PATIENTS WITH HYPOTENSION DURING HEMODIALYSIS	ANNALS OF INTERNAL MEDICINE			English	Note							ENDOTHELIN; UREMIA	Objective: To determine the involvement of nitric oxide production in hemodialysis-induced hypotension. Design: Examination of nitric oxide synthesis, cyclic guanosine 3'5'-monophosphate (cGMP) levels, and endothelin-1 levels in plasma before and after hemodialysis. Setting: Veterans Affairs medical center. Patients: 13 patients with end-stage renal failure who were receiving hemodialysis: Six patients had hypotensive episodes during dialysis and 7 did not. Intervention: Patients received heparin at a bolus dose of 2000 U at the initiation of dialysis followed by 1000 U/h during 4-hour hemodialysis sessions. Results: Nitric oxide production markedly increased during hemodialysis-induced hypotensive episodes; this increase was not seen in patients who did not have a hypotensive episode. In both groups, the plasma cGMP and endothelin-1 levels decreased after hemodialysis. According to multiple regression analysis, standard coefficients of nitric oxide production, plasma cGMP levels, and endothelin-1 levels with mean blood pressure after hemodialysis were -0.743, -0.07, and 0.31, respectively. Conclusion: Nitric oxide production increased in patients who had a hypotensive episode during hemodialysis but did not increase in those who did not have a hypotensive episode.	WRIGHT STATE UNIV, DAYTON, OH 45435 USA	University System of Ohio; Wright State University Dayton	YOKOKAWA, K (corresponding author), OSAKA CITY UNIV, SCH MED, DEPT INTERNAL MED 1, ABENO KU, 1-5-7 ASAHI MACHI, OSAKA 545, JAPAN.							ABBOTT EC, 1966, CAN MED ASSOC J, V94, P1155; BEASLEY D, 1992, KIDNEY INT, V42, pS96; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CONVERSE RL, 1992, J CLIN INVEST, V90, P1657, DOI 10.1172/JCI116037; KOHNO M, 1990, AM J MED, V88, P614, DOI 10.1016/0002-9343(90)90527-K; KOYAMA H, 1989, LANCET, V1, P991; LETTGEN B, 1992, PEDIATR NEPHROL, V6, P60, DOI 10.1007/BF00856837; NORIS M, 1993, KIDNEY INT, V44, P445, DOI 10.1038/ki.1993.264; REA RF, 1993, J CARDIOVASC ELECTR, V4, P587, DOI 10.1111/j.1540-8167.1993.tb01246.x; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213; YOKOKAWA K, 1993, J CLIN INVEST, V92, P2080, DOI 10.1172/JCI116805	12	108	109	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					35	37		10.7326/0003-4819-123-1-199507010-00005	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762912				2022-12-28	WOS:A1995RE66500006
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PUBLIC HEARING ON FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1994, JAMA-J AM MED ASSOC, V272, P1160	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RE354	7783288				2022-12-28	WOS:A1995RE35400008
J	KATSUYA, T; KOIKE, G; YEE, TW; SHARPE, N; JACKSON, R; NORTON, R; HORIUCHI, M; PRATT, RE; DZAU, VJ; MACMAHON, S				KATSUYA, T; KOIKE, G; YEE, TW; SHARPE, N; JACKSON, R; NORTON, R; HORIUCHI, M; PRATT, RE; DZAU, VJ; MACMAHON, S			ASSOCIATION OF ANGIOTENSINOGEN GENE T235 VARIANT WITH INCREASED RISK OF CORONARY HEART-DISEASE	LANCET			English	Article							CONVERTING ENZYME; MYOCARDIAL-INFARCTION; DELETION POLYMORPHISM; CARDIOMYOPATHY; HYPERTENSION	Several genes, including some encoding components of the renin angiotensin system, are associated with the risk of cardiovascular diseases. There have been reports linking a homozygous deletion allele of the angiotensin converting enzyme (ACE) gene (DD) with an increased myocardial infarction, some variants and angiotensinogen gene with hypertension. In a case-control study of a caucasian population from New Zealand, we examined the associations with coronary heart disease (CHD) of ACE DD and of a mis-sense mutation with methionine to threonine aminoacid substitution at codon 235 in the angiotensinogen gene ( T235). We studied 422 patients (mean age 62 years, 81% male) with documented CHD (50% with myocardial infarction) and 406 controls without known CHD (frequency-matched to cases by age and sex). Risk factors for CHD were assessed by standard questionnaire, physical examination, and blood tests. Genomic DNA from leucocytes was analysed for various ACE and angiotensinogen alleles. Angiotensinogen T235 homozygotes were at significantly increased risk of CHD generally (odds ratio 1 . 7, 2p=0 . 008) and of myocardial infarction specifically (1 . 8, 2p=0 . 009). Adjustment for several risk factors increased the estimate of CHD risk associated with this allele to 2 . 6 (2p<0 . 001) and the estimate for myocardial infarction risk to 3 . 4 (2p<0 . 001). By contrast, there was no evidence of a significant increase in the risk of CHD or myocardial infarction among individuals with ACE DD. We conclude that the T235 polymorphism of the angiotensinogen gene is an independent risk factor, which carries an approximately two-fold increased risk of CHD. In this study, however, ACE DD was not associated with any detectable increase in CHD risk.	UNIV AUCKLAND,SCH MED,DEPT MED,CLIN TRIALS RES UNIT,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND; STANFORD UNIV,FALK CARDIOVASC RES CTR,DEPT MED,DIV CARDIOVASC MED,STANFORD,CA	University of Auckland; University of Auckland; Stanford University				Yee, Thomas/0000-0002-9970-3907; Jackson, Rod/0000-0001-5914-6934	NHLBI NIH HHS [HL35252, HL35610, HL46631] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035252, R01HL046631, R01HL035610, R37HL035610] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOHN M, 1993, CLIN GENET, V44, P292; BONNARDEAUX A, 1994, HYPERTENSION, V24, P63, DOI 10.1161/01.HYP.24.1.63; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; DZAU VJ, 1993, J HYPERTENS, V11, pS13; EVANS AE, 1994, Q J MED, V87, P211; HARRAP SB, 1994, LANCET, V344, P901, DOI 10.1016/S0140-6736(94)92262-4; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; LINDPAINTNER K, 1995, NEW ENGL J MED, V332, P706, DOI 10.1056/NEJM199503163321103; LINDPAINTNER K, 1993, CLIN RES, V41, P216; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MARIAN AJ, 1993, LANCET, V342, P1085, DOI 10.1016/0140-6736(93)92064-Z; MIETTINEN HE, 1994, HUM GENET, V94, P189; OHISHI M, 1993, NAT GENET, V5, P324, DOI 10.1038/ng1293-324; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RAYNOLDS MV, 1993, LANCET, V342, P1073, DOI 10.1016/0140-6736(93)92061-W; RIGAT B, 1992, NUCLEIC ACIDS RES, V20, P1433, DOI 10.1093/nar/20.6.1433-a; RUSS AP, 1993, HUM MOL GENET, V2, P609, DOI 10.1093/hmg/2.5.609; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; TIRET L, 1994, LANCET, V344, P910, DOI 10.1016/S0140-6736(94)92268-3; TIRET L, 1992, AM J HUM GENET, V51, P197; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; Zhao Y, 1994, HYPERTENS RES, V17, P55	25	282	309	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1600	1603		10.1016/S0140-6736(95)90115-9	http://dx.doi.org/10.1016/S0140-6736(95)90115-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783537	Bronze			2022-12-28	WOS:A1995RE67000008
J	KULKARNI, AG; BRID, NS				KULKARNI, AG; BRID, NS			HERPES-ZOSTER	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											KULKARNI, AG (corresponding author), KRISHNA HOSP & MED RES CTR,KARAD 415110,MAHARASHTRA,INDIA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1684	1684		10.1056/NEJM199506223322505	http://dx.doi.org/10.1056/NEJM199506223322505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760869				2022-12-28	WOS:A1995RD99600005
J	GALLARD, C				GALLARD, C			FEMALE GENITAL MUTILATION IN FRANCE	BRITISH MEDICAL JOURNAL			English	Article											GALLARD, C (corresponding author), FRENCH FAMILY PLANNING ASSOC,4 IRENEE SQ,F-75011 PARIS,FRANCE.							HOSKEN F, 1994, LIVRE IMAGES UNIVERS; 1993, MUTILATIONS SEXUELLE; EXCISION SA PRESENCE	3	25	25	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1592	1593		10.1136/bmj.310.6994.1592	http://dx.doi.org/10.1136/bmj.310.6994.1592			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787655	Green Published			2022-12-28	WOS:A1995RE35300030
J	VINGERLING, JR; DIELEMANS, I; WITTEMAN, JCM; HOFMAN, A; GROBBEE, DE; DEJONG, PTVM				VINGERLING, JR; DIELEMANS, I; WITTEMAN, JCM; HOFMAN, A; GROBBEE, DE; DEJONG, PTVM			MACULAR DEGENERATION AND EARLY MENOPAUSE - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							RISK; DISEASE; WOMEN		ERASMUS UNIV ROTTERDAM,SCH MED,DEPT OPHTHALMOL,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT BIOSTAT & EPIDEMIOL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam			Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; PALMER JR, 1992, AM J EPIDEMIOL, V136, P408, DOI 10.1093/oxfordjournals.aje.a116513; WITTEMAN JCM, 1989, BRIT MED J, V298, P642, DOI 10.1136/bmj.298.6674.642; 1992, ARCH OPHTHALMOL-CHIC, V110, P1701	5	61	65	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1570	1571		10.1136/bmj.310.6994.1570	http://dx.doi.org/10.1136/bmj.310.6994.1570			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787646	Green Published, Green Submitted			2022-12-28	WOS:A1995RE35300020
J	MORSE, D; SALOIS, P; MARKOVIC, P; HASTINGS, JW				MORSE, D; SALOIS, P; MARKOVIC, P; HASTINGS, JW			A NUCLEAR-ENCODED FORM-II RUBISCO IN DINOFLAGELLATES	SCIENCE			English	Article							CHLOROPHYLL-B; EVOLUTION; CARBOXYLASE; ORIGINS; PLASTIDS; PROTEINS; PHYLOGENIES; GENE	The chloroplasts of most dinoflagellates are unusual in that they are surrounded by three membranes and contain the carotenoid peridinin. The ribulose-1,5-bisphosphate carboxylase-oxygenase (RuBisCO) in dinoflagellate chloroplasts was found here to also be unusual. Unlike other eukaryotes, dinoflagellates containing peridinin use a form of RuBisCO (form II) previously found only in some species of proteobacteria. Furthermore, this RuBisCO is not encoded in the chloroplast DNA, as is the case in other organisms, but is encoded by the nuclear DNA. The unusual nature of this enzyme and location of its gene support the idea that dinoflagellate chloroplasts may have had a distinctive evolutionary origin.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University	MORSE, D (corresponding author), UNIV MONTREAL,INST RECH BIOL VEGETALE,MONTREAL,PQ H1X 2B2,CANADA.			Morse, David/0000-0003-4131-4367	NIGMS NIH HHS [2R01-GM-19536] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019536] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; ASSALI NE, 1991, PLANT MOL BIOL, V17, P853, DOI 10.1007/BF00037066; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CAVALIERSMITH T, 1982, BIOL J LINN SOC, V17, P289, DOI 10.1111/j.1095-8312.1982.tb02023.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CORUZZI G, 1983, J BIOL CHEM, V258, P1399; GIBSON JL, 1977, J BIOL CHEM, V252, P943; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; INNI SM, 1990, PCR PROTOCOLS; KANEVSKI I, 1994, P NATL ACAD SCI USA, V91, P1969, DOI 10.1073/pnas.91.5.1969; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAEMMLI UK, 1974, NATURE, V227, P680; LOEBLICH AR, 1976, J PROTOZOOL, V23, P13, DOI 10.1111/j.1550-7408.1976.tb05241.x; MACHABEE S, 1994, PLANT MOL BIOL, V25, P23, DOI 10.1007/BF00024195; MARTIN W, 1992, J MOL EVOL, V35, P385, DOI 10.1007/BF00171817; MILOS P, 1990, NATURWISSENSCHAFTEN, V77, P87, DOI 10.1007/BF01131782; MORDEN CW, 1992, BIOSYSTEMS, V28, P75, DOI 10.1016/0303-2647(92)90010-V; MORDEN CW, 1991, J MOL EVOL, V32, P379, DOI 10.1007/BF02101278; MORSE DC, UNPUB; NARANG F, 1984, MOL GEN GENET, V193, P220; RAVEN PH, 1970, SCIENCE, V169, P641, DOI 10.1126/science.169.3946.641; RITLAND K, 1987, American Naturalist, V130, pS74, DOI 10.1086/284693; SCHULER M, METHODS PLANT MOL BI; TANGEN K, 1981, Journal of Plankton Research, V3, P389, DOI 10.1093/plankt/3.3.389; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE MM, 1987, J PHYCOL, V23, P382, DOI 10.1111/j.1529-8817.1987.tb04148.x; WILCOX LW, 1985, SCIENCE, V227, P192, DOI 10.1126/science.227.4683.192; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443	30	208	220	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1622	1624		10.1126/science.7777861	http://dx.doi.org/10.1126/science.7777861			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777861				2022-12-28	WOS:A1995RD45900039
J	TANENHAUS, MK; SPIVEYKNOWLTON, MJ; EBERHARD, KM; SEDIVY, JC				TANENHAUS, MK; SPIVEYKNOWLTON, MJ; EBERHARD, KM; SEDIVY, JC			INTEGRATION OF VISUAL AND LINGUISTIC INFORMATION IN SPOKEN LANGUAGE COMPREHENSION	SCIENCE			English	Article							PERCEPTION	Psycholinguists have commonly assumed that as a spoken linguistic message unfolds over time, it is initially structured by a syntactic processing module that is encapsulated from information provided by other perceptual and cognitive systems. To test the effects of relevant visual context on the rapid mental processes that accompany spoken language comprehension, eye movements were recorded with a head-mounted eye-tracking system while subjects followed instructions to manipulate real objects. Visual context influenced spoken word recognition and mediated syntactic processing, even during the earliest moments of language processing.	UNIV ROCHESTER, DEPT LINGUIST, ROCHESTER, NY 14627 USA	University of Rochester	TANENHAUS, MK (corresponding author), UNIV ROCHESTER, DEPT BRAIN & COGNIT SCI, 601 ELMWOOD AVE, ROCHESTER, NY 14627 USA.		Galantucci, Bruno/E-5770-2010; Eberhard, Kathleen/B-4346-2008; Eberhard, Kathleen M/A-2542-2014	Eberhard, Kathleen/0000-0002-0764-4541; 	NCRR NIH HHS [1-P41-RR09283] Funding Source: Medline; NICHD NIH HHS [HD27206] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD027206] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR009283] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALTMANN G, 1988, COGNITION, V30, P191, DOI 10.1016/0010-0277(88)90020-0; BALLARD DH, 1995, J COGNITIVE NEUROSCI, V7, P66, DOI 10.1162/jocn.1995.7.1.66; BRITT MA, 1994, J MEM LANG, V33, P251, DOI 10.1006/jmla.1994.1013; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; CLARK H, 1994, ARENAS LANGUAGE USE; CRAIN S, 1985, NATURAL LANGUAGE PAR, P320, DOI DOI 10.1017/CBO9780511597855.011; FERREIRA F, 1986, J MEM LANG, V25, P348, DOI 10.1016/0749-596X(86)90006-9; Fodor J. A, 1983, MODULARITY MIND; FRAZIER L, 1987, ATTENTION PERFORM, P559; Jackendoff R., 1992, LANGUAGES MIND; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MACDONALD MC, 1994, PSYCHOL REV, V101, P676, DOI 10.1037/0033-295X.101.4.676; MARSLENWILSON WD, 1975, SCIENCE, V189, P226, DOI 10.1126/science.189.4198.226; MATIN E, 1993, PERCEPT PSYCHOPHYS, V53, P372, DOI 10.3758/BF03206780; MCCLELLAND JL, 1987, ATTENTION PERFORM, P3; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Pinker Steven, 1994, LANGUAGE INSTINCT; Pollard C., 1993, HEAD DRIVEN PHRASE S; SPIVEYKNOWLTON M, IN PRESS COGNITION; TANENHAUS M, IN PRESS HDB COGNITI; WILSON WM, 1973, NATURE, V244, P522, DOI 10.1038/244522a0	21	1492	1520	5	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1632	1634		10.1126/science.7777863	http://dx.doi.org/10.1126/science.7777863			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RD459	7777863				2022-12-28	WOS:A1995RD45900042
J	KALE, R				KALE, R			SOUTH-AFRICA HEALTH - RESTRUCTURING SOUTH-AFRICA HEALTH-CARE - DILEMMAS FOR PLANNERS	BRITISH MEDICAL JOURNAL			English	Article																		KALE R, 1995, BMJ, V310; VANDERLINDE I, 1994, S AFR MED J, V84, P11	2	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1397	1399		10.1136/bmj.310.6991.1397	http://dx.doi.org/10.1136/bmj.310.6991.1397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787550	Green Published			2022-12-28	WOS:A1995RB00500035
J	LOPEZLOPEZ, JR; SHACKLOCK, PS; BALKE, CW; WIER, WG				LOPEZLOPEZ, JR; SHACKLOCK, PS; BALKE, CW; WIER, WG			LOCAL CALCIUM TRANSIENTS TRIGGERED BY SINGLE L-TYPE CALCIUM-CHANNEL CURRENTS IN CARDIAC-CELLS	SCIENCE			English	Article							PIG VENTRICULAR MYOCYTES; SARCOPLASMIC-RETICULUM; INDUCED RELEASE; CA2+ RELEASE; HEART-CELLS; CONTRACTION; MUSCLE; DEPENDENCE; EXCHANGE; CA-2+	Excitation-contraction coupling was studied in mammalian cardiac cells in which the opening probability of L-type calcium (Ca2+) channels was reduced. Confocal microscopy during voltage-clamp depolarization revealed distinct local transients in the concentration of intracellular calcium ions ([Ca2+](i)). When voltage was varied, the latency to occurrence and the relative probability of occurrence of local [Ca2+](i) transients varied as predicted if Ca2+ release from the sarcoplasmic reticulum (SR) was linked tightly to Ca2+ flux through L-type Ca2+ channels but not to that through the Na-Ca exchanger or to average [Ca2+](i). Voltage had no effect on the amplitude of local [Ca2+](i) transients. Thus, the most efficacious ''Ca2+ signal'' for activating Ca2+ release from the SR may be a transient microdomain of high [Ca2+](i) beneath an individual, open L-type Ca2+ channel.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT MED,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			López, José Ramón López/A-5541-2009; Wier, Withrow/AAE-2451-2020	López, José Ramón López/0000-0002-3870-421X; 	NHLBI NIH HHS [HL50435, HL29473, HL02466] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050435, R01HL029473] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BERS DM, 1991, EXCITATION CONTRACTI; BEUCKELMANN DJ, 1989, J PHYSIOL-LONDON, V414, P499, DOI 10.1113/jphysiol.1989.sp017700; BEUCKELMANN DJ, 1988, J PHYSIOL-LONDON, V405, P233, DOI 10.1113/jphysiol.1988.sp017331; BOUCHARD RA, 1993, J PHYSIOL-LONDON, V472, P391, DOI 10.1113/jphysiol.1993.sp019953; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CARMELIET E, 1986, J PHYSIOL-LONDON, V376, P143, DOI 10.1113/jphysiol.1986.sp016146; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; DUBELL WH, 1989, AM J PHYSIOL, V257, pH746, DOI 10.1152/ajpheart.1989.257.3.H746; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; GYORKE S, 1993, AM J PHYSIOL, V264, pC1505, DOI 10.1152/ajpcell.1993.264.6.C1505; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; ISENBERG G, 1994, J PHYSIOL-LONDON, V480, P423, DOI 10.1113/jphysiol.1994.sp020372; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LEVI AJ, 1994, AM J PHYSIOL, V266, pH1422, DOI 10.1152/ajpheart.1994.266.4.H1422; LIPP P, 1994, J PHYSIOL-LONDON, V474, P439, DOI 10.1113/jphysiol.1994.sp020035; LOPEZLOPEZ JA, UNPUB; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; PELZER D, 1984, INSERM, V124, P415; RIOS E, 1994, BIOPHYS J, V67, P7, DOI 10.1016/S0006-3495(94)80451-5; ROSE WC, 1992, J PHYSIOL-LONDON, V456, P267, DOI 10.1113/jphysiol.1992.sp019336; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SIPIDO KR, 1991, J PHYSIOL-LONDON, V435, P605, DOI 10.1113/jphysiol.1991.sp018528; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; VARRO A, 1993, PFLUG ARCH EUR J PHY, V423, P158, DOI 10.1007/BF00374975; WIER WG, 1980, SCIENCE, V207, P1085, DOI 10.1126/science.7355274; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037; WIER WG, 1993, BIOPHYS J, V65, P2270, DOI 10.1016/S0006-3495(93)81287-6; YASUI K, 1994, BIOPHYS J, V67, P457, DOI 10.1016/S0006-3495(94)80501-6	35	416	424	0	32	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1042	1045						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754383				2022-12-28	WOS:A1995QY93400039
J	SUAREZ, FL; SAVAIANO, DA; LEVITT, MD				SUAREZ, FL; SAVAIANO, DA; LEVITT, MD			A COMPARISON OF SYMPTOMS AFTER THE CONSUMPTION OF MILK OR LACTOSE-HYDROLYZED MILK BY PEOPLE WITH SELF-REPORTED SEVERE LACTOSE-INTOLERANCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-COLON; MALABSORPTION; LACTASE	Background. Ingestion of a large dose of the milk sugar lactose - for example, the 50-g load in 1 liter of milk - causes symptoms such as abdominal pain, diarrhea, bloating, and flatulence in the majority of people with lactose malabsorption. It is uncertain whether the ingestion of more common doses of lactose, such as the amount in 240 ml (8 oz) of milk, causes symptoms, Some people insist that even smaller quantities of milk, such as the amount used with cereal or coffee, cause severe gastrointestinal distress. Methods. In a randomized, double-blind, crossover trial, we evaluated gastrointestinal symptoms in 30 people (mean age, 29.4 years; range, 18 to 50) who reported severe lactose intolerance and said they consistently had symptoms after ingesting less than 240 mi of milk. The ability to digest lactose was assessed by measuring the subjects' end-alveolar hydrogen concentration after they ingested 15 g of lactose in 250 ml of water. Subjects then received either 240 ml of lactose-hydrolyzed milk containing 2 percent fat or 240 ml of milk containing 2 percent fat and sweetened with aspartame to approximate the taste of lactose-hydrolyzed milk; each type of milk was administered daily with breakfast for a one-week period. Using a standardized scale, subjects rated the occurrence and severity of bloating, abdominal pain, diarrhea, and flatus and recorded each passage flatus. Results. Twenty-one participants were classified as having lactose malabsorption and nine as being able to absorb lactose. During the study periods, gastrointestinal symptoms were minimal (mean symptom-severity scores for bloating, abdominal pain, diarrhea, and flatus between 0.1 and 1.2 [1 indicated trivial symptoms; and 2, mild symptoms]). When the periods were compared, there were no statistically significant differences in the severity of these four gastrointestinal symptoms. For the lactose-malabsorption group, the mean (+/-SEM) differences in episodes of flatus per day was 2.5 +/- 1.1 (95 percent confidence interval, 0.2 to 4.8), Daily dietary records indicated a high degree of compliance, with no additional sources of lactose reported. Conclusions. People who identify themselves as severely lactose-intolerant may mistakenly attribute a variety of abdominal symptoms to lactose intolerance. When lactose intake is limited to the equivalent of 240 ml of milk or less a day, symptoms are likely to be negligible and the use of lactose-digestive aids unnecessary.	VET AFFAIRS MED CTR, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, DEPT FOOD SCI & NUTR, MINNEAPOLIS, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities				Savaiano, Dennis/0000-0001-8872-6276	NIDDK NIH HHS [R01-DK-13093-25] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYLESS TM, 1975, NEW ENGL J MED, V292, P1156, DOI 10.1056/NEJM197505292922205; Bourlioux P, 1988, World Rev Nutr Diet, V56, P217; COOK GC, 1968, GASTROENTEROLOGY, V55, P328; FRIEDL J, 1981, ECOL FOOD NUTR, V11, P37, DOI 10.1080/03670244.1981.9990654; GIBSON GR, 1990, GUT, V31, P679, DOI 10.1136/gut.31.6.679; GILAT T, 1972, GASTROENTEROLOGY, V62, P1125; HAVERBERG L, 1980, AM J CLIN NUTR, V33, P17, DOI 10.1093/ajcn/33.1.17; Jellinek G, 1985, SENSORY EVALUATION F; JOHNSON AO, 1993, AM J CLIN NUTR, V57, P399, DOI 10.1093/ajcn/57.3.399; KRUSE TA, 1988, FEBS LETT, V240, P123, DOI 10.1016/0014-5793(88)80352-1; LEE CM, 1989, AM J CLIN NUTR, V49, P840, DOI 10.1093/ajcn/49.5.840; LEVITT MD, 1970, J LAB CLIN MED, V75, P937; LISKER R, 1975, AM J HUM GENET, V27, P662; LISKER R, 1978, GASTROENTEROLOGY, V74, P1283; MARTINI MC, 1991, AM J CLIN NUTR, V53, P1253, DOI 10.1093/ajcn/53.5.1253; PAIGE DM, 1975, AM J CLIN NUTR, V28, P818, DOI 10.1093/ajcn/28.8.818; RORICK MH, 1979, J GERONTOL, V34, P191, DOI 10.1093/geronj/34.2.191; SACHS L, 1982, APPLIED STATISTICS H; SAHI T, 1974, SCAND J GASTROENTERO, V9, P7; SAUNDERS DR, 1981, AM J PHYSIOL, V241, pG397, DOI 10.1152/ajpgi.1981.241.5.G397; SCRIMSHAW N S, 1988, American Journal of Clinical Nutrition, V48, P1083; SIMOONS FJ, 1978, AM J DIG DIS, V23, P963, DOI 10.1007/BF01263095; SOLOMONS NW, 1980, AM J CLIN NUTR, V33, P545, DOI 10.1093/ajcn/33.3.545; SUAREZ FL, 1994, AM J CLIN NUTR, V59, P1021, DOI 10.1093/ajcn/59.5.1021; UNGER M, 1981, NUTR RES, V1, P1227; VASQUEZVELASQUEZ L, 1985, GASTROENTEROLOGY, V88, P856, DOI 10.1016/0016-5085(85)90182-9; 1992, SYSTAT MACINTOSH	27	330	343	1	52	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					1	4		10.1056/NEJM199507063330101	http://dx.doi.org/10.1056/NEJM199507063330101			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776987				2022-12-28	WOS:A1995RG73500001
J	POPE, AM; INGALLS, CE; RALL, DP				POPE, AM; INGALLS, CE; RALL, DP			ENVIRONMENTAL MEDICINE - INTEGRATING A MISSING ELEMENT INTO MEDICAL-EDUCATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											POPE, AM (corresponding author), NATL ACAD SCI,INST MED,COMM CURRICULUM DEV ENVIRONM MED,ROOM FO-3034,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418, USA.							ENV MED INTEGRATING	1	5	5	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					15	15						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791240				2022-12-28	WOS:A1995RG23300006
J	MARZUK, PM; TARDIFF, K; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N; IQBAL, MI				MARZUK, PM; TARDIFF, K; LEON, AC; HIRSCH, CS; STAJIC, M; PORTERA, L; HARTWELL, N; IQBAL, MI			FATAL INJURIES AFTER COCAINE USE AS A LEADING CAUSE OF DEATH AMONG YOUNG-ADULTS IN NEW-YORK-CITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPLICATIONS; PREVALENCE; EXCRETION; HOMICIDE; HUMANS; COUNTY; ABUSE; CRACK	Background. Cocaine intoxication can lead to fatal cardiovascular and cerebrovascular events. In addition, the neurobehavioral effects of cocaine may increase the likelihood that a user will receive violent fatal injuries. Since New York City is a center for the importation and distribution of cocaine, we sought to determine the extent of cocaine use among city residents with fatal injuries. Methods. Among a total of 14,843 residents of New York City who received fatal injuries from 1990 through 1992, we determined the proportion who had used cocaine shortly before their deaths. We also determined the population-based rates of fatal injuries that were known to follow cocaine use and the proportion of all deaths of New York City residents that was represented by these cases for each demographic stratum. For people 15 to 44 years of age, fatal injury after cocaine use was ranked with other causes of death as though it was a separate cause. Results. Cocaine use, as measured by the detection of the metabolite benzoylecgonine in urine or blood, was found in 26.7 percent of all New York City residents receiving fatal injuries; free cocaine was detected in 18.3 percent. Approximately one third of deaths after cocaine use were the result of drug intoxication, but two thirds involved traumatic injuries resulting from homicides, suicides, traffic accidents, and falls. If fatal injury after cocaine use was considered as a separate cause of death, it would rank among the five leading causes of death among those 15 to 44 years of age in New York City. Conclusions. Fatal injuries among cocaine users account for a substantial proportion of all deaths among young adults in New York City.	CORNELL UNIV, COLL MED, DEPT PSYCHIAT, EPIDEMIOL SECT, NEW YORK, NY USA; CORNELL UNIV, COLL MED, DEPT PUBL HLTH, NEW YORK, NY USA; NYU, SCH MED, DEPT FORENS MED, NEW YORK, NY USA; OFF CHIEF MED EXAMINER, NEW YORK, NY USA	Cornell University; Cornell University; New York University					NIDA NIH HHS [DA-06534] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006534] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMBRE J, 1985, J ANAL TOXICOL, V9, P241, DOI 10.1093/jat/9.6.241; ARMITAGE P, 1987, STATISTICAL METHODS; BAILEY DN, 1989, J FORENSIC SCI, V34, P407; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BASELT RC, 1983, J CHROMATOGR, V268, P502, DOI 10.1016/S0021-9673(01)95449-4; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; HAMID A, 1991, INT J ADDICT, V26, P913, DOI 10.3109/10826089109058930; HAMILTON HE, 1977, J FORENSIC SCI, V22, P697; HANZLICK R, 1991, JAMA-J AM MED ASSOC, V6, P760; HARRUFF RC, 1988, J FORENSIC SCI, V33, P1231; LEVINE SR, 1990, NEW ENGL J MED, V323, P699, DOI 10.1056/NEJM199009133231102; LIU Y, 1982, J CHROMATOGR, V248, P318; LOWRY PW, 1988, AM J EPIDEMIOL, V128, P1130; MARZUK P M, 1992, Journal of the American Medical Association, V267, P2635, DOI 10.1001/jama.267.19.2635; MARZUK PM, 1992, AM J PSYCHIAT, V149, P371; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; ROGERS C, 1993, J FORENSIC SCI, V38, P831; TARDIFF K, 1989, J FORENSIC SCI, V34, P53; 1992, CP134 BUR CENS PUBL; 1993, DHHS PHS931980 RES T; 1989, DHHS PHS891260 PUBL, V1	23	75	78	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1753	1757		10.1056/NEJM199506293322606	http://dx.doi.org/10.1056/NEJM199506293322606			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760893				2022-12-28	WOS:A1995RE66700006
J	HILL, JA; POLGAR, K; ANDERSON, DJ				HILL, JA; POLGAR, K; ANDERSON, DJ			T-HELPER 1-TYPE IMMUNITY TO TROPHOBLAST IN WOMEN WITH RECURRENT SPONTANEOUS-ABORTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCER LYMPHOCYTES-T; GROWTH-FACTOR-BETA; TH2 CLONES; MONOCLONAL-ANTIBODIES; CELL CLONE; CYTOKINE PRODUCTION; ORAL TOLERIZATION; INVITRO; THERAPY; ANTIGEN	Objective.-To test the hypothesis that peripheral blood mononuclear cells in women with unexplained recurrent abortion (URA) produce T-helper 1 (T(H)1)-type cytokines in response to trophoblast antigens. Design.-Cohort study. Setting.-Medical center, Participants.-A total of 244 women with URA, 13 reproductively normal parous control women, and 10 men. Main Outcome Measures.-Supernatants from trophoblast-activated peripheral blood mononuclear cells from all participants were tested for toxic effects on mouse embryos and by enzyme-linked immunosorbent assay (ELISA) for interferon gamma (IFN-gamma). Supernatants from 20 URA patients with embryotoxic activity and IFN-gamma, 13 reproductively normal parous women, and 10 men were further tested by ELISA for other T(H)1-type cytokines (interleukin-2 [IL-2], tumor necrosis factor-beta [TNF-beta]), T(H)2-type cytokines (IL-4, IL-10), and TNF-alpha. Results.-Embryotoxic activity was detected in supernatants from 160 of 244 URA patients and in none of the controls. Interferon gamma was detected in supernatants from 125 of 244 URA patients and was significantly associated with embryotoxicity (121 of 160 supernatants with embryotoxicity vs four of 84 supernatants without embryotoxicity [P<.001]). Of 20 supernatants from patients chosen for further study, all were positive for TNF-alpha, 17 for TNF-beta, two for IL-10, and one for IL-4, No cytokines were detected in supernatants from unstimulated or red blood cell membrane-activated cells of women with URA. In contrast, trophoblast-activated lymphocyte supernatants from reproductively normal women and men neither were embryotoxic nor contained T(H)1-type cytokines, but most contained the T(H)2-type cytokine IL-10. Three supernatants from reproductively normal women also contained IL-4. Conclusion.-Whereas T(H)1-type immunity to trophoblast is associated with URA and may play a role in reproductive failure, T(H)2-type immunity may be a natural response to trophoblast contributing to successful pregnancy.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV REPROD IMMUNOL,HARVARD RECURRENT MISCARRIAGE CTR,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT OBSTET GYNECOL & REPROD BIOL,REPROD MED UNIT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	HILL, JA (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,FEARING RES LAB,250 LONGWOOD AVE,ROOM 204,BOSTON,MA 02115, USA.			Anderson, Deborah/0000-0002-2848-7290	NICHD NIH HHS [HD23547, HD00815] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023547, K11HD000815] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABBAS AK, 1990, J IMMUNOL, V144, P2031; BERKOWITZ RS, 1988, GYNECOL ONCOL, V29, P94, DOI 10.1016/0090-8258(88)90152-7; BERKOWITZ RS, 1988, AM J OBSTET GYNECOL, V158, P199, DOI 10.1016/0002-9378(88)90810-1; BERKOWITZ RS, 1985, GYNECOL ONCOL, V1, P70; BILLINGTON WD, 1988, BAILLIERE CLIN IMMUN, V2, P527; BULMER JN, 1988, BAILLIERE CLIN IMMUN, V2, P697; BULMER JN, 1985, IMMUNOLOGY, V5, P35; CHAOUAT G, 1990, J REPROD FERTIL, V89, P447; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; DELPRETE G, 1993, J IMMUNOL, V150, P353; DWYER JM, 1992, NEW ENGL J MED, V326, P107; ECKER JL, 1993, OBSTET GYNECOL, V81, P84; FATHMAN CG, 1992, NEW ENGL J MED, V326, P1693, DOI 10.1056/NEJM199206183262509; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; GAJEWSKI TF, 1990, J IMMUNOL, V144, P4110; HAIMOVICI F, 1991, BIOL REPROD, V44, P69, DOI 10.1095/biolreprod44.1.69; HILL JA, 1992, AM J OBSTET GYNECOL, V166, P1044, DOI 10.1016/S0002-9378(11)90589-4; HILL JA, 1988, CONTRACEPTIVE RES TO, P171; HILL JA, 1987, J IMMUNOL, V132, P2250; HRICIK DE, 1994, TRANSPLANTATION, V57, P979, DOI 10.1097/00007890-199404150-00001; KABAWAT SE, 1985, AM J PATHOL, V118, P76; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; KURTJONES EA, 1987, J EXP MED, V166, P1774, DOI 10.1084/jem.166.6.1774; LIN H, 1993, J IMMUNOL, V151, P4562; LOKE YW, 1983, BIOL TROPHOBLAST, P663; MAGGI E, 1992, J IMMUNOL, V148, P2142; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOSMANN TR, 1987, IMMUNOL TODAY, V8, P223, DOI 10.1016/0167-5699(87)90171-X; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOSMANN TR, 1991, IMMUNOL TODAY, V12, P49; MOSMANN TR, 1986, J IMMUNOL, V136, P2848; MOSMANN TR, 1989, ADV IMMUNOL, V46, P11; POWRIE F, 1993, IMMUNOL TODAY, V14, P270, DOI 10.1016/0167-5699(93)90044-L; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V4, P279; ROMAGNANI S, 1991, IMMUNOL TODAY, V8, P256; THORBECKE GJ, 1992, P NATL ACAD SCI USA, V89, P7375, DOI 10.1073/pnas.89.16.7375; TITE JP, 1984, J IMMUNOL, V135, P25; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WILLIAMS ME, 1990, J IMMUNOL, V144, P1208; YAMADA H, 1994, AM J OBSTET GYNECOL, V170, P1339	41	457	480	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1933	1936		10.1001/jama.273.24.1933	http://dx.doi.org/10.1001/jama.273.24.1933			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783303				2022-12-28	WOS:A1995RE35400029
J	KIZER, KW				KIZER, KW			THE HEALTH OF PERSIAN-GULF VETERANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285					0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1817	1817		10.1001/jama.273.23.1817	http://dx.doi.org/10.1001/jama.273.23.1817			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776487				2022-12-28	WOS:A1995RD11600005
J	SCOFIELD, RH; KURIEN, B; GROSS, T; WARREN, WL; HARLEY, JB				SCOFIELD, RH; KURIEN, B; GROSS, T; WARREN, WL; HARLEY, JB			HLA-B27 BINDING OF PEPTIDE FROM ITS OWN SEQUENCE AND SIMILAR PEPTIDES FROM BACTERIA - IMPLICATIONS FOR SPONDYLOARTHROPATHIES	LANCET			English	Note							ANKYLOSING-SPONDYLITIS; REACTIVE ARTHRITIS; MOLECULAR MIMICRY; B27	The spondyloarthropathies are associated by an unknown mechanism with HLA-B27 and certain bacteria. HLA-B27 shares sequence with proteins from enteric bacteria. The B*2705 sequence contains a nonapeptide, LRRYLENGK, predicted to bind in the binding cleft of B27. Some nonapeptides from enteric organisms that share sequence with this nonapeptide of B27 also bind B27. These observations suggest an unappreciated mechanism for autoimmunity that may operate in the B27-associated spondyloarthropathies involving peptides bound to and derived from histocompatibility alleles.	UNIV OKLAHOMA,HLTH SCI CTR,COLL MED,DEPT MED,OKLAHOMA CITY,OK; USA,DEPT VET AFFAIRS MED CTR,OKLAHOMA CITY,OK	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	SCOFIELD, RH (corresponding author), OKLAHOMA MED RES FDN,ARTHRITIS & IMMUNOL PROGRAM,825 NE 13TH ST,OKLAHOMA CITY,OK 73104, USA.		Scofield, Robert Hal/AEJ-8314-2022; Kurien, Biji T/C-2392-2008	Kurien, Biji T/0000-0002-7877-6859				BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; CALIN A, 1989, TXB RHEUMATOLOGY, P1023; HAMMER M, 1990, ARTHRITIS RHEUM, V33, P1795, DOI 10.1002/art.1780331206; HERMANN E, 1993, LANCET, V342, P646, DOI 10.1016/0140-6736(93)91760-J; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; PARKER KC, 1992, J BIOL CHEM, V267, P5451; SCHWIMMBECK PL, 1987, J EXP MED, V166, P173, DOI 10.1084/jem.166.1.173; SCOFIELD RH, 1993, P NATL ACAD SCI USA, V90, P9330, DOI 10.1073/pnas.90.20.9330; TERASAKI PI, 1981, ARTHRITIS RHEUM, V30, P353; WILLIAMS RC, 1992, SCAND J RHEUMATOL, V21, P105, DOI 10.3109/03009749209095079	10	90	92	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1542	1544		10.1016/S0140-6736(95)91089-1	http://dx.doi.org/10.1016/S0140-6736(95)91089-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791441				2022-12-28	WOS:A1995RD79000011
J	WALDER, R				WALDER, R			WHY THE PROBLEM CONTINUES IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article											WALDER, R (corresponding author), REGENTS COLL,INT PLANNED PARENTHOOD FEDERAT,REGENTS PK,LONDON NW1 4NS,ENGLAND.								0	9	9	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1593	1594		10.1136/bmj.310.6994.1593	http://dx.doi.org/10.1136/bmj.310.6994.1593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787656	Green Published			2022-12-28	WOS:A1995RE35300031
J	LOCKSHON, D; ZWEIFEL, SG; FREEMANCOOK, LL; LORIMER, HE; BREWER, BJ; FANGMAN, WL				LOCKSHON, D; ZWEIFEL, SG; FREEMANCOOK, LL; LORIMER, HE; BREWER, BJ; FANGMAN, WL			A ROLE FOR RECOMBINATION JUNCTIONS IN THE SEGREGATION OF MITOCHONDRIAL-DNA IN YEAST	CELL			English	Article							CRUCIFORM CUTTING ENDONUCLEASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; REPLICATION; GENOME; LOCALIZATION; PLASMIDS; MUTANTS; ORIGINS; GENE	In S. cerevisiae, mitochondrial DNA (mtDNA) molecules, in spite of their high copy number, segregate as if there were a small number of heritable units. The rapid segregation of mitochondrial genomes can be analyzed using mtDNA deletion variants. These small, amplified genomes segregate preferentially from mixed zygotes relative to wild-type mtDNA. This segregation advantage is abolished by mutations in a gene, MGT1, that encodes a recombination junction-resolving enzyme. We show here that resolvase deficiency causes a larger proportion of molecules to be linked together by recombination junctions, resulting in the aggregation of mtDNA into a small number of cytological structures. This change in mtDNA structure can account far the increased mitotic loss of mtDNA and the altered pattern of mtDNA segregation from zygotes. We propose that the level of unresolved recombination junctions influences the number of heritable units of mtDNA.	UNIV WASHINGTON, DEPT GENET SK50, SEATTLE, WA 98195 USA; CARLETON COLL, DEPT BIOL, NORTHFIELD, MN 55057 USA	University of Washington; University of Washington Seattle; Carleton College	LOCKSHON, D (corresponding author), UNIV WASHINGTON, DEPT PATHOL SM30, SEATTLE, WA 98195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R15AG011435] Funding Source: NIH RePORTER; NIA NIH HHS [AG11435] Funding Source: Medline; NIGMS NIH HHS [GM43847] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLIN V, 1991, METHOD ENZYMOL, V194, P774; BIRKY CW, 1994, J HERED, V85, P355, DOI 10.1093/oxfordjournals.jhered.a111480; BIRKY CW, 1982, MITOCHONDRIAL GENES, P279; BLANC H, 1984, GENE, V30, P47, DOI 10.1016/0378-1119(84)90104-5; BLANC H, 1980, P NATL ACAD SCI-BIOL, V77, P3942, DOI 10.1073/pnas.77.7.3942; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; BROWN MD, 1994, J BIOENERG BIOMEMBR, V26, P273, DOI 10.1007/BF00763099; DEZAMAROCZY M, 1981, NATURE, V292, P75, DOI 10.1038/292075a0; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; EVANS DH, 1988, J MOL BIOL, V201, P69, DOI 10.1016/0022-2836(88)90439-1; EZEKIEL UR, 1993, MOL GEN GENET, V240, P414, DOI 10.1007/BF00280395; FANGMAN WL, 1989, MOL CELL BIOL, V9, P1917, DOI 10.1128/MCB.9.5.1917; FANGMAN WL, 1978, NUCLEIC ACIDS RES, V5, P653, DOI 10.1093/nar/5.3.653; FRIEDMAN KL, 1995, IN PRESS METH ENZYMO, V262; GINGOLD EB, 1988, DIVISION SEGREGATION, P149; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KLEFF S, 1992, EMBO J, V11, P699, DOI 10.1002/j.1460-2075.1992.tb05102.x; MARINI JC, 1980, J BIOL CHEM, V255, P4976; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; OOI BG, 1986, CURR GENET, V10, P713, DOI 10.1007/BF00405093; PISKUR J, 1994, PLASMID, V31, P229, DOI 10.1006/plas.1994.1025; SENA EP, 1986, MOL GEN GENET, V202, P421, DOI 10.1007/BF00333272; SIMONETTI S, 1992, BIOCHIM BIOPHYS ACTA, V1180, P113, DOI 10.1016/0925-4439(92)90059-V; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Williamson D H, 1979, Methods Enzymol, V56, P728; WILLIAMSON D H, 1977, P1; WILLIAMSON DH, 1974, MOL GEN GENET, V131, P193, DOI 10.1007/BF00267959; WILLIAMSON DH, 1976, GENETICS BIOGENESIS, P117; ZWEIFEL SG, 1991, GENETICS, V128, P214	30	148	149	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 16	1995	81	6					947	955		10.1016/0092-8674(95)90014-4	http://dx.doi.org/10.1016/0092-8674(95)90014-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781070	Bronze			2022-12-28	WOS:A1995RD76800015
J	CORNWELL, EE; JACOBS, D; WALKER, M; JACOBS, L; PORTER, J; FLEMING, A				CORNWELL, EE; JACOBS, D; WALKER, M; JACOBS, L; PORTER, J; FLEMING, A			NATIONAL MEDICAL ASSOCIATION SURGICAL SECTION POSITION PAPER ON VIOLENCE PREVENTION - A RESOLUTION OF TRAUMA SURGEONS CARING FOR VICTIMS OF VIOLENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								The epidemic of intentional injury continues to be a leading cause of premature death in America. The ravages of violence are particularly devastating Within the minority community with this position paper from the Surgical Section of the National Medical Association (the country's oldest and largest organization of minority physicians), a group of trauma surgeons and surgical intensivists resolve to focus on underused violence prevention opportunities and to extend their spheres of influence beyond the walls of their institutions and emphasize violence prevention activities.	CAROLINAS MED CTR, DIV TRAUMA CRIT CARE, CHARLOTTE, NC 28203 USA; MOREHOUSE UNIV, SCH MED, DIV TRAUMA CRIT CARE, ATLANTA, GA USA; GRADY MEM HOSP, DIV TRAUMA CRIT CARE, ATLANTA, GA USA; UNIV CONNECTICUT, SCH MED, DIV TRAUMA CRIT CARE, HARTFORD, CT 06112 USA; HARTFORD HOSP, DIV TRAUMA CRIT CARE, HARTFORD, CT 06115 USA; LINCOLN MED CTR, DIV TRAUMA CRIT CARE, BRONX, NY USA; CHARLES R DREW UNIV MED & SCI, DIV TRAUMA CRIT CARE, LOS ANGELES, CA USA; KING DREW MED CTR, DIV TRAUMA CRIT CARE, LOS ANGELES, CA USA	Carolinas Medical Center; Morehouse College; University of Connecticut; Charles R. Drew University of Medicine & Science	CORNWELL, EE (corresponding author), UNIV SO CALIF, LOS ANGELES CTY MED CTR, DIV TRAUMA CRIT CARE, 1200 N STATE ST, ROOM 9900, LOS ANGELES, CA 90033 USA.							DAILEY JT, 1992, J TRAUMA, V33, P539, DOI 10.1097/00005373-199210000-00009; DYSON JL, 1990, J NATL MED ASSOC, V82, P17; FLEMING AW, 1992, ARCH SURG-CHICAGO, V127, P671; GOINS WA, 1992, J NATL MED ASSOC, V84, P431; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; KOOP CE, 1994, JAMA-J AM MED ASSOC, V271, P1404; KOOP CE, 1992, JAMA-J AM MED ASSOC, V268, P3074; NOVELLO AC, 1992, JAMA-J AM MED ASSOC, V267, P3007, DOI 10.1001/jama.267.22.3007; Rosenberg Mark L., 1991, VIOLENCE AM PUBLIC H; WEISBESKI D, 1989, J TRAUMA, V29, P940, DOI 10.1097/00005373-198907000-00006; 1993, INJURY MORTALITY 198; 1994, MMWR-MORBID MORTAL W, V43, P725; 1991, PUBLIC HLTH REP, V106, P225	13	25	27	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1788	1789		10.1001/jama.273.22.1788	http://dx.doi.org/10.1001/jama.273.22.1788			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769775				2022-12-28	WOS:A1995RB80000034
J	SOSIN, DM; SNIEZEK, JE; WAXWELLER, RJ				SOSIN, DM; SNIEZEK, JE; WAXWELLER, RJ			TRENDS IN DEATH ASSOCIATED WITH TRAUMATIC BRAIN INJURY, 1979 THROUGH 1992 - SUCCESS AND FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							UNITED-STATES; HEAD-INJURY	Objective.-To report updated national trends in traumatic brain injury deaths from 1979 through 1992. Design.-Retrospective analysis of Multiple Cause-of-Death Public Use Data Tapes from the National Center for Health Statistics. All deaths associated with traumatic brain injury were identified, the underlying causes of death were categorized, and the annual rates were calculated per 100 000 US residents. Patients.-Residents of the United States who died with traumatic brain injury from 1979 through 1992. Results.-An average of 52 000 US residents die each year with traumatic brain injuries. The brain injury-associated death rate declined 22% from 24.6 per 100 000 US residents in 1979 to 19.3 per 100 000 US residents in 1992. Firearm-related rates increased 13% from 1984 through 1992, undermining a 25% decline in motor vehicle-related rates for the same period. Firearms surpassed motor vehicles as the largest single cause of death associated with traumatic brain injury in 1990. Conclusions.-These data highlight the success of efforts to prevent traumatic brain injury due to motor vehicles and failure to prevent such injuries due to firearms. The increasing importance of penetrating injury has important implications for research, treatment, and prevention of traumatic brain injury in the United States.			SOSIN, DM (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA 30341, USA.							FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1994, FIREARM MOTOR VEHICL; GRAHAM J, 1992, POSITION PAPERS 3RD; IRWIN R, 1970, INTERCENSAL POPULATI; Kraus JF, 1993, HEAD INJURY, P1; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76, DOI DOI 10.1097/00001199-199106000-00010; Mercy J. A., 1993, HLTH AFFAIRS     WIN, P7; Nelson David E., 1993, Morbidity and Mortality Weekly Report, V42, P29; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V268, P791, DOI 10.1001/jama.1992.03490060127048; 1994, MMWR-MORBID MORTAL W, V43, P37; 1993, CURRENT POPULATI P25, V1095; 1994, DOT HS808022 US DEP; 1977, MANUAL INT CLASSIFIC	14	273	279	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1778	1780		10.1001/jama.273.22.1778	http://dx.doi.org/10.1001/jama.273.22.1778			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769773				2022-12-28	WOS:A1995RB80000032
J	DYKHUIZEN, RS; ZAIDI, AM; GODDEN, DJ; JEGARAJAH, S; LEGGE, JS				DYKHUIZEN, RS; ZAIDI, AM; GODDEN, DJ; JEGARAJAH, S; LEGGE, JS			LESSON OF THE WEEK - MINOCYCLINE AND PULMONARY EOSINOPHILIA	BRITISH MEDICAL JOURNAL			English	Article							PNEUMONITIS		BIRCH HILL HOSP,DEPT MED,ROCHDALE OL12 8HS,ENGLAND		DYKHUIZEN, RS (corresponding author), CITY HOSP,DEPT THORAC MED,ABERDEEN AB9 8AU,SCOTLAND.							AKOUN GM, 1991, CHEST, V99, P98, DOI 10.1378/chest.99.1.98; BRIDGES AJ, 1990, J AM ACAD DERMATOL, V22, P959, DOI 10.1016/0190-9622(90)70135-5; DELANEY TJ, 1976, ACTA DERM-VENEREOL, V54, P487; DYKHUIZEN RS, 1995, RESP MED, V89, P61, DOI 10.1016/0954-6111(95)90073-X; FEGUEUX S, 1991, ANN MED INTERNE, V142, P629; GUILLON JM, 1992, ANN INTERN MED, V117, P476, DOI 10.7326/0003-4819-117-6-476; HO D, 1979, CHEST, V76, P33, DOI 10.1378/chest.76.1.33; Horikx P E, 1992, Ned Tijdschr Geneeskd, V136, P530; KOHNO S, 1990, JPN J MED, V29, P248; KUROKI H, 1986, JPN J THORAC DIS, V24, P553; LOPEZ M, 1992, IMMUNOL ALLERGY CLIN, V12, P349; NISHIKAWA H, 1987, JPN RESPIR RES, V6, P777; OTERO M, 1983, JAMA-J AM MED ASSOC, V250, P2602, DOI 10.1001/jama.1983.03340190016010; SHIBATA K, 1991, NIPPON KYOBU RINSHO, V50, P61; Shigematsu T, 1988, Nihon Naika Gakkai Zasshi, V77, P1584; Shintani H, 1991, Nihon Kyobu Shikkan Gakkai Zasshi, V29, P718; SIGMANN P, 1993, ANN INTERN MED, V118, P749; SITBON O, 1994, ARCH INTERN MED, V154, P1633, DOI 10.1001/archinte.154.14.1633; UMEKI S, 1992, ARCH INTERN MED, V152, P1913, DOI 10.1001/archinte.152.9.1913; Watanabe N, 1985, ALLERGY JAPAN, V34, P620; YOKOYAMA A, 1990, JPN J MED, V29, P195	21	19	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1520	1521		10.1136/bmj.310.6993.1520	http://dx.doi.org/10.1136/bmj.310.6993.1520			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787604	Green Published			2022-12-28	WOS:A1995RD28500029
J	PHILP, I; MCKEE, KJ; MELDRUM, P; BALLINGER, BR; GILHOOLY, MLM; GORDON, DS; MUTCH, WJ; WHITTICK, JE				PHILP, I; MCKEE, KJ; MELDRUM, P; BALLINGER, BR; GILHOOLY, MLM; GORDON, DS; MUTCH, WJ; WHITTICK, JE			COMMUNITY CARE FOR DEMENTED AND NONDEMENTED ELDERLY PEOPLE - A COMPARISON STUDY OF FINANCIAL BURDEN, SERVICE USE, AND UNMET NEEDS IN FAMILY SUPPORTERS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure and compare perceived financial burden, use of services, and perceived unmet service needs of supporters of demented and non-demented elderly people. Design-Comparison study of age and sex matched demented and non-demented elderly people and their supporters. Setting-25 primary health care teams in Dundee. Subjects-114 community resident elderly (age over 65) people with dementia, 114 age and sex matched comparators, and the main informal supporter of each elderly person. Main outcome measures-Carers' perceptions of financial impact of looking after an old person, service use (from a list of locally available services), unmet service needs, and needs for three types of generic service (help with supervision, housework, or personal care). Results-Financial impact was low, except for extra household expense in the dementia group. There was significantly greater use of mainstream domiciliary and day care services in the dementia group. Dementia was nevertheless associated with a high level of unmet need, mainly for more mainstream support and help with supervision of the elderly person. Conclusion-Supervisory care for demented elderly people should be further developed within an expanded domiciliary service to meet supporters needs.	ROYAL VICTORIA HOSP,DEPT GERIATR MED,DUNDEE,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT MED,AGING & HLTH SECT,DUNDEE DD1 9SY,SCOTLAND; UNIV ABERDEEN,DEPT PUBL HLTH,HLTH ECON RES UNIT,ABERDEEN,SCOTLAND; ROYAL DUNDEE LIFF HOSP,DUNDEE,SCOTLAND; UNIV GLASGOW,BEHAV SCI GRP,GLASGOW G61 1BD,LANARK,SCOTLAND; BANGOR DIST GEN HOSP,LOTHIAN,SCOTLAND	University of Dundee; University of Aberdeen; University of Glasgow			Gilhooly, Mary/A-6330-2014	Gilhooly, Mary/0000-0003-0504-3619; philp, ian/0000-0002-3972-6496				[Anonymous], 1981, GROWING OLDER; ARIE T, 1986, BRIT MED BULL, V42, P91, DOI 10.1093/oxfordjournals.bmb.a072105; BOND J, 1980, BRIT J PSYCHIAT, V157, P221; BRANCH LG, 1982, AM J PUBLIC HEALTH, V72, P1373, DOI 10.2105/AJPH.72.12.1373; GILHOOLY MLM, 1984, BRIT J MED PSYCHOL, V57, P35, DOI 10.1111/j.2044-8341.1984.tb01578.x; GRAD J, 1986, BRIT J PSYCHIAT, V114, P265; HAY JW, 1987, AM J PUBLIC HEALTH, V77, P1169, DOI 10.2105/AJPH.77.9.1169; HOWELLS J, 1990, Medical Science Research, V18, P843; HUANG LF, 1985, PUBLIC HLTH REP, V130, P3; LEVIN E, 1989, FAMILIES SERVICES CO; MACLENNAN WJ, 1984, BRIT MED J, V288, P701, DOI 10.1136/bmj.288.6418.701; PATTIE AH, 1979, CLIFTOTT ASSESSMENT; PHILP I, 1992, Health Bulletin (Edinburgh), V50, P296; PHILP I, 1988, J ROY COLL GEN PRACT, V38, P153; POULSHOCK SW, 1984, J GERONTOL, V39, P230, DOI 10.1093/geronj/39.2.230; Sheldon F, 1982, Age Ageing, V11, P184, DOI 10.1093/ageing/11.3.184; TONER H, 1985, DEMENTIA RES INNOVAT, P28; WEST P, 1984, SOC SCI MED, V18, P287, DOI 10.1016/0277-9536(84)90117-5; WHITTICK JE, 1988, BRIT J CLIN PSYCHOL, V27, P167, DOI 10.1111/j.2044-8260.1988.tb00765.x; WHITTICK JE, 1993, THESIS U GLASGOW GLA; WILSON L A, 1973, Age and Ageing, V2, P92, DOI 10.1093/ageing/2.2.92; 1987, REPORT MRC ALZHEIMER; 1980, SCOTTISH HLTH AUTHOR	23	63	64	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1503	1506		10.1136/bmj.310.6993.1503	http://dx.doi.org/10.1136/bmj.310.6993.1503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RD285	7787599	Green Published			2022-12-28	WOS:A1995RD28500024
J	HOOGERBRUGGE, PM; BROUWER, OF; BORDIGONI, P; RINGDEN, O; KAPAUN, P; ORTEGA, JJ; OMEARA, A; CORNU, G; SOUILLET, G; FRAPPAZ, D; BLANCHE, S; FISCHER, A				HOOGERBRUGGE, PM; BROUWER, OF; BORDIGONI, P; RINGDEN, O; KAPAUN, P; ORTEGA, JJ; OMEARA, A; CORNU, G; SOUILLET, G; FRAPPAZ, D; BLANCHE, S; FISCHER, A			ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LYSOSOMAL STORAGE DISEASES	LANCET			English	Article							CENTRAL NERVOUS-SYSTEM; GAUCHER DISEASE; MICE	Patients with lysosomal storage disorders have visceral, skeletal, and neurological abnormalities and a limited life expectancy. Bone marrow transplantation has been used to correct the metabolic defects and leads to metabolic improvements in most patients However, the long-term effect of such therapy is uncertain. We analysed the data from 63 patients transplanted for lysosomal storage diseases. The transplant-related mortality was 10% if an HLA-identical sibling marrow donor was available (n=40) and 20-25% if mismatched tissue was used. Data on the effect of bone transplantation on biochemical and clinical variables were available in 29 of the 63. 28 had a follow-up duration of 1.0-10.2 years; 1 patient died of disease progression in the first year after stable engraftment. 13 patients who had severe neurological symptoms at the time of transplantation showed disease progression. Engraftment of bone marrow in 5 patients with non-neuronopathic Gaucher's disease led to complete disappearance of symptoms. 11 patients had skeletal symptoms because of various mucopolysaccharidoses (MPSs). There was stabilisation of the skeletal lesions during the observation period of 1.4-6.4 years, but none of the patients showed significant regression of the skeletal symptoms. The visceral features (hepatosplenomegaly, cardiac hypertrophy, and upper airway obstruction) in these patients abated after transplantation. We could not evaluate the biochemical and clinical variables in 34 patients because of graft rejection, transplant-related mortality, or follow-up of less than 1 year. There were significant beneficial effects of bone marrow transplantation in patients with non-neuronopathic Gaucher's disease, Stabilisation of disease was observed in patients with MPS-I and MPS-II; this potential benefit needs to be confirmed by longer follow-up, Bone marow transplantation was not effective if severe neurological symptoms were already present at the time of transplantation.	UNIV LEIDEN HOSP, DIV GENE THERAPY, 2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT NEUROL, LEIDEN, NETHERLANDS; HOP ENFANTS, SERV PEDIAT 2, NANCY, FRANCE; UNIV HOSP BRUSSELS, BRUSSELS, BELGIUM; UNIV HAMBURG, HOSP EPPENDORF, HAMBURG, GERMANY; HOSP INFANTIL VAN HEBRON, BARCELONA, SPAIN; OUR LADYS HOSP SICK CHILDREN, DUBLIN, IRELAND; HOP DEBROUSSE, LYON, FRANCE; HOP NORD ST ETIENNE, SERV PEDIAT, ST ETIENNE, FRANCE; HOP NECKER ENFANTS MALAD, PARIS, FRANCE; HUDDINGE HOSP, FRANCE & BMT UNIT, S-14186 HUDDINGE, SWEDEN	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); CHU de Nancy; University Hospital Brussels; University of Hamburg; Hospital Universitari Vall d'Hebron; Our Ladys Children Hospital Crumlin; CHU Lyon; CHU de St Etienne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	HOOGERBRUGGE, PM (corresponding author), UNIV LEIDEN HOSP, DEPT PEDIAT, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Hoogerbrugge, Peter M./H-8049-2014					Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BARRANGER JA, 1984, NEW ENGL J MED, V311, P1629, DOI 10.1056/NEJM198412203112509; BARRANGER JA, 1984, MOL BASIS LYSOSOMAL, P1; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BAYEVER E, 1992, J INHERIT METAB DIS, V15, P919, DOI 10.1007/BF01800234; BAYEVER E, 1985, LANCET, V2, P471; GALE RP, 1978, SCIENCE, V192, P1016; GREENFIELD JG, 1963, GREENFIELDS NEUROPAT, P475; HASKINS M, 1991, TREATMENT GENETIC DI, P183; HOBBS JR, 1987, LANCET, V1, P1111; HOOGERBRUGGE PM, 1987, TRANSPLANTATION, V43, P609, DOI 10.1097/00007890-198705000-00001; HOOGERBRUGGE PM, 1988, SCIENCE, V239, P1035, DOI 10.1126/science.3278379; HOOGERBRUGGE PM, 1989, BONE MARROW TRANSPL, P331; HOPWOOD JJ, 1993, J INHERIT METAB DIS, V16, P1024, DOI 10.1007/BF00711520; Hugh-Jones K, 1986, Birth Defects Orig Artic Ser, V22, P25; KOLODNY EH, 1989, METABOLIC BASIS INHE, P1721; KRIVIT W, 1984, NEW ENGL J MED, V311, P1606, DOI 10.1056/NEJM198412203112504; KRIVIT W, 1990, NEW ENGL J MED, V322, P28, DOI 10.1056/NEJM199001043220106; KRIVIT W, 1991, TREATMENT GENETIC DI, P203; Krivit W., 1989, BONE MARROW TRANSPL, P367; OLSEN I, 1983, NATURE, V306, P75, DOI 10.1038/306075a0; RINGDEN O, 1988, TRANSPLANTATION, V46, P66, DOI 10.1097/00007890-198807000-00011; RINGDEN O, 1990, TRANSPL P, V22, P198; SAKIYAMA T, 1983, BIOCHEM BIOPH RES CO, V113, P605, DOI 10.1016/0006-291X(83)91769-2; SHAPIRO E, 1991, TREATMENT GENETIC DI, P223; SHULL RM, 1987, J CLIN INVEST, V79, P435, DOI 10.1172/JCI112830; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; TAYLOR RM, 1987, TRANSPLANT P, V19, P2730; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; TSAI P, 1992, PEDIATR RES, V31, P503, DOI 10.1203/00006450-199205000-00019; VELLODI A, 1992, J INHERIT METAB DIS, V15, P911, DOI 10.1007/BF01800232; WALKLEY SU, 1994, P NATL ACAD SCI USA, V91, P2970, DOI 10.1073/pnas.91.8.2970; WHITLEY CB, 1993, AM J MED GENET, V46, P209, DOI 10.1002/ajmg.1320460222	33	207	220	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 3	1995	345	8962					1398	1402		10.1016/S0140-6736(95)92597-X	http://dx.doi.org/10.1016/S0140-6736(95)92597-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760610				2022-12-28	WOS:A1995RB44100009
J	NASIR, J; FLORESCO, SB; OKUSKY, JR; DIEWERT, VM; RICHMAN, JM; ZEISLER, J; BOROWSKI, A; MARTH, JD; PHILLIPS, AG; HAYDEN, MR				NASIR, J; FLORESCO, SB; OKUSKY, JR; DIEWERT, VM; RICHMAN, JM; ZEISLER, J; BOROWSKI, A; MARTH, JD; PHILLIPS, AG; HAYDEN, MR			TARGETED DISRUPTION OF THE HUNTINGTONS-DISEASE GENE RESULTS IN EMBRYONIC LETHALITY AND BEHAVIORAL AND MORPHOLOGICAL-CHANGES IN HETEROZYGOTES	CELL			English	Article							BULBAR MUSCULAR-ATROPHY; EXPRESSION; TISSUES	Huntington's disease (HD) is an incurable neuropsychiatric disease associated with CAG repeat expansion within a widely expressed gene that causes selective neuronal death. To understand its normal function, we have created a targeted disruption in exon 5 of Hdh (Hdh(ex5)), the murine homolog of the HD gene. Homozygotes die before embryonic day 8.5, initiate gastrulation, but do not proceed to the formation of somites or to organogenesis, Mice heterozygous for the Hdh(ex5) mutation display increased motor activity and cognitive deficits. Neuropathological assessment of two heterozygous mice shows significant neuronal loss in the subthalamic nucleus. These studies show that the HD gene is essential for postimplantation development and that it may play an important role in normal functioning of the basal ganglia.	UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, DEPT PSYCHOL, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL & LAB MED, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, DEPT CLIN DENT SCI, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1Z4, CANADA; UNIV BRITISH COLUMBIA, CTR MOLEC MED & THERAPEUT, VANCOUVER, BC V6T 1Z4, CANADA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia			Richman, Joy M./C-3111-2018; Richman, Joy/AAD-9445-2020; Floresco, Stan B/F-8160-2012; Hayden, Michael R/D-8581-2011	Richman, Joy M./0000-0002-1409-8163; Richman, Joy/0000-0002-1409-8163; Floresco, Stan B/0000-0002-5633-243X; Hayden, Michael R/0000-0001-5159-1419; Nasir, Jamal/0000-0001-6378-5616				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; ARBIZU T, 1983, J NEUROL SCI, V59, P371, DOI 10.1016/0022-510X(83)90022-9; CARPENTER MB, 1950, J COMP NEUROL, V92, P293, DOI 10.1002/cne.900920303; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; DUNNETT SB, 1981, BEHAV BRAIN RES, V2, P189, DOI 10.1016/0166-4328(81)90055-3; FOLSTEIN SE, 1989, HUNTINGTONS DISEASE; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; Harper PS, 1991, HUNTINGTONS DISEASE; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; HOGAN B, 1986, MANIPULATING MOUSE E; JOU YS, 1995, HUM MOL GENET, V4, P465, DOI 10.1093/hmg/4.3.465; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI 10.1056/NEJM199405193302001; LANGE H, 1976, J NEUROL SCI, V28, P401, DOI 10.1016/0022-510X(76)90114-3; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LI SH, 1993, NEURON, V11, P985, DOI 10.1016/0896-6273(93)90127-D; LIN BY, 1995, GENOMICS, V25, P707, DOI 10.1016/0888-7543(95)80014-D; LIN BY, 1994, HUM MOL GENET, V3, P85, DOI 10.1093/hmg/3.1.85; LIN BY, 1993, HUM MOL GENET, V2, P1541, DOI 10.1093/hmg/2.10.1541; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MCDONALD RJ, 1994, BEHAV NEURAL BIOL, V61, P260, DOI 10.1016/S0163-1047(05)80009-3; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MYERS RH, 1989, AM J HUM GENET, V45, P615; NASIR J, 1994, GENOMICS, V22, P198, DOI 10.1006/geno.1994.1361; PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; Sambrook J, 1989, MOL CLONING LABORATO; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STRONG TV, 1993, NAT GENET, V5, P259, DOI 10.1038/ng1193-259; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WEXLER NS, 1987, NATURE, V326, P194, DOI 10.1038/326194a0; WHITTIER JR, 1947, ARCH NEURO PSYCHIATR, V58, P672, DOI 10.1001/archneurpsyc.1947.02300350022002; WILLEMS PJ, 1994, NAT GENET, V8, P213, DOI 10.1038/ng1194-213	37	626	644	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					811	823		10.1016/0092-8674(95)90542-1	http://dx.doi.org/10.1016/0092-8674(95)90542-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774020	Bronze			2022-12-28	WOS:A1995RB96100019
J	LIU, GS; TSIEN, RW				LIU, GS; TSIEN, RW			PROPERTIES OF SYNAPTIC TRANSMISSION AT SINGLE HIPPOCAMPAL SYNAPTIC BOUTONS	NATURE			English	Article							LONG-TERM POTENTIATION; QUANTAL ANALYSIS; SLICES; CURRENTS; NEURONS; VARIABILITY; MINIATURE; SYNAPSES	SYNAPTIC transmission between individual presynaptic terminals and postsynaptic dendrites is a fundamental element of communication among central nervous system neurons. Yet little is known about evoked neurotransmission at the level of single presynaptic boutons(1-5). Here we describe key functional characteristics of individual presynaptic boutons of hippocampal neurons in culture. Excitatory postsynaptic currents (e.p.s.cs) were evoked by localized application of elevated K+/Ca2+ solution to single functional boutons, visually identified by staining with the vital dye FM1-43 (refs 6, 7). Frequent repetitive stimulation produced a decline in the incidence of e.p.s.cs as the pool of releasable vesicles was exhausted; typically, recovery proceeded with a time constant of about 40 s (23 degrees C), and involved a vesicular pool capable of generating about 90 e.p.s.cs without recycling. At individual synapses, synaptic currents were broadly distributed in amplitude(1), but this distribution was remarkably similar at multiple synapses on a given postsynaptic neuron. The average size of synaptic currents and of responses to focal glutamate application varied fourfold across different cells, decreasing markedly with increasingly dense synaptic innervation. This raises the possibility of a very effective mechanism for coordinating synaptic strength at multiple sites throughout the dendritic tree.	STANFORD UNIV,MED CTR,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University								BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; HORRIGAN FT, 1994, J NEURON, V13, P1119; JONAS P, 1993, J PHYSIOL-LONDON, V472, P615, DOI 10.1113/jphysiol.1993.sp019965; JONES KA, 1991, NEURON, V7, P593, DOI 10.1016/0896-6273(91)90372-7; KATZ B, 1967, J PHYSIOL-LONDON, V189, P535, DOI 10.1113/jphysiol.1967.sp008183; LARKMAN A, 1991, NATURE, V350, P344, DOI 10.1038/350344a0; LAVIDIS NA, 1992, J PHYSIOL-LONDON, V454, P9, DOI 10.1113/jphysiol.1992.sp019252; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2	22	253	257	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					404	408		10.1038/375404a0	http://dx.doi.org/10.1038/375404a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760934				2022-12-28	WOS:A1995RB10100053
J	STEWART, JD; BENKOVIC, SJ				STEWART, JD; BENKOVIC, SJ			TRANSITION-STATE STABILIZATION AS A MEASURE OF THE EFFICIENCY OF ANTIBODY CATALYSIS	NATURE			English	Article							HYDROLYSIS; SUBSTRATE	THERE are now about 60 examples of reactions that have been successfully catalysed by monoclonal antibodies(1-3). Not surprisingly, many of the early examples involved reactions that were already favoured kinetically (such as carbonate and ester hydrolysis). But it has since been shown that antibodies can also accelerate reaction pathways that are normally disfavoured kinetically (by at least a few kcal mol(-1))(4-7). Here we use transition-state theory to provide a quantitative analysis of the scope and limitations of antibody catalysis. We show that the observed rate accelerations can be predicted from the ratio of equilibrium binding constants of the reaction substrate and the transition-state analogue used to raise the antibody. This scheme allows us to rationalize the product selectivity displayed in antibody catalysis of disfavoured reactions, to predict the degree of rate acceleration that catalytic antibodies may ultimately afford, and to highlight some differences between the way that they and enzymes catalyse reactions.	PENN STATE UNIV,DEPT CHEM,UNIVERSITY PK,PA 16801	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	STEWART, JD (corresponding author), UNIV FLORIDA,DEPT CHEM,GAINESVILLE,FL 32611, USA.							ASHLEY JA, 1993, J AM CHEM SOC, V115, P2515, DOI 10.1021/ja00059a061; BENKOVIC SJ, 1990, SCIENCE, V250, P1135, DOI 10.1126/science.2251500; BENKOVIC SJ, 1988, P NATL ACAD SCI USA, V85, P5355, DOI 10.1073/pnas.85.15.5355; CAMPBELL DA, 1994, J AM CHEM SOC, V116, P2165, DOI 10.1021/ja00084a075; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; COCHRAN AG, 1990, SCIENCE, V240, P781; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; GIBBS RA, 1992, J AM CHEM SOC, V114, P3528, DOI 10.1021/ja00035a057; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HIRSCHMANN R, 1994, SCIENCE, V265, P234, DOI 10.1126/science.8023141; IVERSON BL, 1990, J AM CHEM SOC, V112, P5320, DOI 10.1021/ja00169a044; IWABUCHI Y, 1994, J AM CHEM SOC, V116, P771, DOI 10.1021/ja00081a049; JACKSON DY, 1991, P NATL ACAD SCI USA, V88, P58, DOI 10.1073/pnas.88.1.58; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; JACOBS JW, 1991, BIO-TECHNOL, V9, P258, DOI 10.1038/nbt0391-258; JACOBSEN JR, 1994, P NATL ACAD SCI USA, V91, P5888, DOI 10.1073/pnas.91.13.5888; JACOBSEN JR, 1992, SCIENCE, V256, P365, DOI 10.1126/science.256.5055.365; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1991, TETRAHEDRON, V47, P2503, DOI 10.1016/S0040-4020(01)81784-1; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LEWIS C, 1991, SCIENCE, V253, P1019, DOI 10.1126/science.1887215; LI TY, 1994, SCIENCE, V264, P1289, DOI 10.1126/science.8191282; MARTIN MT, 1991, BIOCHEMISTRY-US, V30, P9757, DOI 10.1021/bi00104a027; NA J, 1993, J AM CHEM SOC, V115, P8453, DOI 10.1021/ja00071a067; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; POSNER B, 1994, TRENDS BIOCHEM SCI, V19, P145, DOI 10.1016/0968-0004(94)90273-9; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; REYMOND JL, 1991, ANGEW CHEM INT EDIT, V30, P1711, DOI 10.1002/anie.199117111; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SHOKAT KM, 1989, NATURE, V338, P269, DOI 10.1038/338269a0; STEWART JD, 1994, P NATL ACAD SCI USA, V91, P7404, DOI 10.1073/pnas.91.16.7404; STEWART JD, 1993, ACCOUNTS CHEM RES, V26, P396, DOI 10.1021/ar00032a002; STEWART JD, 1993, CHEM SOC REV, V22, P213, DOI 10.1039/cs9932200213; STEWART JD, 1994, BIOCHEMISTRY-US, V33, P1991; TRAMONTANO A, 1988, J AM CHEM SOC, V110, P2282, DOI 10.1021/ja00215a045; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; WOLFENDEN R, 1976, ANNU REV BIOPHYS BIO, V5, P271, DOI 10.1146/annurev.bb.05.060176.001415	39	105	108	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					388	391		10.1038/375388a0	http://dx.doi.org/10.1038/375388a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760931				2022-12-28	WOS:A1995RB10100048
J	CAROLEI, A; MARINI, C; NENCINI, P; GANDOLFO, C; MOTTO, C; ZANETTE, E; PRENCIPE, M; FIESCHI, C; FRONTONI, M; INZITARI, D; FINOCCHI, C; TOTARO, R; LANDI, G; DEZANCHE, L; SCODITTI, U				CAROLEI, A; MARINI, C; NENCINI, P; GANDOLFO, C; MOTTO, C; ZANETTE, E; PRENCIPE, M; FIESCHI, C; FRONTONI, M; INZITARI, D; FINOCCHI, C; TOTARO, R; LANDI, G; DEZANCHE, L; SCODITTI, U			PREVALENCE AND OUTCOME OF SYMPTOMATIC CAROTID LESIONS IN YOUNG-ADULTS	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM PROGNOSIS; ISCHEMIC STROKE; CEREBRAL INFARCTION; ARTERY OCCLUSION; STENOSIS; DISEASE; PEOPLE; RISK	Objective-To estimate the prevalence and outcome of symptomatic internal carotid artery lesions in young adults. Design-Multicentre hospital based observational study with five year follow up. Setting-Seven neurological departments in northern and central Italy. Subjects-240 patients (115 men) aged 15-44 with a recent transient ischaemic attack or stroke in the carotid territory. Main outcome measures-(a) Prevalence of symptomatic internal carotid artery stenosis or occlusion detected by continuous wave Doppler ultrasonography at entry; (b) incidence rates of cerebral, cardiac, and non-vascular death; non-fatal stroke; and non-fatal myocardial infarction. Results-Carotid stenoses of 50-99% and occlusions were found in 38 patients (15.8%). Both conditions were significantly more frequent in patients aged over 35 and in those with hypertension, diabetes mellitus, and stroke at entry. The standardised mortality ratio at five years was 10.5 (95% confidence interval 5.0 to 19.3). Survival of patients with stenoses of 0-49% and occlusions was significantly better than that of patients with stenoses of 50-99%. Carotid stenosis of 50-99% was an independent predictor of death (hazard ratio 7.9; 95% confidence interval 2.2 to 29) and non-fatal stroke (hazard ratio 7.4; 1.5 to 37.4). Conclusions-The prevalence of carotid stenosis or occlusion in young adults after a cerebrovascular event is low. Though patients with high grade symptomatic carotid stenosis are at risk of non-fatal and fatal events, patients with internal artery occlusion apparently have a benign prognosis.	NEUROL CLIN,FLORENCE,ITALY; NEUROL CLIN,GENOA,ITALY; POLICLIN UMBERTO 1,DIPARTIMENTO SCI NEUROL,ROME,ITALY; UNIV ROME,ROME,ITALY; UNIV FLORENCE,FLORENCE,ITALY; UNIV GENOA,GENOA,ITALY; UNIV LAQUILA,LAQUILA,ITALY; OSPED MAGGIORE,MILAN,ITALY; PADUA HOSP,PADUA,ITALY; PARMA HOSP,PARMA,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; University of Florence; University of Genoa; University of L'Aquila; University of Padua; Azienda Ospedaliera - Universita di Padova; University of Parma; University Hospital of Parma	CAROLEI, A (corresponding author), UNIV LAQUILA,OSPED S MARIA COLLEMAGGIO,DIPARTIMENTO MED INTERNA & SANITA PUBBL,NEUROL CLIN,I-67100 LAQUILA COLLEMAGG,ITALY.		Finocchi, Cinzia/AAA-7409-2020; Inzitari, Domenico/AAH-8722-2020	Finocchi, Cinzia/0000-0003-4385-1203; 				BOGOUSSLAVSKY J, 1987, ARCH NEUROL-CHICAGO, V44, P479, DOI 10.1001/archneur.1987.00520170009012; BOGOUSSLAVSKY J, 1985, ARCH NEUROL-CHICAGO, V42, P864, DOI 10.1001/archneur.1985.04060080042014; BORNSTEIN NM, 1989, NEUROLOGY, V39, P6, DOI 10.1212/WNL.39.1.6; BOTS ML, 1992, HYPERTENSION, V19, P717, DOI 10.1161/01.HYP.19.6.717; CAROLEI A, 1992, CEREBROVASC DIS, V2, P266, DOI 10.1159/000109026; CHANCELLOR AM, 1989, STROKE, V20, P477, DOI 10.1161/01.STR.20.4.477; COTE R, 1983, STROKE, V14, P898, DOI 10.1161/01.STR.14.6.898; FURLAN AJ, 1980, NEUROLOGY, V30, P986, DOI 10.1212/WNL.30.9.986; GAUTIER JC, 1989, REV NEUROL, V145, P437; HENNERICI M, 1986, STROKE, V17, P718, DOI 10.1161/01.STR.17.4.718; HINDFELT B, 1992, ACTA NEUROL SCAND, V86, P440, DOI 10.1111/j.1600-0404.1992.tb05120.x; KLEIN GM, 1984, CAN J NEUROL SCI, V11, P302, DOI 10.1017/S0317167100045571; LISOVOSKI F, 1991, J NEUROL NEUROSUR PS, V54, P576, DOI 10.1136/jnnp.54.7.576; MARINI C, 1993, NEUROEPIDEMIOLOGY, V12, P70, DOI 10.1159/000110303; MARSHALL J, 1982, J NEUROL SCI, V53, P473, DOI 10.1016/0022-510X(82)90244-1; MILLIKAN CH, 1975, STROKE, V6, P565; NORRIS JW, 1990, J NEUROL NEUROSUR PS, V53, P235, DOI 10.1136/jnnp.53.3.235; SPENCER MP, 1979, STROKE, V10, P326, DOI 10.1161/01.STR.10.3.326; TELL GS, 1988, STROKE, V19, P423, DOI 10.1161/01.STR.19.4.423; ZHU CZ, 1990, STROKE, V21, P1131, DOI 10.1161/01.STR.21.8.1131; 1991, LANCET, V337, P1235; 1991, NEW ENGL J MED, V325, P445; 1991, CAUSE MORTE ANNO 198, V4, P1	23	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1363	1366		10.1136/bmj.310.6991.1363	http://dx.doi.org/10.1136/bmj.310.6991.1363			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787538	Green Published			2022-12-28	WOS:A1995RB00500021
J	CHAN, R; HEMERYCK, L; OREGAN, M; CLANCY, L; FEELY, J				CHAN, R; HEMERYCK, L; OREGAN, M; CLANCY, L; FEELY, J			ORAL VERSUS INTRAVENOUS ANTIBIOTICS FOR COMMUNITY-ACQUIRED LOWER RESPIRATORY-TRACT INFECTION IN A GENERAL-HOSPITAL - OPEN, RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							CHEST INFECTIONS; MISUSE	Objective-To see whether there is a difference in outcome between patients treated with oral and intravenous antibiotics for lower respiratory tract infection. Design-Open controlled trial in patients admitted consecutively and randomised to treatment with either oral co-amoxiclav, intravenous followed by oral co-amoxiclav, or intravenous followed by oral cephalosporins. Setting-Large general hospital in Dublin. Patients-541 patients admitted for lower respiratory tract infection during one year. Patients represented 87% of admissions with the diagnosis and excluded those who were immunocompromised and patients with severe Life threatening infection. Main outcome measures-Cure, partial cure, extended antibiotic treatment, change of antibiotic, death, and cost and duration of hospital stay. Results-There were no significant differences between the groups in clinical outcome or mortality (6%). However, patients randomised to oral co-amoxiclav had a significantly shorter hospital stay than the two groups given intravenous antibiotic (median 6 v 7 and 9 days respectively). In addition, oral antibiotics were cheaper, easier to administer, and if used routinely in the 800 or so patients admitted annually would lead to savings of around pound 176 000 a year. Conclusions-Oral antibiotics in community acquired lower respiratory tract infection are at least as efficacious as intravenous therapy. Their use reduces labour and equipment costs and may lead to earlier discharge from hospital.	ST JAMES HOSP,TRINITY CTR HLTH SCI,DEPT PHARMACOL & THERAPEUT,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY CTR HLTH SCI,MED EVALUAT UNIT,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY CTR HLTH SCI,DEPT STAT,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY CTR HLTH SCI,DEPT RESP MED,DUBLIN 8,IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin			Clancy, Luke/O-6597-2019; clancy, luke/ABA-1826-2020	Clancy, Luke/0000-0003-2407-2263; 				BAIN PG, 1990, BRIT MED J, V300, P1463; CASTLE M, 1977, JAMA-J AM MED ASSOC, V237, P2819, DOI 10.1001/jama.237.26.2819; DAVEY P, 1990, PHARM J, V244, P793; DAVIES AJ, 1992, J ANTIMICROB CHEMOTH, V29, P1, DOI 10.1093/jac/29.1.1; DENTON M, 1991, BRIT MED J, V302, P327, DOI 10.1136/bmj.302.6772.327-a; DUNAGAN WC, 1989, AM J MED, V87, P253; FEELY J, 1990, BRIT MED J, V300, P38; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; MAKI DG, 1978, AM J MED SCI, V275, P271, DOI 10.1097/00000441-197805000-00005; MCCONNELL J, 1993, LANCET, V341, P1208, DOI 10.1016/0140-6736(93)91025-H; ODONOVAN C, 1987, BRIT J CLIN PRACT, V41, P1044; REEVES JH, 1989, CHEST, V96, P1292, DOI 10.1378/chest.96.6.1292; ROBERTS AW, 1972, AM J HOSP PHARM, V29, P828, DOI 10.1093/ajhp/29.10.828; SCHECKLER WE, 1970, J AMER MED ASSOC, V213, P264, DOI 10.1001/jama.213.2.264; ZALIN AM, 1989, BRIT MED J, V229, P1279; 1986, DRUG THERA B, V24, P101; 1992, MONTHLY INDEX ME SEP	17	84	88	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1360	1362		10.1136/bmj.310.6991.1360	http://dx.doi.org/10.1136/bmj.310.6991.1360			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787537	Green Published			2022-12-28	WOS:A1995RB00500020
J	MAJEED, FA; COOK, DG; POLONIECKI, J; GRIFFITHS, J; STONES, C				MAJEED, FA; COOK, DG; POLONIECKI, J; GRIFFITHS, J; STONES, C			SOCIODEMOGRAPHIC VARIABLES FOR GENERAL PRACTICES - USE OF CENSUS-DATA	BRITISH MEDICAL JOURNAL			English	Article									MERTON SUTTON & WANDSWORTH FAMILY HLTH SERV AUTHO,LONDON SW15 2SW,ENGLAND		MAJEED, FA (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.			Cook, Derek/0000-0002-9723-5759				HOTELLING H, 1940, ANN MATH STAT, V2, P271; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MARTIN D, 1992, T I BRIT GEOGR, V17, P350, DOI 10.2307/622885; MORPHET C, 1992, AREA, V24, P63; ROYSTON P, IN PRESS BIOMETRICS	5	21	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1373	1374		10.1136/bmj.310.6991.1373	http://dx.doi.org/10.1136/bmj.310.6991.1373			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB005	7787543	Green Published			2022-12-28	WOS:A1995RB00500026
J	TABAQCHALI, S; JUMAA, P				TABAQCHALI, S; JUMAA, P			FORTNIGHTLY REVIEW - DIAGNOSIS AND MANAGEMENT OF CLOSTRIDIUM-DIFFICILE INFECTION	BRITISH MEDICAL JOURNAL			English	Article							CLINDAMYCIN-ASSOCIATED COLITIS; POLYMERASE CHAIN-REACTION; PSEUDOMEMBRANOUS COLITIS; TOXIN-A; NOSOCOMIAL ACQUISITION; EPIDEMIOLOGY; ETIOLOGY				TABAQCHALI, S (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT MED MICROBIOL,LONDON EC1A 7BE,ENGLAND.							BACON AE, 1988, J INFECT DIS, V158, P349, DOI 10.1093/infdis/158.2.349; BARTLETT JG, 1977, J INFECT DIS, V136, P701, DOI 10.1093/infdis/136.5.701; BARTLETT JG, 1984, REV INFECT DIS, V6, pS235; BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; BRAZIER JS, 1993, CLIN INFECT DIS, V16, pS228, DOI 10.1093/clinids/16.Supplement_4.S228; CARTMILL TDI, 1994, J HOSP INFECT, V27, P1, DOI 10.1016/0195-6701(94)90063-9; FEKETY R, 1981, AM J MED, V60, P906; Finney JMT, 1893, B JOHNS HOPKINS HOSP, V4, P53; GEORGE RH, 1978, BRIT MED J, V1, P695, DOI 10.1136/bmj.1.6114.695; GEORGE WL, 1978, LANCET, V1, P802; GEORGE WL, 1988, CLOSTRIDIUM DIFFICIL, P31; GUMERLOCK PH, 1991, REV INFECT DIS, V13, P1053; HAFIZ S, 1976, J MED MICROBIOL, V9, P129, DOI 10.1099/00222615-9-2-129; HAFIZ S, 1974, THESIS U LEEDS LEEDS; Hall IC, 1935, AM J DIS CHILD, V49, P390, DOI 10.1001/archpedi.1935.01970020105010; HEARD SR, 1986, J INFECT DIS, V153, P159, DOI 10.1093/infdis/153.1.159; KABINS SA, 1975, ANN INTERN MED, V83, P830, DOI 10.7326/0003-4819-83-6-830; KELLY CP, 1992, GASTROENTEROLOGY, V102, P35, DOI 10.1016/0016-5085(92)91781-X; KHAN MY, 1966, ANN INTERN MED, V65, P1, DOI 10.7326/0003-4819-65-1-1; LARSON HE, 1978, LANCET, V1, P1063; LARSON HE, 1977, BRIT MED J, V1, P1246, DOI 10.1136/bmj.1.6071.1246; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MERZ CS, 1994, J CLIN MICROBIOL, V32, P1142, DOI 10.1128/JCM.32.5.1142-1147.1994; MILLER PD, 1990, CELL IMMUNOL, V126, P155, DOI 10.1016/0008-8749(90)90308-E; MULLIGAN ME, 1988, J CLIN MICROBIOL, V26, P41, DOI 10.1128/JCM.26.1.41-46.1988; MULLIGAN ME, 1988, CLOSTRIDIUM DIFFICIL, P229; POTHOULAKIS C, 1988, J CLIN INVEST, V81, P1741, DOI 10.1172/JCI113514; TABAQCHALI S, 1984, J MED MICROBIOL, V18, P47, DOI 10.1099/00222615-18-1-47; TABAQCHALI S, 1992, EUR J CLIN MICROBIOL, V11, P1049, DOI 10.1007/BF01967798; TEASLEY DG, 1983, LANCET, V2, P1043; TEDESCO FJ, 1974, ANN INTERN MED, V81, P429, DOI 10.7326/0003-4819-81-4-429; WALLEY T, 1990, POSTGRAD MED J, V66, P582, DOI 10.1136/pgmj.66.777.582-a; WILCOX MH, 1992, J HOSP INFECT, V20, P85; WREN BW, 1993, J MED MICROBIOL, V38, P109, DOI 10.1099/00222615-38-2-109; 1994, REPORT PREVENTION MA	35	45	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1375	1380		10.1136/bmj.310.6991.1375	http://dx.doi.org/10.1136/bmj.310.6991.1375			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787544	Green Published			2022-12-28	WOS:A1995RB00500028
J	MATTHES, DJ; SINK, H; KOLODKIN, AL; GOODMAN, CS				MATTHES, DJ; SINK, H; KOLODKIN, AL; GOODMAN, CS			SEMAPHORIN-II CAN FUNCTION AS A SELECTIVE INHIBITOR OF SPECIFIC SYNAPTIC ARBORIZATIONS	CELL			English	Article							GROWTH CONE GUIDANCE; DROSOPHILA-MELANOGASTER; C-ELEGANS; MOTONEURONS; EXPRESSION; MOLECULE; NEURONS; MUSCLES; PROTEIN; EMBRYO	Previous studies showed that grasshopper semaphorin I, a transmembrane semaphorin, functions in vivo to steer a pair of growth cones, prevent defasciculation, and inhibit branching; and that chick collapsin, a secreted semaphorin, can function in vitro to cause growth cone collapse. Semaphorin II, a secreted semaphorin in Drosophila, is transiently expressed by a single large muscle during motoneuron outgrowth and synapse formation. To test the in vivo function of semaphorin II, we created transgenic Drosophila that generate ectopic semaphorin II expression by muscles that normally do not express it. The results show that semaphorin II can function in vivo as a selective target-derived signal that inhibits the formation of specific synaptic terminal arbors.			MATTHES, DJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,DIV NEUROBIOL,BERKELEY,CA 94720, USA.		Matthes, David/N-3529-2017	Matthes, David/0000-0002-0198-9661	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD021294, R01HD021294] Funding Source: NIH RePORTER; NICHD NIH HHS [HD21294] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bate Michael, 1993, P1013; BROADIE K, 1993, DEVELOPMENT S, V119, P227; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHIBA A, 1995, NATURE, V374, P166, DOI 10.1038/374166a0; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Crossley AC, 1978, GENETICS BIOL DROS B, V2, P499; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GOODMAN CS, 1994, CELL, V78, P353, DOI 10.1016/0092-8674(94)90413-8; GOODMAN CS, 1993, CELL S, V10, P77; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V2, P61; HOOPER JE, 1986, EMBO J, V5, P2321, DOI 10.1002/j.1460-2075.1986.tb04500.x; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RAMOS RGP, 1993, GENE DEV, V7, P2533, DOI 10.1101/gad.7.12b.2533; ROSKIES AL, 1994, SCIENCE, V265, P799, DOI 10.1126/science.8047886; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAGHERT PH, 1982, DEV BIOL, V94, P391, DOI 10.1016/0012-1606(82)90356-6; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WHARTON KA, 1993, MECH DEVELOP, V40, P141, DOI 10.1016/0925-4773(93)90072-6	32	183	184	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					631	639		10.1016/0092-8674(95)90084-5	http://dx.doi.org/10.1016/0092-8674(95)90084-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758117	Bronze			2022-12-28	WOS:A1995QZ71000020
J	PATON, C				PATON, C			PRESENT DANGERS AND FUTURE THREATS - SOME PERVERSE INCENTIVES IN THE NHS REFORMS	BRITISH MEDICAL JOURNAL			English	Article								The NHS reforms have come to mean all things to all men (and women). Identifying a market oriented purchaser-provider split as the conceptual heart of the reforms is still, however, useful. There are important perverse incentives in and around the NHS that are associated with the reforms; furthermore, many reactions to the resulting problems are paradoxical and often counterproductive. Hitherto most criticism of the reforms from the health policy and management community (as opposed to the professions and the public) has been tactical rather than fundamental. There are serious problems for the NHS associated both with the NHS market and with current, often tacit, strategies for the future of the service.			PATON, C (corresponding author), KEELE UNIV,CTR HLTH PLANNING & MANAGEMENT,KEELE ST5 5SP,STAFFS,ENGLAND.							BLOOR K, 1994, BRIT MED J, V309, P352, DOI 10.1136/bmj.309.6951.352; Galbraith, 2018, ATLANTIC; HAM C, 1994, BRIT MED J, V309, P351, DOI 10.1136/bmj.309.6951.351; HAM C, 1994, BRIT MED J, V309, P1032, DOI 10.1136/bmj.309.6961.1032; HAM C, 1992, OBSERVER        0329, P4; PATON C, 1995, GUARDIAN S, P26; SMITH P, 1994, BRIT MED J, V309, P1050, DOI 10.1136/bmj.309.6961.1050; TOWNSEND P, 1994, BRIT MED J, V308, P1674; 1994, REV WEIGHTED CAPITAT; 1994, DEV NHS PURCHASING G	10	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1245	1248		10.1136/bmj.310.6989.1245	http://dx.doi.org/10.1136/bmj.310.6989.1245			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767197	Green Published			2022-12-28	WOS:A1995QY87700024
J	SMITH, D; PEARCE, L; PRINGLE, M; CAPLAN, R				SMITH, D; PEARCE, L; PRINGLE, M; CAPLAN, R			ADULTS WITH A HISTORY OF CHILD SEXUAL ABUSE - EVALUATION OF A PILOT THERAPY SERVICE	BRITISH MEDICAL JOURNAL			English	Article							SURVIVORS	Objective-To evaluate a pilot service offering therapy specifically to adults with a history of child sexual abuse. Design-Questionnaire survey. Setting-Specialised therapy unit, Breakfree, which offers care, therapy, and support. Subjects-116 clients presenting to the service who were offered therapy. Main outcome measures-Scores from three psychological questionnaires-the social activities and distress scale, the general health questionnaire, and the delusions, symptoms, and states inventory-and from questionnaires about the clients' abuse, previous use of health services, and opinion of the Breakfree service. Results-Clients had received previous help from health services and other agencies without apparent effect; they were highly distressed according to their psychological scores; and they were very frequent users of the health services. The clients showed significant improvement in their psychological scores (Wilcoxon's matched pairs signed ranks test): social activities and distress scale, z=-3.3, P=0.001; general health questionnaire, z=-5.8, P<0.00001; delusions, symptoms, and states inventory, 2=-4.8, P<0.00001). This was most pronounced for those who had completed therapy by the end of the study. Whereas 82/88 clients had a score for the general health questionnaire that indicated clinical distress at the start, only 28/58 did so at the end of the study (only 17/35 among those who had finished therapy). Conclusions-This group of adults with a history of child sexual abuse were highly disturbed and previous high users of the health service. The specialist service Breakfree was effective in the short term and, if the benefits are sustained, would yield a net cost saving to the health service.	QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND; BREAKFREE SERV ADULT SURVIVORS,LINCOLN LN2 2JP,ENGLAND; SO GEN HOSP,DEPT PSYCHIAT,GLASGOW G51 4TF,LANARK,SCOTLAND	University of Nottingham; University of Glasgow								ARNOLD RP, 1990, BRIT MED J, V300, P705, DOI 10.1136/bmj.300.6726.705; BAKER AW, 1985, CHILD ABUSE NEGLECT, V9, P457, DOI 10.1016/0145-2134(85)90054-7; BEDFORD A, 1977, BRIT J MED PSYCHOL, V50, P163, DOI 10.1111/j.2044-8341.1977.tb02409.x; BEDFORD A, 1978, DSSI MANUAL; Briere J.N., 1992, CHILD ABUSE TRAUMA T; Butler D J, 1993, Arch Fam Med, V2, P29, DOI 10.1001/archfami.2.1.29; Cartmill A, 1992, Seizure, V1, P33, DOI 10.1016/1059-1311(92)90052-3; COURTOIS CA, 1993, PRIMARY CARE, V20, P433; FINKELHOR D, 1994, CHILD ABUSE NEGLECT, V18, P409, DOI 10.1016/0145-2134(94)90026-4; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Gould D A, 1994, Arch Fam Med, V3, P252, DOI 10.1001/archfami.3.3.252; GREEN AH, 1993, J AM ACAD CHILD PSY, V32, P890, DOI 10.1097/00004583-199309000-00002; Greig E, 1992, Seizure, V1, P269, DOI 10.1016/1059-1311(92)90036-Z; Hall L., 1993, SURVIVING CHILD SEXU; KELLY L, 1991, EXPLORATORY STUDY PR; Kirkengen Anne Luise, 1993, Scandinavian Journal of Primary Health Care, V11, P276, DOI 10.3109/02813439308994843; MACPHERSON R, 1994, PSYCHIAT B, V18, P70; NASH C, 1985, SEXUAL VICTIMIZATION; ROWAN AB, 1993, J TRAUMA STRESS, V6, P3, DOI 10.1002/jts.2490060103; van Egmond M, 1993, Crisis, V14, P129; WAHLEN SD, 1992, VIOLENCE ED SOLUTION; WATSON D, 1969, J CONSULT CLIN PSYCH, V33, P448, DOI 10.1037/h0027806; YELLOWLEES PM, 1994, MED J AUSTRALIA, V160, P408, DOI 10.5694/j.1326-5377.1994.tb138264.x	23	23	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1175	1178		10.1136/bmj.310.6988.1175	http://dx.doi.org/10.1136/bmj.310.6988.1175			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX566	7767154	Green Published			2022-12-28	WOS:A1995QX56600026
J	GSTAIGER, M; KNOEPFEL, L; GEORGIEV, O; SCHAFFNER, W; HOVENS, CM				GSTAIGER, M; KNOEPFEL, L; GEORGIEV, O; SCHAFFNER, W; HOVENS, CM			A B-CELL COACTIVATOR OF OCTAMER-BINDING TRANSCRIPTION FACTORS	NATURE			English	Article							IMMUNOGLOBULIN PROMOTERS; REMOTE ENHANCER; DNA MOTIF; ACTIVATION; EXPRESSION; DOMAINS; SEQUENCES; CLONING; OTF-2; OCT-2	THE octamer motif (ATGCAAAT) paradoxically plays a central role in mediating the activity of both B-cell specific and ubiquitous promoters. It has been widely assumed that the predominantly lymphoid-restricted octamer-binding factor Oct-2 mediates tissue-specific promoter activity, whereas the ubiquitously expressed Oct-1 mediates general promoter activity, but this view has been challenged(1-6). Here we use a modified yeast one-hybrid assay to isolate a B-cell factor, Bob1, which associates with either Oct-2 or Oct-1. In transfection experiments, this factor boosts Oct-1-mediated promoter activity and to a lesser extent, that of Oct-2. This coactivation is strictly dependent on the specific interaction with Oct-1 or Oct-2 because deletion of the octamer motif abolishes coactivation. We conclude that Bob1 could represent a new tissue-specific transcriptional coactivator which may convert a ubiquitously expressed transcription factor to a cell-type-specific activator.	UNIV ZURICH,INST MOLEK BIOL 2,CH-8057 ZURICH,SWITZERLAND	University of Zurich				Hovens, Christopher/0000-0002-0610-1289				ARNOSTI DN, 1993, NUCLEIC ACIDS RES, V21, P5570, DOI 10.1093/nar/21.24.5570; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FELDHAUS AL, 1993, EMBO J, V12, P2763, DOI 10.1002/j.1460-2075.1993.tb05937.x; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERR W, 1992, TRANSCRIPTIONAL REGU, P1103; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; KEMLER I, 1991, NUCLEIC ACIDS RES, V19, P237, DOI 10.1093/nar/19.2.237; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MULLERIMMERGLUC.MM, 1990, EMBO J, V9, P1625; PIERANI A, 1990, MOL CELL BIOL, V10, P6204, DOI 10.1128/MCB.10.12.6204; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; STRUBIN M, IN PRESS CELL; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0	21	286	289	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JAN 26	1995	373	6512					360	362		10.1038/373360a0	http://dx.doi.org/10.1038/373360a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QD404	7779176				2022-12-28	WOS:A1995QD40400065
J	KRUMHOLZ, HM; SEEMAN, TE; MERRILL, SS; DELEON, CFM; VACCARINO, V; SILVERMAN, DI; TSUKAHARA, R; OSTFELD, AM; BERKMAN, LF				KRUMHOLZ, HM; SEEMAN, TE; MERRILL, SS; DELEON, CFM; VACCARINO, V; SILVERMAN, DI; TSUKAHARA, R; OSTFELD, AM; BERKMAN, LF			LACK OF ASSOCIATION BETWEEN CHOLESTEROL AND CORONARY HEART-DISEASE MORTALITY AND MORBIDITY AND ALL-CAUSE MORTALITY IN PERSONS OLDER THAN 70 YEARS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH BLOOD CHOLESTEROL; UNITED-STATES ADULTS; SERUM-CHOLESTEROL; CARDIOVASCULAR-HEALTH; PLASMA-LIPIDS; RISK-FACTORS; MEN; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; DESIGN	Objectives.-To determine whether elevated serum cholesterol level is associated with all-cause mortality, mortality from coronary heart disease, or hospitalization for acute myocardial infarction and unstable angina in persons older than 70 years. Also, to evaluate the association between low levels of high-density lipoprotein cholesterol (HDL-C) and elevated ratio of serum cholesterol to HDL-C with these outcomes. Design.-Prospective, community-based cohort study with yearly interviews. Participants.-A total of 997 subjects who were interviewed in 1988 as part of the New Haven, Conn, cohort of the Established Population for the Epidemiologic Study of the Elderly (EPESE) and consented to have blood drawn. Main Outcome Measures.-The risk factor-adjusted odds ratios of the 4-year incidence of all-cause mortality, mortality from coronary heart disease, and hospitalization for myocardial infarction or unstable angina were calculated for the following: subjects with total serum cholesterol levels greater than or equal to 6.20 mmol/L (greater than or equal to 240 mg/dL) compared with subjects with cholesterol levels less than 5.20 mmol/L (<200 mg/dL); subjects in the lowest tertile of HDL-C level compared with those in the highest tertile; and subjects in the highest tertile of the ratio of total serum cholesterol to HDL-C level compared with those in the lowest tertile. Results.-Elevated total serum cholesterol level, low HDL-C, and high total serum cholesterol to HDL-C ratio were not associated with a significantly higher rate of all-cause mortality, coronary heart disease mortality, or hospitalization for myocardial infarction or unstable angina after adjustment for cardiovascular risk factors. The risk factor-adjusted odds ratio for all-cause mortality was 0.99 (95% confidence interval [Cl], 0.56 to 2.69) for the group who had cholesterol levels greater than or equal to 6.20 mmol/L (greater than or equal to 240 mg/dl) compared with the group that had levels less than 5.20 mmol/L (<200 mg/dL); 1.00 (95% Cl, 0.59 to 1.70) for the group in the lowest tertile of HDL-C compared with those in the highest tertile; and 1.03 (95% Cl, 0.62 to 1.71) for subjects in the highest tertile of the ratio of total serum cholesterol to HDL-C compared with those in the lowest tertile. Conclusions.-Our findings do not support the hypothesis that hypercholesterolemia or low HDL-C are important risk factors for all-cause mortality, coronary heart disease mortality, or hospitalization for myocardial infarction or unstable angina in this cohort of persons older than 70 years.	YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, CHRON DIS EPIDEMIOL SECT, NEW HAVEN, CT 06520 USA; UNIV CONNECTICUT, SCH MED, DIV CARDIOL, FARMINGTON, CT USA	Yale University; University of Connecticut	KRUMHOLZ, HM (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED,CARDIOVASC MED SECT, 333 CEDAR ST, POB 208017, NEW HAVEN, CT 06520 USA.		, Harlan/AAI-2875-2020		NIA NIH HHS [1T-32-AG-0-0153, R01-AG-1-1042] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000153, R01AG011042] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P903, DOI 10.1016/0021-9681(84)90066-3; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CASTELLI WP, 1989, AM J CARDIOL, V63, pH12; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CURB JD, 1986, J AM GERIATR SOC, V34, P773, DOI 10.1111/j.1532-5415.1986.tb03980.x; DENKE MA, 1990, ANN INTERN MED, V112, P780, DOI 10.7326/0003-4819-112-10-780; ETTINGER WH, 1992, CIRCULATION, V86, P858, DOI 10.1161/01.CIR.86.3.858; Freeman Daniel H. Jr., 1992, P46; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KAFONEK SD, 1990, ANN INTERN MED, V112, P723, DOI 10.7326/0003-4819-112-10-723; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; LACROIX AZ, 1990, CIRCULATION, V81, P437, DOI 10.1161/01.CIR.81.2.437; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MANOLIO TA, 1992, ANN INTERN MED, V116, P641, DOI 10.7326/0003-4819-116-8-641; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RIFKIND BM, 1979, CIRCULATION, V60, P427; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; SEEMAN T, 1993, AM J EPIDEMIOL, V138, P1037, DOI 10.1093/oxfordjournals.aje.a116822; SEMPOS CT, 1993, JAMA-J AM MED ASSOC, V269, P3009, DOI 10.1001/jama.269.23.3009; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; WONG ND, 1991, ANN INTERN MED, V115, P687, DOI 10.7326/0003-4819-115-9-687; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416; 1971, 5TH WORK GROUP ISCH; 1991, AGING AM, P273; 1988, INT CLASSIFICATON DI; 1977, JAMA-J AM MED ASSOC, V237, P2385	31	365	370	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	1994	272	17					1335	1340		10.1001/jama.272.17.1335	http://dx.doi.org/10.1001/jama.272.17.1335			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP020	7772105				2022-12-28	WOS:A1994PP02000027
J	LUCAS, MJ; LEVENO, KJ; CUNNINGHAM, FG				LUCAS, MJ; LEVENO, KJ; CUNNINGHAM, FG			A COMPARISON OF MAGNESIUM-SULFATE WITH PHENYTOIN FOR THE PREVENTION OF ECLAMPSIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY-INDUCED HYPERTENSION; SEVERE PREECLAMPSIA; PROPHYLAXIS; SEIZURES; MANAGEMENT	Background. Magnesium sulfate is used widely to prevent eclamptic seizures in pregnant women with hypertension, but few studies have compared the efficacy of magnesium sulfate with that of other drugs. Anticonvulsant prophylaxis with phenytoin for eclampsia has been recommended, but there are virtually no data to support its efficacy. Our objective was to compare magnesium sulfate with phenytoin in preventing seizures in hypertensive women during labor. Methods. We randomly assigned women with hypertension who were admitted for delivery to receive either magnesium sulfate or phenytoin. The magnesium sulfate regimen consisted of a 10-g intramuscular loading dose followed by a maintenance dose of 5 g given intramuscularly every four hours. For women with severe preeclampsia, an additional 4-g loading dose was given intravenously. The phenytoin regimen included a 1000-mg loading dose infused over a period of 1 hour, followed by a 500-mg oral dose 10 hours later. With either regimen, anticonvulsant therapy was continued for 24 hours post partum. Results. Ten of 1089 women randomly assigned to the phenytoin regimen had eclamptic convulsions, as compared with none of 1049 women randomly assigned to magnesium sulfate (P=0.004). There were no significant differences in any risk factors for eclampsia between the two study groups. Maternal and infant outcomes were also similar in the two study groups. Conclusions. Magnesium sulfate is superior to phenytoin for the prevention of eclampsia in hypertensive pregnant women. These results validate the long-practiced use of magnesium sulfate in the prevention of eclampsia.			LUCAS, MJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT OBSTET & GYNECOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							APPLETON MP, 1991, AM J OBSTET GYNECOL, V165, P907, DOI 10.1016/0002-9378(91)90437-V; BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; BROWN CEL, 1988, AM J OBSTET GYNECOL, V159, P915, DOI 10.1016/S0002-9378(88)80170-4; CHESLEY LC, 1978, HYPERTENSIVE DISORDE, P309; CHUA S, 1991, LANCET, V337, P250, DOI 10.1016/0140-6736(91)92227-S; CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P763; DOMMISSE J, 1990, BRIT J OBSTET GYNAEC, V97, P104, DOI 10.1111/j.1471-0528.1990.tb01734.x; DONALDSON JO, 1986, CLIN NEUROPHARMACOL, V9, P37, DOI 10.1097/00002826-198602000-00003; Dorsett L, 1926, AM J OBSTET GYNECOL, V11, P227, DOI 10.1016/S0002-9378(15)32334-6; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; DULEY L, 1994, BRIT J OBSTET GYNAEC, V101, P565, DOI 10.1111/j.1471-0528.1994.tb13644.x; EASTMAN NJ, 1945, CAN MED ASSOC J, V52, P562; GEDEKOH RH, 1981, AM J OBSTET GYNECOL, V140, P860, DOI 10.1016/0002-9378(81)90075-2; GERTHOFFER WT, 1987, J CARDIOVASC PHARM, V10, P9, DOI 10.1097/00005344-198707000-00002; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x; KAPLAN PW, 1988, ARCH NEUROL-CHICAGO, V45, P1361, DOI 10.1001/archneur.1988.00520360079017; KAPLAN PW, 1990, ARCH NEUROL-CHICAGO, V47, P1031, DOI 10.1001/archneur.1990.00530090111021; LEZARD EM, 1933, AM J OBSTET GYNECOL, V26, P647; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LUCAS MJ, 1994, AM J PERINAT, V11, P153, DOI 10.1055/s-2007-994577; PRITCHARD JA, 1984, AM J OBSTET GYNECOL, V148, P951, DOI 10.1016/0002-9378(84)90538-6; PRITCHARD JA, 1955, SURG GYNECOL OBSTET, V100, P131; RALL T W, 1990, P436; REPKE JT, 1992, CLIN OBSTET GYNECOL, V35, P365; ROBERTS JM, 1993, LANCET, V342, P504; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; ROBSON SC, 1993, BRIT J OBSTET GYNAEC, V100, P623, DOI 10.1111/j.1471-0528.1993.tb14227.x; SIBAI BM, 1985, AM J OBSTET GYNECOL, V152, P184, DOI 10.1016/S0002-9378(85)80020-X; SIBAI BM, 1990, AM J OBSTET GYNECOL, V163, P1049, DOI 10.1016/0002-9378(90)91123-T; SLATER RM, 1987, LANCET, V1, P1417; WATSON KV, 1986, P NATL ACAD SCI USA, V83, P1075, DOI 10.1073/pnas.83.4.1075; Zuspan F P, 1966, Clin Obstet Gynecol, V9, P954, DOI 10.1097/00003081-196612000-00010; 1990, AM J OBSTET GYNECOL, V163, P1689	33	355	358	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 27	1995	333	4					201	205		10.1056/NEJM199507273330401	http://dx.doi.org/10.1056/NEJM199507273330401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK423	7791836	Bronze			2022-12-28	WOS:A1995RK42300001
J	PEARSON, DC; MAY, GR; FICK, GH; SUTHERLAND, LR				PEARSON, DC; MAY, GR; FICK, GH; SUTHERLAND, LR			AZATHIOPRINE AND 6-MERCAPTOPURINE IN CROHN DISEASE - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							INFLAMMATORY BOWEL-DISEASE; LONG-TERM; CONTROLLED TRIAL; ACTIVITY INDEX; METAANALYSIS; THERAPY; QUALITY	Purpose: To assess the effectiveness of azathioprine and B-mercaptopurine in inducing remission of active Crohn disease and the effectiveness of azathioprine in maintaining remission of quiescent disease. Data Sources: Pertinent studies were selected from the MEDLINE database (1966 to May 1994), abstracts from major gastrointestinal meetings, and references from published articles and reviews. Study Selection: Nine randomized, placebo-controlled trials of azathioprine or g-mercaptopurine therapy were identified: Four addressed active disease, two addressed quiescent disease, and three had multiple therapeutic arms. Data Extraction: Data were extracted by three independent observers on the basis of the intention-to-treat principle and were analyzed with logistic regression. Each study was given a quality score on the basis of predetermined criteria. Data Synthesis: Compared with placebo, azathioprine or 6-mercaptopurine therapy had an odds ratio of response of 3.09 (95% CI, 2.45 to 3.91) in patients with active Crohn disease. When the single trial that used 6-mercaptopurine in active disease was excluded from the analysis, the odds ratio of response was 1.45 (CI, 1.12 to 1.87). No trials of quiescent disease used 6-mercaptopurine; the odds ratio of response in these trials of quiescent disease was 2.27 (CI, 1.76 to 2.93). For active disease, continuation of therapy for at least 17 weeks improved response (P = 0.03). For quiescent disease, a higher dose improved response (P = 0.008). Increased cumulative dose improved response in both groups (P < 0.001 for active disease and P = 0.01 for quiescent disease). A steroid-sparing effect was seen in active disease (odds ratio, 3.69 (CI, 2.12 to 6.42) and in quiescent disease (odds ratio, 4.64 [CI, 1.00 to 21.54]), Fistulae improved with therapy (odds ratio, 4.44 [CI, 1.50 to 13.20]). Adverse events requiring withdrawal from a trial, primarily allergy, leukopenia, pancreatitis, and nausea, were increased with therapy (odds ratio, 5.26 [CI, 2.20 to 12.60]). Conclusions: Azathioprine and 6-mercaptopurine are effective in treating active Crohn disease and in maintaining remission. Cumulative dose was an important factor in predicting response. Adverse effects were more common among patients receiving therapy.	UNIV CALGARY, CALGARY, AB, CANADA	University of Calgary								ABBE KA, 1987, ANN INTERN MED, V107, P224; ALSTEAD EM, 1990, GASTROENTEROLOGY, V99, P443, DOI 10.1016/0016-5085(90)91027-4; ARMITAGE P, 1990, STATISTICAL METHODS, P387; BEST WR, 1979, GASTROENTEROLOGY, V77, P843; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BROOKE BN, 1969, LANCET, V2, P612; BROOKE BN, 1970, LANCET, V2, P1050; BROWN CH, 1970, AM J GASTROENTEROL, V54, P363; CANDY S, 1994, GASTROENTEROLOGY, V106, pA659; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHALMERS TC, 1988, DATA ANAL CLIN MED Q; COLONNA T, 1994, AM J GASTROENTEROL, V89, P362; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DRUCKER WR, 1970, ANN SURG, V172, P618, DOI 10.1097/00000658-197010000-00008; EWE K, 1993, GASTROENTEROLOGY, V105, P367, DOI 10.1016/0016-5085(93)90709-L; FERGUSON A, 1979, ARQ GASTROENTEROL, V16, P67; GARDNER S, 1989, CONFIDENCE INTERVAL; GOLDSTEIN F, 1987, J CLIN GASTROENTEROL, V9, P654, DOI 10.1097/00004836-198712000-00009; HABER CJ, 1986, GASTROENTEROLOGY, V91, P982, DOI 10.1016/0016-5085(86)90703-1; JONES FA, 1966, BRIT MED J, V1, P1418, DOI 10.1136/bmj.1.5500.1418-a; KLEIN M, 1974, GASTROENTEROLOGY, V66, P916; KORELITZ BI, 1981, GASTROENTEROLOGY, V80, P193; KORELITZ BI, 1985, DIGEST DIS SCI, V30, P58, DOI 10.1007/BF01318372; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; LENNARDJONES JE, 1981, DIGEST DIS SCI, V26, P364, DOI 10.1007/BF01308381; MARKOWITZ J, 1990, GASTROENTEROLOGY, V99, P1347, DOI 10.1016/0016-5085(90)91160-8; MATTHEWS DE, 1988, USING UNDERSTANDING, P141; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; NYMAN M, 1985, SCAND J GASTROENTERO, V20, P1197, DOI 10.3109/00365528509089276; OBRIEN JJ, 1991, GASTROENTEROLOGY, V101, P39, DOI 10.1016/0016-5085(91)90457-V; ODONOGHUE DP, 1978, LANCET, V2, P955, DOI 10.1016/S0140-6736(78)92524-2; PATTERSON JF, 1971, AM J DIG DIS, V16, P327, DOI 10.1007/BF02235208; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; PRESENT DH, 1989, ANN INTERN MED, V111, P641, DOI 10.7326/0003-4819-111-8-641; RHODES J, 1971, LANCET, V2, P1273; RHODES J, 1970, LANCET, V2, P1142; ROSENBERG JL, 1975, AM J DIG DIS, V20, P721, DOI 10.1007/BF01070829; ROSMAN M, 1973, ANN INTERN MED, V79, P694, DOI 10.7326/0003-4819-79-5-694; SINGLETON JW, 1981, DIGEST DIS SCI, V26, P368, DOI 10.1007/BF01308382; SPECTOR TD, 1991, J EPIDEMIOL COMMUN H, V45, P89, DOI 10.1136/jech.45.2.89; SUMMERS RW, 1979, GASTROENTEROLOGY, V77, P847; SUTHERLAND LR, 1993, ANN INTERN MED, V118, P540, DOI 10.7326/0003-4819-118-7-199304010-00009; VERHAVE M, 1990, J PEDIATR-US, V117, P809, DOI 10.1016/S0022-3476(05)83349-9; WATSON WC, 1974, GASTROENTEROLOGY, V66, P796; WHITING GW, 1994, INFLAMM BOWEL DIS, P203; WILLOUGHBY JM, 1971, LANCET, V2, P944; WOLBERG G, 1988, PHARM LYMPHOCYTES, P517; 1992, STATISTICAL SCI	48	729	745	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					132	142		10.7326/0003-4819-123-2-199507150-00009	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778826				2022-12-28	WOS:A1995RM43500009
J	PHILLIPS, S; DONALDSON, L; GEISLER, K; PERA, A; KOCHAR, R				PHILLIPS, S; DONALDSON, L; GEISLER, K; PERA, A; KOCHAR, R			STOOL COMPOSITION IN FACTITIAL DIARRHEA - A 6-YEAR EXPERIENCE WITH STOOL ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Article						FACTITIOUS DISORDERS; DIARRHEA; FECES; BODY WATER; CATHARTICS	LAXATIVE ABUSE; OSMOTIC GAP; MALABSORPTION; PREVALENCE	Objective: To evaluate the utility of stool water analysis in the management of patients with chronic diarrhea. Design: Retrospective analysis of 6 years of experience. Setting: A specialized laboratory in a major referral center, Patients: 325 patients with diarrhea who were referred for stool chemistry analysis. Fecal analysis was requested by many internists and gastroenterologists. Patient records were reviewed to establish the final and most likely cause of diarrhea. Results: One third of patients provided samples that were inappropriate for analysis, but data from 202 persons were available, The usefulness of the general separation of cases of chronic diarrhea into those in which patients had predominantly osmotic pathophysiologies and those in which patients had predominantly secretory pathophysiologies was confirmed, but overlap and intra-individual variability limited the usefulness of this approach in individual patients. Thirty-five patients (17%) had a diagnosis of factitial diarrhea (30 because of laxative use and 5 because of fluid added to stools). Conclusions: Among selected subpopulations, the chemical analysis of fresh stools has a role in the evaluation of obscure examples of chronic diarrhea. It is especially useful in identifying factitial diarrhea.			PHILLIPS, S (corresponding author), MAYO CLIN & MAYO FDN, GASTROENTEROL RES UNIT, 200 1ST ST SW, ROCHESTER, MN 55905 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032121] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BINDER HJ, 1992, GASTROENTEROLOGY, V103, P702, DOI 10.1016/0016-5085(92)90870-5; BYTZER P, 1990, SCAND J GASTROENTERO, V25, P572, DOI 10.3109/00365529009095532; BYTZER P, 1989, GUT, V30, P1379, DOI 10.1136/gut.30.10.1379; DALY JA, 1972, CLIN CHEM, V18, P263; DEWOLFF FA, 1983, HUM TOXICOL, V2, P385, DOI 10.1177/096032718300200235; EARNEST DL, 1993, GASTROINTESTINAL DIS, P1563; EHERER AJ, 1992, GASTROENTEROLOGY, V103, P545, DOI 10.1016/0016-5085(92)90845-P; FINE KD, 1992, GASTROENTEROLOGY, V102, P1936, DOI 10.1016/0016-5085(92)90316-Q; FINE KD, 1991, NEW ENGL J MED, V324, P1012, DOI 10.1056/NEJM199104113241502; FINE KD, 1993, GASTROINTESTINAL DIS, P1043; GALATOLA G, 1992, EUR J GASTROEN HEPAT, V4, P533; Grindler E., 1971, CLIN CHEM, V17, P662; HAMMER HF, 1990, J CLIN INVEST, V86, P1936, DOI 10.1172/JCI114927; HAMMER HF, 1989, J CLIN INVEST, V84, P1056, DOI 10.1172/JCI114267; HARVEY RF, 1983, LANCET, V1, P632; KACERE RD, 1993, MAYO CLIN PROC, V68, P355, DOI 10.1016/S0025-6196(12)60130-X; KASPI T, 1978, LANCET, V1, P1162; LADEFOGED K, 1987, SCAND J GASTROENTERO, V22, P813, DOI 10.3109/00365528708991920; MORRISON G, 1987, CLIN DISORDERS FLUID; PHILLIPS SF, 1972, GASTROENTEROLOGY, V63, P495; TALLEY NJ, 1989, ANN INTERN MED, V111, P671, DOI 10.7326/0003-4819-111-8-671; VALENTZAS CG, 1971, JAMA-J AM MED ASSOC, V217, P966	22	29	30	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					97	100		10.7326/0003-4819-123-2-199507150-00003	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00003			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778841				2022-12-28	WOS:A1995RM43500003
J	MILES, DW; RUBENS, RD				MILES, DW; RUBENS, RD			TRANSVERSE LEUKONYCHIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MILES, DW (corresponding author), GUYS HOSP,LONDON SE1 9RT,ENGLAND.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					100	100		10.1056/NEJM199507133330205	http://dx.doi.org/10.1056/NEJM199507133330205			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777013				2022-12-28	WOS:A1995RH22500005
J	EPSTEIN, A				EPSTEIN, A			SOUNDING BOARD - PERFORMANCE REPORTS ON QUALITY - PROTOTYPES, PROBLEMS, AND PROSPECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARE				EPSTEIN, A (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115, USA.							EPSTEIN AM, 1993, NEW ENGL J MED, V329, P1672, DOI 10.1056/NEJM199311253292229; GOLD M, 1994, 93G08 MATH POL RES G; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HUNTINGTON J, 1994, NEW ENGL J MED, V331, P1303, DOI 10.1056/NEJM199411103311910; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P1; JOST TS, 1994, JAMA-J AM MED ASSOC, V271, P1508, DOI 10.1001/jama.271.19.1508; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KASSIRER JP, 1994, NEW ENGL J MED, V330, P634, DOI 10.1056/NEJM199403033300910; LOHR K, 1990, QUALITY ASSURANCE ME; MCNEIL BJ, 1992, INQUIRY-J HEALTH CAR, V29, P298; Nightingale F., 1863, NOTES ON HOSP, V3rd; VLADECK BC, 1995, JAMA-J AM MED ASSOC, V273, P1483, DOI 10.1001/jama.273.19.1483; 1995, 1995 PHYS PAYM REV C; 1993, HLTH PLAN EMPLOYER D; 1995, REPORT CARD PILOT PR; 1994, REPORT CARDS USEFUL	16	192	192	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					57	61		10.1056/NEJM199507063330114	http://dx.doi.org/10.1056/NEJM199507063330114			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7777000				2022-12-28	WOS:A1995RG73500014
J	SCHWARTZ, RS				SCHWARTZ, RS			MOLECULAR MEDICINE - JUMPING GENES AND THE IMMUNOGLOBULIN-V GENE SYSTEM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; HOZUMI N, 1976, P NATL ACAD SCI USA, V73, P3628, DOI 10.1073/pnas.73.10.3628; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHWARTZ RS, 1995, NEW ENGL J MED, V332, P941, DOI 10.1056/NEJM199504063321408; STEWART AK, 1994, BLOOD, V83, P1717	5	16	16	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					42	44		10.1056/NEJM199507063330108	http://dx.doi.org/10.1056/NEJM199507063330108			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776993				2022-12-28	WOS:A1995RG73500008
J	BAYERDORFFER, E; NEUBAUER, A; RUDOLPH, B; THIEDE, C; LEHN, N; EIDT, S; STOLTE, M				BAYERDORFFER, E; NEUBAUER, A; RUDOLPH, B; THIEDE, C; LEHN, N; EIDT, S; STOLTE, M			REGRESSION OF PRIMARY GASTRIC LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE TYPE AFTER CURE OF HELICOBACTER-PYLORI INFECTION	LANCET			English	Article							POLYMERASE CHAIN-REACTION; CAMPYLOBACTER-PYLORI; STAGING CLASSIFICATION; IMMUNE-RESPONSE; MONOCLONALITY; ERADICATION; DNA	Lymphoma of gastric-mucosa-associated lymphatic tissue (MALT) type has been linked to infection with Helicobacter pylori. We investigated the effect on MALT lymphoma of eradicating H pylori infection. 33 patients with primary gastric low-grade MALT lymphoma associated with H pylori gastritis were treated with omeprazole (120 mg daily) and amoxycillin (2 . 25 g daily) for 14 days to eradicate H pylori. In addition to histology, PCR was used to examine proliferation of monoclonal B cells before treatment and during follow-up. All patients had at least two post-treatment examinations, and all became negative for H pylori, 2 after a second treatment course. On histology, 23 (70%) patients showed complete regression and 4 (12%) partial regression of lymphoma. 6 (18%) patients had no change after cure of H pylori infection. 1 was treated with chemotherapy. Of 5 treated surgically, 4 were found to have high-grade B-cell lymphoma on histology of the resected stomach and 1 a high-grade T-cell lymphoma. PCR showed complete disappearance of monoclonal B cells after cure of H pylori infection in 13 of 16 patients investigated. During median follow-up of 1 year no relapse of MALT lymphoma occurred. Low-grade primary gastric MALT lymphoma can completely regress after eradication of H pylori infection. However, longer follow-up is needed to clarify whether the remission is lasting.	FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,DEPT INTERNAL MED & HEMATOL,BERLIN,GERMANY; TECH UNIV MUNICH,INST MICROBIOL,MUNICH,GERMANY; UNIV COLOGNE,INST PATHOL,COLOGNE,GERMANY; INST PATHOL,BAYREUTH,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Technical University of Munich; University of Cologne	BAYERDORFFER, E (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED 2,D-81377 MUNICH,GERMANY.		Thiede, Christian/AAS-7595-2020; Thiede, Christian/A-1417-2008	Thiede, Christian/0000-0003-1241-2048; 				BAYERDORFFER E, 1992, GASTROENTEROLOGY, V102, P1575, DOI 10.1016/0016-5085(92)91716-H; BAYERDORFFER E, 1995, GASTROENTEROLOGY, V108, P1412, DOI 10.1016/0016-5085(95)90689-4; CAMMAROTA G, 1995, LANCET, V345, P192, DOI 10.1016/S0140-6736(95)90195-7; CARBONE PP, 1971, CANCER RES, V31, P1860; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; DISS TC, 1993, J PATHOL, V169, P291, DOI 10.1002/path.1711690303; EIDT S, 1994, PATHOL RES PRACT, V190, P1077, DOI 10.1016/S0344-0338(11)80904-0; HARRIS AW, 1994, LANCET, V343, P1503; HEILMANN KL, 1991, GUT, V32, P137, DOI 10.1136/gut.32.2.137; HORSTMANN M, LANCET, V3438, P94; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON PG, 1994, NEW ENGL J MED, V330, P1310, DOI 10.1056/NEJM199405053301812; MARSHALL BJ, 1988, LANCET, V2, P1437; MUSSHOFF K, 1977, STRAHLENTHER ONKOL, V153, P218; NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; RADASZKIEWICZ T, 1992, GASTROENTEROLOGY, V102, P1628, DOI 10.1016/0016-5085(92)91723-H; SAMBROOK J, 1989, MOL CLONING LANBORAT; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; STOLTE M, 1989, J CLIN PATHOL, V42, P1269, DOI 10.1136/jcp.42.12.1269; STOLTE M, 1993, LANCET, V342, P568, DOI 10.1016/0140-6736(93)91404-A; STOLTE M, 1992, Z GASTROENTEROL, V29, P6; TRAINOR KJ, 1990, BLOOD, V75, P2220; WAN JH, 1990, J CLIN PATHOL, V43, P880; WEBER DM, 1994, GASTROENTEROLOGY, V107, P1835, DOI 10.1016/0016-5085(94)90828-1; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WOTHERSPOON AC, LANCET, V3433, P94; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	29	816	833	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1591	1594		10.1016/S0140-6736(95)90113-2	http://dx.doi.org/10.1016/S0140-6736(95)90113-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783535				2022-12-28	WOS:A1995RE67000006
J	SCHULMAN, S; RHEDIN, AS; LINDMARKER, P; CARLSSON, A; LARFARS, G; NICOL, P; LOOGNA, E; SVENSSON, E; LJUNGBERG, B; WALTER, H; VIERING, S; NORDLANDER, S; LEIJD, B; JONSSON, KA; HJORTH, M; LINDER, O; BOBERG, J; GUSTAFSSON, C; GRONDAHL, A; TORNEBOHM, E; JOHANSSON, M; LOCKNER, D; JOHNSSON, H; KOBOSKO, J; MALMROS, B; ARCINI, N; SAAW, J; STIG, R; WILHELMSSON, S; OHLSSON, A; MALMQVIST, K; ALKHALILI, F; PETRESCU, A; BROHULT, J; HULTING, J; EKLUND, SG; DAHLIN, L; MARJANOVICS, B; MALM, C; LINDGREN, A; FAGRELL, B; KALLNER, M; GRANQVIST, S; WIMAN, B; EGBERG, N; WADMAN, B; SNYDER, M				SCHULMAN, S; RHEDIN, AS; LINDMARKER, P; CARLSSON, A; LARFARS, G; NICOL, P; LOOGNA, E; SVENSSON, E; LJUNGBERG, B; WALTER, H; VIERING, S; NORDLANDER, S; LEIJD, B; JONSSON, KA; HJORTH, M; LINDER, O; BOBERG, J; GUSTAFSSON, C; GRONDAHL, A; TORNEBOHM, E; JOHANSSON, M; LOCKNER, D; JOHNSSON, H; KOBOSKO, J; MALMROS, B; ARCINI, N; SAAW, J; STIG, R; WILHELMSSON, S; OHLSSON, A; MALMQVIST, K; ALKHALILI, F; PETRESCU, A; BROHULT, J; HULTING, J; EKLUND, SG; DAHLIN, L; MARJANOVICS, B; MALM, C; LINDGREN, A; FAGRELL, B; KALLNER, M; GRANQVIST, S; WIMAN, B; EGBERG, N; WADMAN, B; SNYDER, M			A COMPARISON OF 6 WEEKS WITH 6 MONTHS OF ORAL ANTICOAGULANT-THERAPY AFTER A FIRST EPISODE OF VENOUS THROMBOEMBOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; LONG-TERM TREATMENT; PULMONARY-EMBOLISM; WARFARIN SODIUM; DURATION; POPULATION; HEPARIN	Background. The optimal duration of oral anticoaguiant therapy after a first episode of venous thromboembolism is still a matter of debate. Methods. We performed a multicenter trial comparing six weeks of oral anticoagulant treatment with six months of such therapy in patients who had a first episode of venous thromboembolism. Anticoagulant therapy consisted of warfarin or dicumarol. Of the 902 patients enrolled, 5 were later excluded because they had congenital protein C deficiency; 443 were randomly assigned to receive six weeks of oral anticoagulant therapy with a targeted international normalized ratio (INR) of 2.0 to 2.85, and 454 were randomly assigned to receive six months of such therapy. The initial diagnoses were confirmed by means of venography in cases of deep-vein thromboses (n=790) and with perfusion-ventilation scanning or angiography in cases of pulmonary embolism (n=107); recurrences were confirmed in the same way. Results. After two years of follow-up, there had been 123 recurrences of venous thromboembolism that met the diagnostic criteria, 80 in the six-week group (18.1 percent; 95 percent confidence interval, 14.5 to 21.6) and 43 in the six-month group (9.5 percent; 95 percent confidence interval, 6.8 to 12.2). The odds ratio for recurrence in the six-week group was 2.1 (95 percent confidence interval, 1.4 to 3.1). There was no difference in mortality or the rate of major hemorrhage between the six-week and six-month groups. Conclusions. Six months of prophylactic oral anticoagulation after a first episode of venous thromboembolism led to a tower recurrence rate than did treatment tasting for six weeks. The difference between the two groups occurred between 6 weeks and 6 months after the start of treatment, and the rates of recurrence remained nearly parallel for 11/2 years thereafter.	KAROLINSKA HOSP,DEPT INTERNAL MED,S-10401 STOCKHOLM,SWEDEN; HUDDINGE HOSP,DEPT INTERNAL MED,S-14186 HUDDINGE,SWEDEN; DANDERYD HOSP,DEPT INTERNAL MED,S-18288 DANDERYD,SWEDEN; SODER SJUKHUSET,DEPT INTERNAL MED,S-10064 STOCKHOLM,SWEDEN; KOPING HOSP,DEPT INTERNAL MED,KOPING,SWEDEN; NACKA HOSP,DEPT INTERNAL MED,STOCKHOLM,SWEDEN; SODERTALJE HOSP,DEPT INTERNAL MED,SODERTALJE,SWEDEN; NYKOPING HOSP,DEPT INTERNAL MED,NYKOPING,SWEDEN; SABBATSBERGS HOSP,DEPT INTERNAL MED,S-11382 STOCKHOLM,SWEDEN; NORRTALJE HOSP,DEPT INTERNAL MED,NORRTALJE,SWEDEN; CENT HOSP VASTERAS,DEPT INTERNAL MED,VASTERAS,SWEDEN; ST GORANS UNIV HOSP,DEPT INTERNAL MED,STOCKHOLM,SWEDEN; LINKOPING REG HOSP,DEPT INTERNAL MED,LINKOPING,SWEDEN; LIDKOPING HOSP,DEPT INTERNAL MED,LINKOPING,SWEDEN; OREBRO REG HOSP,DEPT INTERNAL MED,OREBRO,SWEDEN; UPPSALA ACAD HOSP,DEPT INTERNAL MED,UPPSALA,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Danderyds Hospital; Sodersjukhuset Hospital; Vasteras Central Hospital; Saint Goran's Hospital; Uppsala University; Uppsala University Hospital			Miranda, Fausto/N-9780-2018; Schulman, Sam/I-7559-2019; Zanatta, Nilo/P-7137-2017	Miranda, Fausto/0000-0003-2954-8638; Schulman, Sam/0000-0002-8512-9043; Zanatta, Nilo/0000-0002-0959-9043				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; COON WW, 1969, ANN SURG, V170, P559, DOI 10.1097/00000658-196910000-00007; FENNERTY A, 1988, BMJ-BRIT MED J, V297, P1285, DOI 10.1136/bmj.297.6659.1285; HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; LAGERSTEDT CI, 1985, LANCET, V2, P515; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; OSULLIVAN EF, 1972, MED J AUSTRALIA, V2, P1104, DOI 10.5694/j.1326-5377.1972.tb103752.x; PETITTI DB, 1986, AM J MED, V81, P255, DOI 10.1016/0002-9343(86)90260-3; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Research Committee of the British Thoracic Society, 1992, LANCET, V340, P873; ROEBUCK DJ, 1992, LANCET, V340, P1296, DOI 10.1016/0140-6736(92)93002-5; SARASIN FP, 1994, THROMB HAEMOSTASIS, V71, P286; SCHULMAN S, 1985, ACTA MED SCAND, V217, P547; SCHULMAN S, 1994, J INTERN MED, V236, P143, DOI 10.1111/j.1365-2796.1994.tb01276.x; SCHULMAN S, 1988, ACTA MED SCAND, V224, P425	18	773	791	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1661	1665		10.1056/NEJM199506223322501	http://dx.doi.org/10.1056/NEJM199506223322501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760866				2022-12-28	WOS:A1995RD99600001
J	BLACK, JA; DEBELLE, GD				BLACK, JA; DEBELLE, GD			FEMALE GENITAL MUTILATION IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							CIRCUMCISION	Much has been written about female genital mutilation in Africa, but little attention has been paid to its existence in Britain. Though it has been illegal in this country since 1985, it is practised secretly or children are sent abroad to have the operation. From the social worker's point of view it is technically a form of child abuse which poses special problems. Black and Debelle review the historical background of female genital mutilation and describe its medical complications. Gallard discusses the problem in France, and Walder considers why such mutilation still continues in Britain.	S BIRMINGHAM HLTH AUTHOR,CHILDRENS SERV UNIT,BIRMINGHAM,W MIDLANDS,ENGLAND		BLACK, JA (corresponding author), VICTORIA MILL HOUSE,WOODBRIDGE IP13 9EG,SUFFOLK,ENGLAND.							[Anonymous], 1991, CHILDREN ACT 1989; DIRIE MA, 1991, TROP DOCT, V21, P146, DOI 10.1177/004947559102100404; Dorkeno E., 1992, FEMALE GENITAL MUTIL; FAYYAD S, 1993, VOICES, P102; HEDLEY R., 1992, CHILD PROTECTION FEM; KORBIN JE, 1991, CHILD ABUSE NEGLECT, V15, P67, DOI 10.1016/0145-2134(91)90010-B; LADJALI M, 1993, BRIT MED J, V307, P460, DOI 10.1136/bmj.307.6902.460; RICHARDS T, 1993, BRIT MED J, V307, P957; SAMI IR, 1986, ANN TROP PAEDIATR, V6, P99, DOI 10.1080/02724936.1986.11748419; WEBB E, 1994, ARCH DIS CHILD, V70, P441, DOI 10.1136/adc.70.5.441; 1986, WHO CHRON, V40, P31	11	62	62	0	26	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1590	1592		10.1136/bmj.310.6994.1590	http://dx.doi.org/10.1136/bmj.310.6994.1590			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787654	Green Published			2022-12-28	WOS:A1995RE35300029
J	HYMAN, A; SCHILLINGER, D; LO, B				HYMAN, A; SCHILLINGER, D; LO, B			LAWS MANDATING REPORTING OF DOMESTIC VIOLENCE - DO THEY PROMOTE PATIENT WELL-BEING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BATTERED WOMEN; ELDER ABUSE; PREVALENCE; EMERGENCY; PHYSICIAN		UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DEPT INTERNAL MED,SAN FRANCISCO,CA 94110; SAN FRANCISCO NEIGHBORHOOD LEGAL ASSISTANCE FDN,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center					NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Beauchamp T, 1989, PRINCIPLES BIOMEDICA; BOWKER L, 1983, BEATING WIFE BEATING; BREWER RA, 1989, ANN EMERG MED, V18, P1217, DOI 10.1016/S0196-0644(89)80063-0; COSTA AJ, 1993, PRIMARY CARE, V20, P375; FAULKNER LR, 1982, FAM LAW QUART, V16, P69; Flitcraft A.H., 1992, DIAGNOSTIC TREATMENT; GIN NE, 1991, J GEN INTERN MED, V6, P317, DOI 10.1007/BF02597429; Hamberger L K, 1992, Fam Med, V24, P283; HAMPTON RL, 1988, COPING FAMILY VIOLEN, P212; HART B, 1993, AM BEHAV SCI, V36, P624, DOI 10.1177/0002764293036005007; HART RJ, 1992, JUV FAM COURT J, V43, P79; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; JANG DL, 1994, CLEARINGHOUSE REV, V28, P397; JECKER NS, 1993, JAMA-J AM MED ASSOC, V269, P776, DOI 10.1001/jama.269.6.776; KINPORTS K, 1993, TEX J WOMEN L, V2, P163; LACHS MS, 1995, NEW ENGL J MED, V332, P437, DOI 10.1056/NEJM199502163320706; LETELLIER P, 1994, SAN FRANCISCO MED, V67, P16; LO B, 1994, RESOLVING ETHICAL DI; MAGUIGAN H, 1991, U PENN LAW REV, V140, P379, DOI 10.2307/3312349; MCLEER SV, 1987, ANN EMERG MED, V16, P1155, DOI 10.1016/S0196-0644(87)80476-6; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; NEWBERGER EH, 1993, PRIMARY CARE, V20, P317; Newman Scott, 1981, Univ Fla Law Rev, V33, P394; NOVELLO AC, 1992, JAMA-J AM MED ASSOC, V267, P3132, DOI 10.1001/jama.267.23.3132; Renzetti C.M., 1988, J INTERPERS VIOLENCE, V3, P381, DOI DOI 10.1177/088626088003004003; ROSENBERG DA, 1994, MAR AM MED ASS NAT C; SASSETTI MR, 1993, PRIMARY CARE, V20, P289; SCHECHTER S, 1992, ENDING VIOLENCE WOME; SEELYE KQ, 1994, NY TIMES        0820, pA9; Smith Steven R, 1986, KY Law J, V75, P473; Stark E., 1988, HDB FAMILY VIOLENCE, P293; Straus M.M.A., 1980, CLOSED DOORS VIOLENC; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; WARSHAW C, 1994, IMPROVING HLTH CARE, P73; 1994, YOUR INSIGHT CALIFOR; 1992, ACCREDITATION MANUAL; 1992, JAMA-J AM MED ASSOC, V267, P3184; 1982, UNIFORM CRIME REPORT; 1993, STUDY FAMILY DOMESTI; 1992, JAMA-J AM MED ASSOC, V267, P3190; 1991, HRD9174 SU GEN ACC O; 1983, NCJ87068 US DEP JUST; 1992, HLTH CARE PROFESSION; 1994, NCJ149259 US DEP JUS; 1994, NATIONAL HLTH I DOME; 1994, MAR HLTH JUST C P	46	107	107	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1781	1787		10.1001/jama.273.22.1781	http://dx.doi.org/10.1001/jama.273.22.1781			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB800	7769774				2022-12-28	WOS:A1995RB80000033
J	KIZER, KW; VASSAR, MJ; HARRY, RL; LAYTON, KD				KIZER, KW; VASSAR, MJ; HARRY, RL; LAYTON, KD			HOSPITALIZATION CHARGES, COSTS AND INCOME FOR FIREARM-RELATED INJURIES AT A UNIVERSITY TRAUMA CENTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To quantify the actual cost of inpatient medical care for firearm-related injuries at a university trauma center. Design.-Retrospective Case Series of all hospital admissions for firearm-related injuries for the 3 years 1990 through 1992. Total inpatient financial data Were examined by means of a recently instituted cost-accounting methodology. Setting.-Level trauma Center at a university hospital that provides trauma care and tertiary care to 3.7 million residents of 23 Counties. Patients.-A total of 787 consecutive patients were admitted to the hospital with firearm-related injuries information from the trauma registry and hospital finance records were linked for 750 (95%) of these patients. Main Outcome Measures.-Total inpatient hospital charges, costs, revenues, and net income according to payer source. Results.-Men aged 15 to 44 years accounted for 77% of patients with firearm-related injuries. The overall mean and median hospital charges per admission were $52 271 and $28 033, respectively, whereas the overall mean and median hospital costs per admission were $13 794 and $7964, respectively. The net income per patient ranged from an average loss of $6980 for each patient having no insurance to an average profit of $28 557 for each patient with a health maintenance organization contract the losses sustained on nonsponsored and Medicaid patients were more than offset by net income from patients having private health insurance, Medicare or other insurance coverage such that there was an average profit of $5809 per admission for a firearm-related injury. Concluslons.-Treatment of firearm-related injuries produces net income for this University trauma center by virtue of the cost shifting built into its pricing structure. if data from this institution ate extrapolated to the nation, then the actual cost of providing medical care for firearm-related injuries in the United States in 1995 is projected to be $4.0 billion. The majority of this cost will be paid indirectly by private health insurance.	UNIV CALIF DAVIS,SCH MED,DEPT COMMUNITY & INT HLTH,DAVIS,CA 95616; UNIV CALIF DAVIS,SCH MED,DEPT INTERNAL MED,DIV EMERGENCY MED & CLIN TOXICOL,DAVIS,CA 95616; UNIV CALIF DAVIS,MED CTR,FINANCIAL SERV ADM,SACRAMENTO,CA 95817; UNIV CALIF DAVIS,MED CTR,TRAUMA PROGRAM,SACRAMENTO,CA 95817	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis			Vassar, Matt/AAD-5385-2020					[Anonymous], 1988, INT CLASSIFICATION D; FINE PR, 1994, J FORENSIC SCI, V39, P674; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HEALTH AFFAIR, V12, P171, DOI 10.1377/hlthaff.12.4.171; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; PAYNE JE, 1993, J TRAUMA, V34, P276, DOI 10.1097/00005373-199302000-00018; Rice DP, 1989, COST INJURY US REPOR; ROPP L, 1992, JAMA-J AM MED ASSOC, V267, P2905, DOI 10.1001/jama.267.21.2905; SMITH SM, 1989, AM J PREV MED, V5, P296, DOI 10.1016/S0749-3797(18)31070-5; TARDIFF K, 1994, JAMA-J AM MED ASSOC, V272, P43, DOI 10.1001/jama.272.1.43; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; 1989, DETERMINING INJURY S; 1990, TRANSITION 1 SOFTWAR; 1994, MMWR-MORBID MORTAL W, V43, P37; 1991, TRAUMA CARE LIFESAVI	18	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1768	1773		10.1001/jama.273.22.1768	http://dx.doi.org/10.1001/jama.273.22.1768			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769771				2022-12-28	WOS:A1995RB80000030
J	BOURGUET, W; RUFF, M; CHAMBON, P; GRONEMEYER, H; MORAS, D				BOURGUET, W; RUFF, M; CHAMBON, P; GRONEMEYER, H; MORAS, D			CRYSTAL-STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE HUMAN NUCLEAR RECEPTOR RXR-ALPHA	NATURE			English	Article							STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; THYROID-HORMONE; TRANSCRIPTIONAL ACTIVATION; ECDYSONE RECEPTOR; IDENTIFICATION; SUPERFAMILY; HETERODIMER; MUTATION	The crystal structure of the human retinoid-X receptor RXR-alpha ligand-binding domain reveals a previously undiscovered fold of an antiparallel alpha-helical sandwich, packed as dimeric units. Two helices and one loop form the homodimerization surface, and hydrophobic heptad repeats participate in stabilizing the fold. The existence of a ligand-binding pocket is proposed that would allow 9-cis retinoic acid to interact with different functional modules, including the AF-2 activating domain. Several lines of evidence indicate that the overall structure is a prototype fold of ligand-binding domains of nuclear receptors.	UNIV STRASBOURG 1,COLL FRANCE,INST GENET & BIOL MOLEC & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Bourguet, William/Y-6600-2019; Bourguet, William/I-5569-2013; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/G-6240-2011; ruff, marc/J-3011-2013; Gronemeyer, Hinrich/H-7002-2016	Bourguet, William/0000-0002-0643-7719; Bourguet, William/0000-0002-0643-7719; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; ruff, marc/0000-0001-5451-6377; Gronemeyer, Hinrich/0000-0001-9454-2449				AMEZ JG, 1994, J APPL CRYSTALLOGR, V27, P649; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; CHAKRABORTI PK, 1991, J BIOL CHEM, V266, P22075; CHAMBON P, 1994, CELL BIOL, V5, P115; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V90, P1293; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HARD T, 1990, SCIENCE, V248, P157; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEDOUARIN B, IN PRESS EMBO J; LEE MS, 1993, SCIENCE, V269, P1117; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; REESE JC, 1992, MOL ENDOCRINOL, V6, P2160, DOI 10.1210/me.6.12.2160; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SCHILTZ M, 1994, J APPL CRYSTALLOGR, V27, P950, DOI 10.1107/S0021889894005923; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; STROMSTEDT PE, 1990, J BIOL CHEM, V265, P12973; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WRENN CK, 1993, J BIOL CHEM, V268, P24089; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311	50	1007	1043	6	62	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					377	382		10.1038/375377a0	http://dx.doi.org/10.1038/375377a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760929				2022-12-28	WOS:A1995RB10100045
J	CHEN, JQ; DEVIVO, M; DINGUS, J; HARRY, A; LI, JR; SUI, JL; CARTY, DJ; BLANK, JL; EXTON, JH; STOFFEL, RH; INGLESE, J; LEFKOWITZ, RJ; LOGOTHETIS, DE; HILDEBRANDT, JD; IYENGAR, R				CHEN, JQ; DEVIVO, M; DINGUS, J; HARRY, A; LI, JR; SUI, JL; CARTY, DJ; BLANK, JL; EXTON, JH; STOFFEL, RH; INGLESE, J; LEFKOWITZ, RJ; LOGOTHETIS, DE; HILDEBRANDT, JD; IYENGAR, R			A REGION OF ADENYLYL-CYCLASE-2 CRITICAL FOR REGULATION BY G-PROTEIN BETA-GAMMA-SUBUNITS	SCIENCE			English	Article							MUSCARINIC K+-CHANNEL; ALPHA-SUBUNIT; BINDING; SITE; STIMULATION; ACTIVATION; CLONING; BRAIN	Receptor-mediated activation of heterotrimeric guanine nucleotide-binding proteins (G proteins) results in the dissociation of alpha from beta gamma subunits, thereby allowing both to regulate effecters. Little is known about the regions of effecters required for recognition of G beta gamma. A peptide encoding residues 956 to 982 of adenylyl cyclase 2 specifically blocked G beta gamma stimulation of adenylyl cyclase 2, phospholipase C-beta 3, potassium channels, and beta-adrenergic receptor kinase as well as inhibition of calmodulin-stimulated adenylyl cyclases, but had no effect on interactions between G beta gamma and G alpha(o). Substitutions in this peptide identified a functionally important motif, Gln-X-X-G lu-Arg, that is also conserved in regions of potassium channels and beta-adrenergic receptor kinases that participate in G beta gamma interactions, Thus, the region defined by residues 956 to 982 of adenylyl cyclase 2 may contain determinants important for receiving signals from G beta gamma.	CUNY,MT SINAI SCH MED,DEPT PHARMACOL,NEW YORK,NY 10029; MED UNIV S CAROLINA,DEPT CELL & MOLEC PHARMACOL,CHARLESTON,SC 29425; CUNY,MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL,NASHVILLE,TN 37232; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Medical University of South Carolina; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Duke University; Howard Hughes Medical Institute; Duke University			Lefkowitz, Robert/AAW-2649-2021		NCI NIH HHS [CA-44998] Funding Source: Medline; NIDDK NIH HHS [DK-38761, DK-37219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, R01DK037219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENOVIC J, 1991, J BIOL CHEM, V261, P14939; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BLANK JL, 1994, METHOD ENZYMOL, V238, P237; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DEVIVO M, 1994, METHOD ENZYMOL, V238, P131; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DINGUS J, 1994, METHOD ENZYMOL, V237, P457; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PREMONT RT, 1993, ENDOCRINOLOGY, V131, P2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9808; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; TAKAO K, 1994, NEURON, V13, P747, DOI 10.1016/0896-6273(94)90041-8; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UEDA N, 1994, J BIOL CHEM, V269, P4388; WATSON PA, 1994, J BIOL CHEM, V269, P28893	33	221	228	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1166	1169		10.1126/science.7761832	http://dx.doi.org/10.1126/science.7761832			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761832				2022-12-28	WOS:A1995RA60400034
J	CANNELL, MB; CHENG, H; LEDERER, WJ				CANNELL, MB; CHENG, H; LEDERER, WJ			THE CONTROL OF CALCIUM-RELEASE IN HEART-MUSCLE	SCIENCE			English	Article							CARDIAC SARCOPLASMIC-RETICULUM; RAT VENTRICULAR MYOCYTES; CA-2+ RELEASE; SKELETAL-MUSCLE; CONTRACTION; ACTIVATION; RYANODINE; CHANNEL; TRANSIENTS; CELLS	The control of calcium release from intracellular stores (the sarcoplasmic reticulum) in cardiac muscle was examined with the use of a confocal microscope and voltage clamp techniques. Depolarization evoked graded calcium release by altering the extent of spatial and temporal summation of elementary calcium release events called ''calcium sparks.'' These evoked sparks were triggered by local L-type calcium channel currents in a stochastic manner, were similar at different potentials, and resembled spontaneous calcium sparks. Once triggered, the calcium release from the sarcoplasmic reticulum during a calcium spark was independent of the duration of the triggering calcium influx. These results were used to develop a unifying model for cardiac excitation-contraction coupling that explains the large (but paradoxically stable) amplification of the trigger calcium influx by a combination of digital and analog behavior.	ST GEORGE HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,LONDON SW17 0RE,ENGLAND; UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR MED BIOTECHNOL,BALTIMORE,MD 21201	St Georges University London; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Lederer, William/B-1285-2010; Heping, Cheng/AAE-2680-2019	Heping, Cheng/0000-0002-9604-6702	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036974, R01HL036974, R01HL025675] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36974, HL25675] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALKE CW, 1994, J PHYSIOL-LONDON, V474, P447, DOI 10.1113/jphysiol.1994.sp020036; BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BERS DM, 1993, AM J PHYSIOL, V264, pC1587, DOI 10.1152/ajpcell.1993.264.6.C1587; CALLEWAERT G, 1988, P NATIONAL ACADEMY S, V82, P2009; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CANNELL MB, 1994, J PHYSIOL-LONDON, V477P, pP25; CHENG H, 1995, CIRC RES, V76, P236, DOI 10.1161/01.RES.76.2.236; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHENG H, 1994, AM J PHYSIOL, V428, P415; CLEEMANN L, 1991, J PHYSIOL-LONDON, V432, P283, DOI 10.1113/jphysiol.1991.sp018385; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; FERGUSON DG, 1984, J CELL BIOL, V99, P1735, DOI 10.1083/jcb.99.5.1735; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LIPP P, 1994, J PHYSIOL-LONDON, V474, P439, DOI 10.1113/jphysiol.1994.sp020035; LOPEZLOPEZ JR, 1994, J PHYSIOL-LONDON, V480, P21, DOI 10.1113/jphysiol.1994.sp020337; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; NABAUER M, 1990, AM J PHYSIOL, V258, pC189, DOI 10.1152/ajpcell.1990.258.1.C189; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; ONEILL SC, 1990, AM J PHYSIOL, V258, pC1165, DOI 10.1152/ajpcell.1990.258.6.C1165; ROSE WC, 1992, J PHYSIOL-LONDON, V456, P267, DOI 10.1113/jphysiol.1992.sp019336; ROUSSEAU E, 1987, AM J PHYSIOL, V253, pC364, DOI 10.1152/ajpcell.1987.253.3.C364; ROUSSEAU E, 1989, AM J PHYSIOL, V256, pH328, DOI 10.1152/ajpheart.1989.256.2.H328; STERN MD, 1992, BIOPHYS J, V63, P497, DOI 10.1016/S0006-3495(92)81615-6; TRAFFORD AW, 1993, PFLUG ARCH EUR J PHY, V425, P181, DOI 10.1007/BF00374521; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; WIER WG, 1994, J PHYSIOL-LONDON, V474, P463, DOI 10.1113/jphysiol.1994.sp020037	31	502	512	0	51	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1045	1049		10.1126/science.7754384	http://dx.doi.org/10.1126/science.7754384			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754384				2022-12-28	WOS:A1995QY93400040
J	SYMONS, JA; ALCAMI, A; SMITH, GL				SYMONS, JA; ALCAMI, A; SMITH, GL			VACCINIA VIRUS ENCODES A SOLUBLE TYPE-I INTERFERON RECEPTOR OF NOVEL STRUCTURE AND BROAD SPECIES-SPECIFICITY	CELL			English	Article							NUCLEOTIDE-SEQUENCE; GAMMA RECEPTOR; ALPHA RECEPTOR; MYXOMA VIRUS; CELLS; MICE; EXPRESSION; PROTEIN; GENOME; GENE	Vaccinia virus (VV) and other orthopoxviruses express a soluble type I interferon (IFN) receptor that for VV strain Western Reserve is encoded by gene B18R. The 60-65 kDa glycoprotein is related to the interleukin-l receptors and is a member of the immunoglobulin superfamily, unlike other type I IFN receptors, which belong to the class II cytokine receptor family. The receptor has high affinity (K-D, 174 pM) for human IFN alpha and, unlike other type I IFN receptors, has broad species specificity, binding to human, rabbit, bovine, rat, and mouse type I IFNs. This may have aided VV replication in multiple host species during evolution. A VV B18R deletion mutant is attenuated in a murine intranasal model. This type I IFN receptor represents the fourth VV protein that interferes with IFN and the fourth soluble cytokine receptor expressed by poxviruses.			SYMONS, JA (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.		Alcami, Antonio/F-8512-2015; Smith, Geoffrey L/G-2894-2012	Alcami, Antonio/0000-0002-3333-6016; Smith, Geoffrey L/0000-0002-3730-9955	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; AMANO H, 1979, J GEN VIROL, V44, P265, DOI 10.1099/0022-1317-44-1-265; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; Baxby D., 1981, TRENDS IMMUNOL, V3, P26; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLAMONICI OR, 1992, J IMMUNOL, V148, P2126; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; Downie AW, 1939, J PATHOL BACTERIOL, V48, P361, DOI 10.1002/path.1700480212; ENGELSTAD M, 1993, VIROLOGY, V194, P627, DOI 10.1006/viro.1993.1302; ESPOSITO J, 1981, J VIROL METHODS, V2, P175, DOI 10.1016/0166-0934(81)90036-7; FALKNER FG, 1990, J VIROL, V64, P3108, DOI 10.1128/JVI.64.6.3108-3111.1990; Fenner F., 1988, HIST INT PUBLIC HLTH; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUGHES SJ, 1991, J BIOL CHEM, V266, P20103; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; ISAACS SN, 1990, VIROLOGY, V178, P626, DOI 10.1016/0042-6822(90)90367-Z; JOHNSON GP, 1993, VIROLOGY, V196, P381, DOI 10.1006/viro.1993.1494; KARUPIAH G, 1993, J VIROL, V67, P4214, DOI 10.1128/JVI.67.7.4214-4226.1993; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERR SM, 1991, VIROLOGY, V180, P625, DOI 10.1016/0042-6822(91)90076-N; KOHONENCORISH MRJ, 1990, EUR J IMMUNOL, V20, P157, DOI 10.1002/eji.1830200123; LANGER JA, 1986, METHOD ENZYMOL, V119, P305; MACKETT M, 1979, J GEN VIROL, V45, P683, DOI 10.1099/0022-1317-45-3-683; MASSUNG RF, 1993, NATURE, V366, P748, DOI 10.1038/366748a0; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MORIKAWA S, 1993, VIROLOGY, V193, P753, DOI 10.1006/viro.1993.1184; MOSS B, 1981, J VIROL, V40, P387, DOI 10.1128/JVI.40.2.387-395.1981; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; NOVICK D, 1992, FEBS LETT, V314, P445, DOI 10.1016/0014-5793(92)81523-O; PARKINSON JE, 1994, VIROLOGY, V204, P376, DOI 10.1006/viro.1994.1542; PESKA S, 1987, ANNU REV BIOCHEM, V56, P727; RODRIGUEZ JR, 1991, VIROLOGY, V185, P929, DOI 10.1016/0042-6822(91)90575-V; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SMITH CA, 1991, BIOCHEM BIOPH RES CO, V176, P335, DOI 10.1016/0006-291X(91)90929-2; Smith Geoffrey L., 1994, Trends in Microbiology, V2, P81, DOI 10.1016/0966-842X(94)90539-8; SMITH GL, 1991, J GEN VIROL, V72, P511, DOI 10.1099/0022-1317-72-3-511; SMITH GL, 1993, J GEN VIROL, V74, P1725, DOI 10.1099/0022-1317-74-9-1725; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SYMONS J A, 1990, Cytokine, V2, P190, DOI 10.1016/1043-4666(90)90015-L; Turner G S, 1967, J Gen Virol, V1, P399, DOI 10.1099/0022-1317-1-3-399; UEDA Y, 1972, VIROLOGY, V49, P794, DOI 10.1016/0042-6822(72)90535-1; UEDA Y, 1969, VIROLOGY, V38, P180, DOI 10.1016/0042-6822(69)90141-X; UEDA Y, 1990, VIROLOGY, V177, P588, DOI 10.1016/0042-6822(90)90524-U; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WILLIAMSON JD, 1990, J GEN VIROL, V71, P2761, DOI 10.1099/0022-1317-71-11-2761; [No title captured]	60	407	437	2	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					551	560		10.1016/0092-8674(95)90076-4	http://dx.doi.org/10.1016/0092-8674(95)90076-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758109	Bronze			2022-12-28	WOS:A1995QZ71000012
J	TOOTELL, RBH; REPPAS, JB; DALE, AM; LOOK, RB; SERENO, MI; MALACH, R; BRADY, TJ; ROSEN, BR				TOOTELL, RBH; REPPAS, JB; DALE, AM; LOOK, RB; SERENO, MI; MALACH, R; BRADY, TJ; ROSEN, BR			VISUAL-MOTION AFTEREFFECT IN HUMAN CORTICAL AREA MT REVEALED BY FUNCTIONAL MAGNETIC-RESONANCE-IMAGING	NATURE			English	Article							HUMAN BRAIN; SENSORY STIMULATION; CORTEX; INFORMATION; ACTIVATION; ADAPTATION; MOVEMENT	FUNCTIONAL magnetic resonance imaging (fMRI)(1-3) was used to measure local haemodynamic changes (reflecting electrical activity) in human visual cortex during production of the visual motion aftereffect, also known as the waterfall illusion(4,5). As in previous studies(6-9), human cortical area MT (V5) responded much better to moving than to stationary visual stimuli. Here we demonstrate a clear increase in activity in MT when subjects viewed a stationary stimulus undergoing illusory motion, following adaptation to stimuli moving in a single local direction. Control stimuli moving in reversing, opposed directions produced neither a perceptual motion aftereffect nor elevated fMRI levels postadaptation. The time course of the motion aftereffect (measured in parallel psychophysical tests) was essentially identical to the time course of the fMRI motion aftereffect. Because the motion aftereffect is direction specific, this indicates that cells in human area MT are also direction specific. In five other retinotopically defined cortical areas, similar motion-specific aftereffects were smaller than those in MT or absent.	UNIV CALIF SAN DIEGO, DEPT COGNIT SCI, LA JOLLA, CA 92093 USA; UNIV OSLO, DEPT NEUROPHYSIOL, OSLO, NORWAY	University of California System; University of California San Diego; University of Oslo	TOOTELL, RBH (corresponding author), MASSACHUSETTS GEN HOSP, NUCL MAGNET RESONANCE CTR, 149 13TH ST, BOSTON, MA 02129 USA.		Dale, Anders M/A-5180-2010; Sereno, Martin I/F-7657-2012	Sereno, Martin I/0000-0002-7598-7829				ADAMS R, 1834, PHILOS MAG, V5, P373; ALIMAN JM, 1981, CORTICAL SENSORY ORG, V2, P171; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BARLOW HB, 1963, NATURE, V200, P1345, DOI 10.1038/2001345a0; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; CARNEY T, 1993, VISION RES, V33, P1977, DOI 10.1016/0042-6989(93)90022-O; CLARKE S, 1990, J COMP NEUROL, V298, P188, DOI 10.1002/cne.902980205; DEYOE EA, 1994, J NEUROSCI METH, V54, P171, DOI 10.1016/0165-0270(94)90191-0; DUPONT P, 1994, J NEUROPHYSIOL, V72, P1420, DOI 10.1152/jn.1994.72.3.1420; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Frith CD, 1995, HUM BRAIN MAPP, V3, P153, DOI 10.1002/hbm.460030209; HAMMOND P, 1985, EXP BRAIN RES, V60, P411; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LAGAE L, 1989, BRAIN RES, V496, P361, DOI 10.1016/0006-8993(89)91089-5; MARTIN SG, 1988, J NEUROPHYSIOL, V59, P1314; MOVSHON JA, 1979, NATURE, V278, P850, DOI 10.1038/278850a0; NISHIDA S, 1994, VISION RES, V34, P2707, DOI 10.1016/0042-6989(94)90227-5; NISHIDA S, 1992, VISION RES, V32, P1635, DOI 10.1016/0042-6989(92)90156-D; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PETERSEN SE, 1985, BRAIN RES, V346, P146, DOI 10.1016/0006-8993(85)91105-9; SCHNEIDER W, 1993, NATURE, V365, P150, DOI 10.1038/365150a0; SERENO MI, IN PRESS SCIENCE; TOOTELL RBH, 1995, CEREB CORTEX, V5, P39, DOI 10.1093/cercor/5.1.39; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; VAUTIN RG, 1977, J NEUROPHYSIOL, V40, P1051, DOI 10.1152/jn.1977.40.5.1051; VONDERHEYDT R, 1978, ARCH ITAL BIOL, V116, P248; WATSON JDG, 1993, CEREB CORTEX, V3, P79, DOI 10.1093/cercor/3.2.79; Wohlgemuth A., 1911, AFTER EFFECT SEEN MO, V1; ZEKI S, 1991, J NEUROSCI, V11, P641; ZEKI S, 1993, P ROY SOC B-BIOL SCI, V252, P215, DOI 10.1098/rspb.1993.0068	30	452	459	3	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	1995	375	6527					139	141		10.1038/375139a0	http://dx.doi.org/10.1038/375139a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753168				2022-12-28	WOS:A1995QX74100049
J	WEINMANN, EE; SALZMAN, EW				WEINMANN, EE; SALZMAN, EW			MEDICAL PROGRESS - DEEP-VEIN THROMBOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOW-MOLECULAR-WEIGHT; TOTAL HIP-REPLACEMENT; EXTERNAL PNEUMATIC COMPRESSION; CONTINUOUS INTRAVENOUS HEPARIN; ILIOFEMORAL VENOUS THROMBOSIS; SERIAL IMPEDANCE PLETHYSMOGRAPHY; SUSPECTED PULMONARY-EMBOLISM; POOR ANTICOAGULANT RESPONSE; GENERAL ABDOMINAL-SURGERY; ACTIVATED PROTEIN-C		HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School	WEINMANN, EE (corresponding author), BETH ISRAEL HOSP, DEPT SURG, 330 BROOKLINE AVE, BOSTON, MA 02215 USA.							ANDERSON DR, 1993, ANN INTERN MED, V118, P25, DOI 10.7326/0003-4819-118-1-199301010-00005; ANDERSON DR, 1993, ANN INTERN MED, V119, P1105, DOI 10.7326/0003-4819-119-11-199312010-00008; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1994, BMJ, V308, P235; ATIK M, 1967, ARCH SURG-CHICAGO, V94, P664; BARNES RW, 1978, CLIN ORTHOP RELAT R, V132, P61; BARRITT DW, 1960, LANCET, V1, P1309; BAUER AR, 1988, SURG GYNECOL OBSTET, V167, P12; BAUER G, 1940, ACTA CHIR SCAND S6, V84, P75; BAXTER GM, 1992, CLIN RADIOL, V46, P198, DOI 10.1016/S0009-9260(05)80445-3; BENTLEY PG, 1979, BRIT J SURG, V66, P687, DOI 10.1002/bjs.1800661005; BERDEAUX DH, 1992, BLOOD S, V80, pA310; BERGQVIST D, 1990, ACTA CHIR SCAND, P36; BERK PD, 1986, SEMIN HEMATOL, V23, P132; BERNSTEIN EF, 1989, VASCULAR SURG, P1575; BETTMANN MA, 1980, AM J ROENTGENOL, V134, P1169, DOI 10.2214/ajr.134.6.1169; BETTMANN MA, 1987, RADIOLOGY, V165, P113, DOI 10.1148/radiology.165.1.3306781; BONNAR J, 1972, LANCET, V1, P614; BORS E, 1954, SURG GYNECOL OBSTET, V99, P451; BOSHKOV LK, 1993, BRIT J HAEMATOL, V84, P322, DOI 10.1111/j.1365-2141.1993.tb03072.x; BOUNAMEAUX H, 1993, ARCH SURG-CHICAGO, V128, P326; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; BOUNAMEAUX H, 1994, THROMB HAEMOSTASIS, V71, P1; BOUNAMEAUX H, 1992, THROMB HAEMOSTASIS, V67, P603; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; BRATT G, 1990, THROMB HAEMOSTASIS, V64, P506; Broze G., 1994, HEMOSTASIS THROMBOSI, P259; BURNS GA, 1993, J TRAUMA, V35, P405, DOI 10.1097/00005373-199309000-00012; CARPENTER JP, 1993, J VASC SURG, V18, P734, DOI 10.1016/0741-5214(93)90325-G; CARTER CJ, 1982, BLOOD, V59, P1239; CLAGETT GP, 1992, CHEST, V102, pS391, DOI 10.1378/chest.102.4_Supplement.391S; CLAGETT GP, 1988, ANN SURG, V208, P227, DOI 10.1097/00000658-198808000-00016; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; COLDITZ GA, 1986, LANCET, V2, P143; Coller BS., 1991, ANN NY ACAD SCI, V614, P193; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; COMEROTA AJ, 1992, AM J SURG, V164, P265, DOI 10.1016/S0002-9610(05)81083-9; COMEROTA AJ, 1992, J VASC SURG, V15, P887, DOI 10.1016/0741-5214(92)90735-Q; COMEROTA AJ, 1988, THROMBOLYTIC THERAPY, P65; COMP PC, 1984, J CLIN INVEST, V74, P2082, DOI 10.1172/JCI111632; CRANDON AJ, 1980, BRIT MED J, V281, P345, DOI 10.1136/bmj.281.6236.345; Culver D, 1970, J Bone Joint Surg Br, V52, P61; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DALEN JE, 1986, CHEST, V89, pS370, DOI 10.1378/chest.89.5_Supplement.370S; DALEN JE, 1974, PULMONARY EMBOLI, P77; DANGELO A, 1988, J CLIN INVEST, V81, P1445, DOI 10.1172/JCI113475; DATA JL, 1974, ANN INTERN MED, V81, P500, DOI 10.7326/0003-4819-81-4-500; DAVIDSON BL, 1992, ANN INTERN MED, V117, P735, DOI 10.7326/0003-4819-117-9-735; DONALDSON GA, 1963, NEW ENGL J MED, V268, P171, DOI 10.1056/NEJM196301242680402; DOYLE DJ, 1987, ANN INTERN MED, V107, P441, DOI 10.7326/0003-4819-107-4-441; DRILL VA, 1968, J AMER MED ASSOC, V206, P77, DOI 10.1001/jama.206.1.77; DUROUX P, 1991, THROMB HAEMOSTASIS, V65, P251; Dvorak HF, 1994, HEMOSTASIS THROMBOSI, P1238; EGEBERG O, 1965, THROMB DIATH HAEMOST, V13, P516, DOI 10.1055/s-0038-1656297; ELIAS A, 1987, INT ANGIOL, V6, P175; ERIKSSON BI, 1994, THROMB HAEMOSTASIS, V72, P227; EVANS AJ, 1993, AM J ROENTGENOL, V161, P131, DOI 10.2214/ajr.161.1.8517292; FENECH A, 1980, BRIT MED J, V280, P1571, DOI 10.1136/bmj.280.6231.1571; FIELD ES, 1972, BRIT J SURG, V59, P377, DOI 10.1002/bjs.1800590512; FRANCIS CW, 1986, LANCET, V1, P769; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; FRANCIS CW, 1989, AM J MED S3B, V87; FREIMAN DG, 1965, NEW ENGL J MED, V272, P1278, DOI 10.1056/NEJM196506172722406; FRIEND J R, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P820; GALLUS A, 1986, LANCET, V2, P1293; GALLUS A, 1983, BRIT J SURG, V70, P17, DOI 10.1002/bjs.1800700106; Gallus AS, 1994, HEMOSTASIS THROMBOSI, P1331; GITEL SN, 1979, J BONE JOINT SURG AM, V61, P653, DOI 10.2106/00004623-197961050-00002; GLAZIER RL, 1976, JAMA-J AM MED ASSOC, V236, P1365, DOI 10.1001/jama.236.12.1365; GOLDBERG RJ, 1987, ARCH INTERN MED, V147, P251, DOI 10.1001/archinte.147.2.251; GOLDHABER SZ, 1987, ARCH INTERN MED, V147, P216, DOI 10.1001/archinte.147.2.216; GOLDHABER SZ, 1992, JAMA-J AM MED ASSOC, V268, P1727, DOI 10.1001/jama.268.13.1727; GOLDHABER SZ, 1990, AM J MED, V88, P235, DOI 10.1016/0002-9343(90)90148-7; GOLDHABER SZ, 1984, AM J MED, V76, P393, DOI 10.1016/0002-9343(84)90656-9; GREENFIELD LJ, 1988, SURGERY, V104, P706; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRIFFIN MR, 1987, ARCH INTERN MED, V147, P1907, DOI 10.1001/archinte.147.11.1907; HAAKE DA, 1989, CLIN ORTHOP RELAT R, P212; HABER E, 1989, SCIENCE, V243, P51, DOI 10.1126/science.2492113; HAEGER K, 1969, ANGIOLOGY, V20, P219, DOI 10.1177/000331976902000406; HARRIS WH, 1975, NEW ENGL J MED, V292, P665, DOI 10.1056/NEJM197503272921303; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; Hirsch J, 1994, HEMOSTASIS THROMBOSI, P1151; HIRSH J, 1992, BLOOD, V79, P1; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; HIRSH J, 1989, CHEST, V95, pS5, DOI 10.1378/chest.95.2.5S; HIRSH J, 1988, THROMB HAEMOSTASIS, V59, P129; Hirsh J, 1989, CHEST, V96, P962; Hirsh J., 1994, HEMOSTASIS THROMBOSI, P1346; HOLLENBACH S, 1992, CIRCULATION, V86, P410; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HUISMAN MV, 1989, CHEST, V95, P498, DOI 10.1378/chest.95.3.498; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1981, NEW ENGL J MED, V304, P1561, DOI 10.1056/NEJM198106253042602; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1990, NEW ENGL J MED, V322, P1260, DOI 10.1056/NEJM199005033221802; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; HULL RD, 1992, NEW ENGL J MED, V326, P975, DOI 10.1056/NEJM199204093261502; HULL RD, 1982, CAN MED ASSOC J, V127, P990; HULL RD, 1990, ANN INTERN MED, V112, P663, DOI 10.7326/0003-4819-112-9-663; HUME M, 1976, J BONE JOINT SURG AM, V58, P933, DOI 10.2106/00004623-197658070-00007; HYERS TM, 1992, CHEST, V102, pS408, DOI 10.1378/chest.102.4_Supplement.408S; HYERS TM, 1993, CHEST, V103, P1636, DOI 10.1378/chest.103.5.1636a; KAKKAR VV, 1970, AM J SURG, V120, P527, DOI 10.1016/S0002-9610(70)80023-X; KAKKAR VV, 1993, LANCET, V341, P259, DOI 10.1016/0140-6736(93)92614-Y; KAKKAR VV, 1985, AM J SURG, V150, P54; KAKKAR VV, 1990, WORLD J SURG, V14, P670, DOI 10.1007/BF01658824; KAKKAR VV, 1969, LANCET, V2, P230; KING DJ, 1984, ANN INTERN MED, V100, P535, DOI 10.7326/0003-4819-100-4-535; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; KUDSK KA, 1989, AM J SURG, V158, P515, DOI 10.1016/0002-9610(89)90182-7; LAGERSTEDT CI, 1985, LANCET, V2, P515; LANDEFELD CS, 1989, AM J MED, V87, P144; LANSING AM, 1968, ANN SURG, V168, P620, DOI 10.1097/00000658-196810000-00009; LECLERC JR, 1988, J NUCL MED, V29, P1498; LEIZOROVICZ A, 1992, BMJ-BRIT MED J, V305, P913, DOI 10.1136/bmj.305.6859.913; LENSING AWA, 1990, RADIOLOGY, V177, P503, DOI 10.1148/radiology.177.2.2217792; LENSING AWA, 1993, THROMB HAEMOSTASIS, V69, P2; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; LENSING AWA, 1994, HEMOSTASIS THROMBOSI, P1297; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LEVINE MN, 1988, NEW ENGL J MED, V318, P404, DOI 10.1056/NEJM198802183180703; LEVINE MN, 1992, CHEST, V102, pS364, DOI 10.1378/chest.102.4_Supplement.364S; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; LEYVRAZ PF, 1983, NEW ENGL J MED, V309, P954, DOI 10.1056/NEJM198310203091605; LINDBLAD B, 1991, BRIT J SURG, V78, P849, DOI 10.1002/bjs.1800780725; LOCKSHIN MD, 1992, JAMA-J AM MED ASSOC, V268, P1451; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V53, P155; LOWE GDO, 1981, CLIN HAEMATOL, V10, P343; LOWE GDO, 1982, LANCET, V1, P409; MAGNANT JG, 1992, J VASC SURG, V16, P701; MAHORNER H, 1957, ANN SURG, V146, P510; MAVOR GE, 1969, BRIT J SURG, V56, P45, DOI 10.1002/bjs.1800560110; MAYO M E, 1971, British Journal of Urology, V43, P738; MCKENZIE PJ, 1985, BRIT J ANAESTH, V57, P853, DOI 10.1093/bja/57.9.853; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; MEYER J, 1989, LANCET, V1, P863; MOORE DJ, 1986, J VASC SURG, V3, P49; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P1908; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P223, DOI 10.1001/jama.271.3.223; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; NEUHAUS KL, 1992, J AM COLL CARDIOL, V19, P885, DOI 10.1016/0735-1097(92)90265-O; NICOLAID.AN, 1972, BRIT J SURG, V59, P487, DOI 10.1002/bjs.1800590620; NICOLAIDES AN, 1980, SURGERY, V87, P69; NICOLAIDES AN, 1975, THROMBOEMBOLISM AETI, P193; OLIN JW, 1993, J VASC SURG, V18, P1037, DOI 10.1016/0741-5214(93)90559-5; ORRON DE, 1992, PERIPHERAL VASCULAR, P183; OTT P, 1986, ACTA MED SCAND, V219, P295; PAIEMENT G, 1988, AM J SURG, V155, P400, DOI 10.1016/S0002-9610(88)80099-0; PAIEMENT GD, 1991, AM J SURG, V161, P519, DOI 10.1016/0002-9610(91)91124-2; PARAMO JA, 1985, THROMB HAEMOSTASIS, V54, P713; PARMET JL, 1993, LANCET, V341, P1057, DOI 10.1016/0140-6736(93)92414-O; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PETITTI DB, 1986, AM J MED, V81, P255, DOI 10.1016/0002-9343(86)90260-3; PHILBRICK JT, 1988, ARCH INTERN MED, V148, P2131, DOI 10.1001/archinte.148.10.2131; PIDALA MJ, 1992, SURG GYNECOL OBSTET, V175, P47; PINI M, 1990, THROMB HAEMOSTASIS, V64, P222; PLATE G, 1984, J VASC SURG, V1, P867, DOI 10.1067/mva.1984.avs0010867; POIKOLAINEN E, 1983, ACTA CHIR SCAND, V149, P361; POLAK JF, 1991, CHEST, V99, pS165, DOI 10.1378/chest.99.4.165S; POLLAK EW, 1975, ARCH SURG-CHICAGO, V110, P613; POWERS PJ, 1989, ARCH INTERN MED, V149, P771, DOI 10.1001/archinte.149.4.771; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; ROGERS FB, 1993, J TRAUMA, V35, P637, DOI 10.1097/00005373-199310000-00021; ROGERS LQ, 1990, AM J MED, V88, P389, DOI 10.1016/0002-9343(90)90494-X; SALZMAN EW, 1980, J CLIN INVEST, V65, P64, DOI 10.1172/JCI109661; SALZMAN EW, 1987, ANN SURG, V206, P636; SALZMAN EW, 1980, ANN SURG, V191, P207, DOI 10.1097/00000658-198002000-00013; SALZMAN EW, 1975, NEW ENGL J MED, V292, P1046, DOI 10.1056/NEJM197505152922002; SALZMAN EW, 1980, SURGERY, V87, P239; SANDLER DA, 1989, J ROY SOC MED, V82, P203, DOI 10.1177/014107688908200407; SCHMITT BP, 1993, AM J MED SCI, V305, P208, DOI 10.1097/00000441-199304000-00003; SEVITT S, 1959, LANCET, V2, P981; SEVITT S, 1974, J CLIN PATHOL, V27, P517, DOI 10.1136/jcp.27.7.517; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SIMONNEAU G, 1993, ARCH INTERN MED, V153, P1541, DOI 10.1001/archinte.153.13.1541; SKILLMAN JJ, 1978, SURGERY, V83, P354; SORENSEN JV, 1992, THROMB RES, V65, P479, DOI 10.1016/0049-3848(92)90199-K; SPRITZER CE, 1993, CHEST, V104, P54, DOI 10.1378/chest.104.1.54; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; STEWART JH, 1992, MAYO CLIN PROC, V67, P1186, DOI 10.1016/S0025-6196(12)61150-1; STRINGER MD, 1989, J BONE JOINT SURG BR, V71, P492, DOI 10.1302/0301-620X.71B3.2785998; SUDLOW MF, 1992, LANCET, V340, P873; SUELING HM, 1986, LANCET, V1, P1173; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; SWEDENBORG J, 1986, BRIT J SURG, V73, P871, DOI 10.1002/bjs.1800731104; TABERNERO MD, 1989, THROMB RES, V56, P565, DOI 10.1016/0049-3848(89)90242-9; THALER E, 1981, CLIN HAEMATOL, V10, P369; THERY C, 1992, CIRCULATION, V85, P1380, DOI 10.1161/01.CIR.85.4.1380; TROUSSEAU A, 1865, PHLEGMASIA ALBA DOLE, V3, P84; TURPIE AGG, 1989, ARCH INTERN MED, V149, P679, DOI 10.1001/archinte.149.3.679; VERSTRAETE M, 1993, NEW ENGL J MED, V329, P1418, DOI 10.1056/NEJM199311043291911; VIANNA JL, 1994, AM J MED, V96, P3, DOI 10.1016/0002-9343(94)90108-2; VOGELZANG RL, 1991, VENOUS DISORDERS, P91; WAKEFIELD TW, 1993, HEMATOL ONCOL CLIN N, V7, P1251, DOI 10.1016/S0889-8588(18)30206-5; WALSH JJ, 1974, J OBSTET GYN BR COMM, V81, P311; WARLOW C, 1976, BRIT MED J, V1, P1178, DOI 10.1136/bmj.1.6019.1178; WEINGARDEN SI, 1992, CHEST, V102, pS636, DOI 10.1378/chest.102.6.636S; WELLS PS, 1994, ARCH INTERN MED, V154, P67, DOI 10.1001/archinte.154.1.67; WELLS PS, 1992, BLOOD S, V80, pA316; WHEELER HB, 1985, AM J SURG, V150, P7; White G.C., 1994, HEMOSTASIS THROMBOSI, P1134; WHITE RH, 1989, ANN INTERN MED, V111, P297, DOI 10.7326/0003-4819-111-4-297; WITTMANN PH, 1991, J ROY SOC MED, V84, P536, DOI 10.1177/014107689108400911; 1992, LANCET, V340, P579	218	259	271	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1630	1641		10.1056/NEJM199412153312407	http://dx.doi.org/10.1056/NEJM199412153312407			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7772110				2022-12-28	WOS:A1994PW44600007
J	SOUMERAI, SB; LIPTON, HL				SOUMERAI, SB; LIPTON, HL			COMPUTER-BASED DRUG-UTILIZATION REVIEW - RISK, BENEFIT, OR BOONDOGGLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STATE; MEDICAID; THERAPY; COST; EXPERIENCE; DIGOXIN; CARE		UNIV CALIF SAN FRANCISCO,SCH PHARM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SOUMERAI, SB (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS007357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009611] Funding Source: NIH RePORTER; AHRQ HHS [HSO7357] Funding Source: Medline; NIA NIH HHS [5R01 AG09611] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLOOM BS, 1985, MED CARE, V23, P872, DOI 10.1097/00005650-198507000-00004; Cook T.C., 1979, QUASIEXPERIMENTATION; CYPRESS BK, 1983, DRUG UTILIZATION GEN, P87; GROVES RE, 1985, AM J HOSP PHARM, V42, P316, DOI 10.1093/ajhp/42.2.316; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; JAY ED, 1991, MEDICAL THERAPEUTIC; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1824, DOI 10.1056/NEJM199406233302512; LEE PR, 1989, LANCET, V1, P263; LeGrady D, 1992, Nebr Med J, V77, P3; LEZOTTE DC, 1993, AUG INT SOC STAT VEN; LIPTON HL, 1991, CLIN PHARMACOL THER, V50, P616, DOI 10.1038/clpt.1991.194; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; LIPTON HL, IN PRESS INT J TECHN; LIPTON HL, 1994, NOV AM PUBL HLTH ASS; MARCUS FI, 1985, J AM COLL CARDIOL, V5, pA82, DOI 10.1016/S0735-1097(85)80466-6; MARONDE RF, 1989, MED CARE, V27, P1159, DOI 10.1097/00005650-198912000-00007; Moore W J, 1994, Med Care Rev, V51, P3, DOI 10.1177/107755879405100102; MUIRHEAD G, 1994, DRUG TOPICS     0905, P76; MUIRHEAD G, 1994, DRUG TOPICS     0905, P80; Muirhead G, 1994, DRUG TOPICS     0905, P67; MUIRHEAD G, 1994, DRUG TOPICS     0905, P73; MULLINEX SC, 1989, 1989 IOW DEP HUM SER; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RODIN SM, 1988, CLIN PHARMACOL THER, V43, P668, DOI 10.1038/clpt.1988.93; RODIN SM, 1988, CLIN PHARMACOKINET, V15, P227, DOI 10.2165/00003088-198815040-00003; RUCKER TD, 1983, SOC MED CONFLICTING, P25; SHADER RI, 1993, NEW ENGL J MED, V328, P1398; SMALLEY WE, 1995, NEW ENGL J MED, V332, P1612, DOI 10.1056/NEJM199506153322406; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Soumerai SB, 1994, PHARMACOEPIDEM DR S, P395; STASON WB, 1977, NEW ENGL J MED, V296, P732, DOI 10.1056/NEJM197703312961307; WALSER BL, 1994, PHARM COST CONTAINME; Wickizer T M, 1990, Med Care Rev, V47, P327, DOI 10.1177/107755879004700303; 1994, GAOAIMD94130 GEN ACC; 1994, ANN INTERN MED, V120, P423; 1992, GREEN SHEET 1992, V41, P3; 1993, AHCPR930550 PUBL; 1990, ANSWERS, V1, P4; 1993, HCFA03341 PUBL; 1992, FED REGISTER, V57, P49397	48	70	70	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1641	1645		10.1056/NEJM199506153322411	http://dx.doi.org/10.1056/NEJM199506153322411			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753146	Green Published, Green Submitted			2022-12-28	WOS:A1995RC19200011
J	CENTERWALL, BS				CENTERWALL, BS			RACE, SOCIOECONOMIC-STATUS, AND DOMESTIC HOMICIDE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-A study of 222 intraracial domestic homicides in Atlanta, Ga, found that when black and white populations were unstratified, the relative risk of homicide in black populations was 5.8 (95% confidence interval [CI], 4.3 to 8.0); when black and white populations were stratified by rates of household crowding, the relative risk of homicide in black populations was no longer significantly elevated (relative risk [RR], 1.2, 95% CI, 0.7 to 2.0). The current study sought to replicate, or not replicate, these findings in New Orleans, La. Methods.-Retrospective study of 349 intraracial domestic homicides perpetrated against residents of Orleans Parish in 1979, 1982, 1985, and 1986. Main Outcome Measure.-Relative risk of homicide in the black and white populations of New Orleans when they are stratified by rates of household crowding. Results.-When black and white populations of New Orleans were unstratified, the relative risk of intraracial domestic homicide in black populations was 6.3 (95% CI, 4.3 to 9.5). When black and white populations were stratified by rates of household crowding, the relative risk of homicide in black populations was no longer significantly elevated (RR, 1.2; 95% CI, 0.4 to 2.9). Conclusion.-The findings of the Atlanta homicide study are replicated in the current study of homicide in New Orleans. In both cities, sixfold differences in black and white rates of intraracial domestic homicide are entirely accounted for by differences in socioeconomic status between the respective black and white populations. There are no significant residual differences requiring cultural explanations.			CENTERWALL, BS (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,MAIL SLOT SC-36,SEATTLE,WA 98195, USA.							Banfield, 1974, UNHEAVENLY CITY REVI; BENSING RC, 1960, HOMICIDES URBAN COMM; BLAU JR, 1982, AM SOCIOL REV, V47, P114, DOI 10.2307/2095046; Bullock HA, 1955, J CRIM LAW CRIMINOL, V45, P565, DOI 10.2307/1139550; CENTERWALL BS, 1984, AM J PUBLIC HEALTH, V74, P813, DOI 10.2105/AJPH.74.8.813; ERBE BM, 1975, AM SOCIOL REV, V40, P801, DOI 10.2307/2094181; HAWKINS DF, 1993, HEALTH AFFAIR, V12, P80, DOI 10.1377/hlthaff.12.4.80; HELMKAMP JC, 1988, MIL MED, V153, P621; KRIEGER N, 1992, AM J PUBLIC HEALTH, V92, P703; LOWRY PW, 1988, AM J EPIDEMIOL, V128, P1130; RAWLINGS JS, 1992, AM J DIS CHILD, V146, P313, DOI 10.1001/archpedi.1992.02160150053020; Robinson WS, 1950, AM SOCIOL REV, V15, P351, DOI 10.2307/2087176; Yankauer A, 1950, AM SOCIOL REV, V15, P644, DOI 10.2307/2086918; 1988, DHHS PHS881122 PUBL, P2; 1983, PHC802259 BUR CENS	15	58	58	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1755	1758		10.1001/jama.273.22.1755	http://dx.doi.org/10.1001/jama.273.22.1755			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB800	7769768				2022-12-28	WOS:A1995RB80000027
J	CUMMINGS, JL				CUMMINGS, JL			DEMENTIA - THE FAILING BRAIN	LANCET			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BEHAV SCI,LOS ANGELES,CA 90024; W LOS ANGELES VET AFFAIRS MED CTR,PSYCHIAT SERV,BEHAV NEUROSCI SECT,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	CUMMINGS, JL (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,REED NEUROL RES CTR,DEPT NEUROL,710 WESTWOOD PLAZA,LOS ANGELES,CA 90024, USA.				NIA NIH HHS [AG 10123] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG010123] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))			0	28	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1481	1484		10.1016/S0140-6736(95)91039-5	http://dx.doi.org/10.1016/S0140-6736(95)91039-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RC189	7769904				2022-12-28	WOS:A1995RC18900011
J	REES, J; PRICE, J				REES, J; PRICE, J			ABC OF ASTHMA - ASTHMA IN CHILDREN - TREATMENT	BRITISH MEDICAL JOURNAL			English	Article																			0	12	12	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1522	1527		10.1136/bmj.310.6993.1522	http://dx.doi.org/10.1136/bmj.310.6993.1522			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787605	Green Submitted, Green Published			2022-12-28	WOS:A1995RD28500030
J	JACOBSON, K; SHEETS, ED; SIMSON, R				JACOBSON, K; SHEETS, ED; SIMSON, R			REVISITING THE FLUID MOSAIC MODEL OF MEMBRANES	SCIENCE			English	Editorial Material							LATERAL DIFFUSION; CELL-SURFACE; NANOVID MICROSCOPY; MOVEMENTS; FIBROBLASTS; TRANSPORT		UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	JACOBSON, K (corresponding author), UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599, USA.			Sheets, Erin/0000-0002-5980-3225				Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHERRY RJ, 1994, BIOCHEM SOC T, V22, P781, DOI 10.1042/bst0220781; DEBRABANDER M, 1991, J CELL BIOL, V112, P111, DOI 10.1083/jcb.112.1.111; EDIDIN M, 1991, SCIENCE, V254, P1379, DOI 10.1126/science.1835798; EDIDIN M, 1994, P NATL ACAD SCI USA, V91, P3378, DOI 10.1073/pnas.91.8.3378; GHOSH RN, 1994, BIOPHYS J, V66, P1301, DOI 10.1016/S0006-3495(94)80939-7; GHOSH RN, 1990, BIOPHYS J, V57, pA286; HOLIFIELD BF, 1991, J CELL SCI, V98, P191; KUSUMI A, 1993, BIOPHYS J, V65, P2021, DOI 10.1016/S0006-3495(93)81253-0; LEE GM, 1993, J CELL BIOL, V120, P25, DOI 10.1083/jcb.120.1.25; OBRIEN C, 1995, SCIENCE, V267, P1263, DOI 10.1126/science.7871418; SAKO Y, 1994, J CELL BIOL, V125, P1251, DOI 10.1083/jcb.125.6.1251; SAKO Y, 1992, MOL BIOL CELL, V3, pA219; SAKO Y, IN PRESS J CELL BIOL; SAXTON MJ, 1993, BIOPHYS J, V64, P1766, DOI 10.1016/S0006-3495(93)81548-0; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; Sheets E. D., 1995, Biophysical Journal, V68, pA306; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; Simson R., 1995, Biophysical Journal, V68, pA436; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2	23	362	367	0	82	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1441	1442		10.1126/science.7770769	http://dx.doi.org/10.1126/science.7770769			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770769				2022-12-28	WOS:A1995RC19000024
J	LIAO, DZ; HESSLER, NA; MALINOW, R				LIAO, DZ; HESSLER, NA; MALINOW, R			ACTIVATION OF POSTSYNAPTICALLY SILENT SYNAPSES DURING PAIRING-INDUCED LTP IN CA1 REGION OF HIPPOCAMPAL SLICE	NATURE			English	Article							LONG-TERM POTENTIATION; PRESYNAPTIC ENHANCEMENT; SYNAPTIC CURRENTS; NMDA RECEPTORS; EXPRESSION; RELEASE; PROBABILITY; MECHANISMS; RESPONSES; INDUCTION	LONG-TERM potentiation (LTP) is an enhancement of synaptic strength that can be produced by pairing of presynaptic activity with postsynaptic depolarization(1). LTP in the hippocampus has been extensively studied as a cellular model of learning and memory, but the nature of the underlying synaptic modification remains elusive, partly because our knowledge of central synapses is still limited(2,3). One proposal(4,5) is that the modification is postsynaptic, and that synapses expressing only NMDA (N-methyl-D-aspartate) receptors before potentiation are induced by LTP to express functional AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate) receptors. Here we report that a high proportion of synapses in hippocampal area CAI transmit with NMDA receptors but not AMPA receptors, making these synapses effectively non-functional at normal resting potentials. These silent synapses acquire AMPA-type responses following LTP induction, Our findings challenge the view(6-10) that LTP in CA1 involves a presynaptic modification, and suggest instead a simple postsynaptic mechanism for both induction and expression of LTP.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA; UNIV IOWA,NEUROSCI PROGRAM,IOWA CITY,IA	Cold Spring Harbor Laboratory; University of Iowa; University of Iowa			hessler, neal/A-7328-2010		NIMH NIH HHS [R29MH49159] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH049159] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AZTELY F, 1992, EUR J NEUROSCI, V4, P681; BASHIR ZI, 1991, NATURE, V349, P156, DOI 10.1038/349156a0; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; DAVIES SN, 1989, NATURE, V330, P500; DOLPHIN AC, 1982, NATURE, V297, P496, DOI 10.1038/297496a0; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1994, SCIENCE, V266, P1195, DOI 10.1126/science.7973700; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MAREN S, 1993, P NATL ACAD SCI USA, V90, P9654, DOI 10.1073/pnas.90.20.9654; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCNAUGHTON BL, 1982, J PHYSIOL-LONDON, V324, P249, DOI 10.1113/jphysiol.1982.sp014110; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; TSIEN RW, 1990, COLD SH Q B, V55, P147; VORONIN LL, 1993, NEUROSCIENCE, V56, P275, DOI 10.1016/0306-4522(93)90332-A; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; WU LG, 1994, J NEUROSCI, V14, P645; XIE XP, 1992, J NEUROPHYSIOL, V67, P1009, DOI 10.1152/jn.1992.67.4.1009	30	1031	1056	2	52	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					400	404		10.1038/375400a0	http://dx.doi.org/10.1038/375400a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760933				2022-12-28	WOS:A1995RB10100052
J	MANTZOROS, CS; GEORGIADIS, EI; TRICHOPOULOS, D				MANTZOROS, CS; GEORGIADIS, EI; TRICHOPOULOS, D			CONTRIBUTION OF DIHYDROTESTOSTERONE TO MALE SEXUAL-BEHAVIOR	BRITISH MEDICAL JOURNAL			English	Article							TESTOSTERONE; MEN	Objective-To document the relative importance of endogenous sex steroids in modulating the frequency of orgasms, the dominant aspect of sexual behaviour in healthy eugonadal men. Design-Measurement of adrenal and testicular sex steroids in a sample of army recruits and study of their relation to frequency of orgasms ascertained by questionnaire after potential confounding variables were controlled for. Setting-Military campus and military hospital laboratories in Athens, Greece. Subjects-92 consecutively enrolled healthy male recruits aged 18-22 years. Main outcome measures-Weekly number of orgasms. Serum concentrations of testosterone, dehydroepiandrosterone sulphate, dihydrotestosterone, oestradiol, oestrone, Delta-4-androstenedione, and sex hormone binding globulin. Results-Serum dihydrotestosterone concentration was the only independent hormonal predictor of the frequency of orgasms; an increase in concentration of 1.36 nmol/l (about 2 SD) corresponded to an average increase of one orgasm a week. Conclusions-Differences in concentrations of circulating dihydrotestosterone within the normal range may represent a major predictor of sexual activity in healthy young men.	MIL HOSP 401,ENDOCRINE UNIT,ATHENS,GREECE; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02215	Harvard University; Harvard T.H. Chan School of Public Health			Mantzoros, Christos/Y-2902-2019					ANDERSON RA, 1992, J CLIN ENDOCR METAB, V75, P1503, DOI 10.1210/jc.75.6.1503; BAGATELL CJ, 1994, J CLIN ENDOCR METAB, V78, P711, DOI 10.1210/jc.78.3.711; BANCROFT J, 1980, CLIN OBSTET GYNAECOL, V7, P253; DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71; KNUSSMANN R, 1986, ARCH SEX BEHAV, V15, P429, DOI 10.1007/BF01543113; KRAEMER HC, 1976, ARCH SEX BEHAV, V5, P125, DOI 10.1007/BF01541869; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; TSITOURAS PD, 1987, ENDOCRIN METAB CLIN, V16, P1045, DOI 10.1016/S0889-8529(18)30458-4; WEINBAUER GF, 1990, ACTA ENDOCRINOL-COP, V122, P432, DOI 10.1530/acta.0.1220432	9	69	73	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1289	1291		10.1136/bmj.310.6990.1289	http://dx.doi.org/10.1136/bmj.310.6990.1289			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773040	Green Published			2022-12-28	WOS:A1995QZ86000018
J	OLIVER, SR				OLIVER, SR			HOW CAN HEALTH-SERVICE USERS CONTRIBUTE TO THE NHS RESEARCH-AND-DEVELOPMENT PROGRAM	BRITISH MEDICAL JOURNAL			English	Article								The National Childbirth Trust, along with other groups of health service users, is working with health professionals and researchers in planning clinical trials, setting priorities for research, systematically reviewing research reports, and getting research findings into practice. User groups may bridge the gap between the public and researchers by explaining research issues to a wide audience, presenting the needs and views of health service users to the research community, and suggesting how members of the public may be approached for their views directly. Service users recognise their need for training and support, and they call for development and evaluation of this work.	NATL CHILDBIRTH TRUST,RES & INFORMAT GRP,LONDON W3 6NH,ENGLAND					Oliver, Sandy/0000-0001-9571-269X				[Anonymous], 1994, LANCET, P619; [Anonymous], 1991, LANCET, V337, P1491; BORTON H, 1989, RUPTURE MEMBRANES LA; Chalmers I, 1989, EFFECTIVE CARE PREGN; DUNNING M, 1994, HLTH SERVICE J  0428, P24; Enkin M, 1989, GUIDE EFFECTIVE CARE; ENKIN M, IN PRESS GUIDE EFFEC; GREENSHIELDS W, 1993, PERINEUM CHILDBIRTH; GREENSHIELDS W, 1988, POSTNATAL INFECTION; GYTE G, 1994, MODERN MIDWIFE, V4, P19; GYTE GML, 1994, MIDWIFERY, V10, P183, DOI 10.1016/0266-6138(94)90054-X; MORAN-ELLIS J, 1991, Journal of Obstetrics and Gynaecology (Abingdon), V11, pS6; OLIVER S, 1994, WILL IT WORK DOCTOR, P28; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; RENFREW MJ, 1992, WOMENS HLTH MATTERS, P81; SACKETT DL, 1994, BRIT MED J, V309, P1514, DOI 10.1136/bmj.309.6967.1514c; Sleep J, 1993, Midwives Chron, V106, P217; Somorjay L, 1987, Birth, V14, P109; STOCKING B, 1993, MILBANK Q, V71, P497, DOI 10.2307/3350412; 1992, 430I HOUS COMM SEL C; 1993, MIDWIFERY HLTH VISIT	21	48	48	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1318	1320		10.1136/bmj.310.6990.1318	http://dx.doi.org/10.1136/bmj.310.6990.1318			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773051	Green Published			2022-12-28	WOS:A1995QZ86000031
J	PANZNER, S; DREIER, L; HARTMANN, E; KOSTKA, S; RAPOPORT, TA				PANZNER, S; DREIER, L; HARTMANN, E; KOSTKA, S; RAPOPORT, TA			POSTTRANSLATIONAL PROTEIN-TRANSPORT IN YEAST RECONSTITUTED WITH A PURIFIED COMPLEX OF SEC PROTEINS AND KAR2P	CELL			English	Article							PREPRO-ALPHA-FACTOR; ENDOPLASMIC-RETICULUM MEMBRANE; POST-TRANSLATIONAL TRANSLOCATION; CELL-FREE SYSTEM; POLYPEPTIDE TRANSLOCATION; SACCHAROMYCES-CEREVISIAE; SECRETORY PROTEINS; ESCHERICHIA-COLI; SIGNAL SEQUENCE; INVITRO	We have reproduced the posttranslational mode of protein translocation across the endoplasmic reticulum membrane with reconstituted proteoliposomes containing a purified complex of seven yeast proteins. This Sec complex includes a heterotrimeric Sec61p complex, homologous to that in mammals, as well as all other membrane proteins found in genetic screens for translocation components. Efficient posttranslational translocation also requires the addition of lumenal Kar2p (BiP) and ATP. The trimeric Sec61p complex also exists as a separate entity that, in contrast with the large Sec complex, is associated with membrane-bound ribosomes. We therefore hypothesize that distinct membrane protein complexes function in co- and posttranslational translocation pathways.			PANZNER, S (corresponding author), MAX DELBRUCK CTR MOLEC MED,ROBERT ROSSLE STR 10,D-13125 BERLIN,GERMANY.		Hartmann, Enno/C-5687-2013					ALLISON DS, 1988, MOL CELL BIOL, V8, P1915, DOI 10.1128/MCB.8.5.1915; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1993, MOL BIOL CELL, V4, P931, DOI 10.1091/mbc.4.9.931; FELDHEIM D, 1994, J CELL BIOL, V126, P935, DOI 10.1083/jcb.126.4.935; GARCIA PD, 1988, J CELL BIOL, V106, P1043, DOI 10.1083/jcb.106.4.1043; GILMORE R, 1982, J CELL BIOL, V95, P470, DOI 10.1083/jcb.95.2.470; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KURIHARA T, 1993, MOL BIOL CELL, V4, P919, DOI 10.1091/mbc.4.9.919; MEYER DI, 1982, NATURE, V297, P503; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NG DTW, 1994, CURR OPIN CELL BIOL, V6, P510, DOI 10.1016/0955-0674(94)90069-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; ROTHBLATT JA, 1987, EMBO J, V6, P3455, DOI 10.1002/j.1460-2075.1987.tb02669.x; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANZ P, 1989, J CELL BIOL, V108, P2101, DOI 10.1083/jcb.108.6.2101; SCHNEIDER HC, 1994, NATURE, V371, P7688; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WALTER P, 1981, J CELL BIOL, V93, P557; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; YAMADA H, 1989, J BIOL CHEM, V264, P1723	37	317	327	1	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					561	570		10.1016/0092-8674(95)90077-2	http://dx.doi.org/10.1016/0092-8674(95)90077-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758110	Bronze			2022-12-28	WOS:A1995QZ71000013
J	KANDEL, E; ABEL, T				KANDEL, E; ABEL, T			NEUROPEPTIDES, ADENYLYL-CYCLASE, AND MEMORY STORAGE	SCIENCE			English	Editorial Material							DEPENDENT PROTEIN-KINASE; DROSOPHILA-MELANOGASTER; ACTIVATING POLYPEPTIDE; TRANSMITTER RELEASE; APLYSIA; FACILITATION; NEURONS; GENE; MUTANT; PHOSPHODIESTERASE				KANDEL, E (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032, USA.		Abel, Ted/AAX-2825-2021	Abel, Ted/0000-0003-2423-4592				ABRAMS TW, 1984, P NATL ACAD SCI-BIOL, V81, P7956, DOI 10.1073/pnas.81.24.7956; ABRAMS TW, 1988, TRENDS NEUROSCI, V11, P128, DOI 10.1016/0166-2236(88)90137-3; AKIMURA A, 1992, REGUL PEPTIDES, V37, P287; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYNTON S, 1992, GENETICS, V131, P655; BRUNELLI M, 1976, SCIENCE, V192, P150; BURBACH JPH, 1993, BRAIN FUNCTIONS NEUR; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CASTELLUCCI VF, 1980, P NATL ACAD SCI-BIOL, V77, P7492, DOI 10.1073/pnas.77.12.7492; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DURA JM, 1993, J NEUROGENET, V9, P1, DOI 10.3109/01677069309167272; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HOKFELT T, 1991, NEURON, V7, P867, DOI 10.1016/0896-6273(91)90333-U; HUANG YY, 1995, P NATL ACAD SCI USA, V92, P2446, DOI 10.1073/pnas.92.7.2446; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; KOVACS GL, 1994, PHARMACOL REV, V46, P269; LEE MC, 1994, NEUROSCI BIOBEHAV R, V18, P313, DOI 10.1016/0149-7634(94)90045-0; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MCGAUGH JL, 1989, ANNU REV NEUROSCI, V12, P255, DOI 10.1146/annurev.neuro.12.1.255; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P104; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; TATSUNO I, 1992, ENDOCRINOLOGY, V131, P73, DOI 10.1210/en.131.1.73; TERENIUS L, 1992, PROG BRAIN RES, V92, P375, DOI 10.1016/S0079-6123(08)61190-5; TLLY T, 1994, CELL, V79, P35; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WRIGHT JW, 1992, BRAIN RES REV, V17, P227, DOI 10.1016/0165-0173(92)90018-H; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; YIN JCP, 1995, CELL, V81, P17; ZGIBG T, IN PRESS NATURE	45	109	111	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					825	826		10.1126/science.7754367	http://dx.doi.org/10.1126/science.7754367			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754367				2022-12-28	WOS:A1995QX85000025
J	RAZA, ST; MUKHERJEE, SK; DANIAS, PG; ABRAHAM, J; JOHNSON, KM; SANDS, MJ; WERNER, MS; SILVERMAN, DI				RAZA, ST; MUKHERJEE, SK; DANIAS, PG; ABRAHAM, J; JOHNSON, KM; SANDS, MJ; WERNER, MS; SILVERMAN, DI			HEMODYNAMICALLY SIGNIFICANT EXTRINSIC LEFT ATRIAL COMPRESSION BY GASTRIC STRUCTURES IN THE MEDIASTINUM	ANNALS OF INTERNAL MEDICINE			English	Note									NEW BRITAIN GEN HOSP, NEW BRITAIN, CT USA; JOHN DEMPSEY HOSP, FARMINGTON, CT USA; YALE UNIV, SCH MED, NEW HAVEN, CT USA; YALE NEW HAVEN MED CTR, NEW HAVEN, CT 06504 USA	Yale University; Yale University			Johnson, Kevin M/A-9705-2008	Johnson, Kevin M/0000-0002-5807-7866				Alam M, 1991, J Am Soc Echocardiogr, V4, P323; BAERMAN JM, 1988, AM HEART J, V116, P198, DOI 10.1016/0002-8703(88)90272-4; BREALL JA, 1992, AM HEART J, V124, P523, DOI 10.1016/0002-8703(92)90626-7; CANEDO MI, 1977, BRIT HEART J, V39, P1038; DCRUZ IA, 1994, ECHOCARDIOGR-J CARD, V11, P523, DOI 10.1111/j.1540-8175.1994.tb01093.x; DeLuca A, 1991, N J Med, V88, P37; IWASE M, 1990, AM HEART J, V119, P968, DOI 10.1016/S0002-8703(05)80344-8; MAIER HC, 1948, ANN SURG, V127, P476, DOI 10.1097/00000658-194803000-00010; Movsowitz H D, 1993, J Am Soc Echocardiogr, V6, P104; NELSON RM, 1985, CRIT CARE MED, V13, P607, DOI 10.1097/00003246-198507000-00022; VOLPI A, 1988, THORAX, V43, P216, DOI 10.1136/thx.43.3.216	11	23	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					114	116		10.7326/0003-4819-123-2-199507150-00006	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778823				2022-12-28	WOS:A1995RM43500006
J	HIBBERD, PL; TOLKOFFRUBIN, NE; CONTI, D; STUART, F; THISTLETHWAITE, JR; NEYLAN, JF; SNYDMAN, DR; FREEMAN, R; LORBER, MI; RUBIN, RH				HIBBERD, PL; TOLKOFFRUBIN, NE; CONTI, D; STUART, F; THISTLETHWAITE, JR; NEYLAN, JF; SNYDMAN, DR; FREEMAN, R; LORBER, MI; RUBIN, RH			PREEMPTIVE GANCICLOVIR THERAPY TO PREVENT CYTOMEGALOVIRUS DISEASE IN CYTOMEGALOVIRUS ANTIBODY-POSITIVE RENAL-TRANSPLANT RECIPIENTS - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						GANCICLOVIR; KIDNEY TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; ANTILYMPHOCYTE SERUM	VIRUS DISEASE; OKT3; PROPHYLAXIS; VIREMIA; ALLOGRAFTS; INFECTION; GLOBULIN; MALG	Objective: To determine whether preemptive ganciclovir therapy administered daily during antilymphocyte antibody therapy can prevent cytomegalovirus disease in renal transplant recipients who are positive for cytomegalovirus antibody. Design: Randomized, controlled, multicenter trial. Setting: 6 university-affiliated transplantation centers. Patients: 113 renal transplant recipients who were positive for cytomegalovirus antibody. Intervention: Patients were randomly assigned to receive either 1) ganciclovir, 2.5 mg/kg body weight administered intravenously on every day that antilymphocyte antibody therapy was administered or 2) no anticytomegalovirus therapy. Measurements: Patients were observed for 6 months after completion of antilymphocyte antibody therapy for development of cytomegalovirus disease and cytomegalovirus viremia. Results: Cytomegalovirus disease occurred in 14% of patients (9 of 64) who received preemptive ganciclovir therapy and in 33% of controls (16 of 49) (P = 0.018). Cytomegalovirus was isolated from buffy-coat specimens from 17% of patients (11 of 64) receiving preemptive ganciclovir and from 35% of controls (17 of 49) (P = 0.03). Controlling for the reason (induction or treatment of rejection) for using antilymphocyte antibodies in a Cox proportional hazards model, we found that preemptive ganciclovir still protected against cytomegalo-virus disease (adjusted relative risk, 0.27; 95% CI, 0.12 to 0.64). No adverse events were attributed to preemptive ganciclovir therapy during or within 6 months of its administration. Conclusions: Preemptive ganciclovir therapy administered daily during courses of treatment with antilymphocyte antibodies reduced the excessive occurrence of cytomegalovirus disease in renal transplant recipients who were positive for cytomegalovirus antibody. This approach, which links the most potent immuno-suppression to intensive antimicrobial therapy, allows preventive therapy to be given to those patients at greatest risk for developing infectious complications. These patients are likely to benefit most from the preventive strategy.	MASSACHUSETTS GEN HOSP, DEPT TRANSPLANTAT, BOSTON, MA 02114 USA; ALBANY MED COLL, DEPT SURG, ALBANY, NY 12208 USA; NW MEM HOSP, DIV ORGAN TRANSPLANTAT, CHICAGO, IL 60611 USA; EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT SURG, BOSTON, MA 02111 USA; YALE UNIV, SCH MED, DIV ORGAN TRANSPLANTAT, NEW HAVEN, CT 06150 USA; UNIV CHICAGO, MED CTR, DEPT TRANSPLANT SURG, CHICAGO, IL 60637 USA	Harvard University; Massachusetts General Hospital; Albany Medical College; Northwestern Memorial Hospital; Emory University; Tufts Medical Center; Yale University; University of Chicago; University of Chicago Medical Center	HIBBERD, PL (corresponding author), MASSACHUSETTS GEN HOSP, INFECT DIS UNIT, FRUIT ST, GRJ-504, BOSTON, MA 02114 USA.		Snydman, David R/O-3889-2014	Snydman, David R/0000-0003-0119-3978; Hibberd, Patricia/0000-0002-7455-8117				BAILEY TC, 1993, AM J KIDNEY DIS, V21, P196, DOI 10.1016/S0272-6386(12)81093-6; BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; BOIVIN G, 1993, J INFECT DIS, V168, P332, DOI 10.1093/infdis/168.2.332; COLE EH, 1994, TRANSPLANTATION, V57, P60, DOI 10.1097/00007890-199401000-00012; COX DR, 1972, J R STAT SOC B, V34, P187; DOCKE WD, 1994, LANCET, V343, P268, DOI 10.1016/S0140-6736(94)91116-9; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; ERICE A, 1989, NEW ENGL J MED, V320, P289, DOI 10.1056/NEJM198902023200505; FREY DJ, 1992, TRANSPLANTATION, V54, P50, DOI 10.1097/00007890-199207000-00008; GLEAVES CA, 1984, J CLIN MICROBIOL, V19, P917, DOI 10.1128/JCM.19.6.917-919.1984; HANTO DW, 1994, TRANSPLANTATION, V57, P377, DOI 10.1097/00007890-199402150-00011; HIBBERD PL, 1992, TRANSPLANTATION, V53, P68, DOI 10.1097/00007890-199201000-00013; HIBBERD PL, 1995, IN PRESS TRANSPLANTA; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MEYERS JD, 1990, J INFECT DIS, V162, P373, DOI 10.1093/infdis/162.2.373; NICOL DL, 1993, TRANSPLANTATION, V55, P841, DOI 10.1097/00007890-199304000-00030; PESCOVITZ MD, 1994, SURGERY, V116, P811; REYNOLDS DW, 1979, DIAGNOSTIC PROCEDURE, V5, P399; RICHARDSON WP, 1981, NEW ENGL J MED, V305, P57, DOI 10.1056/NEJM198107093050201; RUBIN RH, 1991, NEW ENGL J MED, V324, P1057, DOI 10.1056/NEJM199104113241509; RUBIN RH, 1990, REV INFECT DIS, V12, pS754; Rubin Robert H., 1994, P629; SINGH N, 1994, ANN INTERN MED, V120, P375, DOI 10.7326/0003-4819-120-5-199403010-00004; SNYDMAN DR, 1987, NEW ENGL J MED, V317, P1049, DOI 10.1056/NEJM198710223171703; STEINMULLER DR, 1991, TRANSPLANTATION, V52, P67, DOI 10.1097/00007890-199107000-00014; VANDERBERG AP, 1992, J INFECT DIS, V166, P1229; WINSTON DJ, 1995, IN PRESS LONG TERM C	28	211	215	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					18	26		10.7326/0003-4819-123-1-199507010-00002	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762909				2022-12-28	WOS:A1995RE66500003
J	GRINSPOON, L; BAKALAR, JB				GRINSPOON, L; BAKALAR, JB			MARIJUANA AS MEDICINE - A PLEA FOR RECONSIDERATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									MASSACHUSETTS MENTAL HLTH CTR,BOSTON,MA 02115		GRINSPOON, L (corresponding author), HARVARD UNIV,SCH MED,DEPT PSYCHIAT,74 FENWOOD RD,BOSTON,MA 02115, USA.							DOBLIN R, 1991, J CLIN ONCOL, V9, P1275; Grinspoon L., 1993, MARIHUANA FORBIDDEN	2	61	63	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1875	1876		10.1001/jama.273.23.1875	http://dx.doi.org/10.1001/jama.273.23.1875			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RD116	7776506				2022-12-28	WOS:A1995RD11600032
J	GALE, CR; MARTYN, CN; WINTER, PD; COOPER, C				GALE, CR; MARTYN, CN; WINTER, PD; COOPER, C			VITAMIN-C AND RISK OF DEATH FROM STROKE AND CORONARY HEART-DISEASE IN COHORT OF ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							PLASMA-CHOLESTEROL CONCENTRATION; FOLLOW-UP; MORTALITY; CONSUMPTION; ATHEROSCLEROSIS; WHITEHALL; FRUIT; MEN	Objectives-To determine whether vitamin C status, as measured by dietary intake and plasma ascorbic acid concentration, is related to mortality from stroke and coronary heart disease in people aged 65 and over. Design-A 20 year follow up study of a cohort of randomly selected elderly people living in the community who had taken part in the 1973-4 Department of Health and Social Security nutritional survey and for whom dietary and other data had been recorded. Setting-Eight areas in Britain (five in England, two in Scotland, and one in Wales). Subjects-730 men and women who had completed a seven day dietary record and who had no history or symptoms of stroke, cerebral arteriosclerosis, or coronary heart disease when examined by a geriatrician in 1973-4. Results-Mortality from stroke was highest in those with the lowest vitamin C status. Those in the highest third of the distribution of vitamin C intake had a relative risk of 0.5 (95% confidence interval 0.3 to 0.8) compared with those in the lowest third, after adjustment for age, sex, and established cardiovascular risk factors. The relation between Vitamin C intake and stroke was independent of social class and other dietary variables. A similar gradient in risk was present for plasma ascorbic acid concentrations. No association was found between vitamin C status and risk of death from coronary heart disease. Conclusion-In elderly people vitamin C concentration, whether measured by dietary intake or plasma concentration of ascorbic acid, is strongly related to subsequent risk of death from stroke but not from coronary heart disease.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton			Gale, Catharine R/B-1653-2012					ACHESON RM, 1983, LANCET, V1, P1191; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; ARMSTRONG BK, 1975, J CHRON DIS, V28, P455, DOI 10.1016/0021-9681(75)90056-9; BONITA R, 1993, LANCET, V341, P1510, DOI 10.1016/0140-6736(93)90640-3; CASTELLI WP, 1989, AM J CARDIOL, V63, pH12; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; JAJICH CL, 1984, JAMA-J AM MED ASSOC, V252, P2831, DOI 10.1001/jama.252.20.2831; KHAW KT, 1984, STROKE, V15, P244, DOI 10.1161/01.STR.15.2.244; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; MANSON JE, 1992, CIRCULATION, V85, P865; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Roe JH, 1943, J BIOL CHEM, V147, P399; ROSE G, 1980, LANCET, V1, P523; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHIPLEY MJ, 1991, BRIT MED J, V303, P89, DOI 10.1136/bmj.303.6794.89; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STRINGER MD, 1989, BRIT MED J, V298, P281, DOI 10.1136/bmj.298.6669.281; VERLANGIERI AJ, 1985, MED HYPOTHESES, V16, P7, DOI 10.1016/0306-9877(85)90035-0; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WINAWER SJ, 1990, JAMA-J AM MED ASSOC, V263, P2083, DOI 10.1001/jama.263.15.2083; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9	22	231	238	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1563	1566		10.1136/bmj.310.6994.1563	http://dx.doi.org/10.1136/bmj.310.6994.1563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787644	Green Published, Green Submitted			2022-12-28	WOS:A1995RE35300018
J	GOLDBERG, S; SAVAGE, MP; FISCHMAN, DL				GOLDBERG, S; SAVAGE, MP; FISCHMAN, DL			CORONARY-ARTERY STENTS	LANCET			English	Editorial Material							ANGIOPLASTY; OCCLUSION				GOLDBERG, S (corresponding author), JEFFERSON MED COLL,PHILADELPHIA,PA 19107, USA.							COLOMBO A, 1995, CIRCULATION, V91, P1676, DOI 10.1161/01.CIR.91.6.1676; DEFEYTER PJ, 1992, AM HEART J, V123, P1633, DOI 10.1016/0002-8703(92)90818-G; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; HERRMANN HC, 1992, CIRCULATION, V86, P812, DOI 10.1161/01.CIR.86.3.812; HIRSHFELD JW, 1991, J AM COLL CARDIOL, V18, P647, DOI 10.1016/0735-1097(91)90783-6; ROUBIN GS, 1992, CIRCULATION, V85, P916, DOI 10.1161/01.CIR.85.3.916; SAVAGE MP, 1994, J AM COLL CARDIOL, V24, P1207, DOI 10.1016/0735-1097(94)90099-X; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SRIDHAR K, 1994, CIRCULATION, V90, P1; SUTTON JM, 1994, CIRCULATION, V89, P1126, DOI 10.1161/01.CIR.89.3.1126; WALLER BF, 1989, J AM COLL CARDIOL, V13, P969, DOI 10.1016/0735-1097(89)90248-9	12	7	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1523	1524		10.1016/S0140-6736(95)91083-2	http://dx.doi.org/10.1016/S0140-6736(95)91083-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791436	Bronze			2022-12-28	WOS:A1995RD79000005
J	RISCH, N; ZHANG, HP				RISCH, N; ZHANG, HP			EXTREME DISCORDANT SIB PAIRS FOR MAPPING QUANTITATIVE TRAIT LOCI IN HUMANS	SCIENCE			English	Article							LINKAGE	Analysis of differences between siblings (sib pair analysis) is a standard method of genetic linkage analysis for mapping quantitative trait loci, such as those contributing to hypertension and obesity, in humans. In traditional designs, pairs are selected at random or with one sib having an extreme trait value. The majority of such pairs provide little power to detect linkage; only pairs that are concordant for high values, low values, or extremely discordant pairs (for example, one in the top 10 percent and the other in the bottom 10 percent of the distribution) provide substantial power. Focus on discordant pairs can reduce the amount of genotyping necessary over conventional designs by 10- to 40-fold.	YALE UNIV,SCH MED,DEPT GENET,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06520	Yale University					NHGRI NIH HHS [HG00348] Funding Source: Medline; NICHD NIH HHS [HD30712] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD030712] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000348] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AMOS CI, 1989, GENET EPIDEMIOL, V6, P349, DOI 10.1002/gepi.1370060205; BLACKWELDER WC, 1982, COMMUN STAT A-THEOR, V11, P449, DOI 10.1080/03610928208828250; CARDON LR, 1994, SCIENCE, V266, P276, DOI 10.1126/science.7939663; CARDON LR, 1994, AM J HUM GENET, V55, P825; CAREY G, 1991, AM J HUM GENET, V49, P786; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DAVIES JL, 1994, NATURE, V371, P161; Falconer D. S., 1989, Introduction to quantitative genetics.; FULKER DW, 1991, READ WRIT, V3, P299, DOI 10.1007/BF00354964; FULKER DW, 1994, AM J HUM GENET, V54, P1092; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; GOLDGAR DE, 1990, AM J HUM GENET, V47, P957; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; LANDER ES, 1989, GENETICS, V121, P185; OLSON JM, 1993, GENET EPIDEMIOL, V10, P87, DOI 10.1002/gepi.1370100202; RISCH N, 1993, AM J HUM GENET, V53, P702; RISCH N, UNPUB	17	456	464	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1584	1589		10.1126/science.7777857	http://dx.doi.org/10.1126/science.7777857			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RD459	7777857				2022-12-28	WOS:A1995RD45900027
J	JUST, I; SELZER, J; WILM, M; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K				JUST, I; SELZER, J; WILM, M; VONEICHELSTREIBER, C; MANN, M; AKTORIES, K			GLUCOSYLATION OF RHO-PROTEINS BY CLOSTRIDIUM-DIFFICILE TOXIN-B	NATURE			English	Article							TRIPHOSPHATE CONFORMATION; MECHANISM; P21	TOXIN A and B, the major virulence factors of Clostridium difficile, are the causative agents of antibiotic-associated pseudomembranous colitis. In cultured cell lines their potent cytotoxicity results from their ability to induce disaggregation of the microfilament cytoskeleton(1,2). Toxin B acts on the low-molecular-mass GTPase RhoA(3,4), which is involved in the regulation of the actin cytoskeleton. We report here that toxin B catalyses the incorporation of up to one mole of glucose per mole of RhoA at the amino acid threonine at position 37. The modification was identified and localized by tandem electrospray mass spectrometry. UDP-glucose selectively serves as cosubstrate for the monoglucosylation reaction catalysed by toxin B. Microinjection of RhoA previously glucosylated by toxin B into monolayer cells caused disaggregation of actin filaments, indicating a dominant-negative activity of glucosylated RhoA.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; UNIV MAINZ,INST MED MIKROBIOL,D-55101 MAINZ,GERMANY	European Molecular Biology Laboratory (EMBL); Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf	JUST, I (corresponding author), UNIV SAARLAND,INST PHARMAKOL & TOXIKOL,D-66421 HOMBURG,GERMANY.		Aktories, Klaus/CAJ-5682-2022; Mann, Matthias/A-3454-2013	Aktories, Klaus/0000-0002-5397-0436; Mann, Matthias/0000-0003-1292-4799; Wilm, Matthias/0000-0002-5461-6834				BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1994, J CELL SCI, V107, P1653; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SELF AJ, 1993, ONCOGENE, V8, P655; WILM MS, 1994, INT J MASS SPECTROM, V136, P167, DOI 10.1016/0168-1176(94)04024-9	12	856	880	1	36	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					500	503		10.1038/375500a0	http://dx.doi.org/10.1038/375500a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777059				2022-12-28	WOS:A1995RC18800051
J	MULLEY, GP				MULLEY, GP			PREPARING FOR THE LATE YEARS	LANCET			English	Editorial Material							POPULATION; SMOKING; HEALTH				MULLEY, GP (corresponding author), ST JAMES UNIV HOSP,DEPT MED ELDEDRELY,LEEDS LS9 7TF,W YORKSHIRE,ENGLAND.							ABRAMS M, 1989, HUMAN AGEING LATER L, P163; BILDERBECK N, 1981, J HUM NUTR, V35, P448; BLAIKIE A, 1989, HUMAN AGEING LATER L, P69; BRACEY HE, 1966, RETIREMENT PENSIONER; CAMPBELL AJ, 1990, AGE AGEING, V19, P136, DOI 10.1093/ageing/19.2.136; CLARK FLG, 1966, WORK AGE LEISURE; DAVIES L, 1985, HUM NUTR-APPL NUTR, V39A, P315; De Beauvoir S., 1977, OLD AGE; FIELD M, 1972, AGED FAMILY COMMUNIT; FRANDIN K, 1991, GERONTOLOGY, V37, P281; HODGSON SP, 1985, PRINCIPLES PRACTICE, P801; JETTE AM, 1981, AM J PUBLIC HEALTH, V71, P1211, DOI 10.2105/AJPH.71.11.1211; KENNIE DC, 1993, PREVENTIVE CARE ELDE; KNIPSCHEER KCP, 1992, FAMILY SUPPORT ELDER, P147; KUTNER NG, 1994, J AM GERIATR SOC, V42, P757, DOI 10.1111/j.1532-5415.1994.tb06537.x; MELLSTROM D, 1982, AGE AGEING, V11, P45, DOI 10.1093/ageing/11.1.45; NILSSON L, 1987, ACTA OBST SCAND S140, V66, P52; PFEIFFER E, 1968, ARCH GEN PSYCHIAT, V19, P753; PRINZ PN, 1993, SLEEP DISORDERS INSO, P55; RAGSTAD KE, 1991, AGE AGEING, V20, P377; SCHERR PA, 1992, J AM GERIATR SOC, V40, P651, DOI 10.1111/j.1532-5415.1992.tb01954.x; SELTZER CC, 1975, AM J MED SCI, V269, P309, DOI 10.1097/00000441-197505000-00003; VETTER NJ, 1990, AGE AGEING, V19, P164, DOI 10.1093/ageing/19.3.164; WAHLQVIST ML, 1989, NUTR ELDERLY, P123	24	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1409	1413		10.1016/S0140-6736(95)92601-1	http://dx.doi.org/10.1016/S0140-6736(95)92601-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760613				2022-12-28	WOS:A1995RB44100013
J	GACY, AM; GOELLNER, G; JURANIC, N; MACURA, S; MCMURRAY, CT				GACY, AM; GOELLNER, G; JURANIC, N; MACURA, S; MCMURRAY, CT			TRINUCLEOTIDE REPEATS THAT EXPAND IN HUMAN-DISEASE FORM HAIRPIN STRUCTURES IN-VITRO	CELL			English	Article							HUNTINGTONS-DISEASE; MISMATCH REPAIR; BASE PAIR; DNA; MUTATIONS; SEQUENCE; CANCER; DUPLEX; LENGTH; GENES	We show that repeating units from all reported disease genes are capable of forming hairpins of common structure and threshold stability, The threshold stability is roughly -50 kcal per hairpin and is influenced by the flanking sequence of the gene, Hairpin stability has two components, sequence and length; only DNA of select sequences and the correct length can form hairpins of threshold energy. There is a correlation among the ability to form hairpins of threshold stability, the sequence selectivity of expansion, and the length dependence of expansion. Additionally, hairpin formation provides a potential structural basis for the constancy of the CCG region of the Huntington's disease gene in individuals and explains the stabilizing effects of AGG interruptions in FMR1 alleles.	MAYO CLIN & MAYO GRAD SCH MED,DEPT PHARMACOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO GRAD SCH MED,MOLEC NEUROSCI PROGRAM,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic	GACY, AM (corresponding author), MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ANDREW SE, 1994, HUM MOL GENET, V3, P65, DOI 10.1093/hmg/3.1.65; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BAXTER SM, 1993, BIOCHEMISTRY-US, V32, P8702, DOI 10.1021/bi00084a042; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GACY AM, 1994, BIOCHEMISTRY-US, V33, P11951, DOI 10.1021/bi00205a034; GAO XL, 1987, J BIOL CHEM, V262, P16973; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; HAN J, 1994, NUCLEIC ACIDS RES, V22, P1735, DOI 10.1093/nar/22.9.1735; HARAYAMA S, 1991, J BACTERIOL, V173, P7540, DOI 10.1128/jb.173.23.7540-7548.1991; HIRST MC, 1994, HUM MOL GENET, V9, P1553; HOELZEL AR, 1994, J MOL EVOL, V39, P191; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P100, DOI 10.1021/bi00401a017; KOHWI Y, 1993, NUCLEIC ACIDS RES, V21, P5651; KREMER B, 1994, NEW ENGL J MED, V330, P1401, DOI 10.1056/NEJM199405193302001; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; KUNST CB, 1994, CELL, V77, P853, DOI 10.1016/0092-8674(94)90134-1; MANDEL JL, 1994, NAT GENET, V7, P453, DOI 10.1038/ng0894-453; MCMURRAY CT, 1994, BIOCHEMISTRY-US, V33, P11960, DOI 10.1021/bi00205a035; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; OHOY KL, 1993, SCIENCE, V259, P809, DOI 10.1126/science.8094260; PATEL DJ, 1984, BIOCHEMISTRY-US, V23, P3218, DOI 10.1021/bi00309a016; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P9373; REISS AL, 1994, HUM MOL GENET, V3, P393, DOI 10.1093/hmg/3.3.393; RENTEPERIS D, 1993, NUCLEIC ACIDS RES, V9, P133; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; RUBINSZTEIN DC, 1993, HUM MOL GENET, V2, P1713, DOI 10.1093/hmg/2.10.1713; SHELBOURNE P, 1992, HUM MOL GENET, V1, P467, DOI 10.1093/hmg/1.7.467; SNOW K, 1993, AM J HUM GENET, V53, P1217; SNOW K, 1994, HUM MOL GENET, V3, P1543, DOI 10.1093/hmg/3.9.1543; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	41	496	507	0	25	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					533	540						8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758107				2022-12-28	WOS:A1995QZ71000010
J	KEPPLER, E; FRANZ, M; KORTH, A; REUSS, MK; BLAKE, JB; SEIDEL, R; QUENBY, JJ; WITTE, M				KEPPLER, E; FRANZ, M; KORTH, A; REUSS, MK; BLAKE, JB; SEIDEL, R; QUENBY, JJ; WITTE, M			OBSERVATIONS OF ENERGETIC PARTICLES WITH EPAC ON ULYSSES IN POLAR LATITUDES OF THE HELIOSPHERE	SCIENCE			English	Article							SOLAR-WIND; EVOLUTION; STREAM	Measurements with the Energetic Particle Composition instrument (EPAC) aboard Ulysses show particles from near the ecliptic that were apparently accelerated by shocks associated with a corotating interaction region. The particles were detected together with the shocks and even when shocks no longer arrived at Ulysses up to -65 degrees of heliographic latitude but not beyond. Particles could have reached these latitudes along magnetic fields; such connections to the outer lower latitude heliosphere evidently do not exist above that latitude. The accelerated streams have composition similar to solar wind abundances, no dispersion, and a net inward anisotropy. The underlying composition between the recurrent stream is similar to the anomalous component of cosmic rays. The channel sensitive to high-energy protons (>230 megaelectron volts) shows a 26-day variation of the flux superimposed on the heliospheric modulation of galactic ions.	AEROSP CORP, SPACE SCI LAB, LOS ANGELES, CA 90009 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, BLACKETT LAB, LONDON, ENGLAND	Aerospace Corporation - USA; Imperial College London	KEPPLER, E (corresponding author), MAX PLANCK INST AERON, D-37191 KATLENBURG DUHM, GERMANY.							ADAMS J, 1993, 23RD P ICRC CALG, VSH, P358; BALOGH A, 1995, SPACE SCI REV, V72, P171, DOI 10.1007/BF00768774; BALOGH A, 1993, GEOPHYS RES LETT, V20, P2331, DOI 10.1029/93GL02621; BALOGH A, 1995, NUCL PHYS B, P69, DOI 10.1016/0920-5632(95)00008-W; BAME SJ, 1993, GEOPHYS RES LETT, V20, P2323, DOI 10.1029/93GL02630; BARNES CW, 1976, ASTROPHYS J, V210, pL91, DOI 10.1086/182311; CUMMINGS AC, 1995, GEOPHYS RES LETT, V22, P341, DOI 10.1029/94GL03343; CUMMINGS AC, 1993, 23RD P ICRC CALG, VSH, P202; FELDMAN WC, 1991, J GEOPHYS RES, V86, P5408; FRANZ M, 1995, SPACE SCI REV, V72, P339, DOI 10.1007/BF00768802; GLOECKLER G, 1995, SPACE SCI REV, V72, P321, DOI 10.1007/BF00768798; GOSLING JT, 1981, J GEOPHYS RES-SPACE, V86, P5438, DOI 10.1029/JA086iA07p05438; GOSLING JT, 1993, GEOPHYS RES LETT, V20, P2789, DOI 10.1029/93GL03116; GOSLING JT, 1995, SPACE SCI REV, V72, P99, DOI 10.1007/BF00768761; KEPPLER E, 1995, SPACE SCI REV, V72, P285, DOI 10.1007/BF00768792; KEPPLER E, 1992, ASTRON ASTROPHYS SUP, V92, P317; KEPPLER E, 1995, NUCL PHYS B, P87, DOI 10.1016/0920-5632(95)00010-7; KUNOW H, 1995, SPACE SCI REV, V72, P397, DOI 10.1007/BF00768811; MCKIBBEN RB, 1995, SPACE SCI REV, V72, P403, DOI 10.1007/BF00768812; PIZZO VJ, 1989, J GEOPHYS RES, V94, P8673, DOI 10.1029/JA094iA07p08673; REUSS MK, 1995, SPACE SCI REV, V72, P343, DOI 10.1007/BF00768803; RICHARDSON IG, 1993, J GEOPHYS RES-SPACE, V98, P13, DOI 10.1029/92JA01837; ROELOF EC, 1995, SPACE SCI REV, V72, P309, DOI 10.1007/BF00768796; SIMNETT GM, 1994, GEOPHYS RES LETT, V21, P1561, DOI 10.1029/94GL01061; SIMNETT GM, 1995, SPACE SCI REV, V72, P303, DOI 10.1007/BF00768795	25	28	28	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	1995	268	5213					1013	1016		10.1126/science.7754379	http://dx.doi.org/10.1126/science.7754379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754379				2022-12-28	WOS:A1995QY93400030
J	HAY, EM; SNAITH, ML				HAY, EM; SNAITH, ML			ABC OF RHEUMATOLOGY - SYSTEMIC LUPUS-ERYTHEMATOSUS AND LUPUS-LIKE SYNDROMES	BRITISH MEDICAL JOURNAL			English	Article							CRITERIA		UNIV SHEFFIELD,SCH MED,INST BONE & JOINT MED,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	University of Sheffield	HAY, EM (corresponding author), STAFFORDSHIRE RHEUMATOL CTR,STOKE ON TRENT,STAFFS,ENGLAND.							ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P328; ISENBERG DA, 1993, OXFORD TXB RHEUMATOL, V2, P733; MADDISON PJ, 1993, OXFORD TXB RHEUMATOL, V1, P389; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101	4	11	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1257	1261		10.1136/bmj.310.6989.1257	http://dx.doi.org/10.1136/bmj.310.6989.1257			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767201	Green Published			2022-12-28	WOS:A1995QY87700028
J	FREED, GL; ABUSAAD, K; MARGOLIS, CZ				FREED, GL; ABUSAAD, K; MARGOLIS, CZ			REFORM OF CHILD IMMUNIZATION SERVICE DELIVERY IN ISRAEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROGRAMS; INFANTS		BEN GURION UNIV NEGEV,DIV HLTH COMMUNITY,MED DECIS MAKING GRP,BEER SHEVA,ISRAEL	Ben Gurion University	FREED, GL (corresponding author), UNIV N CAROLINA,CECIL G SHEPS CTR HLTH SERV RES,DIV COMMUNITY PEDIAT,CB 7590,CHAPEL HILL,NC 27599, USA.			Abu-Saad, Kathleen/0000-0003-2957-852X	NHLBI NIH HHS [103HR940639P000-000] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHERNICHOVSKY D, 1991, JDR RR2891 ISR BROOK; FITZGERALD FT, 1994, NEW ENGL J MED, V331, P196, DOI 10.1056/NEJM199407213310312; FREED GL, 1993, NEW ENGL J MED, V329, P1957, DOI 10.1056/NEJM199312233292611; FREED GL, 1993, MILBANK Q, V71, P65, DOI 10.2307/3350275; FREED GL, 1993, PEDIATRICS, V91, P699; FREED GL, 1993, J FAM PRACTICE, V36, P153; FREED GL, 1994, PEDIATRICS, V93, P747; GRUSKA T, 1968, HLTH SERVICES ISRAEL; INGLEHART JK, 1994, NEW ENGL J MED, V330, P1167; JONAS HS, 1993, JAMA-J AM MED ASSOC, V270, P1061, DOI 10.1001/jama.270.9.1061; LAZIN FA, 1983, J HEALTH POLIT POLIC, V8, P463, DOI 10.1215/03616878-8-3-463; PORTER B, 1987, ISRAEL J MED SCI, V23, P1079; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; 1994, CHILDREN ISRAEL STAT	14	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1909	1912						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783299				2022-12-28	WOS:A1995RE35400025
J	GUEST, TM; RAMANATHAN, AV; TUTEUR, PG; SCHECHTMAN, KB; LADENSON, JH; JAFFE, AS				GUEST, TM; RAMANATHAN, AV; TUTEUR, PG; SCHECHTMAN, KB; LADENSON, JH; JAFFE, AS			MYOCARDIAL INJURY IN CRITICALLY ILL PATIENTS - A FREQUENTLY UNRECOGNIZED COMPLICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREATINE-KINASE ISOENZYMES; CARDIAC TROPONIN-I; SKELETAL-MUSCLES; INTENSIVE-CARE; MB ISOENZYME; INFARCTION; SERUM; SURVIVAL; DISEASE; ASSAY	Objective.-To determine the incidence and effect of unrecognized cardiac injury in critically ill patients, Design.-Prospective, blinded, single-center study. Setting.-The medical and respiratory intensive care unit of an academic health center, Patients.-Two hundred nine patients (224 admissions), Main Outcome Measures.-Daily measurement of levels of cardiac troponin I, a sensitive, highly specific, and long-lived marker of myocardial injury, Concurrently, signs and symptoms potentially related to myocardial ischemia were tabulated by blinded investigators, All clinical evaluation and management decisions were made by the physicians responsible for the care of the patient, Results.-Thirty-two (15%) of the 209 patients had evidence of myocardial damage based on elevated levels of cardiac troponin !, Only 12 (37%) of these 32 patients were diagnosed as having acute myocardial infarction by the intensive care unit staff, Cardiac damage was unrecognized in the other 20 (63%), Unrecognized cardiac injury was more common in young patients and in blacks, Mortality in patients with myocardial injury that was recognized (42%) or unrecognized (40%) was higher than in those without myocardial injury (15%) (P<.001), Patients with cardiac injury were more frequently hypotensive (75% vs 50%; P=.007) and in need of mechanical ventilation (66% vs 27%; P<.001) and had longer intensive care unit stays (5.3 vs 3.1 days; P<.007) than patients without cardiac injury. Conclusion.-The incidence of myocardial injury defined by elevated levels of cardiac troponin I was unexpectedly high and associated with increased morbidity and mortality, Clinically it was often unrecognized.	WASHINGTON UNIV,SCH MED,DIV PULM & CRIT CARE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOSTAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017646, P60HL017646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 17646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JE, 1994, CLIN CHEM, V40, P1291; ADAMS JE, 1994, NEW ENGL J MED, V330, P670, DOI 10.1056/NEJM199403103301003; ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; ADAMS JE, 1993, CIRCULATION, V88, P750, DOI 10.1161/01.CIR.88.2.750; BODOR GS, 1992, CLIN CHEM, V38, P2203; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHEITLIN MD, 1975, JAMA-J AM MED ASSOC, V231, P951, DOI 10.1001/jama.231.9.951; CUMMINS B, 1987, AM HEART J, V113, P1333, DOI 10.1016/0002-8703(87)90645-4; CUMMINS P, 1987, EUR J CLIN INVEST, V17, P317, DOI 10.1111/j.1365-2362.1987.tb02194.x; DETSKY AS, 1981, NEW ENGL J MED, V305, P667, DOI 10.1056/NEJM198109173051204; DRASNER K, 1992, PRINCIPLES CRITICAL, P959; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; Girard K, 1985, Respir Care, V30, P339; GOSALAKKAL JA, 1991, SCAND J THORAC CARD, V25, P159, DOI 10.3109/14017439109098103; GRAM J, 1990, DAN MED BULL, V37, P210; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; JAFFE AS, 1984, J LAB CLIN MED, V104, P193; JULKUNEN H, 1972, ANN CHIR GYNAECOL FE, V60, P107; KUTOM AH, 1991, CHEST, V100, P571, DOI 10.1378/chest.100.2.571; LARUE C, 1993, CLIN CHEM, V39, P972; LEGALL JR, 1984, CRIT CARE MED, V12, P975; MADIAS JE, 1973, CIRCULATION, V49, P448; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PARMLEY WW, 1976, PROG CARDIOL, V5, P19; PARRY G, 1992, CLIN CARDIOL, V15, P305, DOI 10.1002/clc.4960150416; Perry SV, 1979, BIOCHEM SOC T, V7, P593, DOI 10.1042/bst0070593; PINGLETON SK, 1992, PRINCIPLES CRITICAL, P599; ROSALKI SB, 1967, J LAB CLIN MED, V69, P696; SCHEINMAN MM, 1973, AM J MED, V55, P602, DOI 10.1016/0002-9343(73)90181-2; SCHNEIDER DJ, 1992, CORONARY ARTERY DIS, V3, P26, DOI 10.1097/00019501-199201000-00004; TOYOTA N, 1981, J CELL BIOL, V91, P497, DOI 10.1083/jcb.91.2.497; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; Travis K W, 1973, Crit Care Med, V1, P235, DOI 10.1097/00003246-197309000-00001; TSUNG JS, 1986, CLIN CHEM, V32, P1568; TSUNG SH, 1981, AM J CLIN PATHOL, V75, P711, DOI 10.1093/ajcp/75.5.711; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; VAIDYA HC, 1986, CLIN CHEM, V32, P657; WILHELM A H, 1976, IRCS (International Research Communications System) Medical Science Library Compendium, V4, P418; YOUNG RKB, 1974, BRIT MED J, V1, P307, DOI 10.1136/bmj.1.5903.307	40	269	286	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1945	1949		10.1001/jama.273.24.1945	http://dx.doi.org/10.1001/jama.273.24.1945			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783306				2022-12-28	WOS:A1995RE35400032
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FAMOTIDINE APPROVED FOR OVER-THE-COUNTER USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-28	WOS:A1995RE35400005
J	YOUNG, ID				YOUNG, ID			DIAGNOSING PRADER-WILLI-SYNDROME	LANCET			English	Editorial Material							ANGELMAN				YOUNG, ID (corresponding author), CITY HOSP,CLIN GENET SERV,NOTTINGHAM,ENGLAND.							DITTRICH B, 1992, HUM GENET, V90, P313; DONALDSON MDC, 1994, ARCH DIS CHILD, V70, P58, DOI 10.1136/adc.70.1.58; GILLESSENKAESBA.G, 1995, J MED GENET, V32, P88; HOLM VA, 1993, PEDIATRICS, V91, P398; LERER I, 1994, AM J MED GENET, V52, P79, DOI 10.1002/ajmg.1320520116; NICHOLLS RD, 1993, AM J MED GENET, V46, P16, DOI 10.1002/ajmg.1320460106; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; Prader A., 1956, SCHWEIZ MED WSCHR, V86, P1260, DOI DOI 10.1007/978-3-642-47669-3_24; REIS A, 1994, AM J HUM GENET, V54, P741; Smith, 1982, RECOGNIZABLE PATTERN; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52	11	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1590	1590		10.1016/S0140-6736(95)90112-4	http://dx.doi.org/10.1016/S0140-6736(95)90112-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783534				2022-12-28	WOS:A1995RE67000005
J	GREEN, R				GREEN, R			A SIMPLE ACT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1732	1732		10.1001/jama.273.22.1732	http://dx.doi.org/10.1001/jama.273.22.1732			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769749				2022-12-28	WOS:A1995RB80000002
J	MAJEED, FA; COOK, DG; POLONIECKI, J; MARTIN, D				MAJEED, FA; COOK, DG; POLONIECKI, J; MARTIN, D			USING DATA FROM THE 1991 CENSUS	BRITISH MEDICAL JOURNAL			English	Article								The 1991 census for England and Wales provides a substantial amount of data on demography, ethnicity, housing tenure, employment status, and other social factors for geographical areas ranging in size from enumeration districts upwards. Many in the health service and in the academic community are making use of the data in the 1991 census. However, users of census data need to be aware of the problems and limitations of these data, which include the format of the data, data modification and suppression, sampling error, and underenumeration. An important innovation of the 1991 census was that the census form included a question on the postcode of respondents; this allowed the Office of Population Censuses and Surveys to produce a postcode-enumeration district look up table which overcomes many of the problems previously encountered in trying to assign postcodes to enumeration districts. The new look up table also includes the grid reference of postcodes, and this will improve the geographical referencing of census data.	UNIV SOUTHAMPTON,DEPT GEOG,SOUTHAMPTON SO17 1BJ,HANTS,ENGLAND	University of Southampton	MAJEED, FA (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Martin, David/J-7192-2012	Martin, David/0000-0003-0397-0769; Majeed, Azeem/0000-0002-2357-9858; Cook, Derek/0000-0002-9723-5759				BALARAJAN R, 1994, PUBLIC HLTH 1991 CEN, V309, P287; BARR R, 1993, 1991 CENSUS USERS GU, P70; Dale A, 1993, 1991 CENSUS USERS GU; DORLING D, 1993, RADICAL STATISTICS, V55, P14; ELLIOT P, 1991, STUDIES MED POPULATI, V53, P17; Gatrell A. C., 1989, International Journal of Geographical Information Systems, V3, P335, DOI 10.1080/02693798908941520; MAJEED FA, 1994, BMJ-BRIT MED J, V308, P1426, DOI 10.1136/bmj.308.6941.1426; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT MED J, V310, P1373, DOI 10.1136/bmj.310.6991.1373; MARSH C, 1993, 1991 CENSUS USERS GU, P161; MARTIN D, 1992, T I BRIT GEOGR, V17, P350, DOI 10.2307/622885; READING R, 1993, J EPIDEMIOL COMMUN H, V47, P238, DOI 10.1136/jech.47.3.238; SIMPSON SN, 1994, J ROY STAT SOC A STA, V157, P313; 1991, 1991 CENSUS USER GUI; 1993, 1991 CENSUS USERS GU; 1992, 1991 CENSUS DEFINITI; 1993, 1991 CENSUS USER GUI; 1992, SASPAC USER MANUAL	18	43	43	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1511	1514		10.1136/bmj.310.6993.1511	http://dx.doi.org/10.1136/bmj.310.6993.1511			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787601	Green Published			2022-12-28	WOS:A1995RD28500026
J	LANYI, JK				LANYI, JK			BACTERIORHODOPSIN AS A MODEL FOR PROTON PUMPS	NATURE			English	Article							CYTOCHROME-C-OXIDASE; X-RAY-DIFFRACTION; STRUCTURAL-CHANGES; MECHANISM; PHOTOCYCLE; TRANSPORT; ENERGY; INTERMEDIATE; ACTIVATION; PROTEINS	According to a long-standing hypothesis, membrane pumps function by flip-flopping between two protein conformations that allow alternative access of the ion binding site to the two membrane surfaces. Site-specific mutagenesis, time-resolved spectroscopy and X-ray diffraction confirm this mechanism for bacteriorhodopsin, and implicate change of electrostatic interaction at the active site as the trigger for the global protein conformation change during the proton transport cycle.			LANYI, JK (corresponding author), UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717, USA.		Lanyi, Janos/C-3808-2011; Ueno, Hiroshi/C-3301-2009					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AMES JB, 1990, BIOCHEMISTRY-US, V29, P7181, DOI 10.1021/bi00483a005; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; BIRGE RR, 1990, BIOCHIM BIOPHYS ACTA, V1016, P293, DOI 10.1016/0005-2728(90)90163-X; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BROWN LS, 1994, J MOL BIOL, V239, P401, DOI 10.1006/jmbi.1994.1381; BRZEZINSKI P, 1986, P NATL ACAD SCI USA, V83, P4282, DOI 10.1073/pnas.83.12.4282; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; COHEN GB, 1992, BIOCHEMISTRY-US, V31, P12592, DOI 10.1021/bi00165a008; COPELAND RA, 1989, ANNU REV PHYS CHEM, V40, P671; FILLINGAME RH, 1994, BACTERIA, V12, P345; FODOR SPA, 1988, BIOCHEMISTRY-US, V27, P7097, DOI 10.1021/bi00418a064; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; FUTAI M, 1994, BBA-BIOENERGETICS, V1187, P165, DOI 10.1016/0005-2728(94)90104-X; GRABER P, 1994, BBA-BIOENERGETICS, V1187, P171, DOI 10.1016/0005-2728(94)90105-8; GROTH G, 1993, BIOCHEMISTRY-US, V32, P8103, DOI 10.1021/bi00083a008; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jencks W P, 1980, Adv Enzymol Relat Areas Mol Biol, V51, P75; KATAOKA M, 1994, J MOL BIOL, V243, P621, DOI 10.1016/0022-2836(94)90037-X; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; LANYI JK, 1993, BIOCHIM BIOPHYS ACTA, V1183, P241, DOI 10.1016/0005-2728(93)90226-6; LAUBINGER W, 1989, BIOCHEMISTRY-US, V28, P7194, DOI 10.1021/bi00444a010; LAUBINGER W, 1994, BIOCHEMISTRY-US, V29, P5458; MALMSTROM BG, 1993, ACCOUNTS CHEM RES, V26, P332, DOI 10.1021/ar00030a006; MALMSTROM BG, 1990, ARCH BIOCHEM BIOPHYS, V280, P233, DOI 10.1016/0003-9861(90)90325-S; MALMSTROM BG, 1990, CHEM REV, V90, P1247, DOI 10.1021/cr00105a008; MATHIES RA, 1991, ANNU REV BIOPHYS BIO, V20, P491, DOI 10.1146/annurev.bb.20.060191.002423; Mitchell P, 1966, CHEMIOSMOTIC COUPLIN; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; NAKASAKO M, 1991, FEBS LETT, V292, P73, DOI 10.1016/0014-5793(91)80837-S; OPRIAN DD, 1993, J BIOENERG BIOMEMBR, V24, P211; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SPUDICH JL, 1994, CELL, V79, P747, DOI 10.1016/0092-8674(94)90064-7; STRADER CD, 1994, DEV BIOCHEM, V63, P101; SUBRAMANIAM S, 1993, EMBO J, V12, P1; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; VALPUESTA JM, 1990, J MOL BIOL, V214, P237, DOI 10.1016/0022-2836(90)90158-I; VARO G, 1992, BIOCHEMISTRY-US, V30, P5016; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; WIKSTROM M, 1979, BIOCHIM BIOPHYS ACTA, V549, P177, DOI 10.1016/0304-4173(79)90014-4; ZIMANYI L, 1993, BIOCHEMISTRY-US, V32, P7669, DOI 10.1021/bi00081a010; ZIMANYI L, 1992, BIOCHEMISTRY-US, V3, P8535; ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046	50	133	137	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					461	463		10.1038/375461a0	http://dx.doi.org/10.1038/375461a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777054				2022-12-28	WOS:A1995RC18800039
J	SHIVDASANI, RA; ROSENBLATT, MF; ZUCKERFRANKLIN, D; JACKSON, CW; HUNT, P; SARIS, CJM; ORKIN, SH				SHIVDASANI, RA; ROSENBLATT, MF; ZUCKERFRANKLIN, D; JACKSON, CW; HUNT, P; SARIS, CJM; ORKIN, SH			TRANSCRIPTION FACTOR NF-E2 IS REQUIRED FOR PLATELET FORMATION INDEPENDENT OF THE ACTIONS OF THROMBOPOIETIN/MGDF IN MEGAKARYOCYTE DEVELOPMENT	CELL			English	Article							DOMINANT CONTROL REGION; TARGETED MUTATION; BINDING PROTEINS; GENE; EXPRESSION; CELLS; MOUSE; LINEAGES; MARROW; GROWTH	Despite the importance of blood platelets in health and disease, the mechanisms regulating their formation within megakaryocytes are unknown. We generated mice lacking the hematopoietic subunit (p45) of the heterodimeric erythroid transcription factor NF-E2. Unexpectedly, NF-E2(-/-) mice lack circulating platelets and die of hemorrhage; their megakaryocytes show no cytoplasmic platelet formation. Though platelets are absent, serum levels of the growth factor thrombopoietin/MGDF are not elevated above controls. Nonetheless, NF-E2(-/-) megakaryocytes proliferate in vivo in response to thrombopoietin administration. Thus, as an essential factor for megakaryocyte maturation and platelet production, NF-ES must regulate critical target genes independent of the action of thrombopoietin. These findings provide insight into the genetic analysis of megakaryocyte maturation and thrombopoiesis.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA USA; CHILDRENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; NYU, MED CTR, DEPT MED, NEW YORK, NY 10016 USA; ST JUDE CHILDRENS RES HOSP, DIV EXPTL HEMATOL, MEMPHIS, TN 38105 USA; AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; New York University; St Jude Children's Research Hospital; Amgen	SHIVDASANI, RA (corresponding author), DANA FARBER CANC INST, DIV MED ONCOL, BOSTON, MA 02115 USA.				NHLBI NIH HHS [HL42103, HL51290] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042103, U01HL142103, R01HL051290] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BECKSTEAD JH, 1986, BLOOD, V67, P285; BENDAVID Y, 1992, MOL CELL BIOL, V12, P4449, DOI 10.1128/MCB.12.10.4449; BLOCK KL, 1994, BLOOD, V84, P3385; BRETONGORIUS J, 1981, BRIT J HAEMATOL, V47, P635, DOI 10.1111/j.1365-2141.1981.tb02693.x; BURSTEIN SA, 1992, EXP HEMATOL, V20, P1170; BURSTEIN SA, 1995, WILLIAMS HEMATOLOGY, P1149; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHOI ES, 1995, BLOOD, V85, P402; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEUEL TF, 1977, P NATL ACAD SCI USA, V74, P2256, DOI 10.1073/pnas.74.6.2256; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JACKSON CW, 1984, BLOOD, V63, P768; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KUTER DJ, 1994, BLOOD, V84, P1464; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEVINE RF, 1976, J CELL BIOL, V69, P159, DOI 10.1083/jcb.69.1.159; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lind S.E., 1995, BLOOD PRINCIPLES PRA, P949; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MARTIN DIK, 1990, NATURE, V344, P444, DOI 10.1038/344444a0; MAZUR EM, 1981, J CLIN INVEST, V68, P733, DOI 10.1172/JCI110309; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIURA M, 1988, EXP HEMATOL, V16, P139; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ODELL TT, 1968, BLOOD, V32, P102, DOI 10.1182/blood.V32.1.102.102; OGAWA M, 1989, HEMATOL ONCOL CLIN N, V3, P453, DOI 10.1016/S0889-8588(18)30541-0; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PAULUS JM, 1970, BLOOD-J HEMATOL, V35, P298, DOI 10.1182/blood.V35.3.298.298; PETERS LL, 1990, BLOOD, V76, P745; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; ROBERTSON EJ, 1987, TERATOCARCIOMAS EMBR; ROBINSON MO, 1994, P NATL ACAD SCI USA, V91, P12798, DOI 10.1073/pnas.91.26.12798; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; SWANK RT, 1993, BLOOD, V81, P2626; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZUCKERFRANKLIN D, 1984, J CELL BIOL, V99, P390, DOI 10.1083/jcb.99.2.390; ZUCKERFRANKLIN D, 1989, ATLAS BLOOD CELLS FU, P621	65	602	617	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 2	1995	81	5					695	704		10.1016/0092-8674(95)90531-6	http://dx.doi.org/10.1016/0092-8674(95)90531-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774011	hybrid			2022-12-28	WOS:A1995RB96100008
J	WERNER, MH; RUTH, JR; GRONENBORN, AM; CLORE, GM				WERNER, MH; RUTH, JR; GRONENBORN, AM; CLORE, GM			MOLECULAR-BASIS OF HUMAN 46X,Y SEX REVERSAL REVEALED FROM THE 3-DIMENSIONAL SOLUTION STRUCTURE OF THE HUMAN SRY-DNA COMPLEX	CELL			English	Article							HMG BOX; BINDING DOMAIN; MINOR-GROOVE; XY FEMALES; NUCLEOPROTEIN STRUCTURES; DETERMINING REGION; DETERMINING LOCUS; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; PROTEINS	The solution structure of the specific complex between the high mobility group (HMG) domain of SRY (hSRY-HMG), the protein encoded by the human testis-determining gene, and its DNA target site in the promoter of the Mullerian inhibitory substance gene has been determined by multidimensional NMR spectroscopy. hSRY-HMG has a twisted L shape that presents a concave surface (made up of three helices and the N- and C-terminal strands) to the DNA for sequence-specific recognition. Binding of hSRY-HMG to its specific target site occurs exclusively in the minor groove and induces a large conformational change in the DNA. The DNA in the complex has an overall 70 degrees-80 degrees bend and is helically unwound relative to classical A- and B-DNA. The structure of the complex reveals the origin of sequence-specific binding within the HMG-1/HMG-2 family and provides a framework for understanding the effects of point mutations that cause 46X, Y sex reversal at the atomic level.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				AFFARA NA, 1993, HUM MOL GENET, V2, P785, DOI 10.1093/hmg/2.6.785; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1994, METHOD ENZYMOL, V239, P79; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BRAUN A, 1993, AM J HUM GENET, V52, P578; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A. T, 1993, XPLOR MANUAL VERSION; BRUNGER AT, 1993, AVS XPLOR USERS MANU; CLORE GM, 1994, PROTEIN SCI, V3, P372; CLORE GM, 1989, CRIT REV BIOCHEM MOL, V24, P479, DOI 10.3109/10409238909086962; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; DECASTRO E, 1992, VISP ONE ZERO USERS; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GUSTAFSON ML, 1994, ANNU REV MED, V45, P505, DOI 10.1146/annurev.med.45.1.505; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1992, HUM GENET, V88, P471, DOI 10.1007/BF00215684; HAWKINS JR, 1992, AM J HUM GENET, V51, P979; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; MCELREAVY K, 1992, P NATL ACAD SCI USA, V89, P11016, DOI 10.1073/pnas.89.22.11016; Nicholls A.J., 1993, GRASP MANUAL; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1993, PROTEIN-STRUCT FUNCT, V17, P295; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TAJIMA T, 1994, HUM MOL GENET, V3, P1187, DOI 10.1093/hmg/3.7.1187; THIAN R, 1994, CELL, V77, P5; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0	49	407	413	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					705	714		10.1016/0092-8674(95)90532-4	http://dx.doi.org/10.1016/0092-8674(95)90532-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774012	Bronze			2022-12-28	WOS:A1995RB96100009
J	HOPTON, JL; DLUGOLECKA, M				HOPTON, JL; DLUGOLECKA, M			NEED AND DEMAND FOR PRIMARY HEALTH-CARE - A COMPARATIVE SURVEY APPROACH	BRITISH MEDICAL JOURNAL			English	Article							ORIENTED PRIMARY CARE; RESOURCE-ALLOCATION; PUBLIC-HEALTH; RAWP; NHS	Objective-To develop general practice profiles of needs and demand for primary health care. Design-Postal survey of a stratified random sample of 3478 people registered with five general practices. Data from a single practice were compared with data from the remaining four to identify areas of comparative need. Setting-Five general practices in Lothian. Main outcome measures-Differences between the single practice and the comparison practices in terms of social and economic circumstances, limiting long term illness, specific ongoing conditions, minor illness or symptoms, psychosocial problems, discussion of lifestyle, associated use of services. Results-Respondents from the single practice reported higher rates than those in the four comparison practices of ongoing mental health and respiratory problems and use of antidepressants, tranquillisers, or sleeping tablets. Although rates of limiting long term illness and other specific ongoing conditions were comparable, the rates of minor illness or symptoms and psychosocial difficulties were higher in the single practice. Respondents from the single practice were more likely to consult frequently, to have contacted the practice out of normal working hours, and to have discussed psychosocial difficulties with a general practitioner. For any specific ongoing condition or ''minor'' illness, respondents from the single practice were no more likely to consult. Conclusions-A comparative survey approach is a useful method of developing an understanding of patterns of need and demand among general practice populations. It has the potential to inform planning within individual general practices and the process of commissioning among general practices within a given area.	LOTHIAN HLTH,EDINBURGH,MIDLOTHIAN,SCOTLAND		HOPTON, JL (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND.							ABRAMSON J H, 1988, Public Health Reviews, V16, P35; ASHTON J, 1990, PUBLIC HEALTH, V104, P387, DOI 10.1016/S0033-3506(05)80082-4; BLAXTER M, 1985, Q J SOC AFF, V1, P131; Bradshaw J, 1972, PROBLEMS PROGR MED C, P71; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; DONABEDIAN A, 1973, ASPECTS MED CARE ADM; GAFFY JP, 1994, BRIT MED J, V308, P391; HAM C, 1992, 30 U BIRM HLTH SERV; HANNAY DR, 1993, BRIT MED J, V307, P516, DOI 10.1136/bmj.307.6903.516; HOPTON JL, 1992, BRIT J GEN PRACT, V42, P236; Howie J G, 1972, J R Coll Gen Pract, V22, P310; HOWIE JGR, IN PRESS BR J GEN PR; JARMAN B, 1983, BRIT MED J, V286, P1705, DOI 10.1136/bmj.286.6379.1705; KEVELL PT, 1990, SOC SCI MED, V30, P701; KNOX EG, 1978, J EPIDEMIOL COMMUN H, V32, P3, DOI 10.1136/jech.32.1.3; MAGI M, 1981, SOCIOLOGY HLTH ILLNE, V25, P49; MAYS N, 1989, COMMUNITY MED, V11, P173; MAYS N, 1987, BRIT MED J, V295, P703, DOI 10.1136/bmj.295.6600.703; MCDOWELL I, 1976, INT J EPIDEMIOL, V6, P247; MORLEY V, 1993, BMJ-BRIT MED J, V306, P112, DOI 10.1136/bmj.306.6870.112; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059; SHELDON TA, 1993, BRIT MED J, V306, P835, DOI 10.1136/bmj.306.6881.835; STONE DH, 1987, J ROY COLL GEN PRACT, V37, P218; TOLLMAN S, 1991, SOC SCI MED, V32, P633, DOI 10.1016/0277-9536(91)90142-Y; TUDORHART J, 1984, BRIT MED J, V288, P1670; 1992, LOCAL VOICES; 1989, 1990 CONTRACT GENERA	28	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1369	1373		10.1136/bmj.310.6991.1369	http://dx.doi.org/10.1136/bmj.310.6991.1369			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB005	7787542	Green Published			2022-12-28	WOS:A1995RB00500025
J	KANAI, N; LU, R; SATRIANO, JA; BAO, Y; WOLKOFF, AW; SCHUSTER, VL				KANAI, N; LU, R; SATRIANO, JA; BAO, Y; WOLKOFF, AW; SCHUSTER, VL			IDENTIFICATION AND CHARACTERIZATION OF A PROSTAGLANDIN TRANSPORTER	SCIENCE			English	Article							ISOLATED PERFUSED LUNG; RENAL PROSTAGLANDIN; E RECEPTOR; PROSTACYCLIN PGI2; EXPRESSION SYSTEM; PREGNANT RABBITS; RNA-POLYMERASE; METABOLISM; CLONING; CDNA	Carrier-mediated prostaglandin transport has been postulated to occur in many tissues. On the basis of sequence homology, the protein of unknown function encoded by the rat matrin F/G complementary DNA was predicted to be an organic anion transporter. Expression of the matrin F/G complementary DNA in HeLa cells or Xenopus oocytes conferred the property of specific transport of prostaglandins. The tissue distribution of matrin F/G messenger RNA and the sensitivity of matrin F/G-induced prostaglandin transport to inhibitors were similar to those of endogenous prostaglandin transport. The protein encoded by the matrin F/G complementary DNA is thus preferably called PGT because it is likely to function as a prostaglandin transporter.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, DIV RENAL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, MARION BESSIN LIVER RES CTR, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK023026, R01DK038095, P30DK041296, R01DK049688] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38095, R01 DK049688, DK23026, DK41296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; ANDERSON MW, 1976, PROSTAGLANDINS, V11, P645, DOI 10.1016/0090-6980(76)90067-8; BAROODY RA, 1981, PROSTAGLANDINS, V21, P133, DOI 10.1016/0090-6980(81)90203-3; BIKHAZI AB, 1983, J PHARM SCI, V72, P296, DOI 10.1002/jps.2600720322; BITO LZ, 1976, PROSTAGLANDINS, V12, P639, DOI 10.1016/0090-6980(76)90043-5; BITO LZ, 1976, ADV PROSTAG THROMB R, V1, P297; BITO LZ, 1978, AM J PHYSIOL, V234, pF80, DOI 10.1152/ajprenal.1978.234.1.F80; BITO LZ, 1976, J PHARMACOL EXP THER, V198, P481; BITO LZ, 1976, J PHYSIOL-LONDON, V256, P257, DOI 10.1113/jphysiol.1976.sp011324; BITO LZ, 1975, AM J PHYSIOL, V229, P1580, DOI 10.1152/ajplegacy.1975.229.6.1580; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BOHMAN SO, 1977, PROSTAG OTH LIPID M, V14, P729, DOI 10.1016/0090-6980(77)90201-5; BOIE Y, 1994, J BIOL CHEM, V269, P12173; CAO ZD, 1984, BIOL REPROD, V31, P505, DOI 10.1095/biolreprod31.3.505; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUTHBERT AW, 1984, BRIT J PHARMACOL, V82, P597, DOI 10.1111/j.1476-5381.1984.tb10798.x; DEVEREUX TR, 1987, PROSTAG LEUKOTR ESS, V27, P43, DOI 10.1016/0262-1746(87)90058-8; DIBENEDETTO FE, 1986, J NEUROCHEM, V46, P1725; DUSTING GJ, 1978, BRIT J PHARMACOL, V64, P315, DOI 10.1111/j.1476-5381.1978.tb17307.x; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; ELING TE, 1977, PROSTAGLANDINS, V14, P51, DOI 10.1016/0090-6980(77)90156-3; ELING TE, 1976, AGENTS ACTIONS, V6, P543, DOI 10.1007/BF01973277; FARMAN N, 1987, AM J PHYSIOL, V252, pF53, DOI 10.1152/ajprenal.1987.252.1.F53; FERREIRA SH, 1967, NATURE, V216, P868, DOI 10.1038/216868a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARCIAPEREZ A, 1984, J CLIN INVEST, V74, P63, DOI 10.1172/JCI111419; GORDON JA, 1994, J AM SOC NEPHROL, V5, P680; HAKES DJ, 1991, P NATL ACAD SCI USA, V88, P6186, DOI 10.1073/pnas.88.14.6186; HAWKINS HJ, 1978, PROSTAGLANDINS, V16, P871, DOI 10.1016/0090-6980(78)90103-X; HAWKINS HJ, 1977, PROSTAGLANDINS, V14, P251, DOI 10.1016/0090-6980(77)90170-8; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; IRISH JM, 1979, AM J PHYSIOL, V237, pF268, DOI 10.1152/ajprenal.1979.237.4.F268; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; JOHNSON M C R, 1970, Biochimica et Biophysica Acta, V218, P543, DOI 10.1016/0005-2760(70)90018-4; KANAI N, UNPUB; KATSUYAMA M, 1994, FEBS LETT, V344, P74, DOI 10.1016/0014-5793(94)00355-6; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVINE L, 1985, ADV PROST THROMBOX L, V13; LEVINE L, 1988, ARACHIDONATE METABOL; LEVINE L, 1986, DIGEST DIS SCI S2, V31; LEVINE L, 1986, AM J MED, P80; MCGIFF J C, 1969, Nature (London), V223, P742, DOI 10.1038/223742b0; MCGUIRE JC, 1978, ARCH BIOCHEM BIOPHYS, V189, P92, DOI 10.1016/0003-9861(78)90118-2; NAKAGAWA O, 1994, CIRCULATION, V90, P1643, DOI 10.1161/01.CIR.90.4.1643; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NARUMIYA S, 1993, J LIPID MEDIATOR, V6, P155; Neame K. D., 1972, ELEMENTARY KINETICS; OKITA RT, 1990, ARCH BIOCHEM BIOPHYS, V279, P242, DOI 10.1016/0003-9861(90)90488-K; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PIPER PJ, 1970, NATURE, V225, P600, DOI 10.1038/225600a0; PITT BR, 1983, J PHARMACOL EXP THER, V227, P531; QUIROGA J, 1993, PHARMACOL THERAPEUT, V58, P67, DOI 10.1016/0163-7258(93)90067-N; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; RENNICK BR, 1977, AM J PHYSIOL, V233, pF133, DOI 10.1152/ajprenal.1977.233.2.F133; ROBINSON C, 1982, BIOCHIM BIOPHYS ACTA, V712, P315, DOI 10.1016/0005-2760(82)90349-6; ROSEMAN TJ, 1973, J PHARM SCI-US, V62, P1680, DOI 10.1002/jps.2600621021; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; SCHLONDORFF D, 1986, AM J MED, V81, P1, DOI 10.1016/0002-9343(86)90903-4; SMITH WL, 1977, PROSTAGLANDINS, V13, P873, DOI 10.1016/0090-6980(77)90217-9; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; UEKAMA K, 1978, CHEM PHARM BULL, V26, pF58; ULMANN A, 1992, ACTA OBSTET GYN SCAN, V71, P278, DOI 10.3109/00016349209021052; ULMANN A, 1990, ADV PROST THROMBOX L, V21; ULMANN A, 1989, PROG CLIN BIOL RES, V312; ULMANN A, 1990, METHODS ENZYMOL, V187; WATABE A, 1993, J BIOL CHEM, V268, P20175; WONG PYK, 1978, BIOCHEM BIOPH RES CO, V83, P731, DOI 10.1016/0006-291X(78)91050-1; WONG PYK, 1981, FED PROC, V40, P2001	72	344	365	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					866	869		10.1126/science.7754369	http://dx.doi.org/10.1126/science.7754369			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754369				2022-12-28	WOS:A1995QX85000036
J	SELBY, C; OSMAN, L; DAVIS, M; LEE, M				SELBY, C; OSMAN, L; DAVIS, M; LEE, M			HOW TO DO IT - SET-UP AND RUN AN OBJECTIVE STRUCTURED CLINICAL EXAM	BRITISH MEDICAL JOURNAL			English	Article								Objective structured clinical exams are increasingly used as a way of assessing a range of clinical skills at both undergraduate and postgraduate level. To those planning to introduce such assessments, this article provides basic guidance on their development and structure and the personnel required. For those already using the assessments, our article may provide new ideas or be the impetus for an exchange of ideas. For those who are facing such formal assessment as candidates, we hope this article shows the efforts that are made to achieve the necessary structure and objectivity in this type of examination.	UNIV EDINBURGH,CTR MED EDUC,EDINBURGH EH8 9DR,MIDLOTHIAN,SCOTLAND; NINEWELLS HOSP & MED SCH,CTR MED EDUC,DUNDEE DD1 9SY,SCOTLAND	University of Edinburgh; University of Dundee	SELBY, C (corresponding author), UNIV EDINBURGH,ROYAL INFIRM,DEPT MED RIE,CLIN PHARMACOL UNIT,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND.							Council GM, 1993, TOMORROWS DOCTORS RE; HARDEN RM, 1979, MED EDUC, V13, P41; LOWRY S, 1993, BMJ-BRIT MED J, V306, P51, DOI 10.1136/bmj.306.6869.51; MULHOLLAND H, 1993, HOSPITAL UPDATE PLUS, pS56; NEWBLE DI, 1993, CERTIFICATION RECERT	5	35	37	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1187	1190		10.1136/bmj.310.6988.1187	http://dx.doi.org/10.1136/bmj.310.6988.1187			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767158	Green Published			2022-12-28	WOS:A1995QX56600032
J	FRED, HL; SIDDIQUE, I				FRED, HL; SIDDIQUE, I			IMAGES IN CLINICAL MEDICINE - POLYCYSTIC LIVER AND KIDNEY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											FRED, HL (corresponding author), UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77030, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					31	31		10.1056/NEJM199507063330106	http://dx.doi.org/10.1056/NEJM199507063330106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776991				2022-12-28	WOS:A1995RG73500006
J	LIPSHULTZ, SE; LIPSITZ, SR; MONE, SM; GOORIN, AM; SALLAN, SE; SANDERS, SP; ORAV, EJ; GELBER, RD; COLAN, SD				LIPSHULTZ, SE; LIPSITZ, SR; MONE, SM; GOORIN, AM; SALLAN, SE; SANDERS, SP; ORAV, EJ; GELBER, RD; COLAN, SD			FEMALE SEX AND HIGHER DRUG DOSE AS RISK-FACTORS FOR LATE CARDIOTOXIC EFFECTS OF DOXORUBICIN THERAPY FOR CHILDHOOD-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; CONGESTIVE HEART-FAILURE; RADIONUCLIDE ANGIOGRAPHY; OSTEO-SARCOMA; FREE SURVIVAL; GENDER; ANTHRACYCLINES; CHILDREN; ECHOCARDIOGRAPHY; CARDIOMYOPATHY	Background. Late cardiotoxic effects of doxorubicin are increasingly a problem for patients who survive childhood cancer. Cardiotoxicity is often progressive, and some patients have disabling symptoms. Our objective was to identify risk factors for late cardiotoxicity. Methods. We examined echocardiograms from 120 children and adults who had received cumulative doses of 244 to 550 mg of doxorubicin per square meter of body-surface area for the treatment of acute lymphoblastic leukemia or osteogenic sarcoma in childhood, a mean of 8.1 years earlier. Measurements of blood pressure and left ventricular function, contractility (measured as the stress-velocity index), end-diastolic posterior-wall thickness, end-diastolic dimension, mass, and afterload (measured as end-systolic wall stress) were compared with sex-specific values from a cohort of 296 normal subjects. Results. All echocardiographic measurements were abnormal at follow-up a minimum of two years after the end of therapy, with more frequent and severe abnormalities in female patients. In a multivariate analysis, female sex and a higher cumulative dose of doxorubicin were associated with depressed contractility (P less than or equal to 0.001), and there was an interaction between these two variables. independent and significant associations were found between a higher rate of administration of doxorubicin and increased afterload (P less than or equal to 0.001), left ventricular dilatation, and depressed left ventricular function; between a higher cumulative dose and depressed left ventricular function (P less than or equal to 0.001); between a younger age at diagnosis and reduced left-ventricular-wall thickness and mass and increased afterload; and between a longer time since the completion of doxorubicin therapy and reduced left-ventricular-wall thickness and increased afterload (P less than or equal to 0.001). Conclusions. Female sex and a higher rate of administration of doxorubicin were independent risk factors for cardiac abnormalities after treatment with doxorubicin for childhood cancer; the prevalence and severity of abnormalities increased with longer follow-up.	CHILDRENS HOSP,DEPT HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	LIPSHULTZ, SE (corresponding author), CHILDRENS HOSP,DEPT CARDIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Colan, Steven/ABB-4580-2020	Sanders, Stephen/0000-0003-3521-4044	NATIONAL CANCER INSTITUTE [P01CA034183, R29CA055576, P30CA006516, R01CA055576] Funding Source: NIH RePORTER; NCI NIH HHS [CA34183, CA55576, CA06516] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, JAMA-J AM MED ASSOC, V263, P2189, DOI 10.1001/jama.263.16.2189; ADAMI HO, 1989, JNCI-J NATL CANCER I, V81, P1640, DOI 10.1093/jnci/81.21.1640; BLEYER WA, 1990, CA-CANCER J CLIN, V40, P355, DOI 10.3322/canjclin.40.6.355; BYRNE J, 1990, JAMA-J AM MED ASSOC, V264, P1810, DOI 10.1001/jama.1990.03450140030022; COLAN SD, 1992, J AM COLL CARDIOL, V19, P619, DOI 10.1016/S0735-1097(10)80282-7; CUTHBERTSON DD, 1994, CIRCULATION S, V90, P1; EYSMANN SB, 1993, CARDIOVASCULAR HLTH, P57; FRISANCHO AR, 1974, AM J CLIN NUTR, V27, P1052, DOI 10.1093/ajcn/27.8.1052; GOLAY CC, 1993, ONCOLOGY, V7, P77; GOLAY CC, 1993, ONCOLOGY, V7, P67; GOORIN AM, 1987, J CLIN ONCOL, V5, P1178, DOI 10.1200/JCO.1987.5.8.1178; GOORIN AM, 1990, J PEDIATR-US, V116, P144, DOI 10.1016/S0022-3476(05)81668-3; GOORIN AM, 1991, CLIN ORTHOP RELAT R, V270, P22; HANLEY PC, 1989, J AM COLL CARDIOL, V13, P624, DOI 10.1016/0735-1097(89)90603-7; HAUSDORF G, 1988, BRIT HEART J, V60, P309; HITCHCOCKBRYAN S, 1986, MED PEDIATR ONCOL, V14, P211, DOI 10.1002/mpo.2950140405; HRUSHESKY WJM, 1991, CIRCULATION, V84, P697, DOI 10.1161/01.CIR.84.2.697; KLEWER SE, 1992, J AM COLL CARDIOL, V19, P394, DOI 10.1016/0735-1097(92)90497-B; KREUGER A, 1993, PEDIATR HEMAT ONCOL, V10, P297, DOI 10.3109/08880019309029501; LARSEN RL, 1992, AM J CARDIOL, V70, P73, DOI 10.1016/0002-9149(92)91393-I; LEE YTN, 1982, MED PEDIATR ONCOL, V10, P259, DOI 10.1002/mpo.2950100306; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; LIPSHULTZ SE, 1992, CIRCULATION, V86, P363; MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590; MATTHYS D, 1993, ACTA PAEDIATR, V82, P459, DOI 10.1111/j.1651-2227.1993.tb12722.x; MILLER DR, 1989, J CLIN ONCOL, V7, P316, DOI 10.1200/JCO.1989.7.3.316; MINOW RA, 1975, CANCER CHEMOTH REP 3, V6, P195; PALMERI ST, 1986, AM J CARDIOL, V58, P607, DOI 10.1016/0002-9149(86)90284-5; PIAZZA E, 1981, TUMORI, V67, P533, DOI 10.1177/030089168106700604; RODVOLD KA, 1988, J CLIN ONCOL, V6, P1321, DOI 10.1200/JCO.1988.6.8.1321; SALLAN SE, 1984, SEMIN ONCOL, V11, P19; SALLAN SE, 1994, ACUTE LEUKEMIA, V4, P322; SHUB C, 1994, MAYO CLIN P, V68, P205; SILBER JH, 1993, MED PEDIATR ONCOL, V21, P477, DOI 10.1002/mpo.2950210704; SMITH MA, 1991, JNCI-J NATL CANCER I, V83, P1460, DOI 10.1093/jnci/83.20.1460; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; TANNER JM, 1975, ARCH DIS CHILD, V50, P142, DOI 10.1136/adc.50.2.142; VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710; WEESNER KM, 1991, CANCER, V68, P435, DOI 10.1002/1097-0142(19910715)68:2<435::AID-CNCR2820680237>3.0.CO;2-#; YEUNG ST, 1991, LANCET, V337, P816, DOI 10.1016/0140-6736(91)92516-5	41	558	568	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1738	1743		10.1056/NEJM199506293322602	http://dx.doi.org/10.1056/NEJM199506293322602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760889				2022-12-28	WOS:A1995RE66700002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SEAFOOD SAFETY HOT LINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1897	1897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783288				2022-12-28	WOS:A1995RE35400009
J	BEACH, ME; HAWKINS, RD; OSMAN, M; KANDEL, ER; MAYFORD, M				BEACH, ME; HAWKINS, RD; OSMAN, M; KANDEL, ER; MAYFORD, M			IMPAIRMENT OF SPATIAL BUT NOT CONTEXTUAL MEMORY IN CAMKII MUTANT MICE WITH A SELECTIVE LOSS OF HIPPOCAMPAL LTP IN THE RANGE OF THE THETA-FREQUENCY	CELL			English	Article							LONG-TERM POTENTIATION; RADIAL MAZE; PLACE NAVIGATION; RATS; BEHAVIOR; NEURONS; RHYTHM; AREA; CA1; STIMULATION	We assessed hippocampal-dependent memory in mice with a Ca2+-independent form of CaMKII generated by the introduction of an aspartate at amino acid 286. The CaMKII-Asp-286 mice show normal LTP at high frequency stimulation, but in the 5-10 Hz range, they show a shift in the frequency-response curve favoring LTD. This range of frequencies is similar to the theta rhythm, which is associated with exploration in rodents. Using the Barnes maze to assess spatial memory, we found the transgenic mice could not learn to navigate to a specific location using spatial cues. In contrast, one line of transgenic mice performed normally in contextual fear conditioning, a task that is also hippocampal dependent. This dissociation between spatial and contextual memory suggests that even though both require the hippocampus, they may be mediated by different synaptic mechanisms.			BEACH, ME (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA.			Mayford, Mark/0000-0002-9001-5024	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NIMH NIH HHS [MH50733] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ARAI A, 1992, BRAIN RES, V598, P173, DOI 10.1016/0006-8993(92)90181-8; AUER RN, 1989, J NEUROSCI, V9, P1641; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BEARMF, 1994, CURR OPIN NEUROBIOL, V4, P389; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLANCHARD RJ, 1969, J COMP PHYSIOL PSYCH, V67, P370, DOI 10.1037/h0026779; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BLAND BH, 1988, BRAIN RES, V447, P364, DOI 10.1016/0006-8993(88)91141-9; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLLES RC, 1970, PSYCHOL REV, V77, P32, DOI 10.1037/h0028589; CAREW TJ, 1973, SCIENCE, V182, P1158, DOI 10.1126/science.182.4117.1158; COSTALL B, 1989, PHARMACOL BIOCHEM BE, V32, P777, DOI 10.1016/0091-3057(89)90033-6; DALE RHI, 1986, BEHAV BRAIN RES, V19, P17, DOI 10.1016/0166-4328(86)90043-4; DAVIS HP, 1990, SYMP MED H, V23, P477; DAVIS S, 1992, J NEUROSCI, V12, P21; DEVAN BD, 1992, PSYCHOBIOLOGY, V20, P120; DEVENPORT LD, 1988, BEHAV NEUROSCI, V102, P489; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; FANSELOW MS, 1980, PAVLOVIAN J BIOL SCI, V15, P177; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HEBB DO, 1949, ORG BEHAVIOR; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; KANDEL ER, 1968, PHYSIOL REV, V48, P65, DOI 10.1152/physrev.1968.48.1.65; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LEUNG LWS, 1991, BRAIN RES, V553, P261, DOI 10.1016/0006-8993(91)90834-I; MACVICAR BA, 1989, J PHYSIOL-LONDON, V417, P197, DOI 10.1113/jphysiol.1989.sp017797; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MULLER RU, 1991, BRAIN SPACE, P297; O'Keefe J, 1993, Curr Opin Neurobiol, V3, P917, DOI 10.1016/0959-4388(93)90163-S; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; Olton D., 1978, COGNITIVE PROCESS, P341; OLTON DS, 1978, PHYSIOL BEHAV, V20, P597, DOI 10.1016/0031-9384(78)90252-4; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SCHACTER DL, 1994, MEMORY SYYSTEMS; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; SHAPIRO ML, 1992, BEHAV NEUROSCI, V106, P604, DOI 10.1037/0735-7044.106.4.604; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SMYTHE JW, 1992, NEUROSCI BIOBEHAV R, V16, P289, DOI 10.1016/S0149-7634(05)80203-9; SPARKS PD, 1995, BEHAV NEUROSCI, V109, P184; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STADDON JER, 1983, ADAPTIVE BEHAVIOR LE, P378; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; SUTHERLAND RJ, 1984, CAN J PSYCHOL, V38, P322, DOI 10.1037/h0080832; SUZUKI S, 1980, LEARN MOTIV, V11, P1, DOI 10.1016/0023-9690(80)90018-1; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; WATTS J, 1981, PHYSIOL BEHAV, V26, P845, DOI 10.1016/0031-9384(81)90108-6; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646; YOERG SI, 1982, ANIM LEARN BEHAV, V10, P530, DOI 10.3758/BF03212295; ZOLADEK L, 1978, ANIM LEARN BEHAV, V6, P77, DOI 10.3758/BF03212006; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	61	355	367	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 16	1995	81	6					905	915		10.1016/0092-8674(95)90010-1	http://dx.doi.org/10.1016/0092-8674(95)90010-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781067	Bronze			2022-12-28	WOS:A1995RD76800011
J	JEANLOZ, R; MITCHELL, DL; SPRAGUE, AL; DEPATER, I				JEANLOZ, R; MITCHELL, DL; SPRAGUE, AL; DEPATER, I			EVIDENCE FOR A BASALT-FREE SURFACE ON MERCURY AND IMPLICATIONS FOR INTERNAL HEAT	SCIENCE			English	Article							THERMAL EVOLUTION; ATMOSPHERE; POTASSIUM; MANTLE; PLANETS; SODIUM	Microwave and mid-infrared observations reveal that Mercury's surface contains less FeO + TiO2 and at least as much feldspar as the lunar highlands. The results are compatible with the high albedo (brightness) of Mercury's surface at visible wavelengths in suggesting a rock and soil composition that is devoid of basalt, the primary differentiate of terrestrial mantles. The occurrence of a basalt-free, highly differentiated crust is in accord with recent models of the planet's thermal evolution and suggests that Mercury has retained a hot interior as a result of a combination of inefficient mantle convection and minimal volcanic heat loss.	CALTECH,JET PROP LAB,PASADENA,CA 91109; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; UNIV CALIF BERKELEY,DEPT ASTRON,BERKELEY,CA 94720	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Arizona; University of California System; University of California Berkeley	JEANLOZ, R (corresponding author), UNIV CALIF BERKELEY,DEPT GEOL & GEOPHYS,BERKELEY,CA 94720, USA.							Cameron A. G. W., 1988, MERCURY, P692; CAMPBELL MJ, 1969, J GEOPHYS RES, V74, P5867, DOI 10.1029/JB074i025p05867; Chapman C., 1988, MERCURY, P670; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; GRIEVE RA, 1993, METEORITICS, V28, P602; GRIEVE RAF, 1992, METEORITICS, V27, P526, DOI 10.1111/j.1945-5100.1992.tb01074.x; Heiken GH., 1991, LUNAR SOURCEBOOK; Hunten D.M., 1988, MERCURY, P562; HYNDMAN DW, 1982, PETROLOGY IGNEOUS ME; JEANLOZ R, 1986, ANNU REV EARTH PL SC, V14, P377, DOI 10.1146/annurev.ea.14.050186.002113; KILLEN RM, 1991, SCIENCE, V252, P974, DOI 10.1126/science.252.5008.974; LEDLOW MJ, 1992, ASTROPHYS J, V384, P640, DOI 10.1086/170906; Lewis J.S., 1988, MERCURY, P651; Lissauer J.J., 1993, PROTOSTARS PLANETS, P1061; Melosh H.J., 1988, TECTONICS MERCURY, P374; MITCHELL DL, 1994, ICARUS, V110, P2, DOI 10.1006/icar.1994.1105; NESS NF, 1979, PHYS EARTH PLANET IN, V20, P209, DOI 10.1016/0031-9201(79)90044-X; NESS NF, 1975, J GEOPHYS RES-SPACE, V80, P2708, DOI 10.1029/JA080i019p02708; NESS NF, 1978, SPACE SCI REV, V21, P527, DOI 10.1007/BF00240907; POTTER A, 1985, SCIENCE, V229, P651, DOI 10.1126/science.229.4714.651; POTTER AE, 1990, SCIENCE, V248, P835, DOI 10.1126/science.248.4957.835; POTTER AE, 1986, ICARUS, V67, P336, DOI 10.1016/0019-1035(86)90113-2; Ringwood A.E, 1975, COMPOSITION PETROLOG; ROEDER PL, 1970, CONTRIB MINERAL PETR, V29, P275, DOI 10.1007/BF00371276; Schubert G., 1988, MERCURY, P429; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; SOLOMON SC, 1978, GEOPHYS RES LETT, V5, P461, DOI 10.1029/GL005i006p00461; SPOHN T, 1991, ICARUS, V90, P222, DOI 10.1016/0019-1035(91)90103-Z; SPRAGUE AL, 1994, ICARUS, V109, P156, DOI 10.1006/icar.1994.1083; SPRAGUE AL, 1990, SCIENCE, V249, P1140, DOI 10.1126/science.249.4973.1140; STEVENSON DJ, 1983, ICARUS, V54, P466, DOI 10.1016/0019-1035(83)90241-5; STOLPER E, 1981, J GEOPHYS RES, V86, P6261, DOI 10.1029/JB086iB07p06261; STROM RG, 1989, MERCURY ELUSIVE PLAN; STROM RG, 1984, NASA, P13; Taylor SR, 1992, SOLAR SYSTEM EVOLUTI; TONKS WB, 1992, ICARUS, V109, P326; TYLER AL, 1988, GEOPHYS RES LETT, V15, P808, DOI 10.1029/GL015i008p00808; Veverka J., 1988, MERCURY, P37; Vilas F., 1988, MERCURY; VILAS F, 1988, MERCURY, P59; VONHIPPEL AR, 1952, DIELECTRIC MATERIALS; Wasson J.T., 1988, MERCURY, P622; Yoder H. S. J., 1976, GENERATION BASALTIC; 1981, BASALTIC VOLCANISM T	45	68	68	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1455	1457		10.1126/science.7770770	http://dx.doi.org/10.1126/science.7770770			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770770				2022-12-28	WOS:A1995RC19000027
J	SUZUKI, H; KUNDIG, TM; FURLONGER, C; WAKEHAM, A; TIMMS, E; MATSUYAMA, T; SCHMITS, R; SIMARD, JJL; OHASHI, PS; GRIESSER, H; TANIGUCHI, T; PAIGE, CJ; MAK, TW				SUZUKI, H; KUNDIG, TM; FURLONGER, C; WAKEHAM, A; TIMMS, E; MATSUYAMA, T; SCHMITS, R; SIMARD, JJL; OHASHI, PS; GRIESSER, H; TANIGUCHI, T; PAIGE, CJ; MAK, TW			DEREGULATED T-CELL ACTIVATION AND AUTOIMMUNITY IN MICE LACKING INTERLEUKIN-2 RECEPTOR-BETA	SCIENCE			English	Article							IL-2 RECEPTOR; MOLECULAR-CLONING; HUMAN NEUTROPHILS; LYMPHOCYTE-T; GAMMA-CHAIN; EXPRESSION; GENE; P75; SUBSETS; CDNAS	In mice lacking the interleukin-2 receptor beta chain (lL-2R beta), T cells were shown to be spontaneously activated, resulting in exhaustive differentiation of B cells into plasma cells and the appearance of high serum concentrations of immunoglobulins G1 and E as well as autoantibodies that cause hemolytic anemia. Marked infiltrative granulocytopoiesis was also apparent, and the animals died after about 12 weeks. Depletion of CD4(+) T cells in mutant mice rescued B cells without reversion of granulocyte abnormalities. T cells did not proliferate in response to polyclonal activators, nor could antigen-specific immune responses be elicited. Thus, IL-2R beta is required to keep the activation programs of T cells under control, to maintain homeostasis, and to prevent autoimmunity.	UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,DEPT IMMUNOL,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,WELLESLEY HOSP,RES INST,TORONTO,ON M4Y 1J3,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M4X 1K9,CANADA; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Osaka University				Ohashi, Pamela S./0000-0003-2915-9317				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BEGLEY CG, 1990, LEUKEMIA RES, V14, P263, DOI 10.1016/0145-2126(90)90134-U; CHARAN S, 1986, J VIROL, V57, P1139, DOI 10.1128/JVI.57.3.1139-1144.1986; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DJEU JY, 1993, J IMMUNOL, V150, P960; ESPINOZADELGADO I, 1990, J EXP MED, V171, P1821, DOI 10.1084/jem.171.5.1821; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; JENKINSON EJ, 1994, CURR OPIN IMMUNOL, V6, P293, DOI 10.1016/0952-7915(94)90104-X; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEUNG WP, 1994, J EXP MED, V180, P959; MATSUYAMA T, 1992, CELL, V75, P1; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NISHIKAWA K, 1990, INT IMMUNOL, V2, P481, DOI 10.1093/intimm/2.6.481; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHIBUYA H, 1990, NUCLEIC ACIDS RES, V18, P3697, DOI 10.1093/nar/18.13.3697; STARKEY PM, 1991, IMMUNOLOGY, V73, P64; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKEUCHI Y, 1992, EUR J IMMUNOL, V22, P2929, DOI 10.1002/eji.1830221126; TANAKA K, 1993, J IMMUNOL, V151, P748; TANAKA K, 1994, CELL IMMUNOL, V153, P401; TANAKA T, 1992, INT IMMUNOL, V4, P487, DOI 10.1093/intimm/4.4.487; TORIBIO ML, 1989, NATURE, V342, P82, DOI 10.1038/342082a0; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WEI S, 1993, J IMMUNOL, V150, P1979; YOKOYAMA WM, 1988, J IMMUNOL, V141, P369; ZOLA H, 1991, IMMUNOLOGY, V72, P167	35	729	743	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1472	1476		10.1126/science.7770771	http://dx.doi.org/10.1126/science.7770771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770771				2022-12-28	WOS:A1995RC19000033
J	HOUGHTON, AN				HOUGHTON, AN			ON COURSE FOR A CANCER VACCINE	LANCET			English	Editorial Material							ANTIGEN; ANTIBODY				HOUGHTON, AN (corresponding author), MEM SLOAN KETTERING CANC CTR,1275 YORK AVE,NEW YORK,NY 10021, USA.							BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; DISIS ML, 1994, CANCER RES, V16, P54; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; JONES PC, 1981, J NATL CANCER I, V66, P249; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; KWAK LW, 1995, LANCET, V345, P1016, DOI 10.1016/S0140-6736(95)90757-2; LIVINGSTON PO, 1994, J CLIN ONCOL, V12, P1036, DOI 10.1200/JCO.1994.12.5.1036; Lloyd K. O., 1991, CANCER BIOL, V2, P421; TAI T, 1985, INT J CANCER, V35, P607, DOI 10.1002/ijc.2910350507; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; WATANABE T, 1984, J EXP MED, V156, P1884	16	12	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1384	1385		10.1016/S0140-6736(95)92592-9	http://dx.doi.org/10.1016/S0140-6736(95)92592-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760606				2022-12-28	WOS:A1995RB44100004
J	PEARN, J				PEARN, J			PUBLICATION - AN ETHICAL IMPERATIVE	BRITISH MEDICAL JOURNAL			English	Article								Publication of medical research is both a monitor of the researcher's ethics and an audit of the local or regional ethics committee that approved it. Selectivity of publication or of the intention to publish lessens this audit. Opinions differ about what is ethically allowable in clinical and benchtop medical research. Ethical permission and ethical monitoring of medical research are subject to a hierarchy of pyramidal controls, starting in hospital and ending with the local, institutional, or regional ethics committee. Currently, such committees function with widely varying degrees of efficiency and quality of output, and with differing viewpoints on many ethical issues. Without an a priori insistence by institutional ethics committees that there be an intention to publish all medical research involving human subjects, ethics committees cannot routinely be subject to the scrutiny or audit which they themselves demand of researchers.			PEARN, J (corresponding author), ROYAL CHILDRENS HOSP,DEPT CHILD HLTH,BRISBANE,QLD 4029,AUSTRALIA.			Pearn, John/0000-0002-8815-2994				ALTMAN LK, 1983, BRIT MED J, V286, P2003, DOI 10.1136/bmj.286.6383.2003; ANGELL M, 1983, SCIENCE, V219, P418; BEDER S, 1993, NEW SCI, V139, P36; Broad W., 1982, BETRAYERS TRUTH; BROWN P, 1991, NEW SCI, V130, P6; CHANCE GW, 1992, WESTMINSTER AFFAIRS, V5, P10; DUNN I, 1993, LAW I J, V67, P268; ENGLER RL, 1987, NEW ENGL J MED, V317, P1583; EVANS JG, 1992, J R COLL PHYSICIANS, V26, P423; GOLDWATER PN, 1991, INFECT CONT HOSP EP, V12, P231, DOI 10.2307/30146997; HOFFENBERG R, 1992, J R COLL PHYSICIANS, V26, P423; HUGHES S, 1991, NEW SCI, V130, P6; KOMESAROFF PA, 1993, AUST NZ J MED, V23, P3, DOI 10.1111/j.1445-5994.1993.tb00529.x; LOCK S, 1988, BRIT MED J, V297, P531; MILLSTONE B, 1993, AUSTR HLTH LAW B, V1, P45; MORAN J, 1992, J ROY COLL PHYS LOND, V26, P423; PEAM J, 1973, J MED GENET, V10, P129; PEAM J, 1984, LANCET, V2, P510; PEAM J, 1987, AUST PAEDIATR J, V23, P93; SCOLARO M, 1991, LANCET, V337, P731, DOI 10.1016/0140-6736(91)90312-D; SLAKEY F, 1993, NEW SCI, V139, P42; WELLS FO, 1991, J ROY COLL PHYS LOND, V25, P329; 1988, FRAMEWORK I POLICIES; 1980, BRIT MED J, V280, P229; 1991, J R COLL PHYSICIANS, V25, P89; 1992, LANCET, V40, P823; 1991, NOTES GUIDANCE GOOD; 1991, NEW SCI, V130, P5; 1989, RESPONSIBLE CONDUCT; 1982, MAINTENANCE HIGH ETH	30	63	64	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1313	1315		10.1136/bmj.310.6990.1313	http://dx.doi.org/10.1136/bmj.310.6990.1313			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773049	Green Published			2022-12-28	WOS:A1995QZ86000029
J	LANZEROTTI, LJ; ARMSTRONG, TP; GOLD, RE; MACLENNAN, CG; ROELOF, EC; SIMNETT, GM; THOMSON, DJ; ANDERSON, KA; HAWKINS, SE; KRIMIGIS, SM; LIN, RP; PICK, M; SARRIS, ET; TAPPIN, SJ				LANZEROTTI, LJ; ARMSTRONG, TP; GOLD, RE; MACLENNAN, CG; ROELOF, EC; SIMNETT, GM; THOMSON, DJ; ANDERSON, KA; HAWKINS, SE; KRIMIGIS, SM; LIN, RP; PICK, M; SARRIS, ET; TAPPIN, SJ			OVER THE SOUTHERN SOLAR POLE - LOW-ENERGY INTERPLANETARY CHARGED-PARTICLES	SCIENCE			English	Article							ULYSSES	The heliosphere instrument for spectrum, composition, and anisotropy (HISCALE) recorded the fluxes of low-energy ions and electrons (>50 kiloelectron volts) when Ulysses crossed the southern solar polar region and revealed that the large-scale structure of the heliosphere to at least similar to-75 degrees was significantly influenced by the near-equatorial heliospheric current sheet. Electrons in particular were accelerated by the current sheet-produced and poleward-propagating interplanetary reverse shock at helioradii far from the Ulysses location. At heliolatitudes higher than similar to-75 degrees on the Ulysses ascent to the pole and similar to-50 degrees on the descent, small, less regular enhancements of the lowest energy electron fluxes were measured whose relations to the current sheet were less clear. The anomalous component of low-energy (similar to 2 to 5 megaelectron volts per nucleon) oxygen flux at the highest heliolatitudes was found to be similar to 10(-8) [per square centimeter per second per steradian (per kiloelectronvolt per nucleon)]; the anomalous Ne/O ratio was similar to 0.25.	UNIV KANSAS,DEPT PHYS,LAWRENCE,KS 66045; JOHNS HOPKINS UNIV,APPL PHYS LAB,LAUREL,MD 20723; UNIV BIRMINGHAM,BIRMINGHAM,W MIDLANDS,ENGLAND; UNIV CALIF BERKELEY,SPACE SCI LAB,BERKELEY,CA 94720; OBSERV PARIS,MEUDON,FRANCE; UNIV THRACE,XANTHI,GREECE	University of Kansas; Johns Hopkins University; Johns Hopkins University Applied Physics Laboratory; University of Birmingham; University of California System; University of California Berkeley; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Democritus University of Thrace	LANZEROTTI, LJ (corresponding author), AT&T BELL LABS,600 MT AVE,MURRAY HILL,NJ 07974, USA.		Krimigis, Stamatios/G-4591-2019; Roelof, Edmond/G-6654-2019	Krimigis, Stamatios/0000-0003-2781-2386; Roelof, Edmond/0000-0002-2270-0652				BALOGH A, 1995, SCIENCE, V268, P1007, DOI 10.1126/science.268.5213.1007; BAME SJ, 1993, GEOPHYS RES LETT, V20, P2323, DOI 10.1029/93GL02630; CUMMINGS AC, 1995, GEOPHYS RES LETT, V22, P341, DOI 10.1029/94GL03343; GOSLING JT, 1993, GEOPHYS RES LETT, V20, P2789, DOI 10.1029/93GL03116; LANZEROTTI LJ, 1992, ASTRON ASTROPHYS SUP, V92, P349; LANZEROTTI LJ, 1995, GEOPHYS RES LETT, V22, P333, DOI 10.1029/94GL03210; LANZEROTTI LJ, UNPUB; PHILLIPS JL, 1995, SCIENCE, V268, P1030, DOI 10.1126/science.268.5213.1030; PHILLIPS JL, 1994, GEOPHYS RES LETT, V21, P1105, DOI 10.1029/94GL01065; PIZZO VJ, 1994, J GEOPHYS RES-SPACE, V99, P4173, DOI 10.1029/93JA03239; RICE SO, 1948, AT&T TECH J, V27, P109, DOI 10.1002/j.1538-7305.1948.tb01334.x; SARRIS ET, 1976, J GEOPHYS RES-SPACE, V81, P2341, DOI 10.1029/JA081i013p02341; SLEPIAN D, 1978, BELL SYST TECH J, V57, P1371, DOI 10.1002/j.1538-7305.1978.tb02104.x; SMITH EJ, 1993, GEOPHYS RES LETT, V20, P2327, DOI 10.1029/93GL02632; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; THOMSON DJ, 1990, PHILOS T R SOC A, V332, P539, DOI 10.1098/rsta.1990.0130; THOMSON DJ, UNPUB; TRATTNER KJ, 1995, GEOPHYS RES LETT, V22, P337, DOI 10.1029/94GL03305	18	21	21	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1010	1013		10.1126/science.7754378	http://dx.doi.org/10.1126/science.7754378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754378				2022-12-28	WOS:A1995QY93400029
J	QUINEY, NF; DURKIN, MA				QUINEY, NF; DURKIN, MA			LESSON OF THE WEEK - ADRENOCORTICAL FAILURE IN INTENSIVE-CARE	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MEDICAL ILLNESS				QUINEY, NF (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,DEPT ANAESTHESIA & INTENS CARE,GLOUCESTER GL1 3NN,ENGLAND.							BALDWIN WA, 1993, ARCH SURG-CHICAGO, V128, P673; BETHUNE JE, 1989, ENDOCRINOLOGY, V2, P1647; BOUACHOUR G, 1994, INTENS CARE MED, V20, P138, DOI 10.1007/BF01707669; CLAYTON RN, 1989, BRIT MED J, V298, P271, DOI 10.1136/bmj.298.6669.271; DRUCKER D, 1986, CRIT CARE MED, V14, P789, DOI 10.1097/00003246-198609000-00006; DRUCKER D, 1985, CRIT CARE MED, V13, P477, DOI 10.1097/00003246-198506000-00007; JURNEY TH, 1987, CHEST, V92, P292, DOI 10.1378/chest.92.2.292; KNOWLTON AI, 1989, J INTENSIVE CARE MED, V4, P35, DOI DOI 10.1177/088506668900400104; LORIAUX DL, 1985, NEW ENGL J MED, V312, P1568, DOI 10.1056/NEJM198506133122409	9	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1253	1254		10.1136/bmj.310.6989.1253	http://dx.doi.org/10.1136/bmj.310.6989.1253			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767199	Green Published			2022-12-28	WOS:A1995QY87700026
J	VALITUTTI, S; MULLER, S; CELLA, M; PADOVAN, E; LANZAVECCHIA, A				VALITUTTI, S; MULLER, S; CELLA, M; PADOVAN, E; LANZAVECCHIA, A			SERIAL TRIGGERING OF MANY T-CELL RECEPTORS BY A FEW PEPTIDE-MHC COMPLEXES	NATURE			English	Article							PROTEIN KINASE-C; CLASS-II; ANTIGEN RECEPTOR; RECOGNITION; EXPRESSION; BINDING	T LMPHOCYTES can recognize and be activated by a very small number of complexes of peptide with major histocompatibility complex (MHC) molecules displayed on the surface of antigen-presenting cells (APCs)(1,2). The interaction between the T-cell receptor (TCR) and its ligand has low affinity and high off-rate(3-6). Both findings suggest that an extremely small number of TCRs must be engaged in interaction with APCs and raise the question of how so few receptors can transduce an activation signal. Here we show that a small number of peptide-MHC complexes can achieve a high TCR occupancy, because a single complex can serially engage and trigger up to similar to 200 TCRs, Furthermore, TCR occupancy is proportional to the T cell's biological response. Our findings suggest that the lovv affinity of the TCR can be instrumental in enabling a small number of antigenic complexes to be detected.			VALITUTTI, S (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4005 BASEL,SWITZERLAND.		Cella, Marina/ABA-8564-2020; Valitutti, Salvatore/M-2999-2014; Cella, Marina/G-8850-2011	Valitutti, Salvatore/0000-0002-6432-4421; Cella, Marina/0000-0003-1230-1313; Padovan, Elisabetta/0000-0002-8212-508X				BOITEL B, 1992, J EXP MED, V175, P765, DOI 10.1084/jem.175.3.765; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CLARKE GR, 1994, EUR J IMMUNOL, V24, P837, DOI 10.1002/eji.1830240410; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; KARJALAINEN K, 1994, CURR OPIN IMMUNOL, V6, P9, DOI 10.1016/0952-7915(94)90027-2; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; LUTON F, 1994, J IMMUNOL, V153, P63; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; PADOVAN E, 1995, J EXP MED, V181, P1587, DOI 10.1084/jem.181.4.1587; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VOGT RF, 1989, CYTOMETRY, V10, P294, DOI 10.1002/cyto.990100308; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WILLIAMS AF, 1992, NATURE, V356, P746, DOI 10.1038/356746a0	25	970	988	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					148	151		10.1038/375148a0	http://dx.doi.org/10.1038/375148a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753171				2022-12-28	WOS:A1995QX74100052
J	PRETORIUS, HW				PRETORIUS, HW			MENTAL-DISORDERS AND DISABILITY ACROSS CULTURES - A VIEW FROM SOUTH-AFRICA	LANCET			English	Editorial Material											PRETORIUS, HW (corresponding author), UNIV PRETORIA,DEPT PSYCHIAT,PRETORIA,SOUTH AFRICA.							BROADHEAD J, 1994, TROP DOCT, V24, P27, DOI 10.1177/004947559402400113; GUMEDE MV, 1994, S AFR MED J, V84, P3; KARIM SSA, 1994, S AFR MED J, V84, P5; MASSEL HK, 1990, PSYCHIATRY, V53, P31; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; THOM RGM, 1993, S AFR MED J, V83, P653	6	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					534	534		10.1016/S0140-6736(95)90461-1	http://dx.doi.org/10.1016/S0140-6736(95)90461-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QK444	7776770	Bronze			2022-12-28	WOS:A1995QK44400006
J	DOLL, R; PETO, R; WHEATLEY, K; GRAY, R; SUTHERLAND, I				DOLL, R; PETO, R; WHEATLEY, K; GRAY, R; SUTHERLAND, I			MORTALITY IN RELATION TO SMOKING - 40 YEARS OBSERVATIONS ON MALE BRITISH DOCTORS	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; CANCER; TRIAL	Objective-To assess the hazards associated with long term use of tobacco. Design-Prospective study of mortality in relation to smoking habits assessed in 1951 and again from time to time thereafter, with causes sought of deaths over 40 years (to 1991). Continuation of a study that was last reported after 20 years' follow up (1951-71). Subjects-34 439 British male doctors who replied to a postal questionnaire in 1951, of whom 10 000 had died during the first 20 years and another 10 000 have died during the second 20 years. Results-Excess mortality associated with smoking was about twice as extreme during the second half of the study as it had been during the first half. The death rate ratios during 1971-91 (comparing continuing cigarette smokers with lifelong non-smokers) were approximately threefold at ages 45-64 and twofold at ages 65-84. The excess mortality was chiefly from diseases that can be caused by smoking. Positive associations with smoking were confirmed for death from cancers of the mouth, oesophagus, pharynx, larynx, lung, pancreas, and bladder; from chronic obstructive pulmonary disease and other respiratory diseases; from vascular diseases; from peptic ulcer; and (perhaps because of confounding by personality and alcohol use) from cirrhosis, suicide, and poisoning. A negative association was confirmed with death from Parkinson's disease. Those who stopped smoking before middle age subsequently avoided almost all of the excess risk that they would otherwise have suffered, but even those who stopped smoking in middle age were subsequently at substantially less risk than those who continued to smoke. Conclusion-Results from the first 20 years of this study, and of other studies at that time, substantially underestimated the hazards of long term use of tobacco. It now seems that about half of all regular cigarette smokers will eventually be killed by their habit.			DOLL, R (corresponding author), RADCLIFFE INFIRM,NUFFIELD DEPT CLIN MED,IMPERIAL CANC RES FUND,CANC STUDIES UNIT,OXFORD OX2 6HE,ENGLAND.			Gray, Richard/0000-0003-4440-574X				Alcohol Drinking, 1988, IARC MONOGRAPHS EVAL; [Anonymous], 1962, SMOKING HLTH; BARON JA, 1990, SMOKING HORMONE RELA, P167; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; DOLL R, 1964, BMJ-BRIT MED J, V1, P1460, DOI 10.1136/bmj.1.5396.1460; DOLL R, 1964, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.5395.1399; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451; DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071; DOLL R, 1980, BRIT MED J, V280, P967, DOI 10.1136/bmj.280.6219.967; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; DOLL R, 1993, HLTH ISSUES RELATED; EYSENCK HJ, 1960, BRIT MED J, V1, P456; FLETCHER C, 1969, BRIT J PREV SOC MED, V23, P145; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; GRAVES AB, 1991, INT J EPIDEMIOL, V20, pS48, DOI 10.1093/ije/20.Supplement_2.S48; JARVIS J, IN PRESS ADDICTION; KEY T, IN PRESS J TOBACCO R; LOGAN RFA, 1990, SMOKING HORMONE RELA, P122; LONGNECKER MP, 1990, CANCER CAUSE CONTROL, V1, P59, DOI 10.1007/BF00053184; MARGETTS BM, 1993, BMJ-BRIT MED J, V307, P1381, DOI 10.1136/bmj.307.6916.1381; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MARMOT M, 1990, SMOKING HORMONE RELA, P135; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; PETO R, 1992, LANCET, V339, P1268, DOI 10.1016/0140-6736(92)91600-D; PETO R, 1994, MORTALITY TOBACCO DE; PETRO R, 1986, IARC SCI PUBLICATION, V74; SCHOENBORN CA, 1993, 236 US DEP HLTH HUM; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STELLMAN SD, 1986, IARC SCI PUBLICATION, V74; Thompson R. L., 1992, Nutrition Research Reviews, V5, P131, DOI 10.1079/NRR19920011; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; ZARIDZE D, 1986, IARC SCI PUBLICATION, V74; 1986, IARC MONOGRPAHS EVAL, V38; 1957, BRIT MED J, V1, P1523; 1979, SMOKING HLTH; 1957, MANUAL INT STATISTIC; 1993, 1993 WORLD BANK WORL; 1988, HLTH RISKS RADON OTH; [No title captured]; [No title captured]; 1989, REDUCING HLTH CONSEQ	45	1429	1486	1	88	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					901	911		10.1136/bmj.309.6959.901	http://dx.doi.org/10.1136/bmj.309.6959.901			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7755693	Green Published, Green Submitted			2022-12-28	WOS:A1994PL78100016
J	HERMINE, O; BOUSCARY, D; GESSAIN, A; TURLURE, P; LEBLOND, V; FRANCK, N; BUZYNVEIL, A; RIO, B; MACINTYRE, E; DREYFUS, F; BAZARBACHI, A				HERMINE, O; BOUSCARY, D; GESSAIN, A; TURLURE, P; LEBLOND, V; FRANCK, N; BUZYNVEIL, A; RIO, B; MACINTYRE, E; DREYFUS, F; BAZARBACHI, A			BRIEF REPORT - TREATMENT OF ADULT T-CELL LEUKEMIA-LYMPHOMA WITH ZIDOVUDINE AND INTERFERON-ALFA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							VIRUS; FRESH; GAMMA; LINE; BETA		HOP NECKER ENFANTS MALAD,DEPT BIOL HEMATOL,F-75743 PARIS 15,FRANCE; HOP COCHIN,DEPT CLIN HEMATOL,F-75674 PARIS,FRANCE; HOP COCHIN,DEPT DERMATOL,F-75674 PARIS,FRANCE; INST PASTEUR,DEPT RETROVIRUSES,PARIS,FRANCE; HOP BEAUJON,DEPT CLIN HEMATOL,CLICHY,FRANCE; HOP PITIE,DEPT CLIN HEMATOL,PARIS,FRANCE; HOP HOTEL DIEU,DEPT CLIN HEMATOL,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	HERMINE, O (corresponding author), HOP NECKER ENFANTS MALAD,DEPT CLIN HEMATOL,SERV HEMATOL ADULTE,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		Hermine, Olivier/Q-7072-2018	Bouscary, Didier/0000-0003-3654-5064; Macintyre-Davi, Elizabeth Anne/0000-0003-0520-0493; Bazarbachi, Ali/0000-0002-7171-4997; Hermine, Olivier/0000-0003-2574-3874				BAZARBACHI A, 1994, CR ACAD SCI III-VIE, V317, P264; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; EZAKI K, 1991, CANCER, V68, P695, DOI 10.1002/1097-0142(19910815)68:4<695::AID-CNCR2820680405>3.0.CO;2-K; FRANCHINI G, 1984, P NATL ACAD SCI-BIOL, V81, P6207, DOI 10.1073/pnas.81.19.6207; GABARRE J, 1993, LEUKEMIA, V7, P1904; GILL P, 1992, BLOOD S1, V80, P74; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; KAWANO F, 1985, CANCER-AM CANCER SOC, V55, P851, DOI 10.1002/1097-0142(19850215)55:4<851::AID-CNCR2820550424>3.0.CO;2-J; MATSUSHIMA M, 1987, EUR J HAEMATOL, V39, P282; PICARD F, 1990, CANCER, V66, P1524, DOI 10.1002/1097-0142(19901001)66:7<1524::AID-CNCR2820660715>3.0.CO;2-N; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; SHIMOYAMA M, 1992, GANN MONOGRAPH CANCE, V39, P43; Takatsuki K, 1990, RETROVIRUS BIOL HUMA, P147; TAMURA K, 1987, CANCER, V59, P1059, DOI 10.1002/1097-0142(19870315)59:6<1059::AID-CNCR2820590602>3.0.CO;2-M; TOSI P, 1993, EUR J HAEMATOL, V51, P209; WALDMANN TA, 1993, BLOOD, V82, P1701; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0	22	197	202	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1749	1751		10.1056/NEJM199506293322604	http://dx.doi.org/10.1056/NEJM199506293322604			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760891				2022-12-28	WOS:A1995RE66700004
J	ARMSTRONG, DS; GRIMWOOD, K; CARZINO, R; CARLIN, JB; OLINSKY, A; PHELAN, PD				ARMSTRONG, DS; GRIMWOOD, K; CARZINO, R; CARLIN, JB; OLINSKY, A; PHELAN, PD			LOWER RESPIRATORY-INFECTION AND INFLAMMATION IN INFANTS WITH NEWLY-DIAGNOSED CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT THORAC MED,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,ROYAL CHILDRENS HOSP,CLIN EPIDEMIOL & BIOSTAT UNIT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne			Carlin, John/AAG-4332-2020; Grimwood, Keith/F-9334-2011; Carlin, John B/B-3492-2012	Carlin, John/0000-0002-2694-9463; Carlin, John B/0000-0002-2694-9463; Grimwood, Keith/0000-0003-3174-9834				ABMAN SH, 1991, J PEDIATR-US, V119, P211, DOI 10.1016/S0022-3476(05)80729-2; BIRRER P, 1994, AM J RESP CRIT CARE, V150, P207, DOI 10.1164/ajrccm.150.1.7912987; KAHN FW, 1987, J INFECT DIS, V155, P862, DOI 10.1093/infdis/155.5.862; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331	5	269	273	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1571	1572		10.1136/bmj.310.6994.1571	http://dx.doi.org/10.1136/bmj.310.6994.1571			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787647	Green Published			2022-12-28	WOS:A1995RE35300021
J	SPENCER, I; UNWIN, N; PLEDGER, G				SPENCER, I; UNWIN, N; PLEDGER, G			HOSPITAL INVESTIGATION OF MEN AND WOMEN TREATED FOR ANGINA	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; NEWCASTLE & N TYNESIDE HLTH AUTHOR,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK				Unwin, Nigel/0000-0002-1368-1648				CAMPEAU L, 1975, CIRCULATION, V54, P522; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; JACKSON G, 1994, BRIT MED J, V309, P555, DOI 10.1136/bmj.309.6954.555; PETTICREW M, 1994, BRIT MED J, V306, P1164; Rose G, 1982, CARDIOVASCULAR SURVE	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1576	1576		10.1136/bmj.310.6994.1576	http://dx.doi.org/10.1136/bmj.310.6994.1576			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787649	Green Published			2022-12-28	WOS:A1995RE35300024
J	VANWEEL, C; VERMEULEN, H; VANDENBOSCH, W				VANWEEL, C; VERMEULEN, H; VANDENBOSCH, W			FALLS, A COMMUNITY CARE PERSPECTIVE	LANCET			English	Article							PHYSICAL RESTRAINTS; ELDERLY PEOPLE; MANAGEMENT				VANWEEL, C (corresponding author), UNIV NIJMEGEN,DEPT GEN PRACTICE & SOCIAL MED,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		van Weel, Chris/D-4375-2009; Bosch, W.J.H.M./H-8016-2014	van Weel, Chris/0000-0003-3653-4701; 				ALEXANDER BH, 1992, AM J PUBLIC HEALTH, V82, P1020, DOI 10.2105/AJPH.82.7.1020; BOWLING AP, 1989, J ROY COLL GEN PRACT, V39, P52; Elbrecht E A, 1994, Ned Tijdschr Geneeskd, V138, P1889; EVENS LK, 1989, J AM GERIATR SOC, V37, P65; GRIEF CHI, 1977, AGE AGEING, V6, P201; HART JT, 1990, BRIT J GEN PRACT, V40, P4; ILIFFE S, 1991, BRIT J GEN PRACT, V41, P13; Keet J G, 1987, Ned Tijdschr Geneeskd, V131, P1965; LANGLEY JD, 1989, ACCIDENT ANAL PREV, V21, P243, DOI 10.1016/0001-4575(89)90015-8; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; MCEWAN RT, 1990, BRIT J GEN PRACT, V40, P94; MCWHIRTER M, 1987, J ROY COLL GEN PRACT, V37, P244; POWELL C, 1989, CAN MED ASSOC J, V141, P561; Rhymes J, 1988, Clin Geriatr Med, V4, P613; SHEPHERD J, 1992, J FAM PRACTICE, V35, P43; SMITH R, 1987, BMJ-BRIT MED J, V294, P329, DOI 10.1136/bmj.294.6568.329; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VANDENBOSCH W, 1989, HUISARTS WET, V32, P246; VANWEEL C, 1994, LANCET, V344, P1276, DOI 10.1016/S0140-6736(94)90756-0; VANWEEL C, IN PRESS J EPIDEMIOL; VERMEULEN HBM, 1994, THESIS U NIJMEGEN; WARSHAW GA, 1982, JAMA-J AM MED ASSOC, V248, P847, DOI 10.1001/jama.248.7.847; WERNER P, 1989, J AM GERIATR SOC, V37, P1122, DOI 10.1111/j.1532-5415.1989.tb06675.x; 1994, ARCH PHYS MED REHAB, V75, P427	25	71	71	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1549	1551		10.1016/S0140-6736(95)91091-3	http://dx.doi.org/10.1016/S0140-6736(95)91091-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RD790	7791442				2022-12-28	WOS:A1995RD79000013
J	WEBSTER, C				WEBSTER, C			LOCAL-GOVERNMENT AND HEALTH-CARE - THE HISTORICAL-PERSPECTIVE	BRITISH MEDICAL JOURNAL			English	Article											WEBSTER, C (corresponding author), UNIV OXFORD ALL SOULS COLL,OXFORD OX1 4AL,ENGLAND.							[Anonymous], 1962, REV MED SERVICES GRE; BEVAN A, 1954, MUNICIPAL J     0312, P544; CROSSMAN RHS, 1972, TIMES           0809; CROSSMAN RHS, 1972, M BLOCH LECTURE, V13, P23; CROSSMAN RHS, 1971, HOUSE COMMONS DEBATE; Hall P., 1976, REFORMING WELFARE PO; HONIGSBAUM F, 1979, DIVISION BRIT MED; MORGAN KO, 1984, LABOUR POWER 1945 19, P84; PATER J, 1981, MAKING NATIONAL HLTH, P186; ROBSON WA, 1931, DEV LOCAL GOVT, P287; WEBSTER C, IN PRESS BRIT HLTH S, V2; 1956, CMD9663, P270; 1969, CMD4040, V2; 1969, CMD4040, V1; 1937, BRIT HLTH SERVICES, P388; 1944, CMD6502, P14; 1919, ORG PREVENTIVE CURAT; 1900, TRACT FABIAN SOC, V95; 1942, DRAFT INTERIM REPORT; 1933, SOCIALISED MED SERVI, P7; [No title captured]	21	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1584	1587		10.1136/bmj.310.6994.1584	http://dx.doi.org/10.1136/bmj.310.6994.1584			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RE353	7787652	Green Published			2022-12-28	WOS:A1995RE35300027
J	LANGENBERG, AGM; BURKE, RL; ADAIR, SF; SEKULOVICH, O; TIGGES, M; DEKKER, CL; COREY, L				LANGENBERG, AGM; BURKE, RL; ADAIR, SF; SEKULOVICH, O; TIGGES, M; DEKKER, CL; COREY, L			A RECOMBINANT GLYCOPROTEIN VACCINE FOR HERPES-SIMPLEX TYPE-2 - SAFETY AND EFFICACY	ANNALS OF INTERNAL MEDICINE			English	Article						HERPESVIRUS 2, HUMAN; VIRAL VACCINES; GLYCOPROTEINS; HERPES GENITALIS	RECURRENT GENITAL HERPES; VIRUS TYPE-2; GUINEA-PIGS; INFECTION; ANTIBODY; RISK; DNA; TIME	Objective: To evaluate the safety and immunogenicity of a recombinant glycoprotein vaccine for herpes simplex virus type 2 (HSV-2), which contains glycoproteins gD2 and gB2 combined with the novel MF59 adjuvant emulsion, in HSV-2-seronegative persons. Design: Integrated summary of two phase I and two phase II studies. Setting: University and private outpatient clinics. Patients: 137 persons seronegative for HSV-2 antibodies as determined by HSV Western blot assay. Intervention: Open-label vaccine administration with a dose-escalating design (phase I) was followed by randomized vaccine administration (phase II). Vaccine was administered intramuscularly into the deltoid at 0, 1, and 6 months. Measurements: Neutralizing, HSV-2-binding antibodies and HSV-2-stimulated proliferative responses were measured before and after immunization. Results: Among HSV-seronegative patients, the gD2 and gB2 enzyme-linked immunosorbent assay (ELISA) and HSV-2-neutralizing antibody titers increased to levels equal to or higher than those seen in naturally acquired HSV-2 infection after the full three-dose immunization schedule. Among HSV-1-seropositive patients, one immunization produced increases in gD2 and gB2 ELISA antibody titers and HSV-2-neutralizing antibody titers that were 3 to 5 times greater than those in persons with naturally acquired HSV-2 infection. Among HSV-seronegative patients, frequency analysis assays showed a marked increase in the precursor frequency of gD2- and gB2-specific T cells after vaccination: T-cell responses after two immunizations were equal to the responses of HSV-2-seropositive patients and were sustained at day 180. The vaccine was well tolerated. Conclusions: This subunit vaccine induces both humoral and cellular responses to HSV-2 that are equal to or greater than those of persons with naturally acquired HSV-2 infection. Studies to evaluate this vaccine for the prevention of genital herpes appear warranted.	UNIV WASHINGTON, SCH MED, DIV VIROL, SEATTLE, WA USA	University of Washington; University of Washington Seattle	LANGENBERG, AGM (corresponding author), CHIRON CORP, CHIRON BIOCINE, VACCINE RES PROGRAM, 4560 HORTON ST, EMERYVILLE, CA 94608 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-30731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1991, ANN INTERN MED, V115, P520, DOI 10.7326/0003-4819-115-7-520; BALACHANDRAN N, 1982, INFECT IMMUN, V37, P1132, DOI 10.1128/IAI.37.3.1132-1137.1982; BERMAN PW, 1988, J INFECT DIS, V157, P897, DOI 10.1093/infdis/157.5.897; BREINIG MK, 1990, J INFECT DIS, V162, P299, DOI 10.1093/infdis/162.2.299; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BUCHMAN TG, 1979, J INFECT DIS, V140, P295, DOI 10.1093/infdis/140.3.295; BURKE RL, 1993, SEMIN VIROL, V4, P187, DOI 10.1006/smvy.1993.1014; BURKE RL, 1991, J INFECT DIS, V13, pS906; CHAPEL T, 1978, J INFECT DIS, V137, P50, DOI 10.1093/infdis/137.1.50; CHRISTENSON B, 1992, J INFECTION, V25, P147, DOI 10.1016/0163-4453(92)93943-K; COHEN GH, 1984, J VIROL, V49, P102, DOI 10.1128/JVI.49.1.102-108.1984; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; COREY L, 1989, SEXUALLY TRANSMITTED, P391; DIX RD, 1981, INFECT IMMUN, V34, P192, DOI 10.1128/IAI.34.1.192-199.1981; DUFF R, 1973, NATURE-NEW BIOL, V233, P48; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; FORSGREN M, 1990, SCAND J INFECT DIS, P37; FRENKEL LM, 1993, ANN INTERN MED, V118, P414, DOI 10.7326/0003-4819-118-6-199303150-00003; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GIBSON JJ, 1990, J INFECT DIS, V162, P306, DOI 10.1093/infdis/162.2.306; HO RJY, 1989, J VIROL, V63, P2951, DOI 10.1128/JVI.63.7.2951-2958.1989; JOHNSON RE, 1989, NEW ENGL J MED, V321, P7, DOI 10.1056/NEJM198907063210102; JOHNSON RM, 1989, J VIROL, V63, P819, DOI 10.1128/JVI.63.2.819-827.1989; KOHL S, 1989, J INFECT DIS, V160, P770, DOI 10.1093/infdis/160.5.770; KOUTSKY LA, 1990, SEX TRANSM DIS, V17, P90, DOI 10.1097/00007435-199004000-00009; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LAKEMAN AD, 1986, SEX TRANSM DIS, V13, P61, DOI 10.1097/00007435-198604000-00001; LASKEY LA, 1984, BIOTECHNOLOGY    JUN, P527; LAVERY HA, 1986, GENITOURIN MED, V62, P24; LEFKOVITS I, 1984, IMMUNOL TODAY, V5, P265, DOI 10.1016/0167-5699(84)90137-3; LEHMANN EL, 1983, THEORY POINT ESTIMAT, P106; MAITLAND NJ, 1982, INFECT IMMUN, V38, P834, DOI 10.1128/IAI.38.3.834-842.1982; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1990, J INFECT DIS, V161, P653, DOI 10.1093/infdis/161.4.653; Muggeridge M.I., 1990, IMMUNOCHEM VIRUSES, V2, P459; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; PROBER CG, 1987, NEW ENGL J MED, V316, P240, DOI 10.1056/NEJM198701293160503; REECE JC, 1994, J IMMUNOL METHODS, V172, P241, DOI 10.1016/0022-1759(94)90111-2; REECE JC, 1993, J IMMUNOL, V151, P6175; REEVES WC, 1981, NEW ENGL J MED, V305, P315, DOI 10.1056/NEJM198108063050604; SANCHEZPESCADOR L, 1988, J IMMUNOL, V141, P1720; SCHMIDT OW, 1984, J INFECT DIS, V149, P645, DOI 10.1093/infdis/149.4.645; STANBERRY LR, 1989, ANTIVIR RES, V11, P203, DOI 10.1016/0166-3542(89)90005-3; STANBERRY LR, 1987, J INFECT DIS, V155, P914, DOI 10.1093/infdis/155.5.914; STANBERRY LR, 1988, J INFECT DIS, V157, P156, DOI 10.1093/infdis/157.1.156; STANBERRY LR, 1989, J GEN VIROL, V70, P3177, DOI 10.1099/0022-1317-70-12-3177; STRAUS SE, 1993, J INFECT DIS, V167, P1045, DOI 10.1093/infdis/167.5.1045; STRAUS SE, 1994, LANCET, V343, P1460, DOI 10.1016/S0140-6736(94)92581-X; STUVE LL, 1987, J VIROL, V61, P326, DOI 10.1128/JVI.61.2.326-335.1987; TASWELL C, 1981, J IMMUNOL, V126, P1614	51	147	165	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					889	898		10.7326/0003-4819-122-12-199506150-00001	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755223				2022-12-28	WOS:A1995RC27000001
J	CARRINGTON, WA; LYNCH, RM; MOORE, EDW; ISENBERG, G; FOGARTY, KE; FREDRIC, FS				CARRINGTON, WA; LYNCH, RM; MOORE, EDW; ISENBERG, G; FOGARTY, KE; FREDRIC, FS			SUPERRESOLUTION 3-DIMENSIONAL IMAGES OF FLUORESCENCE IN CELLS WITH MINIMAL LIGHT EXPOSURE	SCIENCE			English	Article							SMOOTH-MUSCLE; MICROSCOPY; NUCLEUS	Fluorescent probes offer insight into the highly localized and rapid molecular events that underlie cell function. However, methods are required that can efficiently transform the limited signals from such probes into high-resolution images. An algorithm has now been developed that produces highly accurate images of fluorescent probe distribution inside cells with minimal light exposure and a conventional light microscope. This method provides resolution nearly four times greater than that currently available from any fluorescence microscope and was used to study several biological problems.	UNIV ARIZONA, DEPT PHYSIOL, TUCSON, AZ 85724 USA; UNIV BRITISH COLUMBIA, DEPT PHYSIOL, VANCOUVER, BC V6T 1Z3, CANADA; UNIV HALLE WITTENBERG, FAK MED, JULIUS BERNSTEIN INST PHYSIOL, DEPT PHYSIOL, D-06097 HALLE, GERMANY	University of Arizona; University of British Columbia; Martin Luther University Halle Wittenberg	CARRINGTON, WA (corresponding author), UNIV MASSACHUSETTS, SCH MED, PROGRAM MOLEC MED, BIOMED IMAGING GRP, WORCESTER, MA 01605 USA.			Moore, Edwin DW/0000-0001-7519-5592				AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; BOYDE A, 1985, SCIENCE, V230, P1270, DOI 10.1126/science.4071051; BRAKENHOFF GJ, 1985, NATURE, V317, P748, DOI 10.1038/317748a0; BRENNER M, 1994, AM LAB, V26, P14; BUTLER JP, 1981, SIAM J NUMER ANAL, V18, P381, DOI 10.1137/0718025; CARRINGTON W, 1987, 13TH P ANN NE BIOENG, P108; CARRINGTON WA, 1990, P SOC PHOTO-OPT INS, V1205, P72, DOI 10.1117/12.17785; CARRINGTON WA, 1989, HANDBOOK OF BIOLOGICAL CONFOCAL MICROSCOPY, REVISED EDITION, P151; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; CARRINGTON WA, 1992, THESIS WASHINGTON U; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; COLEMAN R, 1987, J MICROSC-OXFORD, V153, P233; CONCHELLO JA, 1994, SPIE P, V2302, P369; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; ELLIOTT DJ, 1992, EMBO J, V11, P3731, DOI 10.1002/j.1460-2075.1992.tb05458.x; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; FAY FS, 1986, OPTICAL METHODS CELL, P51; FRISKENGIBSON S, 1989, J OPT SOC AM A, V6, P9; GASBJERG PK, 1994, BIOPHYS J, V66, pA274; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GROETSCH CW, 1984, RES NOTES MATH, V107; GUERRERO A, 1993, BIOPHYS J, V64, pA153; GULL SF, 1978, NATURE, V272, P686, DOI 10.1038/272686a0; Hanson K. M., 1987, IMAGE RECOVERY THEOR, P79; HELL S, 1993, J MICROSC-OXFORD, V169, P391, DOI 10.1111/j.1365-2818.1993.tb03315.x; HIRAOKA Y, 1987, SCIENCE, V238, P36, DOI 10.1126/science.3116667; IINO M, 1987, BIOCHEM BIOPH RES CO, V142, P47, DOI 10.1016/0006-291X(87)90449-9; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOSHY M, 1990, SOC PHOTO OPT INSTRU, V1205, P64; KRISHNAMURTHY V, 1992, SPIE, V1660, P95; Lanni F., 1993, Bioimaging, V1, P187, DOI 10.1002/1361-6374(199312)1:4<187::AID-BIO1>3.3.CO;2-G; LOEW LM, 1993, BIOPHYS J, V65, P2396, DOI 10.1016/S0006-3495(93)81318-3; LOEW LM, 1994, P NATL ACAD SCI USA, V91, P12579, DOI 10.1073/pnas.91.26.12579; LYNCH R M, 1991, Biophysical Journal, V59, p157A; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; TELLA LL, 1985, THESIS WORCESTER POL; Tikhonov A., 1977, SOLUTION ILL POSED P; TUFT R A, 1992, Biophysical Journal, V61, pA34; Wilson J E, 1980, Curr Top Cell Regul, V16, P1; WILSON JE, 1988, MICROCOMPARTMENTATIO, P172	42	285	298	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	1995	268	5216					1483	1487		10.1126/science.7770772	http://dx.doi.org/10.1126/science.7770772			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770772				2022-12-28	WOS:A1995RC19000036
J	FUNAKOSHI, H; BELLUARDO, N; ARENAS, E; YAMAMOTO, Y; CASABONA, A; PERSSON, H; IBANEZ, CF				FUNAKOSHI, H; BELLUARDO, N; ARENAS, E; YAMAMOTO, Y; CASABONA, A; PERSSON, H; IBANEZ, CF			MUSCLE-DERIVED NEUROTROPHIN-4 AS AN ACTIVITY-DEPENDENT TROPHIC SIGNAL FOR ADULT MOTOR-NEURONS	SCIENCE			English	Article							NEUROMUSCULAR-JUNCTIONS; POSTNATAL-DEVELOPMENT; MESSENGER-RNA; CELL-DEATH; NERVE; BRAIN; EXPRESSION; RECEPTORS; SURVIVAL; INVIVO	The production of neurotrophin-4 (NT-4) in rat skeletal muscle was found to depend on muscle activity. The amounts of NT-4 messenger RNA present decreased after blockade of neuromuscular transmission with alpha-bungarotoxin and increased during postnatal development and after electrical stimulation in a dose-dependent manner. NT-4 immunoreactivity was detected in slow, type I muscle fibers. Intramuscular administration of NT-4 induced sprouting of intact adult motor nerves. Thus, muscle-derived NT-4 acted as an activity-dependent neurotrophic signal for growth and remodeling of about motor-neuron innervation. NT-4 may thus be partly responsible for the effects of exercise and electrical stimulation on neuromuscular performance.	KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,MOLEC NEUROBIOL LAB,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,INST WOMAN & CHILD HLTH,S-17177 STOCKHOLM,SWEDEN; UNIV CATANIA,INST FISIOL HUMANA,CATANIA,ITALY	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Catania			Arenas, Ernest/AAO-5231-2020	Arenas, Ernest/0000-0003-0197-6577; Casabona, Antonino/0000-0003-0180-4695				BALICEGORDON RJ, 1990, J NEUROSCI, V10, P894; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BRADLEY WG, 1983, ANN NEUROL, V14, P267, DOI 10.1002/ana.410140304; BROWN MC, 1981, ANNU REV NEUROSCI, V4, P17, DOI 10.1146/annurev.ne.04.030181.000313; CARONI P, 1994, J CELL BIOL, V125, P893, DOI 10.1083/jcb.125.4.893; CONNOLD AL, 1986, DEV BRAIN RES, V28, P99, DOI 10.1016/0165-3806(86)90069-6; CONNOLD AL, 1994, NEUROSCIENCE, V63, P327, DOI 10.1016/0306-4522(94)90027-2; CONNOR EA, 1994, J NEUROBIOL, V25, P722, DOI 10.1002/neu.480250611; CZEH G, 1978, J PHYSIOL-LONDON, V281, P239, DOI 10.1113/jphysiol.1978.sp012419; DENNIS MJ, 1981, ANNU REV NEUROSCI, V4, P43, DOI 10.1146/annurev.ne.04.030181.000355; DESCHENES MR, 1993, J NEUROCYTOL, V22, P603, DOI 10.1007/BF01181487; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; FUNAKOSHI H, 1993, J CELL BIOL, V123, P455, DOI 10.1083/jcb.123.2.455; Funakoshi H., UNPUB; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1983, NATURE, V302, P609, DOI 10.1038/302609a0; HOPKINS WG, 1981, J NEUROCYTOL, V10, P537, DOI 10.1007/BF01262589; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; KAPLAN DB, COMMUNICATION; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; LANDMESSER L, 1992, J NEUROBIOL, V23, P1131, DOI 10.1002/neu.480230906; LIND A, 1991, J HISTOCHEM CYTOCHEM, V39, P589, DOI 10.1177/39.5.1826695; MUNSAT TL, 1976, ARCH NEUROL-CHICAGO, V33, P608, DOI 10.1001/archneur.1976.00500090014004; OPPENHEIM RW, 1992, NATURE, V360, P755, DOI 10.1038/360755a0; PERSSON H, 1993, CURR OPIN NEUROL NEU, V6, P11; PIEHL F, 1994, NEUROREPORT, V5, P697, DOI 10.1097/00001756-199402000-00009; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; WAERHAUG O, 1992, ANAT EMBRYOL, V185, P115; WERNIG A, 1991, J NEUROCYTOL, V20, P903, DOI 10.1007/BF01190468; WERNIG A, 1986, PROG NEUROBIOL, V27, P251, DOI 10.1016/0301-0082(86)90023-7; WIGSTON DJ, 1989, J NEUROSCI, V9, P639; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	38	305	324	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1495	1499		10.1126/science.7770776	http://dx.doi.org/10.1126/science.7770776			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770776				2022-12-28	WOS:A1995RC19000040
J	COLLIS, RE; DAVIES, DWL; AVELING, W				COLLIS, RE; DAVIES, DWL; AVELING, W			RANDOMIZED COMPARISON OF COMBINED SPINAL-EPIDURAL AND STANDARD EPIDURAL ANALGESIA IN LABOR	LANCET			English	Article							FENTANYL; BUPIVACAINE	Epidural analgesia has a well-established role in labour, but has the drawbacks of delayed onset and motor blockade. The combined spinal-epidural technique may overcome these drawbacks. We carried out a randomised observational study to assess maternal satisfaction with the standard and combined techniques among 197 women in labour. For combined spinal-epidural analgesia, bupivacaine (2.5 mg) and fentanyl (25 mu g) were initially injected into the subarachnoid space, followed by top-ups of 15 mL 0.1% bupivacaine with 2 mu g/mL fentanyl into the epidural space, as required. For standard epidural analgesia, 25 mg (10 mL of 0.25%) bupivacaine was injected into the epidural space, followed by top-ups of 6-10 mL 0.25% bupivacaine, as required. Post partum, each woman completed a questionnaire about her labour and scored various items on a visual analogue scale (0=best, 100=worst outcome). Overall satisfaction was greater in the combined spinal-epidural group than in the standard epidural group (median [IQR] score 3 [2-10] vs 9 [3-22]; p=0.0002). Good analgesia was achieved in both groups, but the combined spinal-epidural had faster onset of analgesia and more of this group were satisfied with analgesia at 20 min (92/98 vs 68/99, p<0.0001). 12 women in the combined spinal-epidural group had leg weakness (as shown by an inability to raise the straight legs) at 20 min, but this initial motor block had resolved in most of these mothers by 1 h. In the standard epidural group 32 had leg weakness at 20 min (p=0.001), and the proportion of mothers with weakness increased in this group during labour. There were no differences in side-effects, except for mild pruritus, which was more common in the combined spinal-epidural group (42 vs 1%; p<0.0001). Overall, women seem to prefer the low-dose combined spinal-epidural technique to standard epidurals, perhaps because of the faster onset, less motor block, and feelings of greater self-control.	UCL HOSP, MIDDLESEX HOSP, DEPT SURG, DIV ANAESTHESIA, LONDON W1N 8AA, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London				Collis, Rachel/0000-0003-2107-7990				CARRIE LES, 1990, ANAESTHESIA, V45, P1097, DOI 10.1111/j.1365-2044.1990.tb14932.x; CHESTNUT DH, 1991, ANESTHESIOLOGY, V74, P805, DOI 10.1097/00000542-199105000-00001; CHESTNUT DH, 1990, ANESTHESIOLOGY, V72, P613, DOI 10.1097/00000542-199004000-00006; COHEN SE, 1987, ANESTHESIOLOGY, V67, P403, DOI 10.1097/00000542-198709000-00020; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; COLLIS RE, 1993, LANCET, V341, P767, DOI 10.1016/0140-6736(93)90548-U; DAVIES MW, 1993, ANAESTHESIA, V48, P63; FLYNN AM, 1978, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.6137.591; MCMANUS TJ, 1978, LANCET, V2, P72; MORGAN B, 1982, BMJ-BRIT MED J, V285, P689, DOI 10.1136/bmj.285.6343.689; MURPHY JD, 1991, BRIT MED J, V302, P564, DOI 10.1136/bmj.302.6776.564; PURDY G, 1987, BRIT J ANAESTH, V59, P319, DOI 10.1093/bja/59.3.319; STACEY RGW, 1993, BRIT J ANAESTH, V71, P499, DOI 10.1093/bja/71.4.499	13	203	211	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 3	1995	345	8962					1413	1416		10.1016/S0140-6736(95)92602-X	http://dx.doi.org/10.1016/S0140-6736(95)92602-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760614				2022-12-28	WOS:A1995RB44100014
J	KATZ, JD; BENOIST, C; MATHIS, D				KATZ, JD; BENOIST, C; MATHIS, D			T-HELPER CELL SUBSETS IN INSULIN-DEPENDENT DIABETES	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NOD MICE; INTERFERON-GAMMA; LEISHMANIA-MAJOR; TRANSGENIC MICE; CD4+; ANTIBODY; RECEPTOR; INTERLEUKIN-4; DESTRUCTION	It has been proposed that the development of insulin-dependent diabetes is controlled by the T helper 1 (T(H)1) versus T(H)2 phenotype of autoreactive T-H cells: T(H)1 cells would promote diabetes, whereas, T(H)2 cells would actually protect from disease. This proposition was tested by establishing cultures of T(H)1 and T(H)2 cells that express and identical diabetogenic T cell receptor and comparing their ability to initiate disease in neonatal nonobese diabetic mice. T(H)1-like cells actively promoted diabetes; T(H)2-like cells invaded the islets but did not provoke disease-neither did they provide substantial protection.	UNIV STRASBOURG 1, INST GENET & BIOL MOLEC & CELLULAIRE, CNRS, INSERM, F-67404 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Katz, Jonathan/0000-0002-9864-2268				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; ALZONA M, 1994, J IMMUNOL, V153, P2861; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; BACH JF, 1994, ENDOCR REV, V15, P516, DOI 10.1210/er.15.4.516; BENDELAC A, 1987, J EXP MED, V166, P823, DOI 10.1084/jem.166.4.823; BENDTZEN K, 1986, SCIENCE, V232, P1545, DOI 10.1126/science.3086977; BRADLEY BJ, 1992, DIABETES, V41, P1603, DOI 10.2337/diabetes.41.12.1603; CAMPBELL IL, 1991, J CLIN INVEST, V87, P739, DOI 10.1172/JCI115055; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431; DARDENNE M, 1989, EUR J IMMUNOL, V19, P889, DOI 10.1002/eji.1830190516; DEBRAYSACHS M, 1991, J AUTOIMMUN, V4, P237, DOI 10.1016/0896-8411(91)90021-4; DUNCAN DD, 1994, EUR J IMMUNOL, V24, P2506, DOI 10.1002/eji.1830241037; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; FERRICK DA, 1995, NATURE, V373, P255, DOI 10.1038/373255a0; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; HARADA M, 1986, EXP ANIM TOKYO, V35, P501, DOI 10.1538/expanim1978.35.4_501; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; HASKINS K, 1990, SCIENCE, V249, P1433, DOI 10.1126/science.2205920; HATTORI M, 1986, SCIENCE, V231, P733, DOI 10.1126/science.3003909; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HSIEH CS, 1993, INT IMMUNOL, V5, P371; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; KATZ JE, UNPUB; KOIKE T, 1987, DIABETES, V36, P539, DOI 10.2337/diabetes.36.4.539; LAGOO AS, 1994, EUR J IMMUNOL, V24, P3087, DOI 10.1002/eji.1830241226; LEAL LMCC, 1993, EUR J IMMUNOL, V23, P566, DOI 10.1002/eji.1830230241; LEE MS, 1994, J CLIN INVEST, V93, P1332, DOI 10.1172/JCI117092; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; MAKINO S, 1986, EXP ANIM TOKYO, V35, P495, DOI 10.1538/expanim1978.35.4_495; MILLER BJ, 1988, J IMMUNOL, V140, P52; MIYAZAKI A, 1985, CLIN EXP IMMUNOL, V60, P622; MORI Y, 1986, DIABETOLOGIA, V29, P244, DOI 10.1007/BF00454884; MORITANI M, 1994, INT IMMUNOL, V6, P1927, DOI 10.1093/intimm/6.12.1927; NAKANO N, 1991, J EXP MED, V173, P1091, DOI 10.1084/jem.173.5.1091; NANDA NK, 1994, INT IMMUNOL, V6, P731, DOI 10.1093/intimm/6.5.731; OGAWA M, 1985, BIOMED RES-TOKYO, V6, P103; OREILLY LA, 1991, EUR J IMMUNOL, V21, P1171, DOI 10.1002/eji.1830210512; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PENNLINE KJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P169, DOI 10.1006/clin.1994.1068; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; PUKEL C, 1988, DIABETES, V37, P133, DOI 10.2337/diabetes.37.1.133; RAPOPORT MJ, 1993, J EXP MED, V178, P87, DOI 10.1084/jem.178.1.87; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; SARVETNICK N, 1990, NATURE, V346, P844, DOI 10.1038/346844a0; SCHMITT E, 1994, EUR J IMMUNOL, V24, P343, DOI 10.1002/eji.1830240211; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; SCOTT P, 1993, CURR OPIN IMMUNOL, V5, P391, DOI 10.1016/0952-7915(93)90058-Z; SEDER RA, 1995, J EXP MED, V181, P5, DOI 10.1084/jem.181.1.5; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEMPEP, 1991, EUR J IMMUNOL, V21, P1663; SHEHADEH NN, 1993, J AUTOIMMUN, V6, P291, DOI 10.1006/jaut.1993.1025; SHIZURU JA, 1988, SCIENCE, V240, P659, DOI 10.1126/science.2966437; SWAIN SL, 1994, IMMUNITY, V1, P543, DOI 10.1016/1074-7613(94)90044-2; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TREMBLEAU S, 1995, J EXP MED, V181, P817, DOI 10.1084/jem.181.2.817; VOLLMER S, 1994, EUR J IMMUNOL, V24, P2377, DOI 10.1002/eji.1830241018; WANG Y, 1991, P NATL ACAD SCI USA, V88, P527, DOI 10.1073/pnas.88.2.527; WOGENSEN L, 1994, J EXP MED, V179, P1379, DOI 10.1084/jem.179.4.1379	60	523	544	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1185	1188		10.1126/science.7761837	http://dx.doi.org/10.1126/science.7761837			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761837				2022-12-28	WOS:A1995RA60400040
J	SINGH, R; VALCARCEL, J; GREEN, MR				SINGH, R; VALCARCEL, J; GREEN, MR			DISTINCT BINDING SPECIFICITIES AND FUNCTIONS OF HIGHER EUKARYOTIC POLYPYRIMIDINE TRACT-BINDING PROTEINS	SCIENCE			English	Article							PRE-MESSENGER-RNA; SPLICING FACTOR U2AF; CIS-ACTING ELEMENTS; SEX-LETHAL; PREMESSENGER RNA; TRANSFORMER GENE; DROSOPHILA; SITE; EXON; CLONING	In higher eukaryotes, the polypyrimidine-tract (Py-tract) adjacent to the 3' splice site is recognized by several proteins, including the essential splicing factor U2AF(65), the splicing regulator Sex-lethal (Sxl), and polypyrimidine tract-binding protein (PTB), whose function is unknown. Iterative in vitro genetic selection was used to show that these proteins have distinct sequence preferences. The uridine-rich degenerate sequences selected by U2AF(65) are similar to those present in the diverse array of natural metazoan Py-tracts. In contrast, the Sxl-consensus is a highly specific sequence, which can help explain the ability of Sxl to regulate splicing of transformer pre-mRNA and autoregulate splicing of its own pre-mRNA. The PTB-consensus is not a typical Py-tract; it can be found in certain alternatively spliced pre-mRNAs that undergo negative regulation. Here it is shown that PTB can regulate alternative splicing by selectively repressing 3' splice sites that contain a PTB-binding site.			SINGH, R (corresponding author), UNIV MASSACHUSETTS, MED CTR, HOWARD HUGHES MED INST, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.		Valcarcel, Juan/O-9814-2014	Valcarcel, Juan/0000-0001-5398-3571				BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HORABIN JI, 1993, MOL CELL BIOL, V13, P7734, DOI 10.1128/MCB.13.12.7734; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; IRVINE D, 1991, J MOL BIOL, V222, P739, DOI 10.1016/0022-2836(91)90509-5; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; KANAAR R, 1993, SCIENCE, V262, P569, DOI 10.1126/science.7692602; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; MAYEDA A, 1994, SCIENCE, V265, P1706; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOOREMJ, 1993, RNA WORLD, P1; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NORTON PA, 1994, NUCLEIC ACIDS RES, V22, P3854, DOI 10.1093/nar/22.19.3854; ONEIL MT, 1992, GENETICS, V131, P113; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; POTASHKIN J, 1993, SCIENCE, V262, P573, DOI 10.1126/science.8211184; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; SAKAMOTO H, 1992, NUCLEIC ACIDS RES, V20, P5533, DOI 10.1093/nar/20.21.5533; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SOSNOWSKI BA, 1994, DEV BIOL, V161, P302, DOI 10.1006/dbio.1994.1030; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TSUKAHARA T, 1994, NUCLEIC ACIDS RES, V22, P2318, DOI 10.1093/nar/22.12.2318; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAPP ML, 1989, NUCLEIC ACIDS RES, V17, P2655, DOI 10.1093/nar/17.7.2655	50	467	474	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1173	1176		10.1126/science.7761834	http://dx.doi.org/10.1126/science.7761834			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761834				2022-12-28	WOS:A1995RA60400036
J	KIRKWOOD, A; LEE, HK; BEAR, MF				KIRKWOOD, A; LEE, HK; BEAR, MF			COREGULATION OF LONG-TERM POTENTIATION AND EXPERIENCE-DEPENDENT SYNAPTIC PLASTICITY IN VISUAL-CORTEX BY AGE AND EXPERIENCE	NATURE			English	Article							D-ASPARTATE RECEPTORS; MONOCULAR DEPRIVATION; SLICE PREPARATION; SENSITIVE PERIOD; STRIATE CORTEX; RAT; KITTENS; SUSCEPTIBILITY; HIPPOCAMPUS; NEOCORTEX	LONG-TERM potentiation (LTP) is a lasting enhancement of excitatory synaptic transmission that follows specific patterns of electrical stimulation(1). Although the mechanism of LTP has been intensively studied, particularly in the hippocampus, its significance for normal brain function remains unproven. It has been proposed that LTP-like mechanisms may contribute to naturally occurring, experience-dependent synaptic modifications in the visual cortex(2-8). The formation of normal binocular connections within the, visual cortex: requires simultaneous input from both eyes during a postnatal critical period(9-12) that can be delayed by rearing animals in complete darkness(13,14). To explore the role of LTP in this experience-dependent maturation process, we induced LTP in visual cortical slices taken at different ages from light-reared and dark-reared rats. Susceptibility to LTP coincides with the critical period and, like the critical period, can be prolonged by rearing animals in darkness. These findings support the hypothesis that LTP reflects a normal mechanism of experience-dependent synaptic modification in the developing mammalian brain.	BROWN UNIV, INST BRAIN & NEURAL SYST, PROVIDENCE, RI 02912 USA	Brown University	KIRKWOOD, A (corresponding author), BROWN UNIV, DEPT NEUROSCI, HOWARD HUGHES MED INST, PROVIDENCE, RI 02912 USA.			Lee, Hey-Kyoung/0000-0002-5554-983X; Bear, Mark/0000-0002-9903-2541				ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1992, J NEUROPHYSIOL, V67, P1; BERRY RL, 1989, BRAIN RES, V481, P221, DOI 10.1016/0006-8993(89)90797-X; BERRY RL, 1993, BRAIN RES, V628, P99, DOI 10.1016/0006-8993(93)90943-H; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; BODEGREUEL KM, 1989, DEV BRAIN RES, V46, P197, DOI 10.1016/0165-3806(89)90283-6; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CYNADER M, 1980, J NEUROPHYSIOL, V43, P1026, DOI 10.1152/jn.1980.43.4.1026; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; FOX K, 1991, NATURE, V350, P342, DOI 10.1038/350342a0; FREGNAC Y, 1994, J NEUROPHYSIOL, V71, P1403, DOI 10.1152/jn.1994.71.4.1403; FRIAUF E, 1991, J NEUROPHYSIOL, V66, P2059, DOI 10.1152/jn.1991.66.6.2059; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; KATO N, 1991, DEV BRAIN RES, V60, P43, DOI 10.1016/0165-3806(91)90153-A; KIMURA F, 1989, J PHYSIOL-LONDON, V414, P125, DOI 10.1113/jphysiol.1989.sp017680; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KOMATSU Y, 1981, NEUROSCI LETT, V26, P269, DOI 10.1016/0304-3940(81)90144-0; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KOMATSU Y, 1994, J NEUROSCI, V14, P6488; KOMATSU Y, 1983, DEV BRAIN RES, V8, P136, DOI 10.1016/0165-3806(83)90165-7; LUHMANN HJ, 1990, DEV BRAIN RES, V54, P287, DOI 10.1016/0165-3806(90)90152-O; MOWER GD, 1991, DEV BRAIN RES, V58, P151, DOI 10.1016/0165-3806(91)90001-Y; OLSON CR, 1980, EXP BRAIN RES, V39, P17; PERKINS AT, 1988, BRAIN RES, V439, P222; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6	30	359	365	1	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					328	331		10.1038/375328a0	http://dx.doi.org/10.1038/375328a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753198				2022-12-28	WOS:A1995RA03000054
J	KOOPMANS, PP				KOOPMANS, PP			REGISTRATION OF DRUGS FOR TREATING CANCER AND HIV-INFECTION - A PLEA TO CARRY OUT PHASE-3 TRIALS BEFORE ADMISSION TO THE MARKET	BRITISH MEDICAL JOURNAL			English	Article							CHEMOTHERAPY; THERAPY; QUALITY; AIDS; LIFE	Drugs for cancer and HIV infection tend to be admitted to the market on the basis of results from phase 2 trials. Assessing the benefit-risk balance with phase 2 trials often is difficult-the effect of the drug is usually temporary; the correlation between response or improvement of clinical measurements and the patient's wellbeing is often poor; and the side effects of drugs for these fatal diseases are serious. Therefore, although sometimes difficult to conduct, comparative trials that use standard treatment, placebos, or best supportive care remain the corner-stone for reliably assessing the benefit-risk balance.	UNIV NIJMEGEN ST RADBOUD HOSP,DEPT CLIN PHARMACOL,6500 HB NIJMEGEN,NETHERLANDS	Radboud University Nijmegen	KOOPMANS, PP (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP,DEPT MED,DIV GEN INTERNAL MED,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.		Koopmans, Peter/O-9276-2015					ATZPODIEN J, 1990, LANCET, V335, P1509, DOI 10.1016/0140-6736(90)93039-R; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BOYD KM, 1992, BRIT MED J, V305, P699; BYRNE M, 1992, BRIT MED J, V304, P1523, DOI 10.1136/bmj.304.6841.1523; COATES A, 1987, NEW ENGL J MED, V317, P1490, DOI 10.1056/NEJM198712103172402; GROOPMAN JE, 1989, ANN INTERN MED, V110, P335, DOI 10.7326/0003-4819-110-5-335; HIRSCH MS, 1993, NEW ENGL J MED, V328, P1686, DOI 10.1056/NEJM199306103282307; LAGAKOS SW, 1992, ANN INTERN MED, V116, P599, DOI 10.7326/0003-4819-116-7-599; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; POCOCK SJ, 1983, CLIN TRIALS PRACTICA, P54; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752; SILVERMAN WA, 1994, LANCET, V343, P1585; SOUQUET PJ, 1993, LANCET, V342, P19; TOBIAS JS, 1994, BRIT MED J, V308, P961, DOI 10.1136/bmj.308.6934.961; TRIMBLE EL, 1993, J CLIN ONCOL, V11, P2405, DOI 10.1200/JCO.1993.11.12.2405; TWYCROSS R, 1992, BRIT MED J, V305, P969, DOI 10.1136/bmj.305.6860.969; WALSH TD, 1988, BRIT MED J, V296, P477, DOI 10.1136/bmj.296.6620.477; 1994, LANCET, V343, P871	19	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1305	1306		10.1136/bmj.310.6990.1305	http://dx.doi.org/10.1136/bmj.310.6990.1305			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773046	Green Published, Green Submitted			2022-12-28	WOS:A1995QZ86000026
J	LIPPARD, SJ				LIPPARD, SJ			AT LAST - THE CRYSTAL-STRUCTURE OF UREASE	SCIENCE			English	Editorial Material							MECHANISM				LIPPARD, SJ (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P1335, DOI 10.1139/o80-181; HARTMAN FC, 1993, ANNU REV BIOCHEM, V63, P197; Hausinger R.P., 1993, BIOCH NICKEL, V12, P23; Lippard S. J., 1994, PRINCIPLES BIOINORGA; PARK IS, 1995, SCIENCE, V267, P1156, DOI 10.1126/science.7855593; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Sumner J. B., 1937, J CHEM EDUC, V14, P255; Sumner JB, 1926, J BIOL CHEM, V69, P435; WAGES HE, 1993, INORG CHEM, V32, P4985, DOI 10.1021/ic00075a001	10	94	95	1	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					996	997		10.1126/science.7754394	http://dx.doi.org/10.1126/science.7754394			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754394				2022-12-28	WOS:A1995QY93400025
J	WEIS, K; MATTAJ, IW; LAMOND, AI				WEIS, K; MATTAJ, IW; LAMOND, AI			IDENTIFICATION OF HSRP1-ALPHA AS A FUNCTIONAL RECEPTOR FOR NUCLEAR-LOCALIZATION SEQUENCES	SCIENCE			English	Article							RNA-POLYMERASE-II; BINDING-PROTEIN; 2 STEPS; IMPORT; TRANSLOCATION; ENVELOPE; SIGNALS; PATHWAY; PORE	Import of proteins into the nucleus is a two-step process, involving nuclear localization sequence (NLS)-dependent docking of the substrate at the nuclear envelope followed by translocation through the nuclear pore. A recombinant human protein, hSRP1 alpha, bound in vitro specifically and directly to substrates containing either a simple or bipartite NLS motif. hSRP1 alpha promoted docking of import substrates to the nuclear envelope and together with recombinant human Ran reconstituted complete nuclear protein import. Thus, hSRP1 alpha has the properties of a cytosolic receptor for both simple and bipartite NLS motifs.	EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Weis, Karsten/F-5719-2011	Weis, Karsten/0000-0001-7224-925X; Lamond, Angus/0000-0001-6204-6045; Mattaj, Iain/0000-0002-5537-8284				ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER U, 1991, EMBO J, V10, P705; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; IZAURRARLDE E, UNPUB; KATAOKA N, 1994, NUCLEIC ACIDS RES, V22, P3861, DOI 10.1093/nar/22.19.3861; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MICHAUD N, 1993, EXP CELL RES, V208, P128, DOI 10.1006/excr.1993.1230; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; WEIS K, UNPUB; Yamasaki L, 1992, Trends Cell Biol, V2, P123, DOI 10.1016/0962-8924(92)90083-Y; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640; YAO R, 1994, P NATL ACAD SCI USA, V91, P6880; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	36	317	325	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 19	1995	268	5213					1049	1053		10.1126/science.7754385	http://dx.doi.org/10.1126/science.7754385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754385				2022-12-28	WOS:A1995QY93400041
J	KREGE, JH; JOHN, SWM; LANGENBACH, LL; HODGIN, JB; HAGAMAN, JR; BACHMAN, ES; JENNETTE, JC; OBRIEN, DA; SMITHIES, O				KREGE, JH; JOHN, SWM; LANGENBACH, LL; HODGIN, JB; HAGAMAN, JR; BACHMAN, ES; JENNETTE, JC; OBRIEN, DA; SMITHIES, O			MALE-FEMALE DIFFERENCES IN FERTILITY AND BLOOD-PRESSURE IN ACE-DEFICIENT MICE	NATURE			English	Article							ANGIOTENSIN-CONVERTING ENZYME; ESSENTIAL-HYPERTENSION; GENE; POLYMORPHISM; MOUSE; ASSOCIATION; EXPRESSION	ANGIOTENSIN-CONVERTING enzyme (ACE) is a dipeptidyl carboxypeptidase that generates the vasoconstricting peptide angiotensin II and inactivates the vasodilating peptide bradykinin(1). The gene encoding ACE is composed of two homologous regions and codes for both a somatic and testis isoenzyme(2-4). Experiments with hypertensive rats(5,6) and some(7-9), but not other(10-13), studies of humans suggest that sequences at or linked to the gene influence blood pressure. The testis-specific form of ACE has its own promoter within intron 12 (ref, 14), is encoded by the 3' region of the gene, and is found only in postmeiotic spermatogenic cells and sperm(15). Its function is unknown(16) Here we investigate the role of the Ace gene in blood pressure control and reproduction using mice generated to carry an insertional mutation that is designed to inactivate both forms of ACE. All homozygous female mutants were found to be fertile, but the fertility of homozygous male mutants was greatly reduced. Heterozygous males but not females had blood pressures that were 15-20 mm Hg less than normal, although both male and female heterozygotes had reduced serum ACE activity.	UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	KREGE, JH (corresponding author), UNIV N CAROLINA,DEPT INTERNAL MED,CHAPEL HILL,NC 27599, USA.			Jennette, John Charles/0000-0002-8081-6565	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026485] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; DURU K, 1994, AM J HYPERTENS, V7, P759, DOI 10.1093/ajh/7.8.759; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5313; ERDOS EG, 1990, HYPERTENSION, V16, P363, DOI 10.1161/01.HYP.16.4.363; FORESTA C, 1991, INT J ANDROL, V14, P333, DOI 10.1111/j.1365-2605.1991.tb01101.x; HARRAP SB, 1993, HYPERTENSION, V21, P455, DOI 10.1161/01.HYP.21.4.455; HIGASHIMORI K, 1993, BIOCHEM BIOPH RES CO, V191, P399, DOI 10.1006/bbrc.1993.1231; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KIM HS, IN PRESS P NATN ACAD; KREGE JH, IN PRESS HYPERTENSIO; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; MORISE T, 1994, LANCET, V343, P125, DOI 10.1016/S0140-6736(94)90859-1; SCHMIDT S, 1993, J HYPERTENS, V11, P345, DOI 10.1097/00004872-199304000-00003; SEN I, 1993, J BIOL CHEM, V268, P25748; SIBONY M, 1993, HYPERTENSION, V21, P827, DOI 10.1161/01.HYP.21.6.827; SMITHIES O, 1994, P NATL ACAD SCI USA, V91, P3612, DOI 10.1073/pnas.91.9.3612; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILSON CM, 1981, BIOCHEM GENET, V19, P509, DOI 10.1007/BF00484623; ZEE RYL, 1992, BIOCHEM BIOPH RES CO, V184, P9, DOI 10.1016/0006-291X(92)91150-O	25	577	594	2	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					146	148		10.1038/375146a0	http://dx.doi.org/10.1038/375146a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753170				2022-12-28	WOS:A1995QX74100051
J	ROLFE, S; HARPER, NJN				ROLFE, S; HARPER, NJN			ABILITY OF HOSPITAL DOCTORS TO CALCULATE DRUG DOSES	BRITISH MEDICAL JOURNAL			English	Article											ROLFE, S (corresponding author), MANCHESTER ROYAL INFIRM,DEPT ANAESTHESIA,OXFORD RD,MANCHESTER M13 9WL,LANCS,ENGLAND.							MULLER NF, 1992, EUROPEAN DRUG INDEX; SCRIMSHIRE JA, 1989, BRIT MED J, V298, P1497; 1994, AMPOULE LABELS NHS S; 1993, BRIT MED J, V306, P1589	4	66	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1173	1174		10.1136/bmj.310.6988.1173	http://dx.doi.org/10.1136/bmj.310.6988.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767153	Green Published			2022-12-28	WOS:A1995QX56600023
J	MITCHELL, I; WENDON, J; FITT, S; WILLIAMS, R				MITCHELL, I; WENDON, J; FITT, S; WILLIAMS, R			ANTI-TUBERCULOUS THERAPY AND ACUTE LIVER-FAILURE	LANCET			English	Note								The incidence of tuberculosis has been increasing since 1987, exposing a greater number of patients to the risks of three potentially hepatotoxic drugs, isoniazid, rifampicin, and pyrazinamide. Awareness of potentially severe drug hepatotoxic reactions is vital because fulminant hepatic failure is a devastating and often fatal condition without liver transplantation. We report four cases of fulminant hepatic failure caused by rifampicin, isoniazid, or both. These cases highlight the need for stricter adherence to and review of current guidelines on liver function tests after starting anti-tuberculous therapies.	UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,LONDON SE5 9RS,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London				Mitchell, Imogen/0000-0001-6013-4922; opoku, anita/0000-0001-7243-8157				BRYRD RB, 1979, JAMA-J AM MED ASSOC, V241, P1239; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GARIBALDI RA, 1972, AM REV RESPIR DIS, V106, P357, DOI 10.1164/arrd.1972.106.3.357; GROSSET J, 1983, REV INFECT DIS, V5, pS440; HUGHES R D, 1991, Gut, pS86; MADDREY WC, 1973, ANN INTERN MED, V79, P791; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; 1994, LANCET, V344, P277; 1990, THORAX, V45, P403; 1994, AM J REPSIR CRIT CAR, V149, P1359	10	65	66	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					555	556		10.1016/S0140-6736(95)90468-9	http://dx.doi.org/10.1016/S0140-6736(95)90468-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7786350				2022-12-28	WOS:A1995QK44400013
J	WRIGHT, JD; PEARL, L				WRIGHT, JD; PEARL, L			KNOWLEDGE AND EXPERIENCE OF YOUNG-PEOPLE REGARDING DRUG MISUSE, 1969-94	BRITISH MEDICAL JOURNAL			English	Article							ABUSE	Objective-To monitor young people's knowledge and experience of illicit drugs between 1969 and 1994 at intervals of five years. Design-The same anonymously completed questionnaire was used throughout. Setting-Three Wolverhampton secondary schools representing three different socioeconomic groups. Subjects-392 pupils aged 14 to 15 completed the questionnaire in 1994. Previous sample sizes were 471 in 1969, 523 in 1974, 648 in 1979, 540 in 1984, and 380 in 1989. Main outcome measures-Self reported levels of knowledge and experience of illicit drugs. Results-Over 25 years the proportion of pupils who knew someone taking drugs more than quadrupled from 15% (71/471) to 65% (254/392), and the proportion who had been offered drugs increased ninefold from 5% (24) to 45% (175). Both of these proportions more than doubled over the past five years. In 1994 the proportions of pupils mentioning ''ecstasy'' (methylenedioxymethamphetamine), amphetamines, and crack cocaine increased significantly (P<0.01) and the proportion mentioning opiates decreased significantly (P<0.01). ''Poppers'' (amyl nitrite) were mentioned for the first time. ''To feel big, to show off, look grown up'' has continued to be the main perceived reason for taking drugs. Television has continued to be the main source of information. Conclusions-In the past five years in particular young people's exposure to illicit drugs has increased dramatically. Despite more education about drugs, pupils' knowledge remains limited. Social pressures remain the first perceived reason for taking drugs. The media have a responsibility not to glamorise drugs.	UNIV WOLVERHAMPTON,WOLVERHAMPTON WV1 1SB,ENGLAND	University of Wolverhampton								ALLEN FA, 1991, CRACK BROKEN PROMISE; BALDING J, 1994, YOUNG PEOPLE 1993; BEAN PT, 1988, HLTH ED J, V47, P79; BROWN C, 1988, ILLICIT DRUG USE POR; COHEN J, 1992, PSYCHOACTIVE DRUGS H; Davies OL, 1978, DESIGN ANAL IND EXPT; FRANCIS LJ, 1993, ADDICTION, V88, P665, DOI 10.1111/j.1360-0443.1993.tb02079.x; FRASER A, 1991, DRUG MISUSE LOCAL CO; Measham F., 1993, DRUGLINK, V8, P16; SMITH C, 1992, BRIT J ADDICT, V87, P227; Swadi Harith, 1992, Eur Child Adolesc Psychiatry, V1, P156, DOI 10.1007/BF02091901; WRIGHT JD, 1976, MED SCI LAW, V16, P252, DOI 10.1177/002580247601600408; WRIGHT JD, 1981, BRIT MED J, V282, P793, DOI 10.1136/bmj.282.6266.793; WRIGHT JD, 1986, BRIT MED J, V292, P179, DOI 10.1136/bmj.292.6514.179; WRIGHT JD, 1990, BRIT MED J, V300, P99, DOI 10.1136/bmj.300.6717.99; 1993, PHS6 ST GEORG HOSP M; 1993, DRUG ED SCH; 1993, HOME OFFICE STATISTI; 1993, DRUGS SOLVENTS YOU Y	19	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					20	24		10.1136/bmj.310.6971.20	http://dx.doi.org/10.1136/bmj.310.6971.20			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB060	7755714	Green Published			2022-12-28	WOS:A1995QB06000022
J	HRUSKA, KA; TEITELBAUM, SL				HRUSKA, KA; TEITELBAUM, SL			MECHANISMS OF DISEASE - RENAL OSTEODYSTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OSTEOCLASTIC BONE-RESORPTION; HORMONE-RELATED PROTEIN; GROWTH FACTOR-BETA; PARATHYROID-HORMONE; INTERLEUKIN-6 PRODUCTION; COLLAGEN-SYNTHESIS; RIBONUCLEIC-ACID; POTENT INHIBITOR; VITAMIN-D; RAT BONE		WASHINGTON UNIV, MED CTR, JEWISH HOSP ST LOUIS, DEPT PATHOL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital; Washington University (WUSTL)	HRUSKA, KA (corresponding author), WASHINGTON UNIV, MED CTR,JEWISH HOSP ST LOUIS,DEPT MED,DIV RENAL, 216 S KINGSHIGHWAY BLVD, ST LOUIS, MO 63110 USA.			Teitelbaum, Steven/0000-0002-4054-6679	NIAMS NIH HHS [AR41677, AR39561] Funding Source: Medline; NIDDK NIH HHS [DK09976] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041677, R01AR039561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AARDEN EM, 1994, J CELL BIOCHEM, V55, P287, DOI 10.1002/jcb.240550304; ANDRESS DL, 1989, NEW ENGL J MED, V321, P274, DOI 10.1056/NEJM198908033210502; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CENTRELLA M, 1987, J BIOL CHEM, V262, P2869; Coburn J W, 1980, Contrib Nephrol, V18, P172; COBURN JW, 1993, KIDNEY INT, V43, pS92; Coburn JW, 1991, KIDNEY, V2, P2036; DEMPSTER DW, 1993, 4TH P INT S OST CONS, P144; Descamps-Latscha B, 1993, Curr Opin Nephrol Hypertens, V2, P883, DOI 10.1097/00041552-199311000-00005; DESCAMPSLATSCHA B, 1993, KIDNEY INT S, V41, pS125; DEWHIRST FE, 1987, J BONE MINER RES, V2, P127; DINARELLO CA, 1992, KIDNEY INT, V41, P683, DOI 10.1038/ki.1992.105; EASTWOOD JB, 1977, CLIN SCI MOL MED, V52, P499, DOI 10.1042/cs0520499; FALCHETTI A, 1993, J CLIN ENDOCR METAB, V76, P139, DOI 10.1210/jc.76.1.139; FENTON AJ, 1991, ENDOCRINOLOGY, V129, P3424, DOI 10.1210/endo-129-6-3424; FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720; GALCERAN T, 1987, KIDNEY INT, V32, P801, DOI 10.1038/ki.1987.279; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380; HAMDY NAT, 1995, BRIT MED J, V310, P358, DOI 10.1136/bmj.310.6976.358; HAMILTON JA, 1985, ENDOCRINOLOGY, V116, P2186, DOI 10.1210/endo-116-6-2186; HERBELIN A, 1991, KIDNEY INT, V39, P954, DOI 10.1038/ki.1991.120; HERBELIN A, 1990, KIDNEY INT, V37, P116, DOI 10.1038/ki.1990.16; HERCZ G, 1994, J AM SOC NEPHROL, V5, P851; HERCZ G, 1993, KIDNEY INT, V44, P860, DOI 10.1038/ki.1993.323; HUGHES FJ, 1993, CALCIFIED TISSUE INT, V53, P362, DOI 10.1007/BF01351844; HUTCHISON AJ, 1993, KIDNEY INT, V44, P1071, DOI 10.1038/ki.1993.350; Kurz P., 1993, Journal of the American Society of Nephrology, V4, P410; LINDBERG J, 1994, CONT DIALYSIS NEPHRO, V15, P22; MACINTYRE I, 1991, P NATL ACAD SCI USA, V88, P2936, DOI 10.1073/pnas.88.7.2936; MALLUCHE H, 1990, KIDNEY INT, V38, P193, DOI 10.1038/ki.1990.187; MALLUCHE HH, 1992, KIDNEY INT, V42, pS62; Malluche HH, 1986, ATLAS MINERALIZED BO; MCSHEEHY PMJ, 1986, ENDOCRINOLOGY, V119, P1654, DOI 10.1210/endo-119-4-1654; MEMOLI B, 1992, KIDNEY INT, V42, P320, DOI 10.1038/ki.1992.292; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MORINIERE P, 1989, NEPHRON, V53, P93, DOI 10.1159/000185718; Moutabarrik Abdelkaim, 1993, Journal of the American Society of Nephrology, V4, P413; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; ONISHI S, 1991, KIDNEY INT, V39, P990; ORLOFF JJ, 1993, KIDNEY INT, V43, P1371, DOI 10.1038/ki.1993.193; Owen M., 1985, BONE MINERAL RES ANN, V1, P1; OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo-128-3-1496; Paredes A., 1993, Journal of the American Society of Nephrology, V4, P700; PARTRIDGE NC, 1989, MOL ENDOCRINOL, V3, P232, DOI 10.1210/mend-3-2-232; PEI Y, 1992, KIDNEY INT, V41, P1374, DOI 10.1038/ki.1992.202; PFEILSCHIFTER J, 1988, J CLIN INVEST, V82, P680, DOI 10.1172/JCI113647; QUARLES LD, 1992, J CLIN ENDOCR METAB, V75, P145, DOI 10.1210/jc.75.1.145; REID IR, 1988, AM J PHYSIOL, V255, pE9, DOI 10.1152/ajpendo.1988.255.1.E9; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SAKAGAMI Y, 1993, J BONE MINER RES, V8, P811; SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64; SILVER J, 1985, P NATL ACAD SCI USA, V82, P4270, DOI 10.1073/pnas.82.12.4270; SOLAL MEC, 1991, J CLIN ENDOCR METAB, V73, P516, DOI 10.1210/jcem-73-3-516; SUDA, 1992, ENDOCR REV, V13, P191; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; SWEENEY WE, 1994, PEDIATR RES, V35, pA374; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TOPLEY N, 1993, J AM SOC NEPHROL, V4, P412; TSUKAMOTO Y, 1991, NEPHRON, V57, P23, DOI 10.1159/000186210; WATANABE K, 1990, BIOCHEM BIOPH RES CO, V172, P1035, DOI 10.1016/0006-291X(90)91550-C; WATSON P, 1995, BONE, V16, P357, DOI 10.1016/8756-3282(94)00051-4; WU H, 1994, J BONE MINER RES  S1, V9, P1; Yoneda Toshiyuki, 1993, P375; Young Marian F., 1993, P191	69	379	393	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					166	174		10.1056/NEJM199507203330307	http://dx.doi.org/10.1056/NEJM199507203330307			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791820				2022-12-28	WOS:A1995RK91700007
J	KESSLER, DA				KESSLER, DA			NICOTINE ADDICTION IN YOUNG-PEOPLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KESSLER, DA (corresponding author), US FDA,ROCKVILLE,MD 20857, USA.							BANTLE LF, 1968, JAN MIN SNUFF CHEW T, P3; CUMMINGS KM, 1994, AM J PUBLIC HEALTH, V84, P300, DOI 10.2105/AJPH.84.2.300; FISCHER PM, 1991, JAMA-J AM MED ASSOC, V266, P3145, DOI 10.1001/jama.266.22.3145; FREEDMAN AM, 1994, WALL ST J       0603, pA1; GIOVINO GA, 1994, AUG FOOD DRUG ADM DR; HILTS PJ, 1994, NY TIMES        1127, P1; LYNCH BS, 1994, GROWING TOBACCO FREE, P8; LYNCH BS, 1994, GROWING UP TOBACCO F; LYNCH BS, 1994, GROWING TOBACCO FREE, P3; MCMAHON JP, 1990, COMMUNICATION   0110; MOSS AJ, 1992, ADV DATA VITAL HLTH, V221; PIERCE JP, 1994, JAMA-J AM MED ASSOC, V271, P608, DOI 10.1001/jama.271.8.608; SHAPIRO E, 1994, WALL STREET J   1006; TEINOWITZ I, 1993, ADVERTISING AGE 0426, P3; WARLICK RG, 1990, COMMUNICATION   0405; 1992, 1992 GALLUP SURVEY, P59; 1991, J NATL CANCER I, V83, P1620; 1994, REPORT C PURSUANT FE, P3; 1995, NATIONS 1ST SURVEY R; 1988, OVERALL MARKET CONDI, P6; 1994, MONITORING FUTURE ST; 1988, HLTH CONSEQUENCES SM, P7; 1995, FINDINGS SURVEY APPR, P4; 1993, MMWR-MORBID MORTAL W, V42, P645; 1994, MMWR-MORBID MORTAL W, V43, P580; 1994, PREVENTING TOBACCO U, P124; 1994, PREVENTING TOBACCO U, V5, P58; 1994, MMWR-MORBID MORTAL W, V43, P577; 1982, PROJECT PLUS MINUS 3, P1; 1988, HLTH CONSEQUENCES SM, P9; 1994, PREVENTING TOBACCO U, P249; 1989, REDUCING HLTH CONSEQ, P131; 1994, PREVENTING TOBACCO U, P192; 1977, 16 KWECH MARK RES PR, pR6; 1992, TEENAGE ATTITUDES BE, P54; 1994, PREVENTING TOBACCO U, P70; 1986, NIH 862874 DEP HLTH, pR7	37	91	92	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					186	189		10.1056/NEJM199507203330311	http://dx.doi.org/10.1056/NEJM199507203330311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RK917	7791824				2022-12-28	WOS:A1995RK91700011
J	VLADECK, BC				VLADECK, BC			END-STAGE RENAL-DISEASE CORE INDICATORS PROJECT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,DIV HLTH STAND & QUAL,REG OFF X,SEATTLE,WA, USA.							1994, JAMA-J AM MED ASSOC, V271, P1896	1	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1896	1896		10.1001/jama.273.24.1896	http://dx.doi.org/10.1001/jama.273.24.1896			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783287				2022-12-28	WOS:A1995RE35400004
J	ZAMETKIN, AJ				ZAMETKIN, AJ			ATTENTION-DEFICIT DISORDER - BORN TO BE HYPERACTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							PSYCHIATRIC STATUS; THYROID-HORMONE; CHILDREN; RESISTANCE; METABOLISM; FAMILIES; BOYS				ZAMETKIN, AJ (corresponding author), NIMH,CHILD PSYCHIAT BRANCH,BLDG 10,ROOM 4N317,10 CTR DR MSC 1384,BETHESDA,MD 20892, USA.							ABIKOFF H, 1987, ADV CLIN CHILD PSYCH, V10, P171; BARKLEY RA, 1990, ATTENTION DEFICIT HY, P16; BIEDERMAN J, 1992, ARCH GEN PSYCHIAT, V49, P728; Bradley C, 1937, AM J PSYCHIAT, V94, P577, DOI 10.1176/ajp.94.3.577; BROWN RT, 1991, CHILD PSYCHIAT HUM D, V22, P111, DOI 10.1007/BF00707789; BRUCKERDAVIS F, IN PRESS ANN INTERN; CANTWELL DP, 1972, ARCH GEN PSYCHIAT, V27, P414; DEUTSCH CK, 1990, J AM ACAD CHILD PSY, V29, P189, DOI 10.1097/00004583-199003000-00006; ERNST M, 1994, AM ACAD CHILD ADOLES, V33, P858; Ernst Monique, 1995, P1643; FARAONE SV, 1992, PSYCHIATR GENET, V2, P257, DOI 10.1097/00041444-199210000-00004; GIEDD JN, 1994, AM J PSYCHIAT, V151, P665; GOODMAN R, 1989, J CHILD PSYCHOL PSYC, V30, P691, DOI 10.1111/j.1469-7610.1989.tb00782.x; HAUSER P, 1993, NEW ENGL J MED, V328, P997, DOI 10.1056/NEJM199304083281403; HOFFMANN H, 1956, STRUWWELPETER LUSTIG, P18; HYND GW, 1991, J LEARN DISABIL, V24, P141, DOI 10.1177/002221949102400302; KLORMAN R, 1990, J AM ACAD CHILD PSY, V29, P702, DOI 10.1097/00004583-199009000-00005; MANNUZZA S, 1993, ARCH GEN PSYCHIAT, V50, P565; MATOCHIK JA, 1994, AM J PSYCHIAT, V151, P658; Meyer A, 1904, AM J INSANITY, V60, P373, DOI 10.1176/ajp.60.3.373; MORRISON JR, 1973, ARCH GEN PSYCHIAT, V28, P888; Pelham W. J., 1986, PHARM BEHAVIORAL TRE, P108; RAPOPORT JL, 1978, SCIENCE, V199, P560, DOI 10.1126/science.341313; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; SAFER DJ, 1973, BEHAV GENET, V3, P175, DOI 10.1007/BF01067657; SEMRUDCLIKEMAN M, 1994, J AM ACAD CHILD PSY, V33, P875, DOI 10.1097/00004583-199407000-00014; SHAFFER D, 1994, AM J PSYCHIAT, V151, P633; STEVENSON J, 1993, J CHILD PSYCHOL PSYC, V34, P1137, DOI 10.1111/j.1469-7610.1993.tb01779.x; ZAMETKIN AJ, 1993, ARCH GEN PSYCHIAT, V50, P333; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001; 1994, DIAGNOSTIC STATISTIC; 1987, DIAGNOSTIC STATISTIC, P52; 1991, J AM ACAD CHILD ADOL, V30, pR1; 1980, FINAL REPORT NUTRITI	34	20	20	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1871	1874		10.1001/jama.273.23.1871	http://dx.doi.org/10.1001/jama.273.23.1871			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RD116	7776505				2022-12-28	WOS:A1995RD11600031
J	JUNG, M; ZHANG, Y; LEE, S; DRITSCHILO, A				JUNG, M; ZHANG, Y; LEE, S; DRITSCHILO, A			CORRECTION OF RADIATION SENSITIVITY IN ATAXIA-TELANGIECTASIA CELLS BY A TRUNCATED I-KAPPA-B-ALPHA	SCIENCE			English	Article							INHIBITOR; GENE; RADIOSENSITIVITY; LOCALIZATION; FIBROBLASTS; EXPRESSION; PLASMIDS; SURVIVAL	Cells from patients with ataxia telangiectasia (AT) are hypersensitive to ionizing radiation and are defective in the regulation of DNA synthesis. A complementary DNA that corrects the radiation sensitivity and DNA synthesis defects in fibroblasts from an AT group D patient was isolated by expression cloning and shown to encode a truncated form of I kappa B-alpha, an inhibitor of the nuclear factor kappa B (NF-kappa B) transcriptional activator. The parental AT fibroblasts expressed large amounts of the I kappa B-alpha transcript and showed constitutive activation of NF-kappa B. The AT fibroblasts transfected with the truncated I kappa B-alpha expressed normal amounts of the I kappa B-alpha transcript and showed regulated activation of NF-kappa B. These results suggest that aberrant regulation of NF-kappa B and I kappa B-alpha contribute to the cellular defect in AT.	GEORGETOWN UNIV, SCH MED, DEPT RADIAT MED, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, SCH MED, DEPT IMMUNOL & MICROBIOL, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University					NATIONAL CANCER INSTITUTE [R01CA045408, R29CA063023] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA63023, CA45408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; ARLETT CF, 1988, INT J RADIAT BIOL, V54, P911, DOI 10.1080/09553008814552321; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BODER E, 1985, ATAXIA TELANGIECTASI, P1; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HIRT B, 1967, J MOL BIOL, V26, P265; HOPGOOD R, 1992, BIOTECHNIQUES, V13, P82; JASPERS NGJ, 1988, CYTOGENET CELL GENET, V49, P259, DOI 10.1159/000132673; Jung M, 1992, PCR Methods Appl, V1, P171; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; LEA DE, 1962, ACTIONS RAD LIVING C, P74; LEBEAU MM, 1992, GENOMICS, V14, P529, DOI 10.1016/S0888-7543(05)80261-7; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MEYN MS, 1993, AM J HUM GENET, V53, P1206; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; SALEHI Z, 1991, EXP BIOL M, P377; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WEICHSELBAUM RR, 1988, INT J RADIAT ONCOL, V15, P575, DOI 10.1016/0360-3016(88)90297-0; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	31	171	177	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1619	1621		10.1126/science.7777860	http://dx.doi.org/10.1126/science.7777860			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777860				2022-12-28	WOS:A1995RD45900038
J	DOWELL, SF; TOKO, A; SITA, C; PIARROUX, R; DUERR, A; WOODRUFF, BA				DOWELL, SF; TOKO, A; SITA, C; PIARROUX, R; DUERR, A; WOODRUFF, BA			HEALTH AND NUTRITION IN CENTERS FOR UNACCOMPANIED REFUGEE CHILDREN - EXPERIENCE FROM THE 1994 RWANDAN REFUGEE CRISIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORTALITY		MED MONDE, MARSEILLE, FRANCE; UN, CHILDRENS FUND, KINSHASA, DEM REP CONGO		DOWELL, SF (corresponding author), CTR DIS CONTROL & PREVENT, RESP & ENTER VIRUSES BRANCH, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.			piarroux, renaud/0000-0002-4151-4134				[Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BARRERE B, 1994, ENQUETE DEMOGRAPHIQU; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; PAQUET C, 1994, LANCET, V344, P823, DOI 10.1016/S0140-6736(94)92381-7; SIDDIQUE AK, 1995, LANCET, V345, P359, DOI 10.1016/S0140-6736(95)90344-5; TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V; Williamson J, 1988, UNACCOMPANIED CHILDR; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1992, GUIDELINES CHOLERA C; 1995, LANCET, V348, P339; 1994, MMWR-MORBID MORTAL W, V43, P701; 1992, MMWR MORB MORTAL WKL, V41; 1994, STANDARDS PROTECTION; 1983, MEASURING CHANGE NUT	15	19	19	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1802	1806		10.1001/jama.273.22.1802	http://dx.doi.org/10.1001/jama.273.22.1802			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769778				2022-12-28	WOS:A1995RB80000037
J	KOH, J; ENDERS, GH; DYNLACHT, BD; HARLOW, E				KOH, J; ENDERS, GH; DYNLACHT, BD; HARLOW, E			TUMOR-DERIVED P16 ALLELES ENCODING PROTEINS DEFECTIVE IN CELL-CYCLE INHIBITION	NATURE			English	Article							RETINOBLASTOMA PROTEIN	THE cyclin-dependent kinase inhibitor p16 is a candidate tumour-suppressor protein that maps to a genomic locus strongly associated with familial melanoma and other tumour types(1-3). Screening of primary tumours and linkage analysis of familial melanoma pedigrees have identified many potential mutations in p16, but the functional significance of these sequence variants has remained unclear(1,3-9). We report here that p16 can act as a potent and specific inhibitor of progression through the G1 phase of the cell cycle, and we demonstrate that several tumour-derived alleles of p16 encode functionally compromised proteins. The ability of p16 to arrest cell-cycle progression generally correlates with inhibition of cyclin D1/Cdk4 kinase activity irt vitro, with two exceptions among the alleles tested. In vivo, the presence of functional retinoblastoma protein appears to be necessary but may not be sufficient to confer full sensitivity to p16-mediated growth arrest. Our results provide support for the notion that p16 is an important cell-cycle regulator whose inactivation contributes to the outgrowth of human tumours.	MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	KOH, J (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BLDG 149, 13TH ST, BOSTON, MA 02129 USA.							BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORI T, 1994, CANCER RES, V54, P3396; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	27	530	548	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					506	510		10.1038/375506a0	http://dx.doi.org/10.1038/375506a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777061				2022-12-28	WOS:A1995RC18800053
J	MADINE, MA; KHOO, CY; MILLS, AD; LASKEY, RA				MADINE, MA; KHOO, CY; MILLS, AD; LASKEY, RA			MCM3 COMPLEX REQUIRED FOR CELL-CYCLE REGULATION OF DNA-REPLICATION IN VERTEBRATE CELLS	NATURE			English	Article							LICENSING FACTOR; XENOPUS EGGS; YEAST; INITIATION; PROTEINS; NUCLEI; LOCALIZATION; EXTRACT; GENES	AN intact nuclear membrane restricts DNA replication to only one round in each cell cycle, apparently by excluding an essential replication-licensing factor throughout interphase(1-5). A family of related yeast replication proteins, MCM2, 3 and 5 (also called, after cell-division cycle, CDC46), resemble licensing factor, entering the nucleus only during mitosis(6-8). We have cloned a Xenopus homologue of MCM3 (XMCM3) and raised antibodies against expressed protein, Immunodepletion of Xenopus egg extracts removes a complex of MCM2, 3 and 5 homologues and inhibits replication of Xenopus sperm nuclei or permeable G2 HeLa nuclei. However, G1 HeLa nuclei still replicate efficiently. Mock-depleted extracts replicate all three templates. XMCM3 accumulates in nuclei before replication but anti-XMCM3 staining decreases during replication. These results can explain why replicated nuclei are unable to reinitiate replication in a single cell cycle.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 3EJ,ENGLAND	University of Cambridge	MADINE, MA (corresponding author), WELLCOME CRC INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BUCCI S, 1993, INT J DEV BIOL, V37, P509; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HARLOW E, 1988, ANTIBODIES LABORATOR; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; KUBOTA Y, 1995, IN PRSS CELL; LEMAIRE P, 1993, CR ACAD SCI III-VIE, V316, P938; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MANIATIS T, 1991, MOL CLONING; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1994, J CELL SCI, V107, P253; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	28	241	243	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					421	424		10.1038/375421a0	http://dx.doi.org/10.1038/375421a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760938				2022-12-28	WOS:A1995RB10100058
J	KALE, R				KALE, R			NEW SOUTH-AFRICA DOCTORS - A STATE OF FLUX	BRITISH MEDICAL JOURNAL			English	Article																		Pick WM, 1994, ETHICAL DILEMMAS IN HEALTH AND DEVELOPMENT, P93; Simpson D., 1994, PHARM J, V253, P685; 1994, HLTH TRENDS S AFRICA, P73	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1307	1311		10.1136/bmj.310.6990.1307	http://dx.doi.org/10.1136/bmj.310.6990.1307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773047	Green Published			2022-12-28	WOS:A1995QZ86000027
J	FUNG, PA; GAERTIG, J; GOROVSKY, MA; HALLBERG, RL				FUNG, PA; GAERTIG, J; GOROVSKY, MA; HALLBERG, RL			REQUIREMENT OF A SMALL CYTOPLASMIC RNA FOR THE ESTABLISHMENT OF THERMOTOLERANCE	SCIENCE			English	Article							HEAT-SHOCK RESPONSE; III-TRANSCRIBED RNA; TETRAHYMENA-THERMOPHILA; PROTEIN-SYNTHESIS	Thermotolerance is an inducible state that endows cells with an enhanced resistance to thermal killing. Heat shock proteins are believed, and in a few instances have been shown, to be the agents conferring this resistance. The role of a small cytoplasmic RNA (G8 RNA) in developing thermotolerance in Tetrahymena thermophila was investigated by creating a strain devoid of all functional G8 genes. These G8 null cells mounted an apparently normal heat shock response, but they were unable to establish thermotolerance.	SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244; UNIV ROCHESTER,DEPT BIOL,ROCHESTER,NY 14627	Syracuse University; University of Rochester			Gaertig, Jacek/F-1553-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026973, R01GM046302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46302, GM26973] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		FUNG PA, UNPUB; GAERTIG J, 1994, NUCLEIC ACIDS RES, V22, P5391, DOI 10.1093/nar/22.24.5391; GAERTIG JA, 1994, P NATL ACAD SCI USA, V91, P9196; HALLBERG EM, 1992, NUCLEIC ACIDS RES, V20, P912, DOI 10.1093/nar/20.4.912; HALLBERG EM, UNPUB; HALLBERG RL, 1981, CELL, V26, P47, DOI 10.1016/0092-8674(81)90032-5; HALLBERG RL, 1984, MOL CELL BIOL, V4, P2170, DOI 10.1128/MCB.4.10.2170; HALLBERG RL, 1985, MOL CELL BIOL, V5, P2061, DOI 10.1128/MCB.5.8.2061; HALLBERG RL, 1986, MOL CELL BIOL, V6, P2267, DOI 10.1128/MCB.6.6.2267; HALLBERG RL, 1989, STRESS INDUCED PROTE, P107; HALLBERG RL, 1983, MOL CELL BIOL, V3, P502; KAHN RW, 1993, P NATL ACAD SCI USA, V90, P9295, DOI 10.1073/pnas.90.20.9295; KRAUS KW, 1987, P NATL ACAD SCI USA, V84, P383, DOI 10.1073/pnas.84.2.383; KRAUS KW, 1986, MOL CELL BIOL, V6, P3854, DOI 10.1128/MCB.6.11.3854; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MCMULLIN TW, 1987, MOL CELL BIOL, V7, P4414, DOI 10.1128/MCB.7.12.4414; MCMULLIN TW, 1986, MOL CELL BIOL, V6, P2527, DOI 10.1128/MCB.6.7.2527; NOVER L., 1991, HEAT SHOCK RESPONSE; Parsell DA, 1994, BIOL HEAT SHOCK PROT; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365	21	18	18	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1036	1039		10.1126/science.7754381	http://dx.doi.org/10.1126/science.7754381			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754381				2022-12-28	WOS:A1995QY93400037
J	KJELLMAN, U; BJORK, K; EKROTH, R; KARLSSON, H; JAGENBURG, R; NILSSON, F; SVENSSON, G; WERNERMAN, J				KJELLMAN, U; BJORK, K; EKROTH, R; KARLSSON, H; JAGENBURG, R; NILSSON, F; SVENSSON, G; WERNERMAN, J			ALPHA-KETOGLUTARATE FOR MYOCARDIAL PROTECTION IN HEART-SURGERY	LANCET			English	Note							TRAUMA METABOLISM	A low myocardial content of alpha-ketoglutarate during heart surgery might aggravate ischaemic injury. 24 men undergoing coronary surgery participated in a randomised controlled study. 28 g alpha-ketoglutarate was added to blood cardioplegia for intermittent antegrade intracoronary perfusion in 13 cases. alpha-ketoglutarate reduced the appearance in blood of the ischaemic markers creatine kinase MB and troponin T (at 4 h after release of aortic cross-clamp; median [95% CI] 49 [37-60] mu g/L in controls vs 32 [27-37] mu g/L for creatine kinase MB, 2.0 [1.2-2.8] vs 1.1 [0.8-1.4] mu g/L for troponin T). These findings signify attenuated ischaemic injury, possibly secondary to enhanced myocardial oxidative capacity.	SAHLGRENS UNIV HOSP,DEPT THORAC & CARDIOVASC SURG,GOTHENBURG,SWEDEN; SAHLGRENS UNIV HOSP,DEPT CLIN BIOCHEM,GOTHENBURG,SWEDEN; HUDDINGE HOSP,DEPT ANESTHESIOL,STOCKHOLM,SWEDEN	Sahlgrenska University Hospital; Sahlgrenska University Hospital								DHAINAUT JF, 1987, CIRCULATION, V75, P533, DOI 10.1161/01.CIR.75.3.533; EPUHKURINEN KT, 1983, AM J PHYSIOL, V244, P281; Newsholme E A, 1987, Biochem Soc Symp, V54, P145; SCHOFIELD PS, 1986, BIOCHEM INT, V12, P189; SPITZER JJ, 1972, AM J PHYSIOL, V222, P101, DOI 10.1152/ajplegacy.1972.222.1.101; SVEDJEHOLM R, 1990, THORAC CARDIOV SURG, V38, P1, DOI 10.1055/s-2007-1013981; SVENSSON S, 1990, J THORAC CARDIOV SUR, V99, P1063; WERNERMAN J, 1990, LANCET, V335, P701, DOI 10.1016/0140-6736(90)90811-I	8	31	34	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					552	553		10.1016/S0140-6736(95)90466-2	http://dx.doi.org/10.1016/S0140-6736(95)90466-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776775				2022-12-28	WOS:A1995QK44400011
J	PAUKER, SG; KOPELMAN, RI; LECHAN, RM				PAUKER, SG; KOPELMAN, RI; LECHAN, RM			DIVERTED BY THE CHIEF COMPLAINT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CHRONIC CONSTRICTIVE PERICARDITIS; ASBESTOS; SIGN		TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV GEN INTERNAL MED,BOSTON,MA 02111; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV ENDOCRINOL,BOSTON,MA 02111	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DIV CLIN DECIS MAKING,MAILSTOP 35K9,BOX 301,BOSTON,MA 02111, USA.							BOJAR RM, 1992, ADULT CARDIAC SURGER, P408; BROCKINGTON G M, 1990, Cardiology Clinics, V8, P645; BROWN J, 1992, NEW ENGL J MED, V327, P463, DOI 10.1056/NEJM199208133270704; BUSH CA, 1977, CIRCULATION, V56, P924, DOI 10.1161/01.CIR.56.6.924; CRYER PE, 1992, CECIL TXB MED, P1394; DAVIES D, 1991, THORAX, V46, P429, DOI 10.1136/thx.46.6.429; DEGOWIN RL, 1994, DEGOWIN DEGOWINS BED, P400; DEVALERIA PA, 1991, ANN THORAC SURG, V52, P219, DOI 10.1016/0003-4975(91)91339-W; FISCHBEIN L, 1988, CHEST, V94, P646, DOI 10.1378/chest.94.3.646; HERRERA MF, 1992, ARCH SURG-CHICAGO, V127, P105; HOLMAN E, 1951, JAMA-J AM MED ASSOC, V146, P1; LORELL BH, 1992, HEART DIS TXB CARDIO, V2, P1465; MEYER TE, 1989, AM J CARDIOL, V64, P1069, DOI 10.1016/0002-9149(89)90817-5; MILLER JI, 1994, HURSTS HEART ARTERIE, V2, P1675; POPE AR, 1989, CHEST, V95, P1172, DOI 10.1378/chest.95.5.1172a; ROBERTS LJ, 1992, WILLIAMS TXB ENDOCRI, P1619; ROSENSTOCK L, 1994, TXB CLIN OCCUPATIONA, P254; SHABETAI R, 1994, HURTS HEART ARTERIES, V2, P1647; SONNENBERG FA, 1986, MED DECIS MAKING, V6, P110, DOI 10.1177/0272989X8600600209; TAKATA M, 1992, AM J PHYSIOL, V262, pH763, DOI 10.1152/ajpheart.1992.262.3.H763; YAZICIOGLU S, 1976, CHEST, V70, P43, DOI 10.1378/chest.70.1.43; 1994, NEW ENGL J MED, V330, P126	22	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					45	48		10.1056/NEJM199507063330109	http://dx.doi.org/10.1056/NEJM199507063330109			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776994				2022-12-28	WOS:A1995RG73500009
J	KANNUS, P; HAAPASALO, H; SANKELO, M; SIEVANEN, H; PASANEN, M; HEINONEN, A; OJA, P; VUORI, I				KANNUS, P; HAAPASALO, H; SANKELO, M; SIEVANEN, H; PASANEN, M; HEINONEN, A; OJA, P; VUORI, I			EFFECT OF STARTING AGE OF PHYSICAL-ACTIVITY ON BONE MASS IN THE DOMINANT ARM OF TENNIS AND SQUASH PLAYERS	ANNALS OF INTERNAL MEDICINE			English	Article						EXERCISE; BONE DENSITY; AGE FACTORS; MENARCHE; TENNIS	X-RAY ABSORPTIOMETRY; MINERAL DENSITY; WOMEN; ADOLESCENTS; PRECISION; CHILDREN; SITES	Objective: To determine in female tennis and squash players the effect of biological age (that is, the starting age of playing relative to the age at menarche) at which tennis or squash playing was started on the difference in bone mineral content between the playing and nonplaying arms. Design: Cross-sectional study. Setting: Finnish tennis and squash federations. Participants: 105 female Finnish national-level players and 50 healthy female controls. Main Outcome Measures: Differences in bone mineral content in playing and nonplaying (dominant to nondominant) arms (proximal humerus, humeral shaft, radial shaft, and distal radius) were compared in the players and controls and among six groups of players. Players were divided into groups according to the biological age (years before or after menarche) at which their playing careers began: more than 5 years before; 3 to 5 years before; 2 to 0 years before; 1 to 5 years after; 6 to 15 years after; and more than 15 years after. Results: Compared with controls (whose mean +/- SD differences in bone mineral content were 4.6% +/- 4.6%, 3.2% +/- 2.3%, 3.2% +/- 3.8%, and 3.9% +/- 4.3% at the previously noted anatomical sites), the players had a significantly (P < 0.001) larger side-to-side difference in every measured site (15.5% +/- 8.4%, 16.2% +/- 9.8%, 8.5% +/- 6.6, and 12.5% +/- 7.1%). Among players, the group differences in bone mineral content were significant (P < 0.001 to P = 0.005), with the group means clearly decreasing with increasing starting biological age of playing. The difference was two to four times greater in the players who had started their playing careers before or at menarche (lowest mean difference in bone mineral content, 10.5% +/- 7.2%; highest difference, 23.5% +/- 7.2%) than in those who started more than 15 years after menarche (lowest difference, 2.4% +/- 4.8%; highest difference, 9.6% +/- 4.9%). Adjustment for potential confounding factors (age and height) did not change these trends. Conclusions: Bones of the playing extremity clearly benefit from active tennis and squash training, which increases their mineral mass. The benefit of playing is about two times greater if females start playing at or before menarche rather than after it. The minimal level and minimum number of years of activity necessary to produce these results, the extent to which this benefit is sustained after cessation of intensive training, and the degree to which these results can be extended to other forms of physical activity and other bone sites should be studied further.	TAMPERE RES CTR SPORTS MED, TAMPERE, FINLAND		KANNUS, P (corresponding author), UKK INST HLTH PROMOT RES, KAUPINPUISTONKATU 1, SF-33500 TAMPERE, FINLAND.		Heinonen, Ari/A-9199-2014; Heinonen, Ari/I-5292-2019	Heinonen, Ari/0000-0002-3681-9953; Heinonen, Ari/0000-0002-3681-9953				CONROY BP, 1993, MED SCI SPORT EXER, V25, P1103; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DALSKY GP, 1988, ANN INTERN MED, V108, P824, DOI 10.7326/0003-4819-108-6-824; GRIMSTON SK, 1993, MED SCI SPORT EXER, V25, P1203; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JOHNSTON CC, 1993, OSTEOPOROSIS INT, V3, pS54, DOI 10.1007/BF01621864; KANNUS P, 1994, BONE, V15, P279, DOI 10.1016/8756-3282(94)90289-5; KATZMAN DK, 1991, J CLIN ENDOCR METAB, V73, P1332, DOI 10.1210/jcem-73-6-1332; KROGER H, 1993, BONE MINER, V23, P171, DOI 10.1016/S0169-6009(08)80094-3; LU PW, 1994, J BONE MINER RES, V9, P1451; MATKOVIC V, 1994, J CLIN INVEST, V93, P799, DOI 10.1172/JCI117034; MCCULLOCH RG, 1990, CAN MED ASSOC J, V142, P221; OTT SM, 1991, NEW ENGL J MED, V325, P1646, DOI 10.1056/NEJM199112053252310; SIEVANEN H, 1993, BONE MINER, V20, P235, DOI 10.1016/S0169-6009(08)80004-9; SIEVANEN H, 1992, J NUCL MED, V33, P1137; SLEMENDA CW, 1991, J BONE MINER RES, V6, P1227; TANNER JM, 1981, NUTR REV, V39, P43, DOI 10.1111/j.1753-4887.1981.tb06734.x; THEINTZ G, 1992, J CLIN ENDOCR METAB, V75, P1060, DOI 10.1210/jc.75.4.1060	18	544	549	0	39	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					27	31		10.7326/0003-4819-123-1-199507010-00003	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762910				2022-12-28	WOS:A1995RE66500004
J	JACOBER, SJ				JACOBER, SJ			EXERCISE AND HYPERTENSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											JACOBER, SJ (corresponding author), WAYNE STATE UNIV, SCH MED, DETROIT, MI 48202 USA.							GRASSI G, 1992, CHEST, V101, pS312, DOI 10.1378/chest.101.5.312S; STEWART KJ, 1992, PROG CARDIOVASC DIS, V35, P159, DOI 10.1016/0033-0620(92)90004-J; Tipton C M, 1991, Exerc Sport Sci Rev, V19, P447; 1993, NIH931088 NAT HEART; [No title captured]	5	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1965	1965		10.1001/jama.273.24.1965	http://dx.doi.org/10.1001/jama.273.24.1965			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783310				2022-12-28	WOS:A1995RE35400037
J	ROTHWELL, PM				ROTHWELL, PM			CAN OVERALL RESULTS OF CLINICAL-TRIALS BE APPLIED TO ALL PATIENTS	LANCET			English	Article							MODELS; RISK	It is generally assumed that the overall results of a clinical trial are generalisable to all patients in the trial and all similar future patients; in other words, that the relative treatment effect in individual patients is similar to the overall trial result. Although this assumption underpins the application of trial results to clinical practice, it has rarely been tested. By independently derived prognostic models, the results of the European Carotid Surgery Trial and the UK-TIA Aspirin Trial were reanalysed to find out whether relative treatment effect varied with absolute baseline risk of stroke. There was significant heterogeneity of relative treatment effect in both trials, resulting in substantial variation in absolute treatment effect with predicted baseline risk. Although, on average, the application of overall trial results to all patients will do more good than harm, a knowledge of the association between relative treatment effect and absolute baseline risk will increase the cost-effectiveness of healthcare interventions by identifying those patients in whom treatment is ineffective and those patients who are most likely to benefit.			ROTHWELL, PM (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.		Rothwell, Peter/ABE-5913-2020	Rothwell, Peter/0000-0001-9739-9211				[Anonymous], 1989, NEW ENGL J MED, V321, P406; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; COX DR, 1972, J R STAT SOC B, V34, P187; EVANS SJW, 1988, J EPIDEMIOL COMMUN H, V42, P311, DOI 10.1136/jech.42.4.311; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; HANKEY GJ, 1992, J NEUROL NEUROSUR PS, V55, P640, DOI 10.1136/jnnp.55.8.640; HELGASON CM, 1994, STROKE, V25, P2331, DOI 10.1161/01.STR.25.12.2331; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	12	246	249	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	1995	345	8965					1616	1619		10.1016/S0140-6736(95)90120-5	http://dx.doi.org/10.1016/S0140-6736(95)90120-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783541				2022-12-28	WOS:A1995RE67000013
J	FINLAY, BL; DARLINGTON, RB				FINLAY, BL; DARLINGTON, RB			LINKED REGULARITIES IN THE DEVELOPMENT AND EVOLUTION OF MAMMALIAN BRAINS	SCIENCE			English	Article							POSSUM TRICHOSURUS-VULPECULA; ANTERIOR OLFACTORY NUCLEUS; LATERAL GENICULATE-NUCLEUS; GANGLION-CELL LAYER; REELER MUTANT MICE; RHESUS-MONKEY; AUTORADIOGRAPHIC ANALYSIS; VISUAL-CORTEX; NEURON ORIGIN; THYMIDINE-H-3 AUTORADIOGRAPHY	Analysis of data collected on 131 species of primates, bats, and insectivores showed that the sizes of brain components, from medulla to forebrain, are highly predictable from absolute brain size by a nonlinear function. The order of neurogenesis was found to be highly conserved across a wide range of mammals and to correlate with the relative enlargement of structures as brain size increases, with disproportionately large growth occurring in late-generated structures. Because the order of neurogenesis is conserved, the most likely brain alteration resulting from selection for any behavioral ability may be a coordinated enlargement of the entire nonolfactory brain.			FINLAY, BL (corresponding author), CORNELL UNIV,DEPT PSYCHOL,URIS HALL,ITHACA,NY 14853, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019245] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19245] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1981, EXP BRAIN RES, V42, P411; ALTMAN J, 1981, EXP BRAIN RES, V42, P424; ALTMAN J, 1978, J COMP NEUROL, V182, P945, DOI 10.1002/cne.901820511; ALTMAN J, 1980, J COMP NEUROL, V194, P877, DOI 10.1002/cne.901940410; ALTMAN J, 1980, J COMP NEUROL, V194, P1, DOI 10.1002/cne.901940102; ALTMAN J, 1980, J COMP NEUROL, V194, P905, DOI 10.1002/cne.901940411; ALTMAN J, 1978, J COMP NEUROL, V179, P23, DOI 10.1002/cne.901790104; ALTMAN J, 1978, J COMP NEUROL, V179, P49, DOI 10.1002/cne.901790105; ALTMAN J, 1978, J COMP NEUROL, V188, P455; ALTMAN J, 1980, J COMP NEUROL, V198, P677; ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; ANGEVINE JB, 1974, ANAT REC, V178, P300; ANGEVINE JB, 1964, ANAT REC, V148, P255; BARON G, 1988, J HIRNFORSCH, V29, P509; Bayer S.A., 1991, NEOCORTICAL DEV; BAYER SA, 1979, J COMP NEUROL, V183, P89, DOI 10.1002/cne.901830108; BAYER SA, 1983, EXP BRAIN RES, V50, P329; BAYER SA, 1986, INT J DEV NEUROSCI, V4, P225, DOI 10.1016/0736-5748(86)90062-6; BAYER SA, 1980, J COMP NEUROL, V194, P845, DOI 10.1002/cne.901940409; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BAYER SA, 1987, PROG NEUROBIOL, V29, P57, DOI 10.1016/0301-0082(87)90015-3; BAYER SA, 1990, EXP NEUROL, V107, P48, DOI 10.1016/0014-4886(90)90062-W; BRAND S, 1980, NEUROSCIENCE, V5, P2125, DOI 10.1016/0306-4522(80)90128-1; BRAND S, 1979, NEUROSCIENCE, V4, P767, DOI 10.1016/0306-4522(79)90005-8; BRANDSTATTER R, 1990, BRAIN BEHAV EVOLUT, V35, P195, DOI 10.1159/000115867; BRUNJES PC, 1989, NEUROSCI LETT, V107, P114, DOI 10.1016/0304-3940(89)90801-X; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CAVINESS VS, 1982, DEV BRAIN RES, V4, P293, DOI 10.1016/0165-3806(82)90141-9; CAVINESS VS, 1973, J COMP NEUROL, V151, P113, DOI 10.1002/cne.901510203; CAVINESS VS, 1973, J COMP NEUROL, V148, P141, DOI 10.1002/cne.901480202; COOPER ML, 1981, J COMP NEUROL, V202, P309; CREPS ES, 1974, J COMP NEUROL, V157, P139, DOI 10.1002/cne.901570204; CREPS ES, 1974, J COMP NEUROL, V157, P161, DOI 10.1002/cne.901570205; CROSSLAND WJ, 1982, DEV BRAIN RES, V5, P99, DOI 10.1016/0165-3806(82)90117-1; DAVIS FC, 1990, BRAIN RES, V519, P192, DOI 10.1016/0006-8993(90)90077-O; DEHAY C, 1993, NATURE, V366, P464, DOI 10.1038/366464a0; DELONG GR, 1962, J COMP NEUROL, V118, P205, DOI 10.1002/cne.901180207; DEVOOGD TJ, 1993, P ROY SOC B-BIOL SCI, V254, P75, DOI 10.1098/rspb.1993.0129; DRAGER UC, 1985, PROC R SOC SER B-BIO, V224, P57, DOI 10.1098/rspb.1985.0021; Erwin, 1988, COMP PRIMATE BIOL, V4, P1; FRAHM HD, 1982, J HIRNFORSCH, V23, P375; GALABURDA AM, 1987, NEUROPSYCHOLOGIA, V25, P853, DOI 10.1016/0028-3932(87)90091-1; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; GOULD BB, 1981, EXP BRAIN RES, V44, P195; Gould S. J., 1977, ONTOGENY PHYLOGENY; HICKEY TL, 1984, J COMP NEUROL, V228, P186, DOI 10.1002/cne.902280205; HINDS JW, 1968, J COMP NEUROL, V134, P287, DOI 10.1002/cne.901340304; HOFMAN MA, 1985, BRAIN BEHAV EVOLUT, V27, P28, DOI 10.1159/000118718; HOFMAN MA, 1989, PROG NEUROBIOL, V32, P137, DOI 10.1016/0301-0082(89)90013-0; JERISON HJ, 1991, NATO ADV SCI I A-LIF, V200, P5; Jerison HJ., 1973, EVOLUTION BRAIN INTE; JOHNSTON AM, 1966, ANAT REC, V154, P163; KIMBLE J, 1994, SCIENCE, V266, P577, DOI 10.1126/science.7939710; KORDOWER JH, 1992, DEV BRAIN RES, V68, P9, DOI 10.1016/0165-3806(92)90242-O; KORDOWER JH, 1990, J COMP NEUROL, V291, P637, DOI 10.1002/cne.902910410; KOSTOVIC I, 1980, J NEUROCYTOL, V9, P219, DOI 10.1007/BF01205159; KREBS JR, 1990, PHILOS T R SOC LON B, V329, P161; LAVAIL MM, 1991, J COMP NEUROL, V309, P86, DOI 10.1002/cne.903090107; LEVITT P, 1984, SCIENCE, V223, P299, DOI 10.1126/science.6199842; LEVITT P, 1979, SOC NEUR ABSTR, V5, P341; LEVITT P, 1986, NEUROBIOLOGY DOWN SY, P195; LUSKIN MB, 1985, J COMP NEUROL, V242, P611, DOI 10.1002/cne.902420409; LUSKIN MB, 1985, J NEUROSCI, V5, P1062; MARCHAND R, 1986, NEUROSCIENCE, V17, P573, DOI 10.1016/0306-4522(86)90031-X; MCCONNELL JA, 1975, ANAT REC, V181, P418; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; NOTTEBOHM F, 1981, BRAIN RES, V213, P99, DOI 10.1016/0006-8993(81)91250-6; NUDO RJ, 1990, J COMP NEUROL, V296, P584, DOI 10.1002/cne.902960406; NUSSLEINVOLHARD C, 1994, SCIENCE, V266, P572, DOI 10.1126/science.7939708; PATEL NH, 1994, SCIENCE, V266, P581, DOI 10.1126/science.7939712; PATON JA, 1984, SCIENCE, V225, P1046, DOI 10.1126/science.6474166; PIERCE ET, 1970, ANAT REC, V166, P388; PIERCE ET, 1970, J COMP NEUROL, V131, P27; PIERCE ET, 1967, J COMP NEUROL, V126, P219; Polley E.H., 1989, P3; PURVES D, 1994, P NATL ACAD SCI USA, V91, P5030, DOI 10.1073/pnas.91.11.5030; RAKIC P, 1981, J COMP NEUROL, V196, P99, DOI 10.1002/cne.901960109; RAKIC P, 1974, SCIENCE, V183, P425, DOI 10.1126/science.183.4123.425; RAKIC P, 1977, J COMP NEUROL, V176, P23, DOI 10.1002/cne.901760103; REEP RL, 1990, BRAIN BEHAV EVOLUT, V35, P185, DOI 10.1159/000115866; REESE BE, 1992, NEUROSCIENCE, V46, P419, DOI 10.1016/0306-4522(92)90062-7; REHKAMPER G, 1991, BRAIN BEHAV EVOLUT, V37, P125, DOI 10.1159/000114353; SANDERSON KJ, 1990, BRAIN BEHAV EVOLUT, V35, P339, DOI 10.1159/000115879; SANDERSON KJ, 1990, BRAIN BEHAV EVOLUT, V35, P325, DOI 10.1159/000115878; SCHWERDTFEGER WK, 1984, ANAT EMBRYOL, V170, P11, DOI 10.1007/BF00319453; Sengelaub D.R., 1989, Advances in Comparative and Environmental Physiology, V3, P239; SENGELAUB DR, 1986, J COMP NEUROL, V246, P527, DOI 10.1002/cne.902460409; SHERRY DF, 1992, TRENDS NEUROSCI, V15, P298, DOI 10.1016/0166-2236(92)90080-R; SIDMAN RL, 1962, ANAT REC, V142, P327; Sidman RL, 1961, STRUCTURE EYE, P487; STANFIELD BB, 1979, J COMP NEUROL, V185, P423, DOI 10.1002/cne.901850303; STEPHAN H, 1981, FOLIA PRIMATOL, V35, P1, DOI 10.1159/000155963; TABER E, 1963, ANAT REC, V145, P291; UZMAN LL, 1960, J COMP NEUROL, V114, P137; WOO TU, 1990, CEREB CORTEX, V1, P433; WYSS JM, 1985, DEV BRAIN RES, V21, P89, DOI 10.1016/0165-3806(85)90026-4	96	865	873	4	143	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1578	1584		10.1126/science.7777856	http://dx.doi.org/10.1126/science.7777856			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777856				2022-12-28	WOS:A1995RD45900026
J	ZHANG, GG; KAZANIETZ, MG; BLUMBERG, PM; HURLEY, JH				ZHANG, GG; KAZANIETZ, MG; BLUMBERG, PM; HURLEY, JH			CRYSTAL-STRUCTURE OF THE CYS2 ACTIVATOR-BINDING DOMAIN OF PROTEIN-KINASE C-DELTA IN COMPLEX WITH PHORBOL ESTER	CELL			English	Article							PROGRAM; REFINEMENT; ZINC	Protein kinase Cs (PKCs) are a ubiquitous family of regulatory enzymes that associate with membranes and are activated by diacylglycerol or tumor-promoting agonists such as phorbol esters. The structure of the second activator-binding domain of PKC delta has been determined in complex with phorbol 13-acetate, which binds in a groove between two pulled-apart beta strands at the tip of the domain. The C3, C4, and C20 phorbol oxygens form hydrogen bonds with mai n-chain groups whose orientation is controlled by a set of highly conserved residues. Phorbol binding caps the groove and forms a contiguous hydrophobic surface covering one-third of the domain, explaining how the activator promotes insertion of PKC into membranes.	NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, MOLEC MECHANISMS TUMOR PROMOT SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; BELL RM, 1991, J BIOL CHEM, V266, P4661; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; FINERMOORE JS, 1992, PROTEINS, V12, P203, DOI 10.1002/prot.340120302; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; Hecker E., 1978, CARCINOGENESIS, P11; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOMMEL U, 1994, NAT STRUCT BIOL, V1, P383, DOI 10.1038/nsb0694-383; HUBBARD SR, 1991, SCIENCE, V254, P1776; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; Rando RR, 1992, PROTEIN KINASE C CUR, P41; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P11, DOI 10.1107/S0907444993008224; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90	23	593	601	2	18	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					917	924		10.1016/0092-8674(95)90011-X	http://dx.doi.org/10.1016/0092-8674(95)90011-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781068	Bronze			2022-12-28	WOS:A1995RD76800012
J	SMALLEY, WE; GRIFFIN, MR; FOUGHT, RL; SULLIVAN, L; RAY, WA				SMALLEY, WE; GRIFFIN, MR; FOUGHT, RL; SULLIVAN, L; RAY, WA			EFFECT OF A PRIOR-AUTHORIZATION REQUIREMENT ON THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS BY MEDICAID PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PAYMENT; THERAPY	Background. Prior authorization - mandatory advance approval for the use of expensive medications - is now the primary method by which Medicaid programs control expenditures for drugs. However, whether this policy reduces expenditures for specific drugs without causing the unwanted substitution of other drugs or medical services has been largely unstudied. We evaluated the effects of a prior-authorization policy involving nongeneric nonsteroidal antiinflammatory drugs (NSAIDs) in the Medicaid program in Tennessee. Methods. We compared monthly Medicaid expenditures that were potentially affected by the policy change during the year before and the two years after its implementation. We studied prescriptions for NSAIDs, other analgesic or antiinflammatory drugs, and psychotropic drugs, as well as outpatient services and inpatient admissions for the management of pain or inflammation. Results. At the midpoint of the base-line year, 495,821 people were enrolled in Medicaid. During that year, mean annualized Medicaid expenditures for NSAID prescriptions amounted to $22.41. Expenditures decreased by 53 percent (95 percent confidence interval, 48 to 57 percent) during the next two years, for an estimated savings of $12.8 million. The reduction in expenditures resulted from the increased use of generic NSAIDs, as well as from a 19 percent decrease in overall NSAID use (95 percent confidence interval, 13 to 25 percent). There was no concomitant increase in Medicaid expenditures for other medical care. Regular users of nongeneric NSAIDs, those most affected by the policy change, had similar reductions in NSAID expenditures and use, with no increase in expenditures for other medical care. Conclusions. Prior-authorization requirements may be highly cost effective with regard to expenditures for NSAIDs, drugs that have very similar efficacy and safety but substantial variation in cost.	VANDERBILT UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,NASHVILLE,TN 37212; TENNESSEE STATE DEPT HLTH,BUR TENNCARE,NASHVILLE,TN	Vanderbilt University; Vanderbilt University; Tennessee Department Health	SMALLEY, WE (corresponding author), VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,A-1124 MCN,NASHVILLE,TN 37232, USA.			Sullivan, Lisa/0000-0003-0726-7149	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007768] Funding Source: NIH RePORTER; AHRQ HHS [HS07768] Funding Source: Medline; FDA HHS [FD-U-0000073] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); FDA HHS		BATCHLOR EE, 1992, OSTEOARTHRITIS DIAGN, P465; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; Gondek K, 1994, Health Care Financ Rev, V15, P1; OLIN BR, 1992, DRUG FACTS COMP; POLLARD MR, 1991, HEALTH AFFAIR, V10, P196, DOI 10.1377/hlthaff.10.2.196; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; TOMITA DK, 1988, PB89143325; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; 1980, INT CLASSIFICATION D; 1993, DRUG EVALUATIONS ANN; 1992, STAT B, V73, P25; 1994, SOCIAL SECURITY B AN, P325	20	137	137	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1612	1617		10.1056/NEJM199506153322406	http://dx.doi.org/10.1056/NEJM199506153322406			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753141	Bronze			2022-12-28	WOS:A1995RC19200006
J	DULEY, L; CARROLI, G; BELIZAN, J; GONZALEZ, L; CAMPODONICO, L; BERGEL, E; TAILLADES, P; AYERS, S; WINCOTT, L; GALLAGHER, K; FREDRICK, K; REYNOLDS, J; ADADEVOH, S; ATALLAH, A; GEORGE, K; GRANT, A; MAHOMED, K; MEHTA, S; MMIRO, F; MOODLEY, J; NEILSON, J; SHETH, S; WALKER, G; CHALMERS, I; COLLINS, R; MUNJANJA, S; REDMAN, C; ELBOURNE, D				DULEY, L; CARROLI, G; BELIZAN, J; GONZALEZ, L; CAMPODONICO, L; BERGEL, E; TAILLADES, P; AYERS, S; WINCOTT, L; GALLAGHER, K; FREDRICK, K; REYNOLDS, J; ADADEVOH, S; ATALLAH, A; GEORGE, K; GRANT, A; MAHOMED, K; MEHTA, S; MMIRO, F; MOODLEY, J; NEILSON, J; SHETH, S; WALKER, G; CHALMERS, I; COLLINS, R; MUNJANJA, S; REDMAN, C; ELBOURNE, D			WHICH ANTICONVULSANT FOR WOMEN WITH ECLAMPSIA - EVIDENCE FROM THE COLLABORATIVE ECLAMPSIA TRIAL	LANCET			English	Article							PREGNANCY-INDUCED HYPERTENSION; MAGNESIUM-SULFATE; SEVERE PREECLAMPSIA; PHENYTOIN PROPHYLAXIS; MATERNAL MORTALITY; MANAGEMENT; SEIZURE	Eclampsia, the occurrence of a seizure in association with preeclampsia, remains an important cause of maternal mortality. Although it is standard practice to use an anticonvulsant for management of eclampsia, the choice of agent is controversial and there has been little properly controlled evidence to support any of the options. 1687 women with eclampsia were recruited into an international multicentre randomised trial comparing standard anticonvulsant regimens. Primary measures of outcome were recurrence of convulsions and maternal death. Data are available for 1680 (99.6%) women: 453 allocated magnesium sulphate versus 452 allocated diazepam, and 388 allocated magnesium sulphate versus 387 allocated phenytoin. Most women (99%) received the anticonvulsant that they had been allocated. Women allocated magnesium sulphate had a 52% lower risk of recurrent convulsions (95% CI 64% to 37% reduction) than those allocated diazepam (60 [13.2%] vs 126 [27.9%]; ie, 14.7 [SD 2.6] fewer women with recurrent convulsions per 100 women; 2p<0.00001). Maternal mortality was non-significantly lower among women allocated magnesium sulphate. There were no significant differences in other measures of serious maternal morbidity, or in perinatal morbidity or mortality. Women allocated magnesium sulphate had a 67% lower risk of recurrent convulsions (95% CI 79% to 47% reduction) than those allocated phenytoin (22 [5.7%] vs 66 [17.1%] ie, 11.4 [SD 2.2] fewer women with recurrent convulsions per 100 women; 2p<0.00001). Maternal mortality was nonsignificantly lower among women allocated magnesium sulphate. Women allocated magnesium sulphate were also less likely to be ventilated, to develop pneumonia, and to be admitted to intensive care facilities than those allocated phenytoin. The babies of women who had been allocated magnesium sulphate before delivery were significantly less likely to be intubated at the place of delivery, and to be admitted to a special care nursery, than the babies of mothers who had been allocated phenytoin. There is now compelling evidence in favour of magnesium sulphate, rather than diazepam or phenytoin, for the treatment of eclampsia.			DULEY, L (corresponding author), RADCLIFFE INFIRM, NATL PERINATAL EPIDEMIOL UNIT, PERINATAL TRIALS SERV, OXFORD OX2 6HE, ENGLAND.		Duley, Lelia/E-8107-2015; Atallah, Álvaro N/K-7182-2013	Duley, Lelia/0000-0001-6721-5178; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APPLETON MP, 1991, AM J OBSTET GYNECOL, V165, P907, DOI 10.1016/0002-9378(91)90437-V; BELFORT MA, 1992, AM J OBSTET GYNECOL, V167, P661, DOI 10.1016/S0002-9378(11)91567-1; BERGSTROM S, 1992, J PERINAT MED, V20, P153; BHALLA AK, 1994, AUST NZ J OBSTET GYN, V34, P144, DOI 10.1111/j.1479-828X.1994.tb02677.x; CHALMERS J, 1989, EFFECTIVE CARE PREGN; CHESLEY LC, 1977, HYPERTENSIVE DISORDE; COYAJI KJ, 1990, ACTA OBSTET GYN SCAN, V69, P115, DOI 10.3109/00016349009006154; CROWTHER C, 1990, BRIT J OBSTET GYNAEC, V97, P110, DOI 10.1111/j.1471-0528.1990.tb01735.x; CROWTHER CA, 1985, S AFR MED J, V68, P927; DOMMISSE J, 1990, BRIT J OBSTET GYNAEC, V97, P104, DOI 10.1111/j.1471-0528.1990.tb01734.x; Donaldson J O, 1992, Int J Obstet Anesth, V1, P159, DOI 10.1016/0959-289X(92)90023-W; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; DULEY L, 1992, BRIT J OBSTET GYNAEC, V99, P547, DOI 10.1111/j.1471-0528.1992.tb13818.x; DULEY L, 1994, BRIT J OBSTET GYNAEC, V101, P565, DOI 10.1111/j.1471-0528.1994.tb13644.x; FRIEDMAN SA, 1993, AM J PERINAT, V10, P233; GOLDMAN RS, 1988, NEW ENGL J MED, V319, P1224; HUTTON JD, 1992, BRIT J OBSTET GYNAEC, V99, P554, DOI 10.1111/j.1471-0528.1992.tb13819.x; KAPLAN PW, 1990, ARCH NEUROL-CHICAGO, V47, P1031, DOI 10.1001/archneur.1990.00530090111021; Lazard EM, 1933, AM J OBSTET GYNECOL, V26, P647, DOI 10.1016/S0002-9378(33)90285-9; LEAN T H, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P856; Loudon I., 1992, DEATH CHILDBIRTH INT; MAHLER H, 1987, LANCET, V1, P668; OZUMBIA BC, 1993, ACTA OBSTET GYN SCAN, V72, P189; PRITCHARD JA, 1984, AM J OBSTET GYNECOL, V148, P951, DOI 10.1016/0002-9378(84)90538-6; REDMAN CWG, 1993, LANCET, V341, P1451, DOI 10.1016/0140-6736(93)90890-S; ROBSON SC, 1993, BRIT J OBSTET GYNAEC, V100, P623, DOI 10.1111/j.1471-0528.1993.tb14227.x; ROSENFIELD A, 1985, LANCET, V2, P83; RYAN G, 1989, AM J OBSTET GYNECOL, V161, P1297, DOI 10.1016/0002-9378(89)90687-X; SADEH M, 1989, STROKE, V20, P1273, DOI 10.1161/01.STR.20.9.1273; Sibai B M, 1992, Int J Obstet Anesth, V1, P167, DOI 10.1016/0959-289X(92)90024-X; SIBAI BM, 1990, AM J OBSTET GYNECOL, V163, P1049, DOI 10.1016/0002-9378(90)91123-T; SLATER RM, 1987, LANCET, V1, P1417; ZUSPAN FP, 1978, AM J OBSTET GYNECOL, V131, P591, DOI 10.1016/0002-9378(78)90816-5; 1988, AM J OBSTET GYNECOL, V158, P80; 1993, MANAGEMENT HYPERTENS; 1994, REPORT CONFIDENTIAL	36	598	617	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	1995	345	8963					1455	1463						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769899				2022-12-28	WOS:A1995RC18900006
J	DUNNE, DW; HAGAN, P; ABATH, FGC				DUNNE, DW; HAGAN, P; ABATH, FGC			PROSPECTS FOR IMMUNOLOGICAL CONTROL OF SCHISTOSOMIASIS	LANCET			English	Review							TRIOSE-PHOSPHATE ISOMERASE; GLUTATHIONE-S-TRANSFERASE; PROTECTIVE IMMUNITY; SURFACE-ANTIGEN; ATTENUATED CERCARIAE; RECOMBINANT FRAGMENT; MONOCLONAL-ANTIBODY; HUMAN RESISTANCE; LIFE-CYCLE; MANSONI		UNIV GLASGOW, INST BIOMED & LIFE SCI, DIV MOLEC & CELLULAR BIOL, GLASGOW, LANARK, SCOTLAND; FDN OSWALDO CRUZ, CTR PESQUISAS AGGEU MAGALHAES, DEPT IMMUNOL, RECIFE, PE, BRAZIL	University of Glasgow; Fundacao Oswaldo Cruz	DUNNE, DW (corresponding author), UNIV CAMBRIDGE, DEPT PATHOL, DIV MICROBIOL & PARASITOL, TENNIS COURT RD, CAMBRIDGE CB2 1QP, ENGLAND.		Dunne, David William/AAC-2530-2020	Dunne, David/0000-0002-8940-9886; Hagan, Paul/0000-0002-3516-2283	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALI PO, 1991, MOL BIOCHEM PARASIT, V45, P215, DOI 10.1016/0166-6851(91)90088-N; BALLOUL JM, 1987, NATURE, V326, P149, DOI 10.1038/326149a0; BALLOUL JM, 1987, J IMMUNOL, V138, P3448; BASCH PF, 1993, T ROY SOC TROP MED H, V87, P589, DOI 10.1016/0035-9203(93)90098-B; BOULANGER D, 1991, PARASITE IMMUNOL, V13, P473, DOI 10.1111/j.1365-3024.1991.tb00545.x; BUTTERWORTH A, 1988, BIOCHIMIE, V70, P1053, DOI 10.1016/0300-9084(88)90268-4; BUTTERWORTH AE, 1985, T ROY SOC TROP MED H, V79, P393, DOI 10.1016/0035-9203(85)90391-8; BUTTERWORTH AE, 1992, T ROY SOC TROP MED H, V86, P1, DOI 10.1016/0035-9203(92)90411-5; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; COLLEY DG, 1986, T ROY SOC TROP MED H, V80, P952, DOI 10.1016/0035-9203(86)90268-3; CURRY AJ, 1995, J EXP MED, V181, P769, DOI 10.1084/jem.181.2.769; DEMEURE CE, 1993, J INFECT DIS, V168, P1000, DOI 10.1093/infdis/168.4.1000; DESSEIN AJ, 1988, J IMMUNOL, V140, P2727; DIN MSAN, 1994, AM J TROP MED HYG, V50, P585; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; DUNNE DW, 1988, EUR J IMMUNOL, V18, P123, DOI 10.1002/eji.1830180119; ELSHERBEINI M, 1991, MOL BIOCHEM PARASIT, V49, P83, DOI 10.1016/0166-6851(91)90132-P; FLANIGAN TP, 1989, J CLIN INVEST, V83, P1010, DOI 10.1172/JCI113942; GRZYCH JM, 1993, J IMMUNOL, V150, P527; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HARN DA, 1992, J IMMUNOL, V148, P562; HARN DA, IN PRESS MEM I O CRU; JAMES S L, 1987, Memorias do Instituto Oswaldo Cruz, V82, P121, DOI 10.1590/S0074-02761987000800020; KHALIFE J, 1986, J EXP MED, V164, P1626, DOI 10.1084/jem.164.5.1626; KHALIFE J, 1989, J IMMUNOL, V142, P4422; KNIGHT M, 1989, PARASITOL RES, V75, P280, DOI 10.1007/BF00931812; LANAR DE, 1986, SCIENCE, V234, P593, DOI 10.1126/science.3094144; LANGLEY JG, 1994, IMMUNOLOGY, V83, P651; LIESE B, 1986, PARASITOL TODAY, V2, P339, DOI 10.1016/0169-4758(86)90054-2; MATSUMOTO Y, 1988, NATURE, V333, P76, DOI 10.1038/333076a0; MAZZA G, 1990, PARASITE IMMUNOL, V12, P529, DOI 10.1111/j.1365-3024.1990.tb00986.x; MOSER D, 1991, J BIOL CHEM, V266, P8447; PEARCE EJ, 1988, P NATL ACAD SCI USA, V85, P5678, DOI 10.1073/pnas.85.15.5678; PEARCE EJ, 1986, J IMMUNOL, V137, P3593; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; REYNOLDS SR, 1994, J IMMUNOL, V152, P193; RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106; ROBERTS M, 1993, INFECT IMMUN, V61, P4984, DOI 10.1128/IAI.61.12.4984-4993.1993; SHOEMAKER C, 1992, P NATL ACAD SCI USA, V89, P1842, DOI 10.1073/pnas.89.5.1842; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; SMYTHIES LE, 1992, J IMMUNOL, V149, P3654; SOISSON LA, 1993, J IMMUNOL, V151, P4782; SOISSON LA, 1993, EXP PARASITOL, V77, P492, DOI 10.1006/expr.1993.1111; SOISSON LMA, 1992, J IMMUNOL, V149, P3612; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; TENDLER M, IN PRESS MEM I O CRU; WESTON D, 1993, MOL BIOCHEM PARASIT, V58, P161, DOI 10.1016/0166-6851(93)90100-C; WILKINS HA, 1987, T ROY SOC TROP MED H, V81, P29, DOI 10.1016/0035-9203(87)90273-2; WOLOWCZUK I, 1989, J IMMUNOL, V142, P1342; XU CB, 1993, J IMMUNOL, V150, P940	51	47	60	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	1995	345	8963					1488	1492						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769906				2022-12-28	WOS:A1995RC18900013
J	KEAT, A				KEAT, A			SPONDYLOARTHROPATHIES	BRITISH MEDICAL JOURNAL			English	Article											KEAT, A (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,LONDON,ENGLAND.								0	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1321	1324		10.1136/bmj.310.6990.1321	http://dx.doi.org/10.1136/bmj.310.6990.1321			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773052	Green Published			2022-12-28	WOS:A1995QZ86000033
J	GEISS, J; GLOECKLER, G; VONSTEIGER, R; BALSIGER, H; FISK, LA; GALVIN, AB; IPAVICH, FM; LIVI, S; MCKENZIE, JF; OGILVIE, KW; WILKEN, B				GEISS, J; GLOECKLER, G; VONSTEIGER, R; BALSIGER, H; FISK, LA; GALVIN, AB; IPAVICH, FM; LIVI, S; MCKENZIE, JF; OGILVIE, KW; WILKEN, B			THE SOUTHERN HIGH-SPEED STREAM - RESULTS FROM THE SWICS INSTRUMENT ON ULYSSES	SCIENCE			English	Article							POLAR CORONAL HOLE; SOLAR-WIND; MINOR IONS; IONIZATION EQUILIBRIUM; ABUNDANCES; SKYLAB; STATE	The high-speed solar wind streaming from the southern coronal hole was remarkably uniform and steady and was confined by a sharp boundary that extended to the corona and chromosphere. Charge state measurements indicate that the electron temperature in this coronal hole reached a maximum;of about 1.5 million kelvin within 3 solar radii of the sun. This result, combined with the observed lack of depletion of heavy elements, suggests that an additional source of momentum is required to accelerate the polar wind.	UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; UNIV MARYLAND,DEPT PHYS,COLLEGE PK,MD 20742; MAX PLANCK INST AERON,D-37189 KATLENBURG DUHM,GERMANY; NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771	University of Michigan System; University of Michigan; University System of Maryland; University of Maryland College Park; Max Planck Society; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	GEISS, J (corresponding author), UNIV BERN,INST PHYS,CH-3012 BERN,SWITZERLAND.		Livi, Stefano/H-5348-2012; von Steiger, Rudolf/F-6822-2011; Galvin, Antoinette/A-6114-2013	von Steiger, Rudolf/0000-0002-3350-0023; 				[Anonymous], 1989, AIP C, DOI DOI 10.1063/1.37985; ARNAUD M, 1992, ASTROPHYS J, V398, P394, DOI 10.1086/171864; Arnaud M., 1985, Astronomy & Astrophysics Supplement Series, V60, P425; BAME SJ, 1977, J GEOPHYS RES-SPACE, V82, P1487, DOI 10.1029/JA082i010p01487; BOCHSLER P, 1983, NASA CP2280 C PUBL, P613; BOCHSLER P, 1992, SOLAR WIND SEVEN, V3, P323; BURGI A, 1986, SOL PHYS, V103, P347, DOI 10.1007/BF00147835; BURGI A, 1987, J GEOPHYS RES, V92, P1057, DOI 10.1029/JA092iA02p01057; GEISS J, 1994, PHILOS T R SOC A, V349, P213, DOI 10.1098/rsta.1994.0126; GEISS J, 1995, SPACE SCI REV, V72, P49, DOI 10.1007/BF00768753; GEISS J, 1985, RAPPORTS ISOTOPIQUES, P213; GLOECKLER G, 1992, ASTRON ASTROPHYS SUP, V92, P267; GLOECKLER G, 1989, EOS T AGU, V70, P424; GOSLING JT, 1995, SPACE SCI REV, V72, P99, DOI 10.1007/BF00768761; HOLLWEG JV, 1981, J GEOPHYS RES-SPACE, V86, P8899, DOI 10.1029/JA086iA11p08899; HOLLWEG JV, 1986, J GEOPHYS RES-SPACE, V91, P4111, DOI 10.1029/JA091iA04p04111; HOLLWEG JV, 1978, REV GEOPHYS, V16, P689, DOI 10.1029/RG016i004p00689; HUBER MCE, 1974, ASTROPHYS J, V194, pL115, DOI 10.1086/181682; HUNDHAUSEN AJ, 1968, J GEOPHYS RES, V73, P5485, DOI 10.1029/JA073i017p05485; LALLEMENT R, 1986, J GEOPHYS RES, V91, P6751, DOI 10.1029/JA091iA06p06751; MARSDEN RG, 1986, SUN HELIOSPHERE 3 DI, P173; MCKENZIE JF, 1979, ASTROPHYS SPACE SCI, V64, P183, DOI 10.1007/BF00640041; MEYER JP, 1993, ADV SPACE RES, V13, P377, DOI 10.1016/0273-1177(93)90509-A; MUNRO RH, 1977, ASTROPHYS J, V213, P874, DOI 10.1086/155220; NOLTE JT, 1977, SOL PHYS, V51, P459, DOI 10.1007/BF00216379; OWOCKI SP, 1983, ASTROPHYS J, V275, P354, DOI 10.1086/161538; SHULL JM, 1982, ASTROPHYS J SUPPL S, V48, P95, DOI 10.1086/190769; TOUSEY R, 1973, SOL PHYS, V33, P265; VONSTEIGER R, 1989, ASTRON ASTROPHYS, V225, P222; VONSTEIGER R, 1992, ASTROPHYS J, V389, P791, DOI 10.1086/171252; WIELER R, 1993, LUNAR PLANET SCI, V24, P1519; WITHBROE GL, 1971, SOL PHYS, V21, P271	32	217	218	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1033	1036		10.1126/science.7754380	http://dx.doi.org/10.1126/science.7754380			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754380				2022-12-28	WOS:A1995QY93400036
J	LUO, Y; HURWITZ, J; MASSAGUE, J				LUO, Y; HURWITZ, J; MASSAGUE, J			CELL-CYCLE INHIBITION BY INDEPENDENT CDK AND PCNA BINDING DOMAINS IN P21(CIP1)	NATURE			English	Article							DEPENDENT KINASES; IDENTIFICATION; SUPPRESSION; SUBUNIT; P21	MAMMALIAN cell-cycle control by antimitogenic signals involves p21(Cip1/WAF1) (refs 1-4), p27(Kip1) (refs 5, 6) and p57(Kip2) (refs 7, 8), a family of proteins that bind to and inhibit cyclin-dependent kinases (CDKs) required for initiation of S phase. The protein p21 also binds to the DNA polymerase 6 processivity factor, proliferating-cell nuclear antigen (PCNA), and inhibits in vitro PCNA-dependent DNA replication(9,10). The CDK and PCNA inhibitory activities of p21 are shown here to be functionally independent and to reside in separate protein domains. The PCNA binding and inhibitory activities, which are not observed with p27 or p57, reside in the C-terminal domain of p21, whereas the CDK inhibitory activity resides in the conserved N-terminal domains of these proteins. When separately overexpressed in mammalian cells, the CDK and PCNA inhibitory domains prevent DNA replication, demonstrating a dual function of p21 as a cell-cycle inhibitor in vivo.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center				Massague, Joan/0000-0001-9324-8408				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KELMAN Z, IN PRESS METH ENZYM; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	19	532	554	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					159	161		10.1038/375159a0	http://dx.doi.org/10.1038/375159a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753174				2022-12-28	WOS:A1995QX74100055
J	RIVLIN, MM				RIVLIN, MM			PROTECTING ELDERLY PEOPLE - FLAWS IN AGAINST ARGUMENTS	BRITISH MEDICAL JOURNAL			English	Article								Some form of rationing is necessary in medicine, and to use age as a criterion for rationing seems initially appealing. Many of the criteria currently being used for deciding the distribution of funds depend on subjective judgments. Age, however, is objective and therefore negates the need for value judgments. Justice and fairness, it is sometimes suggested, require that finite resources should be directed at young people, who have not had a chance to live their lives, rather than at elderly people, who have already lived most of theirs. The adoption of ageist policies, however, may not result in the implied savings unless care is also withdrawn. Furthermore, ageist policies, which deny elderly people treatment on the sole grounds of their age, are both unfair and discriminatory and should therefore be resisted.			RIVLIN, MM (corresponding author), UNIV LEEDS,DEPT PHILOSOPHY,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND.							BRANDSTETTER RD, 1992, NEW YORK STATE J MED, V92, P175; BUTLER RN, 1975, WHY SURVIVE BEING OL, P11; Callahan D., 1987, MED GOALS AGEING SOC; DUDLEY NJ, 1992, AGE AGEING, V21, P91; DWORKIN R, 1993, LIFES DOMISION ARGUM, P219; EVANS JG, 1992, MEASURES QUALITY LIF, P109; HACKER C, 1976, HLTH CARE AGEING POP; HANSON MJ, 1994, HASTINGS CENT REP, V24, P4, DOI 10.2307/3563488; JECKER NS, 1992, AM J MED, V92, P191; KILLNER JF, 1990, WHO LIVES ETHICAL CR, P77; LAWRENCE JL, 1995, TIMES           0109; LEVENSKY NG, 1990, NEW ENGL J MED, V322, P1813; SHAW AB, 1994, J MED ETHICS, V20, P188, DOI 10.1136/jme.20.3.188; SHAW AB, 1994, J MED ETHICS, V20, P191; 1994, ENSURING EQUITY QUAL	15	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1179	1182		10.1136/bmj.310.6988.1179	http://dx.doi.org/10.1136/bmj.310.6988.1179			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX566	7767155	Green Published			2022-12-28	WOS:A1995QX56600028
J	KING, M; COKER, E; LEAVEY, G; HOARE, A; JOHNSONSABINE, E				KING, M; COKER, E; LEAVEY, G; HOARE, A; JOHNSONSABINE, E			INCIDENCE OF PSYCHOTIC ILLNESS IN LONDON - COMPARISON OF ETHNIC-GROUPS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AFRO-CARIBBEANS; PSYCHIATRIC-ILLNESS; ADMISSION RATES; SCHIZOPHRENIA; IMMIGRANTS; MANCHESTER; HYPOTHESES; ENGLAND; ASIANS; BORN	Objective-To compare annual incidences of psychosis in people from different ethnic groups as defined in the 1991 census. Setting-Catchment area of district psychiatric hospital. Design-All people aged 16 to 54 years who made contact with a wide range of community and hospital services between 1 July 1991 and 30 June 1992 were screened for psychotic symptoms. Patients with such symptoms were interviewed face to face to collect information on demography, ethnic group, psychiatric history and symptoms, drug use, and how care had been sought. A key informant, usually a close relative, was also interviewed. Main outcome measures-Age standardised incidence of schizophrenia and non-affective psychosis according to the ninth edition of the International Classification of Diseases in each ethnic group. Results-Ninety three patients took part, of whom 38 were assigned a certain or very likely diagnosis of schizophrenia (15 in white population, 14 in black, seven in Asian, and two in others). The age standardised annual incidence of schizophrenia was 2.2 (95% confidence interval 1.5 to 2.9) per 10 000 of the population. The incidence ratio for schizophrenia in all ethnic minority groups compared with the white population was 3.6 (1.9 to 7.1); the corresponding figure for non-affective psychosis was 3.7 (2.2 to 6.2). Conclusions-Raised incidences of schizophrenia were not specific to the African Caribbeans, which suggests that the current focus on schizophrenia in this population is misleading. Members of all ethnic minority groups were more likely to develop a psychosis but not necessarily schizophrenia. The personal and social pressures of belonging to any ethnic minority group in Britain are important determinants in the excess of psychotic disorders found.	ST ANNS HOSP, DEPT PSYCHIAT, LONDON N15 3TH, ENGLAND		KING, M (corresponding author), UNIV LONDON, ROYAL FREE HOSP, SCH MED, DEPT PSYCHIAT, LONDON NW3 2QG, ENGLAND.		King, Michael B/D-7477-2011; Leavey, Gerard/AAU-2912-2020	King, Michael B/0000-0003-4715-7171; Leavey, Gerard/0000-0001-8411-8919				AWAIH J, 1992, REFUGEE GROUPS HARIN; BIRCHWOOD M, 1992, BRIT J PSYCHIAT, V161, P783, DOI 10.1192/bjp.161.6.783; BOYD J, 1982, HDB AFFECTIVE DISORD; BREWIN C, 1980, SOC PSYCHIATR, V15, P17, DOI 10.1007/BF00577957; CARPENTER L, 1980, BRIT J PSYCHIAT, V137, P201, DOI 10.1192/bjp.137.3.201; COCHRANE R, 1987, SOC PSYCHIATR, V22, P181, DOI 10.1007/BF00583553; COCHRANE R, 1989, SOC PSYCH PSYCH EPID, V24, P2, DOI 10.1007/BF01788193; COOPER JE, 1987, BRIT J PSYCHIAT, V151, P619, DOI 10.1192/bjp.151.5.619; DEAN G, 1981, BRIT J PSYCHIAT, V139, P506, DOI 10.1192/bjp.139.6.506; EAGLES JM, 1991, BRIT J PSYCHIAT, V159, P783, DOI 10.1192/bjp.159.6.783; FABREGA H, 1989, J NERV MENT DIS, V177, P415, DOI 10.1097/00005053-198907000-00005; Fernando S., 1988, RACE CULTURE PSYCHIA; GARDNER MJ, 1989, CONFIDENCE INTERVAL; HARRISON G, 1988, PSYCHOL MED, V18, P643, DOI 10.1017/S0033291700008321; HARVEY I, 1990, BRIT J PSYCHIAT, V157, P515, DOI 10.1192/bjp.157.4.515; LITTLEWOOD R, 1988, BRIT MED J, V296, P950, DOI 10.1136/bmj.296.6627.950; LITTLEWOOD R, 1981, PSYCHOL MED, V11, P289, DOI 10.1017/S0033291700052119; MCGOVERN D, 1987, SOC PSYCHIATR, V22, P139, DOI 10.1007/BF00583848; MOODLEY P, 1987, B ROYAL COLLEGE PSYC, V11, P417; SARTORIUS N, 1986, PSYCHOL MED, V16, P909, DOI 10.1017/S0033291700011910; Sashidharan S. P., 1993, International Review of Psychiatry, V5, P129, DOI 10.3109/09540269309028304; SASHIDHARAN SP, 1988, BRIT MED J, V296, P1735, DOI 10.1136/bmj.296.6638.1735-a; TEAGUE A, 1993, POPULATION TRENDS, V72, P12; THOMAS CS, 1993, BRIT J PSYCHIAT, V163, P91, DOI 10.1192/bjp.163.1.91; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; Wing JK, 1974, DESCRIPTION CLASSIFI; 1978, MENTAL DISORDERS GLO; 1987, DIAGNOSTIC STATISTIC; [No title captured]; 1992, 923 LOND RES CTR CEN; 1986, GENERALISED LINEAR I	31	178	180	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	1994	309	6962					1115	1119		10.1136/bmj.309.6962.1115	http://dx.doi.org/10.1136/bmj.309.6962.1115			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7755702	Green Published			2022-12-28	WOS:A1994PP69100019
J	BODENHEIMER, T; GRUMBACH, K				BODENHEIMER, T; GRUMBACH, K			THE RECONFIGURATION OF US MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AMERICAN HEALTH-CARE; BUSINESS		UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Grumbach, Kevin/L-9222-2016					ALBERTSON D, 1991, PHYSICIANS FINA 1115, P32; ALBERTSON D, 1993, PHYSICIANS FINA 0915, P18; BERGTHOLD L, 1991, ANNU REV PUBL HEALTH, V12, P157; BERGTHOLD L, 1990, PURCHASING POWER HLT; BODENHEIMER T, 1994, JAMA-J AM MED ASSOC, V272, P971, DOI 10.1001/jama.272.12.971; BODENHEIMER T, 1994, JAMA-J AM MED ASSOC, V272, P634, DOI 10.1001/jama.272.8.634; BODENHEIMER TS, 1995, UNDERSTANDING HLTH P; CALIFANO JA, 1986, AM HLTH CARE REVOLUT; CANTOR JC, 1991, HEALTH AFFAIR, V10, P98, DOI 10.1377/hlthaff.10.1.98; CASTELLS M, 1980, EC CRISIS AM SOC; CLEMENTS B, 1992, AM MED NEWS     0907, P17; Ellwood P M Jr, 1971, Med Care, V9, P291, DOI 10.1097/00005650-197105000-00008; ESTES CL, 1994, HLTH POLICY NURSING; FINDLAY S, 1993, BUS HEALTH, V11, P27; FREUDENHEIM M, 1993, NY TIMES        0901, P8; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V273, P1223, DOI 10.1001/jama.273.15.1223; GRUMBACH K, 1995, JAMA-J AM MED ASSOC, V273, P160; HAGLAND MM, 1993, HOSPITALS       0320, P26; HARRIS N, 1992, BUS HEALTH, V10, P32; HUDSON T, 1993, HOSPITALS HLTH  0805, P19; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1247, DOI 10.1056/NEJM199004263221728; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; JOHNSSON J, 1993, AM MED NEWS     0809, P3; JOHNSSON J, 1993, AM MED NEWS     0809, P47; KERR P, 1993, NY TIMES        0627, P6; KUTTNER R, 1980, REVOLT HAVES; Langwell K M, 1990, Health Care Financ Rev, V12, P71; Law Sylvia, 1974, BLUE CROSS WHAT WENT; PEAR R, 1993, NY TIMES        0821, P7; RELMAN AS, 1991, NEW ENGL J MED, V325, P854, DOI 10.1056/NEJM199109193251205; RELMAN AS, 1980, NEW ENGL J MED, V303, P963, DOI 10.1056/NEJM198010233031703; RELMAN AS, 1992, CHOICES HEALTHCARE R; SAPOLSKY HM, 1981, MILBANK FUND Q, V59, P561, DOI 10.2307/3349741; SCHAUMBURG R, 1992, MANAGED CARE, V1, P22; Starr P, 1982, SOCIAL TRANSFORMATIO; STEVENS S, 1993, PHYSICIANS FINA 0515, P29; SULLIVAN CB, 1992, HEALTH AFFAIR, V11, P172, DOI 10.1377/hlthaff.11.4.172; WEISS L, 1992, NO BENEFIT CRISIS AM; 1990, MANAGED CARE DIGEST; 1993, 1993 NATIONAL DIRECT	40	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					85	90		10.1001/jama.274.1.85	http://dx.doi.org/10.1001/jama.274.1.85			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RG233	7791264				2022-12-28	WOS:A1995RG23300037
J	KAPLAN, NM				KAPLAN, NM			ALCOHOL AND HYPERTENSION	LANCET			English	Editorial Material							BLOOD-PRESSURE; CONSUMPTION				KAPLAN, NM (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235, USA.							ABE H, 1994, CIRCULATION, V89, P2626, DOI 10.1161/01.CIR.89.6.2626; ALTURA BM, 1994, ALCOHOL CLIN EXP RES, V18, P1057, DOI 10.1111/j.1530-0277.1994.tb00082.x; CUSHMAN WC, 1994, AM J HYPERTENS, V7, P814, DOI 10.1093/ajh/7.9.814; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; Keil U, 1993, CARDIOVASC RISK FACT, V3, P189; KLAG MJ, 1993, HYPERTENSION, V22, P365, DOI 10.1161/01.HYP.22.3.365; KUPARI M, 1983, BRIT HEART J, V49, P174, DOI 10.1136/hrt.49.2.174; Lian C, 1915, B ACAD MED PARIS, V74, P525; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MAHESWARAN R, 1992, HYPERTENSION, V19, P79, DOI 10.1161/01.HYP.19.1.79; VANDONGEN R, 1994, TXB HYPERTENSION, P567; WANNAMETHEE G, 1991, J HUM HYPERTENS, V5, P59	13	35	37	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1588	1589		10.1016/S0140-6736(95)90110-8	http://dx.doi.org/10.1016/S0140-6736(95)90110-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783532				2022-12-28	WOS:A1995RE67000003
J	RATKO, TA; BURNETT, DA; FOULKE, GE; MATUSZEWSKI, KA; SACHER, RA; EHMANN, WC; GIVNER, LB; KAHALEH, B; MATUSZEWSKI, KA; SAMAHA, FJ; SIEGEL, J; WINGARD, JR; WORDELL, CJ; YOCUM, DE				RATKO, TA; BURNETT, DA; FOULKE, GE; MATUSZEWSKI, KA; SACHER, RA; EHMANN, WC; GIVNER, LB; KAHALEH, B; MATUSZEWSKI, KA; SAMAHA, FJ; SIEGEL, J; WINGARD, JR; WORDELL, CJ; YOCUM, DE			RECOMMENDATIONS FOR OFF-LABEL USE OF INTRAVENOUSLY ADMINISTERED IMMUNOGLOBULIN PREPARATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNE GLOBULIN; DRUG-THERAPY; DISEASES	Objective.- To summarize consensus recommendations for off-label uses of standard intravenous immunoglobulin (IVIG), as developed by a University Hospital Consortium (UHC) Expert Panel. These findings are intended to help guide clinicians in the appropriate and efficient use of IVIG. Participants.- The UHC-sponsored panel included eight physicians (board certified in critical care, hematology, immunology, neurology, oncology, pediatrics, or rheumatology) and two hospital pharmacists. Evidence.- MEDLINE and EMBASE were searched to identify all English-language review articles (n=201) and original reports (n=1904) on IVIG (human use only, excluding editorials, letters, and comments) published between January 1982 and March 1994. Relevant original reports (250) and review articles (87) were evaluated by the first author (T.A.R.). Extracted data included laboratory and clinical findings, objective measures, or clinical impressions. The evidence quality was graded by study design according to the US Preventive Services. Task Force. Consensus Process.- Before the panel meeting, a draft literature review and recommendations were produced by one of the authors (T.A.R.). The recommendations herein represent consensus (100% agreement) based on the published evidence. Conclusions.- The UHC Expert Panel made specific recommendations for 53 off-label indications and the following general recommendations: (1) Usually IVIG is indicated only if standard approaches have failed, become intolerable, or are contraindicated; (2) IVIG products should be considered therapeutically equivalent and interchangeable; (3) interproduct pharmaceutical differences should be considered with the patient's clinical and physiological status when selecting an IVIG product; and (4) currently, IVIG manufacturers cannot guarantee freedom from viral contamination in the finished product.	UNIV CALIF DAVIS,SCH MED,DEPT INTERNAL MED,DAVIS,CA 95616; GEORGETOWN UNIV,MED CTR,DEPT LAB MED,WASHINGTON,DC 20007; PENN STATE UNIV,COLL MED,DIV HEMATOL,HERSHEY,PA; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PEDIAT,WINSTON SALEM,NC 27103; MED COLL OHIO,DEPT MED,DIV RHEUMATOL & IMMUNOL,TOLEDO,OH 43699; UNIV CINCINNATI,COLL MED,DEPT NEUROL,CINCINNATI,OH 45267; OHIO STATE UNIV HOSP,COLUMBUS,OH 43210; EMORY UNIV,SCH MED,WINSHIP CANC CTR,BONE MARROW TRANSPLANT PROGRAM,ATLANTA,GA 30322; THOMAS JEFFERSON UNIV HOSP,DRUG INFORMAT SERV,PHILADELPHIA,PA; UNIV ARIZONA,COLL MED,DEPT INTERNAL MED,RHEUMATOL ALLEGY & IMMUNOL SECT,TUCSON,AZ 85724	University of California System; University of California Davis; Georgetown University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Wake Forest University; Wake Forest Baptist Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University; Emory University; Jefferson University; University of Arizona	RATKO, TA (corresponding author), UNIV HOSP CONSORTIUM,CTR CLIN PRACTICE ADV,TECHNOL ASSESSMENT PROGRAM,2001 SPRING RD,SUITE 700,OAK BROOK,IL 60521, USA.							BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; COOK DJ, 1992, CHEST, V102, pS305; DUHEM C, 1994, CLIN EXP IMMUNOL, V97, P79; DWYER JM, 1992, NEW ENGL J MED, V326, P107; FDA Drug Bulletin, 1982, FDA DRUG B, V12, P4; GELFAND EW, 1992, SEMIN HEMATOL, V29, P127; GOLDBLOOM R, 1988, CAN MED ASSOC J, V138, P617; HALL PD, 1993, PHARMACOTHERAPY, V13, P564; KELLER T, 1993, MED J AUSTRALIA, V159, P204, DOI 10.5694/j.1326-5377.1993.tb137790.x; LANGDALE LA, 1992, INFECT DIS CLIN N AM, V6, P731; SCHIFF RI, 1994, NEW ENGL J MED, V331, P1649, DOI 10.1056/NEJM199412153312409; SEKUL EA, 1994, ANN INTERN MED, V121, P259, DOI 10.7326/0003-4819-121-4-199408150-00004; TODD AAM, 1992, BLOOD REV, V6, P105, DOI 10.1016/0268-960X(92)90012-F; 1994, MMWR-MORBID MORTAL W, V43, P505; 1994, DRUG TOPICS RED BOOK; 1986, MMWR-MORBID MORTAL W, V35, P231; 1989, GUIDE CLIN PREVENTIV, pR27; 1992, CLIN PHARM, V11, P117; 1990, JAMA-J AM MED ASSOC, V24, P3189	19	104	105	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1865	1870		10.1001/jama.273.23.1865	http://dx.doi.org/10.1001/jama.273.23.1865			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776504				2022-12-28	WOS:A1995RD11600030
J	VANGENT, DC; MCBLANE, JF; RAMSDEN, DA; SADOFSKY, MJ; HESSE, JE; GELLERT, M				VANGENT, DC; MCBLANE, JF; RAMSDEN, DA; SADOFSKY, MJ; HESSE, JE; GELLERT, M			INITIATION OF V(D)J RECOMBINATION IN A CELL-FREE SYSTEM	CELL			English	Article							RAG-1; GENES; MICE; DNA	Cells performing V(D)J recombination make specific cuts in DNA at recombination signal sequences. Here, we show that nuclear extracts of pre-a cell lines carry out this specific cleavage. The products of cleavage are the same as found previously in thymocytes: full-length, blunt, 5'-phosphorylated signal ends, and covalently sealed (hairpin) coding ends. A complete signal sequence is required. Recombinant RAG1 protein greatly increases activity and complements an inactive extract from a RAG1 (-/-) pre-a cell line. When the extracts are fractionated, cleavage activity correlates with the presence of RAG2 protein. These results suggest that RAG1 and RAG2 are components of the V(D)J recombinase.			VANGENT, DC (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.			Ramsden, Dale/0000-0003-1575-4748; Sadofsky, Moshe/0000-0002-6893-629X				BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; CHEN YY, 1994, GENE DEV, V8, P688, DOI 10.1101/gad.8.6.688; CUOMO CA, 1994, NUCLEIC ACIDS RES, V22, P1810, DOI 10.1093/nar/22.10.1810; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GELLERT M, 1992, ANNU REV GENET, V22, P425; HARLOW E, 1988, ANTIBODIES LABORATOR; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCKEARN JP, 1985, EUR J IMMUNOL, V15, P295, DOI 10.1002/eji.1830150316; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SILVER DP, 1993, P NATL ACAD SCI USA, V90, P6100, DOI 10.1073/pnas.90.13.6100; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	27	253	256	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					925	934		10.1016/0092-8674(95)90012-8	http://dx.doi.org/10.1016/0092-8674(95)90012-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781069	Green Published, Bronze			2022-12-28	WOS:A1995RD76800013
J	DUCKETT, S				DUCKETT, S			OH, CALCUTTA	LANCET			English	Editorial Material									MONASH UNIV,FAC MED,DEPT PHYSIOL,MELBOURNE,VIC 3168,AUSTRALIA	Monash University									0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1493	1494						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769907				2022-12-28	WOS:A1995RC18900014
J	WYATT, J; BEARD, D; GRAY, A; BUSUTTIL, A; ROBERTSON, C				WYATT, J; BEARD, D; GRAY, A; BUSUTTIL, A; ROBERTSON, C			THE TIME OF DEATH AFTER TRAUMA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL EDINBURGH & ASSOCIATED HOSP,DIRECTORATE ACCID & EMERGENCY MED,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,FORENS MED UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh								ANDERSON ID, 1988, BRIT MED J, V296, P1305, DOI 10.1136/bmj.296.6632.1305; TRUNKEY DD, 1983, SCI AM, V249, P20; 1988, REPORT WORKING PARTY; 1994, EMERGENCY HEALTHCARE; 1992, HLTH NATION, P102	5	39	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1502	1502		10.1136/bmj.310.6993.1502	http://dx.doi.org/10.1136/bmj.310.6993.1502			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787598	Green Published			2022-12-28	WOS:A1995RD28500023
J	ROTHEN, HU; SPORRE, B; ENGBERG, G; WEGENIUS, G; REBER, A; HEDENSTIERNA, G				ROTHEN, HU; SPORRE, B; ENGBERG, G; WEGENIUS, G; REBER, A; HEDENSTIERNA, G			PREVENTION OF ATELECTASIS DURING GENERAL-ANESTHESIA	LANCET			English	Article							VENTILATION-PERFUSION RATIOS; CONTINUOUS DISTRIBUTIONS; ANESTHESIA; LUNG; HYPOXEMIA; O2	Atelectasis is an important cause of impaired gas exchange during general anaesthesia; it causes pulmonary shunting. We studied the effects of gas composition on the formation of atelectasis and on gas exchange during the induction of general anaesthesia. In 12 adult patients, the lungs were ventilated with 30% oxygen in nitrogen during anaesthesia induction, and in another 12, a conventional technique was used (100% oxygen during induction and 40% oxygen in nitrogen thereafter). Extent of atelectasis was estimated by computed tomography and the ventilation-perfusion relation (VA/Q) by the multiple inert gas elimination technique, After anaesthesia induction, there was little atelectasis in the 30% oxygen group (mean 0.2 [SD 0.4] cm(2)) and a significantly greater amount (4.2 [5.6] cm(2); p<0.001) in the 100% oxygen group. Patients in the 30% oxygen group were observed for another 40 min. 6 continued to receive 30% oxygen (subgroup A) and 6 were ventilated with 100% oxygen (subgroup B). During this time, the amount of atelectasis increased to 1.6 (1.6) cm(2) in subgroup A and to 4.7 (4.5) cm(2) in subgroup B (p=0.047 for difference between groups). In subgroup A, the shunt (VA/Q) <0.005) increased from 1.6 (2.0)% of cardiac output to 3.2 (2.7)%, but the arterial oxygen tension did not change. In subgroup B, the shunt increased from 2.6 (5.2)% to 9.8 (5.7)% of cardiac output. These results suggest that the composition of inspired gas is important in atelectasis formation during general anaesthesia. Use of a lower oxygen concentration than is now standard practice might prevent the early formation of atelectasis.	UNIV UPPSALA HOSP,DEPT CLIN PHYSIOL,S-75185 UPPSALA,SWEDEN; UNIV HOSP BERN,DEPT ANAESTHESIOL & INTENS CARE,BERN,SWITZERLAND; UNIV UPPSALA HOSP,DEPT ANAESTHESIOL & INTENS CARE,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT RADIOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital; University of Bern; University Hospital of Bern; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital			Rothen, Hans Ulrich/H-7100-2018					BAKER AB, 1993, BRIT J ANAESTH, V70, P259, DOI 10.1093/bja/70.3.259; BENDIXEN HH, 1963, NEW ENGL J MED, V269, P991, DOI 10.1056/NEJM196311072691901; BRISMAR B, 1985, ANESTHESIOLOGY, V62, P422, DOI 10.1097/00000542-198504000-00009; COTE CJ, 1988, ANESTHESIOLOGY, V68, P184, DOI 10.1097/00000542-198802000-00002; DAMGAARDPEDERSE.K, 1980, PEDIATR RADIOL, V9, P145; DANTZKER DR, 1975, J APPL PHYSIOL, V38, P886, DOI 10.1152/jappl.1975.38.5.886; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P118; DON HF, 1972, ANESTHESIOLOGY, V36, P533, DOI 10.1097/00000542-197206000-00003; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; GUNNARSSON L, 1991, BRIT J ANAESTH, V66, P423, DOI 10.1093/bja/66.4.423; JOYCE CJ, 1993, J APPL PHYSIOL, V74, P1107, DOI 10.1152/jappl.1993.74.3.1107; LUNDQUIST H, IN PRESS ACTA RADIOL; MARSHALL BE, 1972, ANESTHESIOLOGY, V37, P178, DOI 10.1097/00000542-197208000-00009; MARSHALL BE, 1994, INTENS CARE MED, V20, P291, DOI 10.1007/BF01708968; MOLLER JT, 1991, BRIT J ANAESTH, V66, P437, DOI 10.1093/bja/66.4.437; NUNN JF, 1978, BRIT J ANAESTH, V50, P91, DOI 10.1093/bja/50.2.91; PRYSROBERTS C, 1967, LANCET, V2, P399; REBER A, 1994, NOV P ANN M SWED MED, P219; ROTHEN HU, 1995, ANESTHESIOLOGY, V82, P832, DOI 10.1097/00000542-199504000-00004; ROTHEN HU, 1993, BRIT J ANAESTH, V71, P788, DOI 10.1093/bja/71.6.788; TOKICS L, 1988, J APPL PHYSIOL, V64, P599, DOI 10.1152/jappl.1988.64.2.599; WAGNER PD, 1974, J APPL PHYSIOL, V36, P588, DOI 10.1152/jappl.1974.36.5.588; WAGNER PD, 1974, J CLIN INVEST, V54, P54, DOI 10.1172/JCI107750; WAGNER PD, 1985, J APPL PHYSIOL, V59, P376, DOI 10.1152/jappl.1985.59.2.376; WAGNER PD, 1980, PULMONARY GAS EXCHAN, V1, P233; WEBB SJS, 1967, ANAESTHESIA, V22, P69, DOI 10.1111/j.1365-2044.1967.tb02696.x; WILLENKIN RL, 1994, ANESTHESIA, P1045; 1992, LANCET, V339, P31	28	243	257	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1387	1391		10.1016/S0140-6736(95)92595-3	http://dx.doi.org/10.1016/S0140-6736(95)92595-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760608				2022-12-28	WOS:A1995RB44100007
J	NOGALES, E; WOLF, SG; KHAN, IA; LUDUENA, RF; DOWNING, KH				NOGALES, E; WOLF, SG; KHAN, IA; LUDUENA, RF; DOWNING, KH			STRUCTURE OF TUBULIN AT 6.5 ANGSTROM AND LOCATION OF THE TAXOL-BINDING SITE	NATURE			English	Article							MICROTUBULE ASSEMBLY INVITRO; ZINC-INDUCED SHEETS; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; BETA-TUBULIN; GUANOSINE 5'-TRIPHOSPHATE; PURPLE MEMBRANE; LOW RESOLUTION; CROSS-LINKING; COLCHICINE	TUBULIN, the major component of microtubules, is a heterodimer of two chains, alpha and beta(1), both of relative molecular mass 50,000 (M(r) 50K) and sith 40-50% identity. The isotypic variety(2) and conformational flexibility of tubulin have so far made it impossible to obtain crystals for X-ray work(3). Structural knowledge of tubulin has been limited to about 20 Angstrom from X-ray diffraction of oriented microtubules(4), and from electron microscopy of microtubules and zinc-induced crystalline sheets in negative stain(5,6). The sheets consist of protofilaments similar to those in microtubules but associated in an antiparallel arrangement(7) and their two-dimensional character is ideal for high-resolution electron microscopy(8,9). Here we present a three-dimensional reconstruction of tubulin to 6.5 Angstrom resolution, obtained by electron crystallography of zinc-induced two-dimensional crystals of the protein, The alpha- and beta-subunits appear topologically similar, in agreement with their sequence homology(10). Several features can be defined in terms of secondary structure. An apparent alpha-helical portion, adjacent to both interdimer and inter-protofilament contacts, is tentatively attributed to a segment near the carboxy terminus of the protein. We can assign the alpha- and beta-subunits on the basis of projection studies of the binding of taxol*, which show one taxol site per tubulin heterodimer, in agreement with the known stoichiometry of taxol in microtubules(11). These studies indicate that taxol affects the interaction between protofilaments; to our knowledge, this is the first time that a ligand-binding site has been visualized in the tubulin molecule.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio	NOGALES, E (corresponding author), LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720, USA.		WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				AMOS LA, 1979, NATURE, V279, P607, DOI 10.1038/279607a0; AMOS LA, 1974, MICROTUBULES, P1; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BEESE L, 1987, J MOL BIOL, V194, P257, DOI 10.1016/0022-2836(87)90373-1; BURNS RG, 1993, MICROTUBULES, P3; CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; COMBEAU C, 1994, BIOCHEMISTRY-US, V33, P6676, DOI 10.1021/bi00187a038; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; DOWNING KH, 1991, SCIENCE, V251, P53, DOI 10.1126/science.1846047; DOWNING KH, 1992, J STRUCT BIOL, V109, P152, DOI 10.1016/1047-8477(92)90046-D; DOWNING KH, 1992, ULTRAMICROSCOPY, V46, P199, DOI 10.1016/0304-3991(92)90015-C; DYE RB, 1993, J BIOL CHEM, V288, P6847; FELLOUS A, 1977, EUR J BIOCHEM, V78, P167, DOI 10.1111/j.1432-1033.1977.tb11726.x; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; HEUSER JE, 1986, J CELL BIOL, V103, P2209, DOI 10.1083/jcb.103.6.2209; HOWARD WD, 1988, J BIOL CHEM, V263, P1342; KIRCHNER K, 1985, EMBO J, V4, P2397, DOI 10.1002/j.1460-2075.1985.tb03945.x; KUHLBRANDT W, 1991, NATURE, V350, P130, DOI 10.1038/350130a0; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; KUMAR N, 1981, J BIOL CHEM, V250, P10435; LOBERT S, 1991, ARCH BIOCHEM BIOPHYS, V290, P93, DOI 10.1016/0003-9861(91)90595-A; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; LUDUENA RF, 1993, MOL BIOL CELL, V44, P445; MANDELKOW E, 1977, P NATL ACAD SCI USA, V74, P3370, DOI 10.1073/pnas.74.8.3370; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MARGOLIS RL, 1980, BIOCHEMISTRY-US, V19, P5550, DOI 10.1021/bi00565a014; NOGALES E, IN PRESS J STRUCT BI; PALANIVELU P, 1982, J BIOL CHEM, V257, P6311; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; ROWINSKY EK, 1993, CANCER SURV, V17, P283; SACKETT DL, 1993, BIOCHEMISTRY-US, V32, P13560, DOI 10.1021/bi00212a023; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; TAMM LK, 1979, J MOL BIOL, V130, P473, DOI 10.1016/0022-2836(79)90435-2; TRACHTENBERG S, 1987, J MOL BIOL, V195, P581, DOI 10.1016/0022-2836(87)90184-7; WANG DN, 1991, J MOL BIOL, V217, P691, DOI 10.1016/0022-2836(91)90526-C; WOLF SG, 1994, J STRUCT BIOL, V111, P190	45	320	325	2	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					424	427		10.1038/375424a0	http://dx.doi.org/10.1038/375424a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760939				2022-12-28	WOS:A1995RB10100059
J	COIERA, E				COIERA, E			RECENT ADVANCES - MEDICAL INFORMATICS	BRITISH MEDICAL JOURNAL			English	Article							COMMUNICATION; ISSUE				COIERA, E (corresponding author), HEWLETT PACKARD CORP,RES LABS,FILTON RD,BRISTOL BS12 6QZ,AVON,ENGLAND.			Coiera, Enrico/0000-0002-6444-6584				ACKERMAN MJ, 1994, J AM MED INFORM ASSN, V1, P1; AHN WK, 1992, COGNITIVE SCI, V16, P81, DOI 10.1207/s15516709cog1601_3; AKELSEN S, 1993, TELEKTRONIKK, V89, P42; BOWLES RA, 1994, BT TECHNOL J, V12, P29; BRANGER PJ, 1992, BRIT MED J, V305, P1068, DOI 10.1136/bmj.305.6861.1068; BRENNAN F, 1994, J AM MED INFORMATICS, V1, P200; BUHLE EL, 1994, J AM MED INFORM ASSN, P103; CALMAN KC, 1994, CMOS UPDATE, V4, P1; CAMPBELL JR, 1994, J AM MED INFORM ASSN, P201; CIMINO JJ, 1994, J AM MED INFORM ASSN, P135; CIMINO JJ, 1994, J AM MED INFORM ASSN, V1, P296, DOI 10.1136/jamia.1994.95236160; CLANCEY WJ, 1993, ARTIF INTELL, V59, P197, DOI 10.1016/0004-3702(93)90186-F; CLANCEY WJ, 1993, ARTIF INTELL, V59, P191, DOI 10.1016/0004-3702(93)90185-E; COIERA E, 1992, ARTIF INTELL MED, V4, P431, DOI 10.1016/0933-3657(92)90011-D; COIERA E, 1994, HP79 LAB TECHN REP; COLERA E, 1994, KNOWLEDGE DECISIONS, P61; Constable J., 1994, British Journal of Healthcare Computing & Information Management, V11, P30; DURINCK J, 1994, KNOWLEDGE DECISIONS, P199; EVANS DA, 1994, J AM MED INFORM ASSN, V1, P207, DOI 10.1136/jamia.1994.95236153; FITZPATRICK K, 1993, PHYSICIAN ASSISS JUN, P87; FRIDSMA DB, 1994, J AM MED INFORM ASSN, P15; FRIEDMAN C, 1995, J AM MED INFORM ASSN, V2, P4, DOI 10.1136/jamia.1995.95202547; GLOWINSKI AJ, 1994, HLTH TELEMATICS CLIN; GLOWINSKI AJ, 1991, LECTURE NOTES MED IN, V44, P72; GOBLE CA, 1993, NINTH INTERNATIONAL CONFERENCE ON DATA ENGINEERING : PROCEEDINGS, P624; GOODLEE F, 1994, BRIT MED J, V309, P969; GREATBATCH D, 1993, INTERACT COMPUT, V5, P193, DOI 10.1016/0953-5438(93)90018-O; HEINSOHN J, 1994, ARTIF INTELL, V68, P367, DOI 10.1016/0004-3702(94)90071-X; Henry S B, 1993, Proc Annu Symp Comput Appl Med Care, P700; HOGARTH RM, 1986, IEEE T SYST MAN CYB, V16, P439, DOI 10.1109/TSMC.1986.4308976; Hunter L., 1993, ARTIFICIAL INTELLIGE; KERAVNOU ET, 1992, DEEP MODELS MED KNOW; KLINE TJ, 1992, RADIOLOGY, V184, P131, DOI 10.1148/radiology.184.1.1609068; LAPORTE RE, 1995, BRIT MED J, V310, P545, DOI 10.1136/bmj.310.6979.545; LEIRER VO, 1991, GERONTOLOGIST, V31, P514, DOI 10.1093/geront/31.4.514; Little AD., 1992, TELECOMMUNICATIONS C; LITTLEWOOD B, 1987, SOFTWARE RELIABILITY; MA HY, 1995, INT J BIOMED COMPUT, V38, P9, DOI 10.1016/0020-7101(94)01029-Z; McCarthy J. C., 1994, Collaborative Computing, V1, P35; MILLER RA, 1994, J AM MED INFORM ASSN, V1, P8, DOI 10.1136/jamia.1994.95236141; MORRIS AH, 1994, J AM MED INFORM ASSN, P501; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MULROW CD, 1994, BRIT MED J, V309, P597, DOI 10.1136/bmj.309.6954.597; NORMAN DA, 1993, COGNITIVE SCI, V17, P1, DOI 10.1207/s15516709cog1701_1; NOWLAN WA, 1994, J AM MED INFORM ASSN, P150; Nymo B. J., 1993, Telektronikk, V89, P4; ONEIL M, 1995, METHOD INFORM MED, V34, P187; RAO JN, 1994, BRIT MED J, V309, P1527, DOI 10.1136/bmj.309.6968.1527; Renaud-Salis J. L., 1994, Knowledge and decisions in health telematics The next decade, P139; Rosch E., 1988, READINGS COGNITIVE S, P312, DOI [10.1016/B978-1-4832-1446-7.50028-5, DOI 10.1016/B978-1-4832-1446-7.50028-5]; ROTHWELL DJ, 1995, METHOD INFORM MED, V34, P209; STOUPA R, 1990, P S COMPUTER APPLICA, P890; Thomsen G E, 1993, Proc Annu Symp Comput Appl Med Care, P339; TUTTLE MS, 1994, J AM MED INFORM ASSN, V1, P298, DOI 10.1136/jamia.1994.95236161; TUTTLE S, 1994, INT J BIOMED COMPUT, V34, P207; van der Lei J., 1994, Knowledge and decisions in health telematics The next decade, P67; Wyatt J., 1994, Knowledge and decisions in health telematics The next decade, P73; WYATT J, 1987, LECTURE NOTES MED IN, V33, P15; [No title captured]; 1995, NHSCCC F6110 REP	60	56	56	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1381	1387		10.1136/bmj.310.6991.1381	http://dx.doi.org/10.1136/bmj.310.6991.1381			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787545	Green Published			2022-12-28	WOS:A1995RB00500030
J	DODD, J; SCHUCHARDT, A				DODD, J; SCHUCHARDT, A			AXON GUIDANCE - A COMPELLING CASE FOR REPELLING GROWTH	CELL			English	Review							CONE GUIDANCE; COLLAPSE; BRAIN		COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University	DODD, J (corresponding author), COLUMBIA UNIV,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032, USA.							BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GUTHRIE S, 1995, IN PRESS NEURON, V14; HEDGECOCK EM, 1990, NEURON, V2, P61; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Keynes Roger J., 1995, Current Opinion in Neurobiology, V5, P75, DOI 10.1016/0959-4388(95)80090-5; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LUO Y, 1995, IN PRESS NEURON; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATTHES DJ, 1995, CELL, V81, P631, DOI 10.1016/0092-8674(95)90084-5; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHIRASAKI R, 1995, NEURON, V14, P961, DOI 10.1016/0896-6273(95)90334-8; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; TAMADA A, 1995, NEURON, V14, P1083, DOI 10.1016/0896-6273(95)90347-X; WALTER J, 1987, DEVELOPMENT, V101, P909; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T	25	95	99	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					471	474		10.1016/0092-8674(95)90066-7	http://dx.doi.org/10.1016/0092-8674(95)90066-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758101	Bronze			2022-12-28	WOS:A1995QZ71000002
J	CRICK, F; KOCH, C				CRICK, F; KOCH, C			ARE WE AWARE OF NEURAL ACTIVITY IN PRIMARY VISUAL-CORTEX	NATURE			English	Article							SELECTIVE CELLS; MACAQUE; MONKEY; ORGANIZATION; CAT	It is usually assumed that people are visually aware of at least some of the neuronal activity in the primary visual area, V1, of the neocortex. But the neuroanatomy of the macaque monkey suggests that, although primates may be aware of neural activity in other visual cortical areas, they are not directly aware of that in area V1. There is some psychophysical evidence in humans that supports this hypothesis.	CALTECH, COMPUTAT & NEURAL SYST PROGRAM, PASADENA, CA 91125 USA	California Institute of Technology	CRICK, F (corresponding author), SALK INST BIOL STUDIES, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Koch, Christof/0000-0001-6482-8067				Barbas H, 1992, Adv Neurol, V57, P91; BARBUR JL, 1993, BRAIN, V116, P1293, DOI 10.1093/brain/116.6.1293; BIRBAUMER N, 1990, PHYSIOL REV, V70, P1, DOI 10.1152/physrev.1990.70.1.1; BLACKWELL KT, 1988, J OPT SOC AM A, V5, P1772, DOI 10.1364/JOSAA.5.001772; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; COWEY A, 1995, NATURE, V373, P247, DOI 10.1038/373247a0; COWEY A, 1991, TRENDS NEUROSCI, V14, P140, DOI 10.1016/0166-2236(91)90085-9; Crick F., 1990, Seminars in the Neurosciences, V2, P263; CRICK F, 1993, NATURE, V361, P109, DOI 10.1038/361109a0; CRICK F, 1992, SCI AM, V267, P153, DOI 10.1038/scientificamerican0992-152; Crick F., 1994, ASTONISHING HYPOTHES; DESIMONE R, 1991, J COGNITIVE NEUROSCI, V3, P1, DOI 10.1162/jocn.1991.3.1.1; DEVALOIS RL, 1982, VISION RES, V22, P545, DOI 10.1016/0042-6989(82)90113-4; ECCLES JC, 1986, PROC R SOC SER B-BIO, V227, P411, DOI 10.1098/rspb.1986.0031; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FRIES W, 1990, VISUAL NEUROSCI, V4, P205, DOI 10.1017/S0952523800003357; Fuster J M, 1993, Curr Opin Neurobiol, V3, P160, DOI 10.1016/0959-4388(93)90204-C; FUSTERJM, 1989, PREFRONTAL CORTEX; GERFEN CR, 1994, MOTOR COGNITIVE FUNC, P78; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; KOCH C, 1994, LARGE SCALE NEURONAL, P93; LAND EH, 1971, J OPT SOC AM, V61, P1, DOI 10.1364/JOSA.61.000001; LEVITT JB, 1994, J NEUROPHYSIOL, V71, P2517, DOI 10.1152/jn.1994.71.6.2517; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; MYERSON J, 1981, BEHAV ANAL LETT, V1, P149; PICKERSGILL MJ, 1961, Q J EXP PSYCHOL, V13, P168, DOI 10.1080/17470216108416489; ROBINSON DL, 1992, TRENDS NEUROSCI, V15, P127, DOI 10.1016/0166-2236(92)90354-B; ROLAND PE, 1994, TRENDS NEUROSCI, V17, P281, DOI 10.1016/0166-2236(94)90057-4; SAINTCYR JA, 1990, J COMP NEUROL, V298, P129, DOI 10.1002/cne.902980202; SCHEIN SJ, 1990, J NEUROSCI, V10, P3369; Sherk H., 1986, CEREB CORTEX, P467, DOI DOI 10.1007/978-1-4613-2149-1_13; SPARKS DL, 1986, PHYSIOL REV, V66, P118, DOI 10.1152/physrev.1986.66.1.118; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; UNGERLEIDER LG, 1984, J COMP NEUROL, V223, P368, DOI 10.1002/cne.902230304; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; YOUNG MP, 1992, NATURE, V358, P152, DOI 10.1038/358152a0; ZEKI S, 1983, PROC R SOC SER B-BIO, V217, P449, DOI 10.1098/rspb.1983.0020; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0; ZEKI S, 1980, NATURE, V284, P412, DOI 10.1038/284412a0	43	580	599	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 11	1995	375	6527					121	123		10.1038/375121a0	http://dx.doi.org/10.1038/375121a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753166				2022-12-28	WOS:A1995QX74100042
J	HALL, FM				HALL, FM			ECHINOCOCCAL CYST OF THE PERICARDIUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											HALL, FM (corresponding author), BETH ISRAEL HOSP,BOSTON,MA 02215, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					165	165		10.1056/NEJM199507203330306	http://dx.doi.org/10.1056/NEJM199507203330306			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791819				2022-12-28	WOS:A1995RK91700006
J	GLOWNIAK, JV				GLOWNIAK, JV			MEDICAL RESOURCES ON THE INTERNET	ANNALS OF INTERNAL MEDICINE			English	Article								Advances in telecommunications technology in the last decade have fostered the development of computer networks that allow access to vast-amounts of information and services. Of the many computer networks that have been developed, the most prominent is the Internet. Originally intended to be a way to share computing resources among academic and research institutions in the United States, the Internet has gradually evolved into a worldwide network of computers that provides various services reflecting the eclectic nature of its component networks. The recent upsurge in interest in the Internet is due to several mutually reinforcing factors: increased ease and availability of access to the Internet, lower access charges, faster communications, and more organizations offering commercial and noncommercial services over the Internet. Of particular interest to the medical community is the large and increasing number of technical, scientific, and biomedical resources that can be accessed through the Internet, Most large medical centers have publicly accessible information, and some large organizations, such as the National Institutes of Health, have extensive databases and services that can be used by medical researchers, clinicians, and educators. In addition, many medical organizations and some medical journals are advertising their services over the Internet and can be contacted through electronic mail. As the cost of telecommunications decreases and the speed of telecommunications increases, new farms of computer communication, such as long-distance, real-time audio, and video services will become available. Computer networks in general and the Internet in particular are likely to play more important roles in many aspects of medicine in the future.			GLOWNIAK, JV (corresponding author), VET ADM MED CTR, POB 1034, PORTLAND, OR 97207 USA.							BRANWYN G, 1994, MOSAIC QUICK TOUR WI; BRANWYN G, 1994, MOSAIC QUICK TOUR MA; BROWNE S, 1994, INTERNET VIA MOSAIC; CATLETT CE, 1993, INTERNET SYSTEM HDB, P717; CHESWICK WR, 1994, FIREWALLS INTERNET S, P11; GILSTER P, 1994, FINDING IT INTERNET; GLOWNIAK JV, 1994, JAMA-J AM MED ASSOC, V271, P1934, DOI 10.1001/jama.271.24.1934; GLOWNIAK JV, 1995, IN PRESS J NUCL MED; GORE A, 1991, SCI AM, V265, P150; HAHN H, 1994, INTERNET YELLOW PAGE; KEHOE BP, 1994, ZEN ART INTERNET BEG; Krol E, 1994, WHOLE INTERNET USERS; LANDLER M, 1995, NY TIMES        1023, pC1; LAWLER A, 1995, SCIENCE, V267, P1584, DOI 10.1126/science.267.5204.1584; LYNCH DC, 1993, INTERNET SYSTEM HDB, P3; MAXWELL C, 1994, NEW RIDERS OFFICIAL; SCHATZ BR, 1994, SCIENCE, V265, P895, DOI 10.1126/science.265.5174.895	17	110	110	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					123	131		10.7326/0003-4819-123-2-199507150-00008	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778825				2022-12-28	WOS:A1995RM43500008
J	ALBERTSEN, P; DALEY, J				ALBERTSEN, P; DALEY, J			A 72-YEAR-OLD MAN WITH LOCALIZED PROSTATE-CANCER - DISCUSSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							ANTIGEN; VOLUME; ADENOCARCINOMA; MEN; CARCINOMA; DISEASE; STAGE		UNIV CONNECTICUT,CTR HLTH,DIV UROL,FARMINGTON,CT	University of Connecticut								Albertsen P, 1995, Contemp Urol, V7, P54; ALBERTSEN PC, IN PRESS JAMA; BAGSHAW MA, 1994, J UROLOGY, V152, P1781, DOI 10.1016/S0022-5347(17)32385-6; BORING CC, 1994, CHEM ABSTR, V44, P1; Byar D P, 1988, NCI Monogr, P165; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1989, J UROLOGY, V142, P1302, DOI 10.1016/S0022-5347(17)39066-3; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHYBOWSKI FM, 1991, J UROLOGY, V145, P313, DOI 10.1016/S0022-5347(17)38325-8; EPSTEIN JI, 1974, JAMA-J AM MED ASSOC, V271, P368; Fleming C, 1993, JAMA, V269, P2650; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; GLEASON DF, 1992, HUM PATHOL, V23, P273, DOI 10.1016/0046-8177(92)90108-F; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; HAMPER UM, 1991, RADIOLOGY, V180, P101, DOI 10.1148/radiology.180.1.2052673; HANKS GE, 1994, J UROLOGY, V152, P1775, DOI 10.1016/S0022-5347(17)32384-4; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KRAMOLOWSKY EV, 1988, J UROLOGY, V139, P1242, DOI 10.1016/S0022-5347(17)42879-5; KUBAN DA, 1989, CANCER, V63, P2415, DOI 10.1002/1097-0142(19890615)63:12<2415::AID-CNCR2820631207>3.0.CO;2-U; LAWTON CA, 1991, INT J RADIAT ONCOL, V21, P935, DOI 10.1016/0360-3016(91)90732-J; LITWIN MS, 1995, JAMA-J AM MED ASSOC, V273, P129, DOI 10.1001/jama.273.2.129; MCLEOD DG, 1992, CANCER-AM CANCER SOC, V70, P324, DOI 10.1002/1097-0142(19920701)70:1+<324::AID-CNCR2820701321>3.0.CO;2-G; MCNEAL JE, 1992, HUM PATHOL, V23, P258, DOI 10.1016/0046-8177(92)90106-D; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; ONIK GM, 1993, CANCER, V72, P1291, DOI 10.1002/1097-0142(19930815)72:4<1291::AID-CNCR2820720423>3.0.CO;2-I; PARTIN AW, 1993, J UROLOGY, V150, P110, DOI 10.1016/S0022-5347(17)35410-1; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; RIFKIN MD, 1990, NEW ENGL J MED, V323, P621, DOI 10.1056/NEJM199009063231001; SCARDINO PT, 1989, UROL CLIN N AM, V16, P635; SCHMID HP, 1993, CANCER-AM CANCER SOC, V71, P2031, DOI 10.1002/1097-0142(19930315)71:6<2031::AID-CNCR2820710618>3.0.CO;2-Q; SHIPLEY WU, 1994, J UROLOGY, V152, P1799, DOI 10.1016/S0022-5347(17)32388-1; STAMEY TA, 1993, CANCER, V71, P933, DOI 10.1002/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L; TERRIS MK, 1992, J UROLOGY, V147, P855, DOI 10.1016/S0022-5347(17)37405-0; VANAUBEL OGJM, 1985, J UROLOGY, V134, P292, DOI 10.1016/S0022-5347(17)47128-X; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITMORE WF, 1990, CANCER-AM CANCER SOC, V65, P667, DOI 10.1002/1097-0142(19900201)65:3+<667::AID-CNCR2820651309>3.0.CO;2-C; WILT TJ, 1994, J UROLOGY, V152, P1910, DOI 10.1016/S0022-5347(17)32413-8; 1991, 1991 ABRIDGED LIFE T	39	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					69	74		10.1001/jama.274.1.69	http://dx.doi.org/10.1001/jama.274.1.69			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791261				2022-12-28	WOS:A1995RG23300033
J	LEAPE, LL; BATES, DW; CULLEN, DJ; COOPER, J; DEMONACO, HJ; GALLIVAN, T; HALLISEY, R; IVES, J; LAIRD, N; LAFFEL, G; NEMESKAL, R; PETERSEN, LA; PORTER, K; SERVI, D; SHEA, BF; SMALL, SD; SWEITZER, BJ; THOMPSON, BT; VANDERVLIET, M				LEAPE, LL; BATES, DW; CULLEN, DJ; COOPER, J; DEMONACO, HJ; GALLIVAN, T; HALLISEY, R; IVES, J; LAIRD, N; LAFFEL, G; NEMESKAL, R; PETERSEN, LA; PORTER, K; SERVI, D; SHEA, BF; SMALL, SD; SWEITZER, BJ; THOMPSON, BT; VANDERVLIET, M			SYSTEMS-ANALYSIS OF ADVERSE DRUG EVENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTION; FAILURES; COMPUTER; ERRORS	Objective.-To identify and evaluate the systems failures that underlie errors causing adverse drug events (ADEs) and potential ADEs. Design.-Systems analysis of events from a prospective cohort study. Participants.-All admissions to 11 medical and surgical units in two tertiary care hospitals over a 6-month period. Main Outcome Measures.-Errors, proximal causes, and systems failures. Methods.-Errors were detected by interviews of those involved. Errors were classified according to proximal cause and underlying systems failure by multidisciplinary teams of physicians, nurses, pharmacists, and systems analysts. Results.-During this period, 334 errors were detected as the causes of 264 preventable ADEs and potential ADEs. Sixteen major systems failures were identified as the underlying causes of the errors. The most common systems failure was in the dissemination of drug knowledge, particularly to physicians, accounting for 29% of the 334 errors. Inadequate availability of patient information, such as the results of laboratory tests, was associated with 18% of errors. Seven systems failures accounted for 78% of the errors; all could be improved by better information systems. Conclusions.-Hospital personnel willingly participated in the detection and investigation of drug use errors and were able to identify underlying systems failures. The most common defects were in systems to disseminate knowledge about drugs and to make drug and patient information readily accessible at the time it is needed. Systems changes to improve dissemination and display of drug and patient data should make errors in the use of drugs less likely.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PHARM, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT NURSING, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PHARM, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; APM INC, NEW YORK, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	LEAPE, LL (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.				AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ackoff R.L., 1974, REDESIGNING FUTURE; ALLNUTT MF, 1987, BRIT J ANAESTH, V59, P856, DOI 10.1093/bja/59.7.856; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bates D W, 1994, Qual Manag Health Care, V2, P18; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bertalanffy Ludwig, 1968, GEN SYSTEM THEORY; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Cook RI, 1994, HUMAN ERROR MED; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; Deming EW., 1986, OUT CRISIS; FOLLI HL, 1987, PEDIATRICS, V79, P718; Gaba D, 1994, HUMAN ERROR MED; GABA DM, 1987, ANESTHESIOLOGY, V66, P670, DOI 10.1097/00000542-198705000-00013; LANGLEY GJ, 1992, F IMPROVEMENT; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; Moray N, 1994, HUMAN ERROR MED; Norman D., 1988, PSYCHOL EVERYDAY THI; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Rasmussen J., 1994, COGNITIVE SYSTEMS EN; REASON J, 1990, PHILOS T ROY SOC B, V327, P475, DOI 10.1098/rstb.1990.0090; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; VANCOTT H, 1994, HUMAN ERROR MED; 1980, MED MALPRACTICE CLOS	31	1354	1409	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					35	43		10.1001/jama.1995.03530010049034	http://dx.doi.org/10.1001/jama.1995.03530010049034			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791256				2022-12-28	WOS:A1995RG23300028
J	BAIN, J; SCOTT, R; SNADDEN, D				BAIN, J; SCOTT, R; SNADDEN, D			INTEGRATING UNDERGRADUATE AND POSTGRADUATE EDUCATION IN GENERAL-PRACTICE - EXPERIENCE IN TAYSIDE	BRITISH MEDICAL JOURNAL			English	Article							MANAGING CHANGE; PRIMARY CARE	Several forces have resulted in the creation in Tayside of the first formally integrated unit of undergraduate and postgraduate education in general practice in the United Kingdom. Forces that helped this integration included the desire for change, national developments in education, financial support through funds set aside to cover the additional cost of teaching, and a management structure which concentrates on shared leadership. Forces that hindered the integration included uneasiness about ideas for reforming traditional structures, institutional inertia, the complexity of financial arrangements, and tensions over priorities. The experience of managing institutional changes in Tayside has been invaluable and will lead to a more cohesive approach to undergraduate teaching, postgraduate training, and the provision of services relevant to the development of general practice.			BAIN, J (corresponding author), WESTGATE HLTH CTR,TAYSIDE CTR GEN PRACTICE,DUNDEE DD2 1AU,SCOTLAND.		Snadden, David/ABF-1586-2020	Snadden, David/0000-0002-4818-1184				ALLAN J, 1993, BRIT MED J, V307, P719; ATKINSON C, 1992, BRIT MED J, V304, P1488, DOI 10.1136/bmj.304.6840.1488; DOWNIE RS, 1992, MAKING DOCTOR; HORDER J, 1984, BRIT MED J, V289, P1117, DOI 10.1136/bmj.289.6452.1117; HOWIE J, 1986, GENERAL PRACTICE MED; Lowry S., 1993, MED ED; MARINKER M, 1983, BRIT MED J, V286, P855, DOI 10.1136/bmj.286.6368.855; METCALFE D, 1992, BRIT MED J, V305, P33, DOI 10.1136/bmj.305.6844.33; RASHID A, 1994, BRIT MED J, V309, P1270, DOI 10.1136/bmj.309.6964.1270; REID M, 1982, SYMB INTERACT, V5, P325; RICHARDSON IM, 1975, BMJ-BRIT MED J, V4, P740, DOI 10.1136/bmj.4.5999.740; Todd Report, 1968, CMND3569; 1992, ACCREDITATION REGION; 1993, RECOMMENDATIONS UNDE	14	5	6	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1577	1579		10.1136/bmj.310.6994.1577	http://dx.doi.org/10.1136/bmj.310.6994.1577			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787650	Green Published			2022-12-28	WOS:A1995RE35300025
J	DUBOIS, RM				DUBOIS, RM			RECENT ADVANCES - RESPIRATORY MEDICINE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CYSTIC-FIBROSIS; ASTHMA				DUBOIS, RM (corresponding author), ROYAL BROMPTON HOSP, LONDON SW3 6NP, ENGLAND.							ANTO JM, 1993, NEW ENGL J MED, V329, P1760, DOI 10.1056/NEJM199312093292402; ANZUETO A, 1994, AM J RESP CRIT CARE, V149, pA567; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; BLUMENTHAL M, 1992, J IMMUNOL, V148, P411; BOUCHER RC, 1994, HUM GENE THER, V5, P615, DOI 10.1089/hum.1994.5.5-615; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CRYSTAL RG, 1995, NAT MED, V1, P15, DOI 10.1038/nm0195-15; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; DAVIS PB, 1994, NEW ENGL J MED, V331, P672, DOI 10.1056/NEJM199409083311011; FISHER CJ, 1994, CRIT CARE MED, V22, P12, DOI 10.1097/00003246-199401000-00008; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; HANSELL DM, 1994, THORAX, V49, P385, DOI 10.1136/thx.49.4.385-c; HANSELL DM, 1994, RADIOLOGY, V193, P369, DOI 10.1148/radiology.193.2.7972745; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LEE KS, 1994, RADIOLOGY, V191, P669, DOI 10.1148/radiology.191.3.8184044; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; PARANJPE DV, 1994, AM J ROENTGENOL, V162, P561, DOI 10.2214/ajr.162.3.8109496; RANASINHA C, 1993, LANCET, V342, P199, DOI 10.1016/0140-6736(93)92297-7; REMYJARDIN M, 1994, RADIOLOGY, V191, P675, DOI 10.1148/radiology.191.3.8184045; REMYJARDIN M, 1994, RADIOLOGY, V193, P375, DOI 10.1148/radiology.193.2.7972746; ROSENFELD MA, 1994, HUM GENE THER, V5, P331, DOI 10.1089/hum.1994.5.3-331; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; TAYLOR AJN, 1995, LANCET, V346, P129; WELLS AU, 1994, EUR RESPIR J, V7, P637, DOI 10.1183/09031936.94.07040637; WELSH MJ, 1994, HUM GENE THER, V5, P209, DOI 10.1089/hum.1994.5.2-209; WILSON JM, 1994, HUM GENE THER, V5, P501, DOI 10.1089/hum.1994.5.4-501; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YEI SP, 1994, GENE THER, V1, P192; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219, DOI 10.1164/ajrccm.151.1.7812558; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585; 1994, HOSPITAL ADMISSIONS	35	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 17	1995	310	6994					1594	1597		10.1136/bmj.310.6994.1594	http://dx.doi.org/10.1136/bmj.310.6994.1594			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787657	Green Published			2022-12-28	WOS:A1995RE35300032
J	ZHAO, K; HART, CM; LAEMMLI, UK				ZHAO, K; HART, CM; LAEMMLI, UK			VISUALIZATION OF CHROMOSOMAL DOMAINS WITH BOUNDARY ELEMENT-ASSOCIATED FACTOR BEAF-32	CELL			English	Article							SCAFFOLD-ATTACHED REGIONS; PROTEIN-DNA INTERACTIONS; BETA-GLOBIN GENE; DROSOPHILA-MELANOGASTER; RNA-POLYMERASE; HEAT-SHOCK; REGULATORY SEQUENCES; IN-VIVO; EXPRESSION; CELLS	We have purified two proteins from Drosophila that bind to the scs' boundary element of the hsp70 domain at locus 87A7. Their palindromic binding sites (CGATA-TATCG) symmetrically abut the previously mapped hypersensitive site of scs'. We have cloned a cDNA for one of these proteins, BEAF-32 (boundary element-associated factor of 32 kDa). It encodes a novel protein that is bound to scs' but not scs in vivo. Immunostaining localizes BEAF to hundreds of interbands and many puff boundaries on polytene chromosomes, suggesting that a chromosomal domain consists of a band (or puff) and part of the flanking interbands. Enhancer blocking assays implicate the palindromic binding site in boundary function. The lack of enhancer blocking in transiently transfected cells suggests an involvement of chromatin, nuclear structure, or both in boundary function.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA,SWITZERLAND	University of Geneva	ZHAO, K (corresponding author), UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA,SWITZERLAND.		Hart, Craig/B-4832-2016	Hart, Craig/0000-0002-9870-991X; Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ASHBURNER M, 1989, DROSOPHILA LABORATOR, P51; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DIXON WJ, 1991, METHOD ENZYMOL, V208, P380; DUBENDORFER A, 1986, INSECT BIOCHEM, V16, P645, DOI 10.1016/0020-1790(86)90007-7; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; FARKAS G, 1992, NUCLEIC ACIDS RES, V20, P2604, DOI 10.1093/nar/20.10.2604; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HELLER RA, 1986, J BIOL CHEM, V261, P8063; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; JAMRICH M, 1977, P NATL ACAD SCI USA, V74, P2079, DOI 10.1073/pnas.74.5.2079; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; RIDDIHOUGH G, 1986, EMBO J, V5, P1653, DOI 10.1002/j.1460-2075.1986.tb04408.x; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; RYKOWSKI MC, 1988, CELL, V54, P461, DOI 10.1016/0092-8674(88)90067-0; Sambrook J, 1989, MOL CLONING LABORATO; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TTSUKIYAMA T, 1994, NATURE, V367, P525; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; VAZQUEZ J, 1994, EMBO J, V13, P5984, DOI 10.1002/j.1460-2075.1994.tb06944.x; VAZQUEZ J, 1993, COLD SPRING HARB SYM, V58, P45, DOI 10.1101/SQB.1993.058.01.008; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365	44	267	277	0	10	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					879	889		10.1016/0092-8674(95)90008-X	http://dx.doi.org/10.1016/0092-8674(95)90008-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781065	Bronze, Green Published			2022-12-28	WOS:A1995RD76800009
J	MULROW, CD; WILLIAMS, JW; GERETY, MB; RAMIREZ, G; MONTIEL, OM; KERBER, C				MULROW, CD; WILLIAMS, JW; GERETY, MB; RAMIREZ, G; MONTIEL, OM; KERBER, C			CASE-FINDING INSTRUMENTS FOR DEPRESSION IN PRIMARY-CARE SETTINGS	ANNALS OF INTERNAL MEDICINE			English	Article						DEPRESSION; PRIMARY HEALTH CARE; MASS SCREENING; PHYSICIANS, FAMILY; SENSITIVITY AND SPECIFICITY	DIAGNOSTIC INTERVIEW SCHEDULE; GENERAL HEALTH QUESTIONNAIRE; PRIMARY MEDICAL-CARE; MENTAL-ILLNESS; RECOGNITION; PHYSICIANS; PREVALENCE; MANAGEMENT; DISORDERS; ANXIETY	Objective: To evaluate the usefulness of case-finding instruments for identifying patients with major depression in primary care settings. Data Sources: A MEDLINE search of the English-language medical literature; bibliographies of selected papers; and experts. Study Selection: Studies that were done in primary care settings with unselected patients and that compared case-finding instruments with accepted diagnostic criterion standards for major depression were selected. Data Synthesis: 9 case-finding instruments were assessed in 18 studies. More than 15000 patients received screening with a case-finding instrument; approximately 5300 of these received criterion standard assessment. Case-finding instruments ranged in length from 2 to 28 questions. Average administration times ranged from less than 2 minutes to 6 minutes. Sensitivities and specificities for detecting major depression ranged from 67% to 99% and from 40% to 95%, respectively. No significant differences between instruments were found. Overall sensitivity was 84% (95% CI, 79% to 89%); overall specificity was 72% (CI, 67% to 77%). If a case-finding instrument were administered to 100 primary care patients with a 5% prevalence of major depression, the clinician could expect that 31 patients would screen positive, that 4 of the 31 would have major depression, and that 1 patient with major depression would not be identified. Conclusions: Several instruments with reasonable operating characteristics are available to help primary care clinicians identify patients with major depression. Because the operating characteristics of these instruments are similar, selection of a particular instrument should depend on issues such as feasibility, administration and scoring times, and the instruments' ability to serve additional purposes, such as monitoring severity or response to therapy.			MULROW, CD (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR, 11C6, 7400 MERTON MINTER BLVD, SAN ANTONIO, TX 78284 USA.		Williams, John W/A-3696-2008; Williams, John/AAM-4572-2020	Williams, John W/0000-0002-5267-5558; Williams, John/0000-0002-5267-5558				[Anonymous], 1989, GUIDE CLIN PREVENTIV; ATTKISSON CC, 1990, DEPRESSION PRIMARY C; BARKER LR, 1986, PRINCIPLES AMBULATOR; BARON JA, 1989, J CLIN EPIDEMIOL, V42, P1013, DOI 10.1016/0895-4356(89)90167-4; BARRETT JE, 1988, ARCH GEN PSYCHIAT, V45, P1100; BEGG CB, 1983, BIOMETRICS, V39, P207, DOI 10.2307/2530820; BOYKO EJ, 1990, J CLIN EPIDEMIOL, V43, P851, DOI 10.1016/0895-4356(90)90068-Z; Broadhead W E, 1995, Arch Fam Med, V4, P211, DOI 10.1001/archfami.4.3.211; BRODY DS, 1990, ARCH INTERN MED, V150, P993, DOI 10.1001/archinte.150.5.993; BURNAM MA, 1988, MED CARE, V26, P775, DOI 10.1097/00005650-198808000-00004; CALLAHAN CM, 1994, J AM GERIATR SOC, V42, P840; COULEHAN JL, 1989, J GEN INTERN MED, V4, P541, DOI 10.1007/BF02599556; COYNE JC, 1995, GEN HOSP PSYCHIAT, V17, P3, DOI 10.1016/0163-8343(94)00056-J; CRUM RM, 1994, PSYCHOSOM MED, V56, P109, DOI 10.1097/00006842-199403000-00006; FECHNERBATES S, 1994, J CONSULT CLIN PSYCH, V62, P550, DOI 10.1037/0022-006X.62.3.550; FEIGHTNER JW, 1990, CAN MED ASSOC J, V142, P1215; FINLAYJONES RA, 1979, BRIT J PSYCHIAT, V134, P609, DOI 10.1192/bjp.134.6.609; Fleiss JL, 1981, STAT METHODS RATES P; GERBER P D, 1989, Journal of General Internal Medicine, V4, P7, DOI 10.1007/BF02596483; GERETY MB, 1994, J AM GERIATR SOC, V42, P1103, DOI 10.1111/j.1532-5415.1994.tb06217.x; GOLDBERG DP, 1970, BMJ-BRIT MED J, V2, P439, DOI 10.1136/bmj.2.5707.439; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; GREENES RA, 1985, INVEST RADIOL, V20, P751, DOI 10.1097/00004424-198510000-00018; Hedges L, 1985, STATISTICAL METHODS; HENDRIE HC, 1995, AM J GERIAT PSYCHIAT, V3, P119, DOI 10.1097/00019442-199500320-00004; HINTON WL, 1994, J GEN INTERN MED, V9, P202, DOI 10.1007/BF02600124; HOEPER EW, 1979, INT J MENT HEALTH, V8, P6, DOI 10.1080/00207411.1979.11448829; HOEPER EW, 1984, LANCET, V1, P33; HOUGH R, 1983, COMP PSYCHIATRIC SCR; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JOHNSTONE A, 1976, LANCET, V1, P605, DOI 10.1016/S0140-6736(76)90415-3; KATON W, 1986, WESTERN J MED, V144, P564; KATON W, 1988, CLIN CHEM, V34, P829; KESSLER RC, 1994, LIFETIME 12 MONTH PR, V51, P8; KIRMAYER LJ, 1993, AM J PSYCHIAT, V150, P734; KRAEMER HC, 1992, EVALUATING MED TESTS; Leserman J., 1993, DRUG INF J, V27, P537; LINN LS, 1980, J MED EDUC, V55, P942; MAGRUDERHABIB K, 1990, MED CARE, V28, P239, DOI 10.1097/00005650-199003000-00004; MAGRUDERHABIB K, 1989, GEN HOSP PSYCHIAT, V11, P201, DOI 10.1016/0163-8343(89)90042-X; MOORE JT, 1978, J FAM PRACTICE, V7, P509; OKIMOTO JT, 1982, AM J PSYCHIAT, V139, P799; ORMEL J, 1991, ARCH GEN PSYCHIAT, V48, P700; PEREZSTABLE EJ, 1990, ARCH INTERN MED, V150, P1083, DOI 10.1001/archinte.150.5.1083; RAFT D, 1977, DIS NERV SYST, V38, P999; RAND EH, 1988, GEN HOSP PSYCHIAT, V10, P189, DOI 10.1016/0163-8343(88)90018-7; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; RING JM, 1991, AM J ORTHOPSYCHIAT, V61, P298, DOI 10.1037/h0079242; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; RUCKER L, 1986, ARCH INTERN MED, V146, P729, DOI 10.1001/archinte.146.4.729; SCHULBERG HC, 1985, ARCH GEN PSYCHIAT, V42, P1164; SCHURMAN RA, 1985, ARCH GEN PSYCHIAT, V42, P89; SHAPIRO S, 1987, MED CARE, V25, P327, DOI 10.1097/00005650-198704000-00006; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Streiff L D, 1986, Image J Nurs Sch, V18, P48, DOI 10.1111/j.1547-5069.1986.tb00542.x; VONKORFF M, 1987, ARCH GEN PSYCHIAT, V44, P152; WILLIAMS JW, 1995, J GEN INTERN MED, V10, P7, DOI 10.1007/BF02599568; ZICH JM, 1990, INT J PSYCHIAT MED, V20, P259, DOI 10.2190/LYKR-7VHP-YJEM-MKM2; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P365; 1993, AGE CHARTS PERIODIC; 1990, CAN MED ASSOC J, V142, P1233; 1993, PHS AHCPR930551 US D	64	373	377	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					913	921		10.7326/0003-4819-122-12-199506150-00004	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RC270	7755226				2022-12-28	WOS:A1995RC27000004
J	HAOUARI, N; WOOD, C; GRIFFITHS, G; LEVENE, M				HAOUARI, N; WOOD, C; GRIFFITHS, G; LEVENE, M			THE ANALGESIC EFFECT OF SUCROSE IN FULL-TERM INFANTS - A RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							NEWBORN; PAIN	Objective-To evaluate the effects of different sucrose concentrations on measures of neonatal pain, Design-Randomised, double blind, placebo controlled trial of sterile water (control) or one of three solutions of sucrose-namely, 12.5%, 25%, and 50% wt/vol. Setting-Postnatal ward, Patients-60 healthy infants of gestational age 37-42 weeks and postnatal age 1-6 days randomised to receive 2 ml of one of the four solutions on to the tongue two minutes before heel prick sampling for serum bilirubin concentrations. Main outcome measure-Duration of crying over the first three minutes after heel prick. Results-There was a significant reduction in overall crying time and heart rate after three minutes in the babies given 50% sucrose as compared with controls. This was maximal one minute after heel prick in the 50% sucrose group and became statistically significant in the 25% sucrose group at two minutes, There was a significant trend for a reduction in crying time with increasing concentrations of sucrose over the first three minutes. Conclusion-Concentrated sucrose solution seems to reduce crying and the autonomic effects of a painful procedure in healthy normal babies, Sucrose may be a useful and safe analgesic for minor procedures in neonates.	UNIV LEEDS,LEEDS GEN INFIRM,DIV PAEDIAT & CHILD HLTH,LEEDS LS2 9NS,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds								ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; BLASS E, 1987, PHARMACOL BIOCHEM BE, V26, P483, DOI 10.1016/0091-3057(87)90153-5; BLASS EM, 1991, PEDIATRICS, V87, P215; BLASS EM, 1989, ANN NY ACAD SCI, V575, P292; CUSIK J, 1985, STAT MED, V4, P87; FITZGERALD M, 1989, ARCH DIS CHILD-FETAL, V64, P441, DOI 10.1136/adc.64.4_Spec_No.441; LIEBLICH I, 1983, SCIENCE, V97, P871; PRECHTL HFR, 1974, BRAIN RES, V76, P185, DOI 10.1016/0006-8993(74)90454-5; RUSHFORTH JA, 1994, ARCH DIS CHILD-FETAL, V70, pF174, DOI 10.1136/fn.70.3.F174; RUSHFORTH JA, 1993, ARCH DIS CHILD, V69, P388, DOI 10.1136/adc.69.3.388	10	114	117	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1498	1500		10.1136/bmj.310.6993.1498	http://dx.doi.org/10.1136/bmj.310.6993.1498			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787595	Green Published			2022-12-28	WOS:A1995RD28500020
J	BRUGGER, P; MARKTL, W; HEROLD, M				BRUGGER, P; MARKTL, W; HEROLD, M			IMPAIRED NOCTURNAL SECRETION OF MELATONIN IN CORONARY HEART-DISEASE	LANCET			English	Note								Patients with coronary heart disease have increased nocturnal urinary noradrenaline. Because melatonin suppresses sympathetic activity, we measured serum melatonin concentrations at night (0200 h) in 15 patients with coronary heart disease. Melatonin was significantly lower in the patients than in 10 healthy controls (median 7.8 [interquartile range 6.5-11.8] vs 36.2 [32.2-42.5] pg/mL, p<0.0001). Thus, impaired nocturnal secretion of melatonin is associated with coronary heart disease. Patients disease nocturnal noradrenaline.	UNIV VIENNA, DEPT PHYSIOL, VIENNA, AUSTRIA; UNIV INNSBRUCK, DEPT INTERNAL MED, A-6020 INNSBRUCK, AUSTRIA	University of Vienna; University of Innsbruck	BRUGGER, P (corresponding author), INST CARDIOVASC DIAGNOSIS & THERAPY, IMBERGSTR 22, A-5020 SALZBURG, AUSTRIA.							Arendt J., 1985, Pineal Research Reviews, V3, P161; AXELROD J, 1981, J NEUROSURG, V55, P669, DOI 10.3171/jns.1981.55.5.0669; BRUGGER P, 1990, WIEN MED WOCHENSCHR, V14, P375; DOLLINS AB, 1993, PHYSIOL BEHAV, V53, P153, DOI 10.1016/0031-9384(93)90024-A; LYNCH HJ, 1975, SCIENCE, V187, P168; MAHATA SK, 1991, J COMP PHYSIOL B, V161, P81, DOI 10.1007/BF00258750; SHAFI S, 1989, PROC R SOC SER B-BIO, V235, P289, DOI 10.1098/rspb.1989.0001; VAUGHAN GM, 1979, NEUROSCI LETT, V14, P81, DOI 10.1016/0304-3940(79)95348-5; VISWANATHAN M, 1986, LIFE SCI, V38, P73, DOI 10.1016/0024-3205(86)90277-8	9	166	172	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 3	1995	345	8962					1408	1408		10.1016/S0140-6736(95)92600-3	http://dx.doi.org/10.1016/S0140-6736(95)92600-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760612				2022-12-28	WOS:A1995RB44100012
J	REUL, J; WEIS, J; JUNG, A; WILLMES, K; THRON, A				REUL, J; WEIS, J; JUNG, A; WILLMES, K; THRON, A			CENTRAL-NERVOUS-SYSTEM LESIONS AND CERVICAL DISC HERNIATIONS IN AMATEUR DIVERS	LANCET			English	Article								Permanent neuropsychological changes such as memory disturbances and depression have been found in professional divers, even in those who have never had decompression sickness. The changes are probably the result of intravascular gas bubbles insufficient to cause acute symptoms. We examined amateur divers with long histories of self-contained underwater breathing apparatus diving by magnetic resonance imaging and compared them with normal controls. Hyperintense lesions of the subcortical cerebral white matter and degenerative changes of the cervical disks were significantly more common in the divers. 27 of 52 divers had a total of 86 focal hyperintensities versus 10 of 50 controls with 14 focal hyperintensities (p<0.01). 32 divers had at least one degenerated intravertebral disc versus 9 controls (P<0.0001). These results suggest that amateur divers are at risk of accumulating lesions in the central nervous system and in cartilage.	RHEIN WESTFAL TH AACHEN,DEPT NEURORADIOL,AACHEN,GERMANY; RHEIN WESTFAL TH AACHEN,DEPT NEUROPATHOL,AACHEN,GERMANY; RHEIN WESTFAL TH AACHEN,DEPT NEUROL,AACHEN,GERMANY	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University			Weis, Joachim/G-1984-2014; Willmes, Klaus F/A-1268-2014	Weis, Joachim/0000-0003-3280-6773; Willmes, Klaus F/0000-0002-9012-0553				BADDLEY A, 1983, LONG TERM NEUROLOGIC, P165; EDMONDS C, 1985, 9TH P INT S UND HYP; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; NIX WA, 1980, DEUT MED WOCHENSCHR, V105, P302, DOI 10.1055/s-2008-1070654; PALMER AC, 1992, NEUROPATH APPL NEURO, V18, P113, DOI 10.1111/j.1365-2990.1992.tb00773.x; PALMER AC, 1987, LANCET, V2, P1365; POLKINGHORNE PJ, 1988, LANCET, V2, P1381; RINCK PA, 1991, JMRI-J MAGN RESON IM, V1, P293, DOI 10.1002/jmri.1880010306; SMYTH E, 1985, NEW SCI, V1439, P8; TODNEM K, 1991, ELECTROEN CLIN NEURO, V79, P322, DOI 10.1016/0013-4694(91)90127-P; TODNEM K, 1991, BRIT J IND MED, V48, P258; VAERNES RJ, 1982, AVIAT SPACE ENVIR MD, V53, P803; WARREN LP, 1988, AM J ROENTGENOL, V151, P1003, DOI 10.2214/ajr.151.5.1003	13	88	89	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1403	1405		10.1016/S0140-6736(95)92598-8	http://dx.doi.org/10.1016/S0140-6736(95)92598-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760611				2022-12-28	WOS:A1995RB44100010
J	EVANS, MR				EVANS, MR			CHILDREN WHO MISS IMMUNIZATION - IMPLICATIONS FOR ELIMINATING MEASLES	BRITISH MEDICAL JOURNAL			English	Article											EVANS, MR (corresponding author), S GLAMORGAN HLTH AUTHOR,ABTON HOUSE,CARDIFF CF4 3QX,S GLAM,WALES.		Evans, Meirion/C-2990-2008	Evans, Meirion/0000-0003-3578-1866				ERDMAN DD, 1994, J MED VIROL, V41, P44; MILLER E, 1994, BRIT MED J, V309, P1102, DOI 10.1136/bmj.309.6962.1102; RAMSAY N, 1994, COMMUN DIS REP CDR R, V4, P141; TULCHINSKY TH, 1993, B WORLD HEALTH ORGAN, V71, P93; WHITE JM, 1994, COMMUN DIS REP CDR R, V4, P129	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1367	1368		10.1136/bmj.310.6991.1367	http://dx.doi.org/10.1136/bmj.310.6991.1367			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787540	Green Published			2022-12-28	WOS:A1995RB00500023
J	HOPTON, JL; DLUGOLECKA, M				HOPTON, JL; DLUGOLECKA, M			PATIENTS PERCEPTIONS OF NEED FOR PRIMARY HEALTH-CARE SERVICES - USEFUL FOR PRIORITY SETTING	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; SATISFACTION	Objectives-To assess the feasibility of using patients' perceptions of need for primary health care services to develop priorities. Design-A postal survey of a random sample of 3478 patients registered with five general practices. Setting-Lothian, Scotland. Main outcome measures-Comparison of rankings of 36 different kinds of help or advice according to (a) popularity in the sample size as a whole and in healthy and unhealthy subgroups and (b) health status (severity of need) of potential service users. Results-Popularity rankings differed between the healthy and unhealthy subgroups and the whole sample. Popularity rankings were almost the inverse of rankings based on health status. The analysis identified two areas of substantial need both in terms of popularity and severity: pain management and advice about welfare benefits. Conclusions-Methodological efforts to ensure equal participation in the processes of assessing health needs and of priority setting do not in themselves promote equity. To promote equity some opinions may need to be given greater weight.	LOTHIAN HLTH,EDINBURGH,MIDLOTHIAN,SCOTLAND		HOPTON, JL (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,MIDLOTHIAN,SCOTLAND.							ALBASHIR MM, 1991, BRIT J GEN PRACT, V41, P6; Bradshaw J, 1972, PROBLEMS PROGR MED C, P71; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; DONABEDIAN A, 1993, ASPECTS MED CARE ADM; FITZPATRICK R, 1991, BMJ-BRIT MED J, V302, P1129, DOI 10.1136/bmj.302.6785.1129; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; HADORN DC, 1991, SOC SCI MED, V32, P773, DOI 10.1016/0277-9536(91)90303-T; HUNTER D, 1992, HLTH SERVICE J   MAY, P17; Jones K, 1978, ISSUES SOCIAL POLICY; MANDERSON L, 1992, SOC SCI MED, V35, P839, DOI 10.1016/0277-9536(92)90098-B; MEREDITH P, 1993, SOC SCI MED, V37, P591, DOI 10.1016/0277-9536(93)90098-O; MOSER CA, 1979, SOCIAL RES PRINCIPLE; ONG BN, 1991, SOC SCI MED, V32, P909, DOI 10.1016/0277-9536(91)90246-9; PARIS JAG, 1993, BRIT MED J, V306, P1518, DOI 10.1136/bmj.306.6891.1518; PFEFFER N, 1993, BRIT MED J, V307, P570; POLLOCK A, 1993, HLTH SERVICE J   SEP, P26; POTTER RG, 1989, J ROY COLL GEN PRACT, V39, P486; RICHARDSON A, 1992, BRIT MED J, V304, P680, DOI 10.1136/bmj.304.6828.680; SALTER B, 1993, POLICY POLIT, V21, P171, DOI 10.1332/030557393782331074; SYKES W, 1992, LISTENING LOCAL VOIC; WINKLER F, 1987, POLICY POLIT, V15, P1, DOI 10.1332/030557387782514609	21	26	26	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1237	1240		10.1136/bmj.310.6989.1237	http://dx.doi.org/10.1136/bmj.310.6989.1237			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QY877	7767195	Green Published			2022-12-28	WOS:A1995QY87700021
J	ARO, A; KARDINAAL, AFM; SALMINEN, I; KARK, JD; RIEMERSMA, RA; DELGADORODRIGUEZ, M; GOMEZARACENA, J; HUTTUNEN, JK; KOHLMEIER, L; MARTIN, BC; MARTINMORENO, JM; MAZAEV, VP; RINGSTAD, J; THAMM, M; VANTVEER, P; KOK, FJ				ARO, A; KARDINAAL, AFM; SALMINEN, I; KARK, JD; RIEMERSMA, RA; DELGADORODRIGUEZ, M; GOMEZARACENA, J; HUTTUNEN, JK; KOHLMEIER, L; MARTIN, BC; MARTINMORENO, JM; MAZAEV, VP; RINGSTAD, J; THAMM, M; VANTVEER, P; KOK, FJ			ADIPOSE-TISSUE ISOMERIC TRANS-FATTY-ACIDS AND RISK OF MYOCARDIAL-INFARCTION IN 9 COUNTRIES - THE EURAMIC STUDY	LANCET			English	Article							UNITED-STATES DIET; HEART-DISEASE; SERUM-LIPIDS; HUMANS; MEN; HYDROGENATION; LIPOPROTEINS; ANTIOXIDANTS; WOMEN; OILS	Dietary isomeric trans fatty acids-mainly produced by hydrogenation of oils-are suspected of increasing the risk of coronary heart disease. Dietary trans fatty acid intake in reflected in the fatty acid composition of adipose tissue. In an international multicentre study in eight European countries and Israel (EURAMIC), adipose tissue aspiration samples were obtained from 671 men with acute myocardial infarction (AMI), aged 70 years or less, and 717 men without a history of AMI (controls). The proportion of fatty acids, including isomeric trans monoenoic fatty acids with 18 carbon atoms (C18:1), was determined by gas chromatography. Although there were considerable differences between countries in mean (SD) proportion of adipose tissue C18:1 trans fatty acids, there was no overall difference between cases (1.61 [0.92]%) and the controls (1.57 [0.86]%). The risk of AMI did not differ significantly from 1.0 over quartiles of adipose C18:1 trans fatty acids: the multivariate odds ratio was 0.97 (95% CI 0.56-1.67) for the highest versus lowest quartile. After exclusion of subjects from Spanish centres because they had far lower proportions of adipose trans fatty acids than subjects from other countries, there was a tendency to increased risk of AMI in the upper quartiles of C18:1 trans; however, the trend was not statistically significant. Our results reflect considerable differences between countries in dietary intake of trans fatty acids but do not suggest a major overall effect of C18:1 trans fatty acids on risk of AMI. We cannot exclude the possibility that trans fatty acids have a significant impact on risk of AMI in populations with high intake.	TNO,INST TOXICOL & NUTR,EURAMIC COORDINATING CTR,3700 AJ ZEIST,NETHERLANDS; HADASSAH MED ORG,JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,JERUSALEM,ISRAEL; UNIV EDINBURGH,CARDIOVASC RES UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV GRANADA,GRANADA,SPAIN; UNIV MALAGA,E-29071 MALAGA,SPAIN; FED HLTH OFF,W-1000 BERLIN,GERMANY; UNIV ZURICH,ZURICH,SWITZERLAND; SCH PUBL HLTH,MADRID,SPAIN; ALL UNION PREVENT MED RES CTR,MOSCOW,RUSSIA; OSTFOLD CTY HOSP,FREDRIKSTAD,NORWAY; AGR UNIV WAGENINGEN,WAGENINGEN,NETHERLANDS	Netherlands Organization Applied Science Research; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; University of Edinburgh; University of Granada; Universidad de Malaga; University of Zurich; National Medical Research Center for Therapy & Preventive Medicine; Wageningen University & Research	ARO, A (corresponding author), NATL PUBL HLTH INST,DEPT NUTR,MANNERHEIMINTIE 166,SF-00300 HELSINKI,FINLAND.		Martin-Moreno, Jose M./S-7733-2016; Mazaev, Vladimir/M-8897-2013; Robles-Sardin, Alma E/M-7714-2015	Martin-Moreno, Jose M./0000-0002-8648-5541; Mazaev, Vladimir/0000-0002-9782-0296; Robles-Sardin, Alma E/0000-0003-2044-7793				ANDERSON JT, J NUTR, V75, P388; ASCHERIO A, 1994, CIRCULATION, V89, P94, DOI 10.1161/01.CIR.89.1.94; BEYNEN AC, 1985, AM J CLIN NUTR, V42, P317, DOI 10.1093/ajcn/42.2.317; BOATELLA J, 1993, EUR J CLIN NUTR, V47, pS62; BURT CT, 1984, BIOCHEM MEDICA, V31, P20; ENIG MG, 1984, HUM NUTR-CLIN NUTR, V38C, P223; ENIG MG, 1990, J AM COLL NUTR, V9, P471, DOI 10.1080/07315724.1990.10720404; HECKERS H, 1979, FETT WISS TECHNOL, V81, P217, DOI 10.1002/lipi.19790810601; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; HUNTER JE, 1991, AM J CLIN NUTR, V54, P363, DOI 10.1093/ajcn/54.2.363; Hyvonen Lea, 1993, Journal of Food Composition and Analysis, V6, P24, DOI 10.1006/jfca.1993.1004; Johansson L., 1994, Scandinavian Journal of Nutrition/Naringsforskning, V38, P62; JOHNSTON PV, 1958, P SOC EXP BIOL MED, V99, P735, DOI 10.3181/00379727-99-24483; KARDINAAL AFM, 1993, EUR J CLIN NUTR, V47, pS64; KARDINAAL AFM, 1993, LANCET, V342, P1379, DOI 10.1016/0140-6736(93)92751-E; LAINE DC, 1982, AM J CLIN NUTR, V35, P683, DOI 10.1093/ajcn/35.4.683; LICHTENSTEIN AH, 1993, ARTERIOSCLER THROMB, V13, P154, DOI 10.1161/01.ATV.13.2.154; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1993, PROG LIPID RES, V32, P111, DOI 10.1016/0163-7827(93)90007-J; MENSINK RP, 1992, J LIPID RES, V33, P1493; NESTEL P, 1992, J LIPID RES, V33, P1029; OHLROGGE JB, 1981, J LIPID RES, V22, P955; THOMAS LH, 1983, J EPIDEMIOL COMMUN H, V37, P16, DOI 10.1136/jech.37.1.16; TROISI R, 1992, AM J CLIN NUTR, V56, P1019, DOI 10.1093/ajcn/56.6.1019; VANDOKKUM W, 1989, VOEDING, V50, P214; VANSTAVEREN WA, 1986, AM J EPIDEMIOL, V123, P455; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WOOD R, 1993, J LIPID RES, V34, P1; ZOCK PL, 1992, J LIPID RES, V33, P399	30	183	188	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					273	278		10.1016/S0140-6736(95)90273-2	http://dx.doi.org/10.1016/S0140-6736(95)90273-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7766242	Green Accepted			2022-12-28	WOS:A1995QE73100007
J	PARTANEN, J; NISKANEN, L; LEHTINEN, J; MERVAALA, E; SIITONEN, O; UUSITUPA, M				PARTANEN, J; NISKANEN, L; LEHTINEN, J; MERVAALA, E; SIITONEN, O; UUSITUPA, M			NATURAL-HISTORY OF PERIPHERAL NEUROPATHY IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEWLY DIAGNOSED NIDDM; 5-YEAR FOLLOW-UP; NONDIABETIC SUBJECTS; PREVALENCE	Background. There is little information on the incidence and natural history of neuropathy in patients with non-insulin-dependent diabetes mellitus (NIDDM). Methods. We studied patients with newly diagnosed NIDDM and control subjects both at base line and 5 and 10 years later. Polyneuropathy was diagnosed on the basis of clinical criteria (pain and paresthesias) and electrodiagnostic studies (nerve conduction velocity and response-amplitude values). We investigated the relation between metabolic variables (results of oral glucose-tolerance tests, serum lipid and insulin concentrations, and glycosylated hemoglobin values) and the development of polyneuropathy. Results. In 10 years, 36 patients with NIDDM and 8 control subjects died; 86 patients and 121 control subjects completed the study. When the study ended, 18 percent of the patients were being treated only with diet, 59 percent with oral hypoglycemic drugs alone, 12 percent with insulin alone, and 11 percent with both insulin and oral hypoglycemic agents. At base line the prevalence of definite or probable polyneuropathy among the patients with NIDDM was 8.3 percent, as compared with 2.1 percent among the control subjects. These values 10 years later were 41.9 percent and 5.8 percent, respectively. The number of patients with NIDDM who had nerve-conduction abnormalities in the legs and feet increased from 8.3 percent at base line to 16.7 percent after 5 years and to 41.9 percent after 10 years. The decrease in sensory and motor amplitudes, indicating axonal destruction, was more pronounced than the slowing of the nerve conduction velocities, which indicates demyelination. Among the patients with NIDDM, those with polyneuropathy had poorer glycemic control than those without. Low serum insulin concentrations before and after the oral administration of glucose were associated with the development of polyneuropathy, regardless of the degree of glycemia. Conclusions. The prevalence of polyneuropathy among patients with NIDDM increases with time, and the increase may be greater in patients with hypoinsulinemia.	KUOPIO UNIV HOSP, DEPT CLIN NUTR, SF-70211 KUOPIO, FINLAND; KUOPIO UNIV HOSP, DEPT INTERNAL MED, SF-70211 KUOPIO, FINLAND; KUOPIO UNIV, KUOPIO, FINLAND	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Eastern Finland	PARTANEN, J (corresponding author), KUOPIO UNIV HOSP, DEPT CLIN NEUROPHYSIOL, POB 1777, SF-70211 KUOPIO, FINLAND.		Uusitupa, Matti Ilmari Julius/AAX-4929-2020					CAMERON NE, 1994, DIABETES METAB REV, V10, P189, DOI 10.1002/dmr.5610100302; DYCK PJ, 1986, ANN NEUROL, V19, P440, DOI 10.1002/ana.410190504; HARATI Y, 1992, NEUROL CLIN, V10, P783, DOI 10.1016/S0733-8619(18)30208-1; LANG AH, 1977, J NEUROL SCI, V33, P229, DOI 10.1016/0022-510X(77)90196-4; LEHTINEN J, 1987, THEIS U KUOPIO KUOPI; LEHTINEN JM, 1989, DIABETES, V38, P1307, DOI 10.2337/diabetes.38.10.1307; LEHTINEN JM, 1993, DIABETOLOGIA, V36, P68, DOI 10.1007/BF00399096; LLEWELYN JG, 1991, BRAIN, V114, P867, DOI 10.1093/brain/114.2.867; Mincu I, 1980, Med Interne, V18, P155; NISKANEN L, 1994, J INTERN MED, V236, P263, DOI 10.1111/j.1365-2796.1994.tb00794.x; NISKANEN LK, 1990, DIABETES CARE, V13, P41, DOI 10.2337/diacare.13.1.41; PENTTILA IM, 1981, SCAND J CLIN LAB INV, V41, P353, DOI 10.3109/00365518109092057; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; RATZMANN K P, 1991, Journal of Diabetic Complications, V5, P1, DOI 10.1016/0891-6632(91)90002-7; SCARPINI E, 1993, J NEUROL SCI, V120, P159, DOI 10.1016/0022-510X(93)90268-4; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; UUSITUPA M, 1985, DIABETOLOGIA, V28, P22, DOI 10.1007/BF00276995; UUSITUPA MIJ, 1993, DIABETOLOGIA, V36, P1175, DOI 10.1007/BF00401063; WAHREN J, 1994, DIABETOLOGIA, V37, pS99, DOI 10.1007/BF00400832; 1980, WHO TECH REP SER, V646, P7	20	429	456	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					89	94		10.1056/NEJM199507133330203	http://dx.doi.org/10.1056/NEJM199507133330203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777034	Bronze			2022-12-28	WOS:A1995RH22500003
J	MASON, JJ; OWENS, DK; HARRIS, RA; COOKE, JP; HLATKY, MA				MASON, JJ; OWENS, DK; HARRIS, RA; COOKE, JP; HLATKY, MA			THE ROLE OF CORONARY ANGIOGRAPHY AND CORONARY REVASCULARIZATION BEFORE NONCARDIAC VASCULAR-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ARTERY BYPASS-SURGERY; CARDIAC RISK; MYOCARDIAL-INFARCTION; GRAFT-SURGERY; CASS REGISTRY; CLINICAL-DIAGNOSIS; DISEASE; MORTALITY; DIPYRIDAMOLE; ANGIOPLASTY	Objective.-To determine whether preoperative coronary angiography and revascularization improve short-term outcomes in patients undergoing noncardiac vascular surgery. Design.-Decision analysis. Patients.-Patients undergoing elective vascular surgery who had either no angina or mild angina and a positive dipyridamole-thallium scan result. Interventions.-Three strategies were compared, The first strategy was to proceed directly to vascular surgery. The second was to perform coronary angiography, followed by selective coronary revascularization, before proceeding to vascular surgery and to cancel vascular surgery in patients with severe inoperable coronary artery disease (CAD), The third was to perform coronary angiography, followed by selective coronary revascularization, before proceeding to vascular surgery and to perform vascular surgery in patients with inoperable CAD. Main Outcome Measures.-Mortality, nonfatal myocardial infarction, stroke, uncorrected vascular disease, and cost. All outcomes were assessed within 3 months. Results.-Proceeding directly to vascular surgery led to lower morbidity and cost in the base case analysis. The coronary angiography strategy led to higher mortality if vascular surgery would proceed in patients with inoperable CAD, but led to slightly lower mortality if vascular surgery were canceled in patients with inoperable CAD. The coronary angiography strategy also led to lower mortality when vascular surgery was particularly risky. Conclusions.-Decision analysis indicates vascular surgery without preoperative coronary angiography generally leads to better outcomes. Preoperative coronary angiography should be reserved for patients whose estimated mortality from vascular surgery is substantially higher than average.	STANFORD UNIV, SCH MED, DEPT MED, DIV CARDIOVASC MED, PALO ALTO, CA 94304 USA; STANFORD UNIV, SCH MED, DEPT HLTH RES & POLICY, DIV HLTH SERV RES, PALO ALTO, CA 94304 USA; DEPT VET AFFAIRS MED CTR, DEPT MED, GEN INTERNAL MED SECT, PALO ALTO, CA USA	Stanford University; Stanford University				Cooke, John/0000-0003-0033-9138; Hlatky, Mark/0000-0003-4686-9441				ABRAHAM SA, 1991, PROG CARDIOVASC DIS, V34, P205, DOI 10.1016/0033-0620(91)90014-D; ALBRO PC, 1978, AM J CARDIOL, V42, P751, DOI 10.1016/0002-9149(78)90094-2; ALDERMAN EL, 1990, CIRCULATION, V82, P1629, DOI 10.1161/01.CIR.82.5.1629; ANDREWS TC, 1994, J VASC MED BIOL, V5, P8; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; BELL MR, 1992, CIRCULATION, V86, P446, DOI 10.1161/01.CIR.86.2.446; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN KA, 1993, J AM COLL CARDIOL, V21, P325, DOI 10.1016/0735-1097(93)90670-V; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CHAITMAN BR, 1981, CIRCULATION, V64, P360, DOI 10.1161/01.CIR.64.2.360; COHEN HA, 1982, CIRCULATION, V66, P49; DAVIS K, 1979, CIRCULATION, V59, P1105, DOI 10.1161/01.CIR.59.6.1105; DETRE K, 1988, NEW ENGL J MED, V318, P265, DOI 10.1056/NEJM198802043180501; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DIAMOND GA, 1980, J CLIN INVEST, V65, P1210, DOI 10.1172/JCI109776; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; EAGLE KA, 1994, J AM COLL CARDIOL, V23, P1091, DOI 10.1016/0735-1097(94)90596-7; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; ELLIS SG, 1988, J AM COLL CARDIOL, V11, P211, DOI 10.1016/0735-1097(88)90082-4; ELMORE JR, 1993, MAYO CLIN PROC, V68, P637, DOI 10.1016/S0025-6196(12)60598-9; FISHER LD, 1981, CIRCULATION, V63, P987, DOI 10.1161/01.CIR.63.5.987; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; FRANCISCO DA, 1982, CIRCULATION, V66, P370, DOI 10.1161/01.CIR.66.2.370; GERSH BJ, 1991, J AM COLL CARDIOL, V18, P203, DOI 10.1016/S0735-1097(10)80241-4; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GOLDEN MA, 1990, ANN SURG, V212, P415, DOI 10.1097/00000658-199010000-00004; GOLDMAN L, 1994, NEW ENGL J MED, V330, P707, DOI 10.1056/NEJM199403103301010; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HAMMERMEISTER KE, 1990, CIRCULATION, V82, P380; HANNAN EL, 1992, JAMA-J AM MED ASSOC, V268, P3092, DOI 10.1001/jama.268.21.3092; HARRIS PJ, 1979, CIRCULATION, V60, P1259, DOI 10.1161/01.CIR.60.6.1259; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; Hertzer N R, 1987, Ann Vasc Surg, V1, P616, DOI 10.1016/S0890-5096(06)61452-0; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; HLATKY MA, 1990, CIRCULATION, V82, P208; HOLMES DR, 1988, J AM COLL CARDIOL, V12, P1149, DOI 10.1016/0735-1097(88)92593-4; JOSEPHSON MA, 1982, AM HEART J, V103, P1008, DOI 10.1016/0002-8703(82)90564-6; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; KENNEDY JW, 1982, CATHETER CARDIO DIAG, V8, P5, DOI 10.1002/ccd.1810080103; KENNEDY JW, 1982, CATHETER CARDIO DIAG, V8, P323, DOI 10.1002/ccd.1810080402; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; LEPPO J, 1982, CIRCULATION, V66, P649, DOI 10.1161/01.CIR.66.3.649; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; MARWICK TH, 1990, CLIN CARDIOL, V13, P14, DOI 10.1002/clc.4960130105; MASSIE BM, 1993, CIRCULATION, V87, P1752, DOI 10.1161/01.CIR.87.5.1752; MCFALLS EO, 1993, J AM COLL CARDIOL, V21, P1347, DOI 10.1016/0735-1097(93)90307-M; MOCK MB, 1982, CIRCULATION, V66, P562, DOI 10.1161/01.CIR.66.3.562; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; PASTERNACK PF, 1985, CIRCULATION, V72, P13; PEDERSEN TR, 1994, LANCET, V344, P1383; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; PRYOR DB, 1993, ANN INTERN MED, V118, P81, DOI 10.7326/0003-4819-118-2-199301150-00001; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; RIHAL CS, 1995, CIRCULATION, V91, P46, DOI 10.1161/01.CIR.91.1.46; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3; RUDDY TD, 1987, J AM COLL CARDIOL, V10, P142, DOI 10.1016/S0735-1097(87)80172-9; RYAN TJ, 1993, J AM COLL CARDIOL, V22, P2033, DOI 10.1016/0735-1097(93)90794-2; SIMONETTI I, 1991, CIRCULATION, V83, P43; SMITH LR, 1991, CIRCULATION, V84, P245; TALLEY JD, 1990, CIRCULATION, V82, P1203, DOI 10.1161/01.CIR.82.4.1203; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743; ZHU YY, 1991, AM HEART J, V121, P33, DOI 10.1016/0002-8703(91)90952-E; 1994, STAT B METROP IN JAN, P12	73	114	116	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1919	1925		10.1001/jama.273.24.1919	http://dx.doi.org/10.1001/jama.273.24.1919			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783301				2022-12-28	WOS:A1995RE35400027
J	MILLERCATCHPOLE, R				MILLERCATCHPOLE, R			TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) - DIAGNOSTIC AND THERAPEUTIC TECHNOLOGY-ASSESSMENT (DATTA)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PORTACAVAL-SHUNT; PORTAL-HYPERTENSION; EARLY EXPERIENCE; STENTS; MANAGEMENT; CREATION; CATHETER	Objective.- To provide clinicians with a technology assessment of the safety and effectiveness of the use of a transjugular intrahepatic portosystemic shunt (TIPS) for reducing portal hypertension and its associated complications of esophageal varices and ascites. Participants.- A literature review and a Diagnostic and Therapeutic Technology Assessment (DATTA) survey questionnaire were mailed to 72 physicians with expertise in gastrointestinal or abdominal surgery or interventional radiology and a special interest in liver disease or esophageal varices. These panelists had been nominated to the DATTA panel by appropriate specialty societies and medical schools. A total of 54 panelists (75%) responded. Evidence.- Assessment was based on the expert opinion of the panelists, as well as on published scientific literature (available as of January 2, 1995). Published studies were identified by a MEDLINE search using the terms transjugular intrahepatic portosystemic shunt, TIPS, and transjugular and by review of the references cited in these primary sources. Consensus Process.- The respondents completed a DATTA survey questionnaire; the survey results were tabulated, analyzed, and interpreted by an American Medical Association staff physician. Conclusions.- The safety of TIPS was considered to be established in the acute control of bleeding from esophageal varices in patients who had failed sclerotherapy. The safety of TIPS was considered to be promising for long-term control of bleeding from esophageal varices. In patients with endstage liver disease and esophageal varices who are liver transplant candidates, the use of TIPS was considered to be an established therapy. The effectiveness of TIPS was considered to be (1) established in the acute control of bleeding in patients who failed sclerotherapy; (2) promising for longterm control of bleeding from esophageal varices; and (3) established in patients with end-stage liver disease and esophageal varices who are candidates for liver transplants.			MILLERCATCHPOLE, R (corresponding author), AMER MED ASSOC,DEPT TECHNOL ASSESSMENT,515 N STATE ST,CHICAGO,IL 60610, USA.							AZOULAY D, 1994, HEPATOLOGY, V19, P129, DOI 10.1016/0270-9139(94)90063-9; CELLO JP, 1984, NEW ENGL J MED, V311, P1589, DOI 10.1056/NEJM198412203112501; CHILD CG, 1984, LIVER PORTAL HYPERTE; CHONG WK, 1993, RADIOLOGY, V189, P789, DOI 10.1148/radiology.189.3.8234705; COLAPINTO RF, 1982, CAN MED ASSOC J, V126, P267; FREEDMAN AM, 1993, RADIOGRAPHICS, V13, P1185, DOI 10.1148/radiographics.13.6.8290720; FREEMAN RB, 1994, TRANSPLANTATION, V58, P297, DOI 10.1097/00007890-199408150-00007; HASKAL ZJ, 1993, RADIOLOGY, V188, P85, DOI 10.1148/radiology.188.1.8511322; HASKAL ZJ, 1992, RADIOLOGY, V185, P813, DOI 10.1148/radiology.185.3.1438768; HELTON WS, 1993, AM J SURG, V165, P566, DOI 10.1016/S0002-9610(05)80436-2; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LIM HL, 1993, AM J GASTROENTEROL, V88, P2095; LIND CD, 1994, GASTROENTEROLOGY, V106, P1277, DOI 10.1016/0016-5085(94)90020-5; MARTIN M, 1993, SURGERY, V114, P719; MAYNAR M, 1993, AM J ROENTGENOL, V161, P301, DOI 10.2214/ajr.161.2.8333367; PALMAZ JC, 1986, AM J ROENTGENOL, V147, P1251, DOI 10.2214/ajr.147.6.1251; PALMAZ JC, 1985, AM J ROENTGENOL, V145, P821, DOI 10.2214/ajr.145.4.821; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; RING EJ, 1992, ANN INTERN MED, V116, P304, DOI 10.7326/0003-4819-116-4-304; ROGERS CG, 1994, AM SURGEON, V60, P114; ROSCH J, 1987, RADIOLOGY, V162, P481; ROSCH J, 1969, RADIOLOGY, V92, P1112; ROSSLE M, 1994, NEW ENGL J MED, V330, P165, DOI 10.1056/NEJM199401203300303; SANYAL AJ, 1992, ANN INTERN MED, V117, P443, DOI 10.7326/0003-4819-117-5-443; TERBLANCHE J, 1993, SURG ENDOSC-ULTRAS, V7, P472, DOI 10.1007/BF00316683; VALJI K, 1994, RADIOLOGY, V191, P173, DOI 10.1148/radiology.191.1.8134565; ZEMEL G, 1991, JAMA-J AM MED ASSOC, V266, P390, DOI 10.1001/jama.266.3.390; ZEMEL G, 1992, RADIOGRAPHICS, V12, P615, DOI 10.1148/radiographics.12.4.1636029	28	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1824	1830						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776491				2022-12-28	WOS:A1995RD11600009
J	BIANCHI, G; SWALES, JD				BIANCHI, G; SWALES, JD			DO WE NEED MORE ANTIHYPERTENSIVE DRUGS - LESSONS FROM THE NEW BIOLOGY	LANCET			English	Editorial Material							SODIUM SENSITIVITY; BLOOD-PRESSURE; RESISTANCE		LEICESTER ROYAL INFIRM,DEPT MED,LEICESTER LE2 7LX,LEICS,ENGLAND; UNIV MILAN,OSPED SAN RAFFAELE,CATTEDRA NEFROL,I-20127 MILAN,ITALY	University of Leicester; University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele				Bianchi, Giuseppe/0000-0002-8365-3618				CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; HARRAP S, 1994, LANCET, V344, P167; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; KAPLAN NM, 1994, TXB HYPERTENSION, P811; KURTZ TW, 1994, LANCET, V344, P167, DOI 10.1016/S0140-6736(94)92761-8; LINDHOLM L, 1984, ACTA MED SCAND, V21, P251; LUFT FC, 1982, AM J MED, V72, P726, DOI 10.1016/0002-9343(82)90537-X; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SWALES JD, 1994, LANCET, V344, P380; SWALES JD, 1993, J HYPERTENS       S5, V2, pS59; WEINBERGER MH, 1987, HYPERTENSION, V10, P443, DOI 10.1161/01.HYP.10.4.443; 1984, HYPERTENSION S1, V6, P198; 1991, NEW ENGL J MED, V325, P293; 1994, NAT GENET, V7, P217	14	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1555	1557		10.1016/S0140-6736(95)91094-8	http://dx.doi.org/10.1016/S0140-6736(95)91094-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791444				2022-12-28	WOS:A1995RD79000016
J	RADFORD, CF; BACON, AS; DART, JKG; MINASSIAN, DC				RADFORD, CF; BACON, AS; DART, JKG; MINASSIAN, DC			RISK-FACTORS FOR ACANTHAMOEBA-KERATITIS IN CONTACT-LENS USERS - A CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article							MICROBIAL-CONTAMINATION; WEARERS	Objective-To investigate reasons for an increase in cases of Acanthamoeba keratitis related to contact lenses. Design-Case-control study. Cases were contact lens related acanthamoeba keratitis patients treated between 1 September 1989 and 31 August 1992. Controls were lens users without lens related disease who presented as new patients to the casualty department from 1 March 1992 to 31 August 1992. All subjects completed a questionnaire detailing lens use and hygiene practices. Setting-Eye hospital. Subjects-35 cases with acanthamoeba keratitis and 378 controls. Main outcome measures-Relative risks comparing different contact lens types, socioeconomic classification, age, sex, lens use, lens wearing experience, hygiene compliance, and hygiene systems. Results-The crude relative risk for developing acanthamoeba keratitis with the use of daily wear disposable lenses was 49.45 (95% confidence interval 6.53 to 2227; P < 0.001) compared with conventional soft lenses (the referent). Multivariable analysis showed that this increased risk could be largely attributed to lack of disinfection (relative risk 55.86 (10 to 302); P < 0.001) and use of chlorine based disinfection (14.63 (2.8 to 76); P = 0.001) compared with other chemical systems (the referent). None of the other outcome measures showed a significant association. Conclusions-Both failure to disinfect daily wear soft contact lenses and the use of chlorine release lens disinfection systems, which have little protective effect against the organism, are major risk factors for acanthamoeba keratitis. These risks have been particularly common in disposable lens use. Over 80% of acanthamoeba keratitis could be avoided by the use of lens. disinfection systems that are effective against the organism.	MOORFIELDS EYE HOSP,LONDON EC1V 2PD,ENGLAND; INST OPHTHALMOL,DEPT PREVENT OPHTHALMOL,LONDON EC1V 9EL,ENGLAND	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London			Dart, John Kenneth/GZM-7807-2022					BACON AS, 1993, EYE, V7, P719, DOI 10.1038/eye.1993.168; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; DARK JK, 1991, LANCET, V338, P650; DEVONSHIRE P, 1993, BRIT J OPHTHALMOL, V77, P41, DOI 10.1136/bjo.77.1.41; DONZIS PB, 1989, AM J OPHTHALMOL, V108, P53, DOI 10.1016/S0002-9394(14)73260-X; Efron N, 1992, INT CONTACT LENS CLI, V19, P8; HELTON D O, 1991, CLAO Journal, V17, P59; KILVINGTON S, 1990, J APPL BACTERIOL, V68, P519, DOI 10.1111/j.1365-2672.1990.tb02904.x; LARKIN DFP, 1990, BRIT J OPHTHALMOL, V74, P133, DOI 10.1136/bjo.74.3.133; LOWE R, 1992, CLAO Journal, V18, P34; MATTHEWS TD, 1992, ARCH OPHTHALMOL-CHIC, V110, P1559, DOI 10.1001/archopht.1992.01080230059020; MINARIK L, 1989, CLAO Journal, V15, P185; Radford CF, 1993, J BRIT CONTACT LENS, V16, P105; Rosenthal R. A., 1992, J BRIT CONTACT LENS, V15, P81; SCHEIN OD, 1994, ARCH OPHTHALMOL-CHIC, V112, P186, DOI 10.1001/archopht.1994.01090140062024; SEAL D, 1992, BRIT J OPHTHALMOL, V76, P424, DOI 10.1136/bjo.76.7.424; Seal D. V., 1992, Pharmaceutical Journal, V248, P717; SHARMA S, 1990, ARCH OPHTHALMOL-CHIC, V108, P676, DOI 10.1001/archopht.1990.01070070062035; Stapleton Fiona, 1993, CLAO (Contact Lens Association of Ophthalmologists) Journal, V19, P204; STEHRGREEN JK, 1987, JAMA-J AM MED ASSOC, V258, P57, DOI 10.1001/jama.258.1.57; STEHRGREEN JK, 1989, AM J OPHTHALMOL, V107, P331, DOI 10.1016/0002-9394(89)90654-5; WILSON LA, 1990, AM J OPHTHALMOL, V110, P193, DOI 10.1016/S0002-9394(14)76991-0; 1982, NOTES APPLICATIONS P, P23; 1990, STANDARD OCCUPATIONA	24	105	107	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1567	1570		10.1136/bmj.310.6994.1567	http://dx.doi.org/10.1136/bmj.310.6994.1567			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787645	Green Published			2022-12-28	WOS:A1995RE35300019
J	GOTZSCHE, PC; GJORUP, I; BONNEN, H; BRAHE, NEB; BECKER, U; BURCHARTH, F				GOTZSCHE, PC; GJORUP, I; BONNEN, H; BRAHE, NEB; BECKER, U; BURCHARTH, F			SOMATOSTATIN V PLACEBO IN BLEEDING ESOPHAGEAL-VARICES - RANDOMIZED TRIAL AND METAANALYSIS	BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; PRESSURE	Objective-To study whether somatostatin or its derivative octreotide is more effective than placebo for treating bleeding oesophageal varices. Methods-Randomised, double blind trial and meta-analysis with blinded analysis of data and writing of manuscripts. Setting-Departments of medical and surgical gastroenterology in Copenhagen. Subjects-Patients suspected of bleeding from oesophageal varices and of having cirrhosis of the liver. Main outcome measures-Survival, number of blood transfusions, and use of Sengstaken-Blakemore tube. Results-86 patients were randomised; in each group 16 died within six weeks (95% confidence interval for difference in mortality -19% to 22%). There were no differences between those treated with somatostatin or placebo in median number of blood transfusions (8 v 5, P=0.07, 0 to 4 transfusions) or in numbers of patients who needed balloon tamponade (16 v 13, P=0.54, -11% to 28%). In a meta-analysis of three trials involving 290 patients somatostatin had no effect on survival compared with placebo (P=0.59, odds ratio 1.16; 0.67 to 2.01). For blood transfusions and use of balloon tamponade there was heterogeneity between the trials with no convincing evidence in favour of somatostatin. No placebo controlled trials have been performed with octreotide. Conclusion-Within the limited power of this study and meta-analysis we were unable to show a clinical benefit of somatostatin in the emergency treatment of bleeding oesophageal varices.	HVIDOVRE UNIV HOSP,DEPT MED GASTROENTEROL,HVIDOVRE,DENMARK; HERLEV HOSP,DEPT SURG GASTROENTEROL,HERLEV,DENMARK	University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital			Becker, Ulrik/D-2657-2012	Becker, Ulrik/0000-0002-1678-7771				BORNMAN PC, 1994, LANCET, V343, P1079, DOI 10.1016/S0140-6736(94)90186-4; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; GRECO AV, 1982, HORM METAB RES, V14, P26, DOI 10.1055/s-2007-1018911; Hanisch E, 1992, Drugs, V44 Suppl 2, P24, DOI 10.2165/00003495-199200442-00005; KLEBER G, 1988, GUT, V29, P153, DOI 10.1136/gut.29.2.153; Samnegard H, 1980, Acta Chir Scand Suppl, V500, P71; Shadish W., 1994, HDB RES SYNTHESIS, P265; SHEPPARD M, 1979, J CLIN ENDOCR METAB, V48, P50, DOI 10.1210/jcem-48-1-50; SHULKES A, 1994, BRIT MED J, V308, P1381, DOI 10.1136/bmj.308.6941.1381; VALENZUELA JE, 1989, HEPATOLOGY, V10, P958, DOI 10.1002/hep.1840100611; WILLIAMS SGJ, 1994, BRIT MED J, V308, P1213; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	12	62	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1495	1498		10.1136/bmj.310.6993.1495	http://dx.doi.org/10.1136/bmj.310.6993.1495			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787594	Green Published			2022-12-28	WOS:A1995RD28500019
J	ZIMRAN, A; ELSTEIN, D; LEVYLAHAD, E; ZEVIN, S; HADASHALPERN, I; BARZIV, Y; FOLDES, J; SCHWARTZ, AJ; ABRAHAMOV, A				ZIMRAN, A; ELSTEIN, D; LEVYLAHAD, E; ZEVIN, S; HADASHALPERN, I; BARZIV, Y; FOLDES, J; SCHWARTZ, AJ; ABRAHAMOV, A			REPLACEMENT THERAPY WITH IMIGLUCERASE FOR TYPE-1 GAUCHERS-DISEASE	LANCET			English	Note							ENZYME	Gaucher's disease, the most common sphingolipidosis, is caused by deficiency of the lysosomal enzyme glucocerebrosidase. Therapy with alglucerase (the placental enzyme) is safe and effective at various dosing regimens. We report the use of low-dose imiglucerase (the recombinant enzyme) at two dosing schedules: 15 u/kg once fortnightly or 2.5 u/kg thrice weekly. Mean reductions in spleen and liver volumes achieved (in all ten patients) by imiglucerase at 12 months were 36.4% and 14.5%, respectively; mean increase in haemoglobin and platelet counts were 13.4% and 25.7%. There were no serious side-effects. No significant differences were observed between the two schedules. Low-dose low-frequency imiglucerase may be an alternative cost-effective approach with satisfactory clinical response and uncompromised quality of life.	SHAARE ZEDEK MED CTR,DEPT RADIOL,IL-91031 JERUSALEM,ISRAEL; SHAARE ZEDEK MED CTR,DEPT PAEDIAT,IL-91031 JERUSALEM,ISRAEL; HADASSAH UNIV HOSP,DEPT RADIOL,JERUSALEM,ISRAEL; HADASSAH UNIV HOSP,OSTEOPOROSIS INST,JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Hebrew University of Jerusalem	ZIMRAN, A (corresponding author), SHAARE ZEDEK MED CTR,GAUCHER CLIN,POB 3235,IL-91031 JERUSALEM,ISRAEL.		Levy-Lahad, Ephrat/F-2186-2018	Levy-Lahad, Ephrat/0000-0002-2637-1921				BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BARTON NW, 1994, GAUCHER CLIN PERSPEC, V2, P8; FIGUEROA ML, 1992, NEW ENGL J MED, V323, P1632; FRADKIN JE, 1991, JAMA-J AM MED ASSOC, V256, P880; GRABOWSKI GA, 1995, ANN INTERN MED, V122, P33, DOI 10.7326/0003-4819-122-1-199501010-00005; PASTORES GM, 1993, BLOOD, V82, P408; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1993, BLOOD, V82, P1107; ZIMRAN A, 1994, AM J MED, V97, P3, DOI 10.1016/0002-9343(94)90042-6	9	93	96	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1479	1480		10.1016/S0140-6736(95)91038-7	http://dx.doi.org/10.1016/S0140-6736(95)91038-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769903				2022-12-28	WOS:A1995RC18900010
J	BOLDUC, JM; DYER, DH; SCOTT, WG; SINGER, P; SWEET, RM; KOSHLAND, DE; STODDARD, BL				BOLDUC, JM; DYER, DH; SCOTT, WG; SINGER, P; SWEET, RM; KOSHLAND, DE; STODDARD, BL			MUTAGENESIS AND LAUE STRUCTURES OF ENZYME INTERMEDIATES - ISOCITRATE DEHYDROGENASE	SCIENCE			English	Article							X-RAY CRYSTALLOGRAPHY; PROTEIN CRYSTALLOGRAPHY; DIFFRACTION; TIME; MECHANISM; PHOTOGRAPHS; HYDROLYSIS; BINDING	Site-directed mutagenesis and Laue diffraction data to 2.5 Angstrom resolution were used to solve the structures of two sequential intermediates formed during the catalytic actions of isocitrate dehydrogenase. Both intermediates are distinct from the enzyme-substrate and enzyme-product complexes. Mutation of key catalytic residues changed the rate determining steps so that protein and substrate intermediates within the overall reaction pathway could be visualized.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; BROOKHAVEN NATL LABS,DEPT BIOL STRUCT,UPTON,NY 11973; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	MRC Laboratory Molecular Biology; United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Berkeley	BOLDUC, JM (corresponding author), FRED HUTCHINSON CANC RES CTR,PROGRAM STRUCT BIOL,DIV BASIC SCI,1124 COLUMBIA ST A3-023,SEATTLE,WA 98104, USA.			Scott, William/0000-0002-9273-3564	NIGMS NIH HHS [GM49857] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049857] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOW DM, 1992, PHILOS T ROY SOC A, V340, P311, DOI 10.1098/rsta.1992.0069; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMERON AD, 1993, BIOCHEMISTRY-US, V32, P13061, DOI 10.1021/bi00211a016; DEAN AM, 1992, BIOCHEMISTRY-US, V132, P9302; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GETZOFF ED, 1993, NUCL INSTRUM METH B, V79, P249, DOI 10.1016/0168-583X(93)95337-5; GRISSOM CB, 1988, BIOCHEMISTRY-US, V27, P2934, DOI 10.1021/bi00408a040; HAJDU J, 1987, NATURE, V329, P178, DOI 10.1038/329178a0; HELLIWELL JR, 1989, J APPL CRYSTALLOGR, V22, P483, DOI 10.1107/S0021889889006564; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; JOHNSON LN, 1992, PROTEIN SCI, V1, P1237, DOI 10.1002/pro.5560011002; LEE ME, 1995, BIOCHEMISTRY-US, V34, P378, DOI 10.1021/bi00001a046; OCHOA S, 1948, J BIOL CHEM, V174, P115; PETSKO GA, 1992, PHILOS T ROY SOC A, V340, P323, DOI 10.1098/rsta.1992.0070; PLAUT G, 1963, ENZYMES, P112; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; SCHEIDIG AJ, 1994, ACTA CRYSTALLOGR D, V50, P512, DOI 10.1107/S090744499301443X; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SINGER PT, 1993, SCIENCE, V259, P669, DOI 10.1126/science.8430314; STODDARD BL, 1991, P NATL ACAD SCI USA, V88, P5503, DOI 10.1073/pnas.88.13.5503; STODDARD BL, 1992, BIOCHEMISTRY-US, V32, P9310; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; WALSH C, 1979, ENZYMATIC REACTION M, P344	24	113	117	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1312	1318		10.1126/science.7761851	http://dx.doi.org/10.1126/science.7761851			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761851	Green Submitted			2022-12-28	WOS:A1995RB19800028
J	FORMAN, BM; GOODE, E; CHEN, J; ORO, AE; BRADLEY, DJ; PERLMANN, T; NOONAN, DJ; BURKA, LT; MCMORRIS, T; LAMPH, WW; EVANS, RM; WEINBERGER, C				FORMAN, BM; GOODE, E; CHEN, J; ORO, AE; BRADLEY, DJ; PERLMANN, T; NOONAN, DJ; BURKA, LT; MCMORRIS, T; LAMPH, WW; EVANS, RM; WEINBERGER, C			IDENTIFICATION OF A NUCLEAR RECEPTOR THAT IS ACTIVATED BY FARNESOL METABOLITES	CELL			English	Article							RETINOID-X-RECEPTOR; THYROID-HORMONE; ECDYSONE RECEPTOR; RXR-BETA; ACID; MEVALONATE; PROTEIN; HETERODIMERIZATION; ULTRASPIRACLE; SUPERFAMILY	Nuclear hormone receptors comprise a superfamily of ligand-modulated transcription factors that mediate the transcriptional activities of steroids, retinoids, and thyroid hormones. A growing number of related proteins have been identified that possess the structural features of hormone receptors, but that lack known ligands, Known as orphan receptors, these proteins represent targets for novel signaling molecules. We have isolated a mammalian orphan receptor that forms a heterodimeric complex with the retinoid X receptor. A screen of candidate ligands identified farnesol and related metabolites as effective activators of this complex. Farnesol metabolites are generated intracellularly and are required for the synthesis of cholesterol, bile acids, steroids, retinoids, and farnesylated proteins. Intermediary metabolites have been recognized as transcriptional regulators in bacteria and yeast. Our results now suggest that metabolite-controlled intracellular signaling systems are utilized by higher organisms.	SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037; NIEHS,RECEPTOR BIOL GRP,RES TRIANGLE PK,NC 27709; NIEHS,REPROD & DEV TOXICOL LAB,ORGAN CHEM GRP,RES TRIANGLE PK,NC 27709; NIH,CELL BIOL LAB,BETHESDA,MD 20892; UNIV KENTUCKY,DEPT BIOCHEM,LEXINGTON,KY 40506; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093; LIGAND PHARMACEUT INC,SAN DIEGO,CA 92121	Howard Hughes Medical Institute; Salk Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; University of Kentucky; University of California System; University of California San Diego; Ligand Pharmaceuticals	FORMAN, BM (corresponding author), SALK INST BIOL STUDIES,GENE EXPRESS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; BROWN MS, 1980, J LIPID RES, V21, P505; EDMOND J, 1976, SCIENCE, V193, P154, DOI 10.1126/science.935865; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOMEZ R, 1993, BIOCHEM J, V289, P25, DOI 10.1042/bj2890025; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KIM CM, 1992, J BIOL CHEM, V267, P23113; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KULKARNI YS, 1987, J ORG CHEM, V52, P1568, DOI 10.1021/jo00384a035; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEID M, 1992, CELL, V71; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MOORE D D, 1990, New Biologist, V2, P100; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OMALLEY BW, 1989, ENDOCRINOLOGY, V125, P1119, DOI 10.1210/endo-125-3-1119; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIGHETTI M, 1976, J BIOL CHEM, V251, P2716; Rilling H. C., 1985, STEROLS BILE ACIDS, P1; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; SUTCLIFFE JG, 1984, SCIENCE, V225, P1308, DOI 10.1126/science.6474179; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; TNTONOZ P, 1994, CELL, V79, P1147; TOMKINS GM, 1975, SCIENCE, V189, P760, DOI 10.1126/science.169570; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILEY MH, 1977, J BIOL CHEM, V252, P548; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	45	924	1043	1	49	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					687	693		10.1016/0092-8674(95)90530-8	http://dx.doi.org/10.1016/0092-8674(95)90530-8			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774010	Bronze			2022-12-28	WOS:A1995RB96100007
J	HELENIUS, A				HELENIUS, A			ALPHAVIRUS AND FLAVIVIRUS GLYCOPROTEINS - STRUCTURES AND FUNCTIONS	CELL			English	Review							SEMLIKI-FOREST VIRUS; MEMBRANE-FUSION; HEMAGGLUTININ; PROTEIN; SINDBIS; PH				HELENIUS, A (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510, USA.							ALLISON SL, 1995, J VIROL, V69, P695, DOI 10.1128/JVI.69.2.695-700.1995; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHENG RH, 1995, CELL, V80, P621; FULLER SD, 1995, CELL, V81, P715, DOI 10.1016/0092-8674(95)90533-2; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; KIELIAN M, 1995, ADV VIRUS RES, V45, P113, DOI 10.1016/S0065-3527(08)60059-7; LEVYMINTZ P, 1991, J VIROL, V65, P4292, DOI 10.1128/JVI.65.8.4292-4300.1991; REY FA, 1995, IN PRESS NATURE; SODERLUND H, 1979, J GEN VIROL, V45, P15, DOI 10.1099/0022-1317-45-1-15; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; STUBBS MJ, 1991, J MOL BIOL, V221, P39, DOI 10.1016/0022-2836(91)80200-E; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WHITE J, 1980, P NATL ACAD SCI-BIOL, V77, P3273, DOI 10.1073/pnas.77.6.3273; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	16	37	37	0	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					651	653		10.1016/0092-8674(95)90523-5	http://dx.doi.org/10.1016/0092-8674(95)90523-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774004	Bronze			2022-12-28	WOS:A1995RB96100001
J	FORMAN, BM; UMESONO, K; CHEN, J; EVANS, RM				FORMAN, BM; UMESONO, K; CHEN, J; EVANS, RM			UNIQUE RESPONSE PATHWAYS ARE ESTABLISHED BY ALLOSTERIC INTERACTIONS AMONG NUCLEAR HORMONE RECEPTORS	CELL			English	Article							RETINOID-X-RECEPTOR; TATA-BINDING PROTEIN; THYROID-HORMONE; DNA-BINDING; TRANSCRIPTION FACTOR; ACID RECEPTORS; AUXILIARY PROTEIN; ORPHAN RECEPTORS; MAMMALIAN-CELLS; GENE-EXPRESSION	Heterodimerization is a common paradigm among eukaryotic transcription factors. The 9-cis retinoic acid receptor (RXR) serves as a common heterodimerization partner for several nuclear receptors, including the thyroid hormone receptor (T(3)R) and retinoic acid receptor (RAR). This raises the question as to whether these complexes possess dual hormonal responsiveness. We devised a strategy to examine the transcriptional properties of each receptor individually or when tethered to a heterodimeric partner. We find that the intrinsic binding properties of RXR are masked in T(3)R-RXR and RAR-RXR heterodimers. In contrast, RXR is active as a non-DNA-binding cofactor with the NGFI-B/Nurr1 orphan receptors. Heterodimerization of RXR with constitutively active NGFI-B/Nurr1 creates a novel hormone-dependent complex. These findings suggest that allosteric interactions among heterodimers create complexes with unique properties. We suggest that allostery is a critical feature underlying the generation of diversity in hormone response networks.	HOWARD HUGHES MED INST, GENE EXPRESS LAB, SAN DIEGO, CA 92037 USA	Howard Hughes Medical Institute	FORMAN, BM (corresponding author), SALK INST BIOL STUDIES, SAN DIEGO, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026444, R01GM026444] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26444] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOEHM MF, 1994, J MED CHEM, V37, P408, DOI 10.1021/jm00029a013; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEHMANN JM, 1993, MOL CELL BIOL, V13, P7698, DOI 10.1128/MCB.13.12.7698; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEYERS RE, 1993, MOL CELL BIOL, V13, P7953, DOI 10.1128/MCB.13.12.7953; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TITCOMB MW, 1994, MOL ENDOCRINOL, V8, P870, DOI 10.1210/me.8.7.870; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UNDERHILL TM, 1994, MOL ENDOCRINOL, V8, P274, DOI 10.1210/me.8.3.274; WILLIAMS GR, 1991, J BIOL CHEM, V266, P19636; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YEN PM, 1992, J BIOL CHEM, V267, P3565; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	76	566	591	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					541	550		10.1016/0092-8674(95)90075-6	http://dx.doi.org/10.1016/0092-8674(95)90075-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758108	Bronze			2022-12-28	WOS:A1995QZ71000011
J	SCHNEEWEIS, DM; SCHNAPF, JL				SCHNEEWEIS, DM; SCHNAPF, JL			PHOTOVOLTAGE OF RODS AND CONES IN THE MACAQUE RETINA	SCIENCE			English	Article							MONKEY MACACA-FASCICULARIS; TURTLE PHOTORECEPTORS; VISUAL TRANSDUCTION; SALAMANDER; SENSITIVITY; SEGMENTS; CAT	The kinetics, gain, and reliability of light responses of rod and cone photoreceptors are important determinants of overall Visual sensitivity. In voltage recordings from photoreceptors in an intact primate retina, rods were found to be functionally isolated from each other, unlike the tightly coupled rods of cold-blooded vertebrates. Cones were observed to receive excitatory input from rods, which indicates that the cone pathway also processes rod signals, This input might be expected to degrade the spatial resolution of mesopic vision.	UNIV CALIF SAN FRANCISCO,DEPT OPHTHALMOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NEI NIH HHS [R01-EY07642, F32-EY06399] Funding Source: Medline; NATIONAL EYE INSTITUTE [F32EY006399, R01EY007642] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BADER CR, 1979, J PHYSIOL-LONDON, V296, P1; BADER CR, 1982, J PHYSIOL-LONDON, V331, P253, DOI 10.1113/jphysiol.1982.sp014372; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BAYLOR DA, 1971, J PHYSIOL-LONDON, V214, P265, DOI 10.1113/jphysiol.1971.sp009432; BAYLOR DA, 1987, J PHYSIOL-LONDON, V390, P145, DOI 10.1113/jphysiol.1987.sp016691; BAYLOR DA, 1973, J PHYSIOL-LONDON, V234, P163, DOI 10.1113/jphysiol.1973.sp010340; BAYLOR DA, 1986, J PHYSIOL-LONDON, V371, P115, DOI 10.1113/jphysiol.1986.sp015964; BAYLOR DA, 1984, J PHYSIOL-LONDON, V387, P575; BAYLOR DA, 1976, COLD SPRING HARB SYM, V40, P529; CONNER JD, 1977, SCIENCE, V195, P698, DOI 10.1126/science.841308; CONNER JD, 1982, J PHYSIOL-LONDON, V332, P139, DOI 10.1113/jphysiol.1982.sp014406; COPENHAGEN DR, 1983, VISION RES, V4, P363; DETWILER PB, 1980, J PHYSIOL-LONDON, V300, P213, DOI 10.1113/jphysiol.1980.sp013159; FAIN GL, 1975, SCIENCE, V187, P838, DOI 10.1126/science.1114328; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KNIGHT R, 1993, VISION RES, V33, P2203, DOI 10.1016/0042-6989(93)90100-B; KRAFT TW, 1993, J PHYSIOL-LONDON, V464, P747, DOI 10.1113/jphysiol.1993.sp019661; LAMB TD, 1976, J PHYSIOL-LONDON, V263, P257, DOI 10.1113/jphysiol.1976.sp011631; NELSON R, 1977, J COMP NEUROL, V172, P109, DOI 10.1002/cne.901720106; Nelson R., 1985, NEUROCIRCUITRY RETIN, P109; RAVIOLA E, 1973, P NATL ACAD SCI USA, V70, P1677, DOI 10.1073/pnas.70.6.1677; SCHNAPF JL, 1990, J PHYSIOL-LONDON, V427, P681, DOI 10.1113/jphysiol.1990.sp018193; SCHNAPF JL, 1983, J PHYSIOL-LONDON, V343, P147, DOI 10.1113/jphysiol.1983.sp014886; SCHNAPF JL, 1983, NATURE, V296, P862; SMITH RG, 1986, J NEUROSCI, V6, P3505; YAGI T, 1994, J NEUROPHYSIOL, V71, P656, DOI 10.1152/jn.1994.71.2.656	26	239	243	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1053	1056		10.1126/science.7754386	http://dx.doi.org/10.1126/science.7754386			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754386				2022-12-28	WOS:A1995QY93400042
J	DONG, JT; LAMB, PW; RINKERSCHAEFFER, CW; VUKANOVIC, J; ICHIKAWA, T; ISAACS, JT; BARRETT, JC				DONG, JT; LAMB, PW; RINKERSCHAEFFER, CW; VUKANOVIC, J; ICHIKAWA, T; ISAACS, JT; BARRETT, JC			KAI1, A METASTASIS SUPPRESSOR GENE FOR PROSTATE-CANCER ON HUMAN-CHROMOSOME 11P11.2	SCIENCE			English	Article							TRANSMEMBRANE PROTEINS; SYNCYTIUM FORMATION; TUMOR PROGRESSION; MOLECULAR-CLONING; INCLUDING CD9; CELL-FUSION; ANTIGEN; FAMILY; IDENTIFICATION; ANTIBODY	A gene from human chromosome 11p11.2 was isolated and was shown to suppress metastasis when introduced into rat AT6.1 prostate cancer cells. Expression of this gene, designated KAI1, was reduced in human cell lines derived from metastatic prostate tumors. KAI1 specifies a protein of 267 amino acids, with four hydrophobic and presumably transmembrane domains and one large extracellular hydrophilic domain with three potential N-glycosylation sites. KAI1 is evolutionarily conserved, is expressed in many human tissues, and encodes a member of a structurally distinct family of leukocyte surface glycoproteins. Decreased expression of this gene may be involved in the malignant progression of prostate and other cancers.	NIEHS, MOLEC CARCINOGENESIS LAB, ENVIRONM CARCINOGENESIS PROGRAM, RES TRIANGLE PK, NC 27709 USA; JOHNS HOPKINS UNIV, SCH MED, JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21231 USA; CHIBA UNIV, SCH MED, DEPT UROL, CHIBA 260, JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; Johns Hopkins Medicine; Chiba University			Criley, Jasminka/ABF-7288-2021	Dong, Jin-Tang/0000-0003-2349-5782	NCI NIH HHS [CA 58236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIOT M, 1990, J IMMUNOL, V145, P4322; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; CLASSON BJ, 1989, J EXP MED, V169, P1497, DOI 10.1084/jem.169.4.1497; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dong J.-K., UNPUB; DRICKAMER K, 1992, CURR OPIN STRUC BIOL, V2, P653; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; GIL ML, 1992, J IMMUNOL, V148, P2826; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HOREJSI V, 1991, FEBS LETT, V288, P1, DOI 10.1016/0014-5793(91)80988-F; Horoszewicz JS, 1980, MODELS PROSTATE CANC, P115; HOTTA H, 1988, CANCER RES, V48, P2955; ICHIKAWA T, 1991, CANCER RES, V51, P3788; ICHIKAWA T, 1992, CANCER RES, V52, P3486; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; IMAI T, 1992, J IMMUNOL, V149, P2879; ISHIKAWA M, 1988, CANCER RES, V48, P665; KAIGHN ME, 1979, INVEST UROL, V17, P16; KONDOH M, 1993, MELANOMA RES, V3, P241; LEVY S, 1991, J BIOL CHEM, V266, P14597; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; NICOLSON GL, 1991, BIOESSAYS, V13, P337, DOI 10.1002/bies.950130706; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; RAMSHAW IA, 1983, INT J CANCER, V32, P471, DOI 10.1002/ijc.2910320414; RINKERSCHAEFFER CW, 1994, CANCER RES, V54, P6249; ROSENBERG SA, 1987, SURGICAL TREATMENT M; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SIDEBOTTOM E, 1983, BRIT J CANCER, V47, P399, DOI 10.1038/bjc.1983.60; STEEG P S, 1992, Current Opinion in Oncology, V4, P134, DOI 10.1097/00001622-199202000-00018; VUKANOVIC J, 1993, CANCER RES, V53, P1833	35	715	847	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					884	886		10.1126/science.7754374	http://dx.doi.org/10.1126/science.7754374			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754374	Green Submitted			2022-12-28	WOS:A1995QX85000041
J	TANAKA, Y; MORITA, CT; TANAKA, Y; NIEVES, E; BRENNER, MB; BLOOM, BR				TANAKA, Y; MORITA, CT; TANAKA, Y; NIEVES, E; BRENNER, MB; BLOOM, BR			NATURAL AND SYNTHETIC NONPEPTIDE ANTIGENS RECOGNIZED BY HUMAN GAMMA-DELTA T-CELLS	NATURE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; EXPANSION; RECEPTOR; PROTEIN; SUBSET	T LYMPHOCYTES express either alpha beta or gamma delta T-cell receptor heterodimers(1,2). Most alpha beta T cells recognize antigenic peptides bound to major histocompatibility complex molecules but the antigen recognition and biological function of gamma delta T cells is unknown. A major human gamma delta T-cell subset expressing V gamma 2 and V delta 2 germline genes, but having diverse junctional sequences, is found in human mycobacterial lesions(3) and responds in vitro to antigens of bacteria and parasites(4-8). In addition, certain haematopoietic tumour cells are specifically recognized and lysed by these T cells(9). V gamma 2V delta 2-bearing T cells were shown to recognize mycobacterial antigens that are protease resistant and phosphatase sensitive(10-13). Because of the difficulty in isolating natural antigens from mycobacterial culture filtrates or extracts, we synthesized a series of monoalkyl phosphates, and found that some, particularly monoethyl phosphate, could mimic the activity of mycobacterial antigens in stimulating these gamma delta T cells(10). Here we report the identification of natural antigens produced by mycobacteria recognized by human V gamma 2V delta 2-bearing T cells as isopentenyl pyrophosphate and related prenyl pyrophosphate derivatives, compounds involved in the synthesis of complex polyisoprenoid compounds in microbial and mammalian cells. Substitution of phosphate for the pyrophosphate moiety, or elimination of the double bond, greatly reduced antigenic activity of these compounds. These results provide formal evidence that, in contrast to recognition of major histocompatibility complex-bound peptide antigens by alpha beta T cells, human gamma delta T cells can recognize naturally occurring small non-peptidic antigens.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; BRIGHAM & WOMENS HOSP,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Morita, Craig T/C-1365-2011	Morita, Craig T/0000-0001-8496-8294; Tanaka, Yoshimasa/0000-0002-5024-0614				Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; BEEKMAN EM, 1994, NATURE, V372, P691, DOI 10.1038/372691a0; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BUKOWSKI JF, 1994, J IMMUNOL, V153, P5133; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; ECKSTEIN F, 1975, BIOCHEMISTRY-US, V23, P5225; FISCH P, 1990, SCIENCE, V250, P1269, DOI 10.1126/science.1978758; GOERLICH R, 1991, EUR J IMMUNOL, V21, P2613, DOI 10.1002/eji.1830211045; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARA T, 1992, J CLIN INVEST, V90, P204, DOI 10.1172/JCI115837; HAVLIR DV, 1991, J CLIN INVEST, V87, P729, DOI 10.1172/JCI115053; KABELITZ D, 1990, J EXP MED, V171, P667, DOI 10.1084/jem.171.3.667; KHOSRAVIFAR R, 1992, CELL GROWTH DIFFER, V3, P461; KNORRE DG, 1976, FEBS LETT, V70, P105, DOI 10.1016/0014-5793(76)80736-3; Marrack P, 1986, Adv Immunol, V38, P1, DOI 10.1016/S0065-2776(08)60005-X; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; Myant, 1981, BIOL CHOLESTEROL REL, P123, DOI DOI 10.1016/B978-0-433-22880-6.50010-2; PANCHAMOORTHY G, 1991, J IMMUNOL, V147, P3360; PFEFFER K, 1990, EUR J IMMUNOL, V20, P1175, DOI 10.1002/eji.1830200534; POPJAK G, 1962, J BIOL CHEM, V237, P56; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHOEL B, 1994, EUR J IMMUNOL, V24, P1886, DOI 10.1002/eji.1830240826; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175	27	820	850	1	21	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					155	158		10.1038/375155a0	http://dx.doi.org/10.1038/375155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753173				2022-12-28	WOS:A1995QX74100054
J	DONNAN, GA; DAVIS, SM; CHAMBERS, BR; GATES, PC; HANKEY, GJ; MCNEIL, JJ; ROSEN, D; STEWARTWYNNE, EG; TUCK, RR				DONNAN, GA; DAVIS, SM; CHAMBERS, BR; GATES, PC; HANKEY, GJ; MCNEIL, JJ; ROSEN, D; STEWARTWYNNE, EG; TUCK, RR			TRIALS OF STREPTOKINASE IN SEVERE ACUTE ISCHEMIC STROKE	LANCET			English	Letter							ACUTE ISCHEMIC STROKE; AGENTS				DONNAN, GA (corresponding author), AUSTIN HOSP,DEPT NEUROL,HEIDELBERG,VIC 3084,AUSTRALIA.		DONNAN, GEOFFREY A/A-9947-2008; Hankey, Graeme J/H-4968-2014; Davis, Stephen M/L-5260-2013; McNeil, John/L-6440-2019	Hankey, Graeme J/0000-0002-6044-7328; Davis, Stephen M/0000-0003-0962-2300; McNeil, John/0000-0002-1049-5129; Donnan, Geoffrey/0000-0001-6324-3403				[Anonymous], 1990, Lancet, V336, P65; BENES V, 1990, STROKE, V21, P1594, DOI 10.1161/01.STR.21.11.1594; DONNAN GA, 1993, THROMBOLYTIC THERAPY, P80; MORI E, 1993, CEREBROVASC DIS, V3, P264, DOI 10.1159/000108713; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826	5	164	167	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					578	579						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776784				2022-12-28	WOS:A1995QK44400029
J	ROBINSON, GR				ROBINSON, GR			SEVERE CRYPTOCOCCAL PNEUMONIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ROBINSON, GR (corresponding author), YORK HOSP, YORK, PA 17405 USA.								0	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1752	1752		10.1056/NEJM199506293322605	http://dx.doi.org/10.1056/NEJM199506293322605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760892				2022-12-28	WOS:A1995RE66700005
J	ZERR, I; BODEMER, M; RACKER, S; GROSCHE, S; POSER, S; KRETZSCHMAR, HA; WEBER, T				ZERR, I; BODEMER, M; RACKER, S; GROSCHE, S; POSER, S; KRETZSCHMAR, HA; WEBER, T			CEREBROSPINAL-FLUID CONCENTRATION OF NEURON-SPECIFIC ENOLASE IN DIAGNOSIS OF CREUTZFELDT-JAKOB-DISEASE	LANCET			English	Note								Neuron-specific enolase (NSE) is among the biochemical markers in cerebrospinal fluid reported to be useful in the differential diagnosis of Creutzfeldt-Jakob disease from other dementing illnesses. In a group of 58 patients definite and Creutzfeldt-Jakob disease, with probable NSE concentrations (median 94 . 0, interquartile range 256 ng/mL) were significantly higher (p<0 . 001) than in 26 control patients (9 . 5, 15 . 5 ng/mL). At a cut-off of 35 ng/mL an optimum sensitivity of 80% with a specificity of 92% for the diagnosis of Creutzfeldt-Jakob disease by NSE in cerebrospinal fluid was obtained.	UNIV GOTTINGEN,NEUROL KLIN & POLIKLIN,D-37075 GOTTINGEN,GERMANY; UNIV GOTTINGEN,INST NEUROPATHOL,D-37075 GOTTINGEN,GERMANY	University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen				Weber, Thomas/0000-0002-3833-6197				BROWN P, 1994, ANN NEUROL, V35, P13; JACOBI C, 1988, CLIN CHIM ACTA, V177, P49, DOI 10.1016/0009-8981(88)90306-3; JIMI T, 1992, CLIN CHIM ACTA, V11, P37; Kretzschmar H A, 1993, Arch Virol Suppl, V7, P261; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; TATEISHI J, 1993, BRIT MED BULL, V49, P971, DOI 10.1093/oxfordjournals.bmb.a072656; TIETJEN GE, 1990, ANN NEUROL, V28, P585, DOI 10.1002/ana.410280420; VERMUYTEN K, 1990, CLIN CHIM ACTA, V187, P69, DOI 10.1016/0009-8981(90)90332-M; WAKAYAMA Y, 1987, KLIN WOCHENSCHR, V65, P798, DOI 10.1007/BF01743256	10	150	153	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1609	1610		10.1016/S0140-6736(95)90118-3	http://dx.doi.org/10.1016/S0140-6736(95)90118-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783539				2022-12-28	WOS:A1995RE67000011
J	GHODSE, B				GHODSE, B			EXTRACONTRACTUAL REFERRALS - SAFETY VALVE OR ADMINISTRATIVE PAPERCHASE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe the extracontractual referrals of residents of a health authority during a six month period in 1994, identifying the number and cost of emergency and non-emergency referrals, including the number of cases costing more than pound 20 000 and those cases when payment was refused. Design-Descriptive analysis of all extracontractual referrals submitted to the health authority between 1 April and 30 September 1994. Setting-A health authority covering a poulation of 614000. Results-Payment of pound 2 583 693 was made to 263 different providers for 2400 episodes of care, of which 1469 were emergencies and 931 were elective or tertiary referrals. Authorisation was granted for an additional 1376 referrals for future treatment but was refused in 713 instances, mostly for technical reasons. Sixteen extracontractual referrals together accounted for over a fifth of total expenditure during the study period. Conclusions-Handling large numbers of episodes of care on an individual cost per case basis imposes an enormous administrative burden on both purchasers and providers, diverting money away from patient care. Extracontractual referrals also expose health authorities to considerable financial risk and may undermine commissioning strategies. Measures are proposed to limit the number of episodes handled in this way.			GHODSE, B (corresponding author), ST GEORGE HOSP,ST GEORGES HEALTHCARE TRUST,GROSVENOR WING,LONDON SW17 0QT,ENGLAND.							Auplish S, 1994, Health Serv J, V104, P24; GHODSE B, 1991, BRIT MED J, V303, P497, DOI 10.1136/bmj.303.6801.497; WILLIAMSON JD, 1991, BRIT MED J, V303, P494; 1993, ESTABLISHING DISTRIC; 1994, FDL9433 NHS EX; 1993, NHS11 AUD COMM REP	6	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1573	1576		10.1136/bmj.310.6994.1573	http://dx.doi.org/10.1136/bmj.310.6994.1573			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787648	Green Published			2022-12-28	WOS:A1995RE35300023
J	KUIPERS, EJ; UYTERLINDE, AM; PENA, AS; ROOSENDAAL, R; PALS, G; NELIS, GF; FESTEN, HPM; MEUWISSEN, SGM				KUIPERS, EJ; UYTERLINDE, AM; PENA, AS; ROOSENDAAL, R; PALS, G; NELIS, GF; FESTEN, HPM; MEUWISSEN, SGM			LONG-TERM SEQUELAE OF HELICOBACTER-PYLORI GASTRITIS	LANCET			English	Article							FOLLOW-UP; CANCER-EPIDEMIOLOGY; INFECTION; CARCINOMA; RISK; CAMPYLOBACTER; POPULATION; ATROPHY; AGE	Chronic Helicobacter pylori gastritis has been put forward as a risk factor for development of gastric mucosal atrophy and gastric cancer. The purpose of our study was to investigate the long-term effects of H pylori gastritis on the gastric mucosa. We prospectively studied 49 subjects negative for H pylori and 58 positive subjects for a mean follow-up of 11.5 years (range 10-13 years). Serum samples were obtained at the initial and follow-up visits for determination of H pylori IgG antibodies. Gastroscopies with biopsy sampling were done in all patients at both visits. Biopsy specimens were used for assessment of H pylori infection and histology. Development of atrophic gastritis and intestinal metaplasia occurred in 2 (4%) uninfected and 16 (28%) infected subjects. Regression of atrophy was noted in 4 (7%) infected subjects. Development of atrophic gastritis and intestinal metaplasia was significantly associated with H pylori infection (p=0.0014; odds ratio 9.0, 95% Cl 1.9-41.3). The proportion of atrophic gastritis in the Study population showed an annual increase of 1.15% (0.5-1.8%). We conclude that H pylori infection is a significant risk factor for development of atrophic gastritis and intestinal metaplasia. Our findings support strongly the causative role of this infection in gastric carcinogenesis.	FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT CLIN MICROBIOL,1007 MB AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT HUMAN GENET,1007 MB AMSTERDAM,NETHERLANDS; SOPHIA HOSP,DEPT GASTROENTEROL,ZWOLLE,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	KUIPERS, EJ (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT GASTROENTEROL,POB 7057,1007 MB AMSTERDAM,NETHERLANDS.		Kuipers, Ernst J/H-3293-2019; Pals, Gerard/A-5198-2011; Beales, Ian/M-5161-2014	Kuipers, Ernst J/0000-0002-0633-3098; Beales, Ian/0000-0003-1923-3237; Pals, Gerard/0000-0003-4091-7115				[Anonymous], 1994, IARC MONOGR EVAL CAR, V61, P1; BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; CORREA P, 1975, LANCET, V2, P58; CORREA P, 1990, CANCER RES, V50, P4737; CORREA P, 1992, CANCER RES, V52, P6735; DIXON MF, 1991, J GASTROEN HEPATOL, V6, P125, DOI 10.1111/j.1440-1746.1991.tb01451.x; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; FORMAN D, 1994, LANCET, V343, P243, DOI 10.1016/S0140-6736(94)91034-0; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; GENTA RM, 1993, MODERN PATHOL, V6, P288; IHAMAKI T, 1985, SCAND J GASTROENTERO, V20, P485, DOI 10.3109/00365528509089685; KATELARIS PH, 1993, GUT, V34, P1032, DOI 10.1136/gut.34.8.1032; KUIPERS EJ, 1993, LANCET, V342, P328, DOI 10.1016/0140-6736(93)91473-Y; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PRICE AB, 1991, J GASTROEN HEPATOL, V6, P209, DOI 10.1111/j.1440-1746.1991.tb01468.x; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; SIPPONEN P, 1984, BRIT J CANCER, V49, P521, DOI 10.1038/bjc.1984.80; SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415; VILLAKO K, 1991, SCAND J GASTROENTERO, V26, P135, DOI 10.3109/00365529109104000; WARREN JR, 1983, LANCET, V1, P1273	23	665	685	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1525	1528		10.1016/S0140-6736(95)91084-0	http://dx.doi.org/10.1016/S0140-6736(95)91084-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791437				2022-12-28	WOS:A1995RD79000006
J	MACPHEE, M; CHEPENIK, KP; LIDDELL, RA; NELSON, KK; SIRACUSA, LD; BUCHBERG, AM				MACPHEE, M; CHEPENIK, KP; LIDDELL, RA; NELSON, KK; SIRACUSA, LD; BUCHBERG, AM			THE SECRETORY PHOSPHOLIPASE-A2 GENE IS A CANDIDATE FOR THE MOM1 LOCUS, A MAJOR MODIFIER OF APC(MIN)-INDUCED INTESTINAL NEOPLASIA	CELL			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; MEMBRANE-ASSOCIATED PHOSPHOLIPASE-A2; COLON-CANCER; COLORECTAL-CANCER; ENHANCING FACTOR; APC GENE; MOUSE; IDENTIFICATION; EXPRESSION; MUTATIONS	Mutations in the APC gene are responsible for various familial and sporadic colorectal cancers. Min mice carry a dominant mutation in the homolog of the Ape gene and develop multiple adenomas throughout their small and large intestine. Quantitative trait loci studies have identified a locus, Mom1, which maps to the distal region of chromosome 4, that dramatically modifies Min-induced tumor number. We report here the identification of a candidate gene for Mom1. The gene for secretory type II phospholipase A2 (Pla2s) maps to the same region that contains Mom1 and displays 100% concordance between allele type and tumor susceptibility. Expression and sequence analysis revealed that Mom1 susceptible strains are most likely null for Pla2s activity. Our results indicate that Pla2s acts as a novel gene that modifies polyp number by altering the cellular microenvironment within the intestinal crypt.	JEFFERSON CANC CTR,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; JEFFERSON CANC INST,PHILADELPHIA,PA 19107; JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University				Buchberg, Arthur/0000-0002-0543-5631	NATIONAL CANCER INSTITUTE [R01CA058586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045717] Funding Source: NIH RePORTER; NCI NIH HHS [CA58586] Funding Source: Medline; NIDDK NIH HHS [DK45717] Funding Source: Medline; NIGMS NIH HHS [GM16439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGESON AC, 1995, GENOMICS, V25, P29, DOI 10.1016/0888-7543(95)80106-V; BELGRADER P, 1994, MOL CELL BIOL, V14, P6326, DOI 10.1128/MCB.14.9.6326; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CHEN J, 1993, BIOCHIM BIOPHYS ACTA, V1215, P115; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DEO MG, 1983, INDIAN J BIOCHEM BIO, V20, P228; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GIARDIELLO FM, 1994, GASTROENTEROLOGY, V106, P1542, DOI 10.1016/0016-5085(94)90408-1; GLASER KB, 1993, TRENDS PHARMACOL SCI, V14, P92, DOI 10.1016/0165-6147(93)90071-Q; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1989, FAMILIAL ADENOMATOUS, P35; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; Johnson L K, 1990, Adv Exp Med Biol, V275, P17; KAISER E, 1990, CLIN BIOCHEM, V23, P349, DOI 10.1016/0009-9120(90)90051-U; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KIRKLAND SC, 1988, CANCER, V61, P1359, DOI 10.1002/1097-0142(19880401)61:7<1359::AID-CNCR2820610714>3.0.CO;2-0; KLEMMER S, 1987, AM J MED GENET, V28, P385, DOI 10.1002/ajmg.1320280217; KOMADA M, 1990, BIOCHEM BIOPH RES CO, V168, P1059, DOI 10.1016/0006-291X(90)91137-H; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V117, P217; KURIZAKI T, 1992, RES COMMUN CHEM PATH, V78, P39; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEISTER I, 1990, CANCER RES, V50, P7232; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LEVY DB, 1994, CANCER RES, V54, P5953; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; Lyon M. F., 1995, Mouse Genome, V93, P23; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MARNETT LJ, 1992, CANCER RES, V52, P5575; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MOSER AR, 1992, J CELL BIOL, V116, P1516; MUKHERJEE AB, 1992, DNA CELL BIOL, V11, P233, DOI 10.1089/dna.1992.11.233; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MULHERKAR R, 1991, HISTOCHEMISTRY, V96, P367, DOI 10.1007/BF00271358; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; PAUL P, 1993, HUM MOL GENET, V2, P925, DOI 10.1093/hmg/2.7.925; PENCE BC, 1985, MUTAT RES, V158, P53, DOI 10.1016/0165-1218(85)90097-7; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; RAO CV, 1995, CANCER RES, V55, P1464; REDDY BS, 1993, PREV MED, V22, P738, DOI 10.1006/pmed.1993.1068; RUMNEY CJ, 1993, NUTR CANCER, V19, P67, DOI 10.1080/01635589309514237; Sambrook J, 1989, MOL CLONING LABORATO; SIRACUSA LD, 1987, GENETICS, V117, P85; SPIRIO L, 1992, AM J HUM GENET, V51, P92; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; THUN MJ, 1994, CANCER METAST REV, V13, P269, DOI 10.1007/BF00666097; UTSUGI T, 1991, CANCER RES, V51, P3062; VANTASSELL RL, 1990, MUTAT RES, V238, P209, DOI 10.1016/0165-1110(90)90013-2	60	526	533	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					957	966		10.1016/0092-8674(95)90015-2	http://dx.doi.org/10.1016/0092-8674(95)90015-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781071	Bronze			2022-12-28	WOS:A1995RD76800016
J	REBAY, I; RUBIN, GM				REBAY, I; RUBIN, GM			YAN FUNCTIONS AS A GENERAL INHIBITOR OF DIFFERENTIATION AND IS NEGATIVELY REGULATED BY ACTIVATION OF THE RAS1/MAPK PATHWAY	CELL			English	Article							PROTEIN-KINASE; NUCLEAR-LOCALIZATION; SEVENLESS PROTEIN; DROSOPHILA; NOTCH; EXPRESSION; SEQUENCE; RECEPTOR; DOMAIN; EYE	Drosophila yan has been postulated to act as an antagonist of the proneural signal mediated by the sevenless/Ras1/MAPK pathway. We have mutagenized the eight MAPK phosphorylation consensus sites of yan and examined the effects of overexpressing the mutant protein in transgenic flies and transfected S2 cultured cells. Our results suggest that phosphorylation by MAPK affects the stability and subcellular localization of yan, resulting in rapid down-regulation of yan activity. Furthermore, MAPK-mediated down-regulation of yan function appears to be critical for the proper differentiation of both neuronal and nonneuronal tissues throughout development, suggesting that yan is an essential component of a general timing mechanism controlling the competence of a cell to respond to inductive signals.			REBAY, I (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; HAY BA, 1994, DEVELOPMENT, V120, P2121; JANCKNECHT R, 1993, EMBO J, V12, P5097; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; WHITESIDE ST, 1993, J CELL SCI, V104, P949; WOLFF T, 1991, DEVELOPMENT, V113, P825; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	29	285	285	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					857	866		10.1016/0092-8674(95)90006-3	http://dx.doi.org/10.1016/0092-8674(95)90006-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781063	Bronze			2022-12-28	WOS:A1995RD76800007
J	GARRAWAY, M; MACLEOD, D				GARRAWAY, M; MACLEOD, D			EPIDEMIOLOGY OF RUGBY FOOTBALL INJURIES	LANCET			English	Article								With the exception of spinal cord injuries, the frequency and consequences of rugby injuries are not clearly understood. We therefore conducted a prospective cohort study involving all the senior rugby clubs in the Scottish Borders. 1169 (96%) of 1216 eligible players provided personal details and recorded all 15-a-side matches they played in the 1993-94 rugby season. Physiotherapists visited the clubs weekly to liaise with volunteer linkmen who were appointed to notify the circumstances of all new or recurrent injuries occurring in matches or rugby-related training. 361 players experienced 584 injuries in 512 injury episodes, 84% of which arose in matches. The period prevalence rate of match injuries was 13.95 (95% CI 12.64-15.26) per 1000 playing hours, the equivalent of an injury episode every 1.8 rugby matches. An injury episode took the player away from the game for an average of 39 days. 28% of injury episodes resulted in absence from employment or school/college work, for an average of 18 days. Rugby injuries are an important source of morbidity in young men. They need to be better understood if their frequency and consequences are to be reduced.	ST JOHNS HOSP,DEPT SURG,LIVINGSTON,W LOTHIAN,SCOTLAND		GARRAWAY, M (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND.							Addley K, 1988, Br J Sports Med, V22, P22; BEER I, 1991, BRIT MED J, V303, P1552, DOI 10.1136/bmj.303.6816.1552; CALCINAI C, 1992, NZ J SPORTS MED, V20, P14; CLARK DR, 1990, S AFR MED J, V77, P559; DALLEY DR, 1982, NZ J SPORTS MED, V10, P5; DALLEY DR, 1992, NZ J SPORTS MED, V20, P205; DAVIES JE, 1978, BRIT MED J, V2, P1759, DOI 10.1136/bmj.2.6154.1759; MYERS PT, 1980, MED J AUSTRALIA, V2, P17, DOI 10.5694/j.1326-5377.1980.tb131804.x; O'Brien C, 1992, Br J Sports Med, V26, P243; O'CONNELL T C, 1954, J Ir Med Assoc, V34, P20; ROY SP, 1974, S AFR MED J, V48, P2321; SCHER AT, 1992, BRIT J SPORT MED, V25, P57; 1993, CENSUS 1991 SCOTLAND	13	118	120	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1485	1487						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769905				2022-12-28	WOS:A1995RC18900012
J	MOLLER, H; MELLEMKJAER, L; MCLAUGHLIN, JK; OLSEN, JH				MOLLER, H; MELLEMKJAER, L; MCLAUGHLIN, JK; OLSEN, JH			OCCURRENCE OF DIFFERENT CANCERS IN PATIENTS WITH PARKINSONS-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							MELANOMA		DANISH CANC SOC,DIV CANC EPIDEMIOL,COPENHAGEN,DENMARK; NCI,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892	Danish Cancer Society; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MOLLER, H (corresponding author), INT AGCY RES CANC,F-69372 LYON,FRANCE.			Olsen, Jorgen Helge/0000-0001-9633-5662; Moller, Henrik/0000-0001-8200-5929				GRANDINETTI A, 1994, AM J EPIDEMIOL, V139, P1129, DOI 10.1093/oxfordjournals.aje.a116960; GRENHOFF J, 1989, BRIT J ADDICT, V84, P477; JANSSON B, 1985, ANN NEUROL, V17, P505, DOI 10.1002/ana.410170514; KOCHAR AS, 1985, AM J MED, V79, P119, DOI 10.1016/0002-9343(85)90555-8; WICK MM, 1977, CANCER RES, V37, P2123	5	79	81	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1500	1501		10.1136/bmj.310.6993.1500	http://dx.doi.org/10.1136/bmj.310.6993.1500			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787596	Green Published			2022-12-28	WOS:A1995RD28500021
J	LIANG, C; WEINREICH, M; STILLMAN, B				LIANG, C; WEINREICH, M; STILLMAN, B			ORC AND CDC6P INTERACT AND DETERMINE THE FREQUENCY OF INITIATION OF DNA-REPLICATION IN THE GENOME	CELL			English	Article							ORIGIN RECOGNITION COMPLEX; YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; S-PHASE; PROTEIN; GENE; CHROMOSOMES; NUCLEAR; MUTANTS; LOCALIZATION	The origin recognition complex (ORC) binds replicators in the yeast S. cerevisiae in a manner consistent with it being an initiator protein for DNA replication. Two-dimensional (2D) gel techniques were used to examine directly initiation of chromosomal DNA replication in temperature-sensitive orc mutants. Unlike in wild-type cells, in orc2-1 and orc5-1 mutant cells, only a subset of replicators formed active origins of DNA replication at the permissive temperature. At the restrictive temperature, the number of active replicators was diminished further. Using a genetic screen, CDC6 was identified as a multicopy suppressor of orc5-1. 2D gel and biochemical analyses demonstrated that Cdc6p interacted functionally and physically with ORC. We suggest that ORC and Cdc6p form a prereplication complex at individual replicators and therefore cooperate to determine the frequency of initiation of DNA replication in the genome.			LIANG, C (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.		Weinreich, Michael/D-2310-2014	Stillman, Bruce/0000-0002-9453-4091	NIAID NIH HHS [AI20460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020460, R01AI020460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CALLAN HG, 1973, COLD SPRING HARB SYM, V38, P195; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALLON S, 1995, P NATL ACAD SCI USA, V92, P2514; DERSHOWITZ A, 1993, MOL CELL BIOL, V13, P391, DOI 10.1128/MCB.13.1.391; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1990, TRENDS GENET, V6, P427, DOI 10.1016/0168-9525(90)90305-P; DOWELL JFX, 1994, SCIENCE, V265, P1243; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GUTHRIE C, 1991, METH ENZYMOL, V194; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HARTWELL LH, 1985, GENETICS, V110, P381; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1993, GENE DEV, V7, P1072, DOI 10.1101/gad.7.6.1072; LOO S, 1995, IN PRESS MOL BIOL CE; MARAHRENS Y, 1994, EMBO J, V13, P3395, DOI 10.1002/j.1460-2075.1994.tb06642.x; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; PALMER RE, 1990, GENETICS, V125, P763; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Rose MD., 1990, METHODS YEAST GENETI; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schiestl Robert H., 1993, Methods (Orlando), V5, P79, DOI 10.1006/meth.1993.1011; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIKORSKI RS, 1989, GENETICS, V12, P19; STILLMAN B, 1993, NATURE, V366, P506, DOI 10.1038/366506a0; STILLMAN B, 1994, J BIOL CHEM, V269, P7074; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZHOU C, 1989, J BIOL CHEM, V264, P9022; ZHOU C, 1990, J BIOL CHEM, V265, P19904; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23352	53	307	313	1	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					667	676		10.1016/0092-8674(95)90528-6	http://dx.doi.org/10.1016/0092-8674(95)90528-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774008	Bronze			2022-12-28	WOS:A1995RB96100005
J	PULENDRAN, B; KANNOURAKIS, G; NOURI, S; SMITH, KGC; NOSSAL, GJV				PULENDRAN, B; KANNOURAKIS, G; NOURI, S; SMITH, KGC; NOSSAL, GJV			SOLUBLE-ANTIGEN CAN CAUSE ENHANCED APOPTOSIS OF GERMINAL-CENTER B-CELLS	NATURE			English	Article							IMMUNE-RESPONSE; AFFINITY MATURATION; SOMATIC MUTATION; C57BL-6 MICE; DEATH; CENTERS; LYMPHOCYTES; REPERTOIRE; ANTIBODIES; PROTEIN	GERMINAL centres are dynamic microenvironments of B-lymphocyte differentiation, which develop in secondary lymphoid tissues during immune responses(1-3). Within germinal centres, activated B lymphocytes proliferate and point mutations are rapidly introduced into the genes encoding their immunoglobulin receptor(4-10). As a result, new specificities of B cells are created, including those with a heightened capacity to bind the immunizing antigen(4-11). Immunoglobulin gene mutation can also lead to reactivity to self antigens(12-14). It has been suggested that any newly formed self-reactive B cells are eliminated within the germinal centre in order to avoid autoimmunity(15,16). Here we present evidence that antigen-specific, high-affinity, germinal-centre B cells are rapidly killed by apoptosis in sits when they encounter soluble antigen. The effect seems to act directly on the B cells, rather than through helper T cells. Furthermore, the apoptosis is unique to germinal-centre cells, and is only incompletely impeded by constitutive expression of the proto-oncogene bcl-2. This phenomenon may reflect clonal deletion of self-reactive B cells within germinal centres.	ROYAL MELBOURNE HOSP, DEPT NEPHROL, PARKVILLE, VIC 3050, AUSTRALIA; ROYAL CHILDRENS HOSP, LARCH CANC RES UNIT, PARKVILLE, VIC 3052, AUSTRALIA	Royal Melbourne Hospital; Royal Children's Hospital Melbourne	PULENDRAN, B (corresponding author), WALTER & ELIZA HALL INST MED RES, PO ROYAL MELBOURNE HOSP, MELBOURNE, VIC 3050, AUSTRALIA.		Pulendran, Bali/AAW-9550-2021	Pulendran, Bali/0000-0001-6517-4333; Smith, Kenneth/0000-0003-3829-4326				ALLEN D, 1988, EMBO J, V7, P1995, DOI 10.1002/j.1460-2075.1988.tb03038.x; ALLEN D, 1987, IMMUNOL REV, V96, P5, DOI 10.1111/j.1600-065X.1987.tb00506.x; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; DIAMOND B, 1992, A REV IMMUN, V10, P737; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HERZENBERG LA, 1980, J EXP MED, V151, P1071, DOI 10.1084/jem.151.5.1071; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACK RS, 1977, EUR J IMMUNOL, V7, P559, DOI 10.1002/eji.1830070813; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JACOB J, 1991, J EXP MED, V173, P1165, DOI 10.1084/jem.173.5.1165; KUPPERS R, 1993, EMBO J, V12, P4955, DOI 10.1002/j.1460-2075.1993.tb06189.x; LALOR PA, 1992, EUR J IMMUNOL, V22, P3001, DOI 10.1002/eji.1830221136; LINTON PJ, 1991, J IMMUNOL, V146, P4099; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MACLENNAN ICM, 1990, CURR TOP MICROBIOL I, V159, P138; MCHEYZERWILLIAMS MG, 1993, J EXP MED, V178, P295, DOI 10.1084/jem.178.1.295; NAKAYAMA KI, 1993, SCIENCE, V261, P1548; NISITANI S, 1993, J EXP MED, V178, P1247, DOI 10.1084/jem.178.4.1247; NOSSAL GJV, 1993, P NATL ACAD SCI USA, V90, P3088, DOI 10.1073/pnas.90.7.3088; RETH M, 1978, EUR J IMMUNOL, V8, P393, DOI 10.1002/eji.1830080605; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; SMITH KGC, 1994, IMMUNITY, V1, P803, DOI 10.1016/S1074-7613(94)80022-7; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; Theofilopoulos A N, 1979, Adv Immunol, V28, P89; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VELS DJ, 1993, J CELL, V75, P229	31	277	282	0	0	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					331	334		10.1038/375331a0	http://dx.doi.org/10.1038/375331a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753199				2022-12-28	WOS:A1995RA03000055
J	BRUSCHWEILER, R; LIAO, XB; WRIGHT, PE				BRUSCHWEILER, R; LIAO, XB; WRIGHT, PE			LONG-RANGE MOTIONAL RESTRICTIONS IN A MULTIDOMAIN ZINC-FINGER PROTEIN FROM ANISOTROPIC TUMBLING	SCIENCE			English	Article							HETERONUCLEAR NMR-SPECTROSCOPY; TRANSCRIPTION FACTOR-IIIA; INTERNAL CONTROL REGION; DNA-BINDING DOMAIN; 5S RNA GENE; BACKBONE DYNAMICS; RELAXATION	Structural characterization of biomolecules in solution by nuclear magnetic resonance (NMR) spectroscopy is based primarily on the use of interproton distances derived from homonuclear cross-relaxation experiments. Information about short time-scale dynamics, on the other hand, is obtained from relaxation rates of heteronuclear spin pairs such as (N-1H)-N-15. By combining the two types of data and utilizing the dependence of heteronuclear NMR relaxation rates on anisotropic diffusional rotational tumbling, it is possible to obtain structural information about long-range motional correlations between protein domains. This approach was applied to characterize the relative orientations and mobilities of the first three zinc-finger domains of the Xenopus transcription factor TFIIIA in aqueous solution. The data indicate that the motions of the individual zinc-finger domains are highly correlated on time scales shorter than 10 nanoseconds and that the average conformation of the three-finger polypeptide is elongated.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute			Bruschweiler, Rafael/F-6624-2015	Wright, Peter/0000-0002-1368-0223	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036643] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36643] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; Debye P., 1929, POLAR MOL, P72; FAVRO LD, 1960, PHYS REV, V107, P7; HUNTRESS WT, 1968, J CHEM PHYS, V48, P3524, DOI 10.1063/1.1669645; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LIAO XB, 1994, J BIOMOL NMR, V4, P433; LIAO XY, UNPUB; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAKASEKO Y, 1992, J MOL BIOL, V228, P619, DOI 10.1016/0022-2836(92)90845-B; ORNICHINSKI JG, 1992, BIOCHEMISTRY-US, V31, P3907; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Perrin F, 1934, J PHYS-PARIS, V5, P497, DOI 10.1051/jphysrad:01934005010049700; Perrin F, 1936, J PHYS-PARIS, V7, P1, DOI 10.1051/jphysrad:01936007010100; RADHAKRISHNAN I, UNPUB; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; Vetterling W.T., 1988, NUMERICAL RECIPES C; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390	24	321	322	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					886	889		10.1126/science.7754375	http://dx.doi.org/10.1126/science.7754375			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754375				2022-12-28	WOS:A1995QX85000042
J	LEE, JE; HOLLENBERG, SM; SNIDER, L; TURNER, DL; LIPNICK, N; WEINTRAUB, H				LEE, JE; HOLLENBERG, SM; SNIDER, L; TURNER, DL; LIPNICK, N; WEINTRAUB, H			CONVERSION OF XENOPUS ECTODERM INTO NEURONS BY NEUROD, A BASIC HELIX-LOOP-HELIX PROTEIN	SCIENCE			English	Review							INTERMEDIATE FILAMENT PROTEIN; PERIPHERAL NERVOUS-SYSTEM; ACHAETE-SCUTE HOMOLOG-1; DNA-BINDING; MESODERM FORMATION; ORGAN FORMATION; MYOGENIN GENE; ALPHA-TUBULIN; HLH PROTEINS; DROSOPHILA	Basic helix-loop-helix (bHLH) proteins are instrumental in determining cell type during development. A bHLH protein, termed NeuroD, for neurogenic differentiation, has now been identified as a differentiation factor for neurogenesis because (i) it is expressed transiently in a subset of neurons in the central and peripheral nervous systems at the time of their terminal differentiation into mature neurons and (ii) ectopic expression of neuroD in Xenopus embryos causes premature differentiation of neuronal precursors. Furthermore, neuroD can convert presumptive epidermal cells into neurons and also act as a neuronal determination gene. However, unlike another previously identified proneural gene (XASH-3), neuroD seems competent to bypass the normal inhibitory influences that usually prevent neurogenesis in ventral and lateral ectoderm and is capable of converting most of the embryonic ectoderm into neurons. The data suggest that neuroD may participate in the terminal differentiation step during vertebrate neuronal development.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; HOWARD HUGHES MED INST, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute								ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P67; BALAK K, 1987, DEV BIOL, V119, P540, DOI 10.1016/0012-1606(87)90057-1; BAROFFIO A, 1991, DEVELOPMENT, V112, P301; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRAND M, 1993, DEVELOPMENT, V119, P1; BUFFINGER N, 1994, DEVELOPMENT, V120, P1443; CABERA CV, 1991, EMBO J, V10, P2965; CABERA CV, 1992, DEVELOPMENT, V115, P893; CAMPOSORTEGA JA, 1994, CELL, V77, P969, DOI 10.1016/0092-8674(94)90437-5; CAMPOSORTEGA JA, 1993, J NEUROBIOL, V24, P1305, DOI 10.1002/neu.480241005; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CHU DTW, 1989, DEV BIOL, V136, P104, DOI 10.1016/0012-1606(89)90134-6; DALE L, 1987, DEVELOPMENT, V99, P527; DAVIS RL, 1992, SCIENCE, V256, P1027, DOI 10.1126/science.1317057; DENT JA, 1989, DEVELOPMENT, V105, P61; DIXON JE, 1989, DEVELOPMENT, V106, P749; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EPPERLEIN HH, 1993, ANN ANAT, V175, P483, DOI 10.1016/S0940-9602(11)80207-4; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; GRUNZ H, 1989, CELL DIFFER DEV, V28, P211, DOI 10.1016/0922-3371(89)90006-3; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HARLAND R, 1985, J CELL BIOL, V101, P1094, DOI 10.1083/jcb.101.3.1094; HARLAND RM, 1994, CURR OPIN GENET DEV, V4, P543, DOI 10.1016/0959-437X(94)90070-J; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HARTENSTEIN V, 1993, J COMP NEUROL, V328, P213, DOI 10.1002/cne.903280205; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; HEMMATIBRIVANLOU A, 1992, NEURON, V9, P417, DOI 10.1016/0896-6273(92)90180-L; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOILLENBERG S, UNPUB; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; JACOBSON M, 1968, DEV BIOL, V17, P219, DOI 10.1016/0012-1606(68)90062-6; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JIMENEZ F, 1993, CURR OPIN GENET DEV, V3, P626, DOI 10.1016/0959-437X(93)90099-B; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JONES EA, 1986, CELL, V44, P345, DOI 10.1016/0092-8674(86)90769-5; JONES EA, 1989, DEVELOPMENT, V107, P785; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KIRSTEN J, UNPUB; KOGAWA K, 1991, ENDOCRINOLOGY, V128, P1434, DOI 10.1210/endo-128-3-1434; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAMATSCHEK B, 1994, DEVELOPMENT, V120, P815; KREIG PA, 1987, METHOD ENZYMOL, V155, P397; LAMB TM, 1993, SCIENCE, V262, P713, DOI 10.1126/science.8235591; LAMBORGHINI JE, 1980, J COMP NEUROL, V189, P323, DOI 10.1002/cne.901890208; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee J.-S., UNPUB; LEWIN B, 1994, CELL, V79, P935, DOI 10.1016/0092-8674(94)90025-6; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NORDLANDER RH, 1989, DEV BRAIN RES, V50, P147, DOI 10.1016/0165-3806(89)90135-1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PENG HB, 1991, METHOD CELL BIOL, V36, P659; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; RIBERA AB, 1993, J NEUROSCI, V13, P4988; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; RONG PM, 1992, DEVELOPMENT, V115, P657; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; SADAGHIANI B, 1987, DEV BIOL, V124, P91, DOI 10.1016/0012-1606(87)90463-5; SINGSON A, 1994, GENE DEV, V8, P2058, DOI 10.1101/gad.8.17.2058; SLACK JMW, 1992, DEVELOPMENT, V114, P285; Spemann H., 1938, EMBRYONIC DEV INDUCT; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUDARWAT.S, 1971, ROUX ARCH DEV BIOL, V166, P189, DOI 10.1007/BF00650029; SZARO BG, 1988, J COMP NEUROL, V273, P344, DOI 10.1002/cne.902730306; TENDONKELAAR HJ, 1991, ANAT EMBRYOL, V183, P589, DOI 10.1007/BF00187908; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WETTS R, 1993, DEV DYNAM, V198, P54, DOI 10.1002/aja.1001980106; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILSON R, IN PRESS NATURE; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	101	904	936	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					836	844		10.1126/science.7754368	http://dx.doi.org/10.1126/science.7754368			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754368				2022-12-28	WOS:A1995QX85000028
J	JIANG, WP; SWIGGARD, WJ; HEUFLER, C; PENG, M; MIRZA, A; STEINMAN, RM; NUSSENZWEIG, MC				JIANG, WP; SWIGGARD, WJ; HEUFLER, C; PENG, M; MIRZA, A; STEINMAN, RM; NUSSENZWEIG, MC			THE RECEPTOR DEC-205 EXPRESSED BY DENDRITIC CELLS AND THYMIC EPITHELIAL-CELLS IS INVOLVED IN ANTIGEN-PROCESSING	NATURE			English	Article							MACROPHAGE MANNOSE RECEPTOR; CARBOHYDRATE-RECOGNITION DOMAINS; LYMPHOCYTES-B; COMPLEX; BINDING; INTERNALIZATION; PROTEIN	DENDRITIC cells and thymic epithelial cells perform important immunoregulatory functions by presenting antigens in the form of peptides bound to cell-surface major histocompatibility complex (MHC) molecules to T cells(1-3). Whereas B cells are known to present specific antigens efficiently through their surface immunoglobins, a comparable mechanism for the capture and efficient presentation of diverse antigens by dendritic cells and thymic epithelial cells has not previously been described. We show here that their antigen-presentation function is associated with the high-level expression of DEC-205, an integral membrane protein homologous to the macrophage mannose receptor and related receptors which are able to bind carbohydrates and mediate endocytosis. DEC-205 is rapidly taken up by means of coated pits and vesicles, and is delivered to a multivesicular endosomal compartment that resembles the MHC class II-containing vesicles implicated in antigen presentation. Rabbit antibodies that bind DEC-205 are presented to reactive T-cell hybridomas 100-fold more efficiently than rabbit antibodies that do not bind DEC-205, Thus DEC-205 is a novel endocytic receptor that can be used by dendritic cells and thymic epithelial cells to direct captured antigens from the extracellular space to a specialized antigen-processing compartment.	ROCKEFELLER UNIV,MOLEC IMMUNOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; ROCKEFELLER UNIV,CELLULAR PHYSIOL LAB,NEW YORK,NY 10021	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University			Steinman, Ralph/F-7729-2012; Nussenzweig, Michel/AAE-7292-2019					AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DANIELS BF, 1994, IMMUNITY, V1, P785, DOI 10.1016/S1074-7613(94)80020-0; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; HARRIS N, 1992, BLOOD, V80, P2363; HUGO P, 1993, IMMUNOL REV, V135, P133, DOI 10.1111/j.1600-065X.1993.tb00647.x; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LANZAVEECHIA A, 1985, NATURE, V314, P538; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0	28	746	783	2	37	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					151	155		10.1038/375151a0	http://dx.doi.org/10.1038/375151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753172				2022-12-28	WOS:A1995QX74100053
J	SIMSKE, JS; KIM, SK				SIMSKE, JS; KIM, SK			SEQUENTIAL SIGNALING DURING CAENORHABDITIS-ELEGANS VULVAR INDUCTION	NATURE			English	Article							C-ELEGANS; CELL LINEAGES; TYROSINE KINASE; NEMATODE; GENE; PATTERN; ENCODES; LET-23	DURING the induction of the Caenorhabditis elegans vulva, cell signalling causes initially equipotent cells to express a reproducible pattern of cell fates(1,2). The position of the anchor cell determines the pattern of vulval precursor cell fates, such that the closest precursor cell (P6.p) expresses the primary cell fate, the next closest cells (P5.p and P7.p) both express the secondary cell fate, and each of the precursor cells located at a distance (P3.p, P4.p and P8.p) express the tertiary cell fate (Fig. 1a)(3-5). We present data indicating that this stereotypical pattern of cell fates can be generated by sequential signals. We identified genetic mosaic animals in which P5.p and P7.p were defective in the anchor-cell signal-transduction pathway and observed that these cells adopted the secondary cell fate, indicating that anchor-cell signal transduction is not required for the expression of the secondary cell fate. These results suggest that the anchor cell induces P6.p to express the primary cell fate, and that P6.p subsequently induces P5.p and P7.p to express the secondary cell fate.			SIMSKE, JS (corresponding author), STANFORD UNIV,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.							AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AROLAN RV, 1994, EMBO J, V13, P360; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HERMAN RK, 1984, GENETICS, V108, P165; HERMAN RK, 1989, J NEUROGENET, V5, P1, DOI 10.3109/01677068909167261; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; INGHAM PW, 1994, CURR BIOL, V4, P347, DOI 10.1016/S0960-9822(00)00076-2; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LACKNER MR, 1994, GENE DEV, V8, P160, DOI 10.1101/gad.8.2.160; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER DM, 1993, GENETICS, V135, P741; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	30	109	116	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					142	146		10.1038/375142a0	http://dx.doi.org/10.1038/375142a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753169				2022-12-28	WOS:A1995QX74100050
J	LENDERS, JWM; KEISER, HR; GOLDSTEIN, DS; WILLEMSEN, JJ; FRIBERG, P; JACOBS, MC; KLOPPENBORG, PWC; THIEN, T; EISENHOFER, G				LENDERS, JWM; KEISER, HR; GOLDSTEIN, DS; WILLEMSEN, JJ; FRIBERG, P; JACOBS, MC; KLOPPENBORG, PWC; THIEN, T; EISENHOFER, G			PLASMA METANEPHRINES IN THE DIAGNOSIS OF PHEOCHROMOCYTOMA	ANNALS OF INTERNAL MEDICINE			English	Article						METANEPHRINE; PHEOCHROMOCYTOMA; HYPERTENSION; CATECHOLAMINES	ELECTROCHEMICAL DETECTION; LIQUID-CHROMATOGRAPHY; CATECHOLAMINES; NOREPINEPHRINE; 3,4-DIHYDROXYPHENYLGLYCOL; DIHYDROXYPHENYLGLYCOL; METABOLITE; CURVES	Objective: To examine whether tests for plasma metanephrines, the o-methylated metabolites of catecholamines, offer advantages for diagnosis of a pheochromocytoma over standard tests for plasma catecholamines or urinary metanephrines. Design: Cross-sectional study. Setting: 3 clinical specialist centers. Patients: 52 patients with a pheochromocytoma; 67 normotensive persons and 51 patients with essential hypertension who provided reference values; and 23 patients with secondary hypertension and 50 patients with either heart failure or angina pectoris who served as comparison groups. Measurements: Plasma concentrations of catecholamines (norepinephrine and epinephrine) and metanephrines (normetanephrine and metanephrine) were measured in all patients. The 24-hour urinary excretion of metanephrines was measured in 46 patients with pheochromocytoma. Results: Pheochromocytomas were associated with increases in plasma concentrations of metanephrines that were greater and more consistent than those in plasma catecholamine concentrations. No patient with a pheochromocytoma had normal plasma concentrations of both normetanephrine and metanephrine. The sensitivity of these tests was 100% (52 of 52 patients [95% CI, 94% to 100%]), and the negative predictive value of normal plasma concentrations of metanephrines was 100% (162 of 162 patients). Tests for plasma catecholamines yielded eight false-negative results and a sensitivity of 85% (44 of 52 patients [CI, 72% to 93%]). The negative predictive value of normal plasma concentrations of catecholamines was 95% (156 of 164 patients). Tests for urinary metanephrines yielded five false-negative results and a sensitivity of 89% (41 of 46 patients [CI, 76% to 96%]). Because no statistical difference was noted in the number of false-positive results between tests for plasma metanephrines (15%) and tests for plasma catecholamines (18%), the specificities of the two tests did not differ. Conclusions: Normal plasma concentrations of metanephrines exclude the diagnosis of pheochromocytoma, whereas normal plasma concentrations of catecholamines and normal urinary excretion of metanephrines do not. Tests for plasma metanephrines are more sensitive than tests for plasma catecholamines or urinary metanephrines for the diagnosis of pheochromocytoma.	NIH, BETHESDA, MD 20892 USA; GOTHENBURG UNIV, GOTHENBURG, SWEDEN	National Institutes of Health (NIH) - USA; University of Gothenburg	LENDERS, JWM (corresponding author), UNIV NIJMEGEN ST RADBOUD HOSP, DEPT INTERNAL MED, DIV GEN INTERNAL MED, GEERT GROOTEPLEIN ZUID 8, 6525 GA NIJMEGEN, NETHERLANDS.		Lenders, J.W.M./L-4487-2015; Eisenhofer, Graeme/AAU-9829-2021	Lenders, J.W.M./0000-0002-7658-4466; Eisenhofer, Graeme/0000-0002-8601-9903				BECK JR, 1986, ARCH PATHOL LAB MED, V110, P13; BRAVO EL, 1979, NEW ENGL J MED, V301, P682, DOI 10.1056/NEJM197909273011302; BRAVO EL, 1981, NEW ENGL J MED, V305, P623, DOI 10.1056/NEJM198109103051107; BRAVO EL, 1984, NEW ENGL J MED, V311, P1298, DOI 10.1056/NEJM198411153112007; BROWN MJ, 1984, EUR J CLIN INVEST, V14, P67, DOI 10.1111/j.1365-2362.1984.tb00706.x; CROUT JR, 1964, J CLIN INVEST, V43, P94, DOI 10.1172/JCI104898; CRYER PE, 1980, NEW ENGL J MED, V303, P436; DEQUATTRO V, 1980, CLIN SCI, V59, pS275, DOI 10.1042/cs059275s; DUNCAN MW, 1988, NEW ENGL J MED, V319, P136, DOI 10.1056/NEJM198807213190303; EISENHOFER G, 1995, CLIN SCI, V88, P533, DOI 10.1042/cs0880533; EISENHOFER G, 1995, AM J PHYSIOL-GASTR L, V268, pG641, DOI 10.1152/ajpgi.1995.268.4.G641; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; EISENHOFER G, 1994, J AUTONOM NERV SYST, V50, P93, DOI 10.1016/0165-1838(94)90127-9; EISENHOFER G, 1995, IN PRESS J CLIN ENDO; FOGARTY J, 1994, ARCH FAM MED, V3, P55; GOLDSTEIN DS, 1988, J CLIN INVEST, V81, P213, DOI 10.1172/JCI113298; GRAEFE KH, 1983, GEN PHARMACOL, V14, P27, DOI 10.1016/0306-3623(83)90058-7; GROSSMAN E, 1991, HYPERTENSION, V17, P733, DOI 10.1161/01.HYP.17.6.733; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; KOPIN IJ, 1960, NATURE, V185, P788, DOI 10.1038/185788a0; LENDERS JWM, 1993, CLIN CHEM, V39, P97; LENDERS JWM, 1992, AM J MED, V92, P147, DOI 10.1016/0002-9343(92)90105-K; Manger WM, 1977, PHEOCHROMOCYTOMA; MARINI M, 1993, ANN ENDOCRINOL-PARIS, V54, P337; MORNEX R, 1991, HORM RES, V36, P220, DOI 10.1159/000182167; PEASTON RT, 1993, J CLIN PATHOL, V46, P734, DOI 10.1136/jcp.46.8.734; PISANO JJ, 1960, CLIN CHIM ACTA, V5, P406; ROSANO TG, 1991, CLIN CHEM, V37, P1854; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SJOERDSMA A, 1958, SCIENCE, V127, P876, DOI 10.1126/science.127.3303.876; STEIN PP, 1991, MEDICINE, V70, P46, DOI 10.1097/00005792-199101000-00004; THOMAS JA, 1978, AM J CARDIOL, V41, P233, DOI 10.1016/0002-9149(78)90162-5; VANDERHOORN FAJ, 1989, J CHROMATOGR-BIOMED, V487, P17, DOI 10.1016/S0378-4347(00)83003-0; 1966, ANN INTERN MED, V65, P1302	34	180	186	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					101	109		10.7326/0003-4819-123-2-199507150-00004	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778821	Green Submitted			2022-12-28	WOS:A1995RM43500004
J	BATES, DW; CULLEN, DJ; LAIRD, N; PETERSEN, LA; SMALL, SD; SERVI, D; LAFFEL, G; SWEITZER, BJ; SHEA, BF; HALLISEY, R; VANDERVLIET, M; NEMESKAL, R; LEAPE, LL				BATES, DW; CULLEN, DJ; LAIRD, N; PETERSEN, LA; SMALL, SD; SERVI, D; LAFFEL, G; SWEITZER, BJ; SHEA, BF; HALLISEY, R; VANDERVLIET, M; NEMESKAL, R; LEAPE, LL			INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; HEALTH-CARE; MEDICATION	Objectives.-To assess incidence and preventability of adverse drug events (ADEs) and potential ADEs. To analyze preventable events to develop prevention strategies. Design.-Prospective cohort study. Participants.-All 4031 adult admissions to a stratified random sample of 11 medical and surgical units in two tertiary care hospitals over a 6-month period. Units included two medical and three surgical intensive care units and four medical and two surgical general care units. Main Outcome Measures.-Adverse drug events and potential ADEs. Methods.-Incidents were detected by stimulated self-report by nurses and pharmacists and by daily review of all charts by nurse investigators. Incidents were subsequently classified by two independent reviewers as to whether they represented ADEs or potential ADEs and as to severity and preventability. Results.-Over 6 months, 247 ADEs and 194 potential ADEs were identified. Extrapolated event rates were 6.5 ADEs and 5.5 potential ADEs per 100 nonobstetrical admissions, for mean numbers per hospital per year of approximately 1900 ADEs and 1600 potential ADEs. Of all ADEs, 1% were fatal (none preventable), 12% life-threatening, 30% serious, and 57% significant. Twenty-eight percent were judged preventable. Of the life-threatening and serious ADEs, 42% were preventable, compared with 18% of significant ADEs, Errors resulting in preventable ADEs occurred most often at the stages of ordering (56%) and administration (34%); transcription (6%) and dispensing errors (4%) were less common. Errors were much more likely to be intercepted if the error occurred earlier in the process: 48% at the ordering stage vs 0% at the administration stage, Conclusion.-Adverse drug events were common and often preventable; serious ADEs were more likely to be preventable. Most resulted from errors at the ordering stage, but many also occurred at the administration stage. Prevention strategies should target both stages of the drug delivery process.	BRIGHAM & WOMENS HOSP, DEPT PHARM, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PHARM, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; APM INC, NEW YORK, NY USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	BATES, DW (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Arán, Teodoro J Martínez/A-4568-2010	Arán, Teodoro J Martínez/0000-0002-5877-3941	AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bates D W, 1994, Qual Manag Health Care, V2, P18; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BERRY LL, 1988, AM J HOSP PHARM, V45, P1534, DOI 10.1093/ajhp/45.7.1534; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; EVANS RS, 1993, P ANN S COMPUT APPL, V17, P161; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FAICH GA, 1991, ARCH INTERN MED, V151, P1645, DOI 10.1001/archinte.151.8.1645; FOLLI HL, 1987, PEDIATRICS, V79, P718; FORRESTER JW, 1971, MIT TECHNOL REV, V73, P2; FUCHSBERG A, 1978, TRIAL LAWYERS Q, V12, P9; GOSNEY M, 1984, LANCET, V2, P564; GRASELA TH, 1993, AM J HOSP PHARM, V50, P1889, DOI 10.1093/ajhp/50.9.1889; HODDINOTT BC, 1967, CAN MED ASSOC J, V97, P1001; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; KEITH MR, 1989, AM J HOSP PHARM, V46, P1809, DOI 10.1093/ajhp/46.9.1809; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; KOCH KE, 1990, AM J HOSP PHARM, V47, P1314, DOI 10.1093/ajhp/47.6.1314; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; OGILVIE RI, 1967, CAN MED ASSOC J, V97, P1450; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; RIND DM, 1991, P ANN S COMPUT APPL, V15, P28; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; Wan T T, 1987, QRB Qual Rev Bull, V13, P61; 1985, INJURY AM; 1991, STATXACT USER MANUAL; 1988, SAS RELEASE 6 03; 1980, MED MALPRACTICE CLOS	41	2209	2297	3	125	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					29	34		10.1001/jama.274.1.29	http://dx.doi.org/10.1001/jama.274.1.29			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791255				2022-12-28	WOS:A1995RG23300027
J	WILLIAMSRUSSO, P; SHARROCK, NE; MATTIS, S; SZATROWSKI, TP; CHARLSON, ME				WILLIAMSRUSSO, P; SHARROCK, NE; MATTIS, S; SZATROWSKI, TP; CHARLSON, ME			COGNITIVE EFFECTS AFTER EPIDURAL VS GENERAL-ANESTHESIA IN OLDER ADULTS - A RANDOMIZED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TOTAL HIP-ARTHROPLASTY; REGIONAL ANESTHESIA; HYPOTENSIVE ANESTHESIA; ELDERLY PATIENTS; DYSFUNCTION; MORBIDITY; OPERATION; RECOVERY; AMNESIA; SURGERY	Objective.-To compare the effect of epidural vs general anesthesia on the incidence of long-term cognitive dysfunction after total knee replacement surgery in older adults. Design.-Randomized controlled clinical trial. Setting.-Orthopedic specialty academic hospital. Patients.-A total of 262 patients undergoing elective primary total knee replacement with a median age of 69 years; 70% women. Intervention.-Random assignment to either epidural or general anesthesia. Main Outcome Measures.-A thorough neuropsychological assessment was performed preoperatively and repeated at 1 week and 6 months postoperatively. Cognitive outcome was assessed by within-patient change on 10 tests of memory, psychomotor, and language skills. Prospective standardized surveillance for cardiovascular complications was performed to allow simultaneous assessment of anesthetic effects on cognitive and cardiovascular outcomes. Results.-The two groups were similar at baseline in terms of age, sex, comorbidity, and cognitive function. There were no significant differences between the epidural and general anesthesia groups in within-subject change from baseline on any of the 10 cognitive test results at either 1 week or 6 months. Overall, 5% of patients showed a long-term clinically significant deterioration in cognitive function. There was no difference between the anesthesia groups in the incidence of major cardiovascular complications (3% overall). Conclusions.-The type of anesthesia, general or epidural, does not affect the magnitude or pattern of postoperative cognitive dysfunction or the incidence of major cardiovascular complications in older adults undergoing elective total knee replacement. This is the largest trial of the effects of general vs regional anesthesia on cerebral function reported to date, with more than 99% power to detect a clinically significant difference on any of the neuropsychological tests.	CORNELL UNIV,COLL MED,NEW YORK HOSP,HOSP SPECIAL SURG,DEPT ANESTHESIA,NEW YORK,NY; CORNELL UNIV,COLL MED,NEW YORK HOSP,HOSP SPECIAL SURG,DEPT PSYCHIAT,NEW YORK,NY	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital	WILLIAMSRUSSO, P (corresponding author), CORNELL UNIV,COLL MED,NEW YORK HOSP,HOSP SPECIAL SURG,DEPT MED,515 E 71ST ST,S-900,NEW YORK,NY 10021, USA.				NIA NIH HHS [R01 AG08562] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008562] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABERG T, 1983, ANN THORAC SURG, V36, P680, DOI 10.1016/S0003-4975(10)60278-0; AMMONS RB, 1962, PSYCHOL REP, V11, P111, DOI 10.1177/003329416201100106; [Anonymous], 1944, ARMY INDIVIDUAL TEST; BEDFORD PD, 1955, LANCET, V2, P259; Benton A.L., 1974, REVISED VISUAL RETEN; Benton AL, 1976, MULTILINGUAL APHASIA; BIGLER D, 1985, ANAESTHESIA, V40, P672, DOI 10.1111/j.1365-2044.1985.tb10949.x; Brink TL., 1982, CLIN GERON, V1, P37, DOI [10.1300/J018v01n01_06, DOI 10.1300/J018V01N01_06]; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHARLSON ME, 1989, J CLIN EPIDEMIOL, V42, P25, DOI 10.1016/0895-4356(89)90022-X; COLSHER PL, 1991, EPIDEMIOL REV, V13, P1; CUCCHIARA R F, 1980, International Anesthesiology Clinics, V18, P123, DOI 10.1097/00004311-198001830-00011; CUMMINGS JL, 1984, NEUROLOGY, V34, P679, DOI 10.1212/WNL.34.5.679; DAVISON LA, 1975, ANESTHESIOLOGY, V43, P313, DOI 10.1097/00000542-197509000-00008; DONEGAN J, 1981, REFRESHER COURSE LEC, V123, P1; ENDERBY GEH, 1985, HYPOTENSIVE ANESTHES, P263; FARHAT SM, 1967, J NEUROSURG, V27, P441, DOI 10.3171/jns.1967.27.5.0441; GAMACHE FW, 1976, J NEUROSURG, V44, P215, DOI 10.3171/jns.1976.44.2.0215; GHONEIM MM, 1988, ANESTHESIOLOGY, V69, P507, DOI 10.1097/00000542-198810000-00010; GILBERSTADT H, 1967, ARCH GEN PSYCHIAT, V16, P210; GRUVSTAD M, 1962, ACTA PSYCHIAT SCAND, V37, P1; HERBERT M, 1983, BRIT MED J, V286, P1539, DOI 10.1136/bmj.286.6377.1539; HOLE A, 1980, ACTA ANAESTH SCAND, V24, P279, DOI 10.1111/j.1399-6576.1980.tb01549.x; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JONES MJT, 1990, BRIT MED J, V300, P1683, DOI 10.1136/bmj.300.6741.1683; JONES MJT, 1988, ACTA CHIR SCAND    S, V550, P169; Kaplan E, 1978, BOSTON NAMING TEST; KARHUNEN U, 1982, ACTA ANAESTH SCAND, V26, P291, DOI 10.1111/j.1399-6576.1982.tb01769.x; Larson C P Jr, 1974, Anesthesiology, V41, P169, DOI 10.1097/00000542-197408000-00007; LASSEN NA, 1976, BRIT J ANAESTH, V48, P719, DOI 10.1093/bja/48.8.719; Lassen NA, 1990, PROTECTION BRAIN ISC; Lee W H Jr, 1969, Ann Thorac Surg, V7, P562; LEVINE NR, 1972, PSYCHOL REP, V29, P167; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MATTIS S, 1987, BRAIN LANG, V6, P179; NEWMAN M, 1992, ADV CARDIOVASC SURG, V3, P243; Newman S, 1993, CARDIAC SURG BRAIN, P34; NIELSON WR, 1990, ANESTHESIOLOGY, V73, P1103, DOI 10.1097/00000542-199012000-00006; PETERSON MGE, 1992, J BONE JOINT SURG AM, V74A, P1530, DOI 10.2106/00004623-199274100-00012; POON LW, 1985, HDB PSYCHOL AGING, P427; REITAN JA, 1986, ANESTH ANALG, V65, P933; RIIS J, 1983, ACTA ANAESTH SCAND, V27, P44, DOI 10.1111/j.1399-6576.1983.tb01903.x; Robinson M, 1990, J CARDIOPULM REHABIL, V10, P180; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; SAVAGEAU JA, 1982, J THORAC CARDIOV SUR, V84, P585; SHAW PJ, 1987, Q J MED, V239, P259; SIMPSON BR, 1961, LANCET, V2, P887; SKINHOJ E, 1973, LANCET, V1, P461, DOI 10.1016/S0140-6736(73)91884-9; Swets JA, 1964, SIGNAL DETECTION REC; THOMPSON GE, 1978, ANESTHESIOLOGY, V48, P91, DOI 10.1097/00000542-197802000-00003; TOWNES BD, 1986, ANESTH ANALG, V65, P955; Wechsler D., 1987, INSTRUCTION MANUAL W; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x; WILLIAMSRUSSO P, 1994, NEUROPSYCHOLOGY BATT; 1985, SAS USERS GUIDE STAT	55	269	295	4	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					44	50		10.1001/jama.274.1.44	http://dx.doi.org/10.1001/jama.274.1.44			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791257				2022-12-28	WOS:A1995RG23300029
J	SIMINOFF, LA; ARNOLD, RM; CAPLAN, AL; VIRNIG, BA; SELTZER, DL				SIMINOFF, LA; ARNOLD, RM; CAPLAN, AL; VIRNIG, BA; SELTZER, DL			PUBLIC-POLICY GOVERNING ORGAN AND TISSUE PROCUREMENT IN THE UNITED-STATES - RESULTS FROM THE NATIONAL ORGAN AND TISSUE PROCUREMENT STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ORGAN TRANSPLANTATION; TISSUE DONORS; ORGAN PROCUREMENT	INTENSIVE-CARE UNITS; FAMILY MEMBERS; DONOR ORGANS; DONATION; EXPERIENCE; SHORTAGE; RESPONSIBILITIES; TRANSPLANTATION; AVAILABILITY; ENGLAND	Objective: To determine why Required Request policies, which mandate that hospitals request donation from donor-eligible families, have not resulted in increased organ procurement. Setting: Stratified sample of 23 acute-care general hospitals in two metropolitan areas. Design: Chart review identified all eligible donors in study hospitals during a 20-month period. Health care professionals who spoke with the families of eligible donors after death were interviewed to determine families' and health care providers' behaviors after patients' deaths with reference to the donation process. Participants: All patient deaths (n = 10 681) were reviewed, and 841 donor-eligible cases were chosen for in-depth study; 1809 health care professionals who provided care to these patients were interviewed. Measurements: The ability of health care providers to identify donor-eligible patients, approach families about donation, and obtain families' consent to donation. Results: 83% of health care professionals correctly identified donor-eligible patients. The families of donor-eligible patients were approached about donation in 73.0% of the cases. Families were more likely to be approached about organ (86.6%) donation than either tissue (69.5%) or cornea (67.3%) donation (P < 0.001). The families of organ-eligible patients were less likely to be approached if the patient was female, was on a general medical or surgical floor, or was being cared for by internists. Only 46.5% of families of eligible donors agreed to donate organs, 34.5% agreed to donate tissues, and 23.5% agreed to donate corneas. Conclusions: Although health care professionals do request that families donate, families consent to donation less frequently than was previously assumed. Empirically based education campaigns are needed so that health care professionals can improve their communication skills and so that discussion about this important issue can be stimulated among family members.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	SIMINOFF, LA (corresponding author), UNIV PITTSBURGH, CTR MED ETH, 3400 FORBES AVE, SUITE 110, PITTSBURGH, PA 15213 USA.		Siminoff, Laura A/H-6277-2012		AHRQ HHS [HS06579] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bartucci M R, 1987, J Neurosci Nurs, V19, P305; BATTEN HL, 1987, HEALTH AFFAIR, V6, P35, DOI 10.1377/hlthaff.6.2.35; BURRIS TE, 1987, CORNEA, V6, P226, DOI 10.1097/00003226-198706030-00015; CAPLAN A, 1991, P SURGEON GENERALS W, P199; CAPLAN AL, 1989, CLIN TRANSPLANT, V3, P170; CAPLAN AL, 1984, NEW ENGL J MED, V311, P981, DOI 10.1056/NEJM198410113111510; CHEUNG AHS, 1990, J TRAUMA, V30, P1366, DOI 10.1097/00005373-199011000-00009; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; EVANS RW, 1988, TRANSPLANT P, V20, P781; FULTON J, 1987, GIFT LIFE EFFECT ORG, P338; GARRISON RN, 1991, SURG GYNECOL OBSTET, V173, P391; GLASSON J, 1994, JAMA-J AM MED ASSOC, V272, P809, DOI 10.1001/jama.1994.03520100071036; GORE SM, 1991, BRIT MED J, V302, P149, DOI 10.1136/bmj.302.6769.149; GORE SM, 1992, BRIT MED J, V304, P349, DOI 10.1136/bmj.304.6823.349; GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; HESSING DJ, 1986, OMEGA-J DEATH DYING, V17, P115, DOI 10.2190/5NB6-DJDW-B68G-6T56; KASS LR, 1992, PUBLIC INTEREST, P65; KITTUR DS, 1991, LANCET, V338, P1441, DOI 10.1016/0140-6736(91)92735-K; LAND W, 1992, TRANSPLANT P, V24, P2165; LIFENET, 1990, OPERATING STANDARDS; Martinelli A M, 1993, AORN J, V58, P236, DOI 10.1016/S0001-2092(07)65228-4; MAY WF, 1985, HASTINGS CENT REP, V15, P38, DOI 10.2307/3561916; MORRIS JA, 1990, SOUTHERN MED J, V83, P884, DOI 10.1097/00007611-199008000-00009; MORRIS JA, 1992, PEDIATRICS, V89, P411; MORRIS JA, 1989, J TRAUMA, V29, P782, DOI 10.1097/00005373-198906000-00014; NATHAN HM, 1991, TRANSPLANTATION, V51, P142, DOI 10.1097/00007890-199101000-00022; OVERCAST TD, 1984, JAMA-J AM MED ASSOC, V251, P1559, DOI 10.1001/jama.251.12.1559; Peele A S, 1994, Crit Care Nurs Clin North Am, V6, P575; PELLEGRINO ED, 1991, JAMA-J AM MED ASSOC, V265, P1305, DOI 10.1001/jama.265.10.1305; PELLETIER M, 1992, J ADV NURS, V17, P90, DOI 10.1111/j.1365-2648.1992.tb01822.x; PELLETIER ML, 1993, HEART LUNG, V22, P151; PERKINS KA, 1987, AM PSYCHOL, V42, P921, DOI 10.1037/0003-066X.42.10.921; PETERS TG, 1991, JAMA-J AM MED ASSOC, V265, P1302, DOI 10.1001/jama.265.10.1302; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PROTTAS J, 1988, JAMA-J AM MED ASSOC, V260, P832; PROTTAS J, 1988, AM J PUBLIC HEALTH, V78, P642, DOI 10.2105/AJPH.78.6.642; PROTTAS JM, 1992, TRANSPLANTATION, V53, P1371, DOI 10.1097/00007890-199206000-00040; ROELS L, 1990, TRANSPLANT P, V22, P368; RUSSELL PS, 1986, SURGERY, V100, P863; SAVARIA DT, 1990, TRANSPLANT P, V22, P316; SIMINOFF LA, 1994, CLIN TRANSPLANT, V8, P460; Stark J, 1994, Crit Care Nurs Clin North Am, V6, P591; TOLLE SW, 1987, ANN INTERN MED, V106, P740, DOI 10.7326/0003-4819-106-5-740; TYMSTRA T, 1992, FAM PRACT, V9, P141, DOI 10.1093/fampra/9.2.141; VIRNIG BA, 1992, TRANSPLANT P, V24, P2155; 1991, MED STANDARDS; 1989, REQUIRED REQUEST ITS; 1990, SOLVING ORGAN DONOR; 1992, ACCREDITATION HOSPIT; 1994, FINANCIAL INCENTIVES; 1995, UNOS UPDATE, V11, P47	51	176	177	2	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					10	17		10.7326/0003-4819-123-1-199507010-00037	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00037			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RE665	7762908				2022-12-28	WOS:A1995RE66500002
J	STEAD, WW				STEAD, WW			MANAGEMENT OF HEALTH-CARE WORKERS AFTER INADVERTENT EXPOSURE TO TUBERCULOSIS - A GUIDE FOR THE USE OF PREVENTIVE THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						HEALTH PERSONNEL; ENVIRONMENTAL EXPOSURE; TUBERCULOSIS; ISONIAZID; TUBERCULIN TEST	EXOGENOUS REINFECTION; HOSPITAL PERSONNEL; MYCOBACTERIUM-TUBERCULOSIS; ELDERLY PERSONS; INFECTION; EMPLOYEES	Objective: To quantify the protection of previously infected persons from developing tuberculosis after intense exposure. Setting: 6 hospitals and 22 nursing homes in which heavy tuberculosis exposure had occurred. Measurements: Results of tuberculin skin tests before and after exposure and the development of tuberculosis among known reactors, both converters and nonconverters. Intervention: All converters were given preventive therapy with isoniazid as soon as they could be identified. Nonconverters and previously known reactors were not treated. Results: In 6 hospital outbreaks, largely aborted by prompt preventive therapy, 98 of 336 nonreactors (29%) showed skin test conversion, and, before therapy could be started, 19 (19% [95% CI, 12% to 29%]) had developed tuberculosis. No tuberculosis developed among the 238 nonconverters (0% [CI, 0% to 1.5%]) or the 76 known reactors who were not treated (0% [CI, 0.5% to 2%]). Tuberculosis developed in 5 of 209 known reactors (2.4% [CI, 0.8% to 5.5%]) in 22 nursing homes with heavy exposure, little more than 10 of 921 known reactors (1.1% [CI, 0.5% to 2%]) in 76 homes where there was no exposure (P = 0.17). Conclusions: Healthy persons who remain nonreactive to tuberculin after heavy exposure have escaped infection and require no chemotherapy. However, if exposure is discovered immediately, it is wise to start preventive therapy in particularly heavily exposed nonreactors-and discontinue it if the skin test result is still negative at 3 months. Persons who react after exposure fall into three groups: 1) converters, in whom the risk for tuberculosis warrants preventive chemotherapy, regardless of age; 2) reactors with no preexposure test results, who should be treated as converters; and 3) previously known reactors, in whom the risk for tuberculosis generally is too slight to warrant therapy. However, those who are younger than age 35 years, have human immunodeficiency virus infection, are receiving cancer chemotherapy or long-term corticosteroid therapy, or are otherwise immunocompromised should be considered for preventive therapy, regardless of the exposure.			STEAD, WW (corresponding author), ARKANSAS DEPT HLTH, TB PROGRAM, 4815 W MARKHAM ST, LITTLE ROCK, AR 72205 USA.							AITKEN ML, 1987, AM REV RESPIR DIS, V136, P805, DOI 10.1164/ajrccm/136.4.805; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; BASS JB, 1985, AM REV RESPIR DIS, V132, P379; CANETTI G, 1972, Bulletin of the International Union Against Tuberculosis, V47, P116; CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; Centers for Disease Control (CDC), 1990, MMWR Morb Mortal Wkly Rep, V39, P718; CHAN J, 1994, TUBERCULOSIS PATHOGE, P400; CORNELL C, 1988, AM J NURS, V88, P484, DOI 10.2307/3426015; DANIELS M, 1948, TUBERCULOSIS YOUNG A, P66; FAGAN MJ, 1994, ANN INTERN MED, V120, P930, DOI 10.7326/0003-4819-120-11-199406010-00005; Ferguson Robert George, 1955, STUDIES TUBERCULOSIS; FRAMPTON MW, 1992, ANN INTERN MED, V117, P312, DOI 10.7326/0003-4819-117-4-312; FRASER VJ, 1994, INFECT CONT HOSP EP, V15, P95; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; Heimbeck J, 1928, ARCH INTERN MED, V41, P336, DOI 10.1001/archinte.1928.00130150043002; HSU KHK, 1984, JAMA-J AM MED ASSOC, V251, P1283, DOI 10.1001/jama.251.10.1283; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; Hyge T. V., 1947, ACTA TUBER SCAND, V21, P1; ISRAEL H. L., 1941, Journal of the American Medical Association, V117, P839; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; LINCOLN EDITH M., 1965, ADVANCES TUBERC RES, V14, P157; Lurie MB, 1929, J EXP MED, V50, P747, DOI [10.1084/jem.50.6.747, 10.1084/jem.51.5.743]; McNeill W.H., 1976, PLAGUES PEOPLES, V1st ed.; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; Orme I M, 1991, Bull Int Union Tuberc Lung Dis, V66, P7; ORMEROD P, 1980, THORAX, V35, P56, DOI 10.1136/thx.35.1.56; PASSANNANTE MR, 1994, CHEST, V106, P431, DOI 10.1378/chest.106.2.431; PATTERSON WB, 1985, ANN INTERN MED, V102, P658, DOI 10.7326/0003-4819-102-5-658; RALEIGH JW, 1973, AM REV RESPIR DIS, V108, P639; RICH AR, 1951, PATHOGENESIS TUBERCU, P123; SEPKOWITZ KA, 1994, ANN INTERN MED, V120, P71, DOI 10.7326/0003-4819-120-1-199401010-00012; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; STEAD WW, 1987, AM REV RESPIR DIS, V136, P803, DOI 10.1164/ajrccm/136.4.803; STEAD WW, 1987, ANN INTERN MED, V107, P837, DOI 10.7326/0003-4819-107-6-837; STEAD WW, 1967, AM REV RESPIR DIS, V95, P729; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304; STEAD WW, 1967, NEW ENGL J MED, V277, P1008, DOI 10.1056/NEJM196711092771906; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; STYBLO K, 1984, EPIDEMIOLOGY TUBERCU; STYBLO K, 1991, SELECTED PAPERS, V24, P1; TEMPLETON GL, 1995, ANN INTERN MED, V122, P922, DOI 10.7326/0003-4819-122-12-199506150-00005; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; ZIEGLER JE, 1985, TUBERCLE, V66, P121, DOI 10.1016/0041-3879(85)90077-7; 1990, MMWR-MORBID MORTAL W, V39, P7; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P427	49	61	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					906	912		10.7326/0003-4819-122-12-199506150-00003	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755225				2022-12-28	WOS:A1995RC27000003
J	KELLERMANN, AL; WESTPHAL, L; FISCHER, L; HARVARD, B				KELLERMANN, AL; WESTPHAL, L; FISCHER, L; HARVARD, B			WEAPON INVOLVEMENT IN-HOME INVASION CRIMES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN OWNERSHIP; PROTECTION; DEATHS	Objective.-To study the epidemiology of home invasion crimes and determine the frequency with which firearms are used to resist these crimes. Design.-Prospective case series. Setting.-Atlanta, Ga (population 402 877). Methods.-Between June 1 and August 31, 1994, Atlanta Police Department reports were screened to identify every case of unwanted entry into an occupied, single-family dwelling. Cases of sexual assault and incidents that involved cohabitants were excluded. Results.-A total of 198 cases were identified during the study interval. Half (99 cases) involved forced entry into the home. The victim and offender were acquainted in one third of cases. A firearm was carried by one or more offenders in 32 cases (17%). Seven offenders (3.5%) carried knives. In 42% of cases, the offender fled without confronting the victim. Victims who avoided confrontation were more likely to lose property but much less likely to be injured than those who were confronted by the offender. Resistance was attempted in 62 cases (31%), but the odds of injury were not significantly affected by the method of resistance. Forty cases (20%) resulted in one or more victims' being injured, including six (3%) who were shot. No one died. Three victims (1.5%) employed a firearm in self-protection. All three escaped injury, but one lost property. Conclusion.-A minority of home invasion crimes result in injury. Measures that increase the difficulty of forced entry or enhance the likelihood of detection could be useful to prevent these crimes. Although firearms are often kept in the home for protection, they are rarely used for this purpose.	ATLANTA POLICE DEPT, ATLANTA, GA USA		KELLERMANN, AL (corresponding author), EMORY UNIV, ROLLINS SCH PUBL HLTH, CTR INJURY CONTROL, 1518 CLIFTON RD NE, ATLANTA, GA 30322 USA.							Block R, 1986, Violence Vict, V1, P241; BRENT DA, 1991, JAMA-J AM MED ASSOC, V266, P2989, DOI 10.1001/jama.266.21.2989; Cook P.J., 1991, CRIME JUSTICE, V14, P1, DOI [10.1086/449183, DOI 10.1086/449183]; COOK PJ, 1986, J LEGAL STUD, V15, P405, DOI 10.1086/467819; HAVEMAN RH, 1979, POLICY STUDIES REV A, V3, P743; HEMENWAY D, 1995, JAMA-J AM MED ASSOC, V273, P46, DOI 10.1001/jama.273.1.46; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KLECK G, 1988, SOC PROBL, V35, P1, DOI 10.1525/sp.1988.35.1.03a00010; LEE RK, 1993, AM J PREV MED, V9, P16, DOI 10.1016/S0749-3797(18)30673-1; MCDOWALL D, 1994, AM J PUBLIC HEALTH, V84, P1982, DOI 10.2105/AJPH.84.12.1982; SKOGAN WG, 1990, PUBLIC OPIN QUART, V54, P256, DOI 10.1086/269202; WEIL DS, 1992, JAMA-J AM MED ASSOC, V267, P3033, DOI 10.1001/jama.267.22.3033; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WRIGHT JD, 1981, WEAPONS CRIME VIOLEN; 1994, US NEWS WORLD R 0805; 1994, CRIME US 1993; 1994, NATIONAL CRIME VICTI; 1994, SUMMARY TAPE FILE 3C; 1994, CRIMINAL VICTIMIZATI	21	33	33	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1759	1762		10.1001/jama.273.22.1759	http://dx.doi.org/10.1001/jama.273.22.1759			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB800	7769769				2022-12-28	WOS:A1995RB80000028
J	ALLAN, NC; RICHARDS, SM; SHEPHERD, PCA				ALLAN, NC; RICHARDS, SM; SHEPHERD, PCA			UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE	LANCET			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC GRANULOCYTIC-LEUKEMIA; BUSULFAN; THERAPY; INTERMITTENT; REMISSION	Interferon-alpha may be better than cytotoxic drugs in the long-term management of patients with chronic myeloid leukaemia (CML) in chronic phase. To test this possibility 587 patients with CML in chronic phase were randomly allocated to receive lymphoblastoid cell-line interferon-alpha n1 (IFN-alpha, n=293) or chemotherapy with busulphan or hydroxyurea (no IFN-alpha, n=294) as maintenance after initial induction treatment with cytotoxic drugs. There was a significant survival benefit for patients in the IFN-alpha arm when analysed on the basis of intention to treat (2p=0.0009). The median survival for those allocated IFN-alpha was 61 months and no IFN-alpha was 41 months. Out of 269 patients with Philadelphia-positive CML in the IFN-alpha arm with at least 6 months follow-up, 211 were evaluable for haematological response: 145 (68%) achieved good responses (A+ or A type), 37 (18%) had partial responses (B type) and 29 (14%) had poor responses (C type). Patients with types A and B responses had a better survival than those in the no IFN-alpha arm; patients with type C responses had survival equivalent to the no IFN-alpha arm. Of these 269 patients, 26 of whom had not started IFN-alpha, 59 (22%) achieved a significant degree of cytogenetic response but 210 (78%) did not have response. Cytogenetic responders survived significantly longer than non-responders and even non-responders survived longer than patients in the no IFN-alpha arm. Since cytogenetic nonresponders had worse than average prognostic features, they may also benefit from IFN-alpha therapy. We conclude that treatment with IFN-alpha prolongs the survival of patients with CML; benefits of IFN-alpha are not confined to cytogenetic responders but may extend to most, if not all patients receiving IFN-alpha treatment; and cytogenetic response to IFN-alpha treatment identifies patients with a relatively good prognosis.	RADCLIFFE INFIRM, CTSU, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary; University of Oxford	ALLAN, NC (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CML TRIAL OFF, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALIMENA G, 1988, BLOOD, V72, P642; BERGAMASCHI G, 1994, BRIT J HAEMATOL, V87, P867, DOI 10.1111/j.1365-2141.1994.tb06755.x; CUNNINGHAM I, 1979, BLOOD, V53, P375; DOUGLAS IDC, 1978, BRIT J HAEMATOL, V40, P59, DOI 10.1111/j.1365-2141.1978.tb03639.x; FINNEY R, 1972, BRIT J HAEMATOL, V23, P283, DOI 10.1111/j.1365-2141.1972.tb08874.x; GALTON DAG, 1953, LANCET, V264, P208; KANTARJIAN HM, 1993, BLOOD, V82, P691; KENNEDY BJ, 1972, CANCER-AM CANCER SOC, V29, P1052, DOI 10.1002/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO;2-7; LION T, 1994, BONE MARROW TRANSPL, V14, P505; MANTEL N, 1974, J AM STAT ASSOC, V69, P81, DOI 10.2307/2285503; MIYAMURA K, 1994, BONE MARROW TRANSPL, V14, P201; MORRA E, 1992, LEUKEMIA LYMPHOMA, V6, P305, DOI 10.3109/10428199209053562; NIEDERLE N, 1991, EUR J CANCER, V27, pS7, DOI 10.1016/0277-5379(91)90556-S; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; SHEPHERD PCA, 1991, BRIT J HAEMATOL, V79, P185, DOI 10.1111/j.1365-2141.1991.tb04520.x; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; TALPAZ M, 1987, BLOOD, V69, P1280; TALPAZ M, 1982, BLOOD S, V559, P60; TURA S, 1994, NEW ENGL J MED, V330, P820; WEATHERALL DJ, 1969, BMJ-BRIT MED J, V1, P638, DOI 10.1136/bmj.1.5644.638-a; 1983, WHO TECH REP SER, V687, P53	21	381	384	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 3	1995	345	8962					1392	1397		10.1016/S0140-6736(95)92596-1	http://dx.doi.org/10.1016/S0140-6736(95)92596-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760609				2022-12-28	WOS:A1995RB44100008
J	LISCOVITCH, M; CANTLEY, LC				LISCOVITCH, M; CANTLEY, LC			SIGNAL-TRANSDUCTION AND MEMBRANE TRAFFIC - THE PITP/PHOSPHOINOSITIDE CONNECTION	CELL			English	Review							TRANSFER PROTEIN; PHOSPHOLIPASE		HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; WEIZMANN INST SCI,DEPT HORMONE RES,IL-76100 REHOVOT,ISRAEL	Harvard University; Harvard Medical School; Weizmann Institute of Science	LISCOVITCH, M (corresponding author), BETH ISRAEL HOSP,DIV SIGNAL TRANSDUCT,BOSTON,MA 02215, USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; HAY JC, 1995, NATURE, V374, P172; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KAUFMANNZEH A, 1995, IN PRESS SCIENCE; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; TERUI T, 1994, J BIOL CHEM, V269, P28130; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WONG K, 1994, J BIOL CHEM, V269, P28878; YAMAMOTO A, 1995, IN PRESS MOL BIOL CE, V6; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	25	260	263	1	7	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					659	662		10.1016/0092-8674(95)90525-1	http://dx.doi.org/10.1016/0092-8674(95)90525-1			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774006	Bronze			2022-12-28	WOS:A1995RB96100003
J	DORIT, RL; AKASHI, H; GILBERT, W				DORIT, RL; AKASHI, H; GILBERT, W			ABSENCE OF POLYMORPHISM AT THE ZFY LOCUS ON THE HUMAN Y-CHROMOSOME	SCIENCE			English	Article							TESTIS-DETERMINING FACTOR; HUMAN MITOCHONDRIAL-DNA; GENE-CLUSTER; SEQUENCES; POPULATIONS; HAPLOTYPES; EVOLUTION; PATTERNS; PROTEIN; TISSUES	DNA polymorphism in the Y chromosome, examined at a 729-base pair intron located immediately upstream of the ZFY zinc-finger exon, revealed no sequence Variation in a worldwide sample of 38 human males. This finding cannot be explained by global constraint on the intron sequence, because interspecific comparisons with other nonhuman primates revealed phylogenetically informative sequence changes. The invariance likely results from either a recent selective sweep, a recent origin for modern Homo sapiens, recurrent male population bottlenecks, or historically small effective male population sizes. A coalescence model predicts an expected time to a most recent common ancestral male lineage of 270,000 years (95 percent confidence limits: 0 to 800,000 years).	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637; HARVARD UNIV,CAMBRIDGE,MA 02138	University of Chicago; Harvard University	DORIT, RL (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511, USA.				NIGMS NIH HHS [GM 37997] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037997] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONARAKIS SE, 1988, HUM GENET, V80, P265, DOI 10.1007/BF01790095; AVRAMOPOULOS D, 1993, GENOMICS, V15, P98, DOI 10.1006/geno.1993.1015; AYALA FJ, 1994, P NATLA CAD SCI US, V91, P6786; BERRY AJ, 1991, GENETICS, V129, P1111; CHAKRAVARTI A, 1986, P NATL ACAD SCI USA, V83, P1045, DOI 10.1073/pnas.83.4.1045; CHAKRAVARTI A, 1984, P NATL ACAD SCI-BIOL, V81, P6085, DOI 10.1073/pnas.81.19.6085; CHAKRAVARTI A, 1981, AM J HUM GENET, V33, pA134; ELLIS N, 1990, NATURE, V344, P663, DOI 10.1038/344663a0; FRAYER DW, 1993, AM ANTHROPOL, V95, P14, DOI 10.1525/aa.1993.95.1.02a00020; HAMMER MF, 1994, MOL BIOL EVOL, V11, P749; HASEGAWA M, 1989, J HUM EVOL, V18, P461, DOI 10.1016/0047-2484(89)90075-4; HASEGAWA M, 1991, J MOL EVOL, V32, P37, DOI 10.1007/BF02099927; HUDSON RR, 1993, MECHANISMS OF MOLECULAR EVOLUTION, P23; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KREITMAN M, 1991, GENETICS, V127, P565; LAU YFC, 1989, AM J HUM GENET, V45, P942; LI WH, 1991, GENETICS, V129, P513; LUCOTTE G, 1985, NUCLEIC ACIDS RES, V13, P8285, DOI 10.1093/nar/13.22.8285; LUCOTTE G, 1988, HUMAN REVOLUTION BEH, P39; MALASPINA P, 1990, ANN HUM GENET, V54, P297, DOI 10.1111/j.1469-1809.1990.tb00385.x; MATTESON KJ, 1985, HUM GENET, V69, P263, DOI 10.1007/BF00293037; MCCOMBIE WR, 1992, NAT GENET, V1, P348, DOI 10.1038/ng0892-348; NAGAMINE CM, 1990, GENE DEV, V4, P63, DOI 10.1101/gad.4.1.63; NGO KY, 1986, AM J HUM GENET, V38, P407; OAKEY R, 1990, GENOMICS, V7, P325, DOI 10.1016/0888-7543(90)90165-Q; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; PALMER MS, 1989, NATURE, V342, P937, DOI 10.1038/342937a0; ROEWER L, 1992, HUM GENET, V89, P389; SCHENIDERGADICK.A, 1989, CELL, V57, P1247; SHIMMIN LC, 1993, NATURE, V362, P745, DOI 10.1038/362745a0; SPRUDLE AB, 1991, AM J HUM GENET, V50, P107; SPURDLE AB, 1994, AM J HUM GENET, V54, P319; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; SU H, 1992, MOL REPROD DEV, V33, P252, DOI 10.1002/mrd.1080330304; TORRONI A, 1990, ANN HUM GENET, V54, P287; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WOLPOFF MH, 1989, HUMAN REVOLUTION, P62	37	168	171	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1183	1185		10.1126/science.7761836	http://dx.doi.org/10.1126/science.7761836			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761836				2022-12-28	WOS:A1995RA60400039
J	NUEZ, B; MICHALOVICH, D; BYGRAVE, A; PLOEMACHER, R; GROSVELD, F				NUEZ, B; MICHALOVICH, D; BYGRAVE, A; PLOEMACHER, R; GROSVELD, F			DEFECTIVE HEMATOPOIESIS IN FETAL LIVER RESULTING FROM INACTIVATION OF THE EKLF GENE	NATURE			English	Article							BETA-GLOBIN GENE; TRANSGENIC MICE; DEVELOPMENTAL REGULATION; PROMOTER ELEMENT; STEM-CELLS; EXPRESSION; MUTATIONS; SEQUENCE; DISTAL	ERYTHROID Kruppel-like factor (EKLF) was originally isolated from erythroid cell RNA by differential screening and shown to be erythroid-specific, although a low level of EKLF was found in mast cell lines(1,2). EKLF contains three zinc-fingers homologous to those found in the Kruppel family of transcription factors, Because it binds the sequence CCACACCCT, EKLF may affect erythroid development as a result of its ability to bind to the CAC box in the promoter of the beta-globin gene(1,2). Mutation of this element leads to reduced beta-globin expression(3-5) and it appears to mediate the effect of the globin locus control region on the promoter(6). Here we inactivate the EKLF gene through insertion of a lacZ reporter gene by homologous recombination in embryonic stem (ES) cells. Heterozygous EKLF(+/-) mice show that the reporter gene is expressed in a developmentally specific manner in all types of erythroblasts in the fetal liver and adult bone marrow. Homozygous EKLF(-/-) mice appear normal during the embryonic stage of haematopoiesis in the yolk sac, but develop a fatal anaemia during early fetal life when haematopoiesis has switched to the fetal liver. Enucleated erythrocytes are formed but these do not contain the proper amount of haemoglobin. We conclude that the transcription factor EKLF is essential for the final steps of definitive erythropoiesis in fetal liver.	ERASMUS UNIV ROTTERDAM, DEPT HAEMATOL, 3015 GE ROTTERDAM, NETHERLANDS; NATL INST MED RES, DEPT GENE STRUCT & EXPRESS, LONDON NW7 1AA, ENGLAND	Erasmus University Rotterdam; MRC National Institute for Medical Research	NUEZ, B (corresponding author), ERASMUS UNIV ROTTERDAM, MGC DEPT CELL BIOL & GENET, DR MOLEWATERPLEIN 50, 3015 GE ROTTERDAM, NETHERLANDS.			Michalovich, David/0000-0003-4452-5776				ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; CHADA K, 1985, NATURE, V314, P377, DOI 10.1038/314377a0; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ELEOUET JF, 1993, EUR J BIOCHEM, V272, P763; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; EPPERLY BR, 1994, GENE, V131, P249; FENG WC, 1994, J BIOL CHEM, V269, P1492; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KULOZIK AE, 1991, BLOOD, V77, P2054; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; ORKIN SH, 1984, J BIOL CHEM, V259, P8679; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; PLOEMACHER RE, 1993, LEUKEMIA, V7, P1374; Robertson E. J., 1987, TERATOCARCINOMAS EMB; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WONG PMC, 1983, BLOOD, V62, P1280	23	471	484	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					316	318		10.1038/375316a0	http://dx.doi.org/10.1038/375316a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753194	Green Submitted			2022-12-28	WOS:A1995RA03000050
J	OGREN, M; HEDBLAD, B; ISACSSON, SO; JANZON, L; JUNGQUIST, G; LINDELL, SE				OGREN, M; HEDBLAD, B; ISACSSON, SO; JANZON, L; JUNGQUIST, G; LINDELL, SE			10-YEAR CEREBROVASCULAR MORBIDITY AND MORTALITY IN 68-YEAR-OLD MEN WITH ASYMPTOMATIC CAROTID STENOSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; ARTERY ATHEROSCLEROSIS; RISK-FACTORS; STROKE; POPULATION; PREVALENCE; BRUITS	Objective-To study the natural course of carotid artery stenosis detected by ultrasonography. Design-Prospective cohort study. Baseline examination in 1982-3 included ultrasound examination of carotid arteries, measurement of ankle-brachial blood pressure index, and detection of atrial fibrillation by 24 hour ambulatory electrocardiography. Setting-Malmo, a city in southern Sweden with 230 000 inhabitants. Subjects-470 men aged 68 years randomly selected hom the population. Main outcome measures-Incidence of stroke and transient ischaemic attack and all cause mortality during 10 years of follow up in relation to carotid stenosis, leg artery disease (ankle-brachial blood pressure index below 0.9), and atrial fibrillation. Results-Fifty men had a stroke; six of these were haemorrhagic. Another 11 had a transient ischaemic attack. Eighteen of the men with carotid stenosis (21.6 events/1000 person years) and 43 of the men with normal carotid arteries (14.8 events/1000 person years) had a stroke or transient ischaemic attack (P = 0.188). Men with atrial fibrillation had an increased rate of cerebrovascular events (36.7/1000 person years (P = 0.048). The highest rate was found in men with asymptomatic disease of the leg arteries (38.6/1000 person years) (P < 0.001). The increased risk of stroke or transient ischaemic attack in this group remained after multivariate analysis (relative risk 2.0; 95% confidence interval 1.1 to 3.7). Conclusions-In this cohort carotid stenosis was not associated with an increased risk of stroke. Part of this lack of association was explained by the high mortality from ischaemic heart disease in men with severe stenosis. Twenty seven of the 61 cerebrovascular events, however, occurred in men who had normal carotid arteries, normal ankle pressure, and no atrial fibrillation.	LUND UNIV, MALMO GEN HOSP, DEPT CLIN PHYSIOL, S-21401 MALMO, SWEDEN	Lund University	OGREN, M (corresponding author), LUND UNIV, MALMO GEN HOSP, DEPT COMMUNITY HLTH SCI, S-21401 MALMO, SWEDEN.							ANDERSON S, 1980, STATISTICAL METHODS; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; CARTER SA, 1968, CIRCULATION, V37, P624, DOI 10.1161/01.CIR.37.4.624; CHAMBERS BR, 1986, NEW ENGL J MED, V315, P860, DOI 10.1056/NEJM198610023151404; COX DR, 1972, J R STAT SOC B, V34, P187; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; Criqui M H, 1991, Drugs, V42 Suppl 5, P16; CULLEN SJ, 1983, CIRCULATION, V68, P83; DYKEN ML, 1984, STROKE, V15, P1105; FOWKES FGR, 1988, INT J EPIDEMIOL, V17, P248, DOI 10.1093/ije/17.2.248; GUNDERSEN J, 1972, ACTA CHIR SCAND S426, V26; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; ISACSSON SO, 1972, ACTA MED SCANDI S537, V192; JANZON L, 1981, CIRCULATION, V63, P1339, DOI 10.1161/01.CIR.63.6.1339; JUNGQUIST G, 1986, CLIN PHYSIOL, V6, P319, DOI 10.1111/j.1475-097X.1986.tb00237.x; JUNGQUIST G, 1989, STROKE, V20, P1327, DOI 10.1161/01.STR.20.10.1327; JUULMOLLER S, 1991, J INTERN MED, V230, P143, DOI 10.1111/j.1365-2796.1991.tb00422.x; LANDI G, 1992, LANCET, V339, P402, DOI 10.1016/0140-6736(92)90086-I; OGREN M, 1993, LANCET, V342, P1138, DOI 10.1016/0140-6736(93)92123-B; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; SUTTON KC, 1987, STROKE, V18, P817, DOI 10.1161/01.STR.18.5.817; WILLEIT J, 1993, ARTERIOSCLER THROMB, V13, P661, DOI 10.1161/01.ATV.13.5.661; WOLF PA, 1987, ARCH INTERN MED, V147, P1561, DOI 10.1001/archinte.147.9.1561	23	62	63	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	1995	310	6990					1294	1298		10.1136/bmj.310.6990.1294	http://dx.doi.org/10.1136/bmj.310.6990.1294			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773042	Green Published			2022-12-28	WOS:A1995QZ86000020
J	CLEVELAND, JL; IHLE, JN				CLEVELAND, JL; IHLE, JN			CONTENDERS IN FASL/TNF DEATH SIGNALING	CELL			English	Review							RECEPTOR; DOMAIN		UNIV TENNESSEE, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	CLEVELAND, JL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA.							BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DARNAY BG, 1994, J BIOL CHEM, V269, P19687; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ENARI M, 1995, IN PRESS NATURE; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH N, 1993, J BIOL CHEM, V268, P10932; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1994, J IMMUNOL, V152, P1751; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	30	312	339	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAY 19	1995	81	4					479	482		10.1016/0092-8674(95)90068-3	http://dx.doi.org/10.1016/0092-8674(95)90068-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758103	Bronze			2022-12-28	WOS:A1995QZ71000004
J	GUO, S; KEMPHUES, KJ				GUO, S; KEMPHUES, KJ			PAR-1, A GENE REQUIRED FOR ESTABLISHING POLARITY IN C-ELEGANS EMBRYOS, ENCODES A PUTATIVE SER/THR KINASE THAT IS ASYMMETRICALLY DISTRIBUTED	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; PROTEIN-KINASE; CYTOPLASMIC LOCALIZATION; CONSERVED FEATURES; SPLICED LEADER; SEQUENCE; MICROFILAMENTS; FAMILY; IDENTIFICATION; EMBRYOGENESIS	The first cleavage of C. elegans is asymmetric, generating daughter cells with different sizes, cytoplasmic components, and fates. Mutations in the par-1 gene disrupt this asymmetry. We report here that par-1 encodes a putative Ser/Thr kinase with similarity to kinases from yeasts and mammals, Two strong alleles have mutations in the kinase domain, suggesting that kinase activity is essential for par-1 function. PAR-1 protein is localized to the posterior periphery of the zygote and is distributed in a polar fashion preceding the asymmetric divisions of the germline lineage. Because PAR-1 distribution in the germline correlates with the distribution of germline-specific P granules, it is possible that PAR-1 functions in germline development as well as in establishing embryonic polarity.			GUO, S (corresponding author), CORNELL UNIV, GENET & DEV SECT, ITHACA, NY 14853 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027689] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27689] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARSTEAD RJ, 1991, CELL MOTIL CYTOSKEL, V20, P69, DOI 10.1002/cm.970200108; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; CARLING D, 1994, J BIOL CHEM, V269, P11432; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHENG NN, 1995, GENETICS, V139, P549; Davidson E. H., 1986, GENE ACTIVITY EARLY; FIRE A, 1991, DEVELOPMENT, V113, P503; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1992, NATURE, V357, P254; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HILL DP, 1990, DEVELOPMENT, V108, P159; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; INGLIS JD, 1993, MAMM GENOME, V4, P401, DOI 10.1007/BF00360595; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEVIN DE, 1990, P NATL ACAD SCI USA, V87, P8272, DOI 10.1073/pnas.87.21.8272; LEVIN DE, 1987, P NATL ACAD SCI USA, V84, P6035, DOI 10.1073/pnas.84.17.6035; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; MORTON DG, 1992, GENETICS, V130, P771; PARSA I, 1988, CANCER RES, V48, P2265; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHIERENBERG E, 1988, ROUX ARCH DEV BIOL, V197, P282, DOI 10.1007/BF00380022; SCHNABEL R, 1994, SCIENCE, V263, P1449, DOI 10.1126/science.8128230; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1986, J CELL BIOL, V103, P2241, DOI 10.1083/jcb.103.6.2241; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1986, J EMBRYOL EXP MORPH, V97, P15; SULSTON J, 1983, DEV BIOL, V100, P67; TELFER A, 1991, THESIS HARVARD U CAM	48	815	1061	7	138	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					611	620		10.1016/0092-8674(95)90082-9	http://dx.doi.org/10.1016/0092-8674(95)90082-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758115	hybrid			2022-12-28	WOS:A1995QZ71000018
J	KUBOTA, Y; MIMURA, S; NISHIMOTO, SI; TAKISAWA, H; NOJIMA, H				KUBOTA, Y; MIMURA, S; NISHIMOTO, SI; TAKISAWA, H; NOJIMA, H			IDENTIFICATION OF THE YEAST MCM3-RELATED PROTEIN AS A COMPONENT OF XENOPUS DNA-REPLICATION LICENSING FACTOR	CELL			English	Article							CELL-FREE-EXTRACT; NUCLEAR-LOCALIZATION; EGG EXTRACTS; CYCLE; INVITRO; INITIATION; SEQUENCE; MITOSIS; MCM3	Replication licensing factor is thought to be involved in the strict control of the initiation of DNA replication in eukaryotes. We identified a 100 kDa protein as a candidate for the licensing factor in Xenopus egg extracts. This protein was required for replication; it bound to sperm DNA before the formation of nuclei and apparently dissociated from the nuclear DNA during the progression of replication without being transported into the nuclei. An immunologically homologous protein in HeLa cells behaved similarly to the Xenopus protein during the cell cycle. Cloning and sequencing of the cDNAs encoding the Xenopus and human proteins revealed that they are homologs of yeast Mcm3, a putative yeast DNA replication licensing factor.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT MOLEC GENET,SUITA,OSAKA 565,JAPAN	Osaka University	KUBOTA, Y (corresponding author), OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN.							ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; DINGWALL C, 1987, EMBO J, V6, P69, DOI 10.1002/j.1460-2075.1987.tb04720.x; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; HUTCHISON C, 1989, J CELL SCI, V93, P605; HUTCHISON CJ, 1988, DEVELOPMENT, V103, P553; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LENO GH, 1994, J CELL BIOL, V127, P5, DOI 10.1083/jcb.127.1.5; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	28	253	255	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					601	609		10.1016/0092-8674(95)90081-0	http://dx.doi.org/10.1016/0092-8674(95)90081-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758114	Bronze			2022-12-28	WOS:A1995QZ71000017
J	MATHEWS, D				MATHEWS, D			BIRTH OF THE MIDWIFE OBSTETRICIAN	LANCET			English	Editorial Material											MATHEWS, D (corresponding author), ALL SAINTS HOSP,CHATHAM,KENT,ENGLAND.							CAMPBELL R, 1994, WHERE TO BE BORN, P131; DUNLOP W, 1994, FUTURE MATERNITY SER; JUDGE S, 1977, IT ALL COMES ROUND R; JUDGE S, 1974, HAPPY NEW YEAR MATER; 1993, CHANGING CHILDBIRT 1; 1970, PEEL REPORT DOMICILI	6	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					532	533		10.1016/S0140-6736(95)90459-X	http://dx.doi.org/10.1016/S0140-6736(95)90459-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776768				2022-12-28	WOS:A1995QK44400004
J	DEMITRI, MS; POUSSIN, K; BACCARINI, P; PONTISSO, P; DERRICO, A; SIMON, N; GRIGIONI, W; ALBERTI, A; BEAUGRAND, M; PISI, E; BRECHOT, C; PATERLINI, P				DEMITRI, MS; POUSSIN, K; BACCARINI, P; PONTISSO, P; DERRICO, A; SIMON, N; GRIGIONI, W; ALBERTI, A; BEAUGRAND, M; PISI, E; BRECHOT, C; PATERLINI, P			HCV-ASSOCIATED LIVER-CANCER WITHOUT CIRRHOSIS	LANCET			English	Article							HEPATITIS-C VIRUS; POLYMERASE CHAIN-REACTION; B SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; DNA; INTEGRATION; SEQUENCES; GENOMES; DISEASE	Chronic infection with hepatitis C virus (HCV) is regarded as a risk factor for hepatocellular cancer, mostly in patients with liver cirrhosis. We looked for HCV genomes in the livers of patients with hepatocellular cancer who did not have cirrhosis to see whether HCV was directly oncogenic. Cancerous and non-cancerous liver tissue, and serum samples from 19 patients negative for hepatitis B surface antigen were analysed by polymerase chain reaction for the presence of HCV genome, HCV replication, HCV genotyping, and HBV genome. 13 of 19 patients were HCV RNA-positive in cancerous and non-cancerous liver tissue; 8 of 17 tested were anti-HCV positive. Among the 13 HCV RNA-positive patients, 11 had genotype 1b and 2 had genotype 2a. 7 of 13 serum samples were HCV RNA positive. 7 of 19 patients were HBV DNA positive in cancerous and non-cancerous liver tissue, 5 of them anti-HBc positive. 4 patients were both HCV RNA and HBV DNA positive and 3 were both HCV RNA and HBV DNA negative. Our results provide evidence for the association of HCV, mostly genotype 1b, with hepatocellular cancer without the intermediate. step of cirrhosis.	FAC MED NECKER ENFANTS MALAD,INSERM,U370,F-75015 PARIS,FRANCE; UNIV BOLOGNA,DEPT INTERNAL MED,BOLOGNA,ITALY; UNIV BOLOGNA,DEPT PATHOL,BOLOGNA,ITALY; UNIV PADUA,DEPT INTERNAL MED,PADUA,ITALY; AURA,PARIS,FRANCE; HOP VERDIER,DEPT GASTROENTEROL,BONDY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Bologna; University of Bologna; University of Padua; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP			PONTISSO, PATRIZIA/K-3574-2018; Foschini, Maria P./A-6306-2016	PONTISSO, PATRIZIA/0000-0003-2077-9202; ALBERTI, ALFREDO/0000-0001-9926-2382; Foschini, Maria P./0000-0001-7079-7260				BLUM HE, 1994, HEPATOLOGY, V19, P251, DOI 10.1016/0270-9139(94)90078-7; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; Brouwer J. T., 1993, Journal of Hepatology, V18, pS10; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOMBO M, 1994, PRIMARY LIVER CANC E, P49; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; FERAY C, IN PRESS GASTROENTER; GERBER MA, 1992, AM J PATHOL, V141, P1271; HERR W, 1993, CLIN INVESTIGATOR, V71, P49, DOI 10.1007/BF00210964; KAKLAMANI E, 1991, JAMA-J AM MED ASSOC, V265, P1974, DOI 10.1001/jama.265.15.1974; KATO N, 1993, HEPATOLOGY, V18, P16, DOI 10.1002/hep.1840180104; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; MELIA WM, 1984, Q J MED, V211, P391; MIYAMURA T, 1994, PRIMARY LIVER CANC E, P125; NOUSBAUM J, IN PRESS ANN INTERN; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; PATERLINI P, 1990, NEW ENGL J MED, V323, P80, DOI 10.1056/NEJM199007123230202; PATERLINI P, IN PRESS VIRAL HEPAT; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; POZZATO G, 1992, Journal of Hepatology, V16, pS3; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SBOLLI G, 1990, J MED VIROL, V30, P230, DOI 10.1002/jmv.1890300316; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	30	243	248	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					413	415		10.1016/S0140-6736(95)90400-X	http://dx.doi.org/10.1016/S0140-6736(95)90400-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7772123				2022-12-28	WOS:A1995QG90400008
J	LANG, CC; STEIN, CM; BROWN, RM; DEEGAN, R; NELSON, R; HE, HB; WOOD, M; WOOD, AJJ				LANG, CC; STEIN, CM; BROWN, RM; DEEGAN, R; NELSON, R; HE, HB; WOOD, M; WOOD, AJJ			ATTENUATION OF ISOPROTERENOL-MEDIATED VASODILATATION IN BLACKS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RACIAL-DIFFERENCES; BLOOD-PRESSURE; SYMPATHETIC ACTIVITY; ETHNIC-DIFFERENCES; HUMAN FOREARM; HYPERTENSION; NOREPINEPHRINE; RESPONSES; RACE; WHITES	Background. The mechanism of enhanced vascular reactivity in young blacks, which may play a part in the development of hypertension, has not been defined. To determine the contribution of blunted vasodilatation mediated by beta(2)-adrenergic receptors to this phenomenon, we compared forearm blood-flow responses to isoproterenol in young black and white normotensive men. Methods. We used venous-occlusion plethysmography to measure the responses of blood flow in the forearm to the intraarterial administration of isoproterenol (10 to 400 ng per minute) in 9 normotensive black men (mean [+/-SD] age, 31.3+/-8.0 years) and 13 normotensive white men (mean age, 32.91+/-5.6 years). Sympathetic activity in the forearm was measured simultaneously by isotope-dilution techniques. Results. Base-line blood flow in the forearm was similar in blacks and whites, but the degree of vasodilatation in response to isoproterenol was markedly lower in blacks. Isoproterenol at an infusion rate of 400 ng per minute produced a 9-fold increase in blood flow in whites but only a 3.5-fold increase in blacks (P<0.001). The base-line rate of norepinephrine spillover in the forearm was higher in blacks (2.0+/-1.3 ng per minute [11.8+/-7.7 nmol per minute]) than in whites (0.6+/-0.5 ng per minute [3.5+/-3.0 nmol per minute], P=0.002), but there was no difference between the groups after isoproterenol stimulation. Conclusions. Forearm blood-flow responses to isoproterenol were markedly attenuated in normotensive blacks, indicating a blunting of vasodilatation mediated by beta(2)-adrenergic receptors. Our findings suggest that the mechanisms responsible for blunted vasodilatation in response to the administration of isoproterenol may contribute to enhanced vascular reactivity in blacks and may play a part in the pathogenesis of hypertension in blacks.	VANDERBILT UNIV, SCH MED, DIV CLIN PHARMACOL, NASHVILLE, TN 37232 USA	Vanderbilt University				Deegan, Robert/0000-0002-1069-3977; Lang, Chim/0000-0002-4530-3078	NIGMS NIH HHS [GM 31304, GM 46622, GM 5 M01-RR00095] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031304, R37GM046622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NB, 1988, PSYCHOSOM MED, V50, P57, DOI 10.1097/00006842-198801000-00007; ANDERSON NB, 1989, J HYPERTENS, V7, P161; BASSETT DR, 1992, AM J HYPERTENS, V5, P781, DOI 10.1093/ajh/5.11.781; CARLSSON I, 1987, J PHYSIOL-LONDON, V389, P147, DOI 10.1113/jphysiol.1987.sp016651; CHANG PC, 1991, HYPERTENSION, V18, P56, DOI 10.1161/01.HYP.18.1.56; COLES DR, 1958, J PHYSIOL-LONDON, V142, P323, DOI 10.1113/jphysiol.1958.sp006019; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; EICHLER HG, 1990, J CARDIOVASC PHARM, V16, P177, DOI 10.1097/00005344-199008000-00001; ESLER M, 1984, AM J PHYSIOL, V247, pE21, DOI 10.1152/ajpendo.1984.247.1.E21; FALKNER B, 1987, HYPERTENSION, V10, P551, DOI 10.1161/01.HYP.10.6.551; FALKNER B, 1990, HYPERTENSION, V15, P681, DOI 10.1161/01.HYP.15.6.681; FELDMAN RD, 1990, J CLIN INVEST, V85, P647, DOI 10.1172/JCI114487; FELDMAN RD, 1987, CAN J PHYSIOL PHARM, V65, P1666, DOI 10.1139/y87-261; FLORAS J, 1986, HYPERTENSION, V8, P641, DOI 10.1161/01.HYP.8.8.641; GILLUM RF, 1979, HYPERTENSION, V1, P468, DOI 10.1161/01.HYP.1.5.468; HE HB, 1992, J CHROMATOGR-BIOMED, V574, P213, DOI 10.1016/0378-4347(92)80032-L; HOHN AR, 1983, HYPERTENSION, V5, P56, DOI 10.1161/01.HYP.5.1.56; ISAACS KD, 1993, MED SCI RES, V21, P313; KAPLAN NM, 1994, LANCET, V344, P450, DOI 10.1016/S0140-6736(94)91774-4; LICHTMAN MA, 1967, J CHRON DIS, V20, P119, DOI 10.1016/0021-9681(67)90046-X; LIGHT KC, 1987, HYPERTENSION, V10, P555, DOI 10.1161/01.HYP.10.6.555; MENDLOWITZ M, 1973, AM HEART J, V85, P252, DOI 10.1016/0002-8703(73)90467-5; MICHEL MC, 1990, HYPERTENSION, V16, P107, DOI 10.1161/01.HYP.16.2.107; MILLS PJ, 1995, HYPERTENSION, V25, P88, DOI 10.1161/01.HYP.25.1.88; MURPHY JK, 1986, HYPERTENSION, V8, P1075, DOI 10.1161/01.HYP.8.11.1075; NASLUND T, 1990, CLIN PHARMACOL THER, V48, P87, DOI 10.1038/clpt.1990.121; SEVER PS, 1979, CLIN EXP HYPERTENS, V1, P733, DOI 10.3109/10641967909068636; STEIN CM, IN PRESS J CLIN INVE; STEIN M, 1993, CLIN PHARMACOL THER, V54, P58, DOI 10.1038/clpt.1993.110; STEIN M, 1990, CLIN PHARMACOL THER, V47, P360, DOI 10.1038/clpt.1990.40; THOMAS J, 1987, J CHRON DIS, V40, P721, DOI 10.1016/0021-9681(87)90109-3; VENTER CP, 1985, BRIT J CLIN PHARMACO, V19, P187, DOI 10.1111/j.1365-2125.1985.tb02630.x; VOORS AW, 1980, HYPERTENSION, V2, P686, DOI 10.1161/01.HYP.2.5.686; 1982, ADV DATA VITAL HLTH, V84; 1980, VITAL STATISTICS U B, V2	35	132	136	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					155	160		10.1056/NEJM199507203330304	http://dx.doi.org/10.1056/NEJM199507203330304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791817	Bronze			2022-12-28	WOS:A1995RK91700004
J	WILCOX, CM; SCHWARTZ, DA; CLARK, WS				WILCOX, CM; SCHWARTZ, DA; CLARK, WS			ESOPHAGEAL ULCERATION IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - CAUSES, RESPONSE TO THERAPY, AND LONG-TERM OUTCOME	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNE-DEFICIENCY-SYNDROME; AVIUM COMPLEX INFECTION; CYTOMEGALOVIRUS VIREMIA; CD4 COUNT; SURVIVAL; AIDS; TRANSPLANTATION; HYBRIDIZATION; ZIDOVUDINE; SYMPTOMS	Objective: To determine the causes of esophageal ulceration, the response rate to currently available therapies, and the long-term outcome in patients with human immunodeficiency virus (HIV) infection. Design: Prospective cohort study. Setting: An urban county hospital. Patients: Consecutive patients with HIV infection and endoscopically detected esophageal ulceration during a 4-year period, Intervention: Causes of ulcers were determined from clinical, endoscopic, and pathologic findings. Standard medical therapies for the identified causes were instituted, and ulcer healing was endoscopically confirmed when possible. Measurements: Symptomatic and endoscopic response to therapy and long-term outcome, including survival. Results: 100 patients with esophageal ulcer were identified. Ulcers caused by cytomegalovirus alone were the most common (n = 45); idiopathic ulcers were almost as frequent (n = 40). Herpes simplex Virus esophagitis alone was identified as a cause in only 5 patients. Several potential causes of ulcer were found in 5 patients, including Candida esophagitis in 27 patients. Ten patients developed more than one cause of ulceration during long-term follow-up. Eighty-five patients had specific medical therapy for their identified disorders and had an overall response rate of 98%. Median survival from time of diagnosis was 8.9 months (range, 2 days to > 42 months). A difference in median survival was found between patients with cytomegalovirus esophagitis and those with idiopathic esophageal ulcer (7.6 months compared with 13.1 months; P = 0.03). Conclusions: Given I)the broad spectrum of causes of esophageal ulceration, 2) that each of these causes requires specific therapy, and 3) the apparent high response rate, it is important to do endoscopic evaluation with mucosal biopsy in patients with HIV infection so that a diagnosis can be established and appropriate therapy instituted. Despite effective therapy, long-term survival is poor; however, long-term remission and survival may occur in some patients.	EMORY UNIV, SCH MED, ATLANTA, GA USA; EMORY UNIV, SCH PUBL HLTH, ATLANTA, GA USA; GRADY MEM HOSP, ATLANTA, GA USA	Emory University; Emory University								ALEXANDER JA, 1988, DIGEST DIS SCI, V33, P1121, DOI 10.1007/BF01535788; BLANSHARD C, 1992, Q J MED, V85, P813; BONACINI M, 1991, ARCH INTERN MED, V151, P1567, DOI 10.1001/archinte.151.8.1567; CASABONA J, 1993, EUR J CANCER, V29A, P877, DOI 10.1016/S0959-8049(05)80430-7; CLAYTON F, 1989, ARCH PATHOL LAB MED, V113, P1124; CONNOLLY GM, 1989, GUT, V30, P1033, DOI 10.1136/gut.30.8.1033; DEGRUTTOLA V, 1993, J ACQ IMMUN DEF SYND, V6, P359; DOHN MN, 1992, ARCH INTERN MED, V152, P2465, DOI 10.1001/archinte.152.12.2465; EDWARDS P, 1990, ANN INTERN MED, V112, P65, DOI 10.7326/0003-4819-112-1-65; GERNA G, AIDS, V190, P1027; HORSBURGH CR, 1991, AM REV RESPIR DIS, V144, P557, DOI 10.1164/ajrccm/144.3_Pt_1.557; INDORF AS, 1992, ANN INTERN MED, V117, P133, DOI 10.7326/0003-4819-117-2-133; JACOBSON MA, 1991, J INFECT DIS, V164, P994, DOI 10.1093/infdis/164.5.994; KOTLER DP, 1992, J CLIN GASTROENTEROL, V15, P284, DOI 10.1097/00004836-199212000-00004; KUITERT LM, 1991, AIDS, V5, P1036, DOI 10.1097/00002030-199108000-00023; LEVINE AM, 1991, CANCER, V68, P2466, DOI 10.1002/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G; LEVINE DS, 1991, GASTROINTEST ENDOSC, V37, P332, DOI 10.1016/S0016-5107(91)70726-8; MCDONALD GB, 1985, GASTROENTEROLOGY, V88, P1111, DOI 10.1016/S0016-5085(85)80068-8; MILES SA, 1994, J CLIN ONCOL, V12, P1910, DOI 10.1200/JCO.1994.12.9.1910; NELSON MR, 1991, AM J GASTROENTEROL, V86, P876; NIGHTINGALE SD, 1993, ARCH INTERN MED, V153, P1313, DOI 10.1001/archinte.153.11.1313; PHILLIPS AN, 1992, JAMA-J AM MED ASSOC, V268, P2662, DOI 10.1001/jama.268.19.2662; RABENECK L, 1990, JAMA-J AM MED ASSOC, V263, P2318, DOI 10.1001/jama.263.17.2318; RAGNI MV, 1993, BLOOD, V81, P1889; SALMON D, 1990, J MED VIROL, V32, P160, DOI 10.1002/jmv.1890320306; SCHWARTZ DA, 1992, HUM PATHOL, V23, P1019, DOI 10.1016/0046-8177(92)90263-3; SEGONDY M, 1990, SCAND J INFECT DIS, V22, P653, DOI 10.3109/00365549009027117; STONEBURNER R, 1992, ARCH INTERN MED, V152, P2033, DOI 10.1001/archinte.152.10.2033; WILCOX CM, 1995, AM J MED, V98, P169, DOI 10.1016/S0002-9343(99)80400-8; WILCOX CM, 1994, AM J GASTROENTEROL, V89, P2163; WILCOX CM, 1994, GASTROINTEST ENDOSC, V40, P481, DOI 10.1016/S0016-5107(94)70215-2; WILCOX CM, 1993, J CLIN GASTROENTEROL, V16, P251, DOI 10.1097/00004836-199304000-00019; WILCOX CM, 1993, AM J GASTROENTEROL, V88, P1459; YARCHOAN R, 1991, ANN INTERN MED, V115, P184, DOI 10.7326/0003-4819-115-3-184	34	69	75	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					143	149		10.7326/0003-4819-123-2-199507150-00010	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778827				2022-12-28	WOS:A1995RM43500010
J	MITCHELL, AA; VANBENNEKOM, CM; LOUIK, C				MITCHELL, AA; VANBENNEKOM, CM; LOUIK, C			A PREGNANCY-PREVENTION PROGRAM IN WOMEN OF CHILDBEARING AGE RECEIVING ISOTRETINOIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THALIDOMIDE	Background. Isotretinoin is effective in treating severe acne, but it is also teratogenic. To minimize pregnancies among exposed women, the manufacturer, together with the U.S. Food and Drug Administration, implemented a multicomponent Pregnancy Prevention Program in 1988. We report the results of an ongoing survey designed to assess compliance with this program. Methods. Treated women enrolled in the survey through their physician, by filling out a form in the medication package, or by calling a toll-free telephone number. They were randomly assigned to be followed by telephone or by mail. Telephone interviews were conducted at the start of therapy, in the middle of it, and 6 months after it ended; mailed questionnaires were completed 6 months after therapy ended (median duration of therapy, 20 weeks). Results. Between 1989 and 1993, 177,216 eligible women enrolled in the survey. Interviews with 24,503 women within one month of enrollment revealed that 99 percent had been told to avoid pregnancy. At that time, approximately 54 percent were not sexually active (of whom 37 percent used contraception) and 42 percent were sexually active (of whom 99 percent used contraception); 4 percent were infertile. Among 124,216 women with completed telephone or mail follow-up results, there were 402 pregnancies during therapy (3.4 per 1000 courses of isotretinoin); 72 percent of the pregnant women had elective abortions, 16 percent spontaneous abortions, 3 percent ectopic pregnancies, and 8 percent live births. Conclusions. The pregnancy rate among women receiving isotretinoin therapy was substantially lower than that in the general population and was compatible with the characteristics and behavior of the enrolled women.			MITCHELL, AA (corresponding author), BOSTON UNIV,SCH MED,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Mitchell, Allen/0000-0003-0950-6799; Louik, Carol/0000-0001-5429-5084				DAI WS, 1992, J AM ACAD DERMATOL, V26, P599, DOI 10.1016/0190-9622(92)70088-W; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; GORMAN C, 1994, TIME            0613, P67; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P287; LAMMER EJ, 1985, NEW ENGL J MED, V343, P837; MAKONKAWKEYOON S, 1993, P NATL ACAD SCI USA, V90, P5974, DOI 10.1073/pnas.90.13.5974; MOSHER WD, 1990, DHHS PHS901250 PUBL; SAMPAIO EP, 1993, J INFECT DIS, V168, P408, DOI 10.1093/infdis/168.2.408; STERN RS, 1989, NEW ENGL J MED, V320, P1007, DOI 10.1056/NEJM198904133201510; TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856; UNDERWOOD AA, 1994, NEWSWEEK        0919, P58; VENTURA SJ, 1992, MON VITAL STAT REP S, V41; WEINBLATT ME, 1995, NEW ENGL J MED, V332, P330, DOI 10.1056/NEJM199502023320512	14	132	141	1	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					101	106		10.1056/NEJM199507133330206	http://dx.doi.org/10.1056/NEJM199507133330206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777014	Bronze			2022-12-28	WOS:A1995RH22500006
J	BOUMPAS, DT; FESSLER, BJ; AUSTIN, HA; BALOW, JE; KLIPPEL, JH; LOCKSHIN, MD				BOUMPAS, DT; FESSLER, BJ; AUSTIN, HA; BALOW, JE; KLIPPEL, JH; LOCKSHIN, MD			SYSTEMIC LUPUS-ERYTHEMATOSUS - EMERGING CONCEPTS .2. DERMATOLOGICAL AND JOINT DISEASE, THE ANTIPHOSPHOLIPID ANTIBODY SYNDROME, PREGNANCY AND HORMONAL-THERAPY, MORBIDITY AND MORTALITY, AND PATHOGENESIS	ANNALS OF INTERNAL MEDICINE			English	Review							PNEUMOCYSTIS-CARINII PNEUMONIA; RETROSPECTIVE CASE-CONTROL; CONGENITAL HEART-BLOCK; AUTOIMMUNE-DISEASE; DNA ANTIBODIES; NEONATAL LUPUS; LPR MICE; ANTICARDIOLIPIN ANTIBODIES; MALIGNANT-LYMPHOMA; GENETIC-ANALYSIS	Purpose: To review 1) advances in the pathogenesis, diagnosis, and management of dermatologic and joint disease and the antiphospholipid antibody syndrome in patients with systemic lupus erythematosus; 2) controversies related to pregnancy and hormonal therapy and to morbidity and mortality in these patients; and 3) current views on the pathogenesis of systemic lupus erythematosus. Data Sources and Study Selection: Review of the English-language medical literature with emphasis on articles published within the last 5 years. More than 400 articles were reviewed. Data Synthesis: Despite considerable overlap, cutaneous lesions specific to lupus erythematosus may be divided into subsets with distinct clinical, histologic, and immunofluorescent features. A recent short-term, prospective, uncontrolled trial found hydroxychloroquine and retinoids to be of similar efficacy in the treatment of cutaneous lupus erythematosus. Optimal treatment for patients with lupus and the anticardiolipin antibody syndrome remains to be defined; uncontrolled, retrospective, and treatment-withdrawal studies suggest that warfarin may be more protective than aspirin. Whether pregnancy induces lupus flares has not yet been established; existing data suggest both that it does and that it does not. Oral contraceptive use and postmenopausal estrogen replacement therapy appear not to cause clinical deterioration in patients with lupus. Recent studies have documented a substantial improvement in the survival of patients with systemic lupus erythematosus; they found 5-year survival rates of 90% or more and 10-year survival rates of more than 80%. Most data suggest that systemic lupus erythematosus results from the activation of self-reactive T cells and B cells by genetic or environmental factors. Conclusions: The optimal treatment for dermatologic disease and the antiphospholipid antibody syndrome in patients with systemic lupus erythematosus remains unknown. Although mortality has decreased substantially, the morbidity related to the disease itself and to complications of therapy is still considerable. More studies are needed to further elucidate the effects of pregnancy on this condition and the pathogenetic mechanisms responsible for the development of this disease.			BOUMPAS, DT (corresponding author), NIH, BLDG 10, ROOM 3N-112, BETHESDA, MD 20892 USA.							ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ADAMS D, 1992, AM J REPROD IMMUNOL, V28, P159, DOI 10.1111/j.1600-0897.1992.tb00781.x; AHMED SA, 1993, J AUTOIMMUN, V6, P265, DOI 10.1006/jaut.1993.1023; ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P1359; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; ARDEN NK, 1994, LUPUS, V3, P11, DOI 10.1177/096120339400300104; BLOOM DD, 1993, J IMMUNOL, V150, P1579; BOUMPAS DT, 1986, ARTHRITIS RHEUM, V29, P755, DOI 10.1002/art.1780290608; BRANCH DW, 1989, OBSTET GYNECOL, V73, P541; BRANCH DW, 1992, OBSTET GYNECOL, V80, P614; BRAND CA, 1992, ANN RHEUM DIS, V51, P173, DOI 10.1136/ard.51.2.173; BURLINGAME RW, 1993, J CLIN INVEST, V91, P1687, DOI 10.1172/JCI116378; BURROWS RF, 1988, NEW ENGL J MED, V319, P142, DOI 10.1056/NEJM198807213190304; BUSKILA D, 1989, J RHEUMATOL, V16, P993; BUYON JP, 1993, ARTHRITIS RHEUM, V36, P1263, DOI 10.1002/art.1780360911; BUYON JP, 1992, ARTHRITIS RHEUM, V35, P55, DOI 10.1002/art.1780350109; CALLEN JP, 1988, RHEUM DIS CLIN N AM, V14, P79; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; COHEN MG, 1992, AUST NZ J MED, V22, P5, DOI 10.1111/j.1445-5994.1992.tb01700.x; COWCHOCK FS, 1992, AM J OBSTET GYNECOL, V166, P1318, DOI 10.1016/0002-9378(92)91596-3; CRONIN ME, 1988, RHEUM DIS CLIN N AM, V14, P99; DAVIDBAJAR KM, 1992, J INVEST DERMATOL, V99, P251, DOI 10.1111/1523-1747.ep12616582; DUBOST JJ, 1993, MEDICINE, V72, P296, DOI 10.1097/00005792-199309000-00002; DUFFY KNW, 1991, J RHEUMATOL, V18, P1180; EHRENSTEIN MR, 1993, BRIT J RHEUMATOL, V32, P362; EMLEN W, 1994, J IMMUNOL, V152, P3685; ESDAILE J, 1991, NEW ENGL J MED, V324, P150; FELSON DT, 1987, LANCET, V1, P902; GINSBERG JS, 1992, BLOOD, V80, P975; GLADMAN D, 1992, J RHEUMATOL, V19, P1820; GODEAU B, 1994, J RHEUMATOL, V21, P246; GOLAN TD, 1992, J CLIN INVEST, V90, P1067, DOI 10.1172/JCI115922; GREENSTEIN B, 1993, LUPUS, V2, P349, DOI 10.1177/096120339300200602; GRIDLEY G, 1994, ANN INTERN MED, V120, P35, DOI 10.7326/0003-4819-120-1-199401010-00006; GULKO PS, 1993, J RHEUMATOL, V20, P1684; Hochberg Marc C., 1993, Current Opinion in Rheumatology, V5, P575; HOOVER RN, 1992, CANCER RES, V52, pS5477; ISHII Y, 1990, ANN RHEUM DIS, V49, P387, DOI 10.1136/ard.49.6.387; JULKUNEN H, 1993, ARTHRITIS RHEUM-US, V36, P1588, DOI 10.1002/art.1780361114; JULKUNEN H, 1993, LUPUS, V2, P125, DOI 10.1177/096120339300200211; JULKUNEN H, 1993, ACTA OBSTET GYN SCAN, V72, P258, DOI 10.3109/00016349309068034; JULKUNEN HA, 1991, SCAND J RHEUMATOL, V20, P427, DOI 10.3109/03009749109096822; JULKUNEN HA, 1993, BRIT J RHEUMATOL, V32, P227; KAHL LE, 1994, J RHEUMATOL, V21, P84; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; KINCAIDSMITH P, 1988, Q J MED, V69, P795; KLINMAN DM, 1990, J CLIN INVEST, V86, P1249, DOI 10.1172/JCI114831; KLIPPEL JH, 1990, JAMA-J AM MED ASSOC, V263, P1812, DOI 10.1001/jama.263.13.1812; KONO DH, 1994, P NATL ACAD SCI USA, V91, P10168, DOI 10.1073/pnas.91.21.10168; LAHITA RG, 1992, J RHEUMATOL, V19, P547; LAMAN SD, 1994, RHEUM DIS CLIN N AM, V20, P195; LE THD, 1993, J RHEUMATOL, V20, P1229; LEE LA, 1993, J INVEST DERMATOL, V100, pS9, DOI 10.1038/jid.1993.17; LEGERTON CW, 1993, ARTHRITIS RHEUM, V36, P135, DOI 10.1002/art.1780360124; LI EK, 1993, BRIT J RHEUMATOL, V32, P66; LIAM CK, 1992, LUPUS, V1, P379, DOI 10.1177/096120339200100607; LIE JT, 1994, J RHEUMATOL, V21, P397; LINDSEY NJ, 1993, BRIT J RHEUMATOL, V32, P123; LOCKSHIN MD, 1984, AM J MED, V77, P893, DOI 10.1016/0002-9343(84)90538-2; LOCKSHIN MD, 1989, ARTHRITIS RHEUM, V32, P665, DOI 10.1002/anr.1780320602; LOCKSHIN MD, 1988, ARTHRITIS RHEUM, V31, P697, DOI 10.1002/art.1780310601; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LOCKSHIN MD, 1992, CLIN EXP RHEUMATOL, V10, P429; LOCKSHIN MD, 1993, LUPUS, V2, P1, DOI 10.1177/096120339300200101; LOCKSHIN MD, 1985, ARTHRITIS RHEUM, V28, P58, DOI 10.1002/art.1780280110; LYNCH A, 1994, ANN INTERN MED, V120, P470, DOI 10.7326/0003-4819-120-6-199403150-00004; MANKIN HJ, 1992, NEW ENGL J MED, V326, P1473; MATSUURA E, 1994, J EXP MED, V179, P457, DOI 10.1084/jem.179.2.457; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; MEEHAN RT, 1987, J RHEUMATOL, V14, P252; MINTZ G, 1986, J RHEUMATOL, V13, P732; MOHAN C, 1993, J EXP MED, V177, P1367, DOI 10.1084/jem.177.5.1367; MYSLER E, 1994, J CLIN INVEST, V93, P1029, DOI 10.1172/JCI117051; NAPARSTEK Y, 1993, ANNU REV IMMUNOL, V11, P79, DOI 10.1146/annurev.immunol.11.1.79; NOSSENT HC, 1990, J RHEUMATOL, V17, P771; Ono K., 1992, CLIN ORTHOP RELAT R, V277, P89; PANUSH RS, 1988, ARCH INTERN MED, V148, P1633, DOI 10.1001/archinte.148.7.1633; PEACEMAN AM, 1992, AM J OBSTET GYNECOL, V166, P1780, DOI 10.1016/0002-9378(92)91569-V; PETRI M, 1992, J RHEUMATOL, V19, P1559; PETRI M, 1991, ARTHRITIS RHEUM, V34, P1538; PETRI M, 1993, J RHEUMATOL, V20, P650; PETTERSSON T, 1992, ANN RHEUM DIS, V51, P437, DOI 10.1136/ard.51.4.437; Pisetsky David S., 1993, Current Opinion in Rheumatology, V5, P549; PISTINER M, 1991, SEMIN ARTHRITIS RHEU, V21, P55, DOI 10.1016/0049-0172(91)90057-7; PORGES AJ, 1992, J RHEUMATOL, V19, P1191; QUDDUS J, 1993, J CLIN INVEST, V92, P38, DOI 10.1172/JCI116576; RAMSEYGOLDMAN R, 1993, AM J EPIDEMIOL, V138, P1057, DOI 10.1093/oxfordjournals.aje.a116824; REICHLIN M, 1994, J CLIN INVEST, V93, P443, DOI 10.1172/JCI116980; REILLY PA, 1990, J RHEUMATOL, V17, P777; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; RIDER LG, 1993, J RHEUMATOL, V20, P1208; RIHNER M, 1992, ARTHRITIS RHEUM, V35, P949, DOI 10.1002/art.1780350816; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; ROSS G, 1993, ARTHRITIS RHEUM, V36, pS87; RUZICKA T, 1992, BRIT J DERMATOL, V127, P513, DOI 10.1111/j.1365-2133.1992.tb14851.x; Schwartz Robert S., 1993, P1033; SELEZNICK MJ, 1991, SEMIN ARTHRITIS RHEU, V21, P73, DOI 10.1016/0049-0172(91)90040-7; SHAHRAM F, 1993, LUPUS, V2, P55, DOI 10.1177/096120339300200110; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SILVEIRA LH, 1992, AM J MED, V93, P403, DOI 10.1016/0002-9343(92)90170-G; SILVER RK, 1993, AM J OBSTET GYNECOL, V169, P1411, DOI 10.1016/0002-9378(93)90410-K; SONTHEIMER RD, 1992, SYSTEMIC LUPUS ERYTH, P657; STEINBERG AD, 1991, ANN INTERN MED, V115, P548, DOI 10.7326/0003-4819-115-7-548; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STURFELT G, 1992, MEDICINE, V71, P216, DOI 10.1097/00005792-199207000-00004; SWAAK AJG, 1989, ANN RHEUM DIS, V48, P447, DOI 10.1136/ard.48.6.447; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P90, DOI 10.1016/0167-5699(95)80095-6; THEOFILOPOULOS AN, 1993, MOL PATHOLOGY AUTOIM, P1; TILLMAN DM, 1992, J EXP MED, V176, P761, DOI 10.1084/jem.176.3.761; TINCANI A, 1992, CLIN EXP RHEUMATOL, V10, P439; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TSOKOS GC, 1992, SYSTEMIC LUPUS ERYTH, P15; UROWITZ MB, 1993, ARTHRITIS RHEUM, V36, P1392, DOI 10.1002/art.1780361011; VANDERSTRAETEN C, 1987, J RHEUMATOL, V14, P1177; Via Charles S., 1993, Current Opinion in Rheumatology, V5, P570; VIANNA JL, 1994, AM J MED, V96, P3, DOI 10.1016/0002-9343(94)90108-2; VLAHAKOS D, 1992, J AM SOC NEPHROL, V2, P1345; WALTUCK J, 1994, ANN INTERN MED, V120, P544, DOI 10.7326/0003-4819-120-7-199404010-00003; WATSON ML, 1992, J EXP MED, V176, P1645, DOI 10.1084/jem.176.6.1645; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461; WU JG, 1994, P NATL ACAD SCI USA, V91, P2344, DOI 10.1073/pnas.91.6.2344; WYSENBEEK AJ, 1992, ANN RHEUM DIS, V51, P717, DOI 10.1136/ard.51.6.717	122	137	144	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					42	53		10.7326/0003-4819-123-1-199507010-00007	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762914				2022-12-28	WOS:A1995RE66500008
J	HILLMAN, AL				HILLMAN, AL			ECONOMIC-ANALYSIS OF HEALTH-CARE TECHNOLOGY - A REPORT ON PRINCIPLES - TASK-FORCE ON PRINCIPLES FOR ECONOMIC-ANALYSIS OF HEALTH-CARE TECHNOLOGY	ANNALS OF INTERNAL MEDICINE			English	Article							PUBLICATION BIAS; COST-EFFECTIVENESS		UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; UNIV PENN,WHARTON SCH,PHILADELPHIA,PA 19104; GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007	University of Pennsylvania; University of Pennsylvania; Georgetown University	HILLMAN, AL (corresponding author), UNIV PENN,CTR HLTH POLICY,LEONARD DAVIS INST HLTH ECON,3641 LOCUST WALK,PHILADELPHIA,PA 19104, USA.							ANGELL M, 1988, NEW ENGL J MED, V318, P1462, DOI 10.1056/NEJM198806023182210; ASCH D, 1981, LDI HLTH POLICY RES, V1, P3; CHALMERS I, 1990, JAMA-J AM MED ASSOC, V263, P1405, DOI 10.1001/jama.263.10.1405; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; Detsky A S, 1993, Pharmacoeconomics, V3, P354, DOI 10.2165/00019053-199303050-00003; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; DONALDSON MS, 1991, PATIENT OUTCOMES RES; DONALDSON MS, 1991, PATIENT OUTCOME RES; Drummond M, 1993, Int J Technol Assess Health Care, V9, P26; Drummond M F, 1992, Pharmacoeconomics, V1, P8, DOI 10.2165/00019053-199201010-00004; ENGLER RL, 1987, NEW ENGL J MED, V317, P1383, DOI 10.1056/NEJM198711263172205; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FREEMAN R, 1992, IN PRESS J RES PHARM; Henry D, 1992, Pharmacoeconomics, V1, P54, DOI 10.2165/00019053-199201010-00010; HILLMAN AL, 1991, NEW ENGL J MED, V324, P1362, DOI 10.1056/NEJM199105093241911; HILLMAN AL, 1995, PHARMACOECONOMICS, V7, P198, DOI 10.2165/00019053-199507030-00003; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; KORENMAN SG, 1994, TEACHING RESPONSIBLE, P191; LUCE BR, 1995, CLIN THER, V17, P263; SCHAFER A, 1982, NEW ENGL J MED, V307, P719; SHARP DW, 1990, JAMA-J AM MED ASSOC, V263, P1390; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; 1994, CONFLICTS INTEREST I; 1990, CLIN RES, V38, P239; 1993, JAMA-J AM MED ASSOC, V269, P282; 1989, CLIN RES, V37, P192; 1989, RESPONSIBLE CONDUCT; 1984, ANN INTERN MED, V101, P263; 1989, CLIN RES, V37, P510; 1995, PANEL COST EFFECTIVE; 1991, HMO OUTCOMES STUDY	31	116	105	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					61	70						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762918				2022-12-28	WOS:A1995RE66500012
J	MCNAMARA, JJ				MCNAMARA, JJ			ON TAKING A BOARD EXAMINATION AT THE AGE OF 54	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MCNAMARA, JJ (corresponding author), BROCKTON HOSP,BROCKTON,MA 02402, USA.							JOHNSON S, 1958, RASSELAS POEMS SELEC, P194; 1948, WEBSTERS COLLEGIATE	2	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1794	1795		10.1056/NEJM199506293322618	http://dx.doi.org/10.1056/NEJM199506293322618			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760910				2022-12-28	WOS:A1995RE66700032
J	COCHI, SL; HULL, HF; WARD, NA				COCHI, SL; HULL, HF; WARD, NA			TO CONQUER POLIOMYELITIS FOREVER	LANCET			English	Editorial Material									WHO,EXPANDED PROGRAMME IMMUNIZAT,GENEVA,SWITZERLAND	World Health Organization	COCHI, SL (corresponding author), CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341, USA.							BART KJ, IN PRESS B WHO; HULL HF, 1994, LANCET, V343, P1331, DOI 10.1016/S0140-6736(94)92472-4; Smith Jane S., 1990, PATENTING SUN POLIO; YANG BP, 1995, PEDIATR INFECT DIS J, V14, P308, DOI 10.1097/00006454-199504000-00011; 1994, MMWR-MORBID MORTAL W, V13, P720; 1988, GLOBAL ERADICATION P; 1995, MMWR-MORBID MORTAL W, V44, P273	7	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1589	1590		10.1016/S0140-6736(95)90111-6	http://dx.doi.org/10.1016/S0140-6736(95)90111-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783533				2022-12-28	WOS:A1995RE67000004
J	THOMAS, JM				THOMAS, JM			GROIN STRAIN VERSUS OCCULT HERNIA - UNCOMFORTABLE ALTERNATIVES OR INCOMPATIBLE RIVALS	LANCET			English	Editorial Material							INGUINAL SURGERY; PAIN				THOMAS, JM (corresponding author), WATFORD DIST GEN HOSP,WATFORD,HERTS,ENGLAND.							ASHBY EC, 1977, ANN ROY COLL SURG, V59, P242; ASHBY EC, 1994, BRIT J SURG, V81, P1632, DOI 10.1002/bjs.1800811123; Carnett J., 1926, SURG GYNECOL OBSTET, P625; Cyriax EF, 1919, PRACTITIONER, V102, P314; EKBERG O, 1988, SPORTS MED, V6, P56, DOI 10.2165/00007256-198806010-00006; GALLEGOS NC, 1990, BRIT J SURG, V77, P1167, DOI 10.1002/bjs.1800771026; MALYCHA P, 1992, AUST NZ J SURG, V62, P123; POLGLASE AL, 1991, MED J AUSTRALIA, V155, P674, DOI 10.5694/j.1326-5377.1991.tb93958.x; Renstrom P, 1980, Br J Sports Med, V14, P30; SCOTT EM, 1993, GUT, V34, P1006, DOI 10.1136/gut.34.7.1006; SMEDBERG SGG, 1985, AM J SURG, V149, P378, DOI 10.1016/S0002-9610(85)80112-4; THOMSON H, 1977, LANCET, V2, P1053; UPPINGTON J, 1988, HOSP PRACT, V23, P37; Zimmerman G, 1988, Aust Fam Physician, V17, P1046	14	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1522	1523		10.1016/S0140-6736(95)91082-4	http://dx.doi.org/10.1016/S0140-6736(95)91082-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791435				2022-12-28	WOS:A1995RD79000004
J	ADAMI, J; FRISCH, M; YUEN, J; GLIMELIUS, B; MELBYE, M				ADAMI, J; FRISCH, M; YUEN, J; GLIMELIUS, B; MELBYE, M			EVIDENCE OF AN ASSOCIATION BETWEEN NON-HODGKINS-LYMPHOMA AND SKIN-CANCER	BRITISH MEDICAL JOURNAL			English	Article							TRANSPLANT RECIPIENTS; UV-RADIATION; TIME TRENDS; RISK; MECHANISMS	Objective-To investigate a possible Link between exposure to ultraviolet light and the almost epidemic increase in non-Hodgkin's lymphoma worldwide. Because ultraviolet light is known to cause skin cancers, the association between non-Hodgkin's lymphoma and skin cancer was studied. Design-Secondary occurrence of either malignant melanoma or squamous cell skin cancer in cohorts of patients with a first diagnosis of either non-Hodgkin's lymphoma or chronic lymphocytic leukaemia, and vice versa, were studied. Expected numbers of subsequent cancers were calculated by sex, age, and period specific national incidence rates multiplied by the person years under observation in the cohorts. Setting-Denmark (1943-89) and Sweden (1958-89). Subjects-Four population based cohorts identified in the nationwide cancer registries (34641 people with non-Hodgkin's lymphoma, 17400 with chronic lymphocytic leukaemia, 34989 with malignant melanoma, 25980 with squamous cell skin cancer). A total of 562085 person years were accrued for the analysis. Main outcome measures-The ratios of observed to expected cancers (the standardised incidence ratio) served as a measure of the relative risk. Results-The relative risk for developing squamous cell skin cancer was 5.5 (95% confidence interval 4.6 to 6.6) among patients with non-Hodgkin's lymphoma and 8.6 (7.2 to 10.3) among patients with chronic lymphocytic leukaemia. The relative risks remained high over more than IS years of follow up. Relative risks for malignant melanoma were 2.4 (1.8 to 3.2) for patients with non-Hodgkin's lymphoma and 3.1 (2.1 to 4.4) for patients with chronic lymphocytic leukaemia. After aquamous cell skin cancer had been diagnosed there was a twofold excess risk for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. By contrast, in each of the cohorts the general cancer risks excluding skin and lymphoproliferative malignancies were close to the expected. Conclusions-The occurrence of non-Hodgkin's lymphoma and skin cancer are strongly associated; this supports the hypothesis that the secular increase in exposure to ultraviolet light may have contributed to the increasing incidence of non-Hodgkin's lymphoma in recent decades	STATENS SERUM INST,DANISH EPIDEMIOL SCI CTR,DK-2300 COPENHAGEN S,DENMARK; UNIV UPPSALA HOSP,DEPT ONCOL,S-75185 UPPSALA,SWEDEN	Aarhus University; Statens Serum Institut; Uppsala University; Uppsala University Hospital	ADAMI, J (corresponding author), UNIV UPPSALA HOSP,DEPT CANC EPIDEMIOL,S-75185 UPPSALA,SWEDEN.		Yuen, Jonathan/AAI-2035-2021; Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Yuen, Jonathan/0000-0003-2944-9226; melbye, mads/0000-0001-8264-6785				BLOMBERG J, 1993, EUR J CANCER, V29A, P2101, DOI 10.1016/0959-8049(93)90042-E; BRESLOW N, 1987, STAT METHODS CANC RE, V2, P71; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; CASABONA J, 1991, INT J CANCER, V47, P49, DOI 10.1002/ijc.2910470110; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; COBEMAN M, 1985, ANN INTERN MED, V103, P140; DEVESA SS, 1992, CANCER RES, V52, pS5432; EBBESEN P, 1981, J NATL CANCER I, V67, P1077; FILIPOVICH AH, 1992, CANCER RES, V52, pS5465; FRISCH M, 1994, AM J EPIDEMIOL, V140, P12, DOI 10.1093/oxfordjournals.aje.a117154; GAIL MH, 1991, JNCI-J NATL CANCER I, V83, P695, DOI 10.1093/jnci/83.10.695; HAKULINEN T, 1985, AM J MED, V78, P29, DOI 10.1016/0002-9343(85)90242-6; HARTGE P, 1992, CANCER RES, V52, pS5566; HERSEY P, 1983, LANCET, V1, P545; HERSEY P, 1983, J IMMUNOL, V31, P171; HOOVER R, 1973, LANCET, V2, P55; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; Kripke M L, 1981, Adv Cancer Res, V34, P69, DOI 10.1016/S0065-230X(08)60239-0; KRIPKE ML, 1990, J NATL CANCER I, V82, P1392, DOI 10.1093/jnci/82.17.1392; Lee JAH, 1982, CANC EPIDEMIOLOGY PR, P984; LENNERT K, 1978, HDB SPEZIELLEN PA 3B, V1, P84; MAGRATH I, 1992, CANCER RES, V52, pS5529; MARTINSSON U, 1992, ACTA ONCOL, V31, P275, DOI 10.3109/02841869209108173; MARTINSSON U, 1989, EUR J HAEMATOL, V43, P332; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; OSTERLIND A, 1991, Current Opinion in Oncology, V3, P355; PARKIN DM, 1993, INT J CANCER, V54, P594; PENN I, 1988, CANCER DETECT PREV, V12, P39; POTTER M, 1992, CANCER RES, V52, pS5522; ROMERDAHL CA, 1988, CANCER RES, V48, P4007; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; STORM HH, 1992, CANCER INCIDENCE DEN; ZHENG TZ, 1992, CANCER, V70, P840, DOI 10.1002/1097-0142(19920815)70:4&lt;840::AID-CNCR2820700420&gt;3.0.CO;2-I; 1993, CANCER INCIDENCE SWE; 1992, IARC MONOGRAPHS EVAL, V55, P73	36	212	213	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1491	1495		10.1136/bmj.310.6993.1491	http://dx.doi.org/10.1136/bmj.310.6993.1491			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787593	Green Published			2022-12-28	WOS:A1995RD28500018
J	FRANKE, TF; YANG, SI; CHAN, TO; DATTA, K; KAZLAUSKAS, A; MORRISON, DK; KAPLAN, DR; TSICHLIS, PN				FRANKE, TF; YANG, SI; CHAN, TO; DATTA, K; KAZLAUSKAS, A; MORRISON, DK; KAPLAN, DR; TSICHLIS, PN			THE PROTEIN-KINASE ENCODED BY THE AKT PROTOONCOGENE IS A TARGET OF THE PDGF-ACTIVATED PHOSPHATIDYLINOSITOL 3-KINASE	CELL			English	Article							POLYMERASE CHAIN-REACTION; GROWTH-FACTOR; C-AKT; V-AKT; REGION; EXPRESSION; RECEPTORS; MICE	The serine/threonine protein kinase encoded by the Akt proto-oncogene is catalytically inactive in serum-starved primary and immortalized fibroblasts. Here we show that Akt and the Akt-related kinase AKT2 are activated by PDGF. The activation was rapid and specific, and it was abrogated by mutations in the Akt Pleckstrin homology (PH) domain. The Akt activation was also shown to depend on PDGFR beta tyrosines Y740 and Y751, which bind phosphatidylinositol 3-kinase (Pl 3-kinase) upon phosphorylation. Moreover, Akt activation was blocked by the Pl 3-kinase-specific inhibitor wortmannin and the dominant inhibitory N17Ras. Conversely, Akt activity was induced following the addition of phosphatidylinositol-3-phosphate to Akt immunoprecipitates from serum-starved cells in vitro, These results identify Akt as a novel target of Pl 3-kinase and suggest that the Akt PH domain may be a mediator of Pl 3-kinase signaling.	NCI, FREDERICK CANC RES FACIL & DEV CTR, ABL BASIC RES PROGRAM, EUKARYOT SIGNAL TRANSDUCT SECT, FREDERICK, MD 21702 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Jewish Health	FRANKE, TF (corresponding author), FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA.			Chan, Tung/0000-0001-6574-9555	NATIONAL CANCER INSTITUTE [R01CA057436, R29CA055063, R01CA038047] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55063, R01-CA38047, R01-CA57436] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DOWNWARD J, 1994, NATURE, V371, P378, DOI 10.1038/371378a0; FRANKE TF, 1994, ONCOGENE, V9, P141; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POWIS G, 1994, CANCER RES, V54, P2419; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STILES CD, 1979, J CELL PHYSIOL, V99, P395, DOI 10.1002/jcp.1040990314; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	31	1814	1867	5	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					727	736		10.1016/0092-8674(95)90534-0	http://dx.doi.org/10.1016/0092-8674(95)90534-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774014	Bronze			2022-12-28	WOS:A1995RB96100011
J	KUNDIG, TM; BACHMANN, MF; DIPAOLO, C; SIMARD, JJL; BATTEGAY, M; LOTHER, H; GESSNER, A; KUHLCKE, K; OHASHI, PS; HENGARTNER, H; ZINKERNAGEL, RM				KUNDIG, TM; BACHMANN, MF; DIPAOLO, C; SIMARD, JJL; BATTEGAY, M; LOTHER, H; GESSNER, A; KUHLCKE, K; OHASHI, PS; HENGARTNER, H; ZINKERNAGEL, RM			FIBROBLASTS AS EFFICIENT ANTIGEN-PRESENTING CELLS IN LYMPHOID ORGANS	SCIENCE			English	Article							CD8+ T-CELLS; INTERCELLULAR-ADHESION MOLECULE-1; FOOTPAD SWELLING REACTION; TUMOR-CELLS; LYMPHOCYTIC CHORIOMENINGITIS; ANTITUMOR IMMUNITY; TRANSGENIC MICE; GENE-TRANSFER; INVIVO; EXPRESSION	Only so-called ''professional'' antigen-presenting cells (APCs) of hematopoietic origin are believed capable of inducing T lymphocyte responses. However, fibroblasts transfected with viral proteins directly induced antiviral cytotoxic T lymphocyte responses in vivo, without involvement of host APCs. Fibroblasts induced T cells only in the milieu of lymphoid organs. Thus, antigen localization affects self-nonself discrimination and cell-based vaccine strategies.	ONTARIO CANC INST, DEPT MED BIOPHYS, TORONTO, ON M4X 1K9, CANADA; ONTARIO CANC INST, DEPT IMMUNOL, TORONTO, ON M4X 1K9, CANADA; UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, W-2000 HAMBURG, GERMANY	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Heinrich Pette Institute; University of Hamburg	KUNDIG, TM (corresponding author), UNIV ZURICH, INST EXPTL IMMUNOL, SCHMELZBERGSTR 12, CH-8091 ZURICH, SWITZERLAND.			Ohashi, Pamela S./0000-0003-2915-9317				BACHMANN MF, 1994, CURR OPIN IMMUNOL, V6, P320, DOI 10.1016/0952-7915(94)90108-2; Barker CF, 1967, TRANSPLANTATION, V5, P962; BASKAR S, 1993, P NATL ACAD SCI USA, V90, P5687, DOI 10.1073/pnas.90.12.5687; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; CHEN LP, 1994, J EXP MED, V179, P523, DOI 10.1084/jem.179.2.523; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; COBBOLD SP, 1984, NATURE, V312, P548, DOI 10.1038/312548a0; COLOMBO MP, 1991, J EXP MED, V173, P889, DOI 10.1084/jem.173.4.889; CROFT M, 1994, CURR OPIN IMMUNOL, V6, P431, DOI 10.1016/0952-7915(94)90123-6; DAMLE NK, 1992, J IMMUNOL, V148, P1985; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; Deichman G I, 1969, Adv Cancer Res, V12, P101, DOI 10.1016/S0065-230X(08)60329-2; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DIPAOLO C, THESIS U ZURICH; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FAUSTMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P5156, DOI 10.1073/pnas.78.8.5156; FAUSTMAN DL, 1984, P NATL ACAD SCI-BIOL, V81, P3864, DOI 10.1073/pnas.81.12.3864; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FREY JR, 1957, INT ARCH ALLER A IMM, V11, P81, DOI 10.1159/000228405; GANSBACHER B, 1990, CANCER RES, V50, P7820; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GESSNER A, 1993, THESIS U HAMBURG; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GORELIK E, 1983, ADV CANCER RES, V39, P71, DOI 10.1016/S0065-230X(08)61033-7; GUERDER S, 1994, IMMUNITY, V1, P155; HANY M, 1989, EUR J IMMUNOL, V19, P417, DOI 10.1002/eji.1830190302; HARLAN DM, 1994, P NATL ACAD SCI USA, V91, P3137, DOI 10.1073/pnas.91.8.3137; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KLEIN G, 1978, MANIPULATION IMMUNE, P339; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; KUHLMAN P, 1991, J IMMUNOL, V146, P1773; LAFFERTY KJ, 1977, IMMUNOL REV, V35, P231, DOI 10.1111/j.1600-065X.1977.tb00241.x; LANE P, 1993, IMMUNOLOGY, V80, P56; LECHLER RI, 1982, J EXP MED, V155, P31, DOI 10.1084/jem.155.1.31; LEIST TP, 1987, J IMMUNOL, V138, P2278; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; MATZINGER P, 1977, CELL IMMUNOL, V33, P92, DOI 10.1016/0008-8749(77)90137-X; NISHIHARA K, 1988, CANCER RES, V48, P4730; NOSSAL GJV, 1989, SCIENCE, V245, P147, DOI 10.1126/science.2526369; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLD LJ, 1964, ANNU REV MED, V15, P167, DOI 10.1146/annurev.me.15.020164.001123; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PORGADOR A, 1992, CANCER RES, V52, P3679; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SIU G, 1989, J IMMUNOL, V143, P3813; SPRENT J, 1986, NATURE, V322, P541, DOI 10.1038/322541a0; SPRENT J, 1990, IMMUNOL REV, V117, P213, DOI 10.1111/j.1600-065X.1990.tb00574.x; TAHARA H, 1994, CANCER RES, V54, P182; TANAKA K, 1988, MOL CELL BIOL, V8, P1857, DOI 10.1128/MCB.8.4.1857; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WACHTEL SS, 1972, J EXP MED, V135, P388, DOI 10.1084/jem.135.2.388; WACHTEL SS, 1971, J EXP MED, V133, P921, DOI 10.1084/jem.133.4.921; ZINKERNAGEL RM, 1985, J EXP MED, V162, P2125, DOI 10.1084/jem.162.6.2125; ZINKERNAGEL RM, 1993, IMMUNOL REV, V133, P199, DOI 10.1111/j.1600-065X.1993.tb01517.x	65	263	273	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	1995	268	5215					1343	1347		10.1126/science.7761853	http://dx.doi.org/10.1126/science.7761853			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761853				2022-12-28	WOS:A1995RB19800037
J	FRUH, K; AHN, K; DJABALLAH, H; SEMPE, P; VANENDERT, PM; TAMPE, R; PETERSON, PA; YANG, Y				FRUH, K; AHN, K; DJABALLAH, H; SEMPE, P; VANENDERT, PM; TAMPE, R; PETERSON, PA; YANG, Y			A VIRAL INHIBITOR OF PEPTIDE TRANSPORTERS FOR ANTIGEN PRESENTATION	NATURE			English	Article							ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; MHC; COMPLEX; TRANSLOCATION; MOLECULES; GOLGI	CYTOTOXIC T lymphocytes lyse target cells after T-cell-receptor-mediated recognition of class I major histocompatibility complex molecules presenting peptides(1). Antigenic peptides are generated in the cytoplasm by proteasomes(2) and translocated into the lumen of the endoplasmic reticulum (ER) by peptide transporters (TAP)3-6. Herpes simplex virus (HSV) expresses a cytoplasmic protein, ICP47, which seems to interfere with such immune surveillance by mediating retention of 'empty' class I molecules in the ER(7,8). BY expressing ICP47 in HeLa cells under an inducible promoter(9), we show that ICP47 efficiently inhibits peptide transport across the ER membrane such that nascent class I molecules fail to acquire antigenic peptides. This inhibition was overcome by transfecting murine TAP. Further, we demonstrate that ICP47 colocalizes and physically associates with TAP within the cell, Inhibition of peptide translocation by a viral protein indicates a previously undocumented potential mechanism for viral immune evasion.	HOP NECKER ENFANTS MALAD, INSERM, U25, F-75743 PARIS 15, FRANCE; MAX PLANCK INST BIOCHEM, STRUKT BIOL ABT, D-82152 MARTINSRIED, GERMANY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Max Planck Society	FRUH, K (corresponding author), SCRIPPS RES INST, RW JOHNSON PHARMACEUT RES INST, DEPT IMMUNOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		; Tampe, Robert/H-2953-2015	Djaballah, Hakim/0000-0002-6039-0181; van Endert, Peter/0000-0003-3782-0750; Frueh, Klaus/0000-0001-8014-3877; Tampe, Robert/0000-0002-0403-2160				ANDERSSON M, 1985, CELL, V43, P215, DOI 10.1016/0092-8674(85)90026-1; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HILL AB, 1994, J IMMUNOL, V152, P2736; JACKSON MR, 1993, ANNU REV CELL BIOL, V9, P207, DOI 10.1146/annurev.cb.09.110193.001231; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PARHAM P, 1979, J IMMUNOL, V123, P342; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; YANG Y, 1992, J BIOL CHEM, V267, P11669; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	22	525	539	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					415	418		10.1038/375415a0	http://dx.doi.org/10.1038/375415a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760936				2022-12-28	WOS:A1995RB10100056
J	LAPORTE, RE; MARLER, E; AKAZAWA, S; SAUER, F; GAMBOA, C; SHENTON, C; GLOSSER, C; VILLASENOR, A; MACLURE, M				LAPORTE, RE; MARLER, E; AKAZAWA, S; SAUER, F; GAMBOA, C; SHENTON, C; GLOSSER, C; VILLASENOR, A; MACLURE, M			THE DEATH OF BIOMEDICAL JOURNALS	BRITISH MEDICAL JOURNAL			English	Article									AT&T GIS,GRP ENTERPRISE DESIGN & DEV,BOCA RATON,FL 33434; PAN AMER HLTH ORG,WASHINGTON,DC; STERLING SOFTWARE,WASHINGTON,DC; NASA,SCI INTERNET,WASHINGTON,DC 20546; HARVARD UNIV,DEPT EPIDEMIOL,CAMBRIDGE,MA	AT&T; Pan American Health Organization; National Aeronautics & Space Administration (NASA); Harvard University	LAPORTE, RE (corresponding author), UNIV PITTSBURGH,DEPT EPIDEMIOL,3460 5TH AVE,PITTSBURGH,PA 15213, USA.							ANDERSON C, 1994, SCIENCE, V264, P900, DOI 10.1126/science.8178148; Ginsparg P., 1994, Computers in Physics, V8, P390; KALE R, 1994, BRIT MED J, V309, P939, DOI 10.1136/bmj.309.6959.939; LAPORTE RE, 1994, BRIT MED J, V308, P1651, DOI 10.1136/bmj.308.6945.1651; LAPORTE RE, 1994, BRIT MED J, V309, P736; SAUER F, IN PRESS CURR ISS PU; SCHATZ BR, 1994, SCIENCE, V265, P895, DOI 10.1126/science.265.5174.895; STIX G, 1994, SCI AM, V271, P106, DOI 10.1038/scientificamerican1294-106; WALDROP MM, 1994, SCIENCE, V295, P882	9	101	104	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1387	1390		10.1136/bmj.310.6991.1387	http://dx.doi.org/10.1136/bmj.310.6991.1387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787546	Green Published			2022-12-28	WOS:A1995RB00500031
J	KAUFFMANNZEH, A; THOMAS, GMH; BALL, A; PROSSER, S; CUNNINGHAM, E; COCKCROFT, S; HSUAN, JJ				KAUFFMANNZEH, A; THOMAS, GMH; BALL, A; PROSSER, S; CUNNINGHAM, E; COCKCROFT, S; HSUAN, JJ			REQUIREMENT FOR PHOSPHATIDYLINOSITOL TRANSFER PROTEIN IN EPIDERMAL GROWTH-FACTOR SIGNALING	SCIENCE			English	Article							PHOSPHOLIPASE-C-GAMMA; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; EGF RECEPTOR; A431 CELLS; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANES; BINDING-SITE; BOVINE BRAIN; KINASE	Stimulation of phosphatidylinositol-4,5-bisphosphate (PIP2) hydrolysis is a widespread mechanism for receptor-mediated signaling in eukaryotes. Cytosolic phosphatidylinositol transfer protein (PITP) is necessary for guanosine triphosphate (GTP)-dependent hydrolysis of PIP2 by phospholipase C-beta (PLC-beta), but the role of PITP is unclear. Stimulation of phospholipase C-gamma (PLC-gamma) in A431 human epidermoid carcinoma cells treated with epidermal growth factor (EGF) required PITP. Stimulation of PI-4 kinase in cells treated with EGF also required PITP. Coprecipitation studies revealed an EGF-dependent association of PITP with the EGF receptor, with PI-4 kinase, and with PLC-gamma.	UCL, SCH MED, LUDWIG INST CANC RES, PROT BIOCHEM GRP, LONDON W1P 8BT, ENGLAND; UCL, DEPT PHYSIOL, LONDON WC1E 6JJ, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London			Hsuan, Justin/C-8825-2009; Cockcroft, Shamshad/F-9480-2011	Hsuan, Justin/0000-0001-6083-7564; Cockcroft, Shamshad/0000-0002-5731-476X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; COCHET C, 1991, J BIOL CHEM, V266, P637; COCKCROFT S, 1992, BIOCHEM J, V288, P1; Cunningham E. S., UNPUB; DOWNES CP, 1993, CURR BIOL, V3, P794; ENDEMANN GC, 1991, BIOCHEM J, V273, P63, DOI 10.1042/bj2730063; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HSUAN JJ, 1993, ANTICANCER RES, V13, P2521; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; KAUFFMANNZEH A, UNPUB; KIM JW, 1990, J BIOL CHEM, V265, P3940; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PAYRASTRE B, 1991, BIOCHIM BIOPHYS ACTA, V1056, P19, DOI 10.1016/S0005-2728(05)80068-4; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, METHOD ENZYMOL, V197, P502; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RYU SH, 1987, J BIOL CHEM, V262, P12511; SCHERMOLY MJ, 1983, BRAIN RES, V268, P197, DOI 10.1016/0006-8993(83)90410-9; SOLER C, 1994, J BIOL CHEM, V269, P12320; SORKIN A, 1992, J BIOL CHEM, V267, P8672; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; VANPARIDON PA, 1988, BIOCHIM BIOPHYS ACTA, V943, P76, DOI 10.1016/0005-2736(88)90348-3; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; WALKER DH, 1988, BIOCHEMISTRY-US, V27, P6504, DOI 10.1021/bi00417a046; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73	40	149	157	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1188	1190		10.1126/science.7761838	http://dx.doi.org/10.1126/science.7761838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761838				2022-12-28	WOS:A1995RA60400041
J	PAABO, S				PAABO, S			THE Y-CHROMOSOME AND THE ORIGIN OF ALL OF US (MEN)	SCIENCE			English	Editorial Material							MITOCHONDRIAL-DNA; EVOLUTION				PAABO, S (corresponding author), UNIV MUNICH,INST ZOOL,POB 202136,D-80021 MUNICH,GERMANY.							CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; DORIT RL, 1995, SCIENCE, V268, P1183, DOI 10.1126/science.7761836; HEDGES SB, 1992, SCIENCE, V255, P737, DOI 10.1126/science.1738849; NACHMAN MW, 1995, MOL BIOL EVOL, V11, P539; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0	6	36	36	1	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1141	1142		10.1126/science.7761828	http://dx.doi.org/10.1126/science.7761828			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761828				2022-12-28	WOS:A1995RA60400025
J	CHERNOFF, YO; LINDQUIST, SL; ONO, B; INGEVECHTOMOV, SG; LIEBMAN, SW				CHERNOFF, YO; LINDQUIST, SL; ONO, B; INGEVECHTOMOV, SG; LIEBMAN, SW			ROLE OF THE CHAPERONE PROTEIN HSP104 IN PROPAGATION OF THE YEAST PRION-LIKE FACTOR [PSI(+)]	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; OMNIPOTENT SUPPRESSORS; SUP35 GENE; DNA DAMAGE; SCRAPIE; SYSTEM; PRP	The yeast non-Mendelian factor [psi(+)] has been suggested to be a self-modified protein analogous to mammalian prions. Here it is reported that an intermediate amount of the chaperone protein Hsp104 was required for the propagation of the [psi(+)] factor. Overproduction or inactivation of Hsp104 caused the loss of [psi(+)]. These results suggest that chaperone proteins play a role in prion-like phenomena, and that a certain level of chaperone expression can cure cells of prions without affecting viability. This may lead to antiprion treatments that involve the alteration of chaperone amounts or activity.	OKAYAMA UNIV, FAC PHARMACEUT SCI, OKAYAMA 700, JAPAN; ST PETERSBURG STATE UNIV, DEPT GENET, ST PETERSBURG 199034, RUSSIA; UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	Okayama University; Saint Petersburg State University; University of Chicago; Howard Hughes Medical Institute; University of Chicago	CHERNOFF, YO (corresponding author), UNIV ILLINOIS, DEPT BIOL SCI, CHICAGO, IL 60607 USA.		Inge-Vechtomov, Sergei G/L-4807-2013; Chernoff, Yury O/J-2833-2014	Inge-Vechtomov, Sergei G/0000-0002-2832-6825; Chernoff, Yury/0000-0002-8934-9051				AIGLE M, COMMUNICATION; BOREHAM DR, 1994, RADIAT RES, V137, P190, DOI 10.2307/3578811; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CHEMOFF YO, UNPUB; CHERNOFF YO, 1992, BIOCHIMIE, V74, P455, DOI 10.1016/0300-9084(92)90086-T; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; CHERNOFF YO, 1992, NATO ASI SER H, V71, P101; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; COX B, 1994, CURR BIOL, V4, P744, DOI 10.1016/S0960-9822(00)00167-6; COX BS, 1988, YEAST, V4, P159, DOI 10.1002/yea.320040302; DOEL SM, 1994, GENETICS, V137, P659; HINNEBUSCH AG, 1991, MOL CELLULAR BIOL YE, P627; Kim G., UNPUB; KOUNAKOV KA, UNPUB; LIEBMAN SW, 1979, J BACTERIOL, V139, P1068, DOI 10.1128/JB.139.3.1068-1071.1979; MAGEE T, COMMUNICATION; MCCLANAHAN T, 1984, MOL CELL BIOL, V4, P2356, DOI 10.1128/MCB.4.11.2356; MCCLANAHAN T, 1986, MOL CELL BIOL, V6, P90, DOI 10.1128/MCB.6.1.90; MURAMATSU T, 1993, PHOTOCHEM PHOTOBIOL, V58, P809, DOI 10.1111/j.1751-1097.1993.tb04974.x; ONO B, 1991, CURR GENET, V19, P243, DOI 10.1007/BF00355049; ONO BI, 1986, GENETICS, V114, P363; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PATINO M, UNPUB; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Rothstein R., 1985, DNA CLONING, VII, P45; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHIRMER E, UNPUB; SHERMAN F, 1986, LABORATORY COURSE MA; SIKORSKI RS, 1989, GENETICS, V122, P19; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; Surguchovs AP, 1984, PHYSICOCHEMICAL BIOL, V4, P147; TAULIEN J, UNPUB; TERAVANESYAN MD, 1994, GENETICS, V137, P671; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Tikhodeev O.N., 1990, MOL MECH GENETIC PRO, P218; TREGER JM, 1988, MOL CELL BIOL, V8, P1132, DOI 10.1128/MCB.8.3.1132; TUITE MF, 1994, NATURE, V370, P327, DOI 10.1038/370327a0; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WAKEM LP, 1990, GENETICS, V124, P515; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	48	884	903	2	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 12	1995	268	5212					880	884		10.1126/science.7754373	http://dx.doi.org/10.1126/science.7754373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754373				2022-12-28	WOS:A1995QX85000040
J	SPRINGER, PS; MCCOMBIE, WR; SUNDARESAN, V; MARTIENSSEN, RA				SPRINGER, PS; MCCOMBIE, WR; SUNDARESAN, V; MARTIENSSEN, RA			GENE TRAP TAGGING OF PROLIFERA, AN ESSENTIAL MCM2-3-5-LIKE GENE IN ARABIDOPSIS	SCIENCE			English	Article							MEDIATED ENHANCER DETECTION; REGULATORY ELEMENTS; CELL-CYCLE; DROSOPHILA; THALIANA; EXPRESSION; AMPLIFICATION; MERISTEM; MUTATION; EXCISION	Gene trap transposon mutagenesis can identify essential genes whose functions in later development are obscured by an early lethal phenotype. In higher plants, many genes are required for haploid gametophyte viability, so that the phenotypic effects of their disruption cannot be readily observed in the diploid plant body. The PROLIFERA (PRL) gene, identified by gene trap transposon mutagenesis in Arabidopsis, is required for megagametophyte and embryo development. Reporter gene expression patterns revealed that PRL was expressed in dividing cells throughout the plant. PRL is related to the MCM2-3-5 family of yeast genes that are required for the initiation of DNA replication.	COLD SPRING HARBOR LAB,LITA ANNENBERG HAZEN GENOME CTR,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory				Sundaresan, Venkatesan/0000-0002-4670-0630; McCombie, W. Richard/0000-0003-1899-0682				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BANCROFT I, 1993, PLANT CELL, V5, P631, DOI 10.1105/tpc.5.6.631; BANCROFT I, 1992, MOL GEN GENET, V233, P449, DOI 10.1007/BF00265443; BARKAN A, 1986, EMBO J, V5, P1421, DOI 10.1002/j.1460-2075.1986.tb04378.x; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BUSSEREAU F, 1993, YEAST, V9, P797, DOI 10.1002/yea.320090714; Carlson W. R., 1988, Corn and corn improvement. Third edition., P259; Cone K., 1989, Maize Genetics Cooperation News Letter, P68; CROXDALE J, 1992, DEV BIOL, V149, P158, DOI 10.1016/0012-1606(92)90272-I; DALTON S, COMMUNICATION; DAVIS EL, 1979, CAN J BOT, V57, P971, DOI 10.1139/b79-119; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; FOE VE, 1989, DEVELOPMENT, V107, P1; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FURNER IJ, 1993, PLANT J, V4, P917, DOI 10.1046/j.1365-313X.1993.04060917.x; GLEESON TJ, 1991, COMPUT APPL BIOSCI, V7, P398; GROSSNIKLAUS U, 1989, DEVELOPMENT, V107, P189; GROSSNIKLAUS U, UNPUB; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HULSKAMP M, 1995, PLANT CELL, V7, P57, DOI 10.1105/tpc.7.1.57; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; KARLINNEUMANN GA, 1991, PLANT CELL, V3, P573, DOI 10.1105/tpc.3.6.573; KAVANGH TA, 1987, EMBO J, V6, P3901; KERTBUNDIT S, 1991, P NATL ACAD SCI USA, V88, P5212, DOI 10.1073/pnas.88.12.5212; LONG D, 1993, P NATL ACAD SCI USA, V90, P10370, DOI 10.1073/pnas.90.21.10370; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MARTINEZ MC, 1992, P NATL ACAD SCI USA, V89, P7360, DOI 10.1073/pnas.89.16.7360; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; ORRWEAVER TL, 1994, TRENDS GENET, V10, P321, DOI 10.1016/0168-9525(94)90035-3; Patterson E. B., 1978, Maize breeding and genetics. Section 8. Cytogenetics., P693; PYKE KA, 1991, J EXP BOT, V42, P1407, DOI 10.1093/jxb/42.11.1407; REDEI GP, 1965, GENETICS, V51, P857; SCOFIELD SR, 1993, CELL, V75, P507, DOI 10.1016/0092-8674(93)90385-4; SKARNES WC, 1990, BIO-TECHNOL, V8, P827, DOI 10.1038/nbt0990-827; SPRINGER PT, UNPUB; STEEVES TA, 1969, CAN J BOTANY, V47, P1367, DOI 10.1139/b69-195; SUNDARESAN V, UNPUB; TOPPING JF, 1991, DEVELOPMENT, V112, P1009; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; VIZIR IY, 1994, GENETICS, V137, P1111; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; 1991, PROGRAM MANUAL GCG P	48	206	230	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					877	880		10.1126/science.7754372	http://dx.doi.org/10.1126/science.7754372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754372				2022-12-28	WOS:A1995QX85000039
J	HAY, RJ				HAY, RJ			CRYPTOCOCCOSIS, AIDS, AND CLINICAL-TRIALS	LANCET			English	Editorial Material							MENINGITIS				HAY, RJ (corresponding author), UNITED MED & DENT SCH,GUYS HOSP,ST JOHNS INST DERMATOL,LONDON SE1 9RT,ENGLAND.							COKER RJ, 1993, AIDS, V7, P829, DOI 10.1097/00002030-199306000-00011; DISMUKES WE, 1988, J INFECT DIS, V157, P624, DOI 10.1093/infdis/157.4.624; KORTING HC, 1988, J CLIN MICROBIOL, V26, P2626, DOI 10.1128/JCM.26.12.2626-2631.1988; LARSEN RA, 1990, ANN INTERN MED, V113, P183, DOI 10.7326/0003-4819-113-3-183; QUAGLIARELLO VJ, 1995, LANCET, V345, P548, DOI 10.1016/S0140-6736(95)90465-4; SAAG MA, 1992, NEW ENGL J MED, V326, P793; SWINNE D, 1987, Revista Iberica de Micologia, V4, P77; TANAKA K, 1993, JAP J THORACIC DIS, V31, P1528; Wheat L. J., 1994, AIDS Clinical Care, V6, P27	9	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					530	531		10.1016/S0140-6736(95)90457-3	http://dx.doi.org/10.1016/S0140-6736(95)90457-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776766				2022-12-28	WOS:A1995QK44400002
J	PANDIT, JC				PANDIT, JC			TESTING ACUITY OF VISION IN GENERAL-PRACTICE - REACHING RECOMMENDED STANDARD	BRITISH MEDICAL JOURNAL			English	Article									TORBAY HOSP,DEPT OPHTHALMOL,TORQUAY TQ2 7AA,DEVON,ENGLAND									BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001; RAFFLE A, 1985, MED ASPECTS FITNESS; 1968, BS4274 BRIT STAND I	3	25	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1994	309	6966					1408	1408		10.1136/bmj.309.6966.1408	http://dx.doi.org/10.1136/bmj.309.6966.1408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU764	7755711	Green Published			2022-12-28	WOS:A1994PU76400020
J	HARVEY, J; PRESCOTT, RJ				HARVEY, J; PRESCOTT, RJ			SIMPLE ASPIRATION VERSUS INTERCOSTAL TUBE DRAINAGE FOR SPONTANEOUS PNEUMOTHORAX IN PATIENTS WITH NORMAL LUNGS	BRITISH MEDICAL JOURNAL			English	Article									UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	HARVEY, J (corresponding author), SOUTHMEAD GEN HOSP,LUNG FUNCT UNIT,BRISTOL BS10 5NB,AVON,ENGLAND.							ARCHER GJ, 1985, BRIT J DIS CHEST, V79, P177, DOI 10.1016/0007-0971(85)90028-2; JONES JS, 1985, THORAX, V40, P66, DOI 10.1136/thx.40.1.66; MILLER AC, 1993, BRIT MED J, V307, P114, DOI 10.1136/bmj.307.6896.114; RUCKLEY CV, 1966, THORAX, V21, P139, DOI 10.1136/thx.21.2.139; STRADLING P, 1966, THORAX, V21, P145, DOI 10.1136/thx.21.2.145	5	124	130	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1338	1339		10.1136/bmj.309.6965.1338	http://dx.doi.org/10.1136/bmj.309.6965.1338			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7755720	Green Published			2022-12-28	WOS:A1994PT62500023
J	SAINSBURY, JRC; ANDERSON, TJ; MORGAN, DAL; DIXON, JM				SAINSBURY, JRC; ANDERSON, TJ; MORGAN, DAL; DIXON, JM			ABC OF BREAST DISEASES - BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article									UNIV EDINBURGH,DEPT PATHOL,EDINBURGH,MIDLOTHIAN,SCOTLAND; CITY HOSP NOTTINGHAM,NOTTINGHAM,ENGLAND; EDINBURGH ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Royal Infirmary of Edinburgh; University of Edinburgh	SAINSBURY, JRC (corresponding author), HUDDERSFIELD ROYAL INFIRM,HUDDERSFIELD,W YORKSHIRE,ENGLAND.			Morgan, David/0000-0002-2291-1740				ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Fisher B, 1992, J Natl Cancer Inst Monogr, P7; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202	3	12	12	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1994	309	6962					1150	1153		10.1136/bmj.309.6962.1150	http://dx.doi.org/10.1136/bmj.309.6962.1150			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP691	7755703	Green Published			2022-12-28	WOS:A1994PP69100033
J	CHRISTENSEN, K; SCHMIDT, MM; VETH, M; OLSEN, J				CHRISTENSEN, K; SCHMIDT, MM; VETH, M; OLSEN, J			ABSENCE OF AN ENVIRONMENTAL-EFFECT ON THE RECURRENCE OF FACIAL-CLEFT DEFECTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PALATE; LIP; GENE	Background. The rate of of a broad range of birth defects may decrease among women who change residence after the birth of their first infant, The aim of the present study was to determine the effect of changing residence on the recurrence of congenital facial-cleft defects. Methods. We identified 4189 women who had had infants with facial-cleft defects by linking a data base comprising the records of children with facial clefts born between 1952 and 1987 with the Central Person Registry in Denmark, Among the 4189 mothers, 1902 each had additional children after the first child with a facial-cleft defect. A total of 2692 younger siblings were identified. We compared the proportion of infants with facial-cleft defects among the younger siblings between mothers who had changed municipalities or sexual partners and those who had not. Results. Changing the municipality of residence did not decrease the frequency with which facial-cleft defects recurred in younger siblings. Among the 907 infants of mothers who changed municipalities but not partners, 29 (3.2 percent) had facial-cleft defects, as compared with 48 (3.4 percent) of 1425 infants of mothers who changed neither municipality nor partner (relative risk, 0.9; 95 percent confidence interval, 0.6 to 1.5), However, a change of partner reduced the recurrence risk significantly. Among 236 infants of mothers who changed partners, 1 (0.4 percent) had a facial-cleft defect, as compared with 77 (3.3 percent) of 2350 infants of mothers who did not change partners (relative risk, 0.1; 95 percent confidence interval, 0.02 to 0.9). Conclusions. Recurrence of facial-cleft defects is not linked to the residence of the mother, but having a different partner reduced a woman's risk of having a second child with this defect.	ODENSE UNIV, SCH MED, ODENSE, DENMARK; AARHUS UNIV, DEPT BIOSTAT, AARHUS, DENMARK	University of Southern Denmark; Aarhus University	CHRISTENSEN, K (corresponding author), STENO INST PUBL HLTH, DEPT EPIDEMIOL & SOCIAL MED, DANISH EPIDEMIOL SCI CTR, RES UNIT, DK-8000 AARHUS C, DENMARK.		Christensen, Kaare/C-2360-2009	Christensen, Kaare/0000-0002-5429-5292				ARDINGER HH, 1989, AM J HUM GENET, V45, P348; BAIRD PA, 1994, TERATOLOGY, V49, P448, DOI 10.1002/tera.1420490604; CARTER CO, 1982, J MED GENET, V19, P246, DOI 10.1136/jmg.19.4.246; CHENEVIXTRENCH G, 1992, AM J HUM GENET, V51, P1377; CHRISTENSEN K, 1993, AM J MED GENET, V47, P910, DOI 10.1002/ajmg.1320470620; CHRISTENSEN K, 1992, AM J HUM GENET, V51, P654; CHRISTENSEN K, 1994, CLIN GENET, V46, P329; FRIIS ML, 1989, ACTA NEUROL SCAND, V79, P433, DOI 10.1111/j.1600-0404.1989.tb03814.x; GOLDBERG R, 1993, AM J MED GENET, V45, P313, DOI 10.1002/ajmg.1320450307; KALLEN B, 1986, ACTA PAEDIATR SCAND, P1; KHOURY MJ, 1987, AM J PUBLIC HEALTH, V77, P623, DOI 10.2105/AJPH.77.5.623; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; MARAZITA ML, 1986, J CRAN GENET DEV BIO, P89; MOORE GE, 1987, NATURE, V326, P91, DOI 10.1038/326091a0; OLSEN J, 1982, UGESKRIFT LAEGER, V4, P1333; PRADAT P, 1994, GENET EPIDEMIOL, V11, P131, DOI 10.1002/gepi.1370110204; WALD N, 1991, LANCET, V338, P131; WANG JH, 1988, AM J HUM GENET, V42, P772; WERLER MM, 1991, AM J EPIDEMIOL, V134, P691, DOI 10.1093/oxfordjournals.aje.a116145	19	45	45	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					161	164		10.1056/NEJM199507203330305	http://dx.doi.org/10.1056/NEJM199507203330305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791818	Bronze			2022-12-28	WOS:A1995RK91700005
J	GUNBY, P				GUNBY, P			MIDDLE MAN IN THE PROSTATE PUZZLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					6	6						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791259				2022-12-28	WOS:A1995RG23300002
J	BAER, L; JACOBS, DG; CUKOR, P; OLAUGHLEN, J; COYLE, JT; MAGRUDER, KM				BAER, L; JACOBS, DG; CUKOR, P; OLAUGHLEN, J; COYLE, JT; MAGRUDER, KM			AUTOMATED TELEPHONE SCREENING SURVEY FOR DEPRESSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To test the application of fully automated telephone screening using computerized digital voice recordings and touch-tone responses to assess symptoms of depression. Design.-A cross-sectional study of a 2-week-long telephone survey. Setting.-Toll-free telephone calls placed from home, work, or school to a central telephone/computer system at a telecommunications company in the Boston, Mass, area. Participants.-A total of 1812 participants called the system. Of these, 278 were students and faculty at a large midwestern state university, 725 were employees of a large northeastern high-technology firm, and 809 did not identify which site they were calling from. Main Outcome Measures.-The 20-question multiple-choice Zung Depression Scale was used to screen for depressive symptoms, and additional questions gathered demographic and caller satisfaction information. Results.-No technical problems were encountered during the trial. Of 1812 callers, 1597 (88.1%) completed all questions. Of these, 412 callers (25.8%) met criteria for ''moderate or marked'' depression and another 194 (12.1%) met criteria for ''severe or extreme'' depression. The majority of callers scoring positive for depression had received no previous treatment for depression. Of callers who completed the screening questionnaire, 74.6% reported the call to have been al least ''moderately'' helpful. Conclusion.-Readily available low-cost technology provides a fully automated, widely accessible, and confidential method of screening for a common mental illness.	HARVARD UNIV,SCH MED,CONSOLIDATED DEPT PSYCHIAT,BOSTON,MA; NATL DEPRESS SCREENING DAY PROJECT,WELLESLEY,MA; NIMH,BETHESDA,MD 20892; DUKE UNIV,MED CTR,DURHAM,NC 27710	Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Duke University			Magruder, Kathryn/V-1576-2019					BAER L, 1993, AM J PSYCHIAT, V150, P1737; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P405; GREENBERG PE, 1993, J CLIN PSYCHIAT, V54, P419; JACOBS D, 1994, NATIONAL DEPRESSION; VANKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; WEISSMAN MM, 1981, ARCH GEN PSYCHIAT, V38, P417; ZUNG W W K, 1990, Journal of Clinical Psychiatry, V51, P77; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; 1987, DIAGNOSTIC STATISTIC	9	57	57	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1943	1944						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783305				2022-12-28	WOS:A1995RE35400031
J	LEVY, JA				LEVY, JA			HIV RESEARCH - A NEED TO FOCUS ON THE RIGHT TARGET	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; T-LYMPHOCYTES; INFECTION; EFFICACY; LEUKEMIA; VACCINE; CELLS				LEVY, JA (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143, USA.							ADA G, 1992, NATURE, V359, P572, DOI 10.1038/359572a0; ALMOND N, 1995, LANCET, V345, P1342, DOI 10.1016/S0140-6736(95)92540-6; CLERICI M, 1994, IMMUNOL TODAY, V15, P575, DOI 10.1016/0167-5699(94)90220-8; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAST PE, 1993, AIDS, V7, pS147, DOI 10.1097/00002030-199301001-00020; FOWKE KR, 1995, 5TH P ANN C HIV AIDS; FULTZ PN, 1992, SCIENCE, V256, P1687, DOI 10.1126/science.256.5064.1687; GARDNER MB, 1994, RETROVIRIDAE, V3, P133; HANSON CV, 1994, AIDS RES HUM RETROV, V10, P645, DOI 10.1089/aid.1994.10.645; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUNSMANN G, 1975, VIROLOGY, V66, P327, DOI 10.1016/0042-6822(75)90203-2; KERKAU T, 1989, AIDS RES HUM RETROV, V5, P613, DOI 10.1089/aid.1989.5.613; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; Levy JA, 1994, HIV PATHOGENESIS AID; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; MACKEWICZ CE, 1994, LANCET, V344, P1671, DOI 10.1016/S0140-6736(94)90459-6; MACKEWICZ CE, 1994, CLIN IMMUNOL IMMUNOP, V73, P80, DOI 10.1006/clin.1994.1172; MURTHY KK, 1994, 7TH P ANN M NAT COOP; PEDERSEN NC, 1993, J VET INTERN MED, V7, P34, DOI 10.1111/j.1939-1676.1993.tb03166.x; PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001; ROWLANDJONES S, 1993, SEMIN VIROL, V4, P83, DOI 10.1006/smvy.1993.1002; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ULRICH PP, 1989, J INFECT DIS, V160, P1; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	28	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1619	1621		10.1016/S0140-6736(95)90121-3	http://dx.doi.org/10.1016/S0140-6736(95)90121-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783542				2022-12-28	WOS:A1995RE67000014
J	DEVILLALOBOS, DH; TAEGTMEYER, H				DEVILLALOBOS, DH; TAEGTMEYER, H			METABOLIC SUPPORT FOR THE POSTISCHEMIC HEART - DISCUSSION	LANCET			English	Discussion							CONTRACTILE FUNCTION; ISCHEMIC MYOCARDIUM; RAT-HEART; REPERFUSION; GLUCOSE; INSULIN; SUBSTRATE; DAMAGE		UNIV TEXAS,SCH MED,DEPT MED,HOUSTON,TX 77030; TEXAS HEART INST,HOUSTON,TX 77025	University of Texas System; Texas Heart Institute					PHS HHS [R0I-43113] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		APSTEIN CS, 1983, CIRC RES, V52, P515, DOI 10.1161/01.RES.52.5.515; BALDWIN JE, 1981, NATURE, V291, P381, DOI 10.1038/291381a0; BOLLI R, 1992, CIRCULATION, V86, P1671, DOI 10.1161/01.CIR.86.6.1671; BOLLI R, 1991, CARDIOVASC DRUG THER, V5, P249, DOI 10.1007/BF00054747; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; BROWN GC, 1992, BIOCHEM J, V284, P1; BUDINGEN T, 1914, ARCH KLIN MED, V114, P534; GOODWIN GW, 1994, AM J PHYSIOL, V267, pH462, DOI 10.1152/ajpheart.1994.267.2.H462; GOULSTON A, 1912, BRIT MED J, V2, P693; GRADINAC S, 1989, ANN THORAC SURG, V48, P484, DOI 10.1016/S0003-4975(10)66844-0; LAZAR HL, 1980, SURGERY, V88, P702; LOPASCHUK GD, 1993, J PHARMACOL EXP THER, V264, P135; MAJID PA, 1972, LANCET, V2, P937; NEELY JR, 1984, CIRC RES, V55, P816, DOI 10.1161/01.RES.55.6.816; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; OPIE L H, 1970, Journal of Molecular and Cellular Cardiology, V1, P107, DOI 10.1016/0022-2828(70)90045-3; PEUHKURINEN KJ, 1984, J MOL CELL CARDIOL, V16, P487, DOI 10.1016/S0022-2828(84)80637-9; Racker E, 1981, Curr Top Cell Regul, V18, P361; RACKLEY CE, 1981, AM HEART J, V102, P1038, DOI 10.1016/0002-8703(81)90488-9; RUSSELL RR, 1991, AM J PHYSIOL, V261, pH1756, DOI 10.1152/ajpheart.1991.261.6.H1756; SHUG AL, 1994, LIFE SCI, V54, P557; SODIPALLARES D, 1962, AM J CARDIOL, V9, P166, DOI 10.1016/0002-9149(62)90035-8; TAEGTMEYER H, 1978, CIRC RES, V43, P808, DOI 10.1161/01.RES.43.5.808; TAEGTMEYER H, 1983, BASIC RES CARDIOL, V78, P435, DOI 10.1007/BF02070167; TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701; Taegtmeyer H, 1994, CURR PROB CARDIOLOGY, V19, P57; 1968, LANCET, V2, P1355	27	35	37	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1552	1555						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791443				2022-12-28	WOS:A1995RD79000015
J	PIERIBONE, VA; SHUPLIAKOV, O; BRODIN, L; HILFIKERROTHENFLUH, S; CZERNIK, AJ; GREENGARD, P				PIERIBONE, VA; SHUPLIAKOV, O; BRODIN, L; HILFIKERROTHENFLUH, S; CZERNIK, AJ; GREENGARD, P			DISTINCT POOLS OF SYNAPTIC VESICLES IN NEUROTRANSMITTER RELEASE	NATURE			English	Article							SYNAPSIN-I; SHORT-TERM; PROTEIN; PHOSPHOPROTEINS; SYNAPTOTAGMIN; PLASTICITY; NEURONS	NERVE terminals are unique among cellular secretory systems in that they can sustain vesicular release at a high rate. Although little is known about the mechanisms that account for the distinctive features of neurotransmitter release, it can be assumed that neuron-specific proteins are involved. One such protein family, the synapsins, are believed to regulate neurotransmitter release through phosphorylation-dependent interactions with synaptic vesicles and cytoskeletal elements(1). Here we show that clusters of vesicles at synaptic release sites are composed of two pools, a distal pool containing synapsin and a proximal pool devoid of synapsin and located adjacent to the presynaptic membrane. Presynaptic injection of synapsin antibodies resulted in the loss of the distal pool, without any apparent effect on the proximal pool. Depletion of this distal pool,vas associated with a marked depression of neurotransmitter release evoked by high-frequency (18-20 Hz) but not by low-frequency (0.2 Hz) stimulation. Thus the availability of the synapsin-associated pool of vesicles seems to be required to sustain release of neurotransmitter in response to high-frequency bursts of impulses.	KAROLINSKA INST, DEPT NEUROSCI, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	PIERIBONE, VA (corresponding author), ROCKEFELLER UNIV, MOLEC & CELLULAR NEUROSCI LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Shupliakov, Oleg/R-9148-2016; Hilfiker, Sabine N/L-6369-2014	Shupliakov, Oleg/0000-0001-5352-6848; Hilfiker, Sabine N/0000-0002-5167-7682; Pieribone, Vincent/0000-0002-5836-5454				ATWOOD HL, 1986, INT REV NEUROBIOL, V28, P275, DOI 10.1016/S0074-7742(08)60111-7; BENFENATI F, 1993, J CELL BIOL, V123, P1845, DOI 10.1083/jcb.123.6.1845; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BRODIN L, 1994, J NEUROPHYSIOL, V72, P592, DOI 10.1152/jn.1994.72.2.592; BRODIN L, 1994, ADV SEC MESS PHOSPH, V29, P205; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BUCHANAN JT, 1992, BIOL CYBERN, V67, P123, DOI 10.1007/BF00201019; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Katz B., 1969, RELEASE NEURAL TRANS; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; MANDELL JW, 1992, J NEUROSCI, V12, P1736; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; Peters A., 1991, FINE STRUCTURE NERVO; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; ROVAINEN CM, 1979, PHYSIOL REV, V59, P1007, DOI 10.1152/physrev.1979.59.4.1007; RUBENSTEIN JL, 1993, SYNAPSE, V13, P161, DOI 10.1002/syn.890130207; SHUPLIAKOV O, 1995, EUR J NEUROSCI, V7, P1111, DOI 10.1111/j.1460-9568.1995.tb01099.x; SHUPLIAKOV O, 1992, J NEUROSCI, V12, P3789; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; WICKELGREN WO, 1985, J NEUROSCI, V5, P1188	24	423	429	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					493	497		10.1038/375493a0	http://dx.doi.org/10.1038/375493a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777058				2022-12-28	WOS:A1995RC18800049
J	GRIEDER, NC; NELLEN, D; BURKE, R; BASLER, K; AFFOLTER, M				GRIEDER, NC; NELLEN, D; BURKE, R; BASLER, K; AFFOLTER, M			SCHNURRI IS REQUIRED FOR DROSOPHILA DPP SIGNALING AND ENCODES A ZINC-FINGER PROTEIN SIMILAR TO THE MAMMALIAN TRANSCRIPTION FACTOR PRDII-BF1	CELL			English	Article							DECAPENTAPLEGIC GENE; GERM LAYERS; BINDING PROTEIN; LARVAL CUTICLE; ZYGOTIC LOCI; BETA FAMILY; PATTERN; EMBRYO; MELANOGASTER; EXPRESSION	Cytokines of the TGF beta superfamily regulate many aspects of cellular function by activating receptor complexes consisting of two distantly related serine/threonine kinases. Previous studies have indicated that Drosophila dpp uses similar signaling complexes and strictly requires the punt and thick veins receptors to transduce the signal across the membrane. Here, we show that the schnurri (shn) gene is required for many aspects of dpp signaling, Genetic epistasis experiments indicate that shn functions downstream of the dpp signal and its receptors. The shn gene encodes a large protein similar to a family of mammalian zinc finger transcription factors. The shn protein might therefore act as a nuclear target in the dpp signaling pathway directly regulating the expression of dpp-responsive genes.	UNIV ZURICH, INST ZOOL, CH-8057 ZURICH, SWITZERLAND	University of Zurich	GRIEDER, NC (corresponding author), UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND.			Basler, Konrad/0000-0003-3534-1529; Affolter, Markus/0000-0002-5171-0016; Burke, Richard/0000-0003-0086-0767				AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; AFFOLTER M, 1993, DEVELOPMENT, V117, P1199; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; CHOU TB, 1993, DEVELOPMENT, V119, P1359; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; CRABTREE GR, 1992, TRANSCRIPTIONAL REGU, P1063; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; HAUPTMANN G, 1994, TRENDS GENET, V10, P266, DOI 10.1016/0168-9525(90)90008-T; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JACKSON PD, 1994, DEV DYNAM, V199, P28, DOI 10.1002/aja.1001990104; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN GH, 1992, GENETICS, V132, P737; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NOMURA N, 1991, J BIOL CHEM, V266, P8590; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; REUTER R, 1990, DEVELOPMENT, V110, P1031; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROOP DR, 1978, CELL, V15, P671, DOI 10.1016/0092-8674(78)90035-1; RUBERTE E, 1995, CELL, V80, P889, DOI 10.1016/0092-8674(95)90292-9; SEGAL D, 1985, GENETICS, V109, P119; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; THURINGER F, 1993, EMBO J, V12, P2419, DOI 10.1002/j.1460-2075.1993.tb05896.x; THURINGER F, 1993, P NATL ACAD SCI USA, V90, P3899, DOI 10.1073/pnas.90.9.3899; TREMML G, 1992, DEVELOPMENT, V116, P447; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WINICK J, 1993, DEVELOPMENT, V119, P1055; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; ZECCA M, 1995, IN PRESS DEVELOPMENT	49	168	173	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					791	800		10.1016/0092-8674(95)90540-5	http://dx.doi.org/10.1016/0092-8674(95)90540-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774018	Green Accepted, Bronze			2022-12-28	WOS:A1995RB96100017
J	WILSON, KL				WILSON, KL			NSF-INDEPENDENT FUSION MECHANISMS	CELL			English	Review							VESICLE FUSION; DYNAMICS				WILSON, KL (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205, USA.							BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DEMANGE P, 1994, TRENDS BIOCHEM SCI, V19, P272, DOI 10.1016/0968-0004(94)90002-7; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SULLIVAN KMC, 1994, CELL CALCIUM, V16, P314, DOI 10.1016/0143-4160(94)90095-7; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; VONMOLLARD F, 1994, TRENDS BIOCHEM SCI, V19, P164; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945	28	22	22	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					475	477		10.1016/0092-8674(95)90067-5	http://dx.doi.org/10.1016/0092-8674(95)90067-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758102	Bronze			2022-12-28	WOS:A1995QZ71000003
J	REJTO, PA; BINDEWALD, E; CHANDLER, D				REJTO, PA; BINDEWALD, E; CHANDLER, D			VISUALIZATION OF FAST ENERGY-FLOW AND SOLVENT CAGING IN UNIMOLECULAR DYNAMICS	NATURE			English	Article							CONFORMATIONAL ISOMERIZATION; TRANSITION-STATE; CYCLOHEXANE; LIQUIDS; RELAXATION; ACTIVATION	ENERGY flow in solution between physically or chemically evolving solute molecules and the surrounding solvent significantly affects the nature of chemical dynamics in liquids. It determines the extent to which the statistical theory of reaction rates(1,2) is valid; the transfer of energy between solute and solvent influences the ease with which the transition state evolves into the products-the process central to transition-state theory. But analysing the energy flow in liquid-phase dynamics is difficult because these systems are so complex, and the degrees of freedom are consequently so numerous. Here we present a way to address this challenge. We introduce an approach for visualizing the energy flow directly, and apply it to the isomerization of cyclohexane (between boat and chair conformations) in liquid carbon disulphide, a process for which detailed information about the molecular motions is available from molecular dynamics simulations(8). Our method reveals in pictorial form the formation and relaxation of a solvent cage, and shows that the relaxation has a strong effect on energy flow to and from the transition state on sub-picosecond timescales. We anticipate that this visualization approach will be generally useful for elucidating dynamical molecular processes in solution.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley			Rejto, Paul/M-4782-2019					ANDERSON JB, 1973, J CHEM PHYS, V58, P4684, DOI 10.1063/1.1679032; Bennett C. H., 1977, ACS SYM SER, V46, P63, DOI DOI 10.1021/BK-1977-0046.CH004; BORKOVEC M, 1986, J CHEM PHYS, V85, P146, DOI 10.1063/1.451651; CAMPBELL DM, 1992, J CHEM PHYS, V96, P2717, DOI 10.1063/1.462019; CHANDLER D, 1988, FARADAY DISCUSS, V85, P329, DOI 10.1039/dc9888500329; CHANDLER D, 1978, J CHEM PHYS, V68, P2959, DOI 10.1063/1.436049; CHANDLER D, 1983, SCIENCE, V220, P787, DOI 10.1126/science.220.4599.787; GERTNER BJ, 1991, J AM CHEM SOC, V113, P74, DOI 10.1021/ja00001a014; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HASHA DL, 1981, J CHEM PHYS, V75, P1571, DOI 10.1063/1.442193; HASHA DL, 1982, J AM CHEM SOC, V104, P2290, DOI 10.1021/ja00372a029; JIMENEZ R, 1994, NATURE, V369, P471, DOI 10.1038/369471a0; Johnston H.S., 1966, GAS PHASE REACTION R; Keck J. C., 1967, ADV CHEM PHYS, V13, P85, DOI 10.1002/9780470140154.ch5; MILLER WH, 1976, ACCOUNTS CHEM RES, V9, P306, DOI 10.1021/ar50104a005; PATRON F, 1991, CHEM PHYS, V152, P121, DOI 10.1016/0301-0104(91)80039-K; PICKETT HM, 1970, J AM CHEM SOC, V92, P7281; REJTO PA, 1994, J PHYS CHEM-US, V98, P12310, DOI 10.1021/j100098a028; SINGER SJ, 1986, J PHYS CHEM-US, V90, P6015, DOI 10.1021/j100280a111; STRAUSS HL, 1971, J CHEM EDUC, V48, P221, DOI 10.1021/ed048p221; Wigner E, 1938, T FARADAY SOC, V34, P0029, DOI 10.1039/tf9383400029; WILSON MA, 1990, CHEM PHYS, V149, P11, DOI 10.1016/0301-0104(90)80127-J	22	11	11	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					129	131		10.1038/375129a0	http://dx.doi.org/10.1038/375129a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753167				2022-12-28	WOS:A1995QX74100045
J	MAIR, P; KORNBERGER, E; HORMANN, C				MAIR, P; KORNBERGER, E; HORMANN, C			ACCIDENTAL HYPOTHERMIA	LANCET			English	Letter											MAIR, P (corresponding author), UNIV INNSBRUCK, SCH MED, DEPT ANAESTHESIA & INTENS CARE MED, A-6020 INNSBRUCK, AUSTRIA.							DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6	1	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 22	1995	345	8956					1048	1049						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7772186				2022-12-28	WOS:A1995QU57300039
J	POEHLMAN, ET; SCHEFFERS, J; GOTTLIEB, SS; FISHER, ML; VAITEKEVICIUS, P				POEHLMAN, ET; SCHEFFERS, J; GOTTLIEB, SS; FISHER, ML; VAITEKEVICIUS, P			INCREASED RESTING METABOLIC-RATE IN PATIENTS WITH CONGESTIVE-HEART-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Note							ENERGY-EXPENDITURE; NOREPINEPHRINE	Objective: To examine resting metabolic rate in patients with congestive heart failure as a cause of cardiac cachexia and associated weight loss. Design: Cross-sectional study. Setting: Baltimore Veterans Affairs Medical Center. Patients: 20 men with heart failure (mean age +/-SD, 69 +/- 7 years) and reduced ejection fraction (mean, 0.24 +/- 0.10) and 40 healthy men (mean age, 69 +/- 7 years). Results: Patients with heart failure had smaller fat-free mass than did controls (53 +/- 8 kg compared with 56 +/- 6 kg; P < 0.09), but no difference in fat mass existed (21 +/- 8 kg compared with 19 +/- 8 kg). Measured resting metabolic rate was 18% higher in patients with heart failure than in controls (1828 +/- 275 kcal/d compared with 1543 +/- 219 kcal/d; P < 0.01); no difference in caloric intake existed (2144 +/- 479 kcal/d compared with 2174 +/- 826 kcal/d). The difference in resting metabolic rate between the two groups was even more striking when indexed per kilogram of fat-free mass. Conclusions: Higher resting metabolic rate in patients with heart failure at least partially accounts for otherwise unexplained weight loss. Present caloric guidelines, which were established in healthy elderly persons, substantially underestimate the resting caloric needs of elderly persons with heart failure.	UNIV MARYLAND, CLAUDE D PEPPER OLDER AMER INDEPENDENCE CTR, BALTIMORE, MD 21201 USA; GERIATR RES EDUC & CLIN CTR, BALTIMORE, MD USA	University System of Maryland; University of Maryland Baltimore; Geriatric Research Education & Clinical Center	POEHLMAN, ET (corresponding author), VET AFFAIRS MED CTR, 10 N GREENE ST, BALTIMORE, MD 21201 USA.				NATIONAL INSTITUTE ON AGING [R01AG007857, R29AG007857] Funding Source: NIH RePORTER; NIA NIH HHS [AG-05564, AG-07857] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1985, ENERGY PROTEIN REQUI; ARCIERO PJ, 1993, METABOLISM, V42, P950, DOI 10.1016/0026-0495(93)90006-A; DAVIS D, 1988, AM J PHYSIOL, V254, pE760, DOI 10.1152/ajpendo.1988.254.6.E760; GORAN MI, 1992, METABOLISM, V41, P744, DOI 10.1016/0026-0495(92)90315-2; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; PITTMAN JG, 1964, NEW ENGL J MED, V271, P403, DOI 10.1056/NEJM196408202710807; POEHLMAN ET, 1991, AM J PHYSIOL, V261, pE233, DOI 10.1152/ajpendo.1991.261.2.E233; POEHLMAN ET, 1993, J AM GERIATR SOC, V41, P552, DOI 10.1111/j.1532-5415.1993.tb01895.x; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363	9	166	170	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1994	121	11					860	862		10.7326/0003-4819-121-11-199412010-00006	http://dx.doi.org/10.7326/0003-4819-121-11-199412010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT628	7772113				2022-12-28	WOS:A1994PT62800006
J	KOUDSTAAL, PJ; VANLATUM, JC; VANGIJN, J; KAPPELLE, LJ; ALGRA, A; DEHAENE, I; DHOOGHE, M; MARCHAU, M; VANZANDIJCKE, M; DELWAIDE, C; DEPRE, A; LATERRE, EC; VANBUGGENHOUT, E; SCHURMANS, J; DESMET, E; SWERTS, L; VANDENABEELE, G; CARTON, H; VERDRU, PMA; INDEKEU, PA; LAM, D; VANDENBERGH, V; MOL, L; VANLANDEGEM, W; STRAUVEN, T; BOYSEN, G; GYRING, J; PETERSEN, P; WURTZENNIELSEN, P; CREPINLEBLOND, T; MOULIN, T; AURIACOMBE, S; ORGOGOZO, JM; BOULLIAT, J; GOAS, JY; MOCQUARD, Y; BESSON, G; HOMMEL, M; ADNETBONTE, C; JOSIEN, E; PETIT, H; CHEDRU, F; EVRARD, S; LEVASSEUR, M; MAS, JL; MEYNIARD, O; ZUBER, M; AMARENCO, P; BOUSSER, MG; ROULLET, E; PINEL, JF; MASSARDIER, E; MIHOUT, B; CHOLLET, F; RASCOL, A; AUTRET, A; SAUNDEAU, D; BUTTNER, T; NIEMCZYK, W; BOHM, KD; HORNIG, C; HACKE, W; HEISS, C; REUTHER, R; HAASS, A; STOLL, M; KRAMER, G; ROTHACHER, G; BAUER, M; BUSSE, O; KOCHROSE, S; MUEFFELMANN, B; DICHGANS, J; THOMAS, C; HENNEN, OAD; JORG, J; SCHWAN, H; SIEPEN, R; BORNSTEIN, NM; CENSORI, B; CERAVOLO, M; PROVINCIALI, L; DALESSANDRO, G; BOTTACCHI, E; CARENINI, L; DUC, E; FEDERICO, F; FIORE, A; LAMBERTI, P; LATTANZI, P; CAMERLINGO, M; CASTO, L; MAMOLI, A; BENEMIO, G; BOLDRINI, F; GATTESCHI, C; SCHILLACI, G; VERDECCHIA, P; VIGNAI, E; ARCELLI, G; BRAVI, S; COLI, L; GIRELLI, L; PURRO, A; DELFAVERO, C; GUIDOTTI, M; PELLEGRINI, G; SANTARONE, M; TADEO, G; BOTTINI, G; CANEPARI, C; STERZI, R; BINDA, A; CANDELISE, L; NADOR, F; PINARDI, G; OLIVA, L; MOMBELLONI, A; PONARI, O; SQUERI, M; BARZIZZA, F; CAVALLINI, A; MICIELI, G; NAPPI, G; RICHICHI, I; CASELLI, P; MORETTI, E; AISA, G; BOSCHETTI, E; CAPUTO, N; CELANI, MG; DELFAVERO, A; NENCI, G; RICCI, S; RIGHETTI, E; SENIN, U; BIOTTI, M; DETTORE, M; FABRIZI, G; GRASSELLI, S; PEZZELLA, F; ANTONUTTI, L; GRANDI, FC; GUERRINI, D; MARZALLI, A; PINAMONTI, B; SALVI, R; SAMMARTINI, C; DUDINE, P; MILONE, FF; VICENZI, M; TERBERG, JWM; GELMERS, HJ; HAAS, JA; LINDEBOOM, SF; HERDERSCHEE, D; HIJDRA, A; VERMEULEN, M; BERTELSMANN, FW; HAZENBERG, GJ; KOETSIER, JC; BERNTSEN, PJIM; GEBBINK, TB; SLEEGERS, FM; VANBEECK, JA; FEIKEMA, WJ; VANGASTEREN, JHM; VELTEMA, AN; VREDEVELD, CJM; CARBAAT, PAT; HERTZBERGER, LI; KLEYWEG, RP; BOON, AM; LIEUWENS, WHG; VISSCHER, F; ARTS, WFM; BOON, A; MOLL, LCM; PERQUIN, WVM; TANS, JTJ; TONK, R; DEWEERD, AW; HAAXMAREICHE, H; OOSTERHUIS, HJGH; SNOEK, JW; FRANKE, CL; MIRANDOLLE, JF; KOEHLER, PJJ; BRIET, PE; VANROSSUM, J; BOITEN, J; BOON, AE; LODDER, J; NIHOM, J; MAUSER, HW; FRENKEN, CWGM; POELS, EFJ; PRICK, MJJ; VERHAGEN, WIM; HOPPENBROUWERS, WJJF; STAAL, A; BENEDER, PR; BULENS, C; DEVRIESBOS, LHP; DECOUL, AAWO; LEYTEN, ACM; TIJSSEN, CC; SCHELLENS, RLLA; CILLESSEN, JPM; DRIESEN, JJM; VANOUDENAARDEN, WF; VERHEY, JCB; FRISVOLD, OJ; HOLE, T; SKOGEN, OR; ASLAKSEN, B; GALLEFOSS, F; LAAKE, KO; BERG, LK; BALSLIEMKE, S; RITLAND, S; HVEEM, K; DEHLI, O; ABILDGAARD, U; DAHL, T; WELUND, B; GONCALVES, JAG; PALMEIRO, JF; AMARAL, R; MACHADO, C; MESTRE, A; RIBEIRO, F; SOUSA, L; SALGADO, AV; BAPTISTA, A; CANDIDO, JM; MORGADO, AV; RAMIRES, IMV; CRESPO, M; FERRO, JM; FRANCO, AS; MELO, TMP; OLIVEIRA, V; LIMA, AFB; CORREIA, MM; LOPEZ, JC; MORGADO, R; SANTOS, M; GRAU, G; LOPEZ, J; MARTIN, R; MATIASGUIU, J; ALIO, J; CALOPA, M; MIRALLES, F; RUBIO, F; FUEYO, J; GOMEZ, C; MOLINA, L; DOLHABERRIAGUE, L; SOLERSINGLA, L; DAVALOS, A; GENIS, D; BASSAGANYAS, J; BARREIRO, P; DIEZTEJEDOR, E; FRANK, A; COSTA, J; MARES, R; LAINEZ, L; SANCHO, J; HENNERDAL, KH; RUDBACK, N; SAMUELSON, M; SIGFRIDSON, P; HEDENUS, M; BOGOUSSLAVSKY, J; GHIKA, J; MARIANI, L; NATER, B; SCHMID, F; KNIGHT, R; HAMILTON, SJC; KANE, J; BELL, R; FOOTE, CK; CASSIDY, T; GRAY, CS; SANDERCOCK, PAG; SELLAR, R; WARLOW, CP; HOWE, JG; MCGOURTY, JC; BAMFORD, J; JOHNSON, M; CASTLEDEN, CM; HARPER, GD; PANAYIOTOU, BN; ROBINSON, T; BARER, D; HUMPHREY, P; KAFETZ, K; MCELLIGOTT, G; BATES, D; CARTLIDGE, NEF; VENABLES, GS; MONRO, P				KOUDSTAAL, PJ; VANLATUM, JC; VANGIJN, J; KAPPELLE, LJ; ALGRA, A; DEHAENE, I; DHOOGHE, M; MARCHAU, M; VANZANDIJCKE, M; DELWAIDE, C; DEPRE, A; LATERRE, EC; VANBUGGENHOUT, E; SCHURMANS, J; DESMET, E; SWERTS, L; VANDENABEELE, G; CARTON, H; VERDRU, PMA; INDEKEU, PA; LAM, D; VANDENBERGH, V; MOL, L; VANLANDEGEM, W; STRAUVEN, T; BOYSEN, G; GYRING, J; PETERSEN, P; WURTZENNIELSEN, P; CREPINLEBLOND, T; MOULIN, T; AURIACOMBE, S; ORGOGOZO, JM; BOULLIAT, J; GOAS, JY; MOCQUARD, Y; BESSON, G; HOMMEL, M; ADNETBONTE, C; JOSIEN, E; PETIT, H; CHEDRU, F; EVRARD, S; LEVASSEUR, M; MAS, JL; MEYNIARD, O; ZUBER, M; AMARENCO, P; BOUSSER, MG; ROULLET, E; PINEL, JF; MASSARDIER, E; MIHOUT, B; CHOLLET, F; RASCOL, A; AUTRET, A; SAUNDEAU, D; BUTTNER, T; NIEMCZYK, W; BOHM, KD; HORNIG, C; HACKE, W; HEISS, C; REUTHER, R; HAASS, A; STOLL, M; KRAMER, G; ROTHACHER, G; BAUER, M; BUSSE, O; KOCHROSE, S; MUEFFELMANN, B; DICHGANS, J; THOMAS, C; HENNEN, OAD; JORG, J; SCHWAN, H; SIEPEN, R; BORNSTEIN, NM; CENSORI, B; CERAVOLO, M; PROVINCIALI, L; DALESSANDRO, G; BOTTACCHI, E; CARENINI, L; DUC, E; FEDERICO, F; FIORE, A; LAMBERTI, P; LATTANZI, P; CAMERLINGO, M; CASTO, L; MAMOLI, A; BENEMIO, G; BOLDRINI, F; GATTESCHI, C; SCHILLACI, G; VERDECCHIA, P; VIGNAI, E; ARCELLI, G; BRAVI, S; COLI, L; GIRELLI, L; PURRO, A; DELFAVERO, C; GUIDOTTI, M; PELLEGRINI, G; SANTARONE, M; TADEO, G; BOTTINI, G; CANEPARI, C; STERZI, R; BINDA, A; CANDELISE, L; NADOR, F; PINARDI, G; OLIVA, L; MOMBELLONI, A; PONARI, O; SQUERI, M; BARZIZZA, F; CAVALLINI, A; MICIELI, G; NAPPI, G; RICHICHI, I; CASELLI, P; MORETTI, E; AISA, G; BOSCHETTI, E; CAPUTO, N; CELANI, MG; DELFAVERO, A; NENCI, G; RICCI, S; RIGHETTI, E; SENIN, U; BIOTTI, M; DETTORE, M; FABRIZI, G; GRASSELLI, S; PEZZELLA, F; ANTONUTTI, L; GRANDI, FC; GUERRINI, D; MARZALLI, A; PINAMONTI, B; SALVI, R; SAMMARTINI, C; DUDINE, P; MILONE, FF; VICENZI, M; TERBERG, JWM; GELMERS, HJ; HAAS, JA; LINDEBOOM, SF; HERDERSCHEE, D; HIJDRA, A; VERMEULEN, M; BERTELSMANN, FW; HAZENBERG, GJ; KOETSIER, JC; BERNTSEN, PJIM; GEBBINK, TB; SLEEGERS, FM; VANBEECK, JA; FEIKEMA, WJ; VANGASTEREN, JHM; VELTEMA, AN; VREDEVELD, CJM; CARBAAT, PAT; HERTZBERGER, LI; KLEYWEG, RP; BOON, AM; LIEUWENS, WHG; VISSCHER, F; ARTS, WFM; BOON, A; MOLL, LCM; PERQUIN, WVM; TANS, JTJ; TONK, R; DEWEERD, AW; HAAXMAREICHE, H; OOSTERHUIS, HJGH; SNOEK, JW; FRANKE, CL; MIRANDOLLE, JF; KOEHLER, PJJ; BRIET, PE; VANROSSUM, J; BOITEN, J; BOON, AE; LODDER, J; NIHOM, J; MAUSER, HW; FRENKEN, CWGM; POELS, EFJ; PRICK, MJJ; VERHAGEN, WIM; HOPPENBROUWERS, WJJF; STAAL, A; BENEDER, PR; BULENS, C; DEVRIESBOS, LHP; DECOUL, AAWO; LEYTEN, ACM; TIJSSEN, CC; SCHELLENS, RLLA; CILLESSEN, JPM; DRIESEN, JJM; VANOUDENAARDEN, WF; VERHEY, JCB; FRISVOLD, OJ; HOLE, T; SKOGEN, OR; ASLAKSEN, B; GALLEFOSS, F; LAAKE, KO; BERG, LK; BALSLIEMKE, S; RITLAND, S; HVEEM, K; DEHLI, O; ABILDGAARD, U; DAHL, T; WELUND, B; GONCALVES, JAG; PALMEIRO, JF; AMARAL, R; MACHADO, C; MESTRE, A; RIBEIRO, F; SOUSA, L; SALGADO, AV; BAPTISTA, A; CANDIDO, JM; MORGADO, AV; RAMIRES, IMV; CRESPO, M; FERRO, JM; FRANCO, AS; MELO, TMP; OLIVEIRA, V; LIMA, AFB; CORREIA, MM; LOPEZ, JC; MORGADO, R; SANTOS, M; GRAU, G; LOPEZ, J; MARTIN, R; MATIASGUIU, J; ALIO, J; CALOPA, M; MIRALLES, F; RUBIO, F; FUEYO, J; GOMEZ, C; MOLINA, L; DOLHABERRIAGUE, L; SOLERSINGLA, L; DAVALOS, A; GENIS, D; BASSAGANYAS, J; BARREIRO, P; DIEZTEJEDOR, E; FRANK, A; COSTA, J; MARES, R; LAINEZ, L; SANCHO, J; HENNERDAL, KH; RUDBACK, N; SAMUELSON, M; SIGFRIDSON, P; HEDENUS, M; BOGOUSSLAVSKY, J; GHIKA, J; MARIANI, L; NATER, B; SCHMID, F; KNIGHT, R; HAMILTON, SJC; KANE, J; BELL, R; FOOTE, CK; CASSIDY, T; GRAY, CS; SANDERCOCK, PAG; SELLAR, R; WARLOW, CP; HOWE, JG; MCGOURTY, JC; BAMFORD, J; JOHNSON, M; CASTLEDEN, CM; HARPER, GD; PANAYIOTOU, BN; ROBINSON, T; BARER, D; HUMPHREY, P; KAFETZ, K; MCELLIGOTT, G; BATES, D; CARTLIDGE, NEF; VENABLES, GS; MONRO, P			OPTIMAL ORAL ANTICOAGULANT-THERAPY IN PATIENTS WITH NONRHEUMATIC ATRIAL-FIBRILLATION AND RECENT CEREBRAL-ISCHEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THROMBOEMBOLIC COMPLICATIONS; BLEEDING COMPLICATIONS; PREVENTION; RANGES; RISK	Background. A number of studies have demonstrated the efficacy of oral anticoagulant therapy in reducing the risk of stroke and systemic embolism in patients with nonrheumatic atrial fibrillation, However, both the targeted and the actual levels of anticoagulation differed widely among the studies, and a number of studies failed to report standardized prothrombin-time ratios as international normalized ratios (INRs), We therefore performed an analysis to determine the intensity of oral anticoagulant therapy in nonrheumatic atrial fibrillation that provides the best balance between the prevention of thromboembolism and the occurrence of bleeding complications. Methods. We calculated INR-specific incidence rates for both ischemic and major hemorrhagic events occurring in 214 patients who received anticoagulant therapy in the European Atrial Fibrillation Trial, a secondary-prevention trial in patients with nonrheumatic atrial fibrillation and a recent episode of minor cerebral ischemia. Results. The optimal intensity of anticoagulation was found to lie between an INR of 2.0 and an INR of 3.9. No treatment effect was apparent with anticoagulation below an INR of 2.0, The rate of thromboembolic events was lowest at INRs from 2.0 to 3.9, and most major bleeding complications occurred with treatment at intensities with INRs of 5.0 or above. Conclusions. To achieve optimal levels of anticoagulation with the lowest risk in patients with atrial fibrillation and a recent episode of cerebral ischemia, the target value for the INR should be set at 3.0, and values below 2.0 and above 5.0 should be avoided.			KOUDSTAAL, PJ (corresponding author), UNIV HOSP DIJKZIGT, DEPT NEUROL, 40 DR MOLEWATERPLEIN, 3015 GD ROTTERDAM, NETHERLANDS.		Cascinu, Stefano/AAN-1923-2020; Hveem, Kristian/AFV-4683-2022; Hacke, Werner/ABE-8661-2020; Mariani, Luigi/AAB-9464-2019; García, Ana Frank/I-5159-2015; AURIACOMBE, Sophie/T-5596-2019; van Gijn, Jan/A-9444-2008; Franco, Andrezza Serpa/V-6469-2019; Grau, Georges/AGR-7139-2022; Censori, Bruno/ABB-9273-2020; celani, maria grazia/AAF-4143-2020; sandercock, peter/GQI-3167-2022	García, Ana Frank/0000-0003-3858-9116; Franco, Andrezza Serpa/0000-0001-5008-1345; Grau, Georges/0000-0002-0442-0462; Censori, Bruno/0000-0001-7235-5909; sandercock, peter/0000-0001-8484-0135				ALBERS GW, 1994, ARCH INTERN MED, V154, P1443, DOI 10.1001/archinte.154.13.1443; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; BUSSEY HI, 1994, LANCET, V343, P234; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1993, NEW ENGL J MED, V328, P148; FROME EL, 1983, BIOMETRICS, V39, P665, DOI 10.2307/2531094; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; HIRSH J, 1992, CHEST, V102, pS312, DOI 10.1378/chest.102.4.312S; KIRKWOOD TBL, 1983, THROMB HAEMOSTASIS, V49, P238; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LAUNBJERG J, 1991, J INTERN MED, V229, P351, DOI 10.1111/j.1365-2796.1991.tb00358.x; LAUPACIS A, 1992, CHEST, V102, pS426, DOI 10.1378/chest.102.4_Supplement.426S; LEVINE M, 1986, STROKE, V17, P111, DOI 10.1161/01.STR.17.1.111; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; LOELIGER EA, 1985, THROMB HAEMOSTASIS, V53, P155; LOELIGER EA, 1985, ACTA HAEMATOL-BASEL, V74, P125, DOI 10.1159/000206187; LOELIGER EA, 1992, ANN HEMATOL, V64, P253, DOI 10.1007/BF01738306; LUNDSTROM T, 1989, J INTERN MED, V225, P137, DOI 10.1111/j.1365-2796.1989.tb00053.x; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; PETERSEN P, 1989, LANCET, V1, P175; POLLER L, 1985, BRIT MED J, V290, P1683, DOI 10.1136/bmj.290.6483.1683; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WINTZEN AR, 1984, ANN NEUROL, V16, P553, DOI 10.1002/ana.410160505; 1993, LANCET, V342, P1255; 1990, EGRET STATISTICAL PA	30	361	371	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					5	10						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776995				2022-12-28	WOS:A1995RG73500002
J	HODIS, HN; MACK, WJ; LABREE, L; CASHINHEMPHILL, L; SEVANIAN, A; JOHNSON, R; AZEN, SP				HODIS, HN; MACK, WJ; LABREE, L; CASHINHEMPHILL, L; SEVANIAN, A; JOHNSON, R; AZEN, SP			SERIAL CORONARY ANGIOGRAPHIC EVIDENCE THAT ANTIOXIDANT VITAMIN INTAKE REDUCES PROGRESSION OF CORONARY-ARTERY ATHEROSCLEROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DENSITY-LIPOPROTEIN; COLESTIPOL-NIACIN THERAPY; D-ALPHA-TOCOPHEROL; OXIDATIVE MODIFICATION; HEART-DISEASE; E CONSUMPTION; SUPPLEMENTATION; CHOLESTEROL; PLASMA; RISK	Objective.- To explore the association of supplementary and dietary vitamin E and C intake with the progression of coronary artery disease. Design.- A subgroup analysis of the on-trial antioxidant vitamin intake database acquired in the Cholesterol Lowering Atherosclerosis Study, a randomized, placebo-controlled, serial angiographic clinical trial evaluating the risk and benefit of colestipol-niacin on coronary artery disease progression. Setting.- Community- and university-based cardiac catheterization laboratories. Subjects.- A total of 156 men aged 40 to 59 years with previous coronary artery bypass graft surgery, Intervention.- Supplementary and dietary vitamin E and C intake (nonrandomized) in association with cholesterol-lowering diet and either colestipol-niacin or placebo (randomized). Outcome.- Change per subject in the percentage of vessel diameter obstructed because of stenosis (%S) determined by quantitative coronary angiography after 2 years of randomized therapy on all lesions, mild/moderate lesions (<50%S), and severe lesions (greater than or equal to 50%S). Results.- Overall, subjects with supplementary vitamin E intake of 100 IU per day or greater demonstrated less coronary artery lesion progression than did subjects with supplementary vitamin E intake less than 100 IU per day for all lesions (P=.04) and for mild/moderate lesions (P=.01). Within the drug group, benefit of supplementary vitamin E intake was found for all lesions (P=.02) and mild/moderate lesions (P=.01). Within the placebo group, benefit of supplementary vitamin E intake was not found. No benefit was found for use of supplementary vitamin C exclusively or in conjunction with supplementary vitamin E, use of multivitamins, or increased dietary intake of vitamin E or vitamin C. Conclusions.- These results indicate an association between supplementary vitamin E intake and angiographically demonstrated reduction in coronary artery lesion progression. Verification from carefully designed, randomized, serial arterial imaging end point trials is needed.	UNIV SO CALIF,SCH MED,DEPT PREVENT MED,CTR STAT CONSULTAT & RES,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033	University of Southern California; University of Southern California	HODIS, HN (corresponding author), UNIV SO CALIF,SCH MED,DEPT MED,DIV CARDIOL,ATHEROSCLEROSIS RES UNIT,2250 ALCAZAR ST,CSC 132,LOS ANGELES,CA 90033, USA.				NHLBI NIH HHS [R01-HL-45005, R01-HL-49885] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049885, R01HL045005] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; BLANKENHORN DH, 1992, CIRCULATION, V86, P1701, DOI 10.1161/01.CIR.86.6.1701; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1990, JAMA-J AM MED ASSOC, V263, P1646, DOI 10.1001/jama.263.12.1646; BLANKENHORN DH, 1987, CONTROL CLIN TRIALS, V8, P354, DOI 10.1016/0197-2456(87)90156-5; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; CARPENTER KLH, 1993, BIOCHIM BIOPHYS ACTA, V1167, P121, DOI 10.1016/0005-2760(93)90151-X; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CASHINHEMPHILL L, 1993, CIRCULATION, V88, P363; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S; HODIS HN, 1992, ATHEROSCLEROSIS, V96, P125, DOI 10.1016/0021-9150(92)90059-P; JANERO DR, 1991, FREE RADICAL BIO MED, V11, P129, DOI 10.1016/0891-5849(91)90193-7; JIALAL I, 1992, J LIPID RES, V33, P899; JOHNSON RL, 1983, J AM DIET ASSOC, V83, P667; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; MCDOWELL MA, 1994, ADV DATA VITAL HLTH, V255; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; PARTHASARATHY S, 1986, J CLIN INVEST, V77, P641, DOI 10.1172/JCI112349; PRINCEN HMG, 1995, ARTERIOSCL THROM VAS, V15, P325, DOI 10.1161/01.ATV.15.3.325; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P601, DOI 10.1161/01.ATV.13.4.601; RENGSTROM J, 1992, LANCET, V339, P1183; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SELZER RH, 1989, J CLIN INVEST, V83, P520, DOI 10.1172/JCI113913; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WILLIAMS RJ, 1992, ATHEROSCLEROSIS, V94, P153, DOI 10.1016/0021-9150(92)90240-H; 1993, JAMA-J AM MED ASSOC, V269, P3015	33	271	276	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1849	1854		10.1001/jama.273.23.1849	http://dx.doi.org/10.1001/jama.273.23.1849			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776501				2022-12-28	WOS:A1995RD11600027
J	MALGAROLI, A; TING, AE; WENDLAND, B; BERGAMASCHI, A; VILLA, A; TSIEN, RW; SCHELLER, RH				MALGAROLI, A; TING, AE; WENDLAND, B; BERGAMASCHI, A; VILLA, A; TSIEN, RW; SCHELLER, RH			PRESYNAPTIC COMPONENT OF LONG-TERM POTENTIATION VISUALIZED AT INDIVIDUAL HIPPOCAMPAL SYNAPSES	SCIENCE			English	Article							FROG NEUROMUSCULAR-JUNCTION; MINIATURE SYNAPTIC CURRENTS; RELEASE; ENHANCEMENT; PROBABILITY; INDUCTION; TRANSMISSION; MECHANISM; FREQUENCY; NEURONS	Long-term potentiation has previously been studied with electrophysiological techniques that do not readily separate presynaptic and postsynaptic contributions. Changes in exocytotic-endocytotic cycling have now been monitored at synapses between cultured rat hippocampal neurons by measuring the differential uptake of antibodies that recognize the intraluminal domain of the synaptic vesicle protein synaptotagmin. Vesicular cycling increased markedly during glutamate-induced long-term potentiation. The degree of potentiation was heterogeneous, appearing greater at synapses at which the initial extent of vesicular turnover was low. Thus, changes in presynaptic activity were visualized directly and the spatial distribution of potentiation could be determined at the level of single synaptic boutons.	STANFORD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; UNIV MILAN,DIPARTIMENTO FARMACOL,I-20132 MILAN,ITALY	Howard Hughes Medical Institute; Stanford University; University of Milan	MALGAROLI, A (corresponding author), SCI INST SAN RAFFAELE,DIBIT,I-20132 MILAN,ITALY.		Bergamaschi, Andrea/AAN-3705-2020; Malgaroli, Antonio/I-5090-2013; Villa, Antonello/B-4781-2012	Malgaroli, Antonio/0000-0003-3758-7477; Ting, Anthony/0000-0002-5058-9576	Telethon [D.016] Funding Source: Medline	Telethon(Fondazione Telethon)		BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; CORMIER RJ, 1993, NEURON, V10, P907, DOI 10.1016/0896-6273(93)90206-7; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; EDWARDS F, 1991, NATURE, V350, P271, DOI 10.1038/350271a0; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; Foster T C, 1991, Hippocampus, V1, P79, DOI 10.1002/hipo.450010108; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LEVTOV A, 1980, J PHYSIOL-LONDON, V309, P247, DOI 10.1113/jphysiol.1980.sp013507; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LYNCH MA, 1986, BRAIN RES, V369, P405, DOI 10.1016/0006-8993(86)90561-5; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; Matteoli M, 1991, Curr Opin Neurobiol, V1, P91, DOI 10.1016/0959-4388(91)90015-Y; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MELDOLESI J, 1988, CURR TOP MEMBR TRANS, V32, P139; MURPHY TH, 1994, SCIENCE, V263, P529, DOI 10.1126/science.7904774; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; YANG XD, 1991, P NATL ACAD SCI USA, V88, P4299, DOI 10.1073/pnas.88.10.4299; ZHENG W, 1991, MOL PHARMACOL, V40, P734	37	148	148	0	11	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 16	1995	268	5217					1624	1628		10.1126/science.7777862	http://dx.doi.org/10.1126/science.7777862			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777862				2022-12-28	WOS:A1995RD45900040
J	SIMPSON, L; THIEMANN, OH				SIMPSON, L; THIEMANN, OH			SENSE FROM NONSENSE - RNA EDITING IN MITOCHONDRIA OF KINETOPLASTID PROTOZOA AND SLIME-MOLDS	CELL			English	Review							MESSENGER-RNA; MINICIRCLES; EVOLUTION		UNIV CALIF LOS ANGELES,DEPT MED MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	SIMPSON, L (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024, USA.		Thiemann, Otavio H/D-9767-2012					BENNE R, 1994, EUR J BIOCHEM, V221, P9, DOI 10.1111/j.1432-1033.1994.tb18710.x; BYRNE E, 1995, IN PRESS MOL BIOCH P; CORELL RA, 1993, NUCLEIC ACIDS RES, V21, P4313, DOI 10.1093/nar/21.18.4313; COVELLO PS, 1993, TRENDS GENET, V9, P265, DOI 10.1016/0168-9525(93)90011-6; FERGUSON ML, 1994, J CELL BIOL, V126, P631, DOI 10.1083/jcb.126.3.631; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; FRECH GC, 1995, EMBO J, V14, P178, DOI 10.1002/j.1460-2075.1995.tb06988.x; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; GOTT JM, 1993, J BIOL CHEM, V268, P25483; KOLLER J, 1994, NUCLEIC ACIDS RES, V22, P1988, DOI 10.1093/nar/22.11.1988; LANDWEBER LF, 1994, P NATL ACAD SCI USA, V91, P918, DOI 10.1073/pnas.91.3.918; LEEGWATER P, 1995, EUR J BIOCHEM, V227, P780, DOI 10.1111/j.1432-1033.1995.tb20201.x; LUKES J, 1994, EMBO J, V13, P5086, DOI 10.1002/j.1460-2075.1994.tb06838.x; MAHENDRAN R, 1994, EMBO J, V13, P232, DOI 10.1002/j.1460-2075.1994.tb06253.x; MASLOV DA, 1994, MOL CELL BIOL, V14, P8174, DOI 10.1128/MCB.14.12.8174; Miller Dennis, 1993, Seminars in Cell Biology, V4, P261, DOI 10.1006/scel.1993.1031; MISSEL A, 1994, NUCLEIC ACIDS RES, V22, P4050, DOI 10.1093/nar/22.20.4050; PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; PILLER KJ, 1995, IN PRESS MOL CELL BI; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; RUSCHE L, 1995, IN PRESS MOL CELL BI; SABATINI R, 1995, J BIOL CHEM, V270, P1; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; Simpson L, 1993, RNA EDITING ALTERATI, P53; STUART K, 1993, RNA EDITING ALTERATI, P25; THIEMANN OH, 1994, EMBO J, V13, P5689, DOI 10.1002/j.1460-2075.1994.tb06907.x	28	68	70	0	5	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					837	840		10.1016/0092-8674(95)90003-9	http://dx.doi.org/10.1016/0092-8674(95)90003-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781060	Bronze			2022-12-28	WOS:A1995RD76800004
J	KIMURA, Y; YAHARA, I; LINDQUIST, S				KIMURA, Y; YAHARA, I; LINDQUIST, S			ROLE OF THE PROTEIN CHAPERONE YDJ1 IN ESTABLISHING HSP90-MEDIATED SIGNAL-TRANSDUCTION PATHWAYS	SCIENCE			English	Article							HEAT-SHOCK PROTEIN; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; YEAST HOMOLOG; HSP90; KINASE; TEMPERATURES; COMPLEXES; BINDING; GROWTH	The substrate-specific protein chaperone Hsp90 (heat shock protein 90) from Saccharomyces cerevisiae functions in diverse signal transduction pathways. A mutation in YDJ1, a member of the DnaJ chaperone family, was recovered in a synthetic-lethal screen with Hsp90 mutants. in an otherwise wild-type background, the ydj1 mutation exerted strong and specific effects an three Hsp90 substrates, derepressing two (the estrogen and glucocorticoid receptors) and reducing the function of the third (the tyrosine kinase p60(v-src)). Analysis of one of these substrates, the glucocorticoid receptor, indicated that Ydj1 exerts its effects through physical interaction with Hsp90 substrates.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637; TOKYO METROPOLITAN INST MED SCI,TOKYO 113,JAPAN	University of Chicago; Howard Hughes Medical Institute; University of Chicago; Tokyo Metropolitan Institute of Medical Science			Kimura, Yoko/E-6845-2013	Kimura, Yoko/0000-0002-3054-9753				ATENCIO DP, 1992, MOL CELL BIOL, V12, P283, DOI 10.1128/MCB.12.1.283; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BOHEN SP, UNPUB; Bohen SP., 1994, BIOL HEAT SHOCK PROT, V26, P313; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRISCO PRG, 1990, J BIOL CHEM, V265, P11667; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CAPLAN A, COMMUNICATION; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CHANG H, UNPUB; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; CRAIG EA, 1985, MOL CELL BIOL, V5, P3517, DOI 10.1128/MCB.5.12.3517; CUTTFORTH T, 1994, CELL, V77, P1027; DOYLE HJ, 1993, GENE DEV, V7, P633, DOI 10.1101/gad.7.4.633; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1994, J BIOL CHEM, V263, P24989; KIMURA Y, 1994, MOL GEN GENET, V242, P517, DOI 10.1007/BF00285275; KIMURA Y, UNPUB; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; NATHAN DF, UNPUB; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SANCHEZ Y, 1993, J BACTERIOL, V175, P6484, DOI 10.1128/jb.175.20.6484-6491.1993; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	34	218	226	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1362	1365		10.1126/science.7761857	http://dx.doi.org/10.1126/science.7761857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761857				2022-12-28	WOS:A1995RB19800042
J	SCHNITZLER, GR; BRISCOE, C; BROWN, JM; FIRTEL, RA				SCHNITZLER, GR; BRISCOE, C; BROWN, JM; FIRTEL, RA			SERPENTINE CAMP RECEPTORS MAY ACT THROUGH A G-PROTEIN-INDEPENDENT PATHWAY TO INDUCE POSTAGGREGATIVE DEVELOPMENT IN DICTYOSTELIUM	CELL			English	Article							MOLECULAR-GENETIC-ANALYSIS; CYCLIC-AMP; SIGNAL-TRANSDUCTION; MULTICELLULAR DEVELOPMENT; CELL-DIFFERENTIATION; KINASE ACTIVATION; PRESTALK GENE; EXPRESSION; DISCOIDEUM; SUBUNITS	The transcription factor G box-binding factor (GBF) is required for the developmental switch between aggregative and postaggregative gene expression, cell-type differentiation, and morphogenesis. We show that constitutive expression of GBF allows ectopic expression of postaggregative genes, but only in response to exogenous cAMP. GBF activation requires the serpentine cAMP receptors required for aggregation, but not the coupled G alpha 2 or the GP subunit, suggesting a novel signaling pathway. in response to high cAMP, g alpha 2-null cells can bypass the aggregation stage, expressing cell type-specific genes and forming fruiting bodies. Our results demonstrate that the same receptors regulate aggregation and cell-type differentiation, but via distinct pathways depending upon whether the receptor perceives a pulsatile or sustained signal.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego								ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; BERKS M, 1990, DEVELOPMENT, V110, P977; BLUMBERG DD, 1988, DEV GENET, V9, P359, DOI 10.1002/dvg.1020090417; BLUMBERG DD, 1989, DIFFERENTIATION, V41, P14, DOI 10.1111/j.1432-0436.1989.tb00727.x; CARREL F, 1994, MOL BIOL CELL, V5, P7, DOI 10.1091/mbc.5.1.7; CECCARELLI A, 1992, DEV BIOL, V152, P188, DOI 10.1016/0012-1606(92)90169-H; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CUBITT AB, 1992, COLD SPRING HARB SYM, V57, P177, DOI 10.1101/SQB.1992.057.01.023; DATTA S, 1988, GENE DEV, V2, P294, DOI 10.1101/gad.2.3.294; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; DHARMAWARDHANE S, 1994, DEVELOPMENT, V120, P3549; DYNES JL, 1994, GENE DEV, V8, P948, DOI 10.1101/gad.8.8.948; FOSNAUGH KL, 1993, DEV BIOL, V157, P38, DOI 10.1006/dbio.1993.1110; GOMER RH, 1985, COLD SPRING HARB SYM, V50, P801, DOI 10.1101/SQB.1985.050.01.098; HABERSTROH L, 1990, GENE DEV, V4, P596, DOI 10.1101/gad.4.4.596; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HADWIGER JA, 1994, P NATL ACAD SCI USA, V91, P10566, DOI 10.1073/pnas.91.22.10566; HARIBABU B, 1986, MOL CELL BIOL, V6, P2402, DOI 10.1128/MCB.6.7.2402; HJORTH AL, 1989, GENE DEV, V3, P747, DOI 10.1101/gad.3.6.747; HJORTH AL, 1990, GENE DEV, V4, P419, DOI 10.1101/gad.4.3.419; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; JERMYN KA, 1987, DEVELOPMENT, V100, P745; JOHNSON RL, 1992, J BIOL CHEM, V267, P4600; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; Kay Robert R., 1992, Current Opinion in Cell Biology, V4, P934, DOI 10.1016/0955-0674(92)90121-R; KESBEKE F, 1988, J CELL BIOL, V107, P521, DOI 10.1083/jcb.107.2.521; KUBOHARA Y, 1994, FASEB J, V11, P869; KUMAGAI A, 1989, CELL, V57, P265, DOI 10.1016/0092-8674(89)90964-1; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; KUMAGAI A, 1988, COLD SPRING HARB SYM, V2, P675; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1994, J BIOL CHEM, V259, P14123; MANN SKO, 1987, MOL CELL BIOL, V7, P458, DOI 10.1128/MCB.7.1.458; MANN SKO, 1989, P NATL ACAD SCI USA, V86, P1924, DOI 10.1073/pnas.86.6.1924; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MEHDY MC, 1983, CELL, V32, P763, DOI 10.1016/0092-8674(83)90062-4; MILNE JLS, 1995, IN PRESS J BIOL CHEM; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; OYAMA M, 1986, P NATL ACAD SCI USA, V83, P4819, DOI 10.1073/pnas.83.13.4819; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PEARS CJ, 1988, NUCLEIC ACIDS RES, V16, P8467, DOI 10.1093/nar/16.17.8467; PEARS CJ, 1987, EMBO J, V6, P195, DOI 10.1002/j.1460-2075.1987.tb04738.x; POWELLCOFFMAN JA, 1994, MOL CELL BIOL, V14, P5840, DOI 10.1128/MCB.14.9.5840; SARAN S, 1994, FEBS LETT, V337, P43, DOI 10.1016/0014-5793(94)80626-8; SCHAAP P, 1986, DEV BIOL, V118, P52, DOI 10.1016/0012-1606(86)90072-2; SCHAAP P, 1985, EXP CELL RES, V159, P388, DOI 10.1016/S0014-4827(85)80012-4; SCHLATTERER C, 1992, EUR J CELL BIOL, V58, P172; SCHNITZLER GR, 1994, GENE DEV, V8, P502, DOI 10.1101/gad.8.4.502; SEGALL J, 1995, IN PRESS J CELL BIOL; SOEDE RDM, 1994, DEVELOPMENT, V120, P1997; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TOWN C, 1978, DEV BIOL, V63, P412, DOI 10.1016/0012-1606(78)90145-8; Williams JG, 1991, CURR OPIN GENET DEV, V1, P358, DOI 10.1016/S0959-437X(05)80300-4; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WU L, 1994, HDB EXPT PHARM, V108, P335; WU LJ, 1991, BIOCHEM BIOPH RES CO, V179, P1141, DOI 10.1016/0006-291X(91)91690-E; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691; WU LJ, 1995, IN PRESS J CELL BIOL	59	55	56	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					737	745		10.1016/0092-8674(95)90535-9	http://dx.doi.org/10.1016/0092-8674(95)90535-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774015	Bronze			2022-12-28	WOS:A1995RB96100012
J	MEHARG, AA; OSBORN, D				MEHARG, AA; OSBORN, D			DIOXINS RELEASED FROM CHEMICAL ACCIDENTS	NATURE			English	Editorial Material							POLYCHLORINATED DIBENZOFURANS; CHLORINATED DIOXINS; COMBUSTION; FURANS				MEHARG, AA (corresponding author), INST TERR ECOL,HUNTINGDON PE17 2LS,CAMBS,ENGLAND.		Meharg, Andrew Alexander/F-8182-2014	Meharg, Andrew Alexander/0000-0003-2019-0449				BERTAZZI PA, 1991, SCI TOTAL ENVIRON, V106, P5, DOI 10.1016/0048-9697(91)90016-8; BUSER HR, 1985, ENVIRON HEALTH PERSP, V60, P259, DOI 10.2307/3429969; CATTABENI F, 1985, NATO C SERIES 1, V11; CHANG R, 1989, CHEMOSPHERE, V19, P481, DOI 10.1016/0045-6535(89)90355-X; CHRISTMANN W, 1990, CHEMOSPHERE, V19, P387; DAO MJ, 1992, J HAZARD MATER, V9, P61; FERNANDEZSALGUE.P, 1995, SCIENCE NEW YORK N Y, V0268; FUNCKE W, 1988, STAUB REINHALT LUFT, V48, P393; HARRAD SJ, 1992, SCI TOTAL ENVIRON, V126, P89, DOI 10.1016/0048-9697(92)90486-C; Hay Alastair, 1982, CHEM SCYTHE LESSONS; HORVATH A, 1995, ENVIRON SCI TECHNOL, V29, pA86, DOI 10.1021/es00002a003; HUTZINGER O, 1985, ENVIRON HEALTH PERSP, V60, P3, DOI 10.2307/3429939; JACOBUS EM, 1993, ENV TOXIC CHEM, V12, P1549; KOESTER CJ, 1992, ENVIRON SCI TECHNOL, V26, P1375, DOI 10.1021/es00031a015; MEHARG AA, 1994, TOXICOL ECOTOXICOL N, V1, P117; NARANG AS, 1991, CHEMOSPHERE, V22, P1029, DOI 10.1016/0045-6535(91)90304-V; PHANEUF D, 1995, ARCH ENVIRON CON TOX, V28, P145, DOI 10.1007/BF00217609; RAPPE C, 1991, BANBURY REPORT, V35; THEISEN J, 1989, CHEMOSPHERE, V19, P423, DOI 10.1016/0045-6535(89)90346-9; 1989, WHO INT PROGRAMME CH, V88; 1994, ACCIDENTS DO HAPPEN; 1995, ENVIRON SCI TECHNOL, V29, pA24	22	64	65	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					353	354		10.1038/375353a0	http://dx.doi.org/10.1038/375353a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760923				2022-12-28	WOS:A1995RB10100022
J	FEDER, HM; HUNT, MS				FEDER, HM; HUNT, MS			PITFALLS IN THE DIAGNOSIS AND TREATMENT OF LYME-DISEASE IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							ERYTHEMA MIGRANS; SEROLOGIC TESTS; REFERRAL CENTER; BORRELIOSIS; DOXYCYCLINE	Objective.-To define pitfalls of diagnosis and treatment of Lyme disease in children. Design.-Case series. Setting.-A university Lyme disease clinic in a Lyme disease endemic area. Patients. A total of 146 pediatric patients (mean age, 9.9 years) referred with possible Lyme disease. Main Outcome Measures.-Of the 146 patients, 56 (38%) were overdiagnosed, 12 (8%) were underdiagnosed, and 75 (51%) were correctly diagnosed with Lyme disease. Treatment errors were made for 19 (25%) of these 75 patients. In addition, three patients (2%) with tick bites were misdiagnosed or mistreated. Frequent pitfalls included misidentifying rashes as erythema migrans, ascribing nonspecific symptoms to Lyme disease, failing to ascribe fleeting objective symptoms to Lyme disease, and inappropriate antibiotic therapy for patients with Lyme disease. Conclusions.-Errors in the diagnosis and treatment of Lyme disease in children are common.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT	University of Connecticut	FEDER, HM (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT FAMILY MED,MC 3960,FARMINGTON,CT 06030, USA.							BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BURDGE DR, 1993, CLIN INFECT DIS, V16, P558, DOI 10.1093/clind/16.4.558; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; FEDER HM, 1993, PEDIATRICS, V91, P456; FEDER HM, 1992, CLIN INFECT DIS, V15, P788, DOI 10.1093/clind/15.5.788; FEDER HM, 1995, J INFECT DIS, V171, P1371, DOI 10.1093/infdis/171.5.1371; FISTER RD, 1984, J CLIN MICROBIOL, V27, P2834; HALPERIN JJ, 1992, NEUROLOGY, V42, P1268, DOI 10.1212/WNL.42.7.1268; Krause P J, 1994, Adv Pediatr Infect Dis, V9, P183; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; MALANE MS, 1991, ANN INTERN MED, V114, P490, DOI 10.7326/0003-4819-114-6-490; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; 1993, MMWR-MORBID MORTAL W, V42, P345	20	26	26	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					66	68		10.1001/jama.274.1.66	http://dx.doi.org/10.1001/jama.274.1.66			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791260				2022-12-28	WOS:A1995RG23300032
J	OCONNOR, N				OCONNOR, N			NEW CLASSIFICATION FOR LYMPHOMAS	LANCET			English	Editorial Material											OCONNOR, N (corresponding author), ROYAL SHREWSBURY HOSP NHS TRUST,SHREWSBURY,SALOP,ENGLAND.							[Anonymous], 1982, CANCER, V49, P2112; [Anonymous], 1975, BRIT J HAEMATOL, DOI DOI 10.1111/J.1365-2141.1975.TB00911.X; CHAN JKC, 1994, HISTOPATHOLOGY, V25, P517, DOI 10.1111/j.1365-2559.1994.tb01371.x; CHAN JKC, IN PRESS AM J CLIN P; HARRIS NL, 1994, BLOOD, V84, P1361; KAY HEM, 1974, LANCET, V2, P586; Lennert K, 1992, HISTOPATHOLOGY NON H; MACLENNAN KA, 1989, CANCER-AM CANCER SOC, V64, P1686, DOI 10.1002/1097-0142(19891015)64:8<1686::AID-CNCR2820640822>3.0.CO;2-I; OCONNOR NTJ, 1987, J PATHOL, V151, P185, DOI 10.1002/path.1711510305; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1521	1522		10.1016/S0140-6736(95)91081-6	http://dx.doi.org/10.1016/S0140-6736(95)91081-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791434				2022-12-28	WOS:A1995RD79000003
J	OPIE, LH				OPIE, LH			GLUCOSE AND THE METABOLISM OF ISCHEMIC MYOCARDIUM	LANCET			English	Editorial Material							HEARTS				OPIE, LH (corresponding author), UNIV CAPE TOWN,SCH MED,HEART RES UNIT,CAPE TOWN,SOUTH AFRICA.							EBERLI FR, 1991, CIRC RES, V68, P466, DOI 10.1161/01.RES.68.2.466; KING LM, 1995, J MOL CELL CARDIOL, V27, P701, DOI 10.1016/S0022-2828(08)80061-2; NEELY JR, 1984, CIRC RES, V55, P816, DOI 10.1161/01.RES.55.6.816; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; OPIE L H, 1970, Journal of Molecular and Cellular Cardiology, V1, P107, DOI 10.1016/0022-2828(70)90045-3; OWEN P, 1990, CIRC RES, V66, P344, DOI 10.1161/01.RES.66.2.344; WEISS JN, 1989, J GEN PHYSIOL, V94, P911, DOI 10.1085/jgp.94.5.911	7	32	35	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1520	1521		10.1016/S0140-6736(95)91080-8	http://dx.doi.org/10.1016/S0140-6736(95)91080-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791433				2022-12-28	WOS:A1995RD79000002
J	KELLER, W				KELLER, W			NO END YET TO MESSENGER-RNA 3' PROCESSING	CELL			English	Review							BINDING DOMAIN; POLY(A) TAIL; POLYADENYLATION; SITE; CLEAVAGE; PROTEIN				KELLER, W (corresponding author), UNIV BASEL,BIOZENTRUM,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND.							BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BUTLER JS, 1990, MOL CELL BIOL, V10, P2599, DOI 10.1128/MCB.10.6.2599; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MANN KP, 1993, MOL CELL BIOL, V13, P2411, DOI 10.1128/MCB.13.4.2411; MINVIELLESEBAST.L, 1994, SCIENCE, V266, P1702; MINVIELLESEBAST.L, 1992, THESIS PARIS U 6 PAR; MINVIELLESEBAST.L, 1991, MOL CELL BIOL, V11, P3075; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; PROUDFOOT NJ, 1991, CELL, V64, P617; RAABE T, 1994, MOL CELL BIOL, V14, P2946, DOI 10.1128/MCB.14.5.2946; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; RUSSNAK R, 1995, MOL CELL BIOL, V15, P1689; SACHS A, 1993, J BIOL CHEM, V268, P22955; SALLES FJ, 1994, SCIENCE, V266, P1996, DOI 10.1126/science.7801127; SHEETS MD, 1995, NATURE, V374, P511, DOI 10.1038/374511a0; TAKAGAKI Y, 1992, P NATL ACAD SCI USA, V89, P1403, DOI 10.1073/pnas.89.4.1403; TAKAGAKI Y, 1992, J BIOL CHEM, V267, P23471; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419	29	147	149	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					829	832		10.1016/0092-8674(95)90001-2	http://dx.doi.org/10.1016/0092-8674(95)90001-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781059	Bronze			2022-12-28	WOS:A1995RD76800002
J	PUI, CH				PUI, CH			CHILDHOOD LEUKEMIAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; PEDIATRIC-ONCOLOGY-GROUP; BONE-MARROW TRANSPLANTATION; ACUTE PROMYELOCYTIC LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; POLYMERASE CHAIN-REACTION; MINIMAL RESIDUAL DISEASE; UNFAVORABLE PRESENTING FEATURES		ST JUDE CHILDRENS RES HOSP, DEPT PATHOL & LAB MED, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, COLL MED, MEMPHIS, TN USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	PUI, CH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.		Pui, Ching-Hon/N-8076-2018	Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-21765, P01 CA-20180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMADORI S, 1993, J CLIN ONCOL, V11, P1046, DOI 10.1200/JCO.1993.11.6.1046; ARCECI RJ, 1993, BLOOD, V81, P2215; BARRETT AJ, 1994, NEW ENGL J MED, V331, P1253, DOI 10.1056/NEJM199411103311902; BASH RO, 1993, BLOOD, V81, P2110; BEATTY PG, 1993, BLOOD, V81, P249; BEHRENDT H, 1995, LEUKEMIA, V9, P102; BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; BIONDI A, 1994, LEUKEMIA, V8, P1264; BLATT J, 1993, PEDIATR HEMAT ONCOL, V10, P3, DOI 10.3109/08880019309016521; BLOOMFIELD CD, 1992, LEUKEMIA, V6, P65; BOEKHORST PAWT, 1993, LEUKEMIA, V7, P1191; BOROWITZ MJ, 1991, NEW ENGL J MED, V325, P1379; BOSANQUET AG, 1991, LANCET, V337, P711, DOI 10.1016/0140-6736(91)90287-Y; Brenner M K, 1991, Baillieres Clin Haematol, V4, P727; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; BUNIN NJ, 1992, BONE MARROW TRANSPL, V9, P119; CAMITTA B, 1994, J CLIN ONCOL, V12, P1383, DOI 10.1200/JCO.1994.12.7.1383; CAMPANA D, 1993, BLOOD, V82, pA49; CAMPANA D, 1991, BLOOD, V77, P1546; CAMPANA D, 1993, LEUKEMIA, V7, P482; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CAVE H, 1994, BLOOD, V83, P1892; CEREZO L, 1991, AM J CLIN PATHOL, V95, P526, DOI 10.1093/ajcp/95.4.526; CHEN CS, 1993, BLOOD, V81, P2386; CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; CLIFT RA, 1992, J CLIN ONCOL, V10, P1723, DOI 10.1200/JCO.1992.10.11.1723; CLINE MJ, 1994, NEW ENGL J MED, V330, P328; CREUTZIG U, 1990, BLOOD, V75, P1932; CREUTZIG U, 1993, J CLIN ONCOL, V11, P279, DOI 10.1200/JCO.1993.11.2.279; CRIST WM, 1990, BLOOD, V76, P117; DEDERA, 1993, CELL, V75, P826; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DOW LW, 1991, CANCER-AM CANCER SOC, V68, P1678, DOI 10.1002/1097-0142(19911015)68:8<1678::AID-CNCR2820680803>3.0.CO;2-J; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EMA H, 1990, BLOOD, V75, P350; EMANUEL PD, 1991, BLOOD, V77, P925; ERICKSON P, 1992, BLOOD, V80, P1825; EVANS WE, 1991, SEMIN HEMATOL, V28, P15; FENAUX P, 1993, BLOOD, V82, P3241; FINK FM, 1993, MED PEDIATR ONCOL, V21, P340, DOI 10.1002/mpo.2950210506; FLETCHER JA, 1992, LEUKEMIA LYMPHOMA, V8, P75, DOI 10.3109/10428199209049820; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; GAMIS AS, 1993, J CLIN ONCOL, V11, P834, DOI 10.1200/JCO.1993.11.5.834; GAYNON PS, 1993, J CLIN ONCOL, V11, P2234, DOI 10.1200/JCO.1993.11.11.2234; GAYNON PS, 1990, MED PEDIATR ONCOL, V18, P273, DOI 10.1002/mpo.2950180403; GIRALT S, 1993, NEW ENGL J MED, V329, P757, DOI 10.1056/NEJM199309093291103; GREAVES M, 1993, BLOOD, V82, P1043; GREEN DM, 1991, NEW ENGL J MED, V325, P141, DOI 10.1056/NEJM199107183250301; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAUPT R, 1994, JAMA-J AM MED ASSOC, V272, P1427, DOI 10.1001/jama.272.18.1427; HAWKINS MM, 1994, BRIT MED J, V309, P1034, DOI 10.1136/bmj.309.6961.1034; HEEREMA NA, 1994, BLOOD, V83, P2274, DOI 10.1182/blood.V83.8.2274.bloodjournal8382274; HSIAO MH, 1994, BLOOD, V83, P2922, DOI 10.1182/blood.V83.10.2922.2922; ITO Y, 1993, J CLIN ONCOL, V11, P546, DOI 10.1200/JCO.1993.11.3.546; JONES B, 1991, MED PEDIATR ONCOL, V19, P269, DOI 10.1002/mpo.2950190411; KALWINSKY DK, 1990, J CLIN ONCOL, V8, P75, DOI 10.1200/JCO.1990.8.1.75; KARP JE, 1994, J NATL CANCER I, V86, P1196, DOI 10.1093/jnci/86.16.1196; KATZ JA, 1993, J PEDIATR-US, V123, P546, DOI 10.1016/S0022-3476(05)80948-5; KIRKLAND MA, 1994, BRIT J HAEMATOL, V87, P447, DOI 10.1111/j.1365-2141.1994.tb08296.x; KITA K, 1992, BLOOD, V80, P470; KOEHLER M, 1993, LEUKEMIA, V7, P2064; KOJIMA S, 1990, BLOOD, V76, P2348; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUERBITZ SJ, 1992, J CLIN ONCOL, V10, P1419, DOI 10.1200/JCO.1992.10.9.1419; LEBEAU MM, 1993, BLOOD, V81, P1979; LION T, 1993, LANCET, V341, P275, DOI 10.1016/0140-6736(93)92619-5; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; LOWENBERG B, 1993, NEW ENGL J MED, V328, P614, DOI 10.1056/NEJM199303043280904; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUM BL, 1992, J CLIN ONCOL, V10, P1635, DOI 10.1200/JCO.1992.10.10.1635; MAHMOUD H, 1993, P AN M AM SOC CLIN, V12, P316; MAHMOUD HH, 1993, NEW ENGL J MED, V329, P314, DOI 10.1056/NEJM199307293290504; MAHMOUD HH, 1993, LANCET, V342, P1394, DOI 10.1016/0140-6736(93)92755-I; MANABE A, 1994, BLOOD, V83, P1731, DOI 10.1182/blood.V83.7.1731.bloodjournal8371731; MANABE A, 1992, BLOOD, V79, P2370; MANABE A, 1993, LEUKEMIA, V7, P1990; MARIN T, 1992, AM J PEDIAT HEMATOL, V14, P229; MARTINEZCLIMENT JA, 1995, LEUKEMIA, V9, P95; MILLER DR, 1989, J CLIN ONCOL, V7, P1807, DOI 10.1200/JCO.1989.7.12.1807; MILLER WH, 1993, BLOOD, V82, P1689; MIRRO J, 1993, LEUKEMIA, V7, P1026; MIYAMURA K, 1993, BLOOD, V81, P1089; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; NESBIT ME, 1994, J CLIN ONCOL, V12, P127, DOI 10.1200/JCO.1994.12.1.127; NIZET Y, 1993, BLOOD, V82, P1618; NUCIFORA G, 1993, BLOOD, V82, P712; OCHS J, 1991, J CLIN ONCOL, V9, P145, DOI 10.1200/JCO.1991.9.1.145; PATTE C, 1993, P AN M AM SOC CLIN, V12, P317; PETERSEN FB, 1993, J CLIN ONCOL, V11, P1353, DOI 10.1200/JCO.1993.11.7.1353; PIETERS R, 1991, LANCET, V338, P399, DOI 10.1016/0140-6736(91)91029-T; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204; POTTER MN, 1993, LEUKEMIA, V7, P1302; POTTER MN, 1993, BRIT J HAEMATOL, V83, P412, DOI 10.1111/j.1365-2141.1993.tb04665.x; PUI CH, 1993, J CLIN ONCOL, V11, P1361, DOI 10.1200/JCO.1993.11.7.1361; PUI CH, 1990, BLOOD, V75, P174, DOI 10.1182/blood.V75.1.174.174; PUI CH, 1993, BLOOD, V82, P343; PUI CH, 1991, BLOOD, V78, P1327, DOI 10.1182/blood.V78.5.1327.1327; PUI CH, 1994, J CLIN ONCOL, V12, P909, DOI 10.1200/JCO.1994.12.5.909; PUI CH, 1994, J CLIN ONCOL, V12, P2601, DOI 10.1200/JCO.1994.12.12.2601; PUI CH, 1990, BLOOD, V75, P198; PUI CH, 1991, NEW ENGL J MED, V325, P1378; PUI CH, 1990, BLOOD, V75, P1170; PUI CH, 1990, BLOOD, V76, P1449; PUI CH, 1994, J PEDIATR-US, V124, P491, DOI 10.1016/S0022-3476(05)83125-7; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PULLEN J, 1993, J CLIN ONCOL, V11, P839, DOI 10.1200/JCO.1993.11.5.839; QUESNEL B, 1995, BLOOD, V85, P657, DOI 10.1182/blood.V85.3.657.bloodjournal853657; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1990, J CLIN ONCOL, V8, P1380, DOI 10.1200/JCO.1990.8.8.1380; RAVINDRANATH Y, 1991, J CLIN ONCOL, V9, P572, DOI 10.1200/JCO.1991.9.4.572; RAVINDRANATH Y, 1992, BLOOD, V80, P2210; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; REITER A, 1992, BLOOD, V80, P2471; RIBEIRO RC, 1993, HEMATOL PATHOL, V7, P121; RIBEIRO RC, 1993, LEUKEMIA LYMPHOMA, V10, P299, DOI 10.3109/10428199309148552; RIES LAG, 1991, NIH912789 PUBL; RITTER J, 1990, J CANCER RES CLIN, V116, P100, DOI 10.1007/BF01612648; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; SANDERS JE, 1991, BONE MARROW TRANSPL, V8, P2; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHELL MJ, 1992, J CLIN ONCOL, V10, P128, DOI 10.1200/JCO.1992.10.1.128; SCHIRO R, 1994, BLOOD, V83, P460; SCHORIN MA, 1994, J CLIN ONCOL, V12, P740, DOI 10.1200/JCO.1994.12.4.740; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SKLAR C, 1993, J PEDIATR-US, V123, P59, DOI 10.1016/S0022-3476(05)81537-9; SMITH FO, 1992, BLOOD, V79, P2415; SMITH M, 1994, MORE UNIFORM APPROAC, P124; SNYDER DS, 1990, HEMATOL ONCOL CLIN N, V4, P535, DOI 10.1016/S0889-8588(18)30477-5; SOEKARMAN D, 1992, BLOOD, V79, P2990; STEINHERZ PG, 1993, CANCER, V72, P3120; STEUBER CP, 1991, J CLIN ONCOL, V9, P247, DOI 10.1200/JCO.1991.9.2.247; STEWARD CG, 1994, BLOOD, V83, P1355; SURYANARAYAN K, 1991, BLOOD, V77, P324; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; TALLMAN MS, 1993, J CLIN ONCOL, V11, P690, DOI 10.1200/JCO.1993.11.4.690; TARBELL NJ, 1992, BLOOD S, V80, pA207; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; TRUEWORTHY R, 1992, J CLIN ONCOL, V10, P606, DOI 10.1200/JCO.1992.10.4.606; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P520, DOI 10.1200/JCO.1993.11.3.520; TURA S, 1994, NEW ENGL J MED, V330, P820; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1992, BLOOD, V79, P2201; UCKUN FM, 1993, NEW ENGL J MED, V329, P1296, DOI 10.1056/NEJM199310283291802; VANDENBERGHE H, 1988, BRIT J HAEMATOL, V68, P487, DOI 10.1111/j.1365-2141.1988.tb04242.x; WABER DP, 1992, J CLIN ONCOL, V10, P810, DOI 10.1200/JCO.1992.10.5.810; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WELLS RJ, 1994, J CLIN ONCOL, V12, P2367, DOI 10.1200/JCO.1994.12.11.2367; WHITEHEAD VM, 1992, BLOOD, V80, P1316; WIERSMA SR, 1991, NEW ENGL J MED, V324, P800, DOI 10.1056/NEJM199103213241204; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; WOLFROM C, 1993, J CLIN ONCOL, V11, P827, DOI 10.1200/JCO.1993.11.5.827; WOODS WG, 1993, J CLIN ONCOL, V11, P1448, DOI 10.1200/JCO.1993.11.8.1448; WOODS WG, 1990, CANCER, V66, P1106, DOI 10.1002/1097-0142(19900915)66:6<1106::AID-CNCR2820660605>3.0.CO;2-Y	160	405	417	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1618	1630		10.1056/NEJM199506153322407	http://dx.doi.org/10.1056/NEJM199506153322407			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753142				2022-12-28	WOS:A1995RC19200007
J	ANNEST, JL; MERCY, JA; GIBSON, DR; RYAN, GW				ANNEST, JL; MERCY, JA; GIBSON, DR; RYAN, GW			NATIONAL ESTIMATES OF NONFATAL FIREARM-RELATED INJURIES - BEYOND THE TIP OF THE ICEBERG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GUN OWNERSHIP; HOMICIDE; HOME	Objective.-To describe the magnitude and characteristics of nonfatal firearm-related injuries treated in hospital emergency departments in the United States and to compare nonfatal injury rates with firearm-related fatality rates. Design.-Data were obtained from medical records for all firearm-related injury cases identified using the National Electronic Injury Surveillance System (NEISS) from June 1, 1992, through May 31, 1993. Setting.-NEISS comprises 91 hospitals that are a stratified probability sample of all hospitals in the United States and its territories that have at least six beds and provide 24-hour emergency service. Main Outcome Measures.-Numbers and population rates for nonfatal and fatal firearm-related injuries. Results.-An estimated 99 025 (95% confidence interval [CI], 56 325 to 141 725) persons (or 38.6 per 100 000 population; 95% CI, 22.0 to 55.2) were treated for nonfatal firearm-related injuries in US hospital emergency departments during the study period. The rate of nonfatal firearm-related injuries treated was 2.6 (95% CI, 1.5 to 3.7) times the national rate of fatal firearm-related injuries for 1992. Conclusions.-Nonfatal firearm-related injuries contribute substantially to the overall public health burden of firearm-related injuries. NEISS can be useful to monitor the number of nonfatal firearm-related injuries in the United States. A national surveillance system is needed to provide uniform data on firearm-related injury morbidity and mortality for use in research and prevention efforts.			ANNEST, JL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,OFF STAT & PROGRAMMING K59,ATLANTA,GA 30341, USA.							ASKRANT AP, 1968, ACCIDENTS HOMICIDE; BRICK M, 1992, STATISTICAL EVALUATI; BURT CW, 1995, ADVANCE DATA VITAL H, V261, P1; Cook P.J., 1991, CRIME JUSTICE, V14, P1, DOI [10.1086/449183, DOI 10.1086/449183]; COOK PJ, 1985, J QUANTITATIVE CRIMI, V0001; FINGERHUT LA, 1992, JAMA-J AM MED ASSOC, V267, P3048, DOI 10.1001/jama.267.22.3048; FINGERHUT LA, 1994, ADV DATA VITAL HLTH, V242, P1; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1993, NEW ENGL J MED, V329, P1084, DOI 10.1056/NEJM199310073291506; KOCHANEK KD, 1994, MONTHLY VITAL STAT S, V43, P56; LEE RK, 1991, AM J EPIDEMIOL, V134, P511, DOI 10.1093/oxfordjournals.aje.a116123; MARKER D, 1988, CPSCC871144 US CONS; RAND MR, 1994, NCJ147003 US DEP JUS, P1; Rice DP, 1989, COST INJURY US REPOR; SALTZMAN LE, 1992, JAMA-J AM MED ASSOC, V267, P3043, DOI 10.1001/jama.267.22.3043; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; WINTEMUTE G, 1993, JAMA-J AM MED ASSOC, V269, P2213, DOI 10.1001/jama.1993.03500170043026; WRIGHT JD, 1981, WEAPONS CRIME VIOLEN, P293; ZWERLING C, 1993, AM J PREV MED, V3, P1; 1991, MMWR-MORBID MORTAL W, V43, P609; 1976, VITAL HLTH STAT 10, V105; 1964, VITAL HLTH STAT 10, V6; 1994, NATIONAL ELECTRONIC; 1994, MMWR-MORBID MORTAL W, V43, P37; 1993, NATIONAL ELECTRONIC; 1994, TIP ICEBERG WEAPON I, P5	28	227	227	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1749	1754		10.1001/jama.273.22.1749	http://dx.doi.org/10.1001/jama.273.22.1749			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB800	7769767				2022-12-28	WOS:A1995RB80000026
J	ROSAHL, TW; SPILLANE, D; MISSLER, M; HERZ, J; SELIG, DK; WOLFF, JR; HAMMER, RE; MALENKA, RC; SUDHOF, TC				ROSAHL, TW; SPILLANE, D; MISSLER, M; HERZ, J; SELIG, DK; WOLFF, JR; HAMMER, RE; MALENKA, RC; SUDHOF, TC			ESSENTIAL FUNCTIONS OF SYNAPSIN-I AND SYNAPSIN-II IN SYNAPTIC VESICLE REGULATION	NATURE			English	Article							PROTEIN; PHOSPHOPROTEINS; ASSOCIATION; PLASTICITY; ACTIN; MICE	SYNAPTIC vesicles are coated by synapsins, phosphoproteins that account for 9% of the vesicle protein(1-3). To analyse the functions of these proteins, we have studied knockout mice lacking either synapsin I, synapsin II, or both. Mice lacking synapsins are viable and fertile with no gross anatomical abnormalities, but experience seizures with a frequency proportional to the number of mutant alleles. Synapsin-II and double knockouts, but not synapsin-I knockouts, exhibit decreased post-tetanic potentiation and severe synaptic depression upon repetitive stimulation. Intrinsic synaptic-vesicle membrane proteins, but not peripheral membrane proteins or other synaptic proteins, are slightly decreased in individual knockouts and more severely reduced in double knockouts, as is the number of synaptic vesicles. Thus synapsins are not required for neurite outgrowth, synaptogenesis or the basic mechanics of synaptic vesicle traffic, but are essential for accelerating this traffic during repetitive stimulation. The phenotype of the synapsin knockouts could be explained either by deficient recruitment of synaptic vesicles to the active zone, or by impaired maturation of vesicles at the active zone, both of which could lead to a secondary destabilization of synaptic vesicles.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR NEUROBIOL & PSYCHIAT, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; GOTHENBURG UNIV, ZENTRUM ANAT, D-37075 GOTTINGEN, GERMANY	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hammer, Robert E./0000-0001-5487-7551; Missler, Markus/0000-0001-8008-984X				ADAMS JC, 1981, J HISTOCHEM CYTOCHEM, V29, P775, DOI 10.1177/29.6.7252134; [Anonymous], 1979, STEREOLOGICAL METHOD; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAINES AJ, 1985, NATURE, V315, P410, DOI 10.1038/315410a0; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; GEPPERT M, 1994, EMBO J, V13, P3720, DOI 10.1002/j.1460-2075.1994.tb06681.x; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Imaizumi K, 1959, EXP ANIM TOKYO, V8, P6; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MISSLER M, 1993, J COMP NEUROL, V333, P53, DOI 10.1002/cne.903330105; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; RUSAKOV DA, 1991, NEUROSCI LETT, V131, P156, DOI 10.1016/0304-3940(91)90602-P; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEINER JP, 1987, J BIOL CHEM, V262, P905; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; WOOLSON RF, 1987, STATISTICAL METHODS, P344; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	24	608	614	2	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 8	1995	375	6531					488	493		10.1038/375488a0	http://dx.doi.org/10.1038/375488a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777057				2022-12-28	WOS:A1995RC18800048
J	ARORA, K; DAI, H; KAZUKO, SG; JAMAL, J; OCONNOR, MB; LETSOU, A; WARRIOR, R				ARORA, K; DAI, H; KAZUKO, SG; JAMAL, J; OCONNOR, MB; LETSOU, A; WARRIOR, R			THE DROSOPHILA SCHNURRI GENE ACTS IN THE DPP/TGF-BETA SIGNALING PATHWAY AND ENCODES A TRANSCRIPTION FACTOR HOMOLOGOUS TO THE HUMAN MBP FAMILY	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ENHANCER-BINDING-PROTEIN; DORSAL-VENTRAL PATTERN; LARVAL CUTICLE; ZYGOTIC LOCI; EMBRYO; MELANOGASTER; LOCALIZATION; EXPRESSION; CHROMOSOME	Decapentaplegic (dpp), a TGF beta-related ligand, plays a key role in Drosophila development. Although dpp receptors have been isolated, the downstream components of the signaling pathway remain to be identified. We have cloned the schnurri (shn) gene and show that it encodes a putative zinc finger transcription factor homologous to the human major histocompatibility complex-binding proteins 1 and 2. Mutations in shn affect multiple events that require dpp signaling as well as the transcription of dpp-responsive genes. Genetic interactions and the strikingly similar phenotypes of mutations in shn and the dpp receptors encoded by thick veins and punt suggest that shn plays a downstream role in dpp signaling.	UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089; UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112	University of Southern California; Utah System of Higher Education; University of Utah	ARORA, K (corresponding author), UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717, USA.		O'Connor, Michael B/C-9977-2014	O'Connor, Michael B/0000-0002-3067-5506	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K04GM000599, R01GM048659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47462, GM 00599, GM48659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER M, 1994, DEVELOPMENT, V120, P3105; ARORA K, 1992, DEVELOPMENT, V114, P1003; ARORA K, 1994, GENE DEV, V8, P2588, DOI 10.1101/gad.8.21.2588; ATTISANO L, 1993, GENE DEV, V7, P1325; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; GEISER AG, 1993, P NATL ACAD SCI USA, V90, P9944, DOI 10.1073/pnas.90.21.9944; HILL CS, 1990, EMBO J, V9, P805, DOI 10.1002/j.1460-2075.1990.tb08177.x; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; LETSOU A, 1995, CELL, V80, P899, DOI 10.1016/0092-8674(95)90293-7; MAEKAWA T, 1989, J BIOL CHEM, V264, P14591; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLER J, 1985, EMBO J, V4, P2961; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NOMURA N, 1991, J BIOL CHEM, V266, P8590; NUSSLEINVOLHARD C, 1984, W ROUXS ARCH DEV BIO, V183, P267; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RAFTERY LA, 1985, GENETICS, V139, P241; RAY RP, 1991, DEVELOPMENT, V113, P35; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; SEELER JS, 1994, J VIROL, V68, P1002, DOI 10.1128/JVI.68.2.1002-1009.1994; Skaer Helen, 1993, P941; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STAEHLINGHAMPTO.K, 1994, NATURE, V372, P783; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; TERRACOL R, 1994, GENETICS, V138, P165; VANTVEER LJ, 1992, P NATL ACAD SCI USA, V89, P8971, DOI 10.1073/pnas.89.19.8971; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; YOUNG PE, 1992, GENE DEV, V7, P29	45	187	193	1	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					781	790		10.1016/0092-8674(95)90539-1	http://dx.doi.org/10.1016/0092-8674(95)90539-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774017	Bronze			2022-12-28	WOS:A1995RB96100016
J	COLLINS, K; KOBAYASHI, R; GREIDER, CW				COLLINS, K; KOBAYASHI, R; GREIDER, CW			PURIFICATION OF TETRAHYMENA TELOMERASE AND CLONING OF GENES ENCODING THE 2 PROTEIN-COMPONENTS OF THE ENZYME	CELL			English	Article							RNA; ELONGATION; SENESCENCE; SEQUENCES; ELEMENTS; MOTIFS; DNA	Telomerase is a ribonucleoprotein DNA polymerase that catalyzes the de novo synthesis of telomeric simple sequence repeats. We describe the purification of telomerase and the cloning of cDNAs encoding two protein subunits from the ciliate Tetrahymena. Two proteins of 80 and 95 kDa copurified and coimmunoprecipitated with telomerase activity and the previously identified Tetrahymena telomerase RNA. The p95 subunit specifically cross-linked to a radiolabeled telomeric DNA primer, while the p80 subunit specifically bound to radiolabeled telomerase RNA. At the primary sequence level, the two telomerase proteins share only limited homologies with other polymerases and polymerase accessory factors.			COLLINS, K (corresponding author), COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724, USA.			Greider, Carol/0000-0002-5494-8126	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043080] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43080] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1992, CURRENT PROTOCOLS MO; AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; BHATTACHARYYA A, 1994, EMBO J, V13, P5721, DOI 10.1002/j.1460-2075.1994.tb06910.x; BLACKBURN EH, 1994, CELL, V77, P621, DOI 10.1016/0092-8674(94)90046-9; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CHERRY JM, 1985, CELL, V43, P747, DOI 10.1016/0092-8674(85)90248-X; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; HARLEY CB, 1994, COLD SPRING HARB SYM, V66, P1; HARRINGTON L, 1995, J BIOL CHEM, V270, P8893, DOI 10.1074/jbc.270.15.8893; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; MAIZELS N, 1993, RNA WORLD, P577; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; MELEK M, 1994, MOL CELL BIOL, V14, P7827, DOI 10.1128/MCB.14.12.7827; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PETERSON MG, 1991, NATURE, V354, P369; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; Sambrook J, 1989, MOL CLONING LABORATO; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; TAKEMASA T, 1989, J BIOL CHEM, P19293; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	37	241	265	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					677	686		10.1016/0092-8674(95)90529-4	http://dx.doi.org/10.1016/0092-8674(95)90529-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774009	Bronze			2022-12-28	WOS:A1995RB96100006
J	HILL, A; JUGOVIC, P; YORK, I; RUSS, G; BENNINK, J; YEWDELL, J; PLOEGH, H; JOHNSON, D				HILL, A; JUGOVIC, P; YORK, I; RUSS, G; BENNINK, J; YEWDELL, J; PLOEGH, H; JOHNSON, D			HERPES-SIMPLEX VIRUS TURNS OFF THE TAP TO EVADE HOST IMMUNITY	NATURE			English	Article							PEPTIDE TRANSLOCATION; ENDOPLASMIC-RETICULUM; TRANSPORTER; CHAINS; CONSTRUCTION; EXPRESSION; MOLECULES; VARIANTS; HEAVY	MANY viruses have evolved mechanisms to avoid detection by the host immune system, Herpes simplex virus (HSV) expresses an immediate early protein, ICP47, which blocks presentation of viral peptides to MHC class I-restricted cells(1). The properties of the newly synthesized class I molecules in HSV-infected cells resemble those of cell lines deficient in the transporter associated with antigen processing (TAP) in that class I molecules are retained in the endoplasmic reticulum(1,2), and the heavy chain and beta(2)-microglubulin subunits dissociate in detergent extracts but the complex can be stabilized by peptides(1). We show here that ICP47 binds to TAP and prevents peptide translocation into the endoplasmic reticulum.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8N 325,CANADA; NIAID,VIRAL DIS LAB,BETHESDA,MD 20892	McMaster University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	HILL, A (corresponding author), MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		York, Ian/X-9351-2019; yewdell, jyewdell@nih.gov jonathan/A-1702-2012	York, Ian/0000-0002-3478-3344; 				ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; ANDROLEWICZ MJ, 1993, P NATL ACAD SCI USA, V90, P9130, DOI 10.1073/pnas.90.19.9130; BEERSMA MFC, 1993, J IMMUNOL, V151, P4455; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P3932, DOI 10.1073/pnas.89.9.3932; COUPAR BEH, 1988, GENE, V68, P1, DOI 10.1016/0378-1119(88)90593-8; COX JH, 1990, SCIENCE, V247, P715, DOI 10.1126/science.2137259; CROMME FV, 1994, J EXP MED, V170, P335; DELASALLE H, 1994, SCIENCE, V265, P237, DOI 10.1126/science.7517574; HEEMELS MT, 1994, IMMUNITY, V1, P775, DOI 10.1016/S1074-7613(94)80019-7; HEEMELS MT, 1993, SCIENCE, V262, P2059, DOI 10.1126/science.8266106; HEEMELS MT, 1995, REV BIOCH, V64, P463; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HILL AB, 1994, J IMMUNOL, V152, P3736; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MAVROMARANAZOS P, 1986, J VIROL, V60, P807, DOI 10.1128/JVI.60.2.807-812.1986; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; ROESLE J, 1994, J EXP MED, V180, P1591; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER TNM, 1994, P NATL ACAD SCI USA, V91, P13004, DOI 10.1073/pnas.91.26.13004; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; STAM NJ, 1986, J IMMUNOL, V137, P2299; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; YORK IA, 1994, CELL, V77, P525, DOI 10.1016/0092-8674(94)90215-1	29	729	744	0	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					411	415		10.1038/375411a0	http://dx.doi.org/10.1038/375411a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760935				2022-12-28	WOS:A1995RB10100055
J	KIM, JS; KIM, Y; MARTI, K; KERRIDGE, JF				KIM, JS; KIM, Y; MARTI, K; KERRIDGE, JF			NITROGEN ISOTOPE ABUNDANCES IN THE RECENT SOLAR-WIND	NATURE			English	Article								ALTHOUGH lunar crystalline rocks are essentially devoid of nitrogen, the same is not true of the lunar regolith. The nitrogen contents of individual regolith samples (which can be as high as 0.012% by mass) correlate strongly with abundances of noble gases known to be implanted in the lunar surface by solar radiation, indicating that lunar regolith nitrogen is also predominantly of solar origin(1). The large variability in N-15/N-14 ratios measured in different regolith samples may thus reflect long-term changes in tbe isotopic composition of the solar radiation(1). But attempts to explain these variations have been hampered by the lack of any firm constraint on N-15/N-14 in, the present solar wind. Here we report measurements of nitrogen isotopes from two lunar samples that have had simple (and relatively recent) exposure histories. We find that nitrogen implanted in the lunar surface during the past 10(5) to 5 x 10(7) years has a N-15/N-14 ratio approximately 40 parts per thousand higher than that in the terrestrial atmosphere, which is substantially lower than most previous estimates(2,3). This isotopic signature probably represents the best measure of N-15/N-14 in, the present-day solar wind.	UNIV CALIF SAN DIEGO,DEPT CHEM 0317,LA JOLLA,CA 92093	University of California System; University of California San Diego								ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BECKER RH, 1994, METEORITICS, V29, P724, DOI 10.1111/j.1945-5100.1994.tb00790.x; BECKER RH, 1975, 6TH P LUN SCI C, P2131; BECKER RH, 1976, 7TH P LUN SCI C, P441; BECKER RH, 1977, P LUNAR PLANET SCI C, P3685; Behrmann C., 1973, P LUNAR PLANET SCI C, P1957; Cameron A., 1982, ESSAYS NUCL ASTROPHY, P23; FRICK U, 1988, 18TH P LUN PLAN SCI, P87; GEISS J, 1982, GEOCHIM COSMOCHIM AC, V46, P529, DOI 10.1016/0016-7037(82)90156-9; Geiss J., 1991, SUN TIME, P98; HEYMANN D, 1975, MOON PLANETS, V13, P81, DOI 10.1007/BF00567509; KERIDGE JF, 1980, ANCIENT SUN, P475; KERRIDGE JF, 1993, REV GEOPHYS, V31, P423, DOI 10.1029/93RG01953; KERRIDGE JF, 1975, SCIENCE, V188, P162, DOI 10.1126/science.188.4184.162; KERRIDGE JF, 1991, 21ST P LUN PLAN SCI, P301; KIM Y, 1992, LUNAR PLANET SCI, V23, P693; KOHL CP, 1978, P LUNAR PLANET SCI C, P2299; MARTI K, 1973, 4TH LUN SCI C, P2037; NORRIS SJ, 1983, 14TH P LUN PLAN SCI; RAO MN, 1958, GEOCHIM COSMOCHIM AC, V58, P4231; RAY J, 1982, LUNAR PLANET; WIELER R, IN PRESS ASTROPHYS J; YANIV A, 1981, ASTROPHYS J, V247, pL143, DOI 10.1086/183609	23	20	20	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					383	385		10.1038/375383a0	http://dx.doi.org/10.1038/375383a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760930				2022-12-28	WOS:A1995RB10100046
J	WALLACE, L; BERNATH, P; LIVINGSTON, W; HINKLE, K; BUSLER, J; GUO, BJ; ZHANG, KQ				WALLACE, L; BERNATH, P; LIVINGSTON, W; HINKLE, K; BUSLER, J; GUO, BJ; ZHANG, KQ			WATER ON THE SUN	SCIENCE			English	Article							HYDROGEN FLAME SPECTRA; RO-VIBRATIONAL LEVELS; MILLIMETER-WAVE; H2O; MOLECULES; CM-1	High-resolution infrared spectra of sunspot umbrae have been recorded with the 1-meter Fourier transform spectrometer on Kitt Peak. The spectra contain a very large number of water absorption features originating on the sun. These lines have been assigned to the pure rotation and the vibration-rotation transitions of hot water by comparison with high-temperature laboratory emission spectra.	UNIV WATERLOO, DEPT CHEM, WATERLOO, ON N2L 3G1, CANADA; KITT PEAK NATL OBSERV, NATL OPT ASTRON OBSERV, TUCSON, AZ 85726 USA; UNIV ARIZONA, DEPT CHEM, TUCSON, AZ 85721 USA; NATL OPT ASTRON OBSERV, NATL SOLAR OBSERV, TUCSON, AZ 85726 USA; UNIV WATERLOO, DEPT CHEM, WATERLOO, ON N2L 3G1, CANADA	University of Waterloo; National Optical Astronomy Observatory; University of Arizona; National Optical Astronomy Observatory; University of Waterloo			Bernath, Peter F/B-6567-2012	Bernath, Peter F/0000-0002-1255-396X				ALLARD F, 1994, ASTROPHYS J, V426, pL39, DOI 10.1086/187334; AMANO T, 1991, CHEM PHYS LETT, V182, P93, DOI 10.1016/0009-2614(91)80109-B; BRAY RJ, 1979, SUNSPOTS, P107; CAMPBELL JC, UNPUB; CAMYPEYRET C, 1977, MOL PHYS, V33, P1641, DOI 10.1080/00268977700101361; CHEUNG AC, 1969, NATURE, V221, P626, DOI 10.1038/221626a0; FLAUD JM, 1976, MOL PHYS, V32, P499, DOI 10.1080/00268977600103251; GELLER M, 1992, NASA REF PUBL, V1224, P92; GLENAR DA, 1985, J MOL SPECTROSC, V111, P403, DOI 10.1016/0022-2852(85)90015-3; HALL DNB, 1972, ASTROPHYS J, V175, pL95, DOI 10.1086/180993; HALL DNB, 1970, THESIS HARVARD U; HINKLE KH, 1979, ASTROPHYS J, V227, P923, DOI 10.1086/156801; JORGENSEN UG, 1993, J MOL SPECTROSC, V161, P219, DOI 10.1006/jmsp.1993.1228; KLEINMANN SG, 1986, ASTROPHYS J SUPPL S, V62, P501, DOI 10.1086/191149; LEBLANC RB, 1994, J MOL SPECTROSC, V164, P574, DOI 10.1006/jmsp.1994.1100; LIEBERT J, 1994, MOL STELLAR ENV, P62; LIVINGSTON W, 1991, NATURE, V350, P45, DOI 10.1038/350045a0; PEARSON JC, 1991, ASTROPHYS J, V379, pL41, DOI 10.1086/186149; Polyansky OL, 1996, J MOL SPECTROSC, V176, P305, DOI 10.1006/jmsp.1996.0091; POLYANSKY OL, 1994, J CHEM PHYS, V101, P7651, DOI 10.1063/1.468258; POLYANSKY OL, 1985, J MOL SPECTROSC, V112, P79, DOI 10.1016/0022-2852(85)90193-6; SINHA K, 1991, P ASTRON SOC AUST, V9, P32, DOI 10.1017/S1323358000024814; SPINARD H, 1969, ANNU REV ASTRON ASTR, V7, P249, DOI 10.1146/annurev.aa.07.090169.001341; TOTH RA, 1994, APPL OPTICS, V33, P4851, DOI 10.1364/AO.33.004851; TSUJI T, IN PRESS ELEMENTARY; TYUTEREV VG, 1992, J MOL SPECTROSC, V151, P97, DOI 10.1016/0022-2852(92)90009-D; WALLACE L, 1992, 92001 NAT OPT ASTR O; WALLACE L, 1994, 199401 NAT OPT ASTR	28	111	113	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1155	1158		10.1126/science.7761830	http://dx.doi.org/10.1126/science.7761830			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761830				2022-12-28	WOS:A1995RA60400030
J	SMITH, EJ; MARSDEN, RG; PAGE, DE				SMITH, EJ; MARSDEN, RG; PAGE, DE			ULYSSES ABOVE THE SUNS SOUTH-POLE - AN INTRODUCTION	SCIENCE			English	Article								Ulysses has explored the field and particle environment of the sun's polar region. The solar wind speed was fast and nearly constant above -50 degrees latitude. Compositional differences were observed in slow (low-latitude) solar wind and in fast (high-latitude) solar wind. The radial magnetic field did not change with latitude, implying that polar cap magnetic fields are transported, toward the equator. The intensity of galactic cosmic rays was nearly independent of latitude. Their access to the polar region is opposed by outward-traveling, large amplitude waves in the magnetic field.	EUROPEAN SPACE TECHNOL CTR,EUROPEAN SPACE AGCY,DEPT SPACE SCI,2200 AG NOORDWIJK,NETHERLANDS	European Space Agency	SMITH, EJ (corresponding author), CALTECH,JET PROP LAB,4800 OAK GROVE DR,PASADENA,CA 91109, USA.							BALOGH A, 1995, SCIENCE, V268, P1007, DOI 10.1126/science.268.5213.1007; FOUKAL PV, 1990, SOLAR ASTROPHYSICS; GEISS J, 1995, SCIENCE, V268, P1033, DOI 10.1126/science.7754380; GRZEDZIELSKI S, 1990, COSPAR C SERIES, V1; PHILLIPS JL, 1995, SCIENCE, V268, P1030, DOI 10.1126/science.268.5213.1030; SIMPSON JA, 1995, SCIENCE, V268, P1019, DOI 10.1126/science.268.5213.1019; SMITH EJ, 1991, EOS T AGU, V72, P241; WENZEL KP, 1992, ASTRON ASTROPHYS SUP, V92, P207; Zirin H, 1988, ASTROPHYSICS SUN; 1992, ASTRON ASTROPHYS S, V92, P207	10	48	49	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1005	1007		10.1126/science.7754377	http://dx.doi.org/10.1126/science.7754377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754377				2022-12-28	WOS:A1995QY93400027
J	ACOURT, CHD; STABLES, RH; TRAVIS, S				ACOURT, CHD; STABLES, RH; TRAVIS, S			HOW TO DO IT - DOCTOR ON A MOUNTAINEERING EXPEDITION	BRITISH MEDICAL JOURNAL			English	Article							ALTITUDE PULMONARY-EDEMA; SICKNESS; NIFEDIPINE; BAG	Doctors are welcome members on mountaineering expeditions to remote areas, but practical advice on how to prepare and what kit to take can be difficult to find. This article is a ragbag of useful advice on diverse topics. It explains the necessary preparation, provides tips for a healthy expedition, and summarises the common disorders encountered at high altitude. The comprehensive drug and equipment lists and first aid kit for climbers were used for the 1992 Everest in winter expedition. They are there to be sacrificed to personal preference and the experience and size of individual expeditions.	DERRIFORD HOSP,GASTROENTEROL UNIT,PLYMOUTH PL6 8DH,DEVON,ENGLAND; ROYAL BROMPTON NATL HEART & LUNG HOSP,LONDON SW3 6NP,ENGLAND; JOHN RADCLIFFE HOSP,INTENS THERAPY UNIT,OXFORD OX3 9DU,ENGLAND	Derriford Hospital; Imperial College London; University of Oxford				A'Court, Christine/0000-0003-1829-3860; Stables, Rodney Hilton/0000-0002-9244-7015				BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805; BARTSCH P, 1993, BRIT MED J, V306, P1098, DOI 10.1136/bmj.306.6885.1098; BRADWELL AR, 1986, LANCET, V1, P1001; DANZL DF, 1994, NEW ENGL J MED, V331, P1756, DOI 10.1056/NEJM199412293312607; DINMORE AJ, 1994, J APPL PHYSIOL, V76, P1903, DOI 10.1152/jappl.1994.76.5.1903; KING SJ, 1990, J WILDERNESS MED, V1, P193, DOI 10.1580/0953-9859-1.3.193; LEVINE BD, 1989, NEW ENGL J MED, V321, P1707, DOI 10.1056/NEJM198912213212504; NICHOLSON AN, 1988, SLEEP, V11, P354, DOI 10.1093/sleep/11.4.354; OELZ O, 1989, LANCET, V2, P1241; REEVES JT, 1991, NEW ENGL J MED, V325, P1306, DOI 10.1056/NEJM199110313251810; ROBERTSON JA, 1991, J WILDERNESS MED, V2, P268, DOI 10.1580/0953-9859-2.4.268; SALAM I, 1994, LANCET, V344, P1537, DOI 10.1016/S0140-6736(94)90350-6; WARD M, 1994, HIGH ALTITUDE MED PH; WESTERTERP KR, 1994, J APPL PHYSIOL, V77, P862, DOI 10.1152/jappl.1994.77.2.862; 1981, LANCET, V2, P180	15	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1248	1252		10.1136/bmj.310.6989.1248	http://dx.doi.org/10.1136/bmj.310.6989.1248			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767198	Green Published			2022-12-28	WOS:A1995QY87700025
J	KALE, R				KALE, R			SOUTH-AFRICA HEALTH - NEW SOUTH-AFRICA MENTAL-HEALTH .3.	BRITISH MEDICAL JOURNAL			English	Article											KALE, R (corresponding author), LAXMI KUNJ,37 SHANWAR,POONA 411030,MAHARASHTRA,INDIA.							DOMMISSE J, 1987, SOC SCI MED, V224, P749; FREEMAN M, 1994, EVALUATION MENTAL HT; Freeman M., 1992, PROVIDING MENTAL HLT; GILLIS LS, 1991, S AFR MED J, V79, P490; KALE R, 1995, BRIT MED J, V310, P1182, DOI 10.1136/bmj.310.6988.1182	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1254	1256		10.1136/bmj.310.6989.1254	http://dx.doi.org/10.1136/bmj.310.6989.1254			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QY877	7767200	Green Published			2022-12-28	WOS:A1995QY87700027
J	PINION, SB; PARKIN, DE; ABRAMOVICH, DR; NAJI, A; ALEXANDER, DA; RUSSELL, IT; KITCHENER, HC				PINION, SB; PARKIN, DE; ABRAMOVICH, DR; NAJI, A; ALEXANDER, DA; RUSSELL, IT; KITCHENER, HC			RANDOMIZED TRIAL OF HYSTERECTOMY, ENDOMETRIAL LASER-ABLATION, AND TRANSCERVICAL ENDOMETRIAL RESECTION FOR DYSFUNCTIONAL UTERINE BLEEDING	BRITISH MEDICAL JOURNAL			English	Article							ABDOMINAL HYSTERECTOMY; MENORRHAGIA; WOMEN; OUTCOMES; AGE	Objective-To evaluate the effectiveness and safety of endometrial laser ablation and transcervical resection of the endometrium compared with hysterectomy in the surgical treatment of women with dysfunctional uterine bleeding. Design-Prospective randomised controlled trial. Setting-Gynaecology department of a large teaching hospital. Subjects-204 women who would otherwise have been undergoing hysterectomy for menorrhagia were recruited between August 1990 and March 1992 and randomly allocated to hysterectomy (n=99) or conservative (hysteroscopic) surgery (transcervical resection (n=52) and laser ablation (n=53)). Main outcome measures-Operative complications, postoperative recovery, relief of menstrual and other symptoms, patient satisfaction with treatment after six and 12 months. Results-Women treated by hysteroscopic surgery had less early morbidity and a significantly shorter recovery period than those treated by hysterectomy (median time to full recovery 2-4 weeks a 2-3 months, P < 0.001). Twelve months later 17 women in the hysteroscopy group had had a hysterectomy, 11 for continuing symptoms; 11 women had had a repeat hysteroscopic procedure; 45 were amenorrhoeic or had only a brown discharge; and 35 had light periods. Dysmenorrhoea and premenstrual symptoms improved in most women in both groups. After 12 months 89% (79/89) in the hysterectomy group and 78% (75/96) in the hysteroscopy group were very Satisfied with the effect of surgery (P < 0.05); 95% (85/89) and 90% (86/ 96) thought that there had been an acceptable improvement in symptoms, and 72% (64/89) and 71% (68/96) would recommend the same operation to others. Conclusions-Hysteroscopic endometrial ablation was superior to hysterectomy in terms of operative complications and postoperative recovery. Satisfaction after hysterectomy was significantly higher, but between 70% and 90% of the women were satisfied with the outcome of hysteroscopic surgery. Hysteroscopic surgery can be recommended as an alternative to hysterectomy for dysfunctional uterine bleeding.	UNIV ABERDEEN,ABERDEEN,SCOTLAND; ABERDEEN ROYAL INFIRM,ABERDEEN,SCOTLAND	University of Aberdeen; University of Aberdeen			Russell, Ian T/H-1181-2012					CENTERWALL BS, 1981, AM J OBSTET GYNECOL, V139, P58, DOI 10.1016/0002-9378(81)90412-9; COULTER A, 1988, SOC SCI MED, V27, P987, DOI 10.1016/0277-9536(88)90289-4; COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; DECHERNEY A, 1983, OBSTET GYNECOL, V61, P392; DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; GANNON MJ, 1991, BRIT MED J, V303, P1362, DOI 10.1136/bmj.303.6814.1362; GARRY R, 1991, BRIT J OBSTET GYNAEC, V98, P357, DOI 10.1111/j.1471-0528.1991.tb13425.x; GATH D, 1982, BRIT J PSYCHIAT, V140, P335, DOI 10.1192/bjp.140.4.335; GOLDRATH MH, 1981, AM J OBSTET GYNECOL, V140, P14, DOI 10.1016/0002-9378(81)90251-9; GOLDRATH MH, 1990, J REPROD MED, V35, P91; LEDGER WJ, 1973, AM J OBSTET GYNECOL, V117, P723; LEFLER HT, 1989, J REPROD MED, V34, P905; MACDONALD R, 1992, GYNAECOL ENDOSC, V1, P7; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; OSBORN MF, 1990, PSYCHOL MED, V20, P565, DOI 10.1017/S0033291700017062; PARYS BT, 1989, NEUROUROL URODYNAM, V8, P315; PERRY CP, 1990, J GYNECOL SURG, V6, P199, DOI 10.1089/gyn.1990.6.199; RANKIN L, 1992, BRIT J OBSTET GYNAEC, V99, P911, DOI 10.1111/j.1471-0528.1992.tb14441.x; SCHOFIELD MJ, 1991, BRIT J OBSTET GYNAEC, V98, P1129, DOI 10.1111/j.1471-0528.1991.tb15365.x; SIDDLE N, 1987, FERTIL STERIL, V47, P94; SLADE RJ, 1991, LANCET, V337, P1473, DOI 10.1016/0140-6736(91)93159-7; TEO PYK, 1987, HYSTERECTOMY SCOTLAN	23	223	226	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 15	1994	309	6960					979	983		10.1136/bmj.309.6960.979	http://dx.doi.org/10.1136/bmj.309.6960.979			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PM417	7772106	Green Published			2022-12-28	WOS:A1994PM41700018
J	GINSBURG, KR; SLAP, GB; CNAAN, A; FORKE, CM; BALSLEY, CM; ROUSELLE, DM				GINSBURG, KR; SLAP, GB; CNAAN, A; FORKE, CM; BALSLEY, CM; ROUSELLE, DM			ADOLESCENTS PERCEPTIONS OF FACTORS AFFECTING THEIR DECISIONS TO SEEK HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFIDENTIALITY; PHYSICIANS	Objective.-To have adolescents, rather than adults, identify characteristics of health care providers and sites that affect their decision to seek care. Design.-Five stages conducted over a 10-month period: (1) focus groups to frame the study questions; (2) nominal group technique to generate student responses; (3) three surveys to assess response importance; (4) one survey to link the most important responses with the decision to seek care; and (5) focus groups to explain the variables associated with the decision to seek care. Setting.-The Philadelphia (Pa) School District. Participants.-The study population consisted of all ninth graders from 39 of Philadelphia's 42 public high schools. The 6821 students who returned the final survey comprised the study sample (69% of in-school youth). Results.-In the final survey, students used a Likert scale (1 to 5) to describe the impact of 31 ideas on their decision to seek care. The most important characteristics were provider hand washing, clean instruments, honesty, respect toward teens, cleanliness, know-how, carefulness, experience, seronegativity for the human immunodeficiency virus, equal treatment of all patients, and confidentiality. There was little variation in the order of the items by sex, race, or socioeconomic status. Factor analysis showed that the most important of four identified latent factors related to infection control and provider competency. Conclusion.-Four of the top 10 characteristics that affect an adolescent's decision to seek care involve cleanliness and infection control. These findings offer providers and planners straightforward, modifiable factors that teens believe influence their decision to seek care.	UNIV PENN, SCH MED,DEPT MED,DIV GEN INTERNAL MED, CRAIG DALSIMER PROGRAM ADOLESCENT MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DEPT PEDIAT, DIV BIOSTAT & EPIDEMIOL, PHILADELPHIA, PA 19104 USA; SCH DIST PHILADELPHIA, OFF STUDENT SERV, PHILADELPHIA, PA USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	GINSBURG, KR (corresponding author), CHILDRENS HOSP PHILADELPHIA, DIV GEN PEDIAT, ADOLESCENT MED SECT, 34TH ST & CIV CTR BLVD, PHILADELPHIA, PA 19104 USA.				AHRQ HHS [1-R03-HS07876-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1993, JAMA, V269, P1420; BARTHOLOMEW DJ, 1987, LATENT VARIABLE MODE, pCH2; BRINDIS CD, 1990, J ADOLESCENT HEALTH, V11, P387, DOI 10.1016/0197-0070(90)90084-F; CHENG TL, 1993, JAMA-J AM MED ASSOC, V269, P1404, DOI 10.1001/jama.269.11.1404; Delbecq AL, 1975, J HUMAN SCI; FRIEDMAN LS, 1990, J ADOLESCENT HEALTH, V11, P227, DOI 10.1016/0197-0070(90)90353-4; GANS J, 1991, PROFILES ADOLESCENT, V2; GREYDANUS DE, 1991, PEDIATR ANN, V20, P80, DOI 10.3928/0090-4481-19910201-09; Hechinger F M, 1992, FATEFUL CHOICES HLTH; HODGSON C, 1986, ADOLESCENCE, V21, P383; JORESKOG KG, 1989, LISREL 7 GUIDE PROGR, pCH1; KINSMAN SB, 1992, J ADOLESCENT HEALTH, V13, P146, DOI 10.1016/1054-139X(92)90082-M; KLEIN JD, 1992, J ADOLESCENT HEALTH, V13, P162, DOI 10.1016/1054-139X(92)90084-O; LEVENSON PM, 1987, J ADOLESCENT HEALTH, V8, P171, DOI 10.1016/0197-0070(87)90261-0; LITT IF, 1984, J ADOLESCENT HEALTH, V5, P196, DOI 10.1016/S0197-0070(84)80042-X; MALUS M, 1987, J FAM PRACTICE, V25, P159; MANNING DT, 1989, J FAM PRACTICE, V29, P173; MILLSTEIN S, 1993, PROMOTING ADOLESCENT; MILLSTEIN SG, 1992, PEDIATRICS, V89, P422; Moore C, 1987, GROUP TECHNIQUES IDE; Resnick M, 1980, J Adolesc Health Care, V1, P137, DOI 10.1016/S0197-0070(80)80039-8; STREHLOW U, 1993, J ADOLESCENT HEALTH, V14, P475, DOI 10.1016/1054-139X(93)90121-5; Witte J. J., 1993, Morbidity and Mortality Weekly Report, V42, P329; 1990, PROMOTING HLTH ADOLE; 1990, HLTH YOUTH 2000 NATI; 1990, CODE BLUE UNITING HL; 1991, OTAH468 US C OFF TEC; 1991, OTAH467 OFF TECHN AS, V3	28	151	153	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1913	1918		10.1001/jama.273.24.1913	http://dx.doi.org/10.1001/jama.273.24.1913			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RE354	7783300				2022-12-28	WOS:A1995RE35400026
J	IRIBARREN, C; REED, DM; BURCHFIEL, CM; DWYER, JH				IRIBARREN, C; REED, DM; BURCHFIEL, CM; DWYER, JH			SERUM TOTAL CHOLESTEROL AND MORTALITY - CONFOUNDING FACTORS AND RISK MODIFICATION IN JAPANESE-AMERICAN MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; FACTOR INTERVENTION TRIAL; CANCER MORTALITY; FOLLOW-UP; CARDIOVASCULAR-DISEASE; INVERSE RELATIONSHIP; PLASMA-CHOLESTEROL; HEMOSTATIC FACTORS; VITAMIN-E	Objective.-To further investigate the relationship between serum total cholesterol CTG) level and mortality due to major causes. in particular, is the elevated mortality among persons with low TC levels due to confounding conditions that both lower TC level and increase the risk of mortality, and is the association between low or high TC level and mortality homogeneous in the population or, alternatively, restricted to persons with other risk factors? Study Design.-Prospective cohort study. Setting.-Free-living population in Oahu, Hawaii. Participants.-A total of 7049 middle-aged men of Japanese ancestry. Main Outcome Measures.-Age- and risk factor-adjusted mortality due to coronary heart disease, hemorrhagic stroke, cancer, chronic obstructive pulmonary disease, nonmalignant liver disease, trauma, miscellaneous and unknown; and all causes. Results.-During 23 years of follow-up, a total of 1954 deaths were documented (38% cancer, 25% cardiovascular, and 37% other). Men with low serum TC levels (<4.66 mmol/L [<180 mg/dL]) were found to have several adverse health characteristics, including a higher prevalence of current smoking, heavy drinking, and certain gastrointestinal conditions. In an age-adjusted model, and in relation to the reference group (4.66 to 6.19 mmol/L [180 to 239 mg/dL]), those in the lowest TC group (<4.66 mmol/L [<180 mg/dL]) were at significantly higher risk of mortality due to hemorrhagic stroke (relative risk [RR], 2.41; 95% confidence interval [Ci], 1.45 to 4.00), cancer (RR, 1.41; 95% CI, 1.17 to 1.69), and all causes (RR, 1.23; 95% Cl, 1.09 to 1.38). Adjustment for confounders in multivariate analysis (and exclusion of cases with prevalent disease at baseline and deaths through year 5) did not explain the risk of fatal hemorrhagic stroke but reduced the excess risk of cancer mortality by 51% (to 1.20 from 1.41) and reduced the excess risk of all-cause mortality by 56% (to 1.10 from 1.32) in the low TC group. In addition, there were clear differences in the patterns of risk when comparing men with and without selected risk factors tie, smoking, alcohol consumption, and untreated hypertension). Conclusions.-We conclude that the excess mortality at low TC levels can be partially explained by confounding with other determinants of death and by preexisting disease at baseline, and TC-mortality associations are not homogeneous in the population. In our study, TC level was not associated with increased cancer or all-cause mortality in the absence of smoking, high alcohol consumption, and untreated hypertension.	UNIV SO CALIF,SCH MED,INST HLTH PROMOT & DIS PREVENT RES,DEPT PREVENT MED,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MED,INST ARTERIOSCLEROSIS RES,LOS ANGELES,CA 90033; BUCK CTR RES AGING,NOVATO,CA; NHLBI,BETHESDA,MD 20892; HONOLULU HAWAII HEART PROGRAM,HONOLULU,HI	University of Southern California; University of Southern California; Buck Institute for Research on Aging; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC002901] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HV-02901, N01-HC-02901] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKEN LS, 1991, MULTIPLE REGRESSION, P67; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; BAPTISTE MS, 1992, INT J EPIDEMIOL, V21, P16, DOI 10.1093/ije/21.1.16; BELSKY JL, 1971, 1271 AT BOM CAS COMM; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BONITHONKOPP C, 1988, ATHEROSCLEROSIS, V71, P71, DOI 10.1016/0021-9150(88)90303-6; Breslow N. E., 1987, STATISTICAL METHODS, VII; CHEN ZM, 1993, BMJ-BRIT MED J, V306, P890, DOI 10.1136/bmj.306.6882.890; Clayton D., 1992, STAT MODELS LONGITUD, P301; COWAN LD, 1990, AM J EPIDEMIOL, V131, P468, DOI 10.1093/oxfordjournals.aje.a115521; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; FRANK JW, 1992, J CLIN EPIDEMIOL, V45, P333, DOI 10.1016/0895-4356(92)90034-K; GARCIAPALMIERI MR, 1981, AM J EPIDEMIOL, V114, P29, DOI 10.1093/oxfordjournals.aje.a113171; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; Higgins M, 1992, Ann Epidemiol, V2, P69, DOI 10.1016/1047-2797(92)90039-S; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; ISO H, 1994, J CLIN EPIDEMIOL, V47, P961, DOI 10.1016/0895-4356(94)90110-4; ISO H, 1989, AM J EPIDEMIOL, V130, P925, DOI 10.1093/oxfordjournals.aje.a115425; KAGAN A, 1981, AM J EPIDEMIOL, V114, P11, DOI 10.1093/oxfordjournals.aje.a113157; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KARK JD, 1982, BRIT MED J, V284, P152, DOI 10.1136/bmj.284.6310.152; KARK JD, 1980, J CHRON DIS, V33, P311, DOI 10.1016/0021-9681(80)90026-0; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KOZAREVIC D, 1981, AM J EPIDEMIOL, V114, P21, DOI 10.1093/oxfordjournals.aje.a113170; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; MANOLIO TA, 1993, CIRCULATION, V87, P728, DOI 10.1161/01.CIR.87.3.728; MARTIN MJ, 1986, LANCET, V2, P933; MEADE TW, 1985, BRIT MED J, V290, P428, DOI 10.1136/bmj.290.6466.428; MENKES MS, 1986, NEW ENGL J MED, V315, P1250, DOI 10.1056/NEJM198611133152003; MIETTINEN OS, 1981, AM J EPIDEMIOL, V114, P593, DOI 10.1093/oxfordjournals.aje.a113225; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; PETERSON B, 1981, JAMA-J AM MED ASSOC, V245, P2056, DOI 10.1001/jama.245.20.2056; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; ROGERS S, 1988, EUR J CLIN NUTR, V42, P197; ROSE G, 1980, LANCET, V1, P523; RUSSELLBRIEFEL R, 1985, AM J EPIDEMIOL, V122, P741, DOI 10.1093/oxfordjournals.aje.a114157; SALMOND CE, 1985, BMJ-BRIT MED J, V290, P422, DOI 10.1136/bmj.290.6466.422; SCHATZKIN A, 1988, CANCER RES, V48, P452; SCHATZKIN A, 1987, LANCET, V2, P298; SCHUIT AJ, 1993, AM J EPIDEMIOL, V137, P966, DOI 10.1093/oxfordjournals.aje.a116769; SINHA R, 1993, CANCER EPIDEM BIOMAR, V2, P473; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STAHELIN HB, 1991, AM J EPIDEMIOL, V133, P766; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STEMMERMANN GN, 1984, INT J EPIDEMIOL, V13, P299, DOI 10.1093/ije/13.3.299; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; WALD NJ, 1989, BRIT J CANCER, V59, P938; WESTLUND K, 1972, SCAND J CLIN LA S127, V30, P2; White A D, 1992, Ann Epidemiol, V2, P85, DOI 10.1016/1047-2797(92)90041-N; WILLIAMS RR, 1981, JAMA-J AM MED ASSOC, V245, P247, DOI 10.1001/jama.245.3.247; WORTH RM, 1970, J CHRON DIS, V23, P389, DOI 10.1016/0021-9681(70)90022-6; YAARI S, 1981, LANCET, V1, P1011; 1988, ARCH INTERN MED, V148, P36; [No title captured]; [No title captured]; 1987, SAS STAT SOFTWARE VE	58	82	83	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1926	1932		10.1001/jama.273.24.1926	http://dx.doi.org/10.1001/jama.273.24.1926			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783302				2022-12-28	WOS:A1995RE35400028
J	SHENKIN, BN				SHENKIN, BN			THE INDEPENDENT PRACTICE ASSOCIATION IN THEORY AND PRACTICE - LESSONS FROM EXPERIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This article examines an advanced managed care area, the San Francisco East Bay Area in California, for basic organizational issues posed by managed care for the medical profession. Of the three basic structures found, the independent practice association (IPA) model is theoretically most promising. Unlike the integrated health plan, the IPA seeks to retain traditional practice autonomy. Unlike the isolating direct gatekeeper model, the IPA assembles physicians in self-directed groups to invent and implement solutions and to exert political influence upward. In practice, however, it has proved difficult to balance practice autonomy with IPA authority. Both large, successful East Bay Area IPAs show signs (perhaps inevitably) of favoring authority over autonomy, as shown by their policies on governance, membership, and administration. Several policies are suggested to help redress this balance. Medical leaders must act now, before all the evidence is in, or the institutions of the past-hospitals and insurance companies-will control our future.	CTR RESPONS HLTH POLICY,BERKELEY,CA; BAYSIDE PEDIAT,OAKLAND,CA									[Anonymous], 1970, EXIT VOICE LOYALTY R, DOI DOI 10.3917/RCE.002.0244; BLUMENTHAL D, 1994, HEALTH AFFAIR, V13, P252, DOI 10.1377/hlthaff.13.1.252; Etzioni A., 1964, MODERN ORG, P75; FREIDSON E, 1970, PROFESSION MED, pCH2; HEILBRONER RL, 1985, NATURE LOGIC CAPITAL, P151; IGLEHART JK, 1992, NEW ENGL J MED, V327, P742, DOI 10.1056/NEJM199209033271029; JAMES C, IN PRESS CAPITATION; Lane R., 1991, MARKET EXPERIENCE; Lewin K., 1958, READINGS SOCIAL PSYC; SHORE MF, 1985, NEW ENGL J MED, V313, P319, DOI 10.1056/NEJM198508013130509; STYMNE B, 1985, NEW CHALLENGES MANAG, P102; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; WHITE KL, 1967, NEW ENGL J MED, V277, P847, DOI 10.1056/NEJM196710192771604	13	24	24	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1937	1942		10.1001/jama.273.24.1937	http://dx.doi.org/10.1001/jama.273.24.1937			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783304				2022-12-28	WOS:A1995RE35400030
J	VERNON, CC; VANDERZEE, J				VERNON, CC; VANDERZEE, J			HYPERTHERMIA IN CANCER-TREATMENT	LANCET			English	Letter									HAMMERSMITH HOSP, DEPT CLIN ONCOL, LONDON W12 0HS, ENGLAND; DR DANIEL DEN HOED CANC CTR, DEPT HYPERTHERMIA, ROTTERDAM, NETHERLANDS	Imperial College London; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute								CORRY PM, 1988, INT J HYPERTHER, V4, P53, DOI 10.3109/02656738809032049; DAHL O, 1990, INTRO PRACTICAL ASPE, P108; KAPP D S, 1986, International Journal of Hyperthermia, V2, P139, DOI 10.3109/02656738609012390; SUIT HD, 1982, CANCER-AM CANCER SOC, V50, P1227, DOI 10.1002/1097-0142(19821001)50:7<1227::AID-CNCR2820500702>3.0.CO;2-J; VERNON CC, 1994, BR J CANCER S22, V70, P10	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	1995	345	8965					1636	1636						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783552				2022-12-28	WOS:A1995RE67000037
J	IGLEHART, JK				IGLEHART, JK			HEALTH-POLICY REPORT - MEDICAID AND MANAGED CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		CHAVKIN DF, 1977, HASTINGS LAW J, V28, P685; Coughlin Teresa A., 1994, MEDICAID 1980 COSTS; FREUND DA, 1995, ANNU REV PUBL HEALTH, V16, P473; HOLOHAN J, 1995, HEALTH AFFAIR, V14, P199, DOI 10.1377/hlthaff.14.1.199; IGLEHART JK, 1993, NEW ENGL J MED, V328, P896, DOI 10.1056/NEJM199303253281226; KIRKMANLIFF BL, 1987, HEALTH AFFAIR, V6, P46, DOI 10.1377/hlthaff.6.4.46; MCCALL N, 1989, 1989 SRI INT FIN REP; MERLIS M, 1993, MEDICAID SOURCE BOOK, P1009; PARINGER L, 1991, HEALTH AFFAIR, V10, P220, DOI 10.1377/hlthaff.10.4.220; PEAR R, 1995, NY TIMES        0926, pA20; Pear Robert, 1995, N Y Times Web, pB13; ROSENBAUM S, 1995, KAISER COMMISSION FU; Schear S, 1995, Natl J (Wash), V27, P294; VLADECK BC, 1995, HEALTH AFFAIR, V14, P217, DOI 10.1377/hlthaff.14.1.217; WINSLOW R, 1995, WALL STREET J   0412, pA1; WINTERBOTTOM C, 1995, STATE LEVEL DATA BOO; 1995, STATES PAYERS MANAGE; 1995, MEDICAID MANAGED CAR; 1993, GAOHRD9346 GEN ACC O; 1995, GAOHEHS9587 GEN ACC; 1995, BACK FUTURE MEDICAL	21	60	60	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1727	1731		10.1056/NEJM199506223322525	http://dx.doi.org/10.1056/NEJM199506223322525			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760887				2022-12-28	WOS:A1995RD99600035
J	STEIN, C				STEIN, C			MECHANISMS OF DISEASE - THE CONTROL OF PAIN IN PERIPHERAL TISSUE BY OPIOIDS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ARTHROSCOPIC KNEE SURGERY; CRUCIATE LIGAMENT REPAIR; MAMMALIAN SPINAL-CORD; SUBSTANCE-P RELEASE; INTRAARTICULAR MORPHINE; INFLAMED TISSUE; ENDOGENOUS OPIOIDS; BETA-ENDORPHIN; IMMUNE CELLS; RECEPTORS				STEIN, C (corresponding author), JOHNS HOPKINS UNIV HOSP,SCH MED,DEPT ANESTHESIOL & CRIT CARE MED,TOWER 711,BALTIMORE,MD 21287, USA.			Stein, Christoph/0000-0001-5240-6836	NINDS NIH HHS [R01NS32466] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032466] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN GC, 1993, ANESTHESIOLOGY, V79, P475, DOI 10.1097/00000542-199309000-00010; ANDREEV N, 1994, NEUROSCIENCE, V58, P793, DOI 10.1016/0306-4522(94)90456-1; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; BARBER A, 1992, MED RES REV, V12, P525, DOI 10.1002/med.2610120505; BARTHO L, 1990, N-S ARCH PHARMACOL, V342, P666, DOI 10.1007/BF00175710; BODEN BP, 1994, ARTHROSCOPY, V10, P104, DOI 10.1016/S0749-8063(05)80301-9; BOTTICELLI LJ, 1981, P NATL ACAD SCI-BIOL, V78, P7783, DOI 10.1073/pnas.78.12.7783; CARR DJJ, 1991, P SOC EXP BIOL MED, V198, P710; CZLONKOWSKI A, 1993, EUR J PHARMACOL, V242, P229, DOI 10.1016/0014-2999(93)90246-E; DALSGAARD J, 1994, PAIN, V56, P151, DOI 10.1016/0304-3959(94)90089-2; DEANDRES J, 1993, ANESTH ANALG, V77, P727; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; HASSAN AHS, 1992, NEUROSCI LETT, V140, P85, DOI 10.1016/0304-3940(92)90688-4; HASSAN AHS, 1993, NEUROSCIENCE, V55, P185, DOI 10.1016/0306-4522(93)90465-R; HAYNES TK, 1994, ANAESTHESIA, V49, P54, DOI 10.1111/j.1365-2044.1994.tb03314.x; HEARD SO, 1992, ANESTH ANALG, V74, P822; HEIJNEN CJ, 1991, IMMUNOL REV, V119, P41, DOI 10.1111/j.1600-065X.1991.tb00577.x; HEINE MF, 1994, BRIT J ANAESTH, V73, P413, DOI 10.1093/bja/73.3.413; INGRAM SL, 1994, NEURON, V13, P179, DOI 10.1016/0896-6273(94)90468-5; JOSHI GP, 1993, BRIT J ANAESTH, V70, P87, DOI 10.1093/bja/70.1.87; JOSHI GP, 1992, J BONE JOINT SURG BR, V74, P749, DOI 10.1302/0301-620X.74B5.1527127; JOSHI GP, 1993, ANESTH ANALG, V76, P333; JOSHI GP, 1993, REGION ANESTH, V18, P254; Juelsgaard P, 1993, Ugeskr Laeger, V155, P4169; KHOURY GF, 1992, ANESTHESIOLOGY, V77, P263, DOI 10.1097/00000542-199208000-00007; LAMOTTE C, 1976, BRAIN RES, V112, P407, DOI 10.1016/0006-8993(76)90296-1; MANSOUR A, 1994, BRAIN RES, V643, P245, DOI 10.1016/0006-8993(94)90031-0; MCSWINEY MM, 1993, ANAESTH INTENS CARE, V21, P201, DOI 10.1177/0310057X9302100212; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; NIEMI L, 1994, ACTA ANAESTH SCAND, V38, P402, DOI 10.1111/j.1399-6576.1994.tb03916.x; OLSSON Y, 1990, CRIT REV NEUROBIOL, V5, P265; PARSONS CG, 1990, PAIN, V41, P81, DOI 10.1016/0304-3959(90)91112-V; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; RUSSELL NJW, 1987, NEUROSCI LETT, V76, P107, DOI 10.1016/0304-3940(87)90201-1; SCHAFER M, 1994, P NATL ACAD SCI USA, V91, P4219, DOI 10.1073/pnas.91.10.4219; SCHAFER M, 1995, EUR J PHARMACOL, V279, P165, DOI 10.1016/0014-2999(95)00150-J; SCHROEDER JE, 1991, NEURON, V6, P13, DOI 10.1016/0896-6273(91)90117-I; SCHULTESTEINBER.H, 1995, ANESTHESIOLOGY, V82, P634; SELLEY DE, 1993, MOL PHARMACOL, V44, P731; SHARP B, 1993, ENDOCRINOLOGY, V133, pA1921, DOI 10.1210/endo.133.5.8404637; STEIN C, 1993, LANCET, V342, P321, DOI 10.1016/0140-6736(93)91471-W; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1990, J NEUROSCI, V10, P1292; STEIN C, 1991, NEW ENGL J MED, V325, P1123, DOI 10.1056/NEJM199110173251602; STEIN C, 1993, ANESTH ANALG, V76, P182; WEIHE E, 1985, NEUROSCI LETT, V58, P347, DOI 10.1016/0304-3940(85)90079-5; WERZ MA, 1983, NEUROSCI LETT, V42, P173, DOI 10.1016/0304-3940(83)90402-0; YAKSH TL, 1980, NATURE, V286, P155, DOI 10.1038/286155a0; YAKSH TL, 1988, BRAIN RES, V458, P319, DOI 10.1016/0006-8993(88)90474-X; ZARBIN MA, 1990, EXP BRAIN RES, V81, P267	50	508	531	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1685	1690		10.1056/NEJM199506223322506	http://dx.doi.org/10.1056/NEJM199506223322506			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760870				2022-12-28	WOS:A1995RD99600006
J	BOUJRAD, N; OGWUEGBU, SO; GARNIER, M; LEE, CH; MARTIN, BM; PAPADOPOULOS, V				BOUJRAD, N; OGWUEGBU, SO; GARNIER, M; LEE, CH; MARTIN, BM; PAPADOPOULOS, V			IDENTIFICATION OF A STIMULATOR OF STEROID-HORMONE SYNTHESIS ISOLATED FROM TESTIS	SCIENCE			English	Article							LEYDIG-CELL STEROIDOGENESIS; RAT SERTOLI CELLS; TISSUE INHIBITOR; SEMINIFEROUS TUBULES; MATRIX METALLOPROTEINASES; TESTICULAR FUNCTION; GRANULOSA-CELLS; INVITRO; PROTEIN; PURIFICATION	Gonadal steroidogenesis is regulated by pituitary gonadotropins and a locally produced, unidentified factor. A 70-kilodalton (kD) protein complex secreted from rat Serloli cells was isolated. The complex, composed of 28- and 38-kD proteins, stimulated steroidogenesis by Leydig cells and ovarian granulosa cells in a dose-dependent and adenosine 3',5'-monophosphate-independent manner. The follicle-stimulating hormone-induced 28-kD protein appeared to be responsible for the bioactivity, but the 38-kD protein was indispensable for maximal activity. The 28- and 38-kD proteins were shown to be identical to the tissue inhibitor of metalloproteinase-1 (TIMP-1) and the proenzyme form of cathepsin L, respectively. Thus, a TIMP-1-procathepsin L complex is a potent activator of steroidogenesis and may regulate steroid concentrations and, thus, germ cell development in both males and females.	GEORGETOWN UNIV, MED CTR, DEPT CELL BIOL, WASHINGTON, DC 20007 USA; NIMH, CLIN NEUROSCI BRANCH, MOLEC NEUROGENET SECT, BETHESDA, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Papadopoulos, Vassilios/AAI-2613-2019; BOUJRAD, Noureddine/L-1367-2015	Papadopoulos, Vassilios/0000-0002-1183-8568; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024633] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01031, HD24633] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AOKI A, 1978, BIOL REPROD, V19, P144, DOI 10.1095/biolreprod19.1.144; BENAHMED M, 1985, AM J PHYSIOL, V248, pE176, DOI 10.1152/ajpendo.1985.248.2.E176; BENNETT B, 1992, J IMMUNOL METHODS, V153, P31, DOI 10.1016/0022-1759(92)90302-A; BENZEEV A, 1987, DIFFERENTIATION, V34, P222, DOI 10.1111/j.1432-0436.1987.tb00070.x; BERGH A, 1982, INT J ANDROL, V5, P325, DOI 10.1111/j.1365-2605.1982.tb00261.x; BERTAUX B, 1991, J INVEST DERMATOL, V97, P679, DOI 10.1111/1523-1747.ep12483956; CHEN YDI, 1976, P SOC EXP BIOL MED, V153, P473; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DEKRETSER DM, 1987, INT REV CYTOL, V109, P89, DOI 10.1016/S0074-7696(08)61720-9; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; DYM M, 1991, ENDOCRINOLOGY, V128, P1167, DOI 10.1210/endo-128-2-1167; ERICKSONLAWRENCE M, 1991, MOL ENDOCRINOL, V5, P1789, DOI 10.1210/mend-5-12-1789; Gamier M., 1994, MOL PHARM, V45, P201; GROTJAN HE, 1982, ANN NY ACAD SCI, V383, P456, DOI 10.1111/j.1749-6632.1982.tb23198.x; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; HSUEH AJW, 1984, J CLIN ENDOCR METAB, V15, P117; JANSZ GF, 1990, J ANDROL, V11, P131; JOHNSON BH, 1971, SCIENCE, V173, P635, DOI 10.1126/science.173.3997.635; JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; Kane S E, 1990, Semin Cancer Biol, V1, P127; KERR JB, 1985, ENDOCRINOLOGY, V116, P2592, DOI 10.1210/endo-116-6-2592; KRETSER DMD, 1979, ENDOCRINOLOGY, V105, P135, DOI 10.1210/endo-105-1-135; MANN JS, 1991, ENDOCRINOLOGY, V128, P1825, DOI 10.1210/endo-128-4-1825; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MELSERT R, 1988, MOL CELL ENDOCRINOL, V59, P221, DOI 10.1016/0303-7207(88)90107-4; MELSERT R, 1967, J ENDOCRINOL, V115, pR17; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONODA M, 1991, MOL CELL ENDOCRINOL, V77, P207, DOI 10.1016/0303-7207(91)90076-5; PAPADOPOULOS V, 1985, FEBS LETT, V188, P312, DOI 10.1016/0014-5793(85)80393-8; PAPADOPOULOS V, 1987, J ENDOCRINOL, V114, P459, DOI 10.1677/joe.0.1140459; PAPADOPOULOS V, 1991, J CLIN ENDOCR METAB, V72, P1332, DOI 10.1210/jcem-72-6-1332; PAPADOPOULOS V, UNPUB; PARVINEN M, 1984, MOL CELL ENDOCRINOL, V37, P331, DOI 10.1016/0303-7207(84)90103-5; RICH KA, 1979, MOL CELL ENDOCRINOL, V13, P123, DOI 10.1016/0303-7207(79)90013-3; RISBRIDGER GP, 1986, J REPROD FERTIL, V77, P239, DOI 10.1530/jrf.0.0770239; RISBRIDGER GP, 1981, ENDOCRINOLOGY, V109, P1234, DOI 10.1210/endo-109-4-1234; ROSWIT WT, 1992, ARCH BIOCHEM BIOPHYS, V292, P402, DOI 10.1016/0003-9861(92)90009-L; SAEZ JM, 1987, J STEROID BIOCHEM, V27, P317, DOI 10.1016/0022-4731(87)90323-2; Setchell B.P., 1978, THE MAMMALIAN TESTIS; SHARPE RM, 1984, MOL CELL ENDOCRINOL, V37, P159, DOI 10.1016/0303-7207(84)90048-0; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SMITH GW, 1994, ENDOCRINOLOGY, V134, P344, DOI 10.1210/en.134.1.344; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; TEERDS KJ, 1989, J ENDOCRINOL, V120, P97, DOI 10.1677/joe.0.1200097; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; VERHOEVEN G, 1986, J STEROID BIOCHEM, V25, P393, DOI 10.1016/0022-4731(86)90252-9; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; ZHU C, 1991, BIOL REPROD, V45, P334, DOI 10.1095/biolreprod45.2.334	50	144	154	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1609	1612		10.1126/science.7777858	http://dx.doi.org/10.1126/science.7777858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777858				2022-12-28	WOS:A1995RD45900035
J	SHIFFMAN, ML; KAPLAN, GD; BRINKMANKAPLAN, V; VICKERS, FF				SHIFFMAN, ML; KAPLAN, GD; BRINKMANKAPLAN, V; VICKERS, FF			PROPHYLAXIS AGAINST GALLSTONE FORMATION WITH URSODEOXYCHOLIC ACID IN PATIENTS PARTICIPATING IN A VERY-LOW-CALORIE DIET PROGRAM	ANNALS OF INTERNAL MEDICINE			English	Article						DIET, REDUCING; CHOLELITHIASIS; CALORIC INTAKE; URSODEOXYCHOLIC ACID; WEIGHT LOSS	GASTRIC BYPASS-SURGERY; RAPID WEIGHT-LOSS; MORBID-OBESITY; SYMPTOMATIC GALLSTONES; CHOLESTEROL SATURATION; NATURAL-HISTORY; BILIARY SLUDGE; GALL-STONES; BILE; DISEASE	Objective: To determine whether prophylactic treatment with ursodeoxycholic acid can prevent gallstone formation in persons participating in a very-low-calorie weight reduction diet program. Design: Multicenter, double-blind, placebo-controlled, multidose clinical trial. Patients were treated with placebo or with 300 mg/d, 600 mg/d, or 1200 mg/d of ursodeoxycholic acid. Setting: 31 Health Management Resources weight management centers. Patients: 1004 patients were initially enrolled in a 16-week, 520-kcal/d, Health Management Resources liquid protein diet program. All patients had a body mass index of 38 kg/m(2) or more and a normal gallbladder ultrasonogram before study entry. Bile analysis was done in 32 patients. Measurements: Body weight and body mass index were measured before the diet was started and at 2-week intervals for 16 weeks. Gallbladder ultrasonography was done before enrollment and after 8 and 16 weeks of dieting. Bile was obtained by endoscopy and analyzed for cholesterol crystals and lipid levels. Results: Mean body weight for all patients at the start of dieting was 128.2 kg +/- 23.2 kg; mean initial body mass index was 44.2 kg/m(2) +/- 6.0 kg/m(2). Gallstones developed in 28% (95% CI, 22% to 35%) of patients receiving placebo, in 8% (CI, 5% to 13%) of patients treated with 300 mg/d of ursodeoxycholic acid, in 3% (CI, 1% to 7%) of patients treated with 600 mg/d of ursodeoxycholic acid, and in 2% (CI, 0.5% to 5%) of patients treated with 1200 mg/d of ursodeoxycholic acid. The differences between patients receiving placebo and patients receiving ursodeoxycholic acid were statistically significant. The percentage of ursodeoxycholic acid in bile increased stepwise with increasing doses of ursodeoxycholic acid. Conclusions: Ursodeoxycholic acid, 600 mg/d, is highly effective in preventing gallstone formation in patients having dietary-induced weight reduction.	HLTH MANAGEMENT RESOURCES, BOSTON, MA USA; CIBA GEIGY PHARMACEUT CORP, SUMMIT, NJ USA		SHIFFMAN, ML (corresponding author), VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, HEPATOL SECT, POB 980711, RICHMOND, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043264] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43264] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARAL JF, 1985, AM J SURG, V149, P551, DOI 10.1016/S0002-9610(85)80055-6; ANGELICO M, 1988, HEPATOLOGY, V8, P907; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENNION LJ, 1978, NEW ENGL J MED, V299, P1221, DOI 10.1056/NEJM197811302992205; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; BROOMFIELD PH, 1988, NEW ENGL J MED, V319, P1567, DOI 10.1056/NEJM198812153192403; CAREY MC, 1978, J LIPID RES, V19, P945; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; CRAIN K, 1990, CLIN THER, V12, P250; DIEHL AK, 1991, GASTROENTEROL CLIN N, V20, P1; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; EVERSON GT, 1991, GASTROENTEROL CLIN N, V20, P85; FORGACS IC, 1984, GASTROENTEROLOGY, V87, P299; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; GRACIE WA, 1982, NEW ENGL J MED, V307, P798, DOI 10.1056/NEJM198209233071305; HAY DW, 1990, SEMIN LIVER DIS, V10, P159, DOI 10.1055/s-2008-1040470; HOY MK, 1994, AM J CLIN NUTR, V60, P249, DOI 10.1093/ajcn/60.2.249; INOUE K, 1992, ANN SURG, V215, P19, DOI 10.1097/00000658-199201000-00002; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; KELLEY JE, 1993, AM SURGEON, V59, P23; KUROKI S, 1986, J LIPID RES, V27, P442; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LEGORRETA AP, 1993, JAMA-J AM MED ASSOC, V270, P1429, DOI 10.1001/jama.270.12.1429; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; Luketic V A, 1994, Gastroenterologist, V2, P74; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MARKS JW, 1992, GASTROENTEROLOGY, V103, P566, DOI 10.1016/0016-5085(92)90848-S; MATON PN, 1977, LANCET, V2, P1297, DOI 10.1016/s0140-6736(77)90358-0; SALEN G, 1980, GASTROENTEROLOGY, V78, P1412; SHIFFMAN ML, 1991, AM J GASTROENTEROL, V86, P1000; SHIFFMAN ML, 1993, INT J OBESITY, V17, P153; SHIFFMAN ML, 1992, GASTROENTEROLOGY, V103, P214, DOI 10.1016/0016-5085(92)91115-K; SHIFFMAN ML, 1993, GASTROENTEROLOGY, V105, P1200, DOI 10.1016/0016-5085(93)90968-I; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; STONE BG, 1992, HEPATOLOGY, V15, P795, DOI 10.1002/hep.1840150508; SUGERMAN HJ, 1995, AM J SURG, V169, P91, DOI 10.1016/S0002-9610(99)80115-9; THIJS C, 1992, AM J EPIDEMIOL, V135, P274, DOI 10.1093/oxfordjournals.aje.a116281; TINT GS, 1982, ANN INTERN MED, V97, P351, DOI 10.7326/0003-4819-97-3-351; VONBERGMANN K, 1984, GASTROENTEROLOGY, V87, P136; WATTCHOW DA, 1983, BRIT MED J, V286, P763, DOI 10.1136/bmj.286.6367.763; WOROBETZ LJ, 1993, AM J GASTROENTEROL, V88, P1705; YANG HY, 1992, DIGEST DIS SCI, V37, P912, DOI 10.1007/BF01300390; ZEMAN RK, 1991, GASTROENTEROL CLIN N, V20, P127	44	95	100	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					899	905		10.7326/0003-4819-122-12-199506150-00002	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755224				2022-12-28	WOS:A1995RC27000002
J	JOHNSON, AD				JOHNSON, AD			THE PRICE OF REPRESSION	CELL			English	Review							PREINITIATION COMPLEX; DROSOPHILA				JOHNSON, AD (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.							Alberts B., 1983, MOL BIOL CELL, V4; ANSARI AZ, 1995, NATURE, V374, P371; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BROWN NL, 1995, CELL, V80, P879, DOI 10.1016/0092-8674(95)90291-0; CARTON KM, 1995, MOL CELL BIOL, V15, P861; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KUCHIN S, 1995, IN PRESS P NATL ACAD; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; ONEILL EM, 1995, NATURE, V374, P121, DOI 10.1038/374121a0; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; TZAMARIS D, 1995, GENE DEV, V9, P321; WAHL M, 1995, GENETICS, V140, P79; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190	27	215	216	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					655	658		10.1016/0092-8674(95)90524-3	http://dx.doi.org/10.1016/0092-8674(95)90524-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774005	Bronze			2022-12-28	WOS:A1995RB96100002
J	WRIGHT, R; LOUGHREY, C				WRIGHT, R; LOUGHREY, C			TELERADIOLOGY	BRITISH MEDICAL JOURNAL			English	Article								Advances in telecommunications and computer software have led to the development of radiology image transfer systems. Radiologists may now report radiographs at a site distant from that of the examination, in some cases almost instantaneously. Computed tomography, magnetic resonance imaging, and ultrasonography may also be supervised from afar. Developments over the past few decades are reviewed, allowing an understanding of the systems currently available. These include systems that transmit static images and real time video systems that enable interactive supervision from a radiologist at a distant site. The implications for the practice of radiology are discussed and the main areas of development over the next few years explored.			WRIGHT, R (corresponding author), ULSTER HOSP,BELFAST BT16 0RH,ANTRIM,NORTH IRELAND.							BELL KE, 1994, ULSTER MED J, V63, P23; CANNAVO MJ, 1994, TELEMEDICINE MONTHLY, V2, P8; Hostetler S, 1994, TELEMEDICINE NEW NOV, V1, P17; McClelland I, 1995, J Telemed Telecare, V1, P7	4	12	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1392	1393		10.1136/bmj.310.6991.1392	http://dx.doi.org/10.1136/bmj.310.6991.1392			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787548	Green Published			2022-12-28	WOS:A1995RB00500033
J	ROBERTS, I				ROBERTS, I			CHINA TAKES TO THE ROADS	BRITISH MEDICAL JOURNAL			English	Article								China is undergoing rapid motorisation-motor vehicle registrations are growing at a rate of 10%-20% a year. Road trauma is already a major public health problem, and road deaths, officially estimated to be around 50 000 a year, will almost certainly rise with increasing motorisation. China, with its millions of bicycles, currently has one of the most environmentally friendly transportation systems on the planet. However, as the trend towards car travel continues, the problems of congestion and environmental pollution so evident in the West will also become critical public health issues in China.			ROBERTS, I (corresponding author), MONTREAL CHILDRENS HOSP,DEPT COMMUNITY PAEDIAT RES,2300 TUPPER ST,MONTREAL,PQ H3H 1P3,CANADA.							GUOHUA L, 1991, AM J PUBLIC HEALTH, V81, P605; 1992, TRANSPORT DEV SO CHI; 1991, MISSION REPORT ACCID; 1991, WORLD MOTOR VEHICLE	4	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1311	1313		10.1136/bmj.310.6990.1311	http://dx.doi.org/10.1136/bmj.310.6990.1311			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773048	Green Published			2022-12-28	WOS:A1995QZ86000028
J	SEN, D; OSBORNE, K				SEN, D; OSBORNE, K			GENERAL-PRACTITIONERS KNOWLEDGE OF NOTIFIABLE, REPORTABLE, AND PRESCRIBED DISEASES	BRITISH MEDICAL JOURNAL			English	Article									HLTH & SAFETY EXECUT,EPIDEMIOL & MED STAT UNIT,BOOTLE L20 3QZ,MERSEYSIDE,ENGLAND		SEN, D (corresponding author), HLTH & SAFETY EXECUT,MERSEYSIDE & CHESHIRE AREA OFF,BOOTLE L20 3PG,MERSEYSIDE,ENGLAND.							BOILLAT MA, 1994, OCCUP MED-OXFORD, V44, P123, DOI 10.1093/occmed/44.3.123; 1991, N12 BEN AG LEAFL; 1992, COMPENDIUM HLTH STAT; 1986, HSR23 OFF SAF EC	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1299	1299		10.1136/bmj.310.6990.1299	http://dx.doi.org/10.1136/bmj.310.6990.1299			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773043	Green Published			2022-12-28	WOS:A1995QZ86000021
J	HSU, HL; XIONG, J; GOEDDEL, DV				HSU, HL; XIONG, J; GOEDDEL, DV			THE TNF RECEPTOR 1-ASSOCIATED PROTEIN TRADD SIGNALS CELL-DEATH AND NF-KAPPA-B ACTIVATION	CELL			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; EXPRESSION; DOMAIN; MONOCYTOGENES; ANTIBODIES; RESISTANT; INFECTION; SYSTEM; VIRUS	Many diverse activities of tumor necrosis factor (TNF) are signaled through TNF receptor 1 (TNFR1). We have identified a novel 34 kDa protein, designated TRADD, that specifically interacts with an intracellular domain of TNFR1 known to be essential for mediating programmed cell death. Overexpression of TRADD leads to two major TNF-induced responses, apoptosis and activation of NF-kappa B. The C-terminal 118 amino acids of TRADD are sufficient to trigger both of these activities and likewise sufficient for interaction with the death domain of TNFR1. TRADD-mediated cell death can be suppressed by the crmA gene, which encodes a specific inhibitor of the interleukin-1 beta-converting enzyme. However, NF-kappa B activation by TRADD is not inhibited by crmA expression, demonstrating that the signaling pathways for TNF-induced cell death and NF-kappa B activation are distinct.			HSU, HL (corresponding author), TULARIK INC,270 E GRAND AVE,S SAN FRANCISCO,CA 94080, USA.							AUSUBEL FM, 1994, CURR PROT MOL BIOL, V1; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GEHR G, 1992, J IMMUNOL, V149, P911; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; HU MH, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; IWABUCHI K, 1993, ONCOGENE, V8, P1693; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KRUPPA G, 1992, J IMMUNOL, V148, P3152; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MIURA M, 1993, CELL, V75, P656; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; RAY CA, 1992, CELL, V69, P587; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONG HY, 1994, J BIOL CHEM, V269, P22492; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOMEI LD, 1991, CURR COMM CELL MOL B, V3, P5; VANARSDALE TL, 1994, J IMMUNOL, V153, P3043; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1994, J IMMUNOL, V152, P1751; WONG GHW, 1992, J IMMUNOL, V149, P3550	44	1683	1757	0	37	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					495	504		10.1016/0092-8674(95)90070-5	http://dx.doi.org/10.1016/0092-8674(95)90070-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758105	Bronze			2022-12-28	WOS:A1995QZ71000006
J	JOHNSTON, SL; PATTEMORE, PK; SANDERSON, G; SMITH, S; LAMPE, F; JOSEPHS, L; SYMINGTON, P; OTOOLE, S; MYINT, SH; TYRRELL, DAJ; HOLGATE, ST				JOHNSTON, SL; PATTEMORE, PK; SANDERSON, G; SMITH, S; LAMPE, F; JOSEPHS, L; SYMINGTON, P; OTOOLE, S; MYINT, SH; TYRRELL, DAJ; HOLGATE, ST			COMMUNITY STUDY OF ROLE OF VIRAL-INFECTIONS IN EXACERBATIONS OF ASTHMA IN 9-11 YEAR-OLD CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							WHEEZY BRONCHITIS; RESPIRATORY-INFECTIONS; VIRUSES; SYMPTOMS; ADULTS; PRECIPITANTS; ASSOCIATION; CORONAVIRUS; CHILDHOOD	Objective-To study the association between upper and lower respiratory viral infections and acute exacerbations of asthma in schoolchildren in the community. Design-Community based 13 month longitudinal study using diary card respiratory symptom and peak expiratory flow monitoring to allow early sampling for viruses. Subjects-1O8 Children aged 9-11 years who had reported wheeze or cough, or both, in a questionnaire. Setting-Southampton and surrounding community. Main outcome measures-Upper and lower respiratory viral infections detected by polymerase chain reaction or conventional methods, reported exacerbations of asthma, computer identified episodes of respiratory tract symptoms or peak flow reductions. Results-Viruses were detected in 80% of reported episodes of reduced peak expiratory flow, 80% of reported episodes of wheeze, and in 85% of reported episodes of upper respiratory symptoms, cough, wheeze, and a fall in peak expiratory flow. The median duration of reported falls in peak expiratory flow was 14 days, and the median maximum fall in peak expiratory flow was 81 1/min. The most commonly identified virus type was rhinovirus. Conclusions-This study supports the hypothesis that upper respiratory viral infections are associated with 80-85% of asthma exacerbations in school age children.	UNIV SOUTHAMPTON,DEPT MED STAT & COMP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV LEICESTER,DEPT MICROBIOL,LEICESTER LE1 9HN,LEICS,ENGLAND; MRC,COMMON COLD UNIT,SALISBURY,WILTS,ENGLAND	University of Southampton; University of Leicester	JOHNSTON, SL (corresponding author), UNIV MED SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.		Johnston, Sebastian Lennox/I-2423-2012; Fahimifar, Sepideh/M-5303-2019; Lampe, Fiona/I-5826-2019	Johnston, Sebastian Lennox/0000-0003-3009-9200; Lampe, Fiona/0000-0001-6851-5471; Josephs, Lynn/0000-0002-7157-2992; Pattemore, Philip/0000-0002-4968-1287				BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; CARLSEN KH, 1984, ARCH DIS CHILD, V59, P310, DOI 10.1136/adc.59.4.310; CLOUGH JB, 1994, AM J RESP CRIT CARE, V150, P48, DOI 10.1164/ajrccm.150.1.8025771; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; Gwaltney J.M., 1979, PRINCIPLES PRACTICE, V1st ed., P429; Hamparian W, 1979, DIAGNOSTIC PROCEDURE, P562; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; HORN MEC, 1975, J HYG-CAMBRIDGE, V74, P157, DOI 10.1017/S0022172400024220; HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; JENNINGS LC, 1987, NEW ZEAL MED J, V100, P488; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111, DOI 10.1128/JCM.31.1.111-117.1993; JOHNSTON SL, 1993, THESIS U SOUTHAMPTON, P99; KRAAIJEVELD CA, 1980, J CLIN MICROBIOL, V12, P493, DOI 10.1128/JCM.12.4.493-497.1980; LARSON HE, 1980, J MED VIROL, V5, P221, DOI 10.1002/jmv.1890050306; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124, DOI 10.1136/adc.66.1.124; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MITCHELL I, 1976, ARCH DIS CHILD, V51, P707, DOI 10.1136/adc.51.9.707; MITCHELL I, 1978, ARCH DIS CHILD, V53, P106, DOI 10.1136/adc.53.2.106; MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PHILLPOTTS RJ, 1983, J VIROL METHODS, V6, P267, DOI 10.1016/0166-0934(83)90041-1; PICADO C, 1992, THORAX, V47, P197, DOI 10.1136/thx.47.3.197; POTTER PC, 1984, S AFR MED J, V66, P397; ROLDAAN AC, 1982, EUR J RESPIR DIS, V63, P140; SCHMIDT NJ, 1979, DIAGNOSTIC PROCEDURE, P67; STORR J, 1989, ARCH DIS CHILD, V64, P103, DOI 10.1136/adc.64.1.103; WILSON NM, 1989, ARCH DIS CHILD, V64, P1194, DOI 10.1136/adc.64.8.1194	31	1472	1525	0	99	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1225	1229		10.1136/bmj.310.6989.1225	http://dx.doi.org/10.1136/bmj.310.6989.1225			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767192	Green Published			2022-12-28	WOS:A1995QY87700015
J	LOWE, CJ; RAYNOR, DK; COURTNEY, EA; PURVIS, J; TEALE, C				LOWE, CJ; RAYNOR, DK; COURTNEY, EA; PURVIS, J; TEALE, C			EFFECTS OF SELF-MEDICATION PROGRAM ON KNOWLEDGE OF DRUGS AND COMPLIANCE WITH TREATMENT IN ELDERLY PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether a programme of self medication for inpatients improves compliance with treatment and knowledge of their drugs after discharge from hospital. Design-Patients were prospectively recruited from four wards: two with a self medication programme and two acting as controls. Ten days after discharge the patients were visited at home. They were questioned about their drugs, and a tablet count was undertaken. Setting-The pharmacy department and four medical wards with an interest in elderly patients at a district general hospital, and the patients' homes. Patients-88 patients discharged to their own homes who were regularly taking one or more drugs. Intervention-A hospital self medication programme in which patients are educated about their medicines and given increasing responsibility for taking them in hospital. Main outcome measure-Compliance with and knowledge of the purpose of their medicines 10 days after discharge from hospital. Results-The mean compliance score in patients taking part in the self medication programme was 95% compared with 83% in the control group (difference 12%, 95% confidence interval 4% to 21%; P<0.02). Of the patients in the self medication group, 90% (38/42) knew the purpose of their drugs compared with 46% (17/37) in the control group (difference 44%, 26% to 63%; P<0.001). Conclusion-A self medication programme is an effective aid for improving compliance with and knowledge of patients' drugs after discharge.	SEACROFT HOSP,PRACTICE DEV UNIT,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND; UNIV BRADFORD,PHARM PRACTICE RES UNIT,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND	University of Bradford	LOWE, CJ (corresponding author), SEACROFT HOSP,DEPT PHARM,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND.							ASPLUND J, 1984, BRIT J CLIN PHARMACO, V17, P547, DOI 10.1111/j.1365-2125.1984.tb02388.x; BAXENDALEC, 1978, BRIT MED J, V2, P1278; Bird C, 1988, Nurs Times, V84, P28; FOSTER H, 1993, AGE AGEING S3, V22, P23; GARDNER MJ, 1989, CONFIDENCE INTERVAL; Ley P., 1988, COMMUNICATING PATIEN; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; RAYNOR DK, 1993, BRIT MED J, V306, P1158, DOI 10.1136/bmj.306.6886.1158; RUDD P, 1979, CLIN PHARMACOL THER, V25, P257; SACKET DL, 1979, COMPLIANCE HEALTHCAR; SANDLER DA, 1989, BRIT MED J, V298, P870, DOI 10.1136/bmj.298.6677.870; Webb C, 1990, Nurs Times, V86, P46; Wood SI, 1992, INT J PHARM PRAC, V1, P240; WRIGHT EC, 1993, LANCET, V342, P909, DOI 10.1016/0140-6736(93)91951-H	15	80	82	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1229	1231		10.1136/bmj.310.6989.1229	http://dx.doi.org/10.1136/bmj.310.6989.1229			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767193	Green Published			2022-12-28	WOS:A1995QY87700016
J	GRONBAEK, M; DEIS, A; SORENSEN, TIA; BECKER, U; SCHNOHR, P; JENSEN, G				GRONBAEK, M; DEIS, A; SORENSEN, TIA; BECKER, U; SCHNOHR, P; JENSEN, G			MORTALITY ASSOCIATED WITH MODERATE INTAKES OF WINE, BEER, OR SPIRITS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ALCOHOL-CONSUMPTION; RED WINE; RISK; WOMEN; MEN	Objective-To examine the association between intake of different types of alcoholic drinks and mortality. Design-Prospective population study with baseline assessment of alcohol intake, smoking habit, income, education, and body mass index, and 10-12 years' follow up of mortality. Setting-Copenhagen city heart study, Denmark. Subjects-6051 men and 7234 women aged 30-70 years. Main outcome measure-Number and time of cause-specific deaths from 1976 to 1988. Results-The risk of dying steadily decreased with an increasing intake of wine-from a relative risk of 1.00 for the subjects who never drank wine to 0.51 (95% confidence interval 0.32 to 0.81) for those who drank three to five glasses a day. Intake of neither beer nor spirits, however, was associated with reduced risk. For spirits intake the relative risk of dying increased from 1.00 for those who never drank to 1.34 (1.05 to 1.71) for those with an intake of three to five drinks a day. The effects of the three types of alcoholic drinks seemed to be independent of each other, and no significant interactions existed with sex, age, education, income, smoking, or body mass index. Wine drinking showed the same relation to risk of death from cardiovascular and cerebrovascular disease as to risk of death from all causes. Conclusion-Low to moderate intake of wine is associated with lower mortality from cardiovascular and cerebrovascular disease and other causes. Similar intake of spirits implied an increased risk, while beer drinking did not affect mortality.	COPENHAGEN HOSP CORP,INST PREVENT MED,DANISH EPIDEMIOL SCI CTR,COPENHAGEN,DENMARK; DANISH COMM ASSESSMENT SUBSTAND LIVES,COPENHAGEN,DENMARK; UNIV COPENHAGEN,HVIDOVRE HOSP,DEPT MED GASTROENTEROL,ALCOHOL UNIT,DK-1168 COPENHAGEN,DENMARK; UNIV COPENHAGEN,RIGSHOSP,DEPT 7117,COPENHAGEN CITY HEART STUDY,DK-2100 COPENHAGEN,DENMARK	Aarhus University; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen			Becker, Ulrik/D-2657-2012	Becker, Ulrik/0000-0002-1678-7771; Gronbaek, Morten Klocker/0000-0002-8473-6474				Appleyard M., 1989, SCAND J SOC MED, V41, P1; BOFFETTA P, 1990, EPIDEMIOLOGY, V1, P337; Carnacini A, 1994, ALCOLOGIA, V6, P41; CHEN J, 1992, INT J EPIDEMIOL, V2, P625; CRIQUI MH, 1990, BRIT J ADDICT, V85, P854; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FRANKEL EN, 1993, LANCET, V341, P454, DOI 10.1016/0140-6736(93)90206-V; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; Gerdes L U, 1992, Ugeskr Laeger, V154, P3580; GRONBAEK M, 1994, BRIT MED J, V308, P302, DOI 10.1136/bmj.308.6924.302; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HENNEKENS CH, 1979, JAMA-J AM MED ASSOC, V242, P1973, DOI 10.1001/jama.242.18.1973; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; JACKSON R, 1991, BRIT MED J, V303, P211, DOI 10.1136/bmj.303.6796.211; KIMBALL AW, 1992, AM J EPIDEMIOL, V135, P1287, DOI 10.1093/oxfordjournals.aje.a116235; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KOZARAREVIC DJ, 1980, LANCET, V1, P613; MARMOT MG, 1981, LANCET, V1, P580; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MIDANIK LT, 1988, BRIT J ADDICT, V83, P1019; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; SAELAN H, 1993, ALCOHOL DRUG ABUSE 1; SEIGNEUR M, 1990, J APPL CARDIOL, V5, P215; SHAPER AG, 1988, LANCET, V1, P1267; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STLEGER AS, 1979, LANCET, V1, P1017, DOI 10.1016/S0140-6736(79)92765-X; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801	31	496	505	2	39	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1165	1169		10.1136/bmj.310.6988.1165	http://dx.doi.org/10.1136/bmj.310.6988.1165			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX566	7767150	Green Published			2022-12-28	WOS:A1995QX56600021
J	DIXON, JM				DIXON, JM			ABC OF BREAST DISEASES - BREAST INFECTION	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh	DIXON, JM (corresponding author), ROYAL EDINBURGH & ASSOCIATED HOSP,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND.								0	24	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 8	1994	309	6959					946	949		10.1136/bmj.309.6959.946	http://dx.doi.org/10.1136/bmj.309.6959.946			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL781	7755694	Green Published			2022-12-28	WOS:A1994PL78100031
J	SEKAS, G; HUTSON, WR				SEKAS, G; HUTSON, WR			MISREPRESENTATION OF ACADEMIC ACCOMPLISHMENTS BY APPLICANTS FOR GASTROENTEROLOGY FELLOWSHIPS	ANNALS OF INTERNAL MEDICINE			English	Article								Objective: To determine whether two applicants who misrepresented their accomplishments in applications for gastroenterology fellowships reflected isolated incidents or whether misrepresentation was more widespread. Design: Retrospective review of all 236 applications submitted for fellowship in a recent year for confirmation of research experience and cited publications. Results: 138 applicants (58.5%) reported research experience during residency in a U.S. training program. Research activity could not be confirmed for 47 of 138 applicants (34.1%). Fifty-three applicants (22.4%) reported published articles, and 16 of these applicants (30.2%) misrepresented articles. Misrepresentation included citations of nonexistent articles in actual journals, articles in nonexistent journals, or articles noted as ''in press.'' Conclusions: Misrepresentation on applications for gastroenterology fellowships was common. The following steps are recommended: 1) Fellowship programs should require that copies of ail publications and letters of acceptance for manuscripts in press be submitted with fellowship applications; 2) applications should contain a statement to be signed by the applicant that the information provided is accurate; 3) persons writing letters of recommendation should verify the information being submitted by applicants; 4) medical students and residents should be taught that embellishment of curricula vitae constitutes misconduct; and 5) institutions and professional organizations should develop policies to deal with this problem.	UNIV PITTSBURGH, MED CTR, SCH MED, DIV GASTROENTEROL & HEPATOL, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								Broad W., 1982, BETRAYERS TRUTH; ENGLER RL, 1987, NEW ENGL J MED, V317, P1383, DOI 10.1056/NEJM198711263172205; SWAZEY JP, 1993, AM SCI, V81, P542; PHYSICIAN COMPENSATI; MSMP DATA APPOINTMEN; 1994, PROJECT PROFESSIONAL; 1992, RESPONSIBLE SCI ENSU, V1	7	78	78	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					38	41		10.7326/0003-4819-123-1-199507010-00006	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762913				2022-12-28	WOS:A1995RE66500007
J	KLAFEHN, PD				KLAFEHN, PD			A TRIAL FOR MY LIFE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1812	1812						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776484				2022-12-28	WOS:A1995RD11600002
J	CUZICK, J; SZAREWSKI, A; TERRY, G; HO, L; HANBY, A; MADDOX, P; ANDERSON, M; KOCJAN, G; STEELE, ST; GUILLEBAUD, J				CUZICK, J; SZAREWSKI, A; TERRY, G; HO, L; HANBY, A; MADDOX, P; ANDERSON, M; KOCJAN, G; STEELE, ST; GUILLEBAUD, J			HUMAN PAPILLOMAVIRUS TESTING IN PRIMARY CERVICAL SCREENING	LANCET			English	Article							TYPE-16; WOMEN; DNA	Several studies have examined the role of tests for human papillomavirus (HPV) We looked at HPV testing for types 16, 18, 31, and 33 on material taken at the time of a cervical smear in 2009 eligible women having routine screening. Women with any degree of dyskaryosis or high levels of one of these HPV types were referred for colposcopy. 44% of the cervical intraepithelial neoplasia (CIN) lesions of grade 2/3 detected had negative cytology and were found only by HPV testing. A further 22% of the CIN 2/3 lesions were positive for HPV but showed only borderline or mild cytological changes. The positive predictive value of HPV testing was 42%, which was similar to that for moderate dyskaryosis. HPV types 16 and 31 were more sensitive and specific for CIN 2/3 than were types 18 or 33. However, 25% of the CIN 2/3 lesions were not detected by these four HPV tests. We suggest that HPV testing could usefully augment but not replace conventional cytology. These results should stimulate a much larger randomised trial to assess the impact of these improved CIN 2/3 detection rates on the subsequent incidence of invasive cancer.	IMPERIAL CANC RES FUND, DEPT HISTOPATHOL, LONDON WC2A 3PX, ENGLAND; UNIV NOTTINGHAM HOSP, DEPT HISTOPATHOL, NOTTINGHAM NG7 2UH, ENGLAND; UCL, SCH MED, DEPT HISTOPATHOL, LONDON W1N 8AA, ENGLAND; UCL, SCH MED, DEPT CYTOL, LONDON W1N 8AA, ENGLAND; UNIV COLL & MIDDLESEX SCH MED, DEPT OBSTET & GYNAECOL, LONDON, ENGLAND; MARGARET PYKE CTR FAMILY PLANNING & REPROD HLTH C, LONDON, ENGLAND	Cancer Research UK; University of Nottingham; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London	CUZICK, J (corresponding author), IMPERIAL CANC RES FUND, DEPT MATH STAT & EPIDEMIOL, LONDON WC2A 3PX, ENGLAND.							BAVIN PJ, 1993, BRIT J CANCER, V67, P602, DOI 10.1038/bjc.1993.110; COX JT, 1992, OBSTET GYNECOL, V80, P389; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; HECHT JL, 1995, INT J CANCER, V60, P369, DOI 10.1002/ijc.2910600317; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Meijer C J, 1992, IARC Sci Publ, P271; REID R, 1991, AM J OBSTET GYNECOL, V164, P1461, DOI 10.1016/0002-9378(91)91425-V; SLATER DN, 1994, J CLIN PATHOL, V47, P27, DOI 10.1136/jcp.47.1.27; SZAREWSKI A, 1993, ACTA CYTOL, V37, P457; TERRY G, 1994, CLIN CHEM, V40, P1890; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; VANWIJNGAARDEN WJ, 1995, BRIT J OBSTET GYNAEC, V102, P137	14	289	296	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 17	1995	345	8964					1533	1536		10.1016/S0140-6736(95)91086-7	http://dx.doi.org/10.1016/S0140-6736(95)91086-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791438				2022-12-28	WOS:A1995RD79000008
J	BOUMPAS, DT; AUSTIN, HA; FESSLER, BJ; BALOW, JE; KLIPPEL, JH; LOCKSHIN, MD				BOUMPAS, DT; AUSTIN, HA; FESSLER, BJ; BALOW, JE; KLIPPEL, JH; LOCKSHIN, MD			SYSTEMIC LUPUS-ERYTHEMATOSUS - EMERGING CONCEPTS .1. RENAL, NEUROPSYCHIATRIC, CARDIOVASCULAR, PULMONARY, AND HEMATOLOGIC DISEASE	ANNALS OF INTERNAL MEDICINE			English	Review							IMMUNE THROMBOCYTOPENIC PURPURA; ACUTE NONLYMPHOCYTIC LEUKEMIA; RIBOSOMAL-P-PROTEINS; ANTI-DNA ANTIBODIES; ANTIPHOSPHOLIPID ANTIBODIES; PULSE CYCLOPHOSPHAMIDE; LONG-TERM; INTRAVENOUS CYCLOPHOSPHAMIDE; CARDIAC ABNORMALITIES; TRANSVERSE MYELITIS	Purpose: To review advances and controversies in the diagnosis and management of systemic lupus erythematosus with visceral involvement (renal, neuropsychiatric, cardiopulmonary, and hematologic disease). Data Sources and Study Selection: Review of the English-language medical literature with emphasis on articles published in the last 5 years. More than 400 articles were reviewed. Data Synthesis: Recent debates pertaining to lupus nephritis have focused on the value of kidney biopsy data and the role of cytotoxic drug therapies. Many studies have shown that estimates of prognosis are enhanced by consideration of clinical, demographic, and histologic features. For patients with severe lupus nephritis, an extended course of pulse cyclophosphamide therapy is more effective than a 6-month course of pulse methylprednisolone therapy in preserving renal function. Adding a quarterly maintenance regimen to monthly pulse cyclophosphamide therapy reduces the rate of exacerbations. Plasmapheresis appears not to enhance the effectiveness of prednisone and daily oral cyclophosphamide. Small case series have shown pulses of cyclophosphamide to be beneficial in patients with lupus and neuropsychiatric disease refractory to glucocorticoid therapy, acute pulmonary disease (pneumonitis or hemorrhage), and thrombocytopenia. Patients with systemic lupus erythematosus have an increased prevalence of valvular and atherosclerotic heart disease, apparently because of factors related to the disease itself and to drug therapy. Conclusions: Cytotoxic agents are superior to glucocorticoid therapy for the treatment of proliferative lupus nephritis, but the optimal duration and intensity of cytotoxic therapy remain undefined. Definitive studies of the treatment of autoimmune thrombocytopenia and acute pulmonary disease and of the diagnosis and treatment of neuropsychiatric disease are not available.			BOUMPAS, DT (corresponding author), NIH, BLDG 10, ROOM 3N-112, BETHESDA, MD 20892 USA.							ABRAMSON SB, 1991, ANN INTERN MED, V114, P941, DOI 10.7326/0003-4819-114-11-941; ALARCONSEGOVIA D, 1989, MEDICINE, V68, P353, DOI 10.1097/00005792-198911000-00003; ANDERSEN JC, 1994, NEW ENGL J MED, V330, P1560, DOI 10.1056/NEJM199406023302203; ANDERSON MJ, 1985, ANN INTERN MED, V103, P548, DOI 10.7326/0003-4819-103-4-548; APPEL AE, 1978, AM J MED, V64, P274, DOI 10.1016/0002-9343(78)90056-6; ASHERSON RA, 1990, J RHEUMATOL, V17, P1292; ASHERSON RA, 1986, J RHEUMATOL, V13, P1; ASHERSON RA, 1987, ANN RHEUM DIS, V46, P605, DOI 10.1136/ard.46.8.605; AUSTIN HA, 1994, KIDNEY INT, V45, P544, DOI 10.1038/ki.1994.70; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; AUSTIN HA, 1992, ANN INTERN MED, V116, P672, DOI 10.7326/0003-4819-116-8-672; BALOW JE, 1984, NEW ENGL J MED, V311, P491, DOI 10.1056/NEJM198408233110802; BARILE L, 1992, J RHEUMATOL, V19, P370; BELLUCCI S, 1988, BLOOD, V71, P1165; BERCHTOLD P, 1989, BLOOD, V74, P2309; BEUTLER E, 1993, BLOOD, V81, P1411; Bluestein HG, 1992, SYSTEMIC LUPUS ERYTH, P639; BOUMPAS DT, 1991, Q J MED, V81, P975, DOI 10.1093/qjmed/81.3.975; BOUMPAS DT, 1993, ANN INTERN MED, V119, P366, DOI 10.7326/0003-4819-119-5-199309010-00003; BOUMPAS DT, 1990, ANN INTERN MED, V112, P674, DOI 10.7326/0003-4819-112-9-674; BOUMPAS DT, 1993, J RHEUMATOL, V20, P1641; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; BOUMPAS DT, 1990, J RHEUMATOL, V17, P89; CERVERA R, 1992, ANN RHEUM DIS, V51, P156, DOI 10.1136/ard.51.2.156; CORITSIDIS G, 1991, KIDNEY INT, V39, P858, DOI 10.1038/ki.1991.108; COUSER WG, 1993, KIDNEY INT, V44, pS19; DINANT HJ, 1982, ANN INTERN MED, V96, P728, DOI 10.7326/0003-4819-96-6-728; DONADIO JV, 1978, NEW ENGL J MED, V299, P1151, DOI 10.1056/NEJM197811232992102; ESDAILE JM, 1991, Q J MED, V81, P907; ESDAILE JM, 1989, Q J MED, V72, P779; ETTINGER WH, 1987, AM J MED, V83, P503, DOI 10.1016/0002-9343(87)90762-5; FAVRE H, 1989, AM J NEPHROL, V9, P57, DOI 10.1159/000168040; FIGUEROA M, 1993, NEW ENGL J MED, V328, P1226, DOI 10.1056/NEJM199304293281703; FOSTER MH, 1993, LAB INVEST, V69, P494; GALVE E, 1988, NEW ENGL J MED, V319, P817, DOI 10.1056/NEJM198809293191302; GARCIA DL, 1987, J CLIN INVEST, V80, P867, DOI 10.1172/JCI113145; GARIN EH, 1979, CLIN NEPHROL, V12, P148; GIBBONS RB, 1988, ARTHRITIS RHEUM, V31, P1552, DOI 10.1002/art.1780311212; GINSBURG KS, 1992, ARTHRITIS RHEUM, V35, P776, DOI 10.1002/art.1780350711; GINZLER EM, 1993, J RHEUMATOL, V20, P1694; GLEASON CB, 1993, AM HEART J, V125, P1123, DOI 10.1016/0002-8703(93)90124-R; GOLBUS J, 1994, RHEUM DIS CLIN N AM, V20, P213; Hahn Bevra H., 1993, P195; HANLY JG, 1992, J RHEUMATOL, V19, P732; HANLY JG, 1992, J RHEUMATOL, V19, P562; HANSON VG, 1992, J EXP MED, V176, P565, DOI 10.1084/jem.176.2.565; HARISDANGKUL V, 1989, SOUTHERN MED J, V82, P321, DOI 10.1097/00007611-198903000-00012; HAY EM, 1992, ARTHRITIS RHEUM, V35, P411, DOI 10.1002/art.1780350409; HELLMANN DB, 1987, MEDICINE, V66, P341, DOI 10.1097/00005792-198709000-00002; HILL GS, 1978, AM J MED, V64, P61, DOI 10.1016/0002-9343(78)90180-8; HOLMAN BL, 1993, ARTHRITIS RHEUM-US, V36, P1193; HOUSSIAU FA, 1991, LUPUS, V1, P31, DOI 10.1177/096120339100100106; JONSSON H, 1989, MEDICINE, V68, P141, DOI 10.1097/00005792-198905000-00002; JOUHIKAINEN T, 1990, EUR J HAEMATOL, V44, P234; KABAKOV AE, 1992, CLIN IMMUNOL IMMUNOP, V63, P214, DOI 10.1016/0090-1229(92)90225-D; KENT DL, 1994, ANN INTERN MED, V120, P872; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; KERJASCHKI D, 1990, VIRCHOWS ARCH B, V58, P253; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; KIMBERLY RP, 1981, AM J MED, V70, P817, DOI 10.1016/0002-9343(81)90538-6; KOREN E, 1992, J CLIN INVEST, V89, P1236, DOI 10.1172/JCI115707; LAITMAN RS, 1989, AM J MED, V87, P132; Laurence J, 1992, SYSTEMIC LUPUS ERYTH, P771; LAVALLE C, 1990, J RHEUMATOL, V17, P34; LEATHERMAN JW, 1987, CHEST, V91, P891, DOI 10.1378/chest.91.6.891; LEHMAN TJA, 1983, J RHEUMATOL, V10, P655; LEHMAN TJA, 1989, J PEDIATR-US, V114, P1055, DOI 10.1016/S0022-3476(89)80463-9; LEUNG WH, 1990, AM J MED, V89, P411, DOI 10.1016/0002-9343(90)90368-N; LEUNG WH, 1990, INT J CARDIOL, V27, P367, DOI 10.1016/0167-5273(90)90294-F; LEVEY AS, 1992, ANN INTERN MED, V116, P114, DOI 10.7326/0003-4819-116-2-114; LEVY RD, 1993, CHEST, V104, P1903, DOI 10.1378/chest.104.6.1903; LEWIS EJ, 1992, NEW ENGL J MED, V326, P1373, DOI 10.1056/NEJM199205213262101; LUCE EB, 1990, ORAL SURG ORAL MED O, V70, P590, DOI 10.1016/0030-4220(90)90405-H; LYNCH JP, 1992, ANNU REV MED, V43, P17, DOI 10.1146/annurev.me.43.020192.000313; MACKWORTHYOUNG CG, 1988, ANN RHEUM DIS, V47, P496, DOI 10.1136/ard.47.6.496; MAGIL AB, 1988, KIDNEY INT, V34, P511, DOI 10.1038/ki.1988.211; MAIER WP, 1990, ARTHRITIS RHEUM, V33, P1233; MARTIN L, 1992, J RHEUMATOL, V19, P1186; MCCUNE WJ, 1988, NEW ENGL J MED, V318, P1423, DOI 10.1056/NEJM198806023182203; MCCUNE WJ, 1988, RHEUM DIS CLIN N AM, V14, P149; MCLAUGHLIN JR, 1994, ARTHRITIS RHEUM, V37, P559, DOI 10.1002/art.1780370417; MITCHELL SR, 1989, AM J MED, V86, P510, DOI 10.1016/0002-9343(89)90369-0; MULHERIN D, 1993, BAILLIERE CLIN RHEUM, V7, P31, DOI 10.1016/S0950-3579(05)80267-5; MULLER NL, 1987, RADIOLOGY, V165, P731; MULLER NL, 1990, AM REV RESPIR DIS, V142, P1206; NIHOYANNOPOULOS P, 1990, CIRCULATION, V82, P369, DOI 10.1161/01.CIR.82.2.369; NOSSENT HC, 1990, ARTHRITIS RHEUM, V33, P970, DOI 10.1002/art.1780330708; ORENS JB, 1994, RHEUM DIS CLIN N AM, V20, P159; PETRI M, 1992, MEDICINE, V71, P291, DOI 10.1097/00005792-199209000-00004; PILLEMER SR, 1988, J RHEUMATOL, V15, P284; REVEILLE JD, 1990, ARTHRITIS RHEUM-US, V33, P37, DOI 10.1002/art.1780330105; ROLDAN CA, 1992, J AM COLL CARDIOL, V20, P1127, DOI 10.1016/0735-1097(92)90368-W; ROUBENOFF R, 1990, ANN INTERN MED, V113, P501, DOI 10.7326/0003-4819-113-7-501; RUBBERT A, 1993, ARTHRITIS RHEUM-US, V36, P1253, DOI 10.1002/art.1780360910; SCHNEEBAUM AB, 1991, AM J MED, V90, P54, DOI 10.1016/0002-9343(91)90506-S; SCHROEDER JO, 1987, ANN INTERN MED, V107, P344, DOI 10.7326/0003-4819-107-2-344; SCHWAB EP, 1993, SEMIN ARTHRITIS RHEU, V23, P8, DOI 10.1016/S0049-0172(05)80022-8; SCHWARTZ RS, 1994, NEW ENGL J MED, V330, P1609, DOI 10.1056/NEJM199406023302212; SHEMESH O, 1985, KIDNEY INT, V28, P830, DOI 10.1038/ki.1985.205; SIMONSON JS, 1989, J RHEUMATOL, V16, P918; STAFFORD FJ, 1994, J RHEUMATOL, V21, P2068; STEINBERG AD, 1991, ARTHRITIS RHEUM-US, V34, P945, DOI 10.1002/art.1780340803; STRAATON KV, 1988, AM J MED, V85, P645; STRICKER RB, 1992, J RHEUMATOL, V19, P1469; STROBER S, 1988, ARTHRITIS RHEUM, V31, P850, DOI 10.1002/art.1780310705; STURFELT G, 1992, MEDICINE, V71, P216, DOI 10.1097/00005792-199207000-00004; TAN EM, 1992, SYSTEMIC LUPUS ERYTH, pR15; TEITEL AD, 1992, SEMIN ARTHRITIS RHEU, V22, P203, DOI 10.1016/0049-0172(92)90020-E; TERMAAT RM, 1992, KIDNEY INT, V42, P1363, DOI 10.1038/ki.1992.428; TOKUDA M, 1994, ARTHRITIS RHEUM, V37, P551, DOI 10.1002/art.1780370416; VANDAM A, 1991, J RHEUMATOL, V18, P1026; VASQUEZ S, 1992, J RHEUMATOL, V19, P1625; VIANNA JL, 1994, AM J MED, V96, P3, DOI 10.1016/0002-9343(94)90108-2; VLAHAKOS D, 1992, J AM SOC NEPHROL, V2, P1345; WACHOLTZ MC, 1992, ARTHRITIS RHEUM, V35, P837, DOI 10.1002/art.1780350721; WEINRIB L, 1990, SEMIN ARTHRITIS RHEU, V20, P48, DOI 10.1016/0049-0172(90)90094-V; WELLS AU, 1993, AM REV RESPIR DIS, V148, P1076, DOI 10.1164/ajrccm/148.4_Pt_1.1076; WEST SG, 1988, ANN INTERN MED, V108, P703, DOI 10.7326/0003-4819-108-5-703; WEST SG, 1994, RHEUM DIS CLIN N AM, V20, P129; WHITINGOKEEFE Q, 1982, ANN INTERN MED, V96, P718, DOI 10.7326/0003-4819-96-6-718; WIEDEMANN HP, 1992, J THORAC IMAG, V7, P1, DOI 10.1097/00005382-199203000-00003; WIEDEMANN HP, 1989, CLIN CHEST MED, V10, P677; WILSON CB, 1985, AM J PHYSIOL, V248, pF319, DOI 10.1152/ajprenal.1985.248.3.F319; ZYSSET MK, 1987, ORAL SURG ORAL MED O, V64, P30, DOI 10.1016/0030-4220(87)90112-5	124	251	255	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					940	950		10.7326/0003-4819-122-12-199506150-00009	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755231				2022-12-28	WOS:A1995RC27000009
J	LUKAS, J; PARRY, D; AAGAARD, L; MANN, DJ; BARTKOVA, J; STRAUSS, M; PETERS, G; BARTEK, J				LUKAS, J; PARRY, D; AAGAARD, L; MANN, DJ; BARTKOVA, J; STRAUSS, M; PETERS, G; BARTEK, J			RETINOBLASTOMA-PROTEIN-DEPENDENT CELL-CYCLE INHIBITION BY THE TUMOR-SUPPRESSOR P16	NATURE			English	Article							GENE; OVEREXPRESSION; PROGRESSION; FIBROBLASTS; G(1); D1	D-TYPE cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle(1-6) by phosphorylating the retinoblastoma protein (RB)(7,8). The activities of Cdk4 and Cdk6 are constrained by inhibitors(9-12) such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb--/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.	DANISH CANC SOC,DIV CANC BIOL,DK-2100 COPENHAGEN 0,DENMARK; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; MAX PLANCK GESELL,D-13122 BERLIN,GERMANY	Danish Cancer Society; Cancer Research UK; Max Planck Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEN J, 1994, CANCER RES, V54, P6353; JIANG W, 1993, ONCOGENE, V8, P3447; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, IN PRESS ONCOGENE; LUKAS J, 1994, J ONCOGENE, V9, P707; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, CANCER RES, V54, P5816; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	26	864	889	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					503	506		10.1038/375503a0	http://dx.doi.org/10.1038/375503a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777060				2022-12-28	WOS:A1995RC18800052
J	BRAHAMS, D				BRAHAMS, D			CLARIFICATION OF THE EGGSHELL SKULL DOCTRINE	LANCET			English	Editorial Material																		1994, LANCET, V343, P1217	1	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1430	1430		10.1016/S0140-6736(95)92614-3	http://dx.doi.org/10.1016/S0140-6736(95)92614-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760618	Bronze			2022-12-28	WOS:A1995RB44100025
J	SICHERI, F; YANG, DSC				SICHERI, F; YANG, DSC			ICE-BINDING STRUCTURE AND MECHANISM OF AN ANTIFREEZE PROTEIN FROM WINTER FLOUNDER	NATURE			English	Article							MOLECULAR-DYNAMICS; GLOBULAR-PROTEINS; ALPHA-HELICES; POLYPEPTIDE; ADSORPTION	ANTIFREEZE proteins provide fish with protection against the freezing effect of polar environments by binding to ice surfaces and inhibiting growth of ice crystals. We present the X-ray crystal structure at 1.5 Angstrom resolution of a lone alpha-helical antifreeze protein from winter flounder, which provides a detailed look at its ice-binding features. These consist of four repeated ice-binding motifs, the side chains of which are inherently rigid or restrained by pairwise side-chain interactions to form a flat binding surface. Elaborate amino- and carboxy-terminal cap structures are also present, which explain the protein's rich alpha-helical content in solution. We propose an ice-binding model that accounts for the binding specificity of the antifreeze protein along the [01 (1) over bar 2] axes of the {20 (2) over bar 1} ice planes(1).	MCMASTER UNIV,FAC HLTH SCI,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA; VET ADM MED CTR,BIOCRYSTALLOG LAB,PITTSBURGH,PA 15240	McMaster University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Sicheri, Frank/F-8856-2013					ANANTHANARAYANA.VS, 1977, BIOCHEM BIOPH RES CO, V74, P685; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAKRABARTTY A, 1989, J BIOL CHEM, V264, P11307; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; HEW CL, 1986, EUR J BIOCHEM, V160, P267, DOI 10.1111/j.1432-1033.1986.tb09966.x; HEW CL, 1987, INTEGRATION CONTROL, P299; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN H, 1993, PROTEIN ENG, V6, P19, DOI 10.1093/protein/6.1.19; KNIGHT CA, 1993, BIOPHYS J, V64, P252, DOI 10.1016/S0006-3495(93)81361-4; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; LAL M, 1993, J FARADAY DISCUSS, V95, P299; MADURA JD, 1994, J AM CHEM SOC, V116, P417, DOI 10.1021/ja00080a066; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; PIELA L, 1987, BIOPOLYMERS, V26, P1273, DOI 10.1002/bip.360260805; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; THANKI N, 1988, J MOL BIOL, V202, P637, DOI 10.1016/0022-2836(88)90292-6; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WEN DY, 1992, J BIOL CHEM, V267, P14102; YANG DSC, 1986, J MOL BIOL, V189, P725, DOI 10.1016/0022-2836(86)90504-8; YANG DSC, 1988, NATURE, V333, P232, DOI 10.1038/333232a0	23	325	346	7	117	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					427	431		10.1038/375427a0	http://dx.doi.org/10.1038/375427a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760940	Green Submitted			2022-12-28	WOS:A1995RB10100060
J	SHOKAT, KM; GOODNOW, CC				SHOKAT, KM; GOODNOW, CC			ANTIGEN-INDUCED B-CELL DEATH AND ELIMINATION DURING GERMINAL-CENTER IMMUNE-RESPONSES	NATURE			English	Article							SOMATIC MUTATION; ANTIBODY; EXPRESSION; CENTERS; SPECIFICITY; GENERATION; SELECTION; LYSOZYME; PROTEINS; CHAIN	DURING an immune response, hypermutation of immunoglobulin genes in B cells proliferating within germinal centres (GCs) generates variant antibodies that react with higher affinity against either foreign or self antigens(1-9). Several experiments suggest that self-reactive B cells may be censored at this stage of the immune response(10-12), but the rarity of these cells and the dynamic nature of GC reactions have prevented direct analysis. We have developed a new approach to visualize the fate of antigen-specific B cells during GC reactions by seeding an ongoing immune response with lysozyme-specific B cells from immunoglobulin-gene transgenic animals. Administration of soluble antigen at the peak of the GC response rapidly eliminates lysozyme-specific GC B cells in two waves of apoptosis, one within the GC and a second in cells that have redistributed to lymphoid zones that are rich in T cells. Elimination of these cells is inhibited by constitutive expression of the follicular lymphoma proto-oncogene bcl-2. These findings reveal censoring steps that may normally prevent affinity maturation of autoantibodies to systemic autoantigens, and might be used by pathogenic microorganisms or in clinical strategies to interfere with antibody responses.	STANFORD UNIV, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, SCH MED, BECKMAN CTR, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University			Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DIAMOND B, 1984, P NATL ACAD SCI-BIOL, V81, P5841, DOI 10.1073/pnas.81.18.5841; DIAMOND B, 1992, ANNU REV IMMUNOL, V10, P731, DOI 10.1146/annurev.iy.10.040192.003503; DINTZIS HM, 1992, P NATL ACAD SCI USA, V89, P1113, DOI 10.1073/pnas.89.3.1113; GAMMON G, 1987, IMMUNOL REV, V98, P53; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GRAY D, 1994, J EXP MED, V180, P141, DOI 10.1084/jem.180.1.141; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; LAGASSE E, 1992, BLOOD, V79, P1907; LAVOIE TB, 1992, J IMMUNOL, V148, P503; LINTON PJ, 1991, J IMMUNOL, V146, P4099; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; NOSSAL GJV, 1993, P NATL ACAD SCI USA, V90, P3088, DOI 10.1073/pnas.90.7.3088; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PRAGER EM, 1971, J BIOL CHEM, V246, P523; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0	29	333	340	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					334	338		10.1038/375334a0	http://dx.doi.org/10.1038/375334a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753200				2022-12-28	WOS:A1995RA03000056
J	HORTON, R				HORTON, R			WOMEN AS WOMEN WITH HIV	LANCET			English	Editorial Material																		CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; MILNICK SL, 1994, JAMA-J AM MED ASSOC, V272, P1915; 1994, LANCET, V344, P207; 1995, MMWR-MORBID MORTAL W, V44, P81	4	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					531	532		10.1016/S0140-6736(95)90458-1	http://dx.doi.org/10.1016/S0140-6736(95)90458-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776767	Bronze			2022-12-28	WOS:A1995QK44400003
J	LIVINGSTON, MG				LIVINGSTON, MG			INTERACTIONS WITH SELECTIVE MAOIS	LANCET			English	Editorial Material							OXIDASE; PSEUDOPHAEOCHROMOCYTOMA; MOCLOBEMIDE; INHIBITORS; SELEGILINE				LIVINGSTON, MG (corresponding author), UNIV GLASGOW,GARTNAVEL ROYAL HOSP,DEPT PSYCHOL MED,GLASGOW,LANARK,SCOTLAND.							BASS C, 1989, BRIT MED J, V298, P345, DOI 10.1136/bmj.298.6670.345; FREEMAN H, 1993, LANCET, V342, P1528, DOI 10.1016/S0140-6736(05)80090-X; KNOLL J, 1978, BIOCHEM PHARMACOL, V27, P1739, DOI 10.1016/0006-2952(78)90550-6; LEFEBVRE H, 1995, CLIN ENDOCRINOL, V42, P95, DOI 10.1111/j.1365-2265.1995.tb02604.x; LEFEBVRE H, 1993, LANCET, V341, P555, DOI 10.1016/0140-6736(93)90314-7; MANN JJ, 1989, ARCH GEN PSYCHIAT, V46, P45; MCGRATH PJ, 1989, J CLIN PSYCHOPHARM, V9, P310; MONTASTRUC JL, 1993, LANCET, V341, P555, DOI 10.1016/0140-6736(93)90313-6; NEUVONEN PJ, 1993, LANCET, V342, P1419, DOI 10.1016/0140-6736(93)92774-N; ZORNBERG GL, 1991, LANCET, V337, P246, DOI 10.1016/0140-6736(91)92219-R; 1989, DRUG THER B, V27, P63	11	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					533	534		10.1016/S0140-6736(95)90460-3	http://dx.doi.org/10.1016/S0140-6736(95)90460-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776769				2022-12-28	WOS:A1995QK44400005
J	MATSUMOTO, A; OGURA, K; HIRATA, Y; KAKOKI, M; WATANABE, F; TAKENAKA, K; SHIRATORI, Y; MOMOMURA, S; OMATA, M				MATSUMOTO, A; OGURA, K; HIRATA, Y; KAKOKI, M; WATANABE, F; TAKENAKA, K; SHIRATORI, Y; MOMOMURA, S; OMATA, M			INCREASED NITRIC-OXIDE IN THE EXHALED AIR OF PATIENTS WITH DECOMPENSATED LIVER-CIRRHOSIS	ANNALS OF INTERNAL MEDICINE			English	Note							SYNTHASE; EXPRESSION; ENDOTOXIN; CYTOKINES; CELLS; RATS	Objective: To determine if nitric oxide output in exhaled air is increased in patients with liver cirrhosis. Design: Cross-sectional study. Setting: A university hospital. Patients: 50 patients with liver cirrhosis, 6 patients with chronic hepatitis, and 15 healthy controls. Measurements: Nitric oxide in exhaled air was measured using a chemiluminescence analyzer. Cardiac index was determined using echocardiography. Results: Patients with decompensated liver cirrhosis had higher levels of exhaled nitric oxide output (Child C patients, 190 +/- 11 nL/min per m(2) body surface area) than controls (97 +/- 8 nL/min per m(2) body surface area; P < 0.001), whereas patients with compensated liver cirrhosis or chronic hepatitis had levels of nitric oxide output similar to those found in controls. Cardiac index was greater in patients with liver cirrhosis (Child C patients, 4.3 +/- 0.3 L/min per m(2) body surface area) than in controls (2.9 +/- 0.2 L/min per m(2) body surface area; P < 0.001). Cardiac index correlated with nitric oxide levels (r = 0.621; P < 0.001). Conclusions: Increased nitric oxide output in exhaled air is associated with systemic circulatory disturbances in patients with liver cirrhosis.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 2, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CLARIA J, 1992, HEPATOLOGY, V15, P343, DOI 10.1002/hep.1840150227; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GUARNER C, 1993, HEPATOLOGY, V18, P1139; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1016/0270-9139(91)92439-F; LEE FY, 1992, HEPATOLOGY, V16, P1043, DOI 10.1002/hep.1840160430; LUMSDEN AB, 1988, HEPATOLOGY, V8, P232, DOI 10.1002/hep.1840080207; MATSUMOTO A, 1994, LANCET, V343, P849, DOI 10.1016/S0140-6736(94)92047-8; MIDGLEY S, 1991, LANCET, V338, P1590, DOI 10.1016/0140-6736(91)92407-S; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURRAY JF, 1958, AM J MED, V24, P358, DOI 10.1016/0002-9343(58)90322-X; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; ROLLA G, 1994, NEW ENGL J MED, V331, P1098, DOI 10.1056/NEJM199410203311617; SPITZER JA, 1994, HEPATOLOGY, V19, P217, DOI 10.1002/hep.1840190132; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4; TILG H, 1992, GASTROENTEROLOGY, V103, P264, DOI 10.1016/0016-5085(92)91122-K; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7	21	99	103	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					110	113		10.7326/0003-4819-123-2-199507150-00005	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778822				2022-12-28	WOS:A1995RM43500005
J	CHANYEUNG, M; MALO, JL				CHANYEUNG, M; MALO, JL			CURRENT CONCEPTS - OCCUPATIONAL ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RED CEDAR ASTHMA; TOLUENE DIISOCYANATE TDI; BRONCHIAL LAVAGE FLUID; NATURAL-HISTORY; PROTEIN-CHANGES; EXPOSURE; FEATURES; MUCOSA		UNIV MONTREAL, SACRE COEUR HOSP, DEPT CHEST MED, MONTREAL, PQ, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, DIV RESP, VANCOUVER, BC, CANADA	Universite de Montreal; University of British Columbia								BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P820, DOI 10.1016/0091-6749(89)90345-X; BERNSTEIN DI, 1993, ASTHMA WORKPLACE, P1; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; BLANC P, 1987, CHEST, V92, P613, DOI 10.1378/chest.92.4.613; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676, DOI 10.1164/ajrccm.149.6.8004329; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; CHANYEUNG M, 1990, CHEST, V98, pS148, DOI 10.1378/chest.98.5.148S; CHANYEUNG M, 1988, CLIN ALLERGY, V18, P359, DOI 10.1111/j.1365-2222.1988.tb02883.x; CHANYEUNG M, 1995, ASTHMA RHINITIS, P44; CONTRERAS GR, 1994, OCCUP ENVIRON MED, V51, P710, DOI 10.1136/oem.51.10.710; COTE J, 1990, J ALLERGY CLIN IMMUN, V85, P592, DOI 10.1016/0091-6749(90)90098-O; COTE J, 1990, AM REV RESPIR DIS, V141, P373, DOI 10.1164/ajrccm/141.2.373; DEWITTE JD, 1994, EUR RESPIR J, V7, P969; FABBRI LM, 1988, AM REV RESPIR DIS, V137, P1494, DOI 10.1164/ajrccm/137.6.1494; FREW A, 1993, J ALLERGY CLIN IMMUN, V92, P466, DOI 10.1016/0091-6749(93)90126-Z; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P12, DOI 10.1016/0091-6749(94)90228-3; KAROL MH, 1994, EUR RESPIR J, V7, P555, DOI 10.1183/09031936.94.07030555; KAY AB, 1991, EUR RESPIR J, V4, pS105; KESKINEN H, 1978, CLIN ALLERGY, V8, P569, DOI 10.1111/j.1365-2222.1978.tb01511.x; KOBAYASHI S, 1974, ALLERGOLOGIE, P124; KUSAKA Y, 1989, IND HEALTH, V27, P155, DOI 10.2486/indhealth.27.155; LAGIER F, 1990, REV MAL RESPIR, V7, P337; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LAM S, 1987, J ALLERGY CLIN IMMUN, V80, P44, DOI 10.1016/S0091-6749(87)80189-6; MALO JL, 1991, AM REV RESPIR DIS, V143, P528, DOI 10.1164/ajrccm/143.3.528; MALO JL, 1990, AM REV RESPIR DIS, V142, P1359, DOI 10.1164/ajrccm/142.6_Pt_1.1359; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; MAPP CE, 1988, EUR RESPIR J, V1, P273; MARABINI A, 1993, CHEST, V104, P821, DOI 10.1378/chest.104.3.821; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; Pepys J, 1972, Clin Allergy, V2, P391, DOI 10.1111/j.1365-2222.1972.tb01303.x; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PERRIN B, 1991, J ALLERGY CLIN IMMUN, V87, P630, DOI 10.1016/0091-6749(91)90381-W; PERRIN B, 1992, EUR RESPIR J, V5, P40; Reilly M J, 1994, MMWR CDC Surveill Summ, V43, P9; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160, DOI 10.1164/ajrccm/145.1.160; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169, DOI 10.1164/ajrccm/145.1.169; SMITH AB, 1990, CHEST, V98, P398, DOI 10.1378/chest.98.2.398; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; VENABLES KM, 1989, BMJ-BRIT MED J, V299, P939, DOI 10.1136/bmj.299.6705.939; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; 1991, PHS DHHS NIH913042 P	49	287	289	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					107	112		10.1056/NEJM199507133330207	http://dx.doi.org/10.1056/NEJM199507133330207			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777015				2022-12-28	WOS:A1995RH22500007
J	WOO, D				WOO, D			APOPTOSIS AND LOSS OF RENAL TISSUE IN POLYCYSTIC KIDNEY-DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL-DEATH; VITRONECTIN RECEPTOR; TRANSGENIC MICE; NEOPLASIA; ATROPHY; EVENTS; MODEL; RAT	Background. Polycystic kidney disease is characterized by the enlargement of renal cysts, interstitial fibrosis, and gradual loss of normal renal tissue in association with progressive deterioration of renal function. The process causing the progressive loss of renal tissue is unknown, but it could be the result of a form of programmed cell death known as apoptosis. Methods. We assayed apoptotic DNA fragmentation in normal and polycystic kidneys biochemically by gel electrophoresis and histochemically by in situ end-labeling. A DNA-specific dye, Hoechst 33258, was used to detect morphologic apoptosis in renal samples from patients with normal kidneys, polycystic kidney disease, and other kidney diseases. Results. Apoptotic DNA fragmentation was detected in polycystic kidneys from 5 patients without renal failure and 11 patients with renal failure but not in kidneys from 12 patients with no renal disease. In situ end-labeling revealed apoptotic cells in glomeruli, in cyst walls, and in both cystic and noncystic tubules of the polycystic kidneys. No tubular apoptosis was detected in renal-biopsy specimens from five patients with IgA nephropathy, three patients with nephrosclerosis, two patients with focal glomerulosclerosis, one patient with diabetic nephropathy, six patients with acute tubular necrosis, or four patients with acute and four patients with chronic renal-transplant rejection. The capacity of polycystic kidney cells to undergo apoptosis was retained in vitro in the absence of uremia, ischemia, and other confounding pathologic conditions. Conclusions. Apoptotic loss of renal tissue may be associated with the progressive deterioration of renal function that occurs in patients with polycystic kidney disease.			WOO, D (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,DIV NEPHROL,LOS ANGELES,CA 90024, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040700, R01DK045663] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40700, DK45663] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BAERT L, 1978, KIDNEY INT, V13, P519, DOI 10.1038/ki.1978.75; BAKER AJ, 1994, J CLIN INVEST, V94, P2105, DOI 10.1172/JCI117565; BASERGA R, 1968, LAB INVEST, V19, P92; CARONE FA, 1993, LAB INVEST, V68, P413; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; COLES HSR, 1993, DEVELOPMENT, V118, P777; CUPPAGE FE, 1980, KIDNEY INT, V17, P372, DOI 10.1038/ki.1980.43; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FADOK VA, 1992, J IMMUNOL, V149, P4029; FINE LG, 1989, ANNU REV PHYSIOL, V51, P19, DOI 10.1146/annurev.ph.51.030189.000315; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOBE GC, 1990, LAB INVEST, V63, P770; GOBE GC, 1987, LAB INVEST, V56, P273; GRANTHAM JJ, 1995, J CLIN INVEST, V95, P195, DOI 10.1172/JCI117638; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; HEGG O, 1966, J PATHOL BACTERIOL, V91, P311, DOI 10.1002/path.1700910204; KAMADA S, 1995, CANCER RES, V55, P354; KELLEY KA, 1991, J AM SOC NEPHROL, V2, P84; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; LEDDACOLUMBANO GM, 1989, AM J PATHOL, V135, P657; MAJNO G, 1995, AM J PATHOL, V146, P3; MIGHELI A, 1994, J NEUROPATH EXP NEUR, V53, P606, DOI 10.1097/00005072-199411000-00008; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; PREMINGER GM, 1982, J UROLOGY, V127, P556, DOI 10.1016/S0022-5347(17)53911-7; Sambrook J, 1989, MOL CLONING LABORATO; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAWCZUK IS, 1989, KIDNEY INT, V35, P1315, DOI 10.1038/ki.1989.128; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; TAKAHASHI H, 1986, J UROLOGY, V135, P1280, DOI 10.1016/S0022-5347(17)46074-5; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILSON PD, 1991, AM J PHYSIOL, V260, pF420, DOI 10.1152/ajprenal.1991.260.3.F420; WOO DDL, 1994, NATURE, V368, P750, DOI 10.1038/368750a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	41	288	304	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					18	25		10.1056/NEJM199507063330104	http://dx.doi.org/10.1056/NEJM199507063330104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776989	Bronze			2022-12-28	WOS:A1995RG73500004
J	PATTERSON, C; CHAMBERS, LW				PATTERSON, C; CHAMBERS, LW			PREVENTIVE HEALTH-CARE	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; ELDERLY PEOPLE; GENERAL-PRACTICE; CLINICAL-TRIAL; CANCER; SURVEILLANCE; HOME; MEN		MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA; HAMILTON WENTWORTH DEPT PUBL HLTH SERV, HAMILTON, ON, CANADA	McMaster University	PATTERSON, C (corresponding author), MCMASTER UNIV, DEPT MED, DIV GERIATR MED, HAMILTON, ON, CANADA.							[Anonymous], 1989, GUIDE CLIN PREVENTIV; AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; EBRAHIM S, 1984, BRIT MED J, V289, P1273, DOI 10.1136/bmj.289.6454.1273; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FRAME PS, 1993, ANN INTERN MED, V119, P411, DOI 10.7326/0003-4819-119-5-199309010-00010; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; GAILLAT J, 1985, REV EPIDEMIOL SANTE, V33, P437; GERMAN K, 1988, CLIN GERIATR MED, V4, P181; Haber D, 1994, HLTH PROMOTION AGING; HALL N, 1992, CAN J AGING, V11, P72, DOI 10.1017/S0714980800014537; HENDRIKSEN C, 1984, BMJ-BRIT MED J, V289, P1522, DOI 10.1136/bmj.289.6457.1522; KENNIE DC, 1993, PREVENTIVE CARE ELDE; LaCroix A Z, 1992, Clin Geriatr Med, V8, P69; LAVIZZOMOUREY R, 1989, PRACTICING PREVENTIO; LEIGH JP, 1992, ARCH INTERN MED, V152, P1201, DOI 10.1001/archinte.152.6.1201; MCEWAN RT, 1990, BRIT J GEN PRACT, V40, P94; MILLER AB, 1991, CAN MED ASSOC J, V145, P1301; PATHY MSJ, 1992, LANCET, V340, P890, DOI 10.1016/0140-6736(92)93294-W; RO OC, 1983, 6 GRUPP HELS FORSKN; ROCKWOOD K, 1994, CAN MED ASSOC J, V150, P489; Rose G., 1992, STRATEGY PREVENTIVE; RUBENSTEIN LV, 1989, ANN INTERN MED, V111, P836, DOI 10.7326/0003-4819-111-10-836; RUBENSTEIN LZ, 1990, ANN INTERN MED, V113, P308, DOI 10.7326/0003-4819-113-4-308; SCOTT RAP, 1994, CHRON DIS CAN S, V15; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Tulloch A J, 1979, J R Coll Gen Pract, V29, P733; VANROSSUM E, 1993, BMJ-BRIT MED J, V307, P27, DOI 10.1136/bmj.307.6895.27; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; 1992, DIAGNOSTIC TREATMENT; 1994, CLIN PREVENTIVE HLTH; 1990, 45 ROYAL COLL GEN PR	36	22	22	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	1995	345	8965					1611	1615		10.1016/S0140-6736(95)90119-1	http://dx.doi.org/10.1016/S0140-6736(95)90119-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783540				2022-12-28	WOS:A1995RE67000012
J	DANZIG, LE; SHORT, LJ; COLLINS, K; MAHONEY, W; SEPE, S; BLAND, L; JARVIS, WR				DANZIG, LE; SHORT, LJ; COLLINS, K; MAHONEY, W; SEPE, S; BLAND, L; JARVIS, WR			BLOOD-STREAM INFECTIONS ASSOCIATED WITH A NEEDLELESS INTRAVENOUS-INFUSION SYSTEM IN PATIENTS RECEIVING HOME INFUSION THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.- To determine risk factors for bloodstream infections (BSIs) in an outbreak among patients receiving home intravenous infusion therapy. Design.- Case-control and retrospective cohort studies. Setting - Home health agency. Patients.- Patients receiving home intravenous infusion therapy from Rhode Island Home Therapeutics (RIHT) from January through December 1993. Main Outcome Measure.- Development of primary BSI. Methods.- We compared patients with BSI (ie, case patients) with randomly selected noninfected RIHT patients receiving intravenous therapy, conducted a cohort study of all RIHT patients receiving intravenous therapy via a central venous catheter (CVC), and conducted a culture survey of injection cap luminal fluid. Results.- Case patients were more likely than controls to have had therapy via a CVC (11/11 vs 14/32; odds ratio [OR] undefined; P<.001) or total parenteral nutrition and intralipid therapy (TPN/IL) (9/11 vs 3/32; OR, 43.5; 95% confidence interval [CI], 4.9 to 510.0). Among RIHT patients with CVCs, risk factors for BSI were receipt of TPN/IL (9/35 vs 2/67; rate ratio [RR], 8.6; 95% CI, 2.0 to 37.7) or use of a needleless infusion system (10/41 vs 1/61; RR, 14.9; 95% CI, 2.0 to 111.8). Only the combination of both exposures was significantly associated with development of a BSI (P<.001). Luminal fluid from injection caps of needleless devices was significantly more likely to be culture positive than fluid from protected-needle devices (5/23 vs 0/18; RR undefined; P=.04). Conclusions.- Our data suggest that a needleless device used for TPN/IL was associated with increased risk of BSI when injection caps were changed every 7 days.	RHODE ISL HOME THERAPEUT,E PROVIDENCE,RI		DANZIG, LE (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.		Mahoney, William/GQB-0802-2022					BENSON JS, 1992, FDA SAFETY ALERT NEE; DEAN AG, 1991, EPIINFO VERSION 5 01; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GARTNER K, 1993, AM J INFECT CONTROL, V20, P75; GOLDMANN DA, 1993, CLIN MICROBIOL REV, V6, P176, DOI 10.1128/CMR.6.2.176-192.1993; GRAHAM DR, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90351-W; IPPOLITO G, 1994, JAMA-J AM MED ASSOC, V272, P607, DOI 10.1001/jama.272.8.607; JARVIS WR, 1991, AM J MED, V91, pS101, DOI 10.1016/0002-9343(91)90352-X; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MAKI DG, 1992, HOSP INFECT, P849; MENDELSON H, 1992, 33RD INT C ANT AG CH; SIMMONS BP, 1982, GUIDELINE PREVENTION; SKOLNICK R, 1993, AM J INFECT CONTROL, V21, P39, DOI 10.1016/0196-6553(93)90206-J; WILLIAMS WW, 1985, JPEN-PARENTER ENTER, V9, P735, DOI 10.1177/0148607185009006735; 1990, SAS PROCEDURES GUIDE	15	101	102	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1862	1864		10.1001/jama.273.23.1862	http://dx.doi.org/10.1001/jama.273.23.1862			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776503				2022-12-28	WOS:A1995RD11600029
J	HARDEN, PN; GEDDES, C; ROWE, PA; MCILROY, JH; BOULTONJONES, M; RODGER, RSC; JUNOR, BJR; BRIGGS, JD; CONNELL, JMC; JARDINE, AG				HARDEN, PN; GEDDES, C; ROWE, PA; MCILROY, JH; BOULTONJONES, M; RODGER, RSC; JUNOR, BJR; BRIGGS, JD; CONNELL, JMC; JARDINE, AG			POLYMORPHISMS IN ANGIOTENSIN-CONVERTING-ENZYME GENE AND PROGRESSION OF IGA NEPHROPATHY	LANCET			English	Note							QUESTIONNAIRE; SUGARS; WOMEN	We have investigated the influence of the functional insertion (I) and deletion (D) polymorphism in intron 16 of the gene for angiotensin-converting enzyme (ACE) in a retrospective study of 100 patients with IgA nephropathy. There was no difference in genotype frequency compared with normal subjects. However, patients homozygous for the D allele tended to present at an earlier age (medians: DD, 33; ID, 34; II, 42 years) and to require renal replacement therapy at a younger age (medians 37, 42, and 48 years, respectively). The rate of progression was significantly worse in patients homozygous for the D allele. The DD genotype is associated with increased severity of disease in patients with IgA nephropathy.	WESTERN INFIRM & ASSOCIATED HOSP,RENAL UNIT,GLASGOW,LANARK,SCOTLAND; ROYAL INFIRM,RENAL UNIT,GLASGOW,LANARK,SCOTLAND; ROYAL INFIRM,DEPT CLIN BIOCHEM,GLASGOW,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT MED,GLASGOW G11 6NT,LANARK,SCOTLAND; UNIV GLASGOW,WESTERN INFIRM,DEPT THERAPEUT,GLASGOW G11 6NT,LANARK,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Glasgow; University of Glasgow			Jardine, Alan/L-5770-2019	Jardine, Alan/0000-0001-5815-9370				ADAMSON AJ, 1980, J HUM NUTRDIET, V5, P371; BARKER M E, 1988, Journal of Human Nutrition and Dietetics, V1, P179, DOI 10.1111/j.1365-277X.1988.tb00187.x; BINGHAM S, 1991, P NUTR SOC, V50, pA32; BLACK AE, 1991, EUR J CLIN NUTR, V45, P583; EMMETT P, 1992, J HUM NUTR DIET, V5, P245, DOI 10.1111/j.1365-277X.1992.tb00159.x; EMMETT PM, 1993, EUR J CLIN NUTR, V47, P20; GIBNEY MJ, 1980, J HUM NUTR DIET, V3, P245; Gregory F., 1990, DIETARY NUTR SURVEY; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; Pryer J. A., 1994, Proceedings of the Nutrition Society, V53, p235A; RUGGGUNN AJ, 1993, J HUM NUTR DIET, V6, P419, DOI 10.1111/j.1365-277X.1993.tb00387.x; WILES SJ, 1980, J HUM NUTR, V34, P189; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103; 1992, GOOD DIETARY PRACTIC, V3, P1; 1992, HLTH NATION STRATEGY; 1991, REPORTS HLTH SOCIAL, V41; 1989, REPORTS HLTH SOCIAL, V37	21	225	232	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1540	1542		10.1016/S0140-6736(95)91088-3	http://dx.doi.org/10.1016/S0140-6736(95)91088-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791440				2022-12-28	WOS:A1995RD79000010
J	MAYFORD, M; WANG, J; KANDEL, ER; ODELL, TJ				MAYFORD, M; WANG, J; KANDEL, ER; ODELL, TJ			CAMKII REGULATES THE FREQUENCY-RESPONSE FUNCTION OF HIPPOCAMPAL SYNAPSES FOR THE PRODUCTION OF BOTH LTD AND LTP	CELL			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; SQUID GIANT SYNAPSE; II MUTANT MICE; VISUAL-CORTEX; CA-2+-INDEPENDENT ACTIVITY; AUTOPHOSPHORYLATION SITES; NEUROTRANSMITTER RELEASE; AREA CA1; CALMODULIN	To investigate the function of the autophosphorylated form of CaMKII in synaptic plasticity, we generated transgenic mice that express a kinase that is Ca2+ independent as a result of a point mutation of Thr-286 to aspartate, which mimics autophosphorylation. Mice expressing the mutant form of the kinase show an increased level of Ca2+-independent CaMKII activity similar to that seen following LTP. The mice nevertheless exhibit normal LTP in response to stimulation at 100 Hz. However, at lower frequencies, in the range of 1-10 Hz, there is a systematic shift in the size and direction of the resulting synaptic change in the transgenic animals that favors LTD. The regulation of this frequency-response function by Ca2+-independent CaMKII activity seems to account for two previously unexplained synaptic phenomena, the relative loss of LTD in adult animals compared with juveniles and the enhanced capability for depression of facilitated synapses.			MAYFORD, M (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.			Mayford, Mark/0000-0002-9001-5024	NIMH NIH HHS [MH50733] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; ARTOLA A, 1990, NATURE, V347, P69, DOI 10.1038/347069a0; BACH ME, 1995, CELL, V81; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BEAR MF, 1990, J NEUROSCI, V10, P909; BEARMF, 1994, CURR OPIN NEUROBIOL, V4, P389; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; CLINE HT, 1990, J NEUROSCI, V10, P1197; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; DUDEK SM, 1993, J NEUROSCI, V13, P2910; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GOODMAN CS, 1993, NEURON S, V10, P77; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HEBB DO, 1949, ORG BEHAVIOR; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; LIN JW, 1990, P NATL ACAD SCI USA, V87, P8257, DOI 10.1073/pnas.87.21.8257; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOU LL, 1989, J NEUROSCI, V9, P2020; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1992, NEURON, V9, P121, DOI 10.1016/0896-6273(92)90227-5; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MILLER SG, 1985, J BIOL CHEM, V260, P9039; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MULLER D, 1989, DEV BRAIN RES, V49, P105, DOI 10.1016/0165-3806(89)90063-1; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; O'Dell T J, 1994, Learn Mem, V1, P129; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; SHATZ CJ, 1928, SCIENCE, V242, P87; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; STEVENS CF, 1994, NATURE, V371, P704, DOI 10.1038/371704a0; STRYKER MP, 1986, J NEUROSCI, V6, P2117; SUNYER T, 1990, P NATL ACAD SCI USA, V87, P278, DOI 10.1073/pnas.87.1.278; TAN SE, 1994, J NEUROSCI, V14, P1123, DOI 10.1523/JNEUROSCI.14-03-01123.1994; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002	61	431	459	0	16	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					891	904		10.1016/0092-8674(95)90009-8	http://dx.doi.org/10.1016/0092-8674(95)90009-8			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781066	hybrid			2022-12-28	WOS:A1995RD76800010
J	VELANDIA, M; FRIDKIN, SK; CARDENAS, V; BOSHELL, J; RAMIREZ, G; BLAND, L; IGLESIAS, A; JARVIS, W				VELANDIA, M; FRIDKIN, SK; CARDENAS, V; BOSHELL, J; RAMIREZ, G; BLAND, L; IGLESIAS, A; JARVIS, W			TRANSMISSION OF HIV IN DIALYSIS CENTER	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BENZALKONIUM CHLORIDE; HEMODIALYSIS; PREVALENCE; BLOOD	In August, 1993, 13 dialysis patients at one dialysis centre. in Colombia, South America, were found to be HIV positive, and this prompted an epidemiological investigation. We carried out a cohort study of all dialysis centre patients during January, 1992 to December, 1993 (epidemic period) to determine risk factors for HIV seroconversion. Haemodialysis and medical records were reviewed, dialysis centre staff and surviving patients were interviewed, and dialysis practices were observed. Stored sera from all dialysis centre patients were tested for HIV antibody. 12 (52%) of 23 patients tested positive for HIV antibody by enzyme immunoassay and western blot during the epidemic period. Of the 23 tested, 9 (39%) converted from HIV antibody negative to positive (seroconverters) and 10 (44%) remained HIV negative (seronegatives). The HIV seroconversion rate was higher among patients dialysed at the centre while a new patient, who was HIV seropositive, was dialysed there (90% vs 0%; p<0.01), or when the dialysis centre reprocessed access needles, dialysers, and bloodlines (60% vs 0%). While 2 of 9 HIV seroconverters had had sex with prostitutes, none had received unscreened blood products or had other HIV risk factors. No surgical or dental procedures were associated with HIV seroconversion. Dialysers were reprocessed separately with 5% formaldehyde and were labelled for use on the same patient. Access needles were reprocessed by soaking them in a common container with a low-level disinfectant, benzalkonium chloride; 4 pairs of needles were placed in one pan creating the potential for cross-contamination or use of one patient's needles on another patient. HIV transmission at the dialysis centre was confirmed, Improperly reprocessed patient-care equipment, most probably access needles, is the likely mechanism of transmission. This outbreak was discovered by accident and similar transmission may be occurring in many other countries where low-level disinfectants are used to sterilise critical patient-care equipment.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,INVEST & PREVENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; COLOMBIAN FIELD EPIDEMIOL TRAINING PROGRAM,BOGOTA,COLOMBIA; NATL INST HLTH,BOGOTA,COLOMBIA; IND UNIV SANTANDER,SCH MED,SANTANDER,SPAIN	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Velandia-Gonzalez, Martha/0000-0002-7636-3604				ARDUINO MJ, 1993, DIALYSIS TRANSPLANT, V22, P652; ARDUINO MJ, 1993, DIALYSIS TRANSPLANT, V22, P701; BLANK S, 1994, LANCET, V344, P512, DOI 10.1016/S0140-6736(94)91900-3; BURCHOVSKY G, 1988, 4TH INT C AIDS STOCK; CHANT K, 1994, LANCET, V342, P1548; CHIRGWIN K, 1989, AIDS, V3, P731, DOI 10.1097/00002030-198911000-00007; DEAN AG, 1991, EPI INFO VERSION 5 0; DYER E, 1993, BRIT MED J, V307, P584; FAVERO MS, 1989, ASPECTS RENAL CARE, P55; FAVERO MS, 1991, MANUAL CLIN MICROBIO, P183; Favero MS, 1992, HOSPITAL INFECTIONS, P375; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; KASLOW RA, 1976, JAMA-J AM MED ASSOC, V236, P2407, DOI 10.1001/jama.236.21.2407; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MARCUS R, 1991, AM J MED, V90, P614, DOI 10.1016/S0002-9343(05)80014-2; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; NAKASHIMA AK, 1987, J CLIN MICROBIOL, V25, P1014, DOI 10.1128/JCM.25.6.1014-1018.1987; NAUS JI, 1965, J AM STAT ASSOC, V60, P532, DOI 10.2307/2282688; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; PLOTT RT, 1990, ARCH DERMATOL, V126, P1441, DOI 10.1001/archderm.126.11.1441; POKROVSKY VV, 1988, 5TH INT C AIDS STOCK; RENGITO B, 1995, 7 C PAN AM INF CART; Rothman K, 1986, MODERN EPIDEMIOLOGY; Tokars J I, 1994, ASAIO J, V40, P1020, DOI 10.1097/00002480-199410000-00021; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; WAINBERG MA, 1990, J CLIN MICROBIOL, V28, P156, DOI 10.1128/JCM.28.1.156-158.1990; WALLENSTEIN S, 1980, AM J EPIDEMIOL, V111, P367, DOI 10.1093/oxfordjournals.aje.a112908; 1992, MMWR-MORBID MORTAL W, V41, P823; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1993, REC PRACT REUSE HEMO; 1992, MMWR-MORBID MORTAL W, V41, P344; 1992, MMWR-MORBID MORTAL W, V41, P575	32	51	51	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1417	1422		10.1016/S0140-6736(95)92603-8	http://dx.doi.org/10.1016/S0140-6736(95)92603-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760615	Bronze			2022-12-28	WOS:A1995RB44100015
J	WALKLEY, SU; DOBRENIS, K				WALKLEY, SU; DOBRENIS, K			BONE-MARROW TRANSPLANTATION FOR LYSOSOMAL DISEASES	LANCET			English	Editorial Material											WALKLEY, SU (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,ROSE F KENNEDY CTR RES MENTAL RETARDAT & HUMAN DEV,BRONX,NY 10461, USA.							Dobrenis K., 1994, Molecular Biology of the Cell, V5, p113A; HASKINS M, 1991, TREATMENT GENETIC DI, P183; HOBBS JR, 1981, LANCET, V2, P709; KRIVIT W, 1991, TREATMENT GENETIC DI, P203; PERRY VH, 1994, MACROPHAGES NERVOUS, P6; RATTAZZI MC, 1991, TREATMENT GENETIC DI, P131; WALKLEY S, 1994, BRAIN PATHOL, V4, P376; WALKLEY SU, 1991, J NEUROL SCI, V104, P1, DOI 10.1016/0022-510X(91)90208-O; WALKLEY SU, 1988, INT REV NEUROBIOL, V29, P191, DOI 10.1016/S0074-7742(08)60087-2; WALKLEY SU, 1991, P NATL ACAD SCI USA, V491, P2970; WALKLEY SU, 1991, BRAIN RES, V410, P89; WHITLEY CB, 1986, BONE MARROW TRANSPL, P7	12	22	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1382	1383		10.1016/S0140-6736(95)92590-2	http://dx.doi.org/10.1016/S0140-6736(95)92590-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760604	Bronze			2022-12-28	WOS:A1995RB44100002
J	VANDIJK, MR; WATERS, AP; JANSE, CJ				VANDIJK, MR; WATERS, AP; JANSE, CJ			STABLE TRANSFECTION OF MALARIA PARASITE BLOOD STAGES	SCIENCE			English	Article							PLASMODIUM-BERGHEI; TRYPANOSOMA-BRUCEI; HOMOLOGOUS RECOMBINATION; PYRIMETHAMINE RESISTANCE; TOXOPLASMA-GONDII; GENE REPLACEMENT; TRANSFORMATION; EXPRESSION; FALCIPARUM; MUTATIONS	Genetic manipulation of malaria parasites would revolutionize the study of this group of pathogens and have implications for vaccine and drug development. This report describes the stable, drug-selectable genetic transformation of the clinically relevant intracellular blood stages of a malaria parasite. A plasmid transfection vector carrying the gene locus that encodes a drug-resistant form of the bifunctional enzyme dihydrofolate reductase-thymidylate synthase from the rodent malaria parasite Plasmodium berghei was constructed. Derivatives of this vector were introduced into merozoites of P. berghei by electroporation, and parasites were selected for successful transformation in the rodent host on the basis of resistance to pyrimethamine. The plasmids were present in a circular, unrearranged form that replicated episomally to an observed maximum of 15 copies per cell in drug-resistant populations.	LEIDEN UNIV,DEPT PARASITOL,2300 RC LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205				BELLOFATTO V, 1991, P NATL ACAD SCI USA, V88, P6711, DOI 10.1073/pnas.88.15.6711; COWMAN AF, 1988, P NATL ACAD SCI USA, V85, P9109, DOI 10.1073/pnas.85.23.9109; COWMAN AF, 1990, MOL BIOCHEM PARASIT, V42, P21, DOI 10.1016/0166-6851(90)90109-Y; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; DONALD RGK, 1993, MOL BIOCHEM PARASIT, V63, P243; DORE E, 1990, MOL CELL BIOL, V10, P2423, DOI 10.1128/MCB.10.5.2423; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; GOONEWARDENE R, 1993, P NATL ACAD SCI USA, V90, P5234, DOI 10.1073/pnas.90.11.5234; JANSE CJ, 1989, INT J PARASITOL, V19, P509, DOI 10.1016/0020-7519(89)90080-5; JANSE CJ, 1984, INT J PARASITOL, V14, P317, DOI 10.1016/0020-7519(84)90083-3; JANSE CJ, 1986, MOL BIOCHEM PARASIT, V20, P173, DOI 10.1016/0166-6851(86)90029-0; JANSE CJ, 1994, METHOD CELL BIOL, V42, P296; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; LABAN A, 1990, NATURE, V343, P572, DOI 10.1038/343572a0; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LONG CA, 1993, CURR OPIN IMMUNOL, V5, P548, DOI 10.1016/0952-7915(93)90036-R; MONS B, 1985, PARASITOLOGY, V91, P423, DOI 10.1017/S0031182000062673; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; PAPADOPOULOU B, 1994, MOL BIOCHEM PARASIT, V65, P39, DOI 10.1016/0166-6851(94)90113-9; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L; PETERSON DS, 1988, P NATL ACAD SCI USA, V85, P9114, DOI 10.1073/pnas.85.23.9114; TANAKA M, 1990, MOL BIOCHEM PARASIT, V39, P127, DOI 10.1016/0166-6851(90)90015-E; TENASBROEK ALMA, 1993, MOL BIOCHEM PARASIT, V59, P133, DOI 10.1016/0166-6851(93)90014-O; VANDIJK MR, 1994, MOL BIOCHEM PARASIT, V68, P167, DOI 10.1016/0166-6851(94)00163-4; VANDIJK MR, UNPUB; VINKENOOG R, IN PRESS MOL BIOCH P; WU Y, 1995, P NATL ACAD SCI USA, V91, P973	29	192	197	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1358	1362		10.1126/science.7761856	http://dx.doi.org/10.1126/science.7761856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761856				2022-12-28	WOS:A1995RB19800041
J	SPECTOR, TD; KEEN, RW; ARDEN, NK; MORRISON, NA; MAJOR, PJ; NGUYEN, TV; KELLY, PJ; BAKER, JR; SAMBROOK, PN; LANCHBURY, JS; EISMAN, JA				SPECTOR, TD; KEEN, RW; ARDEN, NK; MORRISON, NA; MAJOR, PJ; NGUYEN, TV; KELLY, PJ; BAKER, JR; SAMBROOK, PN; LANCHBURY, JS; EISMAN, JA			INFLUENCE OF VITAMIN-D-RECEPTOR GENOTYPE ON BONE-MINERAL DENSITY IN POSTMENOPAUSAL WOMEN - A TWIN STUDY IN BRITAIN	BRITISH MEDICAL JOURNAL			English	Article							GENETIC-FACTORS; MASS	Objectives-To investigate the possible association between vitamin D receptor genotype and bone mineral density in a large group of postmenopausal twins. Design-Cross sectional twin study. Setting-Twin population based in Britain. Subjects-95 dizygotic (non-identical) pairs of twins and 87 monozygotic (identical) pairs of twins aged 50-69 years, postmenopausal, and free of diseases affecting bone, recruited from a national register of twins and with a media campaign. Main outcome measures-Bone mineral density measured at the hip, lumbar spine, forearm, and for the whole body by dual energy x ray absorptiometry in relation to differences in the vitamin D receptor genotype. Results-At all sites the values of bone density among dizygotic twins were more similar in those of the same vitamin D receptor genotype than in those of differing genotype, and the values in the former were closer to the correlations seen in monozygotic twins. Women with the genotype that made them at risk of osteoporotic fracture had an adjusted bone mineral density that was significantly lower by SD 0.5 to 0.6 at the hip, lumbar spine, and for the whole body, The results could not be explained by differences in age, weight, years since menopause, or use of hormone replacement therapy. Conclusions-The findings that in postmenopausal women in Britain bone density-particularly at the hip and spine-is genetically linked and specifically associated with the vitamin D receptor genotypes should lead to novel approaches to the prevention and treatment of osteoporosis.	UNITED MED & DENT SCH,MOLEC IMMUNOGENET UNITS,LONDON SE1 7EH,ENGLAND; GARVAN INST MED RES,DIV BONE & MINERAL RES,SYDNEY,NSW,AUSTRALIA	University of London; King's College London; Garvan Institute of Medical Research	SPECTOR, TD (corresponding author), UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT RHEUMATOL,LONDON SE1 7EH,ENGLAND.		Nguyen, Tuan V./AAD-9503-2020; Spector, Tim D/F-6533-2012; Morrison, Nigel A/F-4082-2012; Eisman, John A/C-2886-2014; Nguyen, Tuan V/B-6147-2008	Nguyen, Tuan V./0000-0002-3246-6281; Morrison, Nigel A/0000-0003-4774-3808; Nguyen, Tuan V/0000-0002-3246-6281	NIAMS NIH HHS [AR 41409] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041409] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		DEFRIES JC, 1985, BEHAV GENET, P467; FALCONER DS, 1989, INTRO QUANTITATIVE G, P163; FARROW S, 1994, LANCET, V343, P1242, DOI 10.1016/S0140-6736(94)92147-4; GARNERO P, 1994, J BONE MINER RES  S1, V9, pS389; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; KELLY PJ, 1991, J CLIN ENDOCR METAB, V72, P808, DOI 10.1210/jcem-72-4-808; MASUD T, 1993, BRIT MED J, V307, P172, DOI 10.1136/bmj.307.6897.172; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173; TOKITA A, 1994, J CLIN ENDOCR METAB, V78, P1461, DOI 10.1210/jc.78.6.1461; WILLIAMS CJ, 1992, COMPUT METH PROG BIO, V38, P167, DOI 10.1016/0169-2607(92)90084-K	13	184	191	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1357	1360		10.1136/bmj.310.6991.1357	http://dx.doi.org/10.1136/bmj.310.6991.1357			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787536	Green Published			2022-12-28	WOS:A1995RB00500019
J	HINTON, GE; DAYAN, P; FREY, BJ; NEAL, RM				HINTON, GE; DAYAN, P; FREY, BJ; NEAL, RM			THE WAKE-SLEEP ALGORITHM FOR UNSUPERVISED NEURAL NETWORKS	SCIENCE			English	Article								An unsupervised learning algorithm for a multilayer network of stochastic neurons is described. Bottom-up ''recognition'' connections convert the input into representations in successive hidden layers, and top-down ''generative'' connections reconstruct the representation in one layer from the representation in the layer above. In the ''wake'' phase, neurons are driven by recognition connections, and generative connections are adapted to increase the probability that they would reconstruct the correct activity vector in the layer below. In the ''sleep'' phase, neurons are driven by generative connections, and recognition connections are adapted to increase the probability that they would produce the correct activity vector in the layer above.			HINTON, GE (corresponding author), UNIV TORONTO, DEPT COMP SCI, 6 KINGS COLL RD, TORONTO, ON M5S 1A4, CANADA.			Dayan, Peter/0000-0003-3476-1839				Barlow HB, 1989, NEURAL COMPUT, V1, P295, DOI 10.1162/neco.1989.1.3.295; CARPENTER GA, 1987, COMPUT VISION GRAPH, V37, P54, DOI 10.1016/S0734-189X(87)80014-2; DAYAN P, IN PRESS NEURAL COMP; GRENANDER U, 1976, LECTURES PATTERN THE; HASSELMO ME, 1993, TRENDS NEUROSCI, V16, P218, DOI 10.1016/0166-2236(93)90159-J; Hinton G. E., 1994, PROC 6 TH INT C NEUR, V6, P3; JORDAN MI, 1992, COGNITIVE SCI, V16, P307, DOI 10.1207/s15516709cog1603_1; KAWATO M, 1993, NETWORK-COMP NEURAL, V4, P415, DOI 10.1088/0954-898X/4/4/001; MUMFORD D, 1994, LARGE SCALE NEURONAL, P125; Rissanen J., 1989, STOCHASTIC COMPLEXIT; ULLMAN S, 1994, LARGE SCALE THEORIES, P257	11	520	572	1	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 26	1995	268	5214					1158	1161		10.1126/science.7761831	http://dx.doi.org/10.1126/science.7761831			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761831				2022-12-28	WOS:A1995RA60400031
J	MARTI, E; BUMCROT, DA; TAKADA, R; MCMAHON, AP				MARTI, E; BUMCROT, DA; TAKADA, R; MCMAHON, AP			REQUIREMENT OF 19K FORM OF SONIC HEDGEHOG FOR INDUCTION OF DISTINCT VENTRAL CELL-TYPES IN CNS EXPLANTS	NATURE			English	Article							POLARITY GENE HEDGEHOG; FLOOR PLATE; DROSOPHILA; TRANSCRIPTION; NOTOCHORD; PATTERN; EMBRYO; SYSTEM	THE identity and patterning of ventral cell types in the vertebrate central nervous system depends on cell interactions(1). For example, induction of a specialized population of ventral midline cells, the Boor plate, appears to require contact-mediated signalling by the underlying notochord, whereas diffusible signals from the notochord and floor plate can induce ventrolaterally positioned motor neurons. Sonic hedgehog (Shh), a vertebrate hedgehog-family member, is processed to generate two peptides (M(r) 19K and 26/27K) which are secreted by both of these organizing centres(2,30). Moreover, experiments in a variety of vertebrate embryos(3-5), and in neural explants in vitro(5), indicate that Shh can mediate floor-plate induction. Here we have applied recombinant Shh peptides to neural explants in serum-free conditions. High concentrations of Shh bound to a matrix induce floor plate and motor neurons, and addition of Shh to the medium leads to dose-dependent induction of motor neurons. All inducing activity resides in a highly conserved amino-terminal peptide (M(r) 19K). Moreover, antibodies that specifically recognize this peptide block induction of motor neurons by the notochord. We propose that Shh acts as a morphogen to induce distinct ventral cell types in the vertebrate central nervous system.			MARTI, E (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, 16 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		MARTI, ELISA/K-7814-2014; McMahon, Andrew P/ABE-7520-2020	MARTI, ELISA/0000-0001-5839-7133; Takada, Ritsuko/0000-0002-1615-056X				BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; CHANG DT, 1994, DEVELOPMENT, V120, P3339; DIAZBENJUMEA FJ, 1994, NATURE, V372, P175, DOI 10.1038/372175a0; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Fietz MJ, 1994, DEVELOPMENT S, V120, P43; FIETZ MJ, IN PRESS CURR BIOL; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1995, CURR BIOL, V5, P432, DOI 10.1016/S0960-9822(95)00084-4; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARTI E, IN PRESS DEVELOPMENT; MOHLER J, 1988, GENETICS, V120, P1061; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	30	423	452	0	15	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					322	325		10.1038/375322a0	http://dx.doi.org/10.1038/375322a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753196				2022-12-28	WOS:A1995RA03000052
J	REY, FA; HEINZ, FX; MANDL, C; KUNZ, C; HARRISON, SC				REY, FA; HEINZ, FX; MANDL, C; KUNZ, C; HARRISON, SC			THE ENVELOPE GLYCOPROTEIN FROM TICK-BORNE ENCEPHALITIS-VIRUS AT 2 ANGSTROM RESOLUTION	NATURE			English	Article							WEST NILE FLAVIVIRUS; PROTEIN-E; NUCLEOTIDE-SEQUENCE; RESISTANT MUTANTS; INFLUENZA-VIRUS; NEUROVIRULENCE; EXPRESSION; MICE; SELECTION; VIRULENCE	The crystallographically determined structure of a soluble fragment from the major envelope protein of a flavivirus reveals an unusual architecture. The flat, elongated dimer extends in a direction that would be parallel to the viral membrane. Residues that influence binding of monoclonal antibodies lie on the outward-facing surface of the protein. The clustering of mutations that affect virulence in various flaviviruses indicates a possible receptor binding site and, together with other mutational and biochemical data, suggests a picture for the fusion-activating, conformational change triggered by low pH.	HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA; UNIV VIENNA, INST VIROL, A-1095 VIENNA, AUSTRIA	Harvard University; Howard Hughes Medical Institute; University of Vienna	REY, FA (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		Rey, Felix/B-6497-2012	Rey, Felix/0000-0002-9953-7988				ALLISON SL, 1995, J VIROL, V69, P695, DOI 10.1128/JVI.69.2.695-700.1995; BLUM M, 1990, THESIS HARVARD U; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CECILIA D, 1991, VIROLOGY, V181, P70, DOI 10.1016/0042-6822(91)90471-M; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GAO GF, 1994, J GEN VIROL, V75, P609, DOI 10.1099/0022-1317-75-3-609; GUIRAKHOO F, 1993, VIROLOGY, V194, P219, DOI 10.1006/viro.1993.1252; GUIRAKHOO F, 1991, J GEN VIROL, V72, P1323, DOI 10.1099/0022-1317-72-6-1323; GUIRAKHOO F, 1992, VIROLOGY, V191, P921, DOI 10.1016/0042-6822(92)90267-S; HASEGAWA H, 1992, VIROLOGY, V191, P158, DOI 10.1016/0042-6822(92)90177-Q; HEINZ FX, 1994, VIROLOGY, V198, P109, DOI 10.1006/viro.1994.1013; HEINZ FX, 1986, ADV VIRUS RES, V31, P103, DOI 10.1016/S0065-3527(08)60263-8; HEINZ FX, 1991, J VIROL, V65, P5579, DOI 10.1128/JVI.65.10.5579-5583.1991; HEINZ FX, 1990, IMMUNOCHEMISTRY VIRU, V2, P289; HOLZMANN H, 1995, ARCH VIROL, V140, P213, DOI 10.1007/BF01309857; HOLZMANN H, 1990, J VIROL, V64, P5156, DOI 10.1128/JVI.64.10.5156-5159.1990; JENNINGS AD, 1994, J INFECT DIS, V169, P512, DOI 10.1093/infdis/169.3.512; JIANG WR, 1993, J GEN VIROL, V74, P931, DOI 10.1099/0022-1317-74-5-931; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWANO H, 1993, J VIROL, V67, P6567, DOI 10.1128/JVI.67.11.6567-6575.1993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWIS JA, 1993, VIROLOGY, V197, P216, DOI 10.1006/viro.1993.1582; LOBIGS M, 1990, VIROLOGY, V176, P587, DOI 10.1016/0042-6822(90)90029-Q; MANDL CW, 1989, J VIROL, V63, P564, DOI 10.1128/JVI.63.2.564-571.1989; MANDL CW, 1988, VIROLOGY, V166, P197, DOI 10.1016/0042-6822(88)90161-4; Monath T.P., 1990, VIROLOGY, P763; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NOWAK T, 1987, VIROLOGY, V156, P127, DOI 10.1016/0042-6822(87)90443-0; PLETNEV AG, 1993, J VIROL, V67, P4956, DOI 10.1128/JVI.67.8.4956-4963.1993; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; ROEHRIG JT, 1989, VIROLOGY, V171, P49, DOI 10.1016/0042-6822(89)90509-6; ROEHRIG JT, 1990, VIROLOGY, V177, P668, DOI 10.1016/0042-6822(90)90532-V; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SUMIYOSHI H, 1987, VIROLOGY, V161, P497, DOI 10.1016/0042-6822(87)90144-9; Theiler M, 1937, J EXP MED, V65, P787, DOI 10.1084/jem.65.6.787; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; WENGLER G, 1989, J VIROL, V63, P2521, DOI 10.1128/JVI.63.6.2521-2526.1989; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	44	1154	1261	1	63	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					291	298		10.1038/375291a0	http://dx.doi.org/10.1038/375291a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753193				2022-12-28	WOS:A1995RA03000042
J	BAKER, M; WILLIAMS, J; PETCHEY, R				BAKER, M; WILLIAMS, J; PETCHEY, R			GPS IN PRINCIPLE BUT NOT IN PRACTICE - A STUDY OF VOCATIONALLY TRAINED DOCTORS NOT CURRENTLY WORKING AS PRINCIPALS	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE	Objectives-To identify doctors who are vocationally trained but not currently practising as principals in general practice; their reasons for not practising as principals; and whether the prospect of a re-entry course would appeal to this group. Design-Postal questionnaire survey based on semistructured interviews. Subjects-Doctors who had been vocationally trained but were not currently practising as principals: 351 possible subjects identified by a process of ''networking.'' Setting-Trent Regional Health Authority. Results-166 of the doctors who replied fitted the criteria (100 women; 66 men). The out of hours commitment was ranked as the most important factor for not practising as a principal-95 women and 50 men rated it important-followed by difficulty in combining work with family commitments-84 women, 31 men. 82 respondents (49%) said they would be interested in a re-entry course if one were available. Conclusions-There is a pool of vocationally trained doctors in Trent region who are not practising as principals in general practice. More flexible working patterns and the availability of a re-entry course could make the post of principal in general practice a more attractive proposition to these doctors.	UNIV NOTTINGHAM,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	BAKER, M (corresponding author), UNIV NOTTINGHAM,QUEENS MED CTR,OFF POSTGRAD DEAN,NOTTINGHAM NG7 2UH,ENGLAND.							Allen, 1988, DOCTORS THEIR CAREER; ALLEN I, 1992, PARTTIME WORKING GEN; Allen I., 1994, DOCTORS THEIR CAREER; BEECHAM L, 1994, BRIT MED J, V309, P1306; BUCHAN J, 1990, 199 I MAN STUD REP; DONALD AG, 1990, BRIT MED J, V301, P1060, DOI 10.1136/bmj.301.6760.1060; GRAY DP, 1990, PRACTITIONER, V234, P1011; HEDGES BM, 1978, SOCIAL ED RES ACTION, P246; OSLER K, 1991, BRIT MED J, V303, P762, DOI 10.1136/bmj.303.6805.762; PARKHOUSE J, 1988, BRIT MED J, V296, P1651, DOI 10.1136/bmj.296.6637.1651; Smith H., 1975, Soil Survey of Hartford County Area, Maryland.; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; [No title captured]; 1991, WOMEN RETURNERS EMPL; 1992, PLANNING MED WORKFOR; 1993, HOSPITAL DOCTORS TRA; 1994, EQUAL OPPORTUNITIES; 1992, YOUR CHOICES FUTURE; 1989, CMND555	19	43	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1301	1304		10.1136/bmj.310.6990.1301	http://dx.doi.org/10.1136/bmj.310.6990.1301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773045	Green Published			2022-12-28	WOS:A1995QZ86000024
J	IKONEN, E; TAGAYA, M; ULLRICH, O; MONTECUCCO, C; SIMONS, K				IKONEN, E; TAGAYA, M; ULLRICH, O; MONTECUCCO, C; SIMONS, K			DIFFERENT REQUIREMENTS FOR NSF, SNAP, AND RAB PROTEINS IN APICAL AND BASOLATERAL TRANSPORT IN MDCK CELLS	CELL			English	Article							SENSITIVE FUSION PROTEIN; VESICULAR TRANSPORT; PLASMA-MEMBRANE; GOLGI-NETWORK; SCHIZOSACCHAROMYCES-POMBE; ATTACHMENT PROTEINS; EPITHELIAL-CELLS; ALPHA-SNAP; GENE; VESICLES	We used an in vitro system based on streptolysin O-permeabilized MDCK cells to study the involvement of NSF, SNAP, SNAREs, and Rab proteins in polarized membrane transport of epithelial cells. In MDCK cells, transport from the trans-Golgi network (TGN) to the basolateral plasma membrane is inhibited by anti-NSF antibodies and stimulated by alpha-SNAP. In contrast, transport from the TGN to the apical cell surface is not affected by anti-NSF antibodies or alpha-SNAP. Furthermore, apical transport is insensitive to Rab-GDI and tetanus and botulinum neurotoxins, which inhibit basolateral transport, These results provide evidence that the Rab-NSF-SNAP-SNARE mechanism operates in basolateral transport, while other molecules constitute the machinery for vesicular delivery in the apical pathway.	TOKYO COLL PHARM, SCH LIFE SCI, HACHIOJI 19203, TOKYO, JAPAN; UNIV PADUA, CTR CONSIGLIO NAZL RIC BIOMEMBRANE, DIPARTIMENTO SCI BIOMED, I-35121 PADUA, ITALY	Tokyo University of Pharmacy & Life Sciences; University of Padua	IKONEN, E (corresponding author), EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, D-69012 HEIDELBERG, GERMANY.			Simons, Kai/0000-0002-9231-9996				BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; BUCCI C, 1994, P NATL ACAD SCI USA, V91, P5061, DOI 10.1073/pnas.91.11.5061; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1992, METHOD ENZYMOL, V219, P319; CRAIGHEAD MW, 1993, MOL BIOL CELL, V4, P1069, DOI 10.1091/mbc.4.10.1069; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FIELDER K, 1994, EMBO J, V13, P1729; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; FULLER SD, 1985, EMBO J, V4, P2475, DOI 10.1002/j.1460-2075.1985.tb03959.x; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HAUBRUCK H, 1990, EMBO J, V9, P1957, DOI 10.1002/j.1460-2075.1990.tb08323.x; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; HUGHSON E, 1988, MOL BIOL INFECTIOUS, P79; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAFONT F, 1994, NATURE, V372, P801; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SIMONS K, 1995, IN PRSS HARVEY LECT; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; ULLRICH O, 1995, INPRESS METH ENZYMOL; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	60	216	217	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					571	580		10.1016/0092-8674(95)90078-0	http://dx.doi.org/10.1016/0092-8674(95)90078-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758111	Bronze			2022-12-28	WOS:A1995QZ71000014
J	ZHENG, H; JIANG, MH; TRUMBAUER, ME; SIRINATHSINGHJI, DJS; HOPKINS, R; SMITH, DW; HEAVENS, RP; DAWSON, GR; BOYCE, S; CONNER, MW; STEVENS, KA; SLUNT, HH; SISODIA, SS; CHEN, HY; VANDERPLOEG, LHT				ZHENG, H; JIANG, MH; TRUMBAUER, ME; SIRINATHSINGHJI, DJS; HOPKINS, R; SMITH, DW; HEAVENS, RP; DAWSON, GR; BOYCE, S; CONNER, MW; STEVENS, KA; SLUNT, HH; SISODIA, SS; CHEN, HY; VANDERPLOEG, LHT			BETA-AMYLOID PRECURSOR PROTEIN-DEFICIENT MICE SHOW REACTIVE GLIOSIS AND DECREASED LOCOMOTOR-ACTIVITY	CELL			English	Article							ALZHEIMERS-DISEASE; NEURITE OUTGROWTH; RAT-BRAIN; GENE; EXPRESSION; MOUSE; DOMAIN; CDNA	In several pedigrees of early onset familial Alzheimer's disease (FAD), point mutations in the beta-amyloid precursor protein (APP) gene are genetically linked to the disease. This finding implicates APP in the pathogenesis of Alzheimer's disease in these individuals. To understand the in vivo function of APP and its processing, we have generated an APP-null mutation in mice. Homozygous APP-deficient mice were viable and fertile. However, the mutant animals weighed 15%-20% less than age-matched wild-type controls. Neurological evaluation showed that the APP-deficient mice exhibited a decreased locomotor activity and forelimb grip strength, indicating a compromised neuronal or muscular function. In addition, four out of six homozygous mice showed reactive gliosis at 14 weeks of age, suggesting an impaired neuronal function as a result of the APP-null mutation.	MERCK SHARP & DOHME LTD, RES LABS, NEUROSCI RES CTR, West Point, PA 19486 USA; JOHNS HOPKINS UNIV, SCH MED, NEUROPATHOL LAB, BALTIMORE, MD 21205 USA	Merck & Company; Johns Hopkins University	ZHENG, H (corresponding author), MERCK & CO INC, MERCK SHARP & DOHME RES LABS, DEPT GENET & MOLEC BIO, ANIM RESOURCES LAB, RAHWAY, NJ 07065 USA.							Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FISHER S, 1991, P NATL ACAD SCI USA, V88, P1779, DOI 10.1073/pnas.88.5.1779; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; KOSIK KS, 1992, SCIENCE, V256, P780, DOI 10.1126/science.1589757; KOSIK KS, 1992, NEUROBIOLOGY AGING, V13; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAMB BT, 1993, NAT GENET, V5, P22, DOI 10.1038/ng0993-22; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1994, ANNU REV MED, V45, P435; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; ROSEN DR, 1989, P NATL ACAD SCI USA, V86, P2478, DOI 10.1073/pnas.86.7.2478; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SARKOZI E, 1994, EXP NEUROL, V128, P27, DOI 10.1006/exnr.1994.1109; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1993, TRENDS NEUROSCI, V16, P403, DOI 10.1016/0166-2236(93)90008-A; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMALL DH, 1993, ANN NY ACAD SCI, V695, P169, DOI 10.1111/j.1749-6632.1993.tb23047.x; SOLA C, 1993, EUR J NEUROSCI, V5, P795, DOI 10.1111/j.1460-9568.1993.tb00931.x; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; VANNOSTRAND WE, 1990, J BIOL CHEM, V265, P9591; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	51	544	563	2	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					525	531		10.1016/0092-8674(95)90073-X	http://dx.doi.org/10.1016/0092-8674(95)90073-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758106	hybrid			2022-12-28	WOS:A1995QZ71000009
J	KELLY, DA; STANTON, A				KELLY, DA; STANTON, A			JAUNDICE IN BABIES - IMPLICATIONS FOR COMMUNITY SCREENING FOR BILIARY ATRESIA	BRITISH MEDICAL JOURNAL			English	Article								Although prompt referral of babies with biliary atresia ensures early surgery and improves outcome,(1) late referral persists in the United Kingdom, leading to calls for systematic screening of babies with neonatal jaundice persisting beyond 14 days.(2) This would entail reviewing the baby, establishing whether the stool is pigmented, testing urine for bilirubin, and measuring blood concentrations of conjugated and unconjugated bilirubin.(2 3) To evaluate the feasibility of systematic screening, we ascertained the prevalence of (a) jaundice in babies aged 2, 4, and 6 weeks, and (b) dark urine or pale stools as reported by the parents or a health visitor. We also established how often stools or urine of jaundiced babies were noted by health visitors at their first visit to gauge the effect on workload.	SOLIHULL HEALTHCARE NATL HLTH SERV TRUST,BIRMINGHAM B37 7XR,W MIDLANDS,ENGLAND; CHILDRENS HOSP,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND									FRIEDMAN L, 1978, BRIT MED J, V1, P1235, DOI 10.1136/bmj.1.6122.1235; HUSSEIN M, 1991, ARCH DIS CHILD, V66, P1177, DOI 10.1136/adc.66.10.1177; MACKINLAY GA, 1993, BRIT MED J, V306, P1426, DOI 10.1136/bmj.306.6890.1426; NELSON R, 1989, BRIT MED J, V298, P1471, DOI 10.1136/bmj.298.6686.1471; WINFIELD CR, 1978, ARCH DIS CHILD, V53, P506, DOI 10.1136/adc.53.6.506	5	35	38	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1172	1173		10.1136/bmj.310.6988.1172	http://dx.doi.org/10.1136/bmj.310.6988.1172			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767152	Green Published			2022-12-28	WOS:A1995QX56600029
J	CARPENTER, ATC				CARPENTER, ATC			CHIASMA FUNCTION	CELL			English	Review							SISTER-CHROMATID ASSOCIATION; MEIOSIS; MUTANT; YEAST; ORD											ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; FLATTERS M, 1993, GENETICS, V134, P423; FLATTERS M, 1994, IN PRESS GENETICS, V137; KOSHLAND D, 1994, CELL, V77, P951, DOI 10.1016/0092-8674(94)90432-4; MAGUIRE MP, 1974, J THEOR BIOL, V48, P485, DOI 10.1016/S0022-5193(74)80017-2; MAGUIRE MP, 1993, MAYDICA, V38, P93; MAGUIRE MP, 1993, GENOME, V36, P797, DOI 10.1139/g93-105; MASON JM, 1976, GENETICS, V84, P545; MIYAZAKI WY, 1992, GENETICS, V132, P1047; MOORE DP, 1994, GENETICS, V136, P953; ROCKMILL B, 1990, GENETICS, V126, P563; ROCKMILL B, 1994, GENETICS, V136, P65; TEASE C, 1978, CHROMOSOMA, V69, P163, DOI 10.1007/BF00329915	13	79	81	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					959	962		10.1016/0092-8674(94)90434-0	http://dx.doi.org/10.1016/0092-8674(94)90434-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	7766240				2022-12-28	WOS:A1994NV42500003
J	ELKAYAM, U; OSTRZEGA, E; SHOTAN, A; MEHRA, A				ELKAYAM, U; OSTRZEGA, E; SHOTAN, A; MEHRA, A			CARDIOVASCULAR PROBLEMS IN PREGNANT-WOMEN WITH THE MARFAN-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article							AORTIC DISSECTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; PROPRANOLOL THERAPY; CESAREAN-SECTION; MANAGEMENT; FIBRILLIN; HYPERTENSION; TACHYCARDIA; ATENOLOL; PATIENT	Purpose: To review the available information on the diagnostic, prognostic, and therapeutic aspects of cardiac complications in women with the Marfan syndrome during the peripartum period and to develop guidelines for the approach to these patients on the basis of this information. Data Sources: A MEDLINE search and a manual search of bibliographies from reviewed articles. Study Selection and Data Extraction: Articles that reported on pregnancy in patients with the Marfan syndrome or that discussed potentially relevant aspects of the syndrome. Results: Pregnancy in the Marfan syndrome is associated with two primary problems: potential catastrophic aortic dissection and the risk for having a child with the syndrome. The risk for peripartum aortic dissection is especially high in women in whom aortic root dilatation is diagnosed before pregnancy. Gestation seems to be safer in women without preexisting cardiovascular disease; however, an event-free pregnancy cannot be guaranteed, The Marfan syndrome is inherited in an autosomal dominant manner, and the fetus has a 50% risk for inheriting the mutant gene. Conclusions: Women with the syndrome should be counseled before conception about the risks of pregnancy to both mother and fetus. Because preconceptual dilatation of the ascending aorta seems to be an important predictor for aortic dissection, it should be excluded before pregnancy. Transesophageal echocardiography seems to be preferable for noninvasive assessment of aortic dilatation before and during pregnancy, Prophylactic use of beta-blockers may be useful in preventing aortic dilatation. Surgery should be considered during gestation in patients with progressive aortic dilatation when or before the aortic roof reaches. 5.5 cm. Because of the potential risk of ionizing radiation to the fetus, noninvasive methods such as transesophageal echocardiography and magnetic resonance imaging are preferred to contrast aortography for the diagnosis of aortic dissection during pregnancy. Vaginal delivery can be done in patients with the Marfan syndrome who do not have cardiovascular system abnormalities. In patients with aortic dilatation, aortic dissection, or other important cardiac abnormalities, cesarean section should be the preferred method of delivery.			ELKAYAM, U (corresponding author), UNIV SO CALIF, SCH MED, DIV CARDIOL, 2025 ZONAL AVE, ROOM 7621, LOS ANGELES, CA 90033 USA.		Shotan, Avraham/ABG-3685-2021					Bailey M K, 1989, J S C Med Assoc, V85, P327; BALTAZAR RF, 1983, ARCH INTERN MED, V143, P781, DOI 10.1001/archinte.143.4.781; BARDEN TP, 1968, AM J OBSTET GYNECOL, V102, P226, DOI 10.1016/0002-9378(68)90323-2; BARKER SGE, 1989, J CARDIOVASC SURG, V30, P953; BAUER JH, 1979, AM J CARDIOL, V43, P860, DOI 10.1016/0002-9149(79)90090-0; BECKER RM, 1983, ANN THORAC SURG, V36, P453, DOI 10.1016/S0003-4975(10)60486-9; BEERS GJ, 1989, MAGN RESON IMAGING, V7, P309, DOI 10.1016/0730-725X(89)90556-0; BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BOTTKANNER G, 1980, BRIT J OBSTET GYNAEC, V87, P110, DOI 10.1111/j.1471-0528.1980.tb04502.x; BULLOCK JL, 1975, AM J OBSTET GYNECOL, V121, P242, DOI 10.1016/0002-9378(75)90648-1; CIGARROA JE, 1993, NEW ENGL J MED, V328, P35, DOI 10.1056/NEJM199301073280107; COLA LM, 1985, J REPROD MED, V30, P685; COTTRILL CM, 1977, J PEDIATR-US, V91, P812, DOI 10.1016/S0022-3476(77)81049-4; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DONALDSON LB, 1965, AM J OBSTET GYNECOL, V92, P629, DOI 10.1016/0002-9378(65)90432-1; DUMESIC DA, 1982, NEW ENGL J MED, V307, P1128, DOI 10.1056/NEJM198210283071806; EAGLE KA, 1992, HEART DISEASE, P1528; ELIAHOU HE, 1978, BRIT J OBSTET GYNAEC, V85, P431, DOI 10.1111/j.1471-0528.1978.tb14909.x; ELIAS S, 1976, OBSTET GYNECOL, V47, P358; ELKAYAM U, 1990, CARDIAC PROBLEMS PRE, P5; Elkayam U, 1990, CARDIAC PROBLEMS PRE, P215; ELKAYAM U, 1990, CARDIAC PROBLEMS PRE, P41; ELSTER AD, 1994, AM J ROENTGENOL, V162, P1493, DOI 10.2214/ajr.162.6.8192041; FERGUSON JE, 1983, AM J OBSTET GYNECOL, V147, P759, DOI 10.1016/0002-9378(83)90031-5; GODFREY M, 1993, AM J HUM GENET, V53, P472; GORDON CF, 1993, J CLIN ANESTH, V5, P248, DOI 10.1016/0952-8180(93)90025-A; GOTT VL, 1986, NEW ENGL J MED, V314, P1070, DOI 10.1056/NEJM198604243141702; HOGSTEDT S, 1985, ACTA OBSTET GYN SCAN, V64, P505; IRONS DW, 1993, BRIT J OBSTET GYNAEC, V100, P279, DOI 10.1111/j.1471-0528.1993.tb15244.x; KAINULAINEN K, 1992, P NATL ACAD SCI USA, V89, P5917, DOI 10.1073/pnas.89.13.5917; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KARLBERG B, 1974, ACTA PHARMACOL TOX, V34, P222; KATZ NM, 1984, AM J CARDIOL, V54, P699, DOI 10.1016/0002-9149(84)90290-X; KLEINMAN CS, 1985, J CLIN ULTRASOUND, V13, P265, DOI 10.1002/jcu.1870130406; LANGER A, 1974, OBSTET GYNECOL, V44, P181; LARDOUX H, 1983, EUR HEART J, V4, P35, DOI 10.1093/eurheartj/4.suppl_G.35; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LIEDHOLM H, 1983, DRUGS, V25, P206, DOI 10.2165/00003495-198300252-00060; LIEDHOLM H, 1981, EUR J CLIN PHARMACOL, V20, P229, DOI 10.1007/BF00544603; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; METCALFE J, 1986, HEART DISEASE PREGNA, P144; MILEWICZ DM, 1992, J CLIN INVEST, V89, P79, DOI 10.1172/JCI115589; Mor-Yosef S, 1988, Obstet Gynecol Surv, V43, P382, DOI 10.1097/00006254-198807000-00002; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; MURGATROYD F, 1991, European Heart Journal, V12, P410; OAKLEY GDG, 1979, BRIT MED J, V1, P1749, DOI 10.1136/bmj.1.6180.1749; OCONNOR PC, 1981, LANCET, V2, P1168; Ose L, 1977, Birth Defects Orig Artic Ser, V13, P163; PRUYN SC, 1979, AM J OBSTET GYNECOL, V135, P485, DOI 10.1016/0002-9378(79)90436-8; PRUZINSKY MS, 1988, AM J CARDIOL, V61, P1159, DOI 10.1016/0002-9149(88)90161-0; PUMPHREY CW, 1986, BRIT HEART J, V55, P106; PYERITZ RE, 1986, AM FAM PHYSICIAN, V34, P83; PYERITZ RE, 1983, CIRCULATION, V68, P365; PYERITZ RE, 1981, AM J MED, V71, P784, DOI 10.1016/0002-9343(81)90365-X; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; ROSEN SE, 1993, AM J MED GENET, V47, P157; ROSENBLUM NG, 1983, AM J OBSTET GYNECOL, V146, P470, DOI 10.1016/0002-9378(83)90834-7; ROSSITER JP, 1992, OBSTET GYN CLIN N AM, V19, P801; SANDSTROM B, 1982, CLIN EXP HYPERTENS B, V1, P127; SCHROEDER JS, 1971, AM J CARDIOL, V27, P445, DOI 10.1016/0002-9149(71)90443-7; SHIME J, 1987, AM J OBSTET GYNECOL, V156, P313, DOI 10.1016/0002-9378(87)90275-4; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; SIMPSON IA, 1993, BRIT HEART J, V69, P104; SMITH VC, 1989, MIL MED, V154, P404; SNIR E, 1988, SURG GYNECOL OBSTET, V167, P463; STODDARD MF, 1992, AM HEART J, V124, P785, DOI 10.1016/0002-8703(92)90294-6; TCHERDAKOFF P, 1978, BRIT MED J, V2, P670, DOI 10.1136/bmj.2.6138.670; TEUSCHER A, 1978, AM J CARDIOL, V42, P304, DOI 10.1016/0002-9149(78)90916-5; TREASURE T, 1993, BRIT HEART J, V69, P101; TUNSTALL ME, 1969, BRIT J ANAESTH, V41, P792; TURNER GM, 1968, BRIT MED J, V4, P281, DOI 10.1136/bmj.4.5626.281; WIDERHORN J, 1992, PRINCIPLES PRACTICE, P767; WLADIMIROFF JW, 1985, BRIT J HOSP MED, V34, P134; WOLINSKY H, 1972, CIRC RES, V30, P341, DOI 10.1161/01.RES.30.3.341; ZAHKA K G, 1989, Journal of the American College of Cardiology, V13, p119A	76	102	107	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					117	122		10.7326/0003-4819-123-2-199507150-00007	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778824	Green Published			2022-12-28	WOS:A1995RM43500007
J	FUCHS, CS; MAYER, RJ				FUCHS, CS; MAYER, RJ			MEDICAL PROGRESS - GASTRIC-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HELICOBACTER-PYLORI INFECTION; STOMACH-CANCER; HIGH-RISK; DIETARY FACTORS; PEPTIC-ULCER; ALCOHOL-CONSUMPTION; CURATIVE RESECTION; PERNICIOUS-ANEMIA; COLORECTAL-CANCER; C-ERBB-2 PROTEIN		BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	FUCHS, CS (corresponding author), DANA FARBER CANC INST, DIV MED ONCOL, 44 BINNEY ST, BOSTON, MA 02115 USA.							AGBOOLA O, 1994, CANCER TREAT REV, V20, P217, DOI 10.1016/0305-7372(94)90001-9; ALCOBENDAS F, 1983, ANN SURG, V198, P13, DOI 10.1097/00000658-198307000-00004; ALEXANDER HR, 1993, CANCER PRINCIPLES PR, P818; An international association between Helicobacter pylori infection and gastric cancer, 1993, LANCET, V341, P1668; [Anonymous], 1990, CANCER-AM CANCER SOC, V66, P2324; ANTMAN KH, 1979, MEDICINE, V58, P377, DOI 10.1097/00005792-197909000-00004; BARKER DJP, 1990, BRIT J CANCER, V61, P575, DOI 10.1038/bjc.1990.129; BLACKBUR.EK, 1968, INT J CANCER, V3, P163, DOI 10.1002/ijc.2910030120; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOT WJ, 1992, CANCER RES, V52, pS2119; BOEING H, 1991, INT J CANCER, V47, P858, DOI 10.1002/ijc.2910470612; BOTET JF, 1991, RADIOLOGY, V181, P419, DOI 10.1148/radiology.181.2.1924783; BOZZETTI F, 1987, SURG GYNECOL OBSTET, V164, P151; BRADY MS, 1991, ARCH SURG-CHICAGO, V126, P359; BRINTON LA, 1989, BRIT J CANCER, V59, P810, DOI 10.1038/bjc.1989.169; BROWN J, 1968, MEDICINE, V47, P33, DOI 10.1097/00005792-196801000-00002; BUNT AMG, 1995, J CLIN ONCOL, V13, P19, DOI 10.1200/JCO.1995.13.1.19; BUTIATTI E, 1990, INT J CANCER, V45, P896; CHYOU PH, 1990, CANCER RES, V50, P7501; COGGON D, 1989, J NATL CANCER I, V81, P1178, DOI 10.1093/jnci/81.15.1178; COLINJONES DG, 1992, GUT, V33, P1280, DOI 10.1136/gut.33.9.1280; COMIS RL, 1974, CANCER-AM CANCER SOC, V34, P1576, DOI 10.1002/1097-0142(197411)34:5<1576::AID-CNCR2820340503>3.0.CO;2-0; COOK AO, 1986, ARCH SURG-CHICAGO, V121, P603; COOMBES RC, 1990, J CLIN ONCOL, V8, P1362, DOI 10.1200/JCO.1990.8.8.1362; CORREA P, 1985, JNCI-J NATL CANCER I, V75, P645; CORREA P, 1970, J NATL CANCER I, V44, P297; CORREA P, 1988, AM J GASTROENTEROL, V83, P504; CORREA P, 1975, LANCET, V2, P58; CORREA P, 1990, CANCER RES, V50, P4731; CORREA P, 1992, CANCER RES, V52, P6735; CRAANEN ME, 1992, AM J GASTROENTEROL, V87, P572; CULLINAN SA, 1994, J CLIN ONCOL, V12, P412, DOI 10.1200/JCO.1994.12.2.412; CUSUMANO A, 1992, ANN THORAC SURG, V53, P1010, DOI 10.1016/0003-4975(92)90376-F; DANTZIG PI, 1973, ARCH DERMATOL, V108, P700, DOI 10.1001/archderm.108.5.700; DEMIRER T, 1990, CANCER, V65, P2344, DOI 10.1002/1097-0142(19900515)65:10&lt;2344::AID-CNCR2820651030&gt;3.0.CO;2-H; DENT DM, 1979, CANCER, V44, P385, DOI 10.1002/1097-0142(197908)44:2<385::AID-CNCR2820440203>3.0.CO;2-8; DENT DM, 1988, BRIT J SURG, V75, P110, DOI 10.1002/bjs.1800750206; DOUGLASS HO, 1982, CANCER-AM CANCER SOC, V49, P1116; DOUGLASS HO, 1985, SEMIN ONCOL, V12, P32; DUBROW R, 1993, J NATL CANCER I, V85, P1268, DOI 10.1093/jnci/85.16.1268; DUPONT JB, 1978, CANCER-AM CANCER SOC, V41, P941, DOI 10.1002/1097-0142(197803)41:3<941::AID-CNCR2820410323>3.0.CO;2-M; EKBOM GA, 1980, SURGERY, V88, P476; ENGSTROM PF, 1985, CANCER-AM CANCER SOC, V55, P1868, DOI 10.1002/1097-0142(19850501)55:9<1868::AID-CNCR2820550904>3.0.CO;2-B; FORMAN D, 1993, LANCET, V341, P1359; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; FORMAN D, 1987, BRIT MED J, V294, P528, DOI 10.1136/bmj.294.6571.528; GOLEMATIS B, 1990, BRIT J SURG, V77, P63, DOI 10.1002/bjs.1800770123; GONZALEZ CA, 1991, INT J CANCER, V49, P513, DOI 10.1002/ijc.2910490407; GONZALEZ CA, 1994, AM J EPIDEMIOL, V139, P466, DOI 10.1093/oxfordjournals.aje.a117029; GOUZI JL, 1989, ANN SURG, V209, P162, DOI 10.1097/00000658-198902000-00005; GRAHAM DY, 1985, ANN INTERN MED, V102, P573, DOI 10.7326/0003-4819-102-5-573; GRAHAM DY, 1982, GASTROENTEROLOGY, V82, P228; HAENSZEL W, 1972, JNCI-J NATL CANCER I, V49, P969; HAENSZEL W, 1976, JNCI-J NATL CANCER I, V56, P265, DOI 10.1093/jnci/56.2.265; HAENSZEL W, 1958, J NATL CANCER I, V21, P213; HALLISSEY MT, 1994, LANCET, V343, P1309, DOI 10.1016/S0140-6736(94)92464-3; HANSSON LE, 1994, INT J CANCER, V57, P26, DOI 10.1002/ijc.2910570106; HARVEY RF, 1985, LANCET, V1, P951; Hellman S, 1993, CANC PRINCIPLES PRAC, P248; HERMANS J, 1993, J CLIN ONCOL, V11, P1441, DOI 10.1200/JCO.1993.11.8.1441; HIGGINS GA, 1983, CANCER, V52, P1105, DOI 10.1002/1097-0142(19830915)52:6<1105::AID-CNCR2820520629>3.0.CO;2-Z; HOLE DJ, 1987, SCAND J GASTROENTERO, V22, P17, DOI 10.3109/00365528708991850; HOSHIYAMA Y, 1992, CANCER CAUSE CONTROL, V3, P441, DOI 10.1007/BF00051357; HOWSON CP, 1986, EPIDEMIOL REV, V8, P1; HSING AW, 1993, CANCER, V71, P745, DOI 10.1002/1097-0142(19930201)71:3<745::AID-CNCR2820710316>3.0.CO;2-1; IMAI T, 1971, J NATL CANCER I, V47, P179; ISENBERG JI, 1983, NEW ENGL J MED, V308, P1319, DOI 10.1056/NEJM198306023082203; Jakesz R, 1988, Recent Results Cancer Res, V110, P44; JOHNSON H, 1993, ARCH SURG-CHICAGO, V128, P314; JOYPAUL BV, 1994, BRIT J CANCER, V69, P943, DOI 10.1038/bjc.1994.182; KABAT GC, 1993, CANCER CAUSE CONTROL, V4, P123, DOI 10.1007/BF00053153; KAKEJI Y, 1993, BRIT J CANCER, V67, P589, DOI 10.1038/bjc.1993.108; KELSEN D, 1992, J CLIN ONCOL, V10, P541, DOI 10.1200/JCO.1992.10.4.541; KLINKENBERGKNOL EC, 1994, ANN INTERN MED, V121, P161, DOI 10.7326/0003-4819-121-3-199408010-00001; KNELLER RW, 1991, CANCER, V68, P672, DOI 10.1002/1097-0142(19910801)68:3<672::AID-CNCR2820680339>3.0.CO;2-T; KNELLER RW, 1992, JNCI-J NATL CANCER I, V84, P1261, DOI 10.1093/jnci/84.16.1261; KNYRIM K, 1993, NEW ENGL J MED, V329, P1302, DOI 10.1056/NEJM199310283291803; KODAMA M, 1984, Nutrition and Cancer, V6, P135, DOI 10.1080/01635588509513817; KROOK JE, 1991, CANCER, V67, P2454, DOI 10.1002/1097-0142(19910515)67:10<2454::AID-CNCR2820671010>3.0.CO;2-2; Kurihara M, 1981, Cancer Detect Prev, V4, P377; KURTZ RC, 1985, SEMIN ONCOL, V12, P11; LANDRY J, 1990, INT J RADIAT ONCOL, V19, P1357, DOI 10.1016/0360-3016(90)90344-J; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LAUREN PA, 1993, CANCER-AM CANCER SOC, V71, P2926, DOI 10.1002/1097-0142(19930515)71:10<2926::AID-CNCR2820711007>3.0.CO;2-X; LAVECCHIA C, 1990, BRIT J CANCER, V62, P136, DOI 10.1038/bjc.1990.245; LAVECCHIA C, 1987, INT J CANCER, V40, P484, DOI 10.1002/ijc.2910400409; LAVECCHIA C, 1990, LANCET, V336, P355, DOI 10.1016/0140-6736(90)91888-H; LAVECCHIA C, 1992, CANCER, V70, P50, DOI 10.1002/1097-0142(19920701)70:1<50::AID-CNCR2820700109>3.0.CO;2-I; LERNER A, 1992, J CLIN ONCOL, V10, P536, DOI 10.1200/JCO.1992.10.4.536; LOIZOU LA, 1992, CANCER, V70, P386, DOI 10.1002/1097-0142(19920715)70:2<386::AID-CNCR2820700203>3.0.CO;2-H; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MALLAIAH L, 1980, AM J PROCTOL GASTRO, V31, P12; MARUYAMA K, 1987, WORLD J SURG, V11, P418, DOI 10.1007/BF01655804; MATZNER MJ, 1951, GASTROENTEROLOGY, V18, P296; MEIJER S, 1983, J SURG ONCOL, V23, P77, DOI 10.1002/jso.2930230205; MENETRIER P, 1888, ARCH PHYSL NORM PATH, V1, P322; MIRVISH SS, 1983, JNCI-J NATL CANCER I, V71, P629; MIZUTANI T, 1993, CANCER, V72, P2083, DOI 10.1002/1097-0142(19931001)72:7<2083::AID-CNCR2820720705>3.0.CO;2-1; MOERTEL CG, 1969, LANCET, V2, P865; MOLLER H, 1992, GUT, V33, P1166, DOI 10.1136/gut.33.9.1166; MORSON BC, 1955, BRIT J CANCER, V9, P377, DOI 10.1038/bjc.1955.36; MUNOZ N, 1971, INT J CANCER, V8, P158, DOI 10.1002/ijc.2910080119; NAKAMURA T, 1985, J CLIN PATHOL, V38, P754, DOI 10.1136/jcp.38.7.754; NANUS DM, 1989, J CLIN ONCOL, V7, P1105, DOI 10.1200/JCO.1989.7.8.1105; NANUS DM, 1990, GASTROENTEROLOGY, V98, P955, DOI 10.1016/0016-5085(90)90019-W; NIGHTINGALE TE, 1994, JNCI-J NATL CANCER I, V86, P1505, DOI 10.1093/jnci/86.20.1505; NOGUCHI Y, 1989, CANCER, V64, P2053, DOI 10.1002/1097-0142(19891115)64:10<2053::AID-CNCR2820641014>3.0.CO;2-J; NOMURA A, 1990, CANCER RES, V50, P627; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; OFFERHAUS GJA, 1992, LANCET, V340, P33, DOI 10.1016/0140-6736(92)92433-G; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PARSONNET J, 1991, J NATL CANCER I, V83, P881; PISANI P, 1994, BRIT J CANCER, V69, P1102, DOI 10.1038/bjc.1994.216; POSNER MR, 1994, HEMATOL ONCOL CLIN N, V8, P533, DOI 10.1016/S0889-8588(18)30167-9; POWELL J, 1990, BRIT J CANCER, V62, P440, DOI 10.1038/bjc.1990.314; PREUSSER P, 1989, J CLIN ONCOL, V7, P1310, DOI 10.1200/JCO.1989.7.9.1310; PREUSSER P, 1988, CANCER TREAT REV, V15, P257, DOI 10.1016/0305-7372(88)90025-4; RAMON JM, 1993, CANCER, V71, P1731, DOI 10.1002/1097-0142(19930301)71:5&lt;1731::AID-CNCR2820710505&gt;3.0.CO;2-X; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; RISCH HA, 1985, AM J EPIDEMIOL, V122, P947, DOI 10.1093/oxfordjournals.aje.a114199; ROBERTSON CS, 1994, ANN SURG, V220, P176, DOI 10.1097/00000658-199408000-00009; ROLLAG A, 1984, ACTA MED SCAND, V216, P105; ROTTERDAM H, 1989, PATHOLOGY STOMACH DU, P142; ROUBEIN LD, 1988, GASTRIC CANCER, V8, P87; SACK GH, 1977, MEDICINE, V56, P1, DOI 10.1097/00005792-197756010-00001; SAKON M, 1989, ACTA CHIR SCAND, V155, P365; SCHEIN PS, 1982, CANCER, V49, P1771, DOI 10.1002/1097-0142(19820501)49:9<1771::AID-CNCR2820490907>3.0.CO;2-M; SINDELAR WF, 1993, AM J SURG, V165, P178, DOI 10.1016/S0002-9610(05)80423-4; Sokoloff B., 1938, AM J SURG, V40, P673; SPECHLER SJ, 1994, SEMIN ONCOL, V21, P431; STALNIKOWICZ R, 1990, ARCH INTERN MED, V150, P2022, DOI 10.1001/archinte.150.10.2022; Staszewski J, 1972, Recent Results Cancer Res, V39, P85; SUEHIRO S, 1984, AM J SURG, V148, P645, DOI 10.1016/0002-9610(84)90343-X; SUGIMACHI K, 1980, GANN, V71, P704; SUSSMAN SK, 1988, RADIOLOGY, V167, P335, DOI 10.1148/radiology.167.2.3357941; TALLEY NJ, 1991, J NATL CANCER I, V83, P1734, DOI 10.1093/jnci/83.23.1734; TATSUTA M, 1993, CANCER, V72, P1841, DOI 10.1002/1097-0142(19930915)72:6<1841::AID-CNCR2820720608>3.0.CO;2-I; TERSMETTE AC, 1990, CANCER RES, V50, P6486; THOMPSON GB, 1993, LANCET, V342, P713, DOI 10.1016/0140-6736(93)91711-T; TIO TL, 1989, RADIOLOGY, V173, P411, DOI 10.1148/radiology.173.2.2678255; Tominaga S, 1992, Gan To Kagaku Ryoho, V19, P1113; TRICHOPOULOS D, 1985, INT J CANCER, V36, P291, DOI 10.1002/ijc.1985.36.3.291; UCHINO S, 1993, CANCER, V72, P3179, DOI 10.1002/1097-0142(19931201)72:11<3179::AID-CNCR2820721108>3.0.CO;2-#; WAKASHIN M, 1980, GASTROENTEROLOGY, V78, P749; WANEBO HJ, 1993, ANN SURG, V218, P583, DOI 10.1097/00000658-199321850-00002; WANG KK, 1993, GASTROENTEROLOGY, V105, P283, DOI 10.1016/0016-5085(93)90039-F; WEED TE, 1981, ANN SURG, V193, P407, DOI 10.1097/00000658-198104000-00003; Whelan SL, 1993, IARC SCI PUBLICATION, P102; WIGGINS CL, 1989, CANCER RES, V49, P1595; WILS JA, 1991, J CLIN ONCOL, V9, P827, DOI 10.1200/JCO.1991.9.5.827; WRIGHT PA, 1993, GUT, V34, P145, DOI 10.1136/gut.34.2.145; WUWILLIAMS AH, 1990, CANCER RES, V50, P2569; YOU WC, 1988, CANCER RES, V48, P3518; ZANGHIERI G, 1990, CANCER, V66, P2047, DOI 10.1002/1097-0142(19901101)66:9<2047::AID-CNCR2820660934>3.0.CO;2-G; 1995, CANCER FACTS FIGURES; 1994, DHHS NIH942789 DEP H; 1993, MANUAL STAGING CANCE	157	577	599	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					32	41		10.1056/NEJM199507063330107	http://dx.doi.org/10.1056/NEJM199507063330107			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776992				2022-12-28	WOS:A1995RG73500007
J	RICHARD, P; DELVALLE, GA; MOREAU, P; MILPIED, N; FELICE, MP; DAESCHLER, T; HAROUSSEAU, JL; RICHET, H				RICHARD, P; DELVALLE, GA; MOREAU, P; MILPIED, N; FELICE, MP; DAESCHLER, T; HAROUSSEAU, JL; RICHET, H			VIRIDANS STREPTOCOCCAL BACTEREMIA IN PATIENTS WITH NEUTROPENIA	LANCET			English	Note							MARROW TRANSPLANT RECIPIENTS; SEPTICEMIA; SEPSIS	Viridans streptococcal bacteraemia is frequent in neutropenic patients. 25 neutropenic patients with viridans streptococcal bacteraemia were compared with 64 control patients. Exposure to repeated chemotherapy or cytarabine were independent risk-factors for streptococcal bacteraemia. The use of carboxyureidopenicillins and stay in laminar-airflow rooms were protective. In a further cohort study of 49 patients, oral streptococci with the same ribotype as blood isolates were recovered from all 7 bacteraemic patients. The oral cavity is a portal of entry for viridans streptococci bacteraemia in neutropenic patients, especially after oral mucosal damage induced by repeated chemotherapy.	HOP HOTEL DIEU,FAC CHIRURG DENT,F-44035 NANTES,FRANCE; HOP HOTEL DIEU,SERV HEMATOL,F-44035 NANTES,FRANCE	Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	RICHARD, P (corresponding author), HOP HOTEL DIEU,INST MED BIOL,BACTERIOL LAB A,F-44035 NANTES,FRANCE.			moreau, philippe/0000-0003-1780-8746; Milpied, Noel/0000-0002-5177-014X				BOCHUD PY, 1994, CLIN INFECT DIS, V1, P25; BOSTROM B, 1984, LANCET, V1, P1120; CLASSEN DC, 1990, AM J MED, V89, P441, DOI 10.1016/0002-9343(90)90373-L; COHEN J, 1983, LANCET, V2, P1452, DOI 10.1016/S0140-6736(83)90799-7; ELTING LS, 1994, CLIN INFECT DIS, V14, P1201; HENSLEE J, 1984, LANCET, V1, P393; MASCRET B, 1984, LANCET, V1, P1185; RINGDEN O, 1984, LANCET, V1, P744; VALTEAU D, 1991, BONE MARROW TRANSPL, V7, P415	9	81	82	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 24	1995	345	8965					1607	1609		10.1016/S0140-6736(95)90117-5	http://dx.doi.org/10.1016/S0140-6736(95)90117-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783538				2022-12-28	WOS:A1995RE67000010
J	HUNTER, JM				HUNTER, JM			DRUG-THERAPY - NEW NEUROMUSCULAR BLOCKING-DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NORMAL RENAL-FUNCTION; INTENSIVE-CARE UNIT; MIVACURIUM CHLORIDE; NITROUS-OXIDE; D-TUBOCURARINE; CLINICAL-PHARMACOLOGY; PIPECURONIUM BROMIDE; HALOTHANE ANESTHESIA; MALIGNANT HYPERTHERMIA; GALLAMINE TRIETHIODIDE				HUNTER, JM (corresponding author), UNIV LIVERPOOL,ROYAL LIVERPOOL UNIV HOSP,DEPT ANAESTHESIA,PRESCOT ST,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND.		garcia, waynice np/K-3914-2015					AGOSTON S, 1980, BRIT J ANAESTH, V52, pS53, DOI 10.1093/bja/52.suppl_1.53S; AGOSTON S, 1978, BRIT J ANAESTH, V50, P345, DOI 10.1093/bja/50.4.345; AGOSTON S, 1973, ACTA ANAESTH SCAND, V17, P267, DOI 10.1111/j.1399-6576.1973.tb00839.x; ALI HH, 1971, BRIT J ANAESTH, V43, P473, DOI 10.1093/bja/43.5.473; BASTA SJ, 1988, ANESTHESIOLOGY, V69, P478, DOI 10.1097/00000542-198810000-00006; Basta SJ, 1992, CURR OPIN ANESTH, V5, P572; BASTA SJ, 1989, ANESTHESIA ANALGESIA, V68, pS18; BELL CF, 1984, ANAESTHESIA, V39, P961, DOI 10.1111/j.1365-2044.1984.tb08883.x; BELL CF, 1985, BRIT J ANAESTH, V57, P160, DOI 10.1093/bja/57.2.160; BENCINI AF, 1985, BRIT J ANAESTH, V57, P782, DOI 10.1093/bja/57.8.782; BEVAN DR, 1992, ANESTHESIOLOGY, V77, P785, DOI 10.1097/00000542-199210000-00025; BOOTH MG, 1992, ANAESTHESIA, V47, P832, DOI 10.1111/j.1365-2044.1992.tb03139.x; BOWMAN WC, 1990, PHARM NEUROMUSCULAR, P134; BOYD AH, 1995, BRIT J ANAESTH, V74, P400, DOI 10.1093/bja/74.4.400; BRAGG P, 1994, ANESTHESIOLOGY, V80, P310, DOI 10.1097/00000542-199402000-00011; BRITT BA, 1974, CAN ANAESTH SOC J, V21, P371, DOI 10.1007/BF03006069; BROTHERTON WP, 1981, ANESTHESIOLOGY, V55, P273, DOI 10.1097/00000542-198109000-00015; CALDWELL JE, 1989, BRIT J ANAESTH, V63, P393, DOI 10.1093/bja/63.4.393; CALDWELL JE, 1989, ANESTHESIOLOGY, V70, P7, DOI 10.1097/00000542-198901000-00004; CHAPPLE DJ, 1987, BRIT J ANAESTH, V59, P218, DOI 10.1093/bja/59.2.218; CHURCHILLDAVIDS.HC, 1963, ANESTHESIOLOGY, V24, P271; CODY MW, 1987, ANAESTHESIA, V42, P993, DOI 10.1111/j.1365-2044.1987.tb05374.x; Cook D R, 1975, Anesthesiology, V42, P662, DOI 10.1097/00000542-197506000-00007; COOK DR, 1991, ANESTH ANALG, V72, P145; COOK DR, 1992, BRIT J ANAESTH, V69, P580, DOI 10.1093/bja/69.6.580; DEVLIN JC, 1993, BRIT J ANAESTH, V71, P227, DOI 10.1093/bja/71.2.227; DHONNEUR G, 1993, ANESTH ANALG, V77, P1203; DONATI F, 1992, BRIT J ANAESTH, V68, P235, DOI 10.1093/bja/68.3.235; DUNDEE JW, 1953, LANCET, V2, P16; DUVALDESTIN P, 1978, BRIT J ANAESTH, V50, P1131, DOI 10.1093/bja/50.11.1131; DUVALDESTIN P, 1985, CLIN ANAESTHESIOL, V3, P293; EAGAR BM, 1984, BRIT J ANAESTH, V56, P447, DOI 10.1093/bja/56.5.447; FAHEY MR, 1984, ANESTHESIOLOGY, V61, P699, DOI 10.1097/00000542-198412000-00011; FAHEY MR, 1985, BRIT J ANAESTH, V57, P1049, DOI 10.1093/bja/57.11.1049; FELDMAN SA, 1963, BRIT J ANAESTH, V35, P804, DOI 10.1093/bja/35.12.804; FISHER DM, 1986, ANESTHESIOLOGY, V65, P6, DOI 10.1097/00000542-198607000-00002; FISHER DM, 1982, ANESTHESIOLOGY, V57, P203, DOI 10.1097/00000542-198209000-00009; FOLDES FF, 1962, ANESTHESIOLOGY, V23, P837, DOI 10.1097/00000542-196211000-00015; GOOCH JL, 1991, CRIT CARE MED, V19, P1125, DOI 10.1097/00003246-199109000-00006; GRIFFITHS RB, 1986, ANAESTHESIA, V41, P375, DOI 10.1111/j.1365-2044.1986.tb13221.x; GRONERT GA, 1980, ANESTHESIOLOGY, V53, P395, DOI 10.1097/00000542-198011000-00007; HANSENFLASCHEN J, 1993, AM REV RESPIR DIS, V147, P234, DOI 10.1164/ajrccm/147.1.234; HEADRAPSON AG, 1994, BRIT J ANAESTH, V73, P613, DOI 10.1093/bja/73.5.613; HILGENBERG JC, 1983, ANESTH ANALG, V62, P524; HUNTER JM, 1985, ANAESTHESIA, V40, P848, DOI 10.1111/j.1365-2044.1985.tb11045.x; HUNTER JM, 1982, BRIT J ANAESTH, V54, P1243, DOI 10.1093/bja/54.12.1243; HUNTER JM, 1984, BRIT J ANAESTH, V56, P941, DOI 10.1093/bja/56.9.941; HUNTER JM, 1987, BRIT J ANAESTH, V59, P46, DOI 10.1093/bja/59.1.46; KATZ RL, 1971, ANESTHESIOLOGY, V34, P550, DOI 10.1097/00000542-197106000-00015; KATZ RL, 1971, ANESTHESIOLOGY, V35, P602, DOI 10.1097/00000542-197112000-00009; KATZ RL, 1967, ANESTHESIOLOGY, V28, P327, DOI 10.1097/00000542-196703000-00008; KENT AP, 1989, BRIT J ANAESTH, V63, P661, DOI 10.1093/bja/63.6.661; KENT AP, 1991, ANAESTHESIA, V46, P271, DOI 10.1111/j.1365-2044.1991.tb11494.x; KHUENIBRADY K, 1990, ANESTHESIOLOGY, V72, P669, DOI 10.1097/00000542-199004000-00016; LEBRAULT C, 1985, ANESTHESIOLOGY, V62, P601, DOI 10.1097/00000542-198505000-00010; LEPAGE JY, 1993, ANESTHESIOLOGY, V79, pA945; LEVY JH, 1994, ANESTH ANALG, V78, P318, DOI 10.1213/00000539-199402000-00020; LIEN CA, 1994, ANESTHESIOLOGY, V80, P1296, DOI 10.1097/00000542-199406000-00017; LIEN CA, 1991, ANESTH ANALG, V73, P39; LYNAM DP, 1988, ANESTHESIOLOGY, V69, P227, DOI 10.1097/00000542-198808000-00012; MARTYN J, 1986, ANESTHESIOLOGY, V65, P67, DOI 10.1097/00000542-198607000-00011; MATTEO RS, 1985, ANESTH ANALG, V64, P23; MATTEO RS, 1993, ANESTH ANALG, V77, P1193; MEIJER DKF, 1979, ANESTHESIOLOGY, V51, P402, DOI 10.1097/00000542-197911000-00007; MEYER KC, 1994, ANESTH ANALG, V78, P772; MILLER RD, 1978, J PHARMACOL EXP THER, V207, P539; MIRAKHUR RK, 1982, CAN ANAESTH SOC J, V29, P55, DOI 10.1007/BF03007949; NIGHTINGALE P, 1985, BRIT J ANAESTH, V57, P1131, DOI 10.1093/bja/57.11.1131; OSTERGAARD D, 1993, ACTA ANAESTH SCAND, V37, P314, DOI 10.1111/j.1399-6576.1993.tb03721.x; PARKER CJR, 1988, BRIT J ANAESTH, V61, P531, DOI 10.1093/bja/61.5.531; PARKER CJR, 1989, BRIT J ANAESTH, V62, P177, DOI 10.1093/bja/62.2.177; PHILLIPS BJ, 1992, BRIT J ANAESTH, V68, P492, DOI 10.1093/bja/68.5.492; RAMZAN IM, 1981, ANESTH ANALG, V60, P289; ROUSE JM, 1977, ANAESTHESIA, V32, P247, DOI 10.1111/j.1365-2044.1977.tb11602.x; RUPP SM, 1984, ANESTHESIOLOGY, V60, P102, DOI 10.1097/00000542-198402000-00004; SAVARESE JJ, 1989, ANESTHESIOLOGY, V70, P386, DOI 10.1097/00000542-198903000-00003; SAVARESE JJ, 1975, ANESTHESIOLOGY, V42, P236, DOI 10.1097/00000542-197503000-00002; SAVARESE JJ, 1977, ANESTHESIOLOGY, V47, P277, DOI 10.1097/00000542-197709000-00009; SAVARESE JJ, 1988, ANESTHESIOLOGY, V68, P723, DOI 10.1097/00000542-198805000-00010; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; SHEARER ES, 1991, BRIT J ANAESTH, V67, P569, DOI 10.1093/bja/67.5.569; SHI WZ, 1989, BRIT J ANAESTH, V63, P598, DOI 10.1093/bja/63.5.598; SMITH CL, 1985, BRIT J ANAESTH, V57, P1113, DOI 10.1093/bja/57.11.1113; STANDAERT FG, 1994, SEMIN ANESTH, V13, P286; STANLEY JC, 1991, EUR J ANAESTH, V8, P151; STANSKI DR, 1979, ANESTHESIOLOGY, V51, P235, DOI 10.1097/00000542-197909000-00011; STENLAKE JB, 1983, BRIT J ANAESTH, V55, pS3; STONE AJ, 1994, BRIT J ANAESTH, V72, pP486; SUFIT RL, 1990, ANESTH ANALG, V71, P285; SZENOHRADSZKY J, 1992, ANESTHESIOLOGY, V77, P899, DOI 10.1097/00000542-199211000-00010; TOLMIE JD, 1967, ANESTHESIOLOGY, V28, P467, DOI 10.1097/00000542-196703000-00039; TSUI D, 1987, ANESTHESIOLOGY, V67, P722, DOI 10.1097/00000542-198711000-00017; VANDENBROM RHG, 1988, ANESTHESIOLOGY, V69, P996, DOI 10.1097/00000542-198812000-00040; WALKER J, 1980, EUR J CLIN PHARMACOL, V17, P449, DOI 10.1007/BF00570163; WHITTAKER M, 1980, ANAESTHESIA, V35, P174, DOI 10.1111/j.1365-2044.1980.tb03800.x; WIERDA JMKH, 1993, ANESTH ANALG, V77, P579; WIERDA JMKH, 1991, EUR J ANAESTH, V8, P451; WILLIAMS CH, 1992, ANESTH ANALG, V74, pS350; WRIGHT PMC, 1994, ANESTHESIOLOGY, V81, P59, DOI 10.1097/00000542-199407000-00010; WRIGLEY SR, 1992, ANAESTHESIA, V47, P653, DOI 10.1111/j.1365-2044.1992.tb02384.x	100	100	105	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1691	1699		10.1056/NEJM199506223322507	http://dx.doi.org/10.1056/NEJM199506223322507			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760871				2022-12-28	WOS:A1995RD99600007
J	DATTA, A; JINKSROBERTSON, S				DATTA, A; JINKSROBERTSON, S			ASSOCIATION OF INCREASED SPONTANEOUS MUTATION-RATES WITH HIGH-LEVELS OF TRANSCRIPTION IN YEAST	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; INDUCED MUTAGENESIS; GENE; RAD6; RECOMBINATION; DISRUPTION; RADIATION; STRAINS; CELLS; CONSTRUCTION	Complex processes such as transcription, replication, repair, and recombination require changes in chromatin structure and the interactions of numerous trans-acting factors with DNA sequences, raising the possibility that these processes may be interrelated. Here the effect of transcription on the rate of spontaneous mutation in the yeast Saccharomyces cerevisiae was examined. With the use of a lys2 frameshift allele under the control of a highly inducible promoter, the rate of spontaneous reversion was shown to increase when the mutant gene was highly transcribed. Thus, transcriptionally active DNA and enhanced spontaneous mutation rates are associated in yeast.	EMORY UNIV, GRAD PROGRAM BIOCHEM & MOLEC BIOL, ATLANTA, GA 30322 USA; EMORY UNIV, DEPT BIOL, ATLANTA, GA 30322 USA	Emory University; Emory University					NIGMS NIH HHS [GM38464] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038464, R29GM038464] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; BALBINDER E, 1970, GENETICS, V66, P31; BARTLETT JD, 1991, MUTAT RES, V255, P247, DOI 10.1016/0921-8777(91)90028-N; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; CASSIERCHAUVAT C, 1991, MUTAT RES, V254, P247, DOI 10.1016/0921-8777(91)90063-U; CHATTOO BB, 1979, GENETICS, V93, P51; Datta A., UNPUB; DAVIS BD, 1989, P NATL ACAD SCI USA, V86, P5005, DOI 10.1073/pnas.86.13.5005; DERR LK, 1993, NATURE, V361, P170, DOI 10.1038/361170a0; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; FOX MS, 1994, EXPERIENTIA, V50, P253, DOI 10.1007/BF01924008; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GANGLOFF S, 1994, EXPERIENTIA, V50, P261, DOI 10.1007/BF01924009; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HERMAN RK, 1971, J BACTERIOL, V106, P543, DOI 10.1128/JB.106.2.543-550.1971; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; KOMBERG RD, 1992, ANN REV CELL BIOL, V8, P563; KOROGODIN VI, 1991, YEAST, V7, P105, DOI 10.1002/yea.320070204; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1984, MOL GEN GENET, V195, P487, DOI 10.1007/BF00341451; LAWRENCE CW, 1976, GENETICS, V82, P207; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Luria SE, 1943, GENETICS, V28, P491; MELAMED C, 1992, MOL CELL BIOL, V12, P1613, DOI 10.1128/MCB.12.4.1613; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; PALOMBO F, 1992, J MOL BIOL, V223, P587, DOI 10.1016/0022-2836(92)90974-O; PLATT T, 1984, MOL CELL BIOL, V4, P994, DOI 10.1128/MCB.4.5.994; PRAKASH L, 1976, GENETICS, V83, P285; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QUAH SK, 1980, GENETICS, V96, P819; RATTRAY AJ, 1994, GENETICS, V138, P587; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAVIC DJ, 1972, MOL GEN GENET, V118, P45, DOI 10.1007/BF02428331; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; STEELE DF, 1992, GENETICS, V132, P9; STEELE DF, 1991, GENETICS, V127, P53; STRATHEM JN, IN PRESS GENETICS; SUNG P, 1990, P NATL ACAD SCI USA, V87, P2695, DOI 10.1073/pnas.87.7.2695; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; VONBORSTEL RC, 1971, GENETICS, V69, P17; WARTERS RL, 1987, MUTAT RES, V180, P21, DOI 10.1016/0027-5107(87)90063-7; WATKINS JF, 1993, GENE DEV, V7, P250, DOI 10.1101/gad.7.2.250	50	207	212	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 16	1995	268	5217					1616	1619		10.1126/science.7777859	http://dx.doi.org/10.1126/science.7777859			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RD459	7777859				2022-12-28	WOS:A1995RD45900037
J	HOLLAK, CEM; AERTS, JMFG; GOUDSMIT, R; PHOA, SSKS; EK, M; VANWEELY, S; VONDEMBORNE, AEGK; VANOERS, MHJ				HOLLAK, CEM; AERTS, JMFG; GOUDSMIT, R; PHOA, SSKS; EK, M; VANWEELY, S; VONDEMBORNE, AEGK; VANOERS, MHJ			INDIVIDUALIZED LOW-DOSE ALGLUCERASE THERAPY FOR TYPE-1 GAUCHERS-DISEASE	LANCET			English	Article							MACROPHAGE-TARGETED GLUCOCEREBROSIDASE; ENZYME REPLACEMENT THERAPY; PERITONEAL-MACROPHAGES; FIBROBLASTS; TOMOGRAPHY; DIAGNOSIS; VOLUME	Previous studies have shown that enzyme supplementation therapy with alglucerase for type 1 Gaucher's disease is effective at doses of 30-130 U/kg per month. Since both the clinical presentation and the response to therapy in Gaucher's disease are highly variable, individual dosing seems indicated, This notion, as well as the high costs of alglucerase and the unknown long-term side-effects, led us to investigate the efficacy of an individualised very low dose of alglucerase. Twenty-five adults with symptomatic type 1 Gaucher's disease (thirteen splenectomised) received alglucerase 1.15 U/kg three times a week (15 U/kg per month). Every 6 months, the dose was halved, maintained, or doubled, according to the response (based on haematological variables and liver and spleen volume). After 6 months of treatment, eighteen (72%) patients had a response (seventeen moderate, one good). After 12 months (in nineteen patients) and 18 months (in seven patients), all had sustained improvement. Severe splenomegaly resulted in slower haematological responses. Our results are similar to those obtained by others with higher-dose regimens and better than a low-dose regimen of 10 U/kg every 2 weeks. We conclude that very low initial doses of alglucerase, when administered frequently, are effective and cost-saving in the treatment of type 1 Gaucher's disease.	UNIV AMSTERDAM,ACAD MED CTR,DEPT HEMATOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT RADIOL,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	HOLLAK, CEM (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,F4-222,POB 22700,1100 DE AMSTERDAM,NETHERLANDS.		Aerts, Johannes/A-1028-2009	Aerts, Johannes/0000-0001-8168-2565				AERTS JMFG, 1986, CLIN CHIM ACTA, V158, P155, DOI 10.1016/0009-8981(86)90231-7; BARTON NW, 1992, J PEDIATR-US, V120, P277, DOI 10.1016/S0022-3476(05)80444-5; BARTON NW, 1993, NEW ENGL J MED, V328, P1564; BARTON NW, 1991, NEW ENGL J MED, V325, P1811; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BARTON NW, 1990, P NATL ACAD SCI USA, V87, P1913, DOI 10.1073/pnas.87.5.1913; BEUTLER E, 1992, BLOOD, V79, P1662; BEUTLER E, 1993, AM J DIS CHILD, V147, P1175, DOI 10.1001/archpedi.1993.02160350049007; BLUEMKE DA, 1992, AM J RADIOL, V160, P787; BREIMAN RS, 1982, AM J ROENTGENOL, V138, P329, DOI 10.2214/ajr.138.2.329; DANIELS LB, 1982, CLIN CHEM, V28, P569; DAS PK, 1986, EUR J BIOCHEM, V154, P445, DOI 10.1111/j.1432-1033.1986.tb09417.x; FIGUEROA ML, 1992, NEW ENGL J MED, V327, P1632, DOI 10.1056/NEJM199212033272304; HEYMSFIELD SB, 1979, ANN INTERN MED, V90, P185, DOI 10.7326/0003-4819-90-2-185; HOLLAK CEM, 1993, NEW ENGL J MED, V328, P1565; NEWBURG DS, 1986, BIOCHIM BIOPHYS ACTA, V877, P121, DOI 10.1016/0005-2760(86)90126-8; PASTORES GM, 1993, BLOOD, V82, P408; VANWEELY S, 1990, EUR J BIOCHEM, V191, P669; VANWEELY S, 1991, BIOCHIM BIOPHYS ACTA, V1096, P301, DOI 10.1016/0925-4439(91)90066-I; ZIMRAN A, 1993, BLOOD, V82, P1107; ZIMRAN A, 1993, BRIT J HAEMATOL, V85, P783, DOI 10.1111/j.1365-2141.1993.tb03224.x; ZIMRAN A, 1994, AM J MED, V97, P3, DOI 10.1016/0002-9343(94)90042-6; ZIMRAN A, 1992, MEDICINE, V71, P337, DOI 10.1097/00005792-199211000-00002	23	96	97	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1474	1478		10.1016/S0140-6736(95)91037-9	http://dx.doi.org/10.1016/S0140-6736(95)91037-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769902				2022-12-28	WOS:A1995RC18900009
J	MAKRIDES, M; NEUMANN, M; SIMMER, K; PATER, J; GIBSON, R				MAKRIDES, M; NEUMANN, M; SIMMER, K; PATER, J; GIBSON, R			ARE LONG-CHAIN POLYUNSATURATED FATTY-ACIDS ESSENTIAL NUTRIENTS IN INFANCY	LANCET			English	Article							BIRTH-WEIGHT INFANTS; 1ST YEAR GROWTH; PRETERM INFANTS; VISUAL-ACUITY; BREAST-MILK; MARINE-OIL; DIETARY OMEGA-3-FATTY-ACIDS; LINOLENIC ACID; FORMULAS; HEALTHY	We investigated whether the disparity in neural maturation between breastfed and formula-fed term infants could be corrected by the addition of fish oil, a source of docosahexaenoic acid (DHA, 22:6 omega 3), to infant formula. Healthy, term infants were randomised at birth to receive either a supplemented or placebo formula if their mothers had chosen to bottle feed. Breastfed term infants were enrolled as a reference group. Infant erythrocyte fatty acids and anthropometry were assessed on day 5 and at 6, 16, and 30 weeks of age. Visual evoked potential (VEP) acuity was determined at 16 and 30 weeks. VEP acuities of breastfed and supplemented-formula-fed infants were better than those of placebo-formula-fed infants at both 16 and 30 weeks of age (p<0.001 and p<0.01). Erythrocyte DHA in breastfed and supplemented-formula-fed infants was maintained near birth levels throughout the 30-week study period but fell in placebo-formula-fed infants (p<0.001). Erythrocyte DHA was the only fatty acid that consistently correlated with VEP acuity in all infants at both ages tested. A continuous supply of DHA may be required to achieve optimum VEP acuity since infants breastfed for short periods (<16 weeks) had slower development of VEP than infants receiving a continuous supply of DHA from either breastmilk or supplemented formula. Erythrocyte arachidonic acid (20:4 omega 6) in supplemented-formula-fed infants was reduced below that of infants fed breastmilk or placebo formula at 16 and 30 weeks (p<0.001), although no adverse effects were noted, with growth of all infants being similar. DHA seems to be an essential nutrient for the optimum neural maturation of term infants as assessed by VEP acuity. Whether supplementation of formula-fed infants with DHA has long-term benefits remains to be elucidated.	FLINDERS MED CTR,DEPT PAEDIAT & CHILD HLTH,ADELAIDE,SA 5042,AUSTRALIA; FLINDERS MED CTR,DEPT OPHTHALMOL,ADELAIDE,SA 5042,AUSTRALIA	Flinders Medical Centre; Flinders Medical Centre			Makrides, Maria/B-6392-2014; Simmer, Karen N/H-5834-2014; Gibson, Robert Alan/E-7546-2012	Makrides, Maria/0000-0003-3832-541X; Gibson, Robert Alan/0000-0002-8750-525X				BIRCH DG, 1992, INVEST OPHTH VIS SCI, V33, P2365; BIRCH E, 1993, J PEDIATR OPHTHALMOL, V30, P33; BIRCH EE, 1992, INVEST OPHTH VIS SCI, V32, P3242; CARLSON SE, 1992, LIPIDS, V27, P901, DOI 10.1007/BF02535870; CARLSON SE, 1991, PEDIATR RES, V30, P404, DOI 10.1203/00006450-199111000-00003; CARLSON SE, 1993, P NATL ACAD SCI USA, V90, P1073, DOI 10.1073/pnas.90.3.1073; CARLSON SE, 1993, AM J CLIN NUTR, V58, P35, DOI 10.1093/ajcn/58.1.35; CLARK KJ, 1992, J PEDIATR-US, V120, pS151, DOI 10.1016/S0022-3476(05)81250-8; CLELAND LG, 1992, AM J CLIN NUTR, V55, P395, DOI 10.1093/ajcn/55.2.395; DANIEL A, 1983, POWER PREVILEGE PRES; DOBSON V, 1978, VISION RES, V18, P1469, DOI 10.1016/0042-6989(78)90001-9; FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; GIBSON RA, 1981, AM J CLIN NUTR, V34, P252, DOI 10.1093/ajcn/34.2.252; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HARRIS WS, 1984, AM J CLIN NUTR, V40, P780, DOI 10.1093/ajcn/40.4.780; HOFFMAN DR, 1992, LIPIDS, V27, P886, DOI 10.1007/BF02535868; INNIS SM, 1994, AM J CLIN NUTR, V60, P347, DOI 10.1093/ajcn/60.3.347; JACKSON KA, 1989, AM J CLIN NUTR, V50, P980, DOI 10.1093/ajcn/50.5.980; JORGENSEN MH, 1994, FASEB J, V8, P460; LAMKIN JC, 1992, INT OPHTHALMOL CLIN, V32, P1, DOI 10.1097/00004397-199203210-00003; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MAKRIDES M, 1993, PEDIATR RES, V33, P425; MAKRIDES M, 1994, AM J CLIN NUTR, V60, P189, DOI 10.1093/ajcn/60.2.189; NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202; SOKOL S, 1985, INVEST OPHTH VIS SCI, V26, P359; SPEKREIJSE H, 1983, BEHAV BRAIN RES, V10, P107, DOI 10.1016/0166-4328(83)90156-0; SPRECHER H, 1992, ESSENTIAL FATTY ACID, P18; UAUY R, 1994, J PEDIATR-US, V124, P612, DOI 10.1016/S0022-3476(05)83144-0; UAUY RD, 1990, PEDIATR RES, V28, P485, DOI 10.1203/00006450-199011000-00014; 1981, J FOOD NUTR, V38, P11	30	388	411	0	34	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1463	1468		10.1016/S0140-6736(95)91035-2	http://dx.doi.org/10.1016/S0140-6736(95)91035-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769900				2022-12-28	WOS:A1995RC18900007
J	NEED, AG; WISHART, JM; SCOPACASA, F; HOROWITZ, M; MORRIS, HA; NORDIN, BEC				NEED, AG; WISHART, JM; SCOPACASA, F; HOROWITZ, M; MORRIS, HA; NORDIN, BEC			EFFECT OF PHYSICAL-ACTIVITY ON FEMORAL BONE-DENSITY IN MEN	BRITISH MEDICAL JOURNAL			English	Article									ROYAL ADELAIDE HOSP,DEPT MED,ADELAIDE,SA 5000,AUSTRALIA; UNIV ADELAIDE,DEPT PATHOL,ADELAIDE,SA 5001,AUSTRALIA	Royal Adelaide Hospital; University of Adelaide	NEED, AG (corresponding author), INST MED & VET SCI,DIV CLIN BIOCHEM,ADELAIDE,SA 5000,AUSTRALIA.		Morris, Howard A/G-4564-2010; Morris, Howard/L-6272-2019					MCARDLE WD, 1986, EXERCISE PHYSL ENERG, P642; SLEMENDA CW, 1993, BONE MINER, V20, P125, DOI 10.1016/S0169-6009(08)80021-9; SNOWHARTER C, 1992, J BONE MINER RES, V7, P1291; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; WISHART JM, IN PRESS CLIN ENDOCR	5	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1501	1502		10.1136/bmj.310.6993.1501	http://dx.doi.org/10.1136/bmj.310.6993.1501			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787597	Green Published			2022-12-28	WOS:A1995RD28500022
J	SKEGG, DCG				SKEGG, DCG			CERVICAL SCREENING BLUES	LANCET			English	Editorial Material							CANCER; MORTALITY				SKEGG, DCG (corresponding author), UNIV OTAGO, DEPT SOCIAL & PREVENT MED, DUNEDIN, NEW ZEALAND.							BERAL V, 1986, LANCET, V1, P495; BERAL V, 1994, CANCER SURV, V20, P265; BRINTON LA, 1991, CONTRACEPTION, V43, P581, DOI 10.1016/0010-7824(91)90005-Z; BRITTEN N, 1988, BRIT MED J, V296, P1191; COX B, 1992, J EPIDEMIOL COMMUN H, V46, P373, DOI 10.1136/jech.46.4.373; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; DAY NE, 1989, J EPIDEMIOL COMMUN H, V43, P103, DOI 10.1136/jech.43.2.103; HAKAMA M, 1986, SCREENING CANCER UTE; Johnson AM, 1994, SEXUAL ATTITUDES LIF; MCINTYRE N, 1983, BRIT MED J, V287, P1919, DOI 10.1136/bmj.287.6409.1919; MUNOZ N, 1992, EPIDEMIOLOGY CERVICA; 1994, 1993 DEP HLTH CHIEF	12	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	1995	345	8963					1451	1452		10.1016/S0140-6736(95)91030-1	http://dx.doi.org/10.1016/S0140-6736(95)91030-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769896				2022-12-28	WOS:A1995RC18900002
J	FLOR, H; ELBERT, T; KNECHT, S; WIENBRUCH, C; PANTEV, C; BIRBAUMER, N; LARBIG, W; TAUB, E				FLOR, H; ELBERT, T; KNECHT, S; WIENBRUCH, C; PANTEV, C; BIRBAUMER, N; LARBIG, W; TAUB, E			PHANTOM-LIMB PAIN AS A PERCEPTUAL CORRELATE OF CORTICAL REORGANIZATION FOLLOWING ARM AMPUTATION	NATURE			English	Article							CORTEX	ALTHOUGH phantom-limb pain is a frequent consequence of the amputation of an extremity, little is known about its origin(1-4). On the basis of the demonstration of substantial plasticity of the somatosensory cortex after amputation(5) or somatosensory deafferentation in adult monkeys(6), it has been suggested that cortical reorganization could account for some non-painful phantom-limb phenomena in amputees and that cortical reorganization has an adaptive (that is, pain-preventing) function(2,5,7,8). Theoretical and empirical work on chronic back pain(9,10) has revealed a positive relationship between the amount of cortical alteration and the magnitude of pain, so we predicted that cortical reorganization and phantom-limb pain should be positively related. Using non-invasive neuromagnetic imaging techniques to determine cortical reorganization in humans(11-13), we report a very strong direct relationship (r = 0.93) between the amount of cortical reorganization and the magnitude of phantom limb pain (but not non-painful phantom phenomena) experienced after arm amputation. These data indicate that phantom-limb pain is related to, and may be a consequence of, plastic changes in primary somatosensory cortex.	UNIV KONSTANZ,DEPT PSYCHOL,D-78434 CONSTANCE,GERMANY; UNIV MUNSTER,DEPT NEUROL,D-48129 MUNSTER,GERMANY; UNIV MUNSTER,INST EXPTL AUDIOL,D-48129 MUNSTER,GERMANY; UNIV TUBINGEN,INST MED PSYCHOL & BEHAV NEUROBIOL,D-72074 TUBINGEN,GERMANY; UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35294	University of Konstanz; University of Munster; University of Munster; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Alabama System; University of Alabama Birmingham	FLOR, H (corresponding author), HUMBOLDT UNIV BERLIN,DEPT PSYCHOL,HAUSVOGTEIPL 5-7,D-10117 BERLIN,GERMANY.		Elbert, Thomas/C-8556-2009	Elbert, Thomas/0000-0003-1332-4939; Birbaumer, Niels/0000-0002-6786-5127; Knecht, Stefan/0000-0003-1056-9228; Flor, Herta/0000-0003-4809-5398				CALFORD MB, 1991, P ROY SOC B-BIOL SCI, V243, P269, DOI 10.1098/rspb.1991.0041; Casey K., 1991, PAIN CENTRAL NERVOUS; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; Flor H, 1990, Schmerz, V4, P82, DOI 10.1007/BF02527839; FLOR H, 1994, AM PAIN SOC J, V3, P1187; FLOR H, IN PRESS RECENT ADV; GEISSNER E, IN PRESS SCHMERZEMPF; Gilbert C D, 1993, Curr Opin Neurobiol, V3, P100, DOI 10.1016/0959-4388(93)90042-W; Jensen TS., 1994, TXB PAIN, P651; KATZ J, 1992, CAN J PSYCHIAT, V37, P282, DOI 10.1177/070674379203700502; KERNS RD, 1985, PAIN, V23, P345, DOI 10.1016/0304-3959(85)90004-1; LUND JP, 1994, SCIENCE, V265, P546, DOI 10.1126/science.8036500; LUTKENHONER B, IN PRESS BRAIN TOPOG; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MELZACK R, 1989, CAN PSYCHOL, V30, P1, DOI 10.1037/h0079793; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAMACHANDRAN VS, 1992, SCIENCE, V258, P1159, DOI 10.1126/science.1439826; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; SHERMAN RA, 1989, BIOFEEDBACK SELF-REG, V14, P267, DOI 10.1007/BF00999118; WILLIS WD, 1994, 7TH P WORLD C PAIN, P301; YANG TT, 1994, NATURE, V368, P592, DOI 10.1038/368592b0; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	24	1253	1284	2	184	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					482	484		10.1038/375482a0	http://dx.doi.org/10.1038/375482a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777055	Green Submitted			2022-12-28	WOS:A1995RC18800046
J	CHONG, JPJ; MAHBUBANI, HM; KHOO, CY; BLOW, JJ				CHONG, JPJ; MAHBUBANI, HM; KHOO, CY; BLOW, JJ			PURIFICATION OF AN MCM-CONTAINING COMPLEXES A COMPONENT OF THE DNA-REPLICATION LICENSING SYSTEM	NATURE			English	Article							CELL-FREE-EXTRACTS; SUBCELLULAR-LOCALIZATION; YEAST; CYCLE; INITIATION; PROTEIN; FAMILY; NUCLEI	REPLICATION licensing factor (RLF) ensures that eukaryotic chromosomal DNA is replicated exactly once in each cell cycle(1-4). On exit from metaphase, RLF is activated and binds to or modifies chromatin. This modification (the 'licence') is required for subsequent DNA replication; the licence is also inactivated in the process of replication. Active RLF is not imported into the nucleus, so further DNA replication cannot occur until the DNA is relicensed by passage throught mitosis. We have developed an assay to purify RLF from Xenopus eggs(4). Activity resolves into two components, RLF-M and RLF-B, both of which are required for licensing, RLF-M has been purified to apparent homogeneity: it consists of three polypeptides, one of which is a Xenopus homologue of the yeast MCM3 protein. Xenopus Mcm3 associates with chomatin in G1 and is removed during replication, consistent with its being a component of the RLF system.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND; WELLCOME CRC INST, CAMBRIDGE CB2 1QR, ENGLAND				Chong, James/AAC-4957-2019; Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849; Chong, James/0000-0001-9447-7421	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; BUCCI S, 1993, INT J DEV BIOL, V37, P509; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; CREVEL G, 1991, EMBO J, V10, P4361, DOI 10.1002/j.1460-2075.1991.tb05014.x; DEROEPER A, 1977, NATURE, V265, P469, DOI 10.1038/265469a0; FORSBURG SL, 1994, J CELL SCI, V107, P2779; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1993, J CELL BIOL, V123, P1321, DOI 10.1083/jcb.123.6.1321; KUBOTA Y, IN PRESS CELL; LENO GH, 1992, CELL, V69, P151, DOI 10.1016/0092-8674(92)90126-W; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAITI AK, 1992, J MOL BIOL, V224, P545, DOI 10.1016/0022-2836(92)90543-S; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; SHIVJI MKK, 1994, J CURR BIOL, V4, P1062; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1994, J CELL SCI, V107, P253; Tye Bik-Kwoon, 1994, Trends in Cell Biology, V4, P160, DOI 10.1016/0962-8924(94)90200-3; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	28	319	321	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 1	1995	375	6530					418	421		10.1038/375418a0	http://dx.doi.org/10.1038/375418a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760937				2022-12-28	WOS:A1995RB10100057
J	HONIG, B; NICHOLLS, A				HONIG, B; NICHOLLS, A			CLASSICAL ELECTROSTATICS IN BIOLOGY AND CHEMISTRY	SCIENCE			English	Review							POISSON-BOLTZMANN EQUATION; SOLVATION FREE-ENERGIES; ACTIVE-SITE; SUPEROXIDE-DISMUTASE; CRYSTAL-STRUCTURE; MULTIGRID SOLUTION; TITRATION CURVES; IONIZABLE GROUPS; HELIX DIPOLES; PH-DEPENDENCE	A major revival in the use of classical electrostatics as an approach to the study of charged and polar molecules in aqueous solution has been made possible through the development of fast numerical and computational methods to solve the Poisson-Boltzmann equation for solute molecules that have complex shapes and charge distributions. Graphical visualization of the calculated electrostatic potentials generated by proteins and nucleic acids has revealed insights into the role of electrostatic interactions in a wide range of biological phenomena. Classical electrostatics has also proved to be a successful quantitative tool yielding accurate descriptions of electrical potentials, diffusion limited processes, pH-dependent properties of proteins, ionic strength-dependent phenomena, and the solvation free energies of organic molecules.			HONIG, B (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.				NIGMS NIH HHS [GM30518, GM41371] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030518, R37GM030518, R01GM041371] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALLISON SA, 1988, BIOPOLYMERS, V27, P251, DOI 10.1002/bip.360270207; ANDERSON CF, 1993, J PHYS CHEM-US, V97, P7116, DOI 10.1021/j100129a032; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BENNAIM A, 1991, J PHYS CHEM-US, V95, P1437, DOI 10.1021/j100156a074; BENNAIM A, 1984, J CHEM PHYS, V81, P2016, DOI 10.1063/1.447824; BEROZA P, 1991, P NATL ACAD SCI USA, V88, P5804, DOI 10.1073/pnas.88.13.5804; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; CHEN JL, 1994, J PHYS CHEM-US, V98, P11059, DOI 10.1021/j100094a013; CHURG AK, 1986, BIOCHEMISTRY-US, V25, P1675, DOI 10.1021/bi00355a035; CRAMER CJ, 1992, J COMPUT AID MOL DES, V6, P629, DOI 10.1007/BF00126219; DAVIS ME, 1989, J COMPUT CHEM, V10, P386, DOI 10.1002/jcc.540100313; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; EISENHABER F, 1993, J COMPUT CHEM, V14, P1272, DOI 10.1002/jcc.540141103; FERSHT AR, 1984, TRENDS BIOCHEM SCI, V9, P145, DOI 10.1016/0968-0004(84)90122-1; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104; GILSON MK, 1991, J COMPUT AID MOL DES, V5, P5; GILSON MK, 1993, PROTEINS, V15, P266, DOI 10.1002/prot.340150305; GILSON MK, 1989, P NATL ACAD SCI USA, V86, P1524, DOI 10.1073/pnas.86.5.1524; GILSON MK, 1988, J COMPUT CHEM, V9, P327, DOI 10.1002/jcc.540090407; GUENOT J, 1994, PROTEIN SCI, V3, P1276, DOI 10.1002/pro.5560030814; GUNNER MR, 1991, P NATL ACAD SCI USA, V88, P9151, DOI 10.1073/pnas.88.20.9151; HARVEY SC, 1989, PROTEINS, V5, P78, DOI 10.1002/prot.340050109; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HERMANN RB, 1972, J PHYS CHEM-US, V76, P2754, DOI 10.1021/j100663a023; HOLST M, 1994, PROTEINS, V18, P231, DOI 10.1002/prot.340180304; HOLST M, 1993, J COMPUT CHEM, V14, P105, DOI 10.1002/jcc.540140114; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; HU CQ, 1992, BIOCHEMISTRY-US, V31, P4876, DOI 10.1021/bi00135a019; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; JAYARAM B, 1989, BIOPOLYMERS, V28, P975, DOI 10.1002/bip.360280506; JEANCHARLES A, 1991, J AM CHEM SOC, V113, P1454, DOI 10.1021/ja00004a079; JOHNSON LN, 1994, PROTEIN SCI, V3, P1726, DOI 10.1002/pro.5560031011; Kirkwood JG, 1938, J CHEM PHYS, V6, P506, DOI 10.1063/1.1750302; Kirkwood JG, 1939, J CHEM PHYS, V7, P911, DOI 10.1063/1.1750343; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; KONG XP, 1992, CELL, V63, P425; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOEWENTHAL R, 1993, J MOL BIOL, V232, P574, DOI 10.1006/jmbi.1993.1412; LUZHKOV V, 1992, J COMPUT CHEM, V13, P199, DOI 10.1002/jcc.540130212; MACKERELL AD, 1995, J MOL BIOL, V247, P774, DOI 10.1016/S0022-2836(05)80155-X; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MCDONALD NQ, 1991, NATURE, V354, P411, DOI 10.1038/354411a0; MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2; MISRA VK, 1994, J MOL BIOL, V238, P245, DOI 10.1006/jmbi.1994.1285; MISRA VK, 1994, J MOL BIOL, V238, P264, DOI 10.1006/jmbi.1994.1286; MOHAN V, 1992, J PHYS CHEM-US, V96, P6428, DOI 10.1021/j100194a060; NARAYSZABO G, 1989, BIOCHEMISTRY-US, V28, P3629; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NOVOTNY J, 1992, PROG BIOPHYS MOL BIO, V58, P203, DOI 10.1016/0079-6107(92)90006-R; OBEROI H, 1993, BIOPHYS J, V65, P48, DOI 10.1016/S0006-3495(93)81032-4; Onsager L, 1936, J AM CHEM SOC, V58, P1486, DOI 10.1021/ja01299a050; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; PARSEGIAN A, 1969, NATURE, V221, P884; PERROT G, 1992, J COMPUT CHEM, V13, P1, DOI 10.1002/jcc.540130102; POTTER MJ, 1994, J AM CHEM SOC, V116, P10298, DOI 10.1021/ja00101a059; RAJASEKARAN E, 1994, J AM CHEM SOC, V116, P8238, DOI 10.1021/ja00097a033; RASHIN AA, 1994, BIOPHYS CHEM, V51, P375, DOI 10.1016/0301-4622(94)00059-X; RASHIN AA, 1985, J PHYS CHEM-US, V89, P5588, DOI 10.1021/j100272a006; RASHIN AA, 1987, J PHYS CHEM-US, V91, P6003, DOI 10.1021/j100307a038; RASHIN AA, 1994, BIOPHYS CHEM, V51, P167, DOI 10.1016/0301-4622(94)00060-3; RASHIN AA, 1990, J PHYS CHEM-US, V94, P725; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1990, THEORETICAL CHEM MOL, V1, P285; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RIPOLL DR, 1993, P NATL ACAD SCI USA, V90, P5128, DOI 10.1073/pnas.90.11.5128; RYDEN M, 1994, EMBO J; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SCOTT DL, 1994, BIOPHYS J, V67, P493, DOI 10.1016/S0006-3495(94)80546-6; SHARP BA, IN PRESS BIOPOLYMERS; SHARP K, 1992, J PHYS CHEM-US, V96, P3822, DOI 10.1021/j100188a047; SHARP K, 1987, SCIENCE, V236, P1460, DOI 10.1126/science.3589666; SHARP K, 1991, J COMPUT CHEM, V12, P454, DOI 10.1002/jcc.540120407; SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505; SHARP KA, 1990, J PHYS CHEM-US, V94, P7684, DOI 10.1021/j100382a068; SIMONSONT, 1994, J PHYS CHEM-US, V98, P4683; SINES JJ, 1990, BIOCHEMISTRY-US, V29, P9403, DOI 10.1021/bi00492a014; SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043; SOMAN K, 1989, BIOCHEMISTRY-US, V28, P9918, DOI 10.1021/bi00452a007; SRIDHARAN S, 1992, Biophysical Journal, V61, pA174; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TANFORD C, 1972, BIOCHEMISTRY-US, V11, P2192, DOI 10.1021/bi00761a029; TANNOR DJ, 1994, J AM CHEM SOC, V116, P11875, DOI 10.1021/ja00105a030; THOMAS PG, 1985, NATURE, V316, P378; VOROBJEV YN, 1994, J PHYS CHEM-US, V98, P10940, DOI 10.1021/j100093a042; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WARSHEL A, 1981, BIOCHEMISTRY-US, V20, P3167, DOI 10.1021/bi00514a028; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WARWICKER J, 1986, J THEOR BIOL, V121, P199, DOI 10.1016/S0022-5193(86)80093-5; YANG AS, 1994, J MOL BIOL, V237, P602, DOI 10.1006/jmbi.1994.1258; YANG AS, 1993, PROTEINS, V15, P252, DOI 10.1002/prot.340150304; YANG AS, 1992, J MOL BIOL, V227, P889, DOI 10.1016/0022-2836(92)90229-D; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294; YANG AS, 1995, ADV PROTEIN CHEM, V46, P27; YOU TJ, 1993, J COMPUT CHEM, V14, P484, DOI 10.1002/jcc.540140413; ZACHARIAS M, 1992, BIOPHYS J, V63, P1280, DOI 10.1016/S0006-3495(92)81723-X; ZAUHAR RJ, 1991, J COMPUT CHEM, V12, P575, DOI 10.1002/jcc.540120507; ZAUHAR RJ, 1985, J MOL BIOL, V186, P815, DOI 10.1016/0022-2836(85)90399-7	109	2437	2471	6	334	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1144	1149		10.1126/science.7761829	http://dx.doi.org/10.1126/science.7761829			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761829				2022-12-28	WOS:A1995RA60400027
J	PERKINS, AC; SHARPE, AH; ORKIN, SH				PERKINS, AC; SHARPE, AH; ORKIN, SH			LETHAL BETA-THALASSEMIA IN MICE LACKING THE ERYTHROID CACCC-TRANSCRIPTION FACTOR EKLF	NATURE			English	Article							HUMAN GAMMA-GLOBIN; TARGETED MUTATION; MAMMALIAN-CELLS; TRANSGENIC MICE; FACTOR GATA-1; GENE; BINDING; EXPRESSION; EXTRACTION; PROMOTER	GLOBIN genes are regulated in a tissue-specific and developmental stage-specific manner, with the beta-globin gene being the last to be activated in the beta-gene cluster(1). CACCC-nucleotide sequences, which bind multiple nuclear proteins, including ubiquitously expressed Sp1 and erythroid Kruppel-like factor (EKLF), are among the cis-regulatory sequences critical for transcription of globin and non-globin erythroid-expressed genes(2-5). To determine the function of EKLF in vivo, we created mice deficient in EKLF by gene targeting(6). These embryos die of anaemia during fetal liver erythropoiesis and show the molecular and haematological features of beta-globin deficiency, found in beta-thalassaemia. Although it is expressed at all stages, EKLF is not required for yolk sac erythropoiesis, erythroid commitment or expression of other potential target genes. Its stage-specific and beta-globin-gene-specific requirement suggests that EKLF may facilitate completion of the fetal-to-adult (haemoglobin gamma to beta) switch in humans.	CHILDRENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; DANA FARBER CANC INST, DEPT PEDIAT, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Howard Hughes Medical Institute			Perkins, Andrew C/M-3216-2014; Perkins, Andrew/X-4180-2019; Perkins, Andrew/AAJ-9696-2020; Brugnara, Carlo/A-8041-2010	Perkins, Andrew C/0000-0003-3644-7093; Perkins, Andrew/0000-0003-3644-7093; Brugnara, Carlo/0000-0001-8192-8713				ALTER BP, 1982, HEMOGLOBIN, V6, P517, DOI 10.3109/03630268209083764; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BROTHERTON TW, 1979, P NATL ACAD SCI USA, V76, P2853, DOI 10.1073/pnas.76.6.2853; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DILLON N, 1991, NATURE, V350, P252, DOI 10.1038/350252a0; FENG WC, 1994, J BIOL CHEM, V269, P1493; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LLOYD JA, 1992, MOL CELL BIOL, V12, P1561, DOI 10.1128/MCB.12.4.1561; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCDONAGH KT, 1992, HEMATOLOGY INFANCY C; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NATHAN DG, 1966, AM J MED, V41, P815, DOI 10.1016/0002-9343(66)90039-8; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PORCHER C, 1991, J BIOL CHEM, V266, P10562; Sambrook J, 1989, MOL CLONING LABORATO; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STAMATOYANNOPOULOS G, 1993, MOL CELL BIOL, V13, P7636, DOI 10.1128/MCB.13.12.7636; THIEN SL, 1993, BLOOD, V82, P961; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675	29	520	532	0	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					318	322						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753195				2022-12-28	WOS:A1995RA03000051
J	TENNANT, A; FEAR, J; PICKERING, A; HILLMAN, M; CUTTS, A; CHAMBERLAIN, MA				TENNANT, A; FEAR, J; PICKERING, A; HILLMAN, M; CUTTS, A; CHAMBERLAIN, MA			PREVALENCE OF KNEE PROBLEMS IN THE POPULATION AGED 55 YEARS AND OVER - IDENTIFYING THE NEED FOR KNEE ARTHROPLASTY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OSTEOARTHRITIS; GUIDELINES; ARTHRITIS; HIP	Objective-To determine the prevalence of knee problems in people aged 55 years and over and identify those who should be considered for knee arthroplasty. Design-Postal survey; questionnaires were sent to a multistage stratified probability sample of residents of North Yorkshire Health Authority aged 55 and over. Setting-A health district with a population of 210 000 aged 55 and over. Results-An initial four page postal questionnaire produced an 86% response rate among 18 827 eligible patients. A subsequent detailed questionnaire sent to 1277 patients with knee problems (with a response rate of 78%) then determined the prevalence of severe pain and severe disability. Pain and disability consistent with the need to consider arthroplasty was found in 20.4/1000 (95% confidence interval 18.0 to 23.1); of these, 4.1 (2.7 to 5.8)/1000 had extreme disability. Age and sex specific rates in men who might benefit from arthroplasty were, in those aged 55-64, 12.9 (8.4 to 19.0)/1000; aged 65-74, 12.1 (7.4 to 18.4)/1000; aged 75 and over, 20.3 (12.9 to 30.5)/ 1000. In women aged 55-64 the rates were 12.9 (8.6 to 18.7)/1000; aged 65-74, 19.6 (13.9 to 26.7)/1000; aged 75 years and over, 42.6 (34.3 to 52.4)/1000. Conclusions-Total knee replacement has until recently been considered unreliable and often seen as a last resort for many with severe knee problems. Advances in prosthesis design and surgical and anaesthetic techniques have transformed this procedure into a reliable option with a potential for reducing disability and dependency in a large number of people in the community. Understandably, the prevalence pool of those who may benefit is large; health authorities and, increasingly, general practitioners should consider purchasing more total knee replacement surgery to offer real choice to those in need.	N YORKSHIRE HLTH, PUBL HLTH MED, YORK YO1 1PE, N YORKSHIRE, ENGLAND		TENNANT, A (corresponding author), UNIV LEEDS, RES SCH MED, RHEUMATOL & REHABIL RES UNIV, LEEDS LS2 9NZ, W YORKSHIRE, ENGLAND.							COOPER C, 1994, ANN RHEUM DIS, V53, P90, DOI 10.1136/ard.53.2.90; CROFT P, 1992, SCAND J WORK ENV HEA, V18, P59, DOI 10.5271/sjweh.1608; FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; HARRIS AI, 1971, SAMPLE SURVEYS LOCAL; Harris Amelia I, 1971, HANDICAPPED IMPAIRED; KIRWAN JR, 1994, BRIT J RHEUMATOL, V33, P357; KIRWAN JR, 1986, BRIT J RHEUMATOL, V25, P206; LEQUESNE MG, 1987, SCAND J RHEUMATOL, P85; LIANG MH, 1986, ARTHRITIS RHEUM, V29, P937, DOI 10.1002/art.1780290801; MARTIN J, 1988, OPCS1 SURV DIS GREAT; RAND JA, 1991, J BONE JOINT SURG AM, V73A, P397, DOI 10.2106/00004623-199173030-00011; SCHOENBERG B S, 1983, Neuroepidemiology, V2, P257, DOI 10.1159/000110529; SCOTT DL, 1993, J ROY COLL PHYS LOND, V27, P391; STEVENS A, 1994, HLTH NEEDS ASSESSMEN, V1; TENNANT A, 1991, J EPIDEMIOL COMMUN H, V45, P81, DOI 10.1136/jech.45.1.81; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILKIN D, 1992, HOSPITAL REFERRALS, P76; WILLIAMS MH, 1994, HLTH CARE NEEDS ASSE, V1, P448; 1971, SERVICES HANDICAPPED	19	80	81	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	1995	310	6990					1291	1293		10.1136/bmj.310.6990.1291	http://dx.doi.org/10.1136/bmj.310.6990.1291			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773041	Green Published			2022-12-28	WOS:A1995QZ86000019
J	HUG, C; JAY, PY; REDDY, I; MCNALLY, JG; BRIDGMAN, PC; ELSON, EL; COOPER, JA				HUG, C; JAY, PY; REDDY, I; MCNALLY, JG; BRIDGMAN, PC; ELSON, EL; COOPER, JA			CAPPING PROTEIN-LEVELS INFLUENCE ACTIN ASSEMBLY AND CELL MOTILITY IN DICTYOSTELIUM	CELL			English	Article							F-ACTIN; LENGTH DISTRIBUTION; BINDING PROTEINS; AMEBOID CELLS; DISCOIDEUM; FILAMENTS; POLYMERIZATION; IDENTIFICATION; MORPHOGENESIS; STIMULATION	Actin assembly is important for cell motility, but the mechanism of assembly and how it relates to motility in vivo is largely unknown. In vitro, actin assembly can be controlled by proteins, such as capping protein, that bind filament ends. To investigate the function of actin assembly in vivo, we altered the levels of capping protein in Dictyostelium cells and found changes in resting and chemoattractant-induced actin assembly that were consistent with the in vitro properties of capping protein in capping but not nucleation. Significantly, overexpressers moved faster and underexpressers moved slower than control cells. Mutants also exhibited changes in cytoskeleton architecture. These results provide insights into in vivo actin assembly and the role of the actin cytoskeleton in motility.	WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT BIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	HUG, C (corresponding author), WASHINGTON UNIV,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110, USA.		Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Cooper, John/0000-0002-0933-4571	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026150] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38838, GM 38542] Funding Source: Medline; NINDS NIH HHS [NS 26150] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CASELLA JF, 1994, J BIOL CHEM, V269, P6992; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; COOPER JA, 1984, J CELL BIOL, V99, P217, DOI 10.1083/jcb.99.1.217; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Cooper John A., 1993, P34; CORTESE JD, 1988, J CELL BIOL, V107, P1477, DOI 10.1083/jcb.107.4.1477; COX D, 1994, J CELL BIOL, V128, P819; DOOLITTLE KW, 1995, DEV BIOL, V167, P118, DOI 10.1006/dbio.1995.1011; FURUKAWA R, 1993, BIOCHEMISTRY-US, V32, P12346, DOI 10.1021/bi00097a010; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HARTMAN R, 1993, COMPUT METH PROG BIO, V39, P195, DOI 10.1016/0169-2607(93)90021-C; HARTMANN H, 1989, J BIOL CHEM, V264, P12639; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; JACOBSON K, 1984, P NATL ACAD SCI-BIOL, V81, P6747, DOI 10.1073/pnas.81.21.6747; KLEIN PS, 1988, SCIENCE, V241, P1467, DOI 10.1126/science.3047871; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LIU TY, 1992, MOL BIOL CELL, V3, P1403, DOI 10.1091/mbc.3.12.1403; MADDEN TL, 1994, J CELL BIOL, V126, P169, DOI 10.1083/jcb.126.1.169; NELLEN W, 1988, BIOCHEM BIOPH RES CO, V154, P54, DOI 10.1016/0006-291X(88)90648-1; PODOLSKI JL, 1988, J BIOL CHEM, V263, P638; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; Sambrook J, 1989, MOL CLONING LABORATO; SCHAFER DA, 1994, J CELL BIOL, V127, P453, DOI 10.1083/jcb.127.2.453; SIEGERT F, 1994, J CELL SCI, V107, P97; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; VOGEL G, 1980, J CELL BIOL, V86, P456; WATTS RG, 1994, CELL MOTIL CYTOSKEL, V28, P155, DOI 10.1002/cm.970280207; WEBER A, 1994, BIOCHEMISTRY-US, V33, P4780, DOI 10.1021/bi00182a005; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; ZANER KS, 1988, J BIOL CHEM, V263, P4532	40	144	145	0	4	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 19	1995	81	4					591	600		10.1016/0092-8674(95)90080-2	http://dx.doi.org/10.1016/0092-8674(95)90080-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758113	Bronze			2022-12-28	WOS:A1995QZ71000016
J	SAKAS, DE; DIAS, LS; BEALE, D				SAKAS, DE; DIAS, LS; BEALE, D			LESSON OF THE WEEK - SUBARACHNOID HEMORRHAGE PRESENTING AS HEAD-INJURY	BRITISH MEDICAL JOURNAL			English	Article									WALSGRAVE GEN HOSP,COVENTRY CV2 2DX,W MIDLANDS,ENGLAND; N STAFFORDSHIRE ROYAL INFIRM,STOKE ON TRENT ST4 7NL,STAFFS,ENGLAND	Keele University; University Hospital of North Staffordshire NHS Trust								KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; MCCORMICK WF, 1973, STROKE, V4, P946, DOI 10.1161/01.STR.4.6.946; PAKARINEN S, 1967, ACTA NEUROL SCAND  S, V29, P1; SMITH R, 1982, NEUROLOGICAL SURG, P1627; STEHBENS WE, 1963, ARCH PATHOL, V75, P45	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1186	1187		10.1136/bmj.310.6988.1186	http://dx.doi.org/10.1136/bmj.310.6988.1186			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767157	Green Published			2022-12-28	WOS:A1995QX56600031
J	PETO, J; HODGSON, JT; MATTHEWS, FE; JONES, JR				PETO, J; HODGSON, JT; MATTHEWS, FE; JONES, JR			CONTINUING INCREASE IN MESOTHELIOMA MORTALITY IN BRITAIN	LANCET			English	Article							ASBESTOS WORKERS	Mesothelioma is closely related to exposure to asbestos, and mesothelioma mortality can be taken as an index of past exposure to asbestos in the population. We analysed mesothelioma mortality since 1968 to assess the current state of the mesothelioma epidemic, and to predict its future course. We found that rates of mesothelioma in men formed a clear pattern defined by age and date of birth. Rates rose steeply with age showing a very similar pattern in all five-year birth cohorts. By date of birth, rates increased from mid-1893 to mid-1948, and then fell. Relative to the 1943-48 cohort, the risk for the 1948-53 cohort is 0.79 and for the 1953-58 cohort 0.48. Despite these falls, if the age profile of rates for these cohorts follows the pattern of past cohorts, their predicted lifetime mesothelioma risks will be 1.3%, 1.0%, and 0.6%. Combining projections for all cohorts results in a peak of annual male mesothelioma deaths in about the year 2020 of between 2700 and 3300 deaths. If diagnostic trend is responsible for a 20% growth in recorded cases every 5 years-an extreme but arguable case-and if this trend has now ceased, the peak of annual male deaths will be reduced to 1300, reached around the year 2010. Analysis of occupations recorded on death certificates indicate that building workers, especially plumbers and gas fitters, carpenters and electricians are the largest high-risk group. These data indicate that mesothelioma deaths will continue to increase for at least 15 and more likely 25 years. For the worst affected cohorts-men born in the 1940s-mesothelioma may account for around 1% of all deaths. Asbestos exposure at work in construction and building maintenance will account for a large proportion of these deaths, and it is important that such workers should be aware of the risks and take appropriate precautions.	HLTH & SAFETY EXECUT,EPIDEMIOL & MED STAT UNIT,BOOTLE,MERSEYSIDE,ENGLAND		PETO, J (corresponding author), INST CANC RES,EPIDEMIOL SECT,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Hodgson, John/HGD-6550-2022; Matthews, Fiona/O-6932-2015	Matthews, Fiona/0000-0002-1728-2388				BERRY G, 1991, BRIT J IND MED, V48, P793; Burdett GJ, 1989, IARC SCI PUBL, V90, P277; CARBONE M, 1994, ONCOGENE, V9, P781; DINI S, 1992, AM J IND MED, V21, P569, DOI 10.1002/ajim.4700210412; HODGSON JT, 1986, BRIT J IND MED, V43, P158; JONES RD, 1988, SCAND J WORK ENV HEA, V14, P145, DOI 10.5271/sjweh.1938; NEWHOUSE ML, 1985, BRIT J IND MED, V42, P4; PETO J, 1982, BRIT J CANCER, V45, P124, DOI 10.1038/bjc.1982.15; PETO J, 1981, BANBURY REPORT, V9; Selikoff I J, 1979, Ann N Y Acad Sci, V330, P91, DOI 10.1111/j.1749-6632.1979.tb18711.x; Wagner JC, 1960, BR J IND MED, V17, P266; [No title captured]; 1995, IN PRESS OCCUPATIO S; 1968, ANN OCCUP HYG, V11, P47	14	457	463	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					535	539		10.1016/S0140-6736(95)90462-X	http://dx.doi.org/10.1016/S0140-6736(95)90462-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776771				2022-12-28	WOS:A1995QK44400007
J	PHILLIPS, DM				PHILLIPS, DM			MYCOPLASMA-PNEUMONIAE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,1230 YORK AVE,NEW YORK,NY 10021, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1421	1421						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7772108				2022-12-28	WOS:A1994PU53300005
J	TUGWELL, P; PINCUS, T; YOCUM, D; STEIN, M; GLUCK, O; KRAAG, G; MCKENDRY, R; TESSER, J; BAKER, P; WELLS, G				TUGWELL, P; PINCUS, T; YOCUM, D; STEIN, M; GLUCK, O; KRAAG, G; MCKENDRY, R; TESSER, J; BAKER, P; WELLS, G			COMBINATION THERAPY WITH CYCLOSPORINE AND METHOTREXATE IN SEVERE RHEUMATOID-ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED CLINICAL-TRIAL; DISEASE; CLASSIFICATION; DISABILITY; EFFICACY; DRUGS	Background. Patients with severe rheumatoid arthritis who are treated with methotrexate frequently have only partial improvement. Methods. In a six-month randomized, double-blind trial, we compared combination therapy with cyclosporine (2.5 to 5 mg per kilogram of body weight per day) and methotrexate (at the maximal tolerated dose) with methotrexate and placebo in 148 patients with rheumatoid arthritis who had residual inflammation and disability despite partial but substantial responses to prior methotrexate treatment. The primary outcome measure was the change in the number of tender joints. Results. As compared with the placebo group, the patients in the treatment group had a net improvement in the tender-joint count of 25 percent, or 4.8 joints (95 percent confidence interval, 0.7 to 8.9; P=0.02), and in the swollen-joint count of 25 percent, or 3.8 joints (95 percent confidence interval, 1.3 to 6.3; P=0.005); improvement in overall disease activity as assessed by the physician (19 percent, P<0.001) and the patient (21 per cent, P<0.001); and improvement in joint pain (23 percent, P=0.04) and in the degree of disability (26 percent, P<0.001). Thirty-six patients (48 percent) in the cyclosporine group and 12 patients (16 percent) in the placebo group (P<0.001) met the 1993 criteria for improvement of the American College of Rheumatology (more than 20 percent improvement in the numbers of both swollen and tender joints and improvement in three of five other variables). Serum creatinine concentrations increased by a mean of 0.14+/-0.27 mg per deciliter (12+/-24 mmol per liter) in the cyclosporine group and by 0.05+/-0.19 mg per deciliter (4+/-17 mmol per liter) in the placebo group (P=0.02). Conclusions. Patients with severe rheumatoid arthritis and only partial responses to methotrexate had clinically important improvement after combination therapy with cyclosporine and methotrexate. Side effects were not substantially increased. Long-term follow-up of patients treated with this combination is needed.	UNIV OTTAWA,CLIN EPIDEMIOL UNIT,OTTAWA,ON K1H 8L6,CANADA; VANDERBILT UNIV,DIV RHEUMATOL & IMMUNOL,NASHVILLE,TN; UNIV ARIZONA,DIV RHEUMATOL & IMMUNOL,TUCSON,AZ; ARIZONA RHEUMATOL CTR,PHOENIX,AZ	University of Ottawa; Vanderbilt University; University of Arizona	TUGWELL, P (corresponding author), UNIV OTTAWA,DEPT MED,501 SMYTH RD,RM LM 12,OTTAWA,ON K1H 8L6,CANADA.		Baker, Philip R A/J-1109-2012; Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556				ARELLANO F, 1993, BRIT J RHEUMATOL, V32, P72; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BENSEN W, 1994, J RHEUMATOL, V21, P2034; BENSEN WG, 1990, J RHEUMATOL, V17, P987; BRAHN E, 1991, ARTHRITIS RHEUM, V34, P1282, DOI 10.1002/art.1780341012; CASH JM, 1994, NEW ENGL J MED, V330, P1368; EDMONDS JP, 1993, ARTHRITIS RHEUM, V36, P336, DOI 10.1002/art.1780360308; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FELSON DT, 1994, ARTHRITIS RHEUM, V37, P1487, DOI 10.1002/art.1780371012; FELSON DT, IN PRESS ARTHRITIS R; FRIES JF, 1982, J RHEUMATOL, V9, P789; GORDON DA, 1994, RHEUMATOLOGY; HARRIS ED, 1993, TXB RHEUMATOLOGY, V1, P874; KREMER JM, 1993, ARTHRITIS RHEUM, V36, pS77; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; MORSE ML, 1986, MONITORING DRUG SAFE, P237; OMERACT, 1993, J RHEUMATOL, V20, P527; PALACIOS R, 1985, EUR J IMMUNOL, V15, P204, DOI 10.1002/eji.1830150220; PAULUS HE, 1990, ARTHRITIS RHEUM, V33, P113, DOI 10.1002/art.1780330116; PINCUS T, 1990, J RHEUMATOL, V17, P1582; PINCUS T, 1993, BRIT J RHEUMATOL, V32, P28; PINCUS T, 1994, ANN INTERN MED, V120, P26, DOI 10.7326/0003-4819-120-1-199401010-00005; PINCUS T, 1992, J RHEUMATOL, V19, P1885; PINCUS T, 1993, RHEUM DIS CLIN N AM, V19, P123; REEM GH, 1983, SCIENCE, V221, P63, DOI 10.1126/science.6407112; SHIROKY JB, 1991, J RHEUMATOL, V18, P1172; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; TUGWELL P, 1987, ANN INTERN MED, V107, P358, DOI 10.7326/0003-4819-107-2-358; TUGWELL P, 1994, RHEUMATOID ARTHRITIS, P357; WELLS G, 1993, BRIT J RHEUMATOL, V32, P51; WILLIAMS HJ, 1992, ARTHRITIS RHEUM, V35, P259, DOI 10.1002/art.1780350304; WILLIAMS JH, 1993, PRIMER RHEUMATIC DIS, P96; WILLKENS RF, 1992, ARTHRITIS RHEUM-US, V35, P849, DOI 10.1002/art.1780350802; WILSKE KR, 1989, J RHEUMATOL, V16, P565; WOLFE F, 1990, J RHEUMATOL, V17, P994; Zar JH., 1999, BIOSTAT ANAL; 1993, BR J RHEUMATOL S1, V32, P65	38	503	518	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					137	141		10.1056/NEJM199507203330301	http://dx.doi.org/10.1056/NEJM199507203330301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791814	Bronze			2022-12-28	WOS:A1995RK91700001
J	MACALLAN, DC; NOBLE, C; BALDWIN, C; JEBB, SA; PRENTICE, AM; COWARD, WA; SAWYER, MB; MCMANUS, TJ; GRIFFIN, GE				MACALLAN, DC; NOBLE, C; BALDWIN, C; JEBB, SA; PRENTICE, AM; COWARD, WA; SAWYER, MB; MCMANUS, TJ; GRIFFIN, GE			ENERGY-EXPENDITURE AND WASTING IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-COMPOSITION; WEIGHT CHANGE; MEN	Background. Increased expenditure of energy at rest has been considered a contributing factor to the negative energy balance and weight loss that occur in patients with human immunodeficiency virus (HIV) infection. However, the true determinant of energy balance is not resting but total energy expenditure. We sought to determine the contribution of total energy expenditure to weight changes in patients with HIV-associated wasting. Methods. We performed 51 assessments of energy metabolism in 27 men with HIV infection at different stages of disease, including periods of both rapid and slow weight loss. Resting energy expenditure was measured by indirect calorimetry, total energy expenditure by the doubly-labeled-water technique, and energy intake by recording the weight of food consumed. The results were compared with the rate of weight loss or gain. Results. The mean (+/-SD) total energy expended by the HIV-infected men was 2750+/-670 kcal per day, no more than that expended by normal men. There was a significant positive relation between total energy expenditure and the rate of weight change (r=0.61, P<0.001); thus, during rapid weight loss, total energy expenditure was reduced to 2180+/-580 kcal per day (P = 0.009), primarily because of reduced physical activity. During rapid weight loss, the negative energy balance (-8501+/-580 kcal per day) was primarily the result of the reduction in energy intake, to 1330+/-610 kcal per day; intake correlated strongly with the rate of weight change (r=0.84, P<0.001). Conclusions. In patients with HIV infection, total energy expenditure is reduced during episodes of weight loss. Reduced energy intake, not elevated energy expenditure, is the prime determinant of weight loss in HIV-associated wasting.	KINGS HEALTHCARE,DEPT GENITOURINARY MED,LONDON,ENGLAND; DUNN CLIN NUTR CTR,CAMBRIDGE,ENGLAND		MACALLAN, DC (corresponding author), ST GEORGE HOSP,SCH MED,DIV INFECT DIS,LONDON SW17 0RE,ENGLAND.		Prentice, Andrew/AAG-1961-2019	Macallan, Derek/0000-0002-3014-7148; Jebb, Susan/0000-0001-9190-2920				BLACK AE, IN PRESS EUR J CLIN; COLE TJ, 1992, AM J PHYSIOL, V263, pE965, DOI 10.1152/ajpendo.1992.263.5.E965; Coward W, 1991, NEW TECHNIQUES NUTR, P139; DURNIN JVGA, 1974, BRIT J NUTR, V32, P77, DOI 10.1079/BJN19740060; FOSKETT M, 1991, J HUM NUTR DIET, V4, P149, DOI 10.1111/j.1365-277X.1991.tb00092.x; GORAN MI, 1993, METABOLISM, V42, P487, DOI 10.1016/0026-0495(93)90108-Z; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; GRUNFELD C, 1992, AM J CLIN NUTR, V55, P455, DOI 10.1093/ajcn/55.2.455; HOMMES MJT, 1991, METABOLISM, V40, P651, DOI 10.1016/0026-0495(91)90059-6; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; MACALLAN DC, 1995, AM J CLIN NUTR, V61, P818, DOI 10.1093/ajcn/61.4.818; MACALLAN DC, 1993, AM J CLIN NUTR, V58, P417, DOI 10.1093/ajcn/58.3.417; Paul A.A., 1978, MCCANCE WIDDOWSONS C; Prentice A.M., 1991, NEW TECHNIQUES NUTR, P177; RAVUSSIN E, 1989, AM J CLIN NUTR, V49, P968, DOI 10.1093/ajcn/49.5.968; Schofield W N, 1985, Hum Nutr Clin Nutr, V39 Suppl 1, P5; STEIN TP, 1990, METABOLISM, V39, P876, DOI 10.1016/0026-0495(90)90136-Z; SUTTMANN U, 1994, CLIN SCI, V86, P461; 1987, MMWR CDC SURVEILL S3, V36, pS3; 1990, DOUBLY LABELLED WATE	22	295	298	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 13	1995	333	2					83	88		10.1056/NEJM199507133330202	http://dx.doi.org/10.1056/NEJM199507133330202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH225	7777033	Bronze			2022-12-28	WOS:A1995RH22500002
J	LOTKE, M				LOTKE, M			SHE WONT LOOK AT ME	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Early-onset hearing impairment is a common disability in the United States. Persons with hearing loss, whether they use American Sign Language or lip-read, must look at those with whom they are speaking. Lip reading is not a reliable method of communication for most deaf persons. Reading and writing also limit the amount of communication between health care providers and deaf patients. The best way to communicate with most deaf persons is through a qualified American Sign Language interpreter. This paper discusses communication with deaf persons and ways in which health care providers and hospitals can improve their interactions with deaf patients.	STANFORD UNIV, ROBERT WOOD JOHNSON CLIN SCHOLAR PROGRAM, STANFORD, CA USA	Robert Wood Johnson Foundation (RWJF); Stanford University								MCEWEN E, 1988, J FAM PRACTICE, V26, P289; Schein J.D., 1974, DEAF POPULATION US	2	17	17	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					54	57		10.7326/0003-4819-123-1-199507010-00008	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762915				2022-12-28	WOS:A1995RE66500009
J	BOOTSMA, H; SPRONK, P; DERKSEN, R; DEBOER, G; WOLTERSDICKE, H; HERMANS, J; LIMBURG, P; GMELIGMEYLING, F; KATER, L; KALLENBERG, C				BOOTSMA, H; SPRONK, P; DERKSEN, R; DEBOER, G; WOLTERSDICKE, H; HERMANS, J; LIMBURG, P; GMELIGMEYLING, F; KATER, L; KALLENBERG, C			PREVENTION OF RELAPSES IN SYSTEMIC LUPUS-ERYTHEMATOSUS	LANCET			English	Article							DOUBLE-STRANDED DNA; LONG-TERM; DISEASE-ACTIVITY; ANTI-DSDNA; COMPLEMENT PROFILES; SERUM COMPLEMENT; PREDICTIVE VALUE; CONTROLLED TRIAL; NEPHRITIS; CYCLOPHOSPHAMIDE	Many relapses of systemic lupus erythematosus (SLE) are preceded by a rise in antibodies against double-stranded DNA (anti-dsDNA). We investigated whether these relapses can be prevented by giving prednisone when a rise in anti-dsDNA occurs. 156 patients with SLE were studied. Anti-dsDNA was measured by Farr assay monthly. When a rise in anti-dsDNA was found, patients were randomly assigned either conventional treatment or 30 mg prednisone added to the current daily dose and tapering off to baseline over 18 weeks. A rise in anti-dsDNA was detected in 46 patients (24 assigned conventional treatment and 22 prednisolone). The relapse rate was higher in the conventional group than in the prednisolone group (20 vs 2, p<0 . 001). Although rises in anti-dsDNA in the prednisone group were treated with additional prednisone, the cumulative oral doses of prednisone in the two groups did not differ significantly (p=0 . 025). 7 major relapses requiring additional cytotoxic immunosuppressive treatment occurred in the conventional group Versus 2 in the prednisone group. Treatment with prednisone as soon as a significant rise in anti-dsDNA occurs prevents relapse in most cases, without increasing the cumulative dose of prednisdone given.	UNIV UTRECHT HOSP, UTRECHT, NETHERLANDS; LEIDEN UNIV, DEPT MED STAT, LEIDEN, NETHERLANDS	Utrecht University; Utrecht University Medical Center; Leiden University; Leiden University - Excl LUMC	BOOTSMA, H (corresponding author), UNIV GRONINGEN HOSP, DEPT INTERNAL MED, DIV CLIN IMMUNOL, POB 30001, 9700 RB GRONINGEN, NETHERLANDS.							APPEL AE, 1978, AM J MED, V64, P274, DOI 10.1016/0002-9343(78)90056-6; APPEL GB, 1987, AM J MED, V83, P877, DOI 10.1016/0002-9343(87)90645-0; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; BOUMPAS DT, 1992, LANCET, V340, P741, DOI 10.1016/0140-6736(92)92292-N; DAVIS P, 1977, ANN RHEUM DIS, V36, P157, DOI 10.1136/ard.36.2.157; DONADIO JV, 1993, AM J KIDNEY DIS, V21, P239, DOI 10.1016/S0272-6386(12)80741-4; DYKMAN TR, 1985, ARTHRITIS RHEUM, V28, P361, DOI 10.1002/art.1780280402; ESDAILE JM, 1994, ARTHRITIS RHEUM, V37, P359, DOI 10.1002/art.1780370309; FELTKAMP TEW, 1988, ANN RHEUM DIS, V47, P740, DOI 10.1136/ard.47.9.740; GOULET JR, 1993, J RHEUMATOL, V20, P59; GRIPENBERG M, 1991, SCAND J RHEUMATOL, V20, P104, DOI 10.3109/03009749109165284; JARRETT MP, 1981, AM J MED, V70, P1067, DOI 10.1016/0002-9343(81)90870-6; LAITMAN RS, 1989, AM J MED, V87, P132; LANGE K, 1965, ARTHRITIS RHEUM-US, V8, P244, DOI 10.1002/art.1780080208; LIGHTFOOT RW, 1975, SCAND J RHEUMATOL, P52; LLOYD W, 1981, MEDICINE, V60, P208, DOI 10.1097/00005792-198105000-00004; MCCUNE WJ, 1988, NEW ENGL J MED, V318, P1423, DOI 10.1056/NEJM198806023182203; MINITER MF, 1979, ARTHRITIS RHEUM, V22, P959, DOI 10.1002/art.1780220903; SCHUR PH, 1968, NEW ENGL J MED, V278, P533, DOI 10.1056/NEJM196803072781004; STEINBERG AD, 1991, ARTHRITIS RHEUM-US, V34, P945, DOI 10.1002/art.1780340803; SWAAK AJG, 1979, ARTHRITIS RHEUM, V22, P226, DOI 10.1002/art.1780220304; SWAAK AJG, 1986, ANN RHEUM DIS, V45, P359, DOI 10.1136/ard.45.5.359; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; TERBORG EJ, 1990, CLIN EXP IMMUNOL, V82, P21; TERBORG EJ, 1990, ARTHRITIS RHEUM-US, V33, P634, DOI 10.1002/art.1780330505; WARD MM, 1993, ARTHRITIS RHEUM, V36, pS68	27	199	208	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	1995	345	8965					1595	1599		10.1016/S0140-6736(95)90114-0	http://dx.doi.org/10.1016/S0140-6736(95)90114-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783536				2022-12-28	WOS:A1995RE67000007
J	PIMENTA, W; KORYTKOWSKI, M; MITRAKOU, A; JENSSEN, T; YKIJARVINEN, H; EVRON, W; DAILEY, G; GERICH, J				PIMENTA, W; KORYTKOWSKI, M; MITRAKOU, A; JENSSEN, T; YKIJARVINEN, H; EVRON, W; DAILEY, G; GERICH, J			PANCREATIC BETA-CELL DYSFUNCTION AS THE PRIMARY GENETIC LESION IN NIDDM - EVIDENCE FROM STUDIES IN NORMAL GLUCOSE-TOLERANT INDIVIDUALS WITH A FIRST-DEGREE NIDDM RELATIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; INDUCED INSULIN RELEASE; BODY-FAT DISTRIBUTION; PIMA-INDIANS; GLYCOGEN-SYNTHASE; INCREASED RISK; ISLET FUNCTION; RESISTANCE; SENSITIVITY; SECRETION	Objective.- To test the hypothesis that insulin resistance precedes impaired insulin secretion in individuals genetically predisposed to non-insulin-dependent diabetes mellitus (NIDDM). Design.- Case-control study. Setting.- Outpatient facility of clinical research center. Participants.- One hundred volunteers of European ancestry having normal glucose tolerance, 50 with and 50 without a first-degree NIDDM relative, matched for age, sex, and degree of obesity. Main Outcome Measures.- Insulin secretion and insulin sensitivity assessed by hyperglycemic (N=100) and euglycemic-hyperinsulinemic (N=62) clamp experiments. Results.- The individuals with a first-degree NIDDM relative had reduced first-and second-phase insulin responses (mean+/-SEM, 939+/-68 vs 1209+/-82 pmol/L, and 322+/-19 vs 407+/-24 pmol/L, respectively, P=.001 and .01), but their insulin sensitivity (148+/-6 and 92+/-6 nmol . kg(-1). min(-1)/pmol . L(-1) in hyperglycemic and euglycemic clamp studies) did not differ from that of the control group (126+/-5 and 81+/-7 nmol . kg(-1). min(-1)/pmol . L(-1), in hyperglycemic and euglycemic clamp studies, P=.07 and .24, respectively). In some individuals only first- or only second-phase insulin responses were reduced. Conclusion.- In this study population, heterogeneous defects in insulin secretion were demonstrated, while defects in insulin sensitivity were not evident. We therefore conclude that since the earliest defects identified in a group genetically at high risk to develop NIDDM are those related to insulin secretion, defects in insulin secretion rather than insulin sensitivity are likely the major genetic factor predisposing to development of NIDDM.	UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA; UNIV ATHENS,DEPT INTERNAL MED PROPAEDEUT 2,ATHENS,GREECE; UNIV TROMSO HOSP,DEPT MED,TROMSO,NORWAY; HELSINKI UNIV,DEPT MED 2,HELSINKI,FINLAND; SCRIPPS CLIN & RES FDN,LA JOLLA,CA 92037	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National & Kapodistrian University of Athens; UiT The Arctic University of Tromso; University Hospital of North Norway; University of Helsinki; Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044, M01RR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020411, R37DK020411] Funding Source: NIH RePORTER; NCRR NIH HHS [M501 RR00044, M501 RR00056] Funding Source: Medline; NIDDK NIH HHS [DK20411] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNER P, 1991, DIABETOLOGIA, V34, P483, DOI 10.1007/BF00403284; ARONOFF SL, 1977, DIABETES, V26, P827, DOI 10.2337/diabetes.26.9.827; BAK JF, 1992, DIABETOLOGIA, V35, P777; BANERJI MA, 1989, DIABETES, V38, P784, DOI 10.2337/diabetes.38.6.784; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BARNETT AH, 1981, BRIT MED J, V282, P1656, DOI 10.1136/bmj.282.6277.1656; BEARD JC, 1987, J CLIN ENDOCR METAB, V65, P59, DOI 10.1210/jcem-65-1-59; Berntorp K, 1985, Diabetes Res, V2, P151; BOBERG J, 1976, SCAND J CLIN LAB INV, V36, P145, DOI 10.3109/00365517609055241; BODEN G, 1968, J CLIN INVEST, V47, P729, DOI 10.1172/JCI105768; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BONORA E, 1984, DIABETES METAB, V10, P250; CAMPBELL PJ, 1988, METABOLISM, V37, P15, DOI 10.1016/0026-0495(88)90023-6; CARLES M, 1991, DIABETES, V40, P796; CERASI E, 1967, ACTA ENDOCRINOL-COP, V55, P330, DOI 10.1530/acta.0.0550330; CERASI E, 1972, DIABETES, V21, P224, DOI 10.2337/diab.21.4.224; COLWELL JA, 1967, DIABETES, V16, P560, DOI 10.2337/diab.16.8.560; DAWKE H, 1968, DIABETOLOGIA, V4, P349; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; EFENDIC S, 1971, METABOLISM, V20, P568, DOI 10.1016/0026-0495(71)90005-9; ELBEIN SC, 1991, DIABETES, V40, P1024, DOI 10.2337/diabetes.40.8.1024; ENSINCK JW, 1976, CLIN RES, V24, pA155; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; FUJITA Y, 1975, DIABETES, V24, P17, DOI 10.2337/diabetes.24.1.17; GERICH JE, 1988, BAILLIERE CLIN ENDOC, V2, P307, DOI 10.1016/S0950-351X(88)80034-X; GINSBERG H, 1981, DIABETES, V30, P739, DOI 10.2337/diab.30.9.739; GOTTLIEB MS, 1974, DIABETES, V23, P684, DOI 10.2337/diab.23.8.684; GRODSKY GM, 1965, LANCET, V1, P290; GULLI G, 1992, DIABETES, V41, P1575, DOI 10.2337/diabetes.41.12.1575; HAFFNER SM, 1986, NEW ENGL J MED, V315, P220, DOI 10.1056/NEJM198607243150403; HAMMAN RF, 1992, DIABETES METAB REV, V8, P287, DOI 10.1002/dmr.5610080402; HANDBERG A, 1993, DIABETOLOGIA, V36, P668, DOI 10.1007/BF00404079; HARRIS H, 1950, ANN EUGENIC, V15, P95; HENIKSEN J, 1994, J CLIN INVEST, V94, P1196; HO LT, 1989, DIABETIC MED, V7, P31; HOSKER JP, 1989, METABOLISM, V38, P767, DOI 10.1016/0026-0495(89)90064-4; ISELIUS L, 1985, CLIN GENET, V28, P8; JACKSON WPU, 1972, LANCET, V1, P1040; JOHNSTON C, 1990, DIABETIC MED, V7, P119, DOI 10.1111/j.1464-5491.1990.tb01345.x; KALANT N, 1979, DIABETOLOGIA, V16, P365, DOI 10.1007/BF01223156; KELLER U, 1979, SCHWEIZ MED WSCHR, V109, P595; KOBBERLING J, 1990, WORLD REV NUTR DIET, P102; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; LAWS A, 1989, J CLIN ENDOCR METAB, V69, P343, DOI 10.1210/jcem-69-2-343; LEMIEUX S, 1992, DIABETOLOGIA, V35, P653, DOI 10.1007/BF00400258; LERNER RL, 1972, J CLIN INVEST, V51, P1624, DOI 10.1172/JCI106963; LESLIE RDG, 1988, DIABETES NUTR METAB, V3, P235; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; LUNDGREN H, 1990, DIABETIC MED, V7, P407, DOI 10.1111/j.1464-5491.1990.tb01415.x; MANDARINO L, 1984, DIABETOLOGIA, V27, P358, DOI 10.1007/BF00304850; MARTIN BC, 1992, DIABETES, V41, P850, DOI 10.2337/diabetes.41.7.850; MITRAKOU A, 1992, J CLIN ENDOCR METAB, V75, P379, DOI 10.1210/jc.75.2.379; NESHER R, 1987, EUR J CLIN INVEST, V17, P266, DOI 10.1111/j.1365-2362.1987.tb01247.x; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; ORAHILLY SP, 1986, LANCET, V2, P360; OSEI K, 1991, DIABETES CARE, V14, P890, DOI 10.2337/diacare.14.10.890; PAULSEN EP, 1968, DIABETES, V17, P261, DOI 10.2337/diab.17.5.261; PORTE D, 1991, DIABETES, V40, P166, DOI 10.2337/diabetes.40.2.166; POZEFSKY T, 1973, J CLIN INVEST, V52, P1608, DOI 10.1172/JCI107338; PYKE DA, 1967, BRIT MED J, V4, P21, DOI 10.1136/bmj.4.5570.21; RAMACHANDRAN A, 1990, DIABETIC MED, V7, P331, DOI 10.1111/j.1464-5491.1990.tb01400.x; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RICKETTS HT, 1966, DIABETES, V15, P880, DOI 10.2337/diab.15.12.880; ROJAS L, 1969, J CLIN ENDOCR METAB, V29, P1569, DOI 10.1210/jcem-29-12-1569; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; RULL AJ, 1970, DIABETES, V19, P1; SAAD MF, 1991, AM J MED, V90, P229; SAAD MF, 1994, DIABETES, V43, P1114, DOI 10.2337/diabetes.43.9.1114; SCHALINJANTTI C, 1992, DIABETES, V41, P598, DOI 10.2337/diabetes.41.5.598; SELTZER HS, 1967, J CLIN INVEST, V46, P323, DOI 10.1172/JCI105534; SERRANORIOS M, 1970, DIABETOLOGIA, V6, P392, DOI 10.1007/BF01212071; SICREE RA, 1987, DIABETES, V36, P179, DOI 10.2337/diabetes.36.2.179; SIMPSON RG, 1968, DIABETES, V17, P684, DOI 10.2337/diab.17.11.684; SIPERSTEIN MD, 1968, J CLIN INVEST, V47, P1973, DOI 10.1172/JCI105886; SKARFORS ET, 1991, BRIT MED J, V303, P755, DOI 10.1136/bmj.303.6805.755; SOELDNER S, 1968, DIABETES, V17, P17; SONKSEN PH, 1973, DIABETOLOGIA, V9, P426, DOI 10.1007/BF01239440; STAFFEL M, 1992, NATURE, V2, P153; TAYLOR S, 1994, DIABETES, V43, P785; TURNER RC, 1988, BAILLIERE CLIN ENDOC, V2, P327, DOI 10.1016/S0950-351X(88)80035-1; VAAG A, 1992, J CLIN INVEST, V89, P782, DOI 10.1172/JCI115656; VAAG A, 1995, J CLIN INVEST, V95, P690, DOI 10.1172/JCI117715; VIGNERI R, 1976, DIABETES, V25, P167, DOI 10.2337/diabetes.25.3.167; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WELBORN TA, 1966, LANCET, V1, P280; YKIJARVINEN H, 1990, ANN MED, V22, P197, DOI 10.3109/07853899009147269; YKIJARVINEN H, 1994, LANCET, V343, P91, DOI 10.1016/S0140-6736(94)90821-4; YKIJARVINEN H, 1992, ENDOCR REV, V13, P415; Zar JH., 1999, BIOSTAT ANAL; 1985, WHO TECH REP SER, V727, P9	93	314	327	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1855	1861		10.1001/jama.273.23.1855	http://dx.doi.org/10.1001/jama.273.23.1855			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776502				2022-12-28	WOS:A1995RD11600028
J	HUNTER, DJ				HUNTER, DJ			THE CASE FOR CLOSER COOPERATION BETWEEN LOCAL-AUTHORITIES AND THE NHS	BRITISH MEDICAL JOURNAL			English	Article											HUNTER, DJ (corresponding author), UNIV LEEDS,NUFFIELD INST HLTH,LEEDS LS2 9PL,W YORKSHIRE,ENGLAND.							BEVAN A, 1978, PLACE FEAR, P114; BLACKMAN T, 1995, POLICY POLIT, V23, P31, DOI 10.1332/030557395782227320; Challis L., 1988, JOINT APPROACHES SOC; CLARKE M, 1994, LOCAL GOVT NATIONAL; HARDY B, 1992, INNOVATIONS COMMUNIT; HARRISON S, 1991, 4 PUBL POL RES SOC P; Harrison Stephan, 1994, RATIONING HLTH CARE; Hunter D. J., 1987, COMMUNITY CARE BRITA; KENNEDY I, 1993, 85 NOT OUT ESSAYS HO; MAWHINNEY B, 1993, PURCHASING HLTH FRAM; MORONE JA, 1993, J HLTH POLITICS POLI, V18, P724; STEWART J, 1992, ACCOUNTABILITY PUBLI; WISTOW G, 1988, JOINT PLANNING JOINT, P13; 1993, LOCAL GOVT REV NHS; 1995, DOH HSG958 DEP HLTH; 1993, PUBLIC HLTH RESPONSI; 1993, HLTH SERVICE J  0617, P12; 1993, SECURING EFFECTIVE P; 1994, DEV NHS PURCHASING G; 1994, LOCAL AUTHORITIES HL; 1992, CMD1986	21	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1587	1589		10.1136/bmj.310.6994.1587	http://dx.doi.org/10.1136/bmj.310.6994.1587			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787653	Green Published			2022-12-28	WOS:A1995RE35300028
J	KHAW, KT; WOODHOUSE, P				KHAW, KT; WOODHOUSE, P			INTERRELATION OF VITAMIN-C, INFECTION, HEMOSTATIC FACTORS, AND CARDIOVASCULAR-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; SEASONAL-VARIATION; E CONSUMPTION; RISK FACTOR; MORTALITY; STROKE; POPULATION; PREVENTION; FIBRINOGEN	Objective-To examine the hypothesis that the increase in fibrinogen concentration and respiratory infections in winter is related to seasonal variations in vitamin C status (assessed with serum ascorbate concentration). Design-Longitudinal study of individuals seen at intervals of two months over one year. Setting-Cambridge. Subjects-96 men and women aged 65-74 years living in their own homes. Main outcome measures-Haemostatic factors fibrinogen and factor VIIC; acute phase proteins; respiratory symptoms; respiratory function. Results-Mean dietary intake of vitamin C varied from about 65 mg/24 h in winter to 90 mg/24 h in summer; mean serum ascorbate concentration ranged from 50 mu mol/l in winter to 60 mu mol/l in summer. Serum ascorbate concentration was strongly inversely related to haemostatic factors fibrinogen and factor VIIC as well as to acute phase proteins but not to self reported respiratory symptoms or neutrophil count. Serum ascorbate concentration was also related positively to forced expiratory volume in one second. An increase in dietary vitamin C of 60 mg daily (about one orange) was associated with a decrease in fibrinogen concentrations of 0.15 g/l, equivalent (according to prospective studies) to a decline of approximately 10% in risk of ischaemic heart disease. Conclusion-High intake of vitamin C has been suggested as being protective both for respiratory infection and for cardiovascular disease. These findings support the hypothesis that vitamin C may protect against cardiovascular disease through an effect on haemostatic factors at least partly through the response to infection; this may have implications both for our understanding of the pathogenetic mechanisms in respiratory and cardiovascular disease and for the prevention of such conditions.			KHAW, KT (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN MED,CLIN GERONTOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.		Khaw, Kay-Tee/AAZ-3209-2021					AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALEXANDER RW, 1994, NEW ENGL J MED, V331, P468, DOI 10.1056/NEJM199408183310709; BLOCK G, 1991, AM J CLIN NUTR, V53, pS270, DOI 10.1093/ajcn/53.1.270S; CALVIN J, 1986, ANN CLIN BIOCHEM, V23, P206, DOI 10.1177/000456328602300212; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; Curwen M., 1991, HLTH TRENDS, V22, P169; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN M, 1994, AM J EPIDEMIOL, V139, pS47; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; GREGORY J, 1990, DIETARY NUTRITIONAL, P126; HEMILA H, 1992, BRIT J NUTR, V67, P3, DOI 10.1079/BJN19920004; KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILLER GJ, 1985, BRIT J HAEMATOL, V59, P249, DOI 10.1111/j.1365-2141.1985.tb02991.x; Nyyssonen K., 1994, European Heart Journal, V15, P168; Paul A.A., 1978, MCCANCE WIDDOWSONS C; Pauling L., 1970, VITAMIN C COMMON COL; QIZILBASH N, 1991, BRIT MED J, V303, P605, DOI 10.1136/bmj.303.6803.605; RAO CR, 1973, LINEAR STATISTICAL I, P418; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SCHWARTZ J, 1994, AM J CLIN NUTR, V59, P110, DOI 10.1093/ajcn/59.1.110; SIMON JA, 1992, J AM COLL NUTR, V11, P107; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STRACHAN DP, 1992, J EPIDEMIOL COMMUN H, V46, P66, DOI 10.1136/jech.46.1.66; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; VOLLSET SE, 1983, LANCET, V2, P742; VUILLEUMIER JP, 1989, J MICRONUTR ANAL, V5, P25; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILSONT W, 1993, AM J EPIDEMIOL, V137, P292; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	38	90	91	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1559	1563		10.1136/bmj.310.6994.1559	http://dx.doi.org/10.1136/bmj.310.6994.1559			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787643	Green Published			2022-12-28	WOS:A1995RE35300017
J	TEMPLETON, GL; ILLING, LA; YOUNG, L; CAVE, MD; STEAD, WW; BATES, JH				TEMPLETON, GL; ILLING, LA; YOUNG, L; CAVE, MD; STEAD, WW; BATES, JH			RISK FOR TRANSMISSION OF MYCOBACTERIUM-TUBERCULOSIS AT THE BEDSIDE AND DURING AUTOPSY	ANNALS OF INTERNAL MEDICINE			English	Note								Objective: To emphasize the differing infectious potentials of a patient with tuberculosis. Setting: Hospital ward and autopsy room. Design: An epidemiologic investigation of tuberculin skin test conversions in a clinical setting and during autopsy when results of tuberculin tests done before exposure were available for all participants. Measurements: Tuberculin skin test results after the discovery of tuberculosis exposure from a patient with unsuspected tuberculosis for comparison with the test results before exposure; culture of sputum and autopsy material for Mycobacterium tuberculosis; and DNA fingerprinting of organisms. Intervention: Preventive therapy for persons with skin test conversion. Results: None of the 40 skin test-negative health care workers caring for the patient for 3 weeks on an open medical ward showed a skin test conversion, even though they had not used respiratory precautions. By contrast, among personnel present during the 3-hour autopsy, the test results of all five nonreactors converted from negative to positive (mean reaction, 24 mm). Two of these persons had a positive sputum culture 8 weeks later. The DNA fingerprints of all three isolates were identical. Conclusions: A patient who did not transmit tuberculosis before death released a prodigious number of tubercle bacilli during autopsy.	UNIV ARKANSAS, COLL MED, LITTLE ROCK, AR 72204 USA; ARKANSAS STATE DEPT HLTH, LITTLE ROCK, AR 72205 USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock	TEMPLETON, GL (corresponding author), JOHN L MCCLELLAN MEM VET ADM HOSP, 4300 W 7TH ST, LITTLE ROCK, AR 72205 USA.				NIAID NIH HHS [AI 01136] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI001136] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CATANZARO A, 1982, AM REV RESPIR DIS, V125, P559, DOI 10.1164/arrd.1982.125.5.559; FRAMPTON MW, 1992, ANN INTERN MED, V117, P312, DOI 10.7326/0003-4819-117-4-312; HARRINGTON JM, 1976, BRIT MED J, V1, P759, DOI 10.1136/bmj.1.6012.759; HEDVALL ERIK, 1940, AMER REV TUBERC, V41, P770; HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286; JOHNSON GK, 1991, J MED VIROL, V33, P47, DOI 10.1002/jmv.1890330110; KANTOR HS, 1988, AM J MED, V84, P833, DOI 10.1016/0002-9343(88)90060-5; KOHN GJ, 1992, DIAGN MICR INFEC DIS, V15, P527, DOI 10.1016/0732-8893(92)90103-Z; MEADE GM, 1948, AM REV TUBERC PULM, V58, P675; MORRIS SI, 1946, AM REV TUBERC PULM, V54, P140; NARDELL EA, 1993, MED CLIN N AM, V77, P1315, DOI 10.1016/S0025-7125(16)30196-1; OSLER W, 1892, PRINCIPLES PRACTICE, P198; REID DD, 1957, BMJ-BRIT MED J, V2, P10, DOI 10.1136/bmj.2.5035.10; RIEDER HL, 1991, CHEST, V100, P678, DOI 10.1378/chest.100.3.678; RILEY RL, 1959, AM J HYG, V70, P185, DOI 10.1093/oxfordjournals.aje.a120069; RILEY RL, 1961, AIRBORNE INFECTION, P91; SLOAN R. A., 1942, New York State Journal of Medicine, V42, P133	17	90	92	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					922	925		10.7326/0003-4819-122-12-199506150-00005	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755227				2022-12-28	WOS:A1995RC27000005
J	GARGAS, A; DEPRIEST, PT; GRUBE, M; TEHLER, A				GARGAS, A; DEPRIEST, PT; GRUBE, M; TEHLER, A			MULTIPLE ORIGINS OF LICHEN SYMBIOSES IN FUNGI SUGGESTED BY SSU RDNA PHYLOGENY	SCIENCE			English	Article							CLADISTIC OUTLINE	Phylogenetic hypotheses provide a context for examining the evolution of heterotrophic lifestyles. The lichen lifestyle, which is the symbiotic association of fungi with algae, is found in various representatives of Dicaryomycotina, both Ascomycetes and Basidiomycetes. A highly resolved parsimony analysis of small subunit ribosomal DNA (SSU rDNA) sequences suggests at least five independent origins of the lichen habit in disparate groups of Ascomycetes and Basidiomycetes. Because lichen associations arose from parasitic, mycorrhizal, or free-living saprobic fungi, neither mutualism nor parasitism should be construed as endpoints in symbiont evolution.	GRAZ UNIV,INST BOT,A-8010 GRAZ,AUSTRIA; UNIV STOCKHOLM,INST BOT,S-10691 STOCKHOLM,SWEDEN	University of Graz; Stockholm University	GARGAS, A (corresponding author), SMITHSONIAN INST,NATL MUSEUM NAT HIST,DEPT BOT,NHB-166,WASHINGTON,DC 20560, USA.		DePriest, Paula T./K-6633-2015	DePriest, Paula T./0000-0002-6079-7870; Grube, Martin/0000-0001-6940-5282				Ahmadjian V, 1983, ALGAL SYMBIOSIS, P147; Ahmadjian V., 1967, LICHEN SYMBIOSIS; BERBEE ML, 1992, MOL BIOL EVOL, V9, P278; BLACKWELL M, 1994, MYCOLOGIA, V86, P1, DOI 10.2307/3760716; Bruns TD, 1992, MOL PHYLOGENET EVOL, V1, P231, DOI 10.1016/1055-7903(92)90020-H; Caullery M., 1952, PARASITISM SYMBIOSIS; de Bary Anton, 1879, VORTRAG VERSAMMLUNG, P1; ERIKSSON OE, 1993, SYST ASCOMYCETUM, V12, P52; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FUTUYAMA DJ, 1991, GENES ECOLOGY, P139; GARGAS A, 1995, EXP MYCOL, V19, P7, DOI 10.1006/emyc.1995.1002; Hawksworth D.L., 1982, J HATTORI BOT LAB, V52, P323; Hawksworth David L., 1994, Cryptogamic Botany, V4, P117; HAWKSWORTH DL, 1978, ESSAYS PLANT TAXONOM, P122; Henssen A, 1973, LICHENES; HONEGGER R, 1991, ANNU REV PLANT PHYS, V42, P553, DOI 10.1146/annurev.arplant.42.1.553; Kappen Ludger, 1994, Cryptogamic Botany, V4, P193; Landvik Sara, 1993, Systema Ascomycetum, V11, P107; Margulis L., 1988, 5 KINGDOMS ILLUSTRAT; NISHIDA H, 1993, MOL BIOL EVOL, V10, P431; Oberwinkler F., 1984, NOVA HEDWIGIA S, V79, P739; POELT J, 1958, PLANTA, V51, P288, DOI 10.1007/BF02125723; Rambold G., 1992, BIBLIOTHECA LICHENOL, V48, P1; SAENZ GS, 1994, MYCOLOGIA, V86, P212, DOI 10.2307/3760639; SPATAFORA JW, 1993, MYCOLOGIA, V85, P912, DOI 10.2307/3760674; SWANN EC, 1993, MYCOLOGIA, V85, P923, DOI 10.2307/3760675; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; TEHLER A, 1990, CAN J BOT, V68, P2458, DOI 10.1139/b90-312; TEHLER A, 1988, CLADISTICS, V4, P227, DOI 10.1111/j.1096-0031.1988.tb00474.x; Tucker S. C., 1991, TROPICAL LICHENS THE, P171; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; WIRTH V, 1995, FLECHTEN BADEN WURTL, P137	32	245	251	2	63	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1492	1495		10.1126/science.7770775	http://dx.doi.org/10.1126/science.7770775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770775				2022-12-28	WOS:A1995RC19000039
J	KIEFHABER, T; LABHARDT, AM; BALDWIN, RL				KIEFHABER, T; LABHARDT, AM; BALDWIN, RL			DIRECT NMR EVIDENCE FOR AN INTERMEDIATE PRECEDING THE RATE-LIMITING STEP IN THE UNFOLDING OF RIBONUCLEASE-A	NATURE			English	Article							STRUCTURAL CHARACTERIZATION; TRANSITION-STATE; PROTEIN; LYSOZYME	IT is commonly believed that there are no detectable intermediates in the kinetic unfolding reactions of small proteins(1-6). If such intermediates could be found, they would give important information about the nature of the transition state for unfolding, which is thought to occur close to the native state. We report here that one-dimensional proton magnetic resonance spectra recorded during the unfolding of ribonuclease A provide direct evidence for at least one unfolding intermediate in which side chains are free to rotate. This intermediate appears to be a 'dry molten globule' of the kind hypothesized by Shakhnovich and Finkelstein(7).	F HOFFMANN LA ROCHE & CO LTD,PHARMA RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305	Roche Holding; Stanford University	KIEFHABER, T (corresponding author), UNIV BASEL,BIOCTR,BIOPHYS CHEM ABT,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND.		Kiefhaber, Thomas/A-3028-2010					CHEN BL, 1989, BIOCHEMISTRY-US, V28, P691, DOI 10.1021/bi00428a042; CHEN XW, 1994, BIOCHEMISTRY-US, V33, P6356, DOI 10.1021/bi00186a040; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P2657, DOI 10.1073/pnas.92.7.2657; KUWAJIMA K, 1989, J MOL BIOL, V206, P547, DOI 10.1016/0022-2836(89)90500-7; MUCKE M, 1994, BIOCHEMISTRY-US, V33, P12930; PITITSYN GB, 1992, PROTEIN FOLDING, P243; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; ROBERTSON AD, 1989, BIOCHEMISTRY-US, V28, P5930, DOI 10.1021/bi00440a033; Schmid Franz X., 1992, P197; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2473; SERRANO L, 1992, J MOL BIOL, V224, P805, DOI 10.1016/0022-2836(92)90563-Y; SHAKHNOVICH EI, 1989, BIOPOLYMERS, V28, P1667, DOI 10.1002/bip.360281003; VANDAEL H, 1993, BIOCHEMISTRY-US, V32, P11886, DOI 10.1021/bi00095a018; Wuthrich K., 1986, NMR PROTEINS NUCL AC	17	146	146	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					513	515		10.1038/375513a0	http://dx.doi.org/10.1038/375513a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777063				2022-12-28	WOS:A1995RC18800055
J	COX, S; ALCORN, R				COX, S; ALCORN, R			LOFEXIDINE AND OPIOID WITHDRAWAL	LANCET			English	Editorial Material											COX, S (corresponding author), MIDDLESEX HOSP & HAMPSTEAD RD CTR,ACAD DEPT PSYCHIAT,LONDON,ENGLAND.							[Anonymous], 1988, AIDS DRUG MISUSE 1; COOK CCH, 1988, LANCET, V1, P524; GOLD MS, 1981, DRUG ALCOHOL DEPEN, V8, P307, DOI 10.1016/0376-8716(81)90040-5; GOLD MS, 1978, LANCET, V2, P599; GOLD MS, 1980, NEW ENGL J MED, V302, P1421; GUTHRIE SK, 1990, DICP ANN PHARMAC, V24, P721, DOI 10.1177/106002809002400716; PRESTON KL, 1985, INT J ADDICT, V20, P845, DOI 10.3109/10826088509047756; WASHTON A M, 1982, Psychopharmacology Bulletin, V18, P220; WASHTON AM, 1980, LANCET, V1, P1078; WASHTON AM, 1983, J CLIN PSYCHIAT, V44, P335; 1994, TACKLING DRUGS TOGET; 1994, 94198 DEP HLTH PRESS	12	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1385	1386		10.1016/S0140-6736(95)92593-7	http://dx.doi.org/10.1016/S0140-6736(95)92593-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760607				2022-12-28	WOS:A1995RB44100005
J	MARKOWITZ, S; WANG, J; MYEROFF, L; PARSONS, R; SUN, LZ; LUTTERBAUGH, J; FAN, RS; ZBOROWSKA, E; KINZLER, KW; VOGELSTEIN, B; BRATTAIN, M; WILLSON, JKV				MARKOWITZ, S; WANG, J; MYEROFF, L; PARSONS, R; SUN, LZ; LUTTERBAUGH, J; FAN, RS; ZBOROWSKA, E; KINZLER, KW; VOGELSTEIN, B; BRATTAIN, M; WILLSON, JKV			INACTIVATION OF THE TYPE-II TGF-BETA RECEPTOR IN COLON-CANCER CELLS WITH MICROSATELLITE INSTABILITY	SCIENCE			English	Article							DIFFERENTIAL SENSITIVITY; CARCINOMA-CELLS; GROWTH; EXPRESSION; INHIBITION; KINASE; LIGAND; LINES	Transforming growth factor-beta (TGF-beta) is a potent inhibitor of epithelial cell growth. Human colon cancer cell lines with high rates of microsatellite instability were found to harbor mutations in the type II TGF-beta receptor (RII) gene. Eight such examples, due to three different mutations, were identified. The mutations were clustered within small repeated sequences in the RII gene, were accompanied by the absence of cell surface RII receptors, and were usually associated with small amounts of RII transcript. RII mutation, by inducing the escape of cells from TGF-beta-mediated growth control, links DNA repair defects with a specific pathway of tumor progression.	UNIV CLEVELAND HOSP, IRELAND CANC CTR, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; MED COLL OHIO, DEPT BIOCHEM & MOLEC BIOL, TOLEDO, OH 43699 USA; JOHNS HOPKINS UNIV, CTR ONCOL, BALTIMORE, MD 21231 USA; HOWARD HUGHES MED INST, CHEVY CHASE, MD 20815 USA	Case Western Reserve University; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute	MARKOWITZ, S (corresponding author), UNIV CLEVELAND HOSP, DEPT MED, ROOM 200, 11001 CEDAR RD, CLEVELAND, OH 44106 USA.		, LuZhe/AAW-4095-2021	Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R37CA038173, R01CA050457, R01CA038173, R29CA063480] Funding Source: NIH RePORTER; NCI NIH HHS [CA63480, CA50457, CA38173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AVERY A, 1993, BRIT J CANCER, V68, P137, DOI 10.1038/bjc.1993.301; BOYD FT, 1989, J BIOL CHEM, V264, P2272; Brattain Michael G., 1994, Current Opinion in Oncology, V6, P77, DOI 10.1097/00001622-199401000-00011; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHEN JS, 1995, CANCER RES, V55, P174; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GEISER AG, 1992, J BIOL CHEM, V267, P2588; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LEACH F, 1994, NATURE, V371, P75; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, UNPUB; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SUN LZ, 1994, J BIOL CHEM, V269, P26449; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU SP, 1993, CELL GROWTH DIFFER, V4, P115; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187	36	2092	2183	2	54	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 2	1995	268	5215					1336	1338		10.1126/science.7761852	http://dx.doi.org/10.1126/science.7761852			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761852				2022-12-28	WOS:A1995RB19800035
J	CHALMERS, I				CHALMERS, I			WHAT DO I WANT FROM HEALTH RESEARCH AND RESEARCHERS WHEN I AM A PATIENT	BRITISH MEDICAL JOURNAL			English	Article								I have attempted to adopt the perspective of a patient-albeit one with a rather atypical background-to explore what I want from health research and researchers. This has left me with the impression that health researchers could serve the interests of the public more effectively in a variety of ways, and that they would be helped to do so by greater lay involvement in planning and promoting health research.										OLIVER SR, 1995, BRIT MED J, V310, P1318, DOI 10.1136/bmj.310.6990.1318; 1991, CODE CONDUCT ETHICAL, P5	2	136	137	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1315	1318		10.1136/bmj.310.6990.1315	http://dx.doi.org/10.1136/bmj.310.6990.1315			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773050	Green Published			2022-12-28	WOS:A1995QZ86000030
J	MONACO, HL; RIZZI, M; CODA, A				MONACO, HL; RIZZI, M; CODA, A			STRUCTURE OF A COMPLEX OF 2 PLASMA-PROTEINS - TRANSTHYRETIN AND RETINOL-BINDING PROTEIN	SCIENCE			English	Article							CRYSTAL-STRUCTURE DETERMINATION; HUMAN SERUM TRANSTHYRETIN; AMINO-ACID-SEQUENCE; HEREDITARY AMYLOIDOSIS; PRE-ALBUMIN; PREALBUMIN; RESOLUTION; VARIANT; RECOGNITION; REFINEMENT	The three-dimensional structure of the complex formed by two plasma proteins, transthyretin and retinol-binding protein, was determined from x-ray diffraction data to a nominal resolution of 3.1 angstroms. One tetramer of transthyretin was bound to two molecules of retinol-binding protein. The two retinol-binding protein molecules established molecular interactions with the same transthyretin dimer, and each also made contacts with one of the other two monomers. Thus, the other two potential binding sites in a transthyretin tetramer were blocked. The amino acid residues of the retinol-binding protein that were involved in the contacts were close to the retinol-binding protein that were involved in the contacts were close to the retinol-binding site.			MONACO, HL (corresponding author), UNIV PAVIA,DEPT GENET,I-27100 PAVIA,ITALY.			Monaco, Hugo L./0000-0002-2067-0365				AQVIST J, 1992, J MOL GRAPHICS, V10, P120, DOI 10.1016/0263-7855(92)80065-L; BENSON MD, 1983, ARTHRITIS RHEUM, V26, P1493, DOI 10.1002/art.1780261211; BENSON MD, 1993, METABOLIC BASIS INHE, P6262; BERNI R, 1994, J BIOL CHEM, V269, P23395; BERNI R, 1990, EUR J BIOCHEM, V192, P507, DOI 10.1111/j.1432-1033.1990.tb19254.x; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DUAN W, 1991, EUR J BIOCHEM, V200, P679, DOI 10.1111/j.1432-1033.1991.tb16232.x; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HAMILTON JA, 1993, J BIOL CHEM, V268, P2416; HELLER J, 1975, J BIOL CHEM, V250, P3019; HORWITZ J, 1974, J BIOL CHEM, V249, P7181; JACOBSON DR, 1990, AM J HUM GENET, V47, P127; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KOPELMAN M, 1976, BIOCHIM BIOPHYS ACTA, V439, P449, DOI 10.1016/0005-2795(76)90082-9; MONACO HL, 1994, J MOL BIOL, V244, P110, DOI 10.1006/jmbi.1994.1708; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023; PETERSON PA, 1971, J BIOL CHEM, V246, P44; RASK L, 1979, FEBS LETT, V104, P55, DOI 10.1016/0014-5793(79)81084-4; RASK L, 1974, EUR J BIOCHEM, V44, P1, DOI 10.1111/j.1432-1033.1974.tb03451.x; RAZ A, 1969, J BIOL CHEM, V244, P3230; STEINRAUF LK, 1993, J BIOL CHEM, V268, P2425; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; TERRY CJ, 1993, EMBO J, V12, P735, DOI 10.1002/j.1460-2075.1993.tb05707.x; TRAGARDH L, 1980, J BIOL CHEM, V255, P9243; UENO S, 1990, BIOCHEM BIOPH RES CO, V169, P143, DOI 10.1016/0006-291X(90)91445-X; VANJAARSVELD PP, 1973, J BIOL CHEM, V248, P4698; WALLACE MR, 1988, AM J HUM GENET, V43, P182; WOJTCZAK A, 1993, J BIOL CHEM, V268, P6202; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; ZANOTTI G, 1993, J MOL BIOL, V230, P613, DOI 10.1006/jmbi.1993.1173; ZANOTTI G, 1993, J BIOL CHEM, V268, P10728; ZAPPONI MC, 1992, EUR J BIOCHEM, V210, P937, DOI 10.1111/j.1432-1033.1992.tb17498.x	39	340	366	0	22	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					1039	1041		10.1126/science.7754382	http://dx.doi.org/10.1126/science.7754382			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754382				2022-12-28	WOS:A1995QY93400038
J	SAUER, F; FONDELL, JD; OHKUMA, Y; ROEDER, RG; JACKLE, H				SAUER, F; FONDELL, JD; OHKUMA, Y; ROEDER, RG; JACKLE, H			CONTROL OF TRANSCRIPTION BY KRUPPEL THROUGH INTERACTIONS WITH TFIIB AND TFIIE-BETA	NATURE			English	Article							ACTIVATION DOMAIN; RNA-POLYMERASE; DROSOPHILA; INITIATION; PROTEIN; REPRESSION; MECHANISM; SEQUENCE; BINDING; STRIPE	THE zinc-finger protein Kruppel (Kr)(1) is an integral part of the Drosophila segmentation gene cascade(2) and is essential in organogenesis during later embryonic development(3). In tissue culture, Kr regulates transcription(4-9). Monomeric Kr can act as a transcriptional activator, whereas Kr dimers formed at high concentrations cause repression(6). Here we show that Kr-dependent control of transcription involves functional interactions with components of the basal RNA polymerase II transcription machinery, which includes the initiation factors TFIIA, B, E, F, H and I (refs 10, 11) as well as the TATA-binding protein (TBP) and TBP-associated factors (TAFs) contained in the multisubunit TFIID (ref. 12). Our results indicate that when acting from a site close to a basal promoter, monomeric Kr interacts with TFIIB to activate transcription, whereas an interaction of the Kr dimer with TFIIE beta w, a subunit of TFIIE, results in transcriptional repression.	MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,D-37077 GOTTINGEN,GERMANY; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021	Max Planck Society; Rockefeller University								CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KIM TK, IN PRESS P NATN ACAD; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LILLIE JW, 1991, NATURE, V338, P39; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1992, NATURE, V358, P841; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAUER F, 1993, THESIS U OSNABRUCK G; SCHMUCKER D, 1992, NEURON, V5, P1025; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZHUO P, 1990, GENE DEV, V5, P254	30	132	135	1	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					162	164		10.1038/375162a0	http://dx.doi.org/10.1038/375162a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753175				2022-12-28	WOS:A1995QX74100056
J	EVANS, P; GRAY, DP				EVANS, P; GRAY, DP			VALUE OF SCREENING FOR SECONDARY CAUSES OF HYPERLIPIDEMIA IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article											EVANS, P (corresponding author), UNIV EXETER,POSTGRAD MED SCH,INST GEN PRACTICE,EXETER EX2 5DW,DEVON,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				BRUNZELL JD, 1988, CECIL TXB MED, P1143; Gray D J, 1979, J R Coll Gen Pract, V29, P666; LEWIS B, 1987, OXFORD TXB MED, V9, P111; 1992, 55 ROYAL COLL GEN PR; 1988, EUR HEART J, V9, P571	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					509	510		10.1136/bmj.309.6953.509	http://dx.doi.org/10.1136/bmj.309.6953.509			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	7755687	Green Published			2022-12-28	WOS:A1994PD30800018
J	TYRING, S; BARBARASH, RA; NAHLIK, JE; CUNNINGHAM, A; MARLEY, J; HENG, M; JONES, T; REA, T; BOON, R; SALTZMAN, R; BRUCE, S; HARRIS, A; EPSTEIN, A; LOWRY, L; RUBIN, H; DUPUY, J; HENDRICKS, J; GREER, J; RAPAPORT, M; MILLER, DJ; FRIEDMANN, BS; SILVERBROOK, RM; MARLEY, W; ZELLNER, SR; MICHIE, DD; MESTAS, F; KLUGE, R; PURVIS, QR; SCHLEIDER, N; DOMINGO, J; SWINEHART, JM; WILLIAMS, K; SHULTZ, L; ROCHAMBEAUM, B; CAMPBELL, D; PRICE, J; KING, M; MORALEDA, P; TORO, M; MORTENSEN, M; WALKER, M; STEELE, B; CASTELLANOS, K; MILLER, C; TERRELL, MD; CRANE, J; ZINK, R; SOERRIES, S; NESTER, C; NESTER, S; FOX, G; CRECELIUS, C; SINGER, M; STANTON, L; ELGART, ML; MASRIFRIDLING, G; NOONAN, M; SCHEINMAN, P; MCNEELEY, MC; TURNER, M; SULICA, VI; KRAUS, SJ; GRIFFIN, EI; KAREMPELIS, DS; POTTER, BC; SMITH, DM; COREY, L; GILL, T; RODMAN, OG; NORUM, R; BABEL, D; MARTEL, A; NESBITT, LT; LEE, BD; HEITLER, DG; HOLLABAUGH, E; THOMAS, JBR; JONES, CM; CANNON, TB; LITTLEJOHN, TW; VANZANDT, KV; SHAR, GG; BRASWELL, SD; ROACH, JG; WORF, RC; HELLYAR, A; KATZ, HI; PRAWER, SE; LINDHOLM, JS; HIEN, NT; FISH, FS; SCOTT, JC; KEMPERS, S; BRIDEN, ME; LASSONDE, M; OLIEL, V; SIMOR, A; LOW, D; VELLAND, H; GOLD, W; BENEDUM, JL; GARMONBROWN, OE; TUCKER, WS; TAM, K; LANDIS, E; BLOUNT, CW; SPANGENTHAL, S; CHAPMAN, G; FISCHER, L; HADLEY, HW; GREGSON, D; HAMMERBERG, O; FONG, I; VONBEHREN, LA; RABINOVICH, S; KHARDORI, N; FITTS, D; GRIER, C; GRIFFIN, D; MCKAY, D; BIRKENMAIER, R; BISHOP, S; MARKS, GL; LOCKE, L; JUREWICZ, R; WEILL, S; MAYEWSKI, T; FRAZIER, C; GROSSMAN, A; MACDONALD, J; MURPHY, P; STIEDE, K; WEIGART, MB; LEVIDIOTIS, M; HOSANG, M; PARSONS, J; RACHLIS, AR; SCHACHTER, GD; SCHACHTER, RK; GORDON, D; HALLSWORTH, P; MARKHAM, D; WILKINSON, E; SMITH, G; WELCH, K; PIACQUADIO, D; FLEMING, A; BRENEMAN, DL; CHETTY, BV; MANDERS, S; LUSHNIAK, B; HOGAN, D; REID, A; TANNOCK, G; DICK, N; CROSSLEY, L; PURVIS, R; DIVEN, D; PORTER, N; HEBERT, AA; BOWDEN, JB; SCHULZE, KE; WILLIAMS, KE; CONLY, JM; ANDERSON, C; SMITH, J; KRYWONIS, N; HENG, MCY; TUCKER, R; LEE, BW; WEINTRAUB, JS; DWYER, D; HOLLAND, D; FORDHAM, M; MILLER, G; SYLVESTER, T; MARLOWE, SI; TANNER, ML; DILORENZO, PA				TYRING, S; BARBARASH, RA; NAHLIK, JE; CUNNINGHAM, A; MARLEY, J; HENG, M; JONES, T; REA, T; BOON, R; SALTZMAN, R; BRUCE, S; HARRIS, A; EPSTEIN, A; LOWRY, L; RUBIN, H; DUPUY, J; HENDRICKS, J; GREER, J; RAPAPORT, M; MILLER, DJ; FRIEDMANN, BS; SILVERBROOK, RM; MARLEY, W; ZELLNER, SR; MICHIE, DD; MESTAS, F; KLUGE, R; PURVIS, QR; SCHLEIDER, N; DOMINGO, J; SWINEHART, JM; WILLIAMS, K; SHULTZ, L; ROCHAMBEAUM, B; CAMPBELL, D; PRICE, J; KING, M; MORALEDA, P; TORO, M; MORTENSEN, M; WALKER, M; STEELE, B; CASTELLANOS, K; MILLER, C; TERRELL, MD; CRANE, J; ZINK, R; SOERRIES, S; NESTER, C; NESTER, S; FOX, G; CRECELIUS, C; SINGER, M; STANTON, L; ELGART, ML; MASRIFRIDLING, G; NOONAN, M; SCHEINMAN, P; MCNEELEY, MC; TURNER, M; SULICA, VI; KRAUS, SJ; GRIFFIN, EI; KAREMPELIS, DS; POTTER, BC; SMITH, DM; COREY, L; GILL, T; RODMAN, OG; NORUM, R; BABEL, D; MARTEL, A; NESBITT, LT; LEE, BD; HEITLER, DG; HOLLABAUGH, E; THOMAS, JBR; JONES, CM; CANNON, TB; LITTLEJOHN, TW; VANZANDT, KV; SHAR, GG; BRASWELL, SD; ROACH, JG; WORF, RC; HELLYAR, A; KATZ, HI; PRAWER, SE; LINDHOLM, JS; HIEN, NT; FISH, FS; SCOTT, JC; KEMPERS, S; BRIDEN, ME; LASSONDE, M; OLIEL, V; SIMOR, A; LOW, D; VELLAND, H; GOLD, W; BENEDUM, JL; GARMONBROWN, OE; TUCKER, WS; TAM, K; LANDIS, E; BLOUNT, CW; SPANGENTHAL, S; CHAPMAN, G; FISCHER, L; HADLEY, HW; GREGSON, D; HAMMERBERG, O; FONG, I; VONBEHREN, LA; RABINOVICH, S; KHARDORI, N; FITTS, D; GRIER, C; GRIFFIN, D; MCKAY, D; BIRKENMAIER, R; BISHOP, S; MARKS, GL; LOCKE, L; JUREWICZ, R; WEILL, S; MAYEWSKI, T; FRAZIER, C; GROSSMAN, A; MACDONALD, J; MURPHY, P; STIEDE, K; WEIGART, MB; LEVIDIOTIS, M; HOSANG, M; PARSONS, J; RACHLIS, AR; SCHACHTER, GD; SCHACHTER, RK; GORDON, D; HALLSWORTH, P; MARKHAM, D; WILKINSON, E; SMITH, G; WELCH, K; PIACQUADIO, D; FLEMING, A; BRENEMAN, DL; CHETTY, BV; MANDERS, S; LUSHNIAK, B; HOGAN, D; REID, A; TANNOCK, G; DICK, N; CROSSLEY, L; PURVIS, R; DIVEN, D; PORTER, N; HEBERT, AA; BOWDEN, JB; SCHULZE, KE; WILLIAMS, KE; CONLY, JM; ANDERSON, C; SMITH, J; KRYWONIS, N; HENG, MCY; TUCKER, R; LEE, BW; WEINTRAUB, JS; DWYER, D; HOLLAND, D; FORDHAM, M; MILLER, G; SYLVESTER, T; MARLOWE, SI; TANNER, ML; DILORENZO, PA			FAMCICLOVIR FOR THE TREATMENT OF ACUTE HERPES-ZOSTER - EFFECTS ON ACUTE DISEASE AND POSTHERPETIC NEURALGIA - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						FAMCICLOVIR; HERPES ZOSTER; NEURALGIA; VIRUS SHEDDING; ACYCLOVIR	ORAL ACYCLOVIR; SIMPLEX VIRUS; CELL-CULTURE; MRC-5 CELLS; PENCICLOVIR; MODE; INFECTIONS; EFFICACY	Objective: To document the effects of treatment with famciclovir on the acute signs and symptoms of herpes zoster and postherpetic neuralgia. Design: A randomized, double-blind, placebo-controlled, multicenter trial. Setting: 36 centers in the United States, Canada, and Australia. Patients: 419 immunocompetent adults with uncomplicated herpes tester. Intervention: Patients were assigned within 72 hours of rash onset to famciclovir, 500 mg; famciclovir, 750 mg; or placebo, three times daily for 7 days. Measurements: Lesions were assessed daily for as long as 14 days until full crusting occurred rand then weekly until the lesions healed. Viral cultures were obtained daily while vesicles were present. Pain was assessed at each of the visits at which lesions were examined and then monthly for 5 months after the lesions healed. Safety was assessed throughout the study. Results: Famciclovir was well tolerated, with a safety profile similar to that of placebo. Famciclovir accelerated lesion healing and reduced the duration of viral shedding. Most importantly, famciclovir recipients had faster resolution of postherpetic neuralgia (approximately twofold faster) than placebo recipients; differences between the placebo group and both the 500-mg famciclovir group (hazard ratio, 1.7 [95% CI, 1.1 to 2.7]) and the 750-mg famciclovir group (hazard ratio, 1.9 [CI, 1.2 to 2.9]) were statistically significant (P = 0.02 and 0.01, respectively), The median duration of postherpetic neuralgia was reduced by approximately 2 months. Conclusions: Oral famciclovir, 500 mg or 750 mg three times daily for 7 days, is an effective and well-tolerated therapy for herpes tester that decreases the duration of the disease's most debilitating complication, postherpetic neuralgia.	DEACONESS FAMILY MED, ST LOUIS, MO USA; ST JOHNS HOSP, NASSAU BAY, TX USA; VOLUNTEERS PHARMACEUT RES, BRYAN, TX USA; SMITHKLINE BEECHAM PHARMACEUT, PHILADELPHIA, PA USA; SMITHKLINE BEECHAM PHARMACEUT, BRENTFORD, ENGLAND; BAYLOR COLL MED, HOUSTON, TX 77030 USA; BUCKS CTY CLIN RES, MORRISVILLE, PA USA; CLIN STUDY CTR, FT MYERS, FL USA; CLIN STUDY CTR, CAPE CORAL, FL USA; COLORADO MED RES CTR, DENVER, CO USA; OLD ORCHARD GERIATR & FAMILY MED, ST LOUIS, MO USA; SOUTHSIDE FAMILY PRACTICE & SPURGEON MED GRP, ST LOUIS, MO USA; ST LOUIS MED RES, ST LOUIS, MO USA; GEORGE WASHINGTON UNIV, MED CTR, WASHINGTON, DC 20037 USA; HARBORVIEW MED CTR, SEATTLE, WA USA; GEORGETOWN UNIV, MED CTR, WASHINGTON, DC 20007 USA; GEORGIA CLIN RES CTR, ATLANTA, GA USA; HENRY FORD HOSP, DETROIT, MI 48202 USA; CHU LAVAL, ST FOY, PQ, CANADA; LOUISIANA STATE UNIV, CHAR HOSP LOUISIANA, SCH MED, LIONS CLIN, NEW ORLEANS, LA USA; MAPLEWOOD FAMILY PRACTICE, WINSTON SALEM, NC USA; PIEDMONT RES ASSOCIATES, WINSTON SALEM, NC USA; MINNESOTA CLIN STUDY CTR, FRIDLEY, MN USA; MT SINAI HOSP, TORONTO, ON M5G 1X5, CANADA; METROLINA, NALLE CLIN, CHARLOTTE, NC USA; PALM BEACH CTR CLIN INVEST, W PALM BEACH, FL USA; ST JOSEPHS HLTH CTR LONDON, LONDON, ON, CANADA; ST MICHAELS HOSP, TORONTO, ON M5B 1W8, CANADA; SO ILLINOIS UNIV, ST JOHNS HOSP, MEM MED CTR, SCH MED, SPRINGFIELD, IL USA; ST LOUIS UNIV, ST LOUIS, MO 63103 USA; WESTMEAD HOSP, WESTMEAD, NSW 2145, AUSTRALIA; UNIV ADELAIDE, ADELAIDE, SA, AUSTRALIA; VET ADM MED CTR, SEPULVEDA, CA 91343 USA; SMITHKLINE BEECHAM PHARMACEUT, MELBOURNE, VIC, AUSTRALIA; SMITHKLINE BEECHAM PHARMACEUT, OAKVILLE, ON, CANADA; SUNNYBROOK MED CTR, TORONTO, ON M4N 3M5, CANADA; UNIV ARIZONA, HLTH SCI CTR, TUCSON, AZ USA; VET ADM MED CTR, SAN DIEGO, CA 92161 USA; UNIV CALIF SAN DIEGO, SCH MED, SAN DIEGO, CA 92103 USA; UNIV CINCINNATI, CINCINNATI, OH USA; UNIV MIAMI, MIAMI, FL 33152 USA; UNIV NEWCASTLE, CALLAGHAN, NSW, AUSTRALIA; UNIV TEXAS, SCH MED, HOUSTON, TX USA; UNIV SASKATCHEWAN HOSP, SASKATOON, SK S7N 0W8, CANADA; VET ADM MED CTR, MINNEAPOLIS, MN USA; WENATCHEE VALLEY CLIN, WENATCHEE, WA USA; W PACES FERRY HOSP, ATLANTA, GA USA	GlaxoSmithKline; GlaxoSmithKline; Baylor College of Medicine; Saint Louis University; George Washington University; Harborview Medical Center; Georgetown University; Henry Ford Health System; Henry Ford Hospital; Laval University; Louisiana State University System; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Southern Illinois University System; Southern Illinois University; Saint Louis University; University of Sydney; University of Adelaide; US Department of Veterans Affairs; Veterans Health Administration (VHA); GlaxoSmithKline; GlaxoSmithKline; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Arizona; University of Arizona Health Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Diego; University System of Ohio; University of Cincinnati; University of Miami; University of Newcastle; University of Texas System; University of Saskatchewan; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	TYRING, S (corresponding author), UNIV TEXAS, MED BRANCH, ROUTE J-19, GALVESTON, TX 77555 USA.		Marley, John/F-1239-2010; Corey, Lawrence/AAE-1796-2020; Potter, Brian/GYE-3596-2022	Corey, Lawrence/0000-0002-2179-2436; Cunningham, Anthony/0000-0002-6744-5667; Gordon, David/0000-0003-3276-9685	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000073] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR0073] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BACON TH, 1993, ANTIVIR CHEM CHEMOTH, V4, P25, DOI 10.1177/09563202930040S603; BOYD MR, 1993, ANTIVIR CHEM CHEMOTH, V4, P3, DOI 10.1177/095632029300401S01; BOYD MR, 1988, ANTIVIR RES, V9, P146; BOYD MR, 1987, ANTIMICROB AGENTS CH, V31, P1238, DOI 10.1128/AAC.31.8.1238; COBO LM, 1986, OPHTHALMOLOGY, V93, P763; COX DR, 1972, J R STAT SOC B, V34, P187; DECLERCQ E, 1982, ANTIMICROB AGENTS CH, V21, P661, DOI 10.1128/AAC.21.4.661; DEGREEF H, 1994, INT J ANTIMICROB AG, V4, P241, DOI 10.1016/0924-8579(94)90024-8; DEMORAGAS JM, 1957, ARCH DERMATOL, V75, P193, DOI 10.1001/archderm.1957.01550140037006; EARNSHAW DL, 1992, ANTIMICROB AGENTS CH, V36, P2747, DOI 10.1128/AAC.36.12.2747; GELB LD, 1989, CURR OPIN INFECT DIS, V2, P256, DOI 10.1097/00001432-198904000-00016; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; HODGE RAV, 1993, ANTIVIR CHEM CHEMOTH, V4, P13, DOI 10.1177/09563202930040S601; HODGE RAV, 1989, ANTIMICROB AGENTS CH, V33, P223, DOI 10.1128/AAC.33.2.223; HODGE RAV, 1993, CHIRALITY, V5, P583, DOI 10.1002/chir.530050804; HUFF JC, 1988, AM J MED, V85, P84; HUFF JC, 1993, J MED VIROL, P93; LOESER JD, 1986, PAIN, V25, P149, DOI 10.1016/0304-3959(86)90089-8; MCKENDRICK MW, 1986, BRIT MED J, V293, P1529, DOI 10.1136/bmj.293.6561.1529; MCKENDRICK MW, 1989, BRIT MED J, V298, P431, DOI 10.1136/bmj.298.6671.431; MORTON P, 1989, NEW ZEAL MED J, V102, P93; PORTENOY RK, 1986, ANN NEUROL, V20, P651, DOI 10.1002/ana.410200602; PUE MA, 1993, ANTIVIR CHEM CHEMOTH, V4, P47, DOI 10.1177/09563202930040S602; SALTZMAN R, 1994, ANTIMICROB AGENTS CH, V38, P2454, DOI 10.1128/AAC.38.10.2454; SASADEUSZ JJ, 1993, DERMATOL CLIN, V11, P171, DOI 10.1016/S0733-8635(18)30294-8; Standring-Cox R., 1994, Antiviral Research, V23, P96; STROMMEN GL, 1988, PHARMACOTHERAPY, V8, P52; WATSON PN, 1986, ARCH NEUROL-CHICAGO, V43, P836, DOI 10.1001/archneur.1986.00520080074027; WOOD MJ, 1987, INFECTION, V15, pS9, DOI 10.1007/BF01650105; WOOD MJ, 1988, AM J MED, V85, P79; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304	31	348	355	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1995	123	2					89	96		10.7326/0003-4819-123-2-199507150-00002	http://dx.doi.org/10.7326/0003-4819-123-2-199507150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM435	7778840				2022-12-28	WOS:A1995RM43500002
J	GILL, PS; HARRINGTON, W; KAPLAN, MH; RIBEIRO, RC; BENNETT, JM; LIEBMAN, HA; BERNSTEINSINGER, M; ESPINA, BM; CABRAL, L; ALLEN, S; KORNBLAU, S; PIKE, MC; LEVINE, AM				GILL, PS; HARRINGTON, W; KAPLAN, MH; RIBEIRO, RC; BENNETT, JM; LIEBMAN, HA; BERNSTEINSINGER, M; ESPINA, BM; CABRAL, L; ALLEN, S; KORNBLAU, S; PIKE, MC; LEVINE, AM			TREATMENT OF ADULT T-CELL LEUKEMIA-LYMPHOMA WITH A COMBINATION OF INTERFERON-ALFA AND ZIDOVUDINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS TYPE-I; HTLV-I; C RETROVIRUS; ANTIBODIES; LYMPHOCYTES; BETA; REPLICATION; INFECTION; PATIENT; THERAPY	Background. Infection with the human T-cell lymphotropic virus type I, a retrovirus, can cause a distinctive cancer, adult T-cell leukemia-lymphoma. The median survival of patients with the acute and lymphomatous forms of the disease is short, despite the use of cytotoxic chemotherapy. Methods: We treated 19 patients with acute or lymphomatous forms of adult T-cell leukemia-lymphoma with oral zidovudine (200 mg five times dairy) and interferon alfa (Intron A, 5 million to 10 million units subcutaneously each day). Seven of these patients had either relapsed after multiagent cytotoxic chemotherapy or failed to respond to that treatment. Results. Major responses were achieved in 58 percent of the patients (11 of 19), including complete remission in 26 percent (5 of 19). Four patients in whom prior cytotoxic therapy had failed had major responses, two of which were complete remissions. Six patients have survived for more than 12 months, with the longest remission since the discontinuation of treatment lasting more than 59 months. Conclusions. The combination of zidovudine and interferon alfa has activity against adult T-cell leukemia-lymphoma, even in patients in whom prior cytotoxic therapy has failed. This regimen should be evaluated further for its role in the treatment of adult T-cell leukemia-lymphoma.	UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90033 USA; UNIV MIAMI, MIAMI, FL 33152 USA; N SHORE UNIV HOSP, DEPT MED, MANHASSET, NY 11030 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN USA; ST JUDE CHILDRENS RES HOSP, DEPT PEDIAT, MEMPHIS, TN USA; UNIV TENNESSEE, MEMPHIS, TN 38163 USA; UNIV ROCHESTER, MED CTR, DEPT MED, ROCHESTER, NY 14642 USA; KAISER PERMANENTE SUNSET HOSP, DEPT INTERNAL MED, LOS ANGELES, CA USA; UNIV TEXAS, MD ANDERSON CANC CTR, DIV MED, HOUSTON, TX USA	University of Southern California; University of Miami; Northwell Health; North Shore University Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Rochester; Kaiser Permanente; University of Texas System; UTMD Anderson Cancer Center	GILL, PS (corresponding author), UNIV SO CALIF, SCH MED,NORRIS CANC HOSP & RES INST, DEPT INTERNAL MED,1441 EASTLAKE AVE, RM 162, LOS ANGELES, CA 90033 USA.		Allen, Steven/N-6088-2019; Kornblau, Steven/A-9366-2009	Allen, Steven/0000-0002-3482-3182; 	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180] Funding Source: NIH RePORTER; NCI NIH HHS [CA 20180, P30-CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLATTNER WA, 1982, INT J CANCER, V30, P257, DOI 10.1002/ijc.2910300302; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GENDELMAN HE, 1990, J IMMUNOL, V145, P2669; HANCHARD B, 1990, HUMAN RETROVIROLOGY : HTLV, P173; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; ICHIMARU M, 1988, JPN J CANC CHEMOTHER, V15, P2975; ISONO T, 1990, LEUKEMIA RES, V14, P841, DOI 10.1016/0145-2126(90)90172-6; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAMIHIRA S, 1983, JPN J CANC CHEMOTHER, V10, P2188; KIMURA K, 1985, JPN J CANC CHEMOTHER, V12, P928; LOFTERS W, 1987, CANCER, V60, P2605, DOI 10.1002/1097-0142(19871201)60:11<2605::AID-CNCR2820601104>3.0.CO;2-T; MATSUSHIMA M, 1987, EUR J HAEMATOL, V39, P282; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MEYTES D, 1990, LANCET, V336, P1533, DOI 10.1016/0140-6736(90)93308-C; MORRIS A, 1987, J GEN VIROL, V68, P99, DOI 10.1099/0022-1317-68-1-99; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; REITZ MS, 1981, P NATL ACAD SCI-BIOL, V78, P1887, DOI 10.1073/pnas.78.3.1887; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; SAITO N, 1994, AM J HEMATOL, V47, P246, DOI 10.1002/ajh.2830470324; SAXINGER W, 1984, SCIENCE, V225, P1473, DOI 10.1126/science.6089348; SHIBATA D, 1989, ANN INTERN MED, V111, P871, DOI 10.7326/0003-4819-111-11-871; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P128, DOI 10.1200/JCO.1988.6.1.128; TAJIMA K, 1990, HUMAN RETROVIROLOGY : HTLV, P267; TAMURA K, 1987, CANCER, V59, P1059, DOI 10.1002/1097-0142(19870315)59:6<1059::AID-CNCR2820590602>3.0.CO;2-M; TARONE RE, 1977, BIOMETRIKA, V64, P156, DOI 10.1093/biomet/64.1.156; TSUDA H, 1994, BRIT J CANCER, V70, P771, DOI 10.1038/bjc.1994.394; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WALDMANN TA, 1993, J ACQ IMMUN DEF SYND, V6, P671; WALDMANN TA, 1988, BLOOD, V72, P1805; 1993, NIH932770 NCI DIV CA; 1991, LEUKEMIA RES, V15, P81	35	278	291	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1744	1748		10.1056/NEJM199506293322603	http://dx.doi.org/10.1056/NEJM199506293322603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760890				2022-12-28	WOS:A1995RE66700003
J	GREAVES, MW				GREAVES, MW			CURRENT CONCEPTS - CHRONIC URTICARIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC IDIOPATHIC URTICARIA; DELAYED PRESSURE URTICARIA; LABORATORY INVESTIGATIONS; CHOLINERGIC URTICARIA; HEREDITARY ANGIOEDEMA; CLINICAL-FEATURES; VASCULITIS; HISTAMINE; THERAPY; SKIN		ST THOMAS HOSP,SCH DENT,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	GREAVES, MW (corresponding author), ST THOMAS HOSP,UNITED MED SCH,ST JOHNS INST DERMATOL,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.							ABOOBAKER J, 1986, CLIN EXP DERMATOL, V11, P436, DOI 10.1111/j.1365-2230.1986.tb00490.x; ALEXANDER EL, 1983, J INVEST DERMATOL, V80, P386, DOI 10.1111/1523-1747.ep12552002; BARLOW RJ, 1993, J AM ACAD DERMATOL, V29, P954, DOI 10.1016/0190-9622(93)70273-V; BARLOW RJ, 1994, BRIT J DERMATOL, V131, P341, DOI 10.1111/j.1365-2133.1994.tb08521.x; BARLOW RJ, 1993, EUR J DERMATOL, V3, P273; BISACCIA E, 1988, ARCH DERMATOL, V124, P1088, DOI 10.1001/archderm.124.7.1088; BLACK AK, 1991, BRIT J DERMATOL, V124, P100, DOI 10.1111/j.1365-2133.1991.tb03292.x; BLEEHEN SS, 1987, BRIT J DERMATOL, V117, P81, DOI 10.1111/j.1365-2133.1987.tb04095.x; BREATHNACH SM, 1983, CLIN EXP DERMATOL, V8, P463, DOI 10.1111/j.1365-2230.1983.tb01814.x; BRESSLER RB, 1989, J ALLERGY CLIN IMMUN, V83, P756, DOI 10.1016/0091-6749(89)90011-0; BRIGGS GG, 1986, DRUGS PREGNANCY LACT, P84; CHAMPION RH, 1988, BRIT J DERMATOL, V119, P427, DOI 10.1111/j.1365-2133.1988.tb03246.x; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; CICARDI M, 1982, AM J MED SCI, V284, P2, DOI 10.1097/00000441-198207000-00001; COMMENS CA, 1978, BRIT J DERMATOL, V98, P47, DOI 10.1111/j.1365-2133.1978.tb07332.x; CZARNETZKI BM, 1986, URTICARIA, P38; DOVER JS, 1988, J AM ACAD DERMATOL, V18, P1289, DOI 10.1016/S0190-9622(88)70137-1; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; FIEBIGER E, 1994, J INVEST DERMATOL, V103, P436; FRADIN MS, 1991, J AM ACAD DERMATOL, V25, P1065, DOI 10.1016/0190-9622(91)70308-O; GRATTAN CEH, 1992, LANCET, V339, P1078, DOI 10.1016/0140-6736(92)90666-Q; GREAVES MW, 1988, IMMUNOLOGICAL DISEAS, V2, P1187; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HIDE M, 1994, CLIN EXP ALLERGY, V24, P624, DOI 10.1111/j.1365-2222.1994.tb00965.x; HIDE M, 1993, NEW ENGL J MED, V328, P1599, DOI 10.1056/NEJM199306033282204; JUHLIN L, 1969, ACTA DERM-VENEREOL, V49, P26; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KENNES B, 1977, CLIN ALLERGY, V7, P35, DOI 10.1111/j.1365-2222.1977.tb01422.x; KOBLENZER CS, 1987, PSYCHOCUTANEOUS DISE, P191; LAWLOR F, 1989, BRIT J DERMATOL, V120, P403, DOI 10.1111/j.1365-2133.1989.tb04167.x; LEZNOFF A, 1989, J ALLERGY CLIN IMMUN, V84, P66, DOI 10.1016/0091-6749(89)90180-2; LINDELOF B, 1990, BRIT J DERMATOL, V123, P453; MAXWELL DL, 1990, J ALLERGY CLIN IMMUN, V86, P759, DOI 10.1016/S0091-6749(05)80180-0; MEHREGAN DR, 1992, J AM ACAD DERMATOL, V26, P441, DOI 10.1016/0190-9622(92)70069-R; MEKORI YA, 1983, J ALLERGY CLIN IMMUN, V72, P681, DOI 10.1016/0091-6749(83)90629-2; MICHAELSSON G, 1973, BRIT J DERMATOL, V88, P525, DOI 10.1111/j.1365-2133.1973.tb08014.x; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; MONROE EW, 1988, J AM ACAD DERMATOL, V19, P842, DOI 10.1016/S0190-9622(88)70243-1; MONROE EW, 1981, J INVEST DERMATOL, V76, P103, DOI 10.1111/1523-1747.ep12525403; MONROE EW, 1985, URTICARIAS, P205; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; ODONNELL F, 1994, BR J DERMATOL S44, V131, P23; SANCHEZ NP, 1982, J AM ACAD DERMATOL, V7, P599, DOI 10.1016/S0190-9622(82)70139-2; SCHATZ M, 1993, ALLERGY PRINCIPLES P, V2, P1301; SHELDON JM, 1954, J ALLERGY, V25, P525, DOI 10.1016/S0021-8707(54)90034-9; SIBBALD RG, 1991, INT J DERMATOL, V30, P381, DOI 10.1111/j.1365-4362.1991.tb03891.x; SIM TC, 1990, AM J MED, V88, P656, DOI 10.1016/0002-9343(90)90535-L; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; SMITH CH, 1992, LANCET, V339, P91, DOI 10.1016/0140-6736(92)91000-X; SOTER NA, 1977, NEW ENGL J MED, V296, P1440, DOI 10.1056/NEJM197706232962505; SPANGLER DL, 1980, ANN ALLERGY, V45, P246; STRICKER BHC, 1986, BRIT MED J, V293, P536, DOI 10.1136/bmj.293.6546.536; SUPRAMANIAM G, 1986, LANCET, V2, P907; Swinny B, 1941, SOUTH MED J, V34, P855; TANUS T, 1994, J ALLERGY CLIN IMMUN, V93, P227; WARIN RP, 1960, BRIT J DERMATOL, V72, P350, DOI 10.1111/j.1365-2133.1960.tb13817.x; WILLIS I, 1974, ARCH DERMATOL, V110, P389, DOI 10.1001/archderm.110.3.389; WINKELMANN RK, 1988, HUM PATHOL, V19, P389, DOI 10.1016/S0046-8177(88)80486-6	59	309	319	1	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1767	1772		10.1056/NEJM199506293322608	http://dx.doi.org/10.1056/NEJM199506293322608			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760895				2022-12-28	WOS:A1995RE66700008
J	SANCHEZGUERRERO, J; COLDITZ, GA; KARLSON, EW; HUNTER, DJ; SPEIZER, FE; LIANG, MH				SANCHEZGUERRERO, J; COLDITZ, GA; KARLSON, EW; HUNTER, DJ; SPEIZER, FE; LIANG, MH			SILICONE BREAST IMPLANTS AND THE RISK OF CONNECTIVE-TISSUE DISEASES AND SYMPTOMS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; REVISED CRITERIA; WOMEN; POLYMYOSITIS; EPIDEMIOLOGY; SCLERODERMA; DERMATOMYOSITIS; CLASSIFICATION; AUGMENTATION	Background. Silicone breast implants have been linked to a variety of illnesses, the most controversial of which are connective-tissue diseases and symptoms. To study this relation, we analyzed data from 14 years of follow-up of the Nurses' Health Study cohort. Methods. Women who were free from connective-tissue disease in June 1976 were followed through May 31, 1990, before there was widespread media coverage of the possible association of breast implants and connective-tissue diseases. Information was collected through biennial and supplementary mailed questionnaires and blinded reviews of medical records with the use of standardized criteria. Relative risk, the measure of association, was defined as the incidence rate of connective-tissue disease among women with breast implants divided by the corresponding incidence rate among women without breast implants. Results. Among 87,501 women who were eligible for follow-up, 516 were confirmed as having definite connective-tissue diseases and 1183 as having breast implants (of which 876 were silicone-gel-filled, 170 saline-filled, 67 double-lumen, 14 polyurethane-coated, and 56 of unknown type). The mean (+/-SD) period of follow-up after surgery was 9.9+/-6.4 years (range, 1 month to 40.5 years). Three of the patients with definite connective-tissue disease - all had rheumatoid arthritis - had implants (one silicone-gel-filled, one saline-filled, and one double-lumen). The age-adjusted relative risk of a definite connective-tissue disease among women with any type of implant was 0.6 (95 percent confidence interval, 0.2 to 2.0), as compared with women without implants. For women with silicone-gel-filled implants, the comparable relative risk was 0.3 (95 percent confidence interval, 0 to 1.9). The relative risk of self-reported signs or symptoms of connective-tissue disease for women with implants was 1.5 (95 percent confidence interval, 0.9 to 2.4); the risk of having any 1 of 41 signs, symptoms, or laboratory features of connective-tissue disease was 0.7 (95 percent confidence interval, 0.3 to 1.6). Conclusions. In a large cohort study, we did not find an association between silicone breast implants and connective-tissue diseases, defined according to a variety of standardized criteria, or signs and symptoms of these diseases.	HARVARD UNIV,SCH MED,DEPT RHEUMATOL & IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CHANNING LAB,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,RB BRIGHAM MULTIP ARTHRIT & MUSCULOSKEL DIS CTR,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308, R01AR042630] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356-08S1] Funding Source: Medline; NIAMS NIH HHS [AR36308, AR42630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P328; ANGELL M, 1994, NEW ENGL J MED, V330, P1748, DOI 10.1056/NEJM199406163302409; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BORENSTEIN D, 1994, SEMIN ARTHRITIS RHEU, V24, P1, DOI 10.1016/0049-0172(94)90102-3; BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; COOK RR, 1995, J CLIN EPIDEMIOL, V48, P519, DOI 10.1016/0895-4356(94)00208-8; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; DUGOWSON CE, 1991, ARTHRITIS RHEUM-US, V34, P1502; FESSEL WJ, 1974, ARCH INTERN MED, V134, P1027, DOI 10.1001/archinte.134.6.1027; FOX RI, 1986, SCAND J RHEUMATOL S, V61, P28; FREUNDLICH B, 1994, SEMIN ARTHRITIS RHEU, V24, P44, DOI 10.1016/0049-0172(94)90109-0; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GILTAY EJ, 1994, ANN RHEUM DIS, V53, P194, DOI 10.1136/ard.53.3.194; GOLDMAN JA, 1992, ARTHRITIS RHEUM, V35, pS65; HOCHBERG MC, 1985, ARTHRITIS RHEUM-US, V28, P80, DOI 10.1002/art.1780280113; HOCHBERG MC, 1994, ARTHRITIS RHEUM, V37, P1249; KARLSON EW, IN PRESS ANN EPIDEMI; KESSLER DA, 1992, NEW ENGL J MED, V326, P1713, DOI 10.1056/NEJM199206183262525; MEDSGER TA, 1970, AM J MED, V48, P715, DOI 10.1016/S0002-9343(70)80006-7; MEDSGER TA, 1971, ANN INTERN MED, V74, P714, DOI 10.7326/0003-4819-74-5-714; MICHET CJ, 1985, MAYO CLIN PROC, V60, P105, DOI 10.1016/S0025-6196(12)60294-8; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, 1980, ARTHRITIS RHEUM, V23, P581; ROTHMAN KJ, 1979, PHS NIH791649 PUBL; SANCHEZGUERRERO J, 1994, ARTHRITIS RHEUM-US, V37, P158; SILMAN A, 1988, BRIT J RHEUMATOL, V27, P286; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; STEEN V, 1988, Arthritis and Rheumatism, V31, pS57; STROM BL, 1994, J CLIN EPIDEMIOL, V47, P1211, DOI 10.1016/0895-4356(94)90109-0; SYMMONS DPM, 1992, ARTHRITIS RHEUM, V35, P126; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VASEY FB, 1994, SEMIN ARTHRITIS RHEU, V24, P22, DOI 10.1016/0049-0172(94)90106-6; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; WELLS KE, 1994, PLAST RECONSTR SURG, V93, P907, DOI 10.1097/00006534-199404001-00002; WIGLEY FM, 1992, ARTHRITIS RHEUM, V35, pS46; 1992, CAN MED ASSOC J, V147, P1141; 1993, STATA REFERENCE MANU	39	314	323	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1666	1670		10.1056/NEJM199506223322502	http://dx.doi.org/10.1056/NEJM199506223322502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760867				2022-12-28	WOS:A1995RD99600002
J	LITTENBERG, B				LITTENBERG, B			A PRACTICE GUIDELINE REVISITED - SCREENING FOR HYPERTENSION	ANNALS OF INTERNAL MEDICINE			English	Article							BLOOD-PRESSURE; PROGRAM	In 1993, the Clinical Efficacy Assessment Subcommittee began evaluation of new topics and reevaluation of previous guidelines on common screening tests, which were published in Annals of Internal Medicine between 1988 and 1990 and republished as a collection in 1991 (Eddy DM, ed. Common Screening Tests. Philadelphia: American College of Physicians; 1991). Of the 11 guidelines contained in Common Screening Tests, only 3 (for breast, colon, and cholesterol screening) wilt be published with new data supporting new recommendations. Dr. Littenberg's analysis of the evidence that has appeared since the publication of the original paper on screening for hypertension (Littenberg B, Garber AM, Sox HC. Screening for Hypertension. Ann intern Med. 1990;112:192-202) presents a new format for updating Clinical Efficacy Assessment Project (CEAP) guidelines that have not been altered by new evidence. This ''updated guideline'' reports on new published studies and its analysis affirms the approved American College of Physicians recommendations of 1990. The Clinical Efficacy Assessment Subcommittee carried out the internal and external review procedures that are used for all CEAP guidelines. The plan is to keep all American College of Physicians guidelines updated in this way on a regular basis. Direct any comments or suggestions to Director, Scientific Policy, American College of Physicians, 6th Street at Race, Philadelphia, PA 19106.	WASHINGTON UNIV, SCH MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL)				Littenberg, Benjamin/0000-0002-7647-1808				ABBOTT SD, 1989, CAN J PUBLIC HEALTH, V80, P406; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1989, GUIDE CLIN PREVENTIV; BROWN HR, 1989, J OCCUP ENVIRON MED, V31, P354; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAMPTON A, 1990, FAM PRACT, V7, P52, DOI 10.1093/fampra/7.1.52; HOLMEN J, 1991, BRIT MED J, V302, P219, DOI 10.1136/bmj.302.6770.219; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; RADICE M, 1991, ACTA CARDIOL, V46, P207; SAGIE A, 1993, NEW ENGL J MED, V329, P1912, DOI 10.1056/NEJM199312233292602; SUGGS TF, 1990, J OCCUP ENVIRON MED, V32, P220, DOI 10.1097/00043764-199003000-00008; Wandel J C, 1990, Appl Nurs Res, V3, P122, DOI 10.1016/S0897-1897(05)80129-6	15	21	21	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					937	939		10.7326/0003-4819-122-12-199506150-00008	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755230				2022-12-28	WOS:A1995RC27000008
J	MEEHAN, TP; HENNEN, J; RADFORD, MJ; PETRILLO, MK; ELSTEIN, P; BALLARD, DJ				MEEHAN, TP; HENNEN, J; RADFORD, MJ; PETRILLO, MK; ELSTEIN, P; BALLARD, DJ			PROCESS AND OUTCOME OF CARE FOR ACUTE MYOCARDIAL-INFARCTION AMONG MEDICARE BENEFICIARIES IN CONNECTICUT - A QUALITY IMPROVEMENT DEMONSTRATION PROJECT	ANNALS OF INTERNAL MEDICINE			English	Article								Objective: To evaluate the feasibility of linking claims-based pattern analysis with medical record review in the assessment of quality of hospital care among Medicare beneficiaries with acute myocardial infarction. Design: An analysis of risk-adjusted mortality after hospital admission for acute myocardial infarction using the regression model from the Health Care Financing Administration for predicting mortality rates. Hospital records for 300 patients admitted for myocardial infarction were abstracted to evaluate the accuracy of diagnostic coding and the adequacy of claims data-based risk adjustment and to assess process measures of quality care. Setting: Six Connecticut hospitals in the pilot study of the Medicare Hospital information Project. Patients: Medicare beneficiaries 65 years of age or older who were hospitalized with a primary diagnosis of acute myocardial infarction from 1989 to 1991. Main Outcome Measures: Principal diagnosis code verification rates for acute myocardial infarction; observed mortality rates at 30 and 365 days; 30-day standardized mortality ratios; and utilization rates for thrombolytic agents, aspirin, and beta-blockers. Results: The coding of acute myocardial infarction diagnosis had an overall accuracy of 96%. Little change was noted in relative mortality ratio hospital rank order after the exclusion of 13 patients who did not fulfill criteria for acute myocardial infarction and after additional risk adjustment with Killip class data. Utilization rates for therapies among eligible patients were as follows: aspirin, 73%; beta-blockers, 41%; and thrombolytic agents, 43%. The use of thrombolytic agents was associated with a lower 30-day mortality; the use of thrombolytic agents, aspirin, and beta-blockers was related to lower mortality rates at 1 year after discharge; and the use of these three therapies was lower in the two hospitals with the highest risk-adjusted mortality. Conclusions: Medicare principal diagnosis codes for acute myocardial infarction were accurate in the six study hospitals. Therapies that have been endorsed by clinicians in Connecticut were underused in elderly patients. Pattern analysis of Medicare claims data can be useful as a quality-of-care screening tool; however, additional clinical information is required to stimulate quality improvement efforts within hospitals.	EMORY UNIV, CTR CLIN EVALUAT SCI, DECATUR, GA 30030 USA; CONNECTICUT PEER REVIEW ORG, MIDDLETOWN, CT 06457 USA; KERR L WHITE INST HLTH SERV RES, DECATUR, GA USA; UNIV CONNECTICUT, SCH MED, FARMINGTON, CT USA; US HLTH CARE FINANCING ADM, OFF PROGRAM ASSESSMENT & INFORMAT, BALTIMORE, MD 21207 USA	Emory University; University of Connecticut			Ballard, David J/H-1062-2018	Radford, Martha/0000-0001-7503-9557				BALLARD DJ, 1994, HEALTH SERV RES, V28, P771; BERWICK DM, 1990, JAMA-J AM MED ASSOC, V263, P247, DOI 10.1001/jama.263.2.247; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Corn R F, 1981, Inquiry, V18, P351; COX DR, 1972, J R STAT SOC B, V34, P187; DEMLO LK, 1978, MED CARE, V16, P995, DOI 10.1097/00005650-197812000-00003; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Feldman S E, 1993, Med Care Rev, V50, P123, DOI 10.1177/107755879305000202; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; Hayes R P, 1994, Med Care Rev, V51, P39, DOI 10.1177/107755879405100103; HAYES RP, 1994, CLIN PERFORMANCE QUA, V2, P233; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KRAKAUER H, 1991, STAT MED, V10, P521, DOI 10.1002/sim.4780100405; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; NASH DB, 1992, JAMA-J AM MED ASSOC, V268, P917, DOI 10.1001/jama.268.7.917; SULLIVAN LW, 1992, MEDICARE HOSPITAL S, V55	19	57	57	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					928	936		10.7326/0003-4819-122-12-199506150-00007	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RC270	7755229				2022-12-28	WOS:A1995RC27000007
J	ABBOTT, J; JOHNSON, R; KOZIOLMCLAIN, J; LOWENSTEIN, SR				ABBOTT, J; JOHNSON, R; KOZIOLMCLAIN, J; LOWENSTEIN, SR			DOMESTIC VIOLENCE AGAINST WOMEN - INCIDENCE AND PREVALENCE IN AN EMERGENCY DEPARTMENT POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAGE QUESTIONNAIRE; BATTERED WOMEN; ABUSE; PREGNANCY; MEDICINE; INJURIES; VICTIMS; CARE; RISK	Objective.-To determine the incidence, 1-year prevalence, and cumulative prevalence of domestic violence (DV) among female emergency department (ED) patients. Design.-Descriptive written survey. Setting.-Two teaching EDs, two hospital walk-in clinics, and one private hospital ED in Denver, Colo. Participants.-Of 833 women presenting during 30 randomly selected 4-hour time blocks, 648 (78%) agreed to participate. Most respondents were young (median age, 34 years) and unemployed (62%); half (49%) had annual household incomes less than $10 000. Main Outcome Measures.-Domestic violence was defined as an assault, threat, or intimidation by a male partner. Acute DV (incidence) and past DV exposure (1-year prevalence and cumulative prevalence) were determined. Results.-The incidence of acute DV among the 418 women with a current male partner was 11.7% (95% confidence interval [CI], 8.7% to 15.2%). Only 11 (23%) of these 47 women subjected to acute DV presented for care because of trauma, and only six (13%) either told staff about DV or were asked about DV by ED professionals. Among 230 women without current partners, 13 (5.6%) reported an episode of DV within the previous 30 days. For the entire sample, the cumulative lifetime prevalence of DV exposure was 54.2% (95% CI, 50.2% to 58.1%). Women exposed to acute or prior DV were more likely than unexposed women to have made suicide attempts (26% vs 8%; P<.001) and to report excessive ethanol use (24% vs 13%; P=.001). Conclusions.-The incidence of acute DV is not as common among women visiting an ED as previously reported, although the cumulative prevalence of DV is strikingly high. Women who have experienced DV are seldom identified by ED professionals.	MEM HOSP,COLORADO SPRINGS,CO		ABBOTT, J (corresponding author), UNIV COLORADO,HLTH SCI CTR,COLORADO EMERGENCY MED RES CTR,DIV EMERGENCY MED,4200 E 9TH AVE,DENVER,CO 80262, USA.			Koziol-McLain, Jane/0000-0003-3453-023X				APPLETON W, 1980, ANN EMERG MED, V9, P84, DOI 10.1016/S0196-0644(80)80336-2; BERRIOS DC, 1991, WESTERN J MED, V155, P133; BUSH B, 1987, AM J MED, V82, P231, DOI 10.1016/0002-9343(87)90061-1; CAMPBELL JC, 1986, ADV NURS SCI, V8, P36, DOI 10.1097/00012272-198607000-00006; CHEZ RA, 1988, AM J OBSTET GYNECOL, V158, P1; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; GIN NE, 1991, J GEN INTERN MED, V6, P317, DOI 10.1007/BF02597429; GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P3259, DOI 10.1001/jama.251.24.3259; HAACK D, 1992, SUGGESTED PROTOCOLS; Hamberger L K, 1992, Fam Med, V24, P283; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; HUDSON WW, 1981, J MARRIAGE FAM, P873; ISAAC NE, 1994, ANN EMERG MED, V23, P855, DOI 10.1016/S0196-0644(94)70325-6; JONES RF, 1993, OBSTET GYNECOL, V81, P1; MARWICK C, 1994, JAMA-J AM MED ASSOC, V271, P1147; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; MCLEER SV, 1987, ANN EMERG MED, V16, P1151; NILSSEN O, 1994, J TRAUMA, V36, P784, DOI 10.1097/00005373-199406000-00006; PARKER B, 1993, NURS RES, V42, P173; RANDALL T, 1990, JAMA-J AM MED ASSOC, V264, P939, DOI 10.1001/jama.264.8.939; Rath G D, 1989, J Am Board Fam Pract, V2, P227; ROBERTS GL, 1993, MED J AUSTRALIA, V159, P307, DOI 10.5694/j.1326-5377.1993.tb137866.x; STARK E, 1979, INT J HEALTH SERV, V9, P461, DOI 10.2190/KTLU-CCU7-BMNQ-V2KY; Stark E., 1988, HDB FAMILY VIOLENCE, P293; STARK E, 1992, MAXCYROSENEAU TXB PR, P1040; STARK E, 1981, WIFE ABUSE MED SETTI; Warshaw C, 1989, GENDER SOC, V3, P506, DOI 10.1177/089124389003004008; 1994, POSITION STATEMENT D	29	462	467	0	42	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1763	1767		10.1001/jama.273.22.1763	http://dx.doi.org/10.1001/jama.273.22.1763			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB800	7769770				2022-12-28	WOS:A1995RB80000029
J	CRAVATT, BF; PROSPEROGARCIA, O; SIUZDAK, G; GILULA, NB; HENRIKSEN, SJ; BOGER, DL; LERNER, RA				CRAVATT, BF; PROSPEROGARCIA, O; SIUZDAK, G; GILULA, NB; HENRIKSEN, SJ; BOGER, DL; LERNER, RA			CHEMICAL CHARACTERIZATION OF A FAMILY OF BRAIN LIPIDS THAT INDUCE SLEEP	SCIENCE			English	Article							FATTY-ACID AMIDES	A molecule isolated from the cerebrospinal fluid of sleep-deprived cats has been chemically characterized and identified as cis-9,10-octadecenoamide. Other fatty acid primary amides in addition to cis-9,10-octadecenoamide were identified as natural constituents of the cerebrospinal fluid of cat, rat, and human, indicating that these compounds compose a distinct family of brain lipids. Synthetic cis-9,10-octadecenoamide induced physiological sleep when injected into rats. Together, these results suggest that fatty acid primary amides may represent a previously unrecognized class of biological signaling molecules.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Siuzdak, Gary/0000-0002-4749-0014	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR07273-01] Funding Source: Medline; NIDA NIH HHS [R01 DA015648] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARAFAT ES, 1989, LIFE SCI, V45, P1679, DOI 10.1016/0024-3205(89)90278-6; CHRISTIE WW, 1973, LIPID ANAL, P128; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DEVANE WA, 1994, P NATL ACAD SCI USA, V91, P6698, DOI 10.1073/pnas.91.14.6698; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; GENARD S, 1991, B SOC CHIM FR, P397; INOUE S, 1989, BIOL SLEEP SUBSTANCE; JAIN MK, 1992, J MED CHEM, V35, P3584, DOI 10.1021/jm00097a018; LERNER RA, 1994, P NATL ACAD SCI USA, V91, P9505, DOI 10.1073/pnas.91.20.9505; PRIVETT OS, 1966, PROGR CHEMISTRY FATS, V9, P91; PROSPEROGARCIA O, 1994, PHARMACOL BIOCHEM BE, V49, P413, DOI 10.1016/0091-3057(94)90442-1; SCHOENENBERGER GA, 1984, EUR NEUROL, V23, P321, DOI 10.1159/000115711; UENO R, 1982, BIOCHEM BIOPH RES CO, V109, P576, DOI 10.1016/0006-291X(82)91760-0; WAKAMATSU K, 1990, BIOCHEM BIOPH RES CO, V168, P423, DOI 10.1016/0006-291X(90)92338-Z	14	535	565	1	35	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1506	1509		10.1126/science.7770779	http://dx.doi.org/10.1126/science.7770779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770779				2022-12-28	WOS:A1995RC19000043
J	WHITE, N; COHEN, S				WHITE, N; COHEN, S			TRADEMARKS MUST NOT GO GENERIC	NATURE			English	Editorial Material											WHITE, N (corresponding author), TAYLOR JOYNSON GARRETT,50 VICTORIA EMBANKMENT,LONDON EC4Y 0DX,ENGLAND.							1995, NATURE, V373, P370; 1995, NATURE, V374, P208	2	1	1	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					432	432		10.1038/375432a0	http://dx.doi.org/10.1038/375432a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760941	Bronze			2022-12-28	WOS:A1995RB10100063
J	JABRI, E; CARR, MB; HAUSINGER, RP; KARPLUS, PA				JABRI, E; CARR, MB; HAUSINGER, RP; KARPLUS, PA			THE CRYSTAL-STRUCTURE OF UREASE FROM KLEBSIELLA-AEROGENES	SCIENCE			English	Article							JACK-BEAN UREASE; SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; HELICOBACTER-PYLORI; BETA-MERCAPTOETHANOL; PROTEIN-STRUCTURE; EC 3.5.1.5; NICKEL; GENES; SEQUENCE	The crystal structure of urease from Klebsiella aerogenes has been determined at 2.2 Angstrom resolution and refined to an R factor of 18.2 percent. The enzyme contains four structural domains: three with novel folds playing structural roles, and an (alpha beta)8 barrel domain, which contains the bi-nickel center. The two active site nickels are 3.5 Angstrom apart. One nickel ion is coordinated by three ligands (with low occupancy of a fourth ligand) and the second is coordinated by five ligands. A carbamylated lysine provides an oxygen ligand to each nickel, explaining why carbon dioxide is required for the activation of urease apoenzyme. The structure is compatible with a catalytic mechanism whereby urea ligates Ni-1 to complete its tetrahedral coordination and a hydroxide ligand of Ni-2 attacks the carbonyl carbon. A surprisingly high structural similarity between the urease catalytic domain and that of the zinc-dependent adenosine deaminase reveals a remarkable example of active site divergence.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Cornell University; Michigan State University; Michigan State University				Karplus, Paul/0000-0001-8725-6292; Hausinger, Robert/0000-0002-3643-2054; Jabri, Evelyn/0000-0002-5117-1892	NIGMS NIH HHS [5T32-GM08384-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008384] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER J, 1993, SCIENCE, V260, P159, DOI 10.1126/science.8469968; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BENNING MM, 1994, BIOCHEMISTRY-US, V33, P15001, DOI 10.1021/bi00254a008; BLAKELEY RL, 1983, BIOCHIM BIOPHYS ACTA, V744, P219, DOI 10.1016/0167-4838(83)90094-8; BOUTONNET NS, 1994, PROTEIN SCI, V3, P769; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CARR MB, IN PRESS MECHANISMS; CHOTHIA C, 1986, EMBO J, V4, P823; CLAYTON CL, 1990, NUCLEIC ACIDS RES, V18, P362, DOI 10.1093/nar/18.2.362; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DICKERSO.RE, 1968, ACTA CRYSTALL B-STRU, VB 24, P997, DOI 10.1107/S0567740868003626; DIXON NE, 1975, J AM CHEM SOC, V97, P4131, DOI 10.1021/ja00847a045; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P1335, DOI 10.1139/o80-181; DIXON NE, 1980, CAN J BIOCHEM CELL B, V58, P481, DOI 10.1139/o80-064; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FARBER GK, 1993, CURR OPIN STRUC BIOL, V3, P409, DOI 10.1016/S0959-440X(05)80114-9; FINNEGAN MG, 1991, J AM CHEM SOC, V113, P4030, DOI 10.1021/ja00010a076; GRIFFITH DP, 1979, UROL RES, V7, P215; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HARTMAN FC, 1993, ANNU REV BIOCHEM, V63, P197; HAUSINGER RP, 1993, BIOCH NICKEL, pCH4; Hausinger RP, 1993, BIOCH NICKEL; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JABRI E, 1992, J MOL BIOL, V227, P934, DOI 10.1016/0022-2836(92)90232-9; JABRI E, UNPUB; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSE J, 1991, FEMS MICROBIOL LETT, V80, P277, DOI 10.1111/j.1574-6968.1991.tb04675.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LABIGNE A, 1991, J BACTERIOL, V173, P1920, DOI 10.1128/jb.173.6.1920-1931.1991; LEE A, 1993, INFECT IMMUN, V61, P1601, DOI 10.1128/IAI.61.5.1601-1610.1993; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARTIN PR, 1992, J BIOL CHEM, V267, P20024; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOBLEY HLT, 1989, MICROBIOL REV, V53, P85, DOI 10.1128/MMBR.53.1.85-108.1989; MOBLEY HLT, IN PRESS MICROBIOL R; MULROONEY SB, 1990, J BACTERIOL, V172, P5837, DOI 10.1128/jb.172.10.5837-5843.1990; PARK IS, 1995, SCIENCE, V267, P1156, DOI 10.1126/science.7855593; PARK IS, 1993, PROTEIN SCI, V2, P1034, DOI 10.1002/pro.5560020616; PARK IS, 1993, J PROTEIN CHEM, V12, P51, DOI 10.1007/BF01024914; Polacco Joseph C., 1993, V145, P65; READ RJ, 1990, ACTA CRYSTALLOGR A, V46, P900, DOI 10.1107/S0108767390005529; REARDON D, IN PRESS FASEB J; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Sumner JB, 1926, J BIOL CHEM, V69, P435; TAKISHIMA K, 1988, EUR J BIOCHEM, V175, P151, DOI 10.1111/j.1432-1033.1988.tb14177.x; TODD MJ, 1989, J BIOL CHEM, V264, P15835; TODD MJ, 1987, J BIOL CHEM, V262, P5963; TODD MJ, 1991, J BIOL CHEM, V266, P10260; TODD MJ, 1991, J BIOL CHEM, V266, P24327; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WANG S, 1993, INORG CHEM, V33, P1589; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; 1994, ACTA CRYSTALLOGR, V50, P760	60	737	776	6	100	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 19	1995	268	5213					998	1004		10.1126/science.7754395	http://dx.doi.org/10.1126/science.7754395			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QY934	7754395				2022-12-28	WOS:A1995QY93400026
J	BERNINI, JC; FORT, DW; GRIENER, JC; KANE, BJ; CHAPPELL, WB; KAMEN, BA				BERNINI, JC; FORT, DW; GRIENER, JC; KANE, BJ; CHAPPELL, WB; KAMEN, BA			AMINOPHYLLINE FOR METHOTREXATE-INDUCED NEUROTOXICITY	LANCET			English	Article							CHILDHOOD LEUKEMIA; ADENOSINE; FOLATE; ACCUMULATION; INHIBITOR; THERAPY; TISSUE; BRAIN; ACID	Methotrexate, a mainstay treatment for children with acute lymphoblastic leukaemia, can cause neurotoxicity, with paralysis, seizures, somnolence, anorexia, and headaches. The pathophysiology of this reaction is unknown. It has been suggested that the anti-inflammatory effect of methotrexate in patients with arthritis is due to adenosine release brought on by inhibition of purine synthesis. Since adenosine is a central nervous system depressant, we wondered whether adenosine release in the central nervous system could account for some of the neurotoxicity due to methotrexate, and whether that toxicity could be lessened by displacement of adenosine from its receptor by aminophylline. 6 patients (age 3-16 years) who had methotrexate-induced neurotoxicity unresponsive to standard treatment received 2.5 mg/kg aminophylline. In addition, the concentration of adenosine in the cerebrospinal fluid (CSF) from 11 children completing a 24-h systemic methotrexate protocol was compared with that in 8 newly diagnosed patients and 12 who had not received any treatment for at least a week. 4 of 6 patients with toxic signs and symptoms attributed to methotrexate and unrelieved by steroids, epidural blood patch, promethazine, 5-hydroytryptamine antagonists, paracetamol, and narcotics, had complete resolution of neurotoxicity after or during a l-h infusion of aminophylline; 2 others had a pronounced improvement but persistent nausea. CSF adenosine concentrations of patients receiving methotrexate, even when there was very slight or no toxicity, were greatly increased compared with control subjects (mean values of 217 and 51 nmol/L, median 175 and 52 nmol/L). Subacute methotrexate neurotoxicity may be mediated by adenosine and relieved by aminophylline.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; CHILDRENS MED CTR,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; BAKER WJ, 1991, J CLIN ONCOL, V9, P679, DOI 10.1200/JCO.1991.9.4.679; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; BLEYER WA, 1981, CANCER TREAT REP, V65, P89; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CAMITTA B, 1989, J CLIN ONCOL, V7, P1539, DOI 10.1200/JCO.1989.7.10.1539; CASH JM, 1994, NEW ENGL J MED, V330, P1368; CHEN LS, 1992, J CHROMATOGRPAHY, V16, P2791; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; GREGORIOS JB, 1990, BRAIN RES, V516, P20, DOI 10.1016/0006-8993(90)90892-F; HEDQVIST P, 1978, CIRC RES, V43, P592, DOI 10.1161/01.RES.43.4.592; HERRMANN SC, 1992, J CHROMATOGR-BIOMED, V574, P247, DOI 10.1016/0378-4347(92)80036-P; JACOBSON KA, 1991, BIOCHEM PHARMACOL, V41, P1399, DOI 10.1016/0006-2952(91)90555-J; JONSSON OG, 1991, CANCER INVEST, V9, P53, DOI 10.3109/07357909109032800; KAMEN BA, 1984, CANCER RES, V44, P5092; KAMEN BA, 1986, NEUROTOXICOLOGY, V7, P209; KAMEN BA, 1987, METABOLISM ACTION AN, P141; KANE BJ, 1992, ANN PHARMACOTHER, V26, P939, DOI 10.1177/106002809202600718; KREMER JM, 1992, ARTHRITIS RHEUM, V35, P138, DOI 10.1002/art.1780350203; LUCOCK MD, 1993, NEUROCHEM RES, V18, P617, DOI 10.1007/BF00966940; Mastrangelo R, 1983, CENTRAL NERVOUS SYST, P71; MCINTOSH S, 1976, CANCER-AM CANCER SOC, V37, P853, DOI 10.1002/1097-0142(197602)37:2<853::AID-CNCR2820370234>3.0.CO;2-Q; MCLEAN AM, 1990, J PHARM SCI, V79, P1005, DOI 10.1002/jps.2600791112; OCHS JJ, 1989, AM J PEDIAT HEMATOL, V11, P93; OLNEY JW, 1981, NATURE, V292, P165, DOI 10.1038/292165a0; RALL T W, 1990, P618; SOLLEVI A, 1986, PROG NEUROBIOL, V27, P319, DOI 10.1016/0301-0082(86)90005-5; WINICK N, 1990, CANCER THER CONTROL, V1, P245; WINICK NJ, 1987, CANC DRUG DEL, V4, P25, DOI 10.1089/cdd.1987.4.25	30	111	116	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					544	547		10.1016/S0140-6736(95)90464-6	http://dx.doi.org/10.1016/S0140-6736(95)90464-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776773				2022-12-28	WOS:A1995QK44400009
J	OVERGAARD, J; GONZALEZ, DG; HULSHOF, MCCM; ARCANGELI, G; DAHL, O; MELLA, O; BENTZEN, SM				OVERGAARD, J; GONZALEZ, DG; HULSHOF, MCCM; ARCANGELI, G; DAHL, O; MELLA, O; BENTZEN, SM			RANDOMIZED TRIAL OF HYPERTHERMIA AS ADJUVANT TO RADIOTHERAPY FOR RECURRENT OR METASTATIC MALIGNANT-MELANOMA	LANCET			English	Article							COMBINED RADIATION-THERAPY; ONCOLOGY-GROUP; COMPLICATIONS; IRRADIATION	The value of hyperthermia as an adjuvant to radiotherapy in patients with malignant melanoma was studied in European multicentre trial. 134 metastatic or recurrent lesions of malignant melanoma in 70 patients were randomly assigned to receive radiotherapy (three fractions of 8 Gy or 9 Gy in 8 days) alone or followed by hyperthermia (43 degrees C for 60 min). Overall, the 2-year actuarial local tumour control was 37(SE 5)%. Univariate analysis showed a beneficial effect of hyperthermia (radiation alone 28% vs combined treatment 46%, p=0.008) and radiation dose (24 Gy 25% vs 27 Gy 56%, p=0.02), but no effect of tumour size (less than or equal to 4 cm 42% vs >4 cm 29%, p=021). Cox multivariate regression analysis showed the most important prognostic variables to be hyperthermia (odds ratio for 2-year local control 1.73 [95% CI 1.07-2.78], p=0.023), tumour size (0.91 [0.85-0.99], p=0.05), and radiation dose (1.17 [1.01-1.36], p=0.05). Addition of heat did not significantly increase acute or late radiation reactions. Heating was well tolerated, but because of difficulties with equipment only 14% of treatments achieved the protocol objective. The overall 5-year survival rate was 19%, but 38% of the patients for whom all known disease was controlled survived 5 years. Adjuvant hyperthermia significantly improved local tumour control when applied in association with radiation in treatment of malignant melanoma. Successful local treatment of patients with a single or a few metastatic malignant melanoma lesions has significant curative potential.	AARHUS UNIV HOSP,DEPT ONCOL,DK-8000 AARHUS,DENMARK; ACAD MED CTR,DEPT RADIOTHERAPY,AMSTERDAM,NETHERLANDS; G PORFIRI ONCOL CTR,DEPT RADIOTHERAPY,LATINA,ITALY; HAUKELAND HOSP,DEPT ONCOL,N-5021 BERGEN,NORWAY	Aarhus University; University of Amsterdam; Academic Medical Center Amsterdam; University of Bergen; Haukeland University Hospital	OVERGAARD, J (corresponding author), DANISH CANC SOC,DEPT EXPTL CLIN ONCOL,RADIUMSTN,NORREBROGADE 44,DK-8000 AARHUS C,DENMARK.		Bentzen, Søren M/E-3997-2012; Bentzen, Soren M/O-7787-2019	Bentzen, Søren M/0000-0002-7444-7564; Bentzen, Soren M/0000-0002-7444-7564; Hulshof, Maarten CCM/0000-0001-5240-3467				BENTZEN SM, 1989, RADIOTHER ONCOL, V16, P169, DOI 10.1016/0167-8140(89)90017-0; BENYOSEF R, 1992, INT J HYPERTHER, V8, P733, DOI 10.3109/02656739209005021; BERDEAUX DH, 1985, CANCER TREAT REP, V69, P397; BLOIS MS, 1983, CANCER-AM CANCER SOC, V52, P1330, DOI 10.1002/1097-0142(19831001)52:7<1330::AID-CNCR2820520732>3.0.CO;2-M; COX RS, 1992, INT J HYPERTHER, V8, P719, DOI 10.3109/02656739209005020; DEWHIRST MW, 1993, J NATL CANCER I, V85, P951, DOI 10.1093/jnci/85.12.951; ENGIN K, 1992, INT J RADIAT ONCOL, V25, P87; GONZALEZ DG, 1986, RADIOTHER ONCOL, V6, P105, DOI 10.1016/S0167-8140(86)80016-0; HAND JW, 1989, INT J HYPERTHER, V5, P421, DOI 10.3109/02656738909140469; KIM JH, 1982, CANCER-AM CANCER SOC, V50, P478, DOI 10.1002/1097-0142(19820801)50:3<478::AID-CNCR2820500316>3.0.CO;2-6; LEE YTNM, 1980, CANCER TREAT REV, V7, P59; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; OVERETT TK, 1985, CANCER, V56, P1222, DOI 10.1002/1097-0142(19850901)56:5<1222::AID-CNCR2820560544>3.0.CO;2-A; OVERGAARD J, 1989, INT J RADIAT ONCOL, V16, P535, DOI 10.1016/0360-3016(89)90470-7; OVERGAARD J, 1986, INT J RADIAT ONCOL, V12, P867, DOI 10.1016/0360-3016(86)90378-0; OVERGAARD J, 1987, INT J HYPERTHER, V3, P483, DOI 10.3109/02656738709140422; OVERGAARD J, 1986, RADIOTHER ONCOL, V5, P183, DOI 10.1016/S0167-8140(86)80048-2; OVERGAARD J, 1987, STRAHLENTHER ONKOL, V163, P453; OVERGAARD J, 1990, INTRO PRACTICAL ASPE, P213; OVERGAARD J, 1990, PIGMENT CELL, V10, P14; OVERGAARD M, 1987, RADIOTHER ONCOL, V9, P1, DOI 10.1016/S0167-8140(87)80213-X; PEREZ CA, 1991, AM J CLIN ONCOL-CANC, V14, P133, DOI 10.1097/00000421-199104000-00008; PEREZ CA, 1989, INT J RADIAT ONCOL, V16, P551, DOI 10.1016/0360-3016(89)90471-9; 1978, ICRU29 INT COMM RAD	24	457	466	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					540	543		10.1016/S0140-6736(95)90463-8	http://dx.doi.org/10.1016/S0140-6736(95)90463-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776772				2022-12-28	WOS:A1995QK44400008
J	BURNS, JP; REARDON, FE; TRUOG, RD				BURNS, JP; REARDON, FE; TRUOG, RD			USING NEWLY DECEASED PATIENTS TO TEACH RESUSCITATION PROCEDURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONSENT; INFANTS		HASSAN & REARDON, BOSTON, MA 02116 USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital	BURNS, JP (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV PEDIAT CRIT CARE, NEMC 93, 750 WASHINGTON ST, BOSTON, MA 02111 USA.		Burns, Jeffrey P/AAW-8474-2021					ABRAMSON NS, 1981, JAMA-J AM MED ASSOC, V246, P2828; BENFIELD DG, 1991, JAMA-J AM MED ASSOC, V265, P2360, DOI 10.1001/jama.265.18.2360; BRATTEBO G, 1988, LANCET, V2, P1078; Clayton M., 1992, DRAWINGS COLLECTION; FEINBERG J, 1985, HASTINGS CENT REP, V15, P31, DOI 10.2307/3561915; Iserson K V, 1991, J Emerg Med, V9, P509, DOI 10.1016/0736-4679(91)90225-5; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; MAY WF, 1985, HASTINGS CENT REP, V15, P38, DOI 10.2307/3561916; MORHAIM D K, 1991, Journal of Emergency Medicine, V9, P515, DOI 10.1016/0736-4679(91)90233-6; Orlowski J P, 1990, J Clin Ethics, V1, P201; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; ROELS L, 1991, TRANSPLANT P, V23, P903; ROSNER F, 1991, MODERN MED JEWISH ET, P313; TACHAKRA SS, 1991, JAMA-J AM MED ASSOC, V266, P1649, DOI 10.1001/jama.1991.03470120051027; 1991, JAMA-J AM MED ASSOC, V266, P2837; 1993, AM MED NEWS     0322, P10	16	46	46	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1652	1655		10.1056/NEJM199412153312411	http://dx.doi.org/10.1056/NEJM199412153312411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7772111				2022-12-28	WOS:A1994PW44600011
J	PEPPELENBOSCH, MP; QIU, RG; DEVRIESSMITS, AMM; TERTOOLEN, LGJ; DELAAT, SW; MCCORMICK, F; HALL, A; SYMONS, MH; BOS, JL				PEPPELENBOSCH, MP; QIU, RG; DEVRIESSMITS, AMM; TERTOOLEN, LGJ; DELAAT, SW; MCCORMICK, F; HALL, A; SYMONS, MH; BOS, JL			RAC MEDIATES GROWTH FACTOR-INDUCED ARACHIDONIC-ACID RELEASE	CELL			English	Article							SIGNAL-REGULATED KINASE-2; RHO GENE-PRODUCT; PROTEIN; ACTIN; PHOSPHOLIPASE-A2; ACTIVATION; P21RAS; CELLS; IDENTIFICATION; FIBROBLASTS	Growth factor-induced stress fiber formation involves signal transduction through Rac and Rho proteins and production of leukotrienes from arachidonic acid metabolism. In exploring the relationship between these pathways, we found that Rac is essential for EGF-induced arachidonic acid production and subsequent generation of leukotrienes and that Rac V12, a constitutively activated mutant of Rac, generates leukotrienes in a growth factor-independent manner. Leukotrienes generated by EGF or Rac V12 are necessary and sufficient for stress fiber formation. Furthermore, leukotriene-dependent stress fiber formation requires Rho proteins. We have therefore identified elements of a pathway from growth factor receptors that includes Rac, arachidonic acid production, arachidonic acid metabolism to leukotrienes, and leukotriene-dependent Rho activation. This appears to be the major pathway by which Rac influences Rho-dependent cytoskeleton rearrangements.	UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS; ONYX PHARMACEUT, RICHMOND, CA 94806 USA; NETHERLANDS INST DEV BIOL, HUBRECHT LAB, 3584 CT UTRECHT, NETHERLANDS; UCL, MRC, MOLEC CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of London; University College London; University of London; University College London				Peppelenbosch, Maikel/0000-0001-9112-6028				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BRETCHER A, 1989, J CELL BIOL, V64, P573; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DOMIN J, 1993, J BIOL CHEM, V268, P8927; DOWNEY GP, 1990, J CELL BIOL, V110, P1975, DOI 10.1083/jcb.110.6.1975; GILLARD J, 1989, CAN J PHYSIOL PHARM, V67, P456, DOI 10.1139/y89-073; GOLDBERG H, 1994, BIOCHEM BIOPH RES CO, V198, P220, DOI 10.1006/bbrc.1994.1031; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HABETS GGM, 1994, CELL, V77, P539; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; NOBES CD, 1995, J CELL SCI, V108, P225; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SPAARGAREN M, 1992, BIOCHEM J, V287, P37, DOI 10.1042/bj2870037; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; WARNER LC, 1993, ONCOGENE, V8, P3249; XU XX, 1994, J BIOL CHEM, V269, P31693	34	197	198	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 16	1995	81	6					849	856		10.1016/0092-8674(95)90005-5	http://dx.doi.org/10.1016/0092-8674(95)90005-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781062	Bronze			2022-12-28	WOS:A1995RD76800006
J	SU, TT; FOLLETTE, PJ; OFARRELL, PH				SU, TT; FOLLETTE, PJ; OFARRELL, PH			QUALIFYING FOR THE LICENSE TO REPLICATE	CELL			English	Review							CELL-CYCLE; DNA-SYNTHESIS; MITOSIS; PROTEINS; FAMILY				SU, TT (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Follette, Peter/0000-0003-1791-4960; O'Farrell, Patrick/0000-0003-0011-2734	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM037193, R01 GM037193-10] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CHONG JPC, 1995, IN PRESS NATURE; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MADINE MA, 1995, IN PRESS NATURE; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; SAUER K, 1995, IN PRESS GENES DEV; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; TREISMAN JE, 1995, IN PRESS GENES DEV; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275	21	47	48	0	0	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					825	828		10.1016/0092-8674(95)90000-4	http://dx.doi.org/10.1016/0092-8674(95)90000-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781058	Bronze, Green Accepted			2022-12-28	WOS:A1995RD76800001
J	CASANO, AA				CASANO, AA			REIMBURSEMENT OVER THE ATLANTIC	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											CASANO, AA (corresponding author), ALBANY MED CTR, A38, 47 NEW SCOTLAND AVE, ALBANY, NY 12208 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					957	958		10.7326/0003-4819-122-12-199506150-00012	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755234				2022-12-28	WOS:A1995RC27000012
J	ROEGGLA, G; ROEGGLA, H; ROEGGLA, M; BINDER, M; LAGGNER, AN				ROEGGLA, G; ROEGGLA, H; ROEGGLA, M; BINDER, M; LAGGNER, AN			EFFECT OF ALCOHOL ON ACUTE VENTILATORY ADAPTATION TO MILD HYPOXIA AT MODERATE ALTITUDE	ANNALS OF INTERNAL MEDICINE			English	Note							ACUTE MOUNTAIN-SICKNESS	Objective: To evaluate the influence of alcohol on acute adaptation to mild hypoxia at moderate altitude. Design: Randomized, double-blind, placebo-controlled crossover trial. Setting: University clinic and mountaineering resort at altitudes of 171 m and 3000 m, respectively, in the Austrian Alps. Participants: 10 healthy male alpinists, 22 to 24 years of age. Intervention: Single dose of 50 g of alcohol or placebo at altitudes of 171 m and 3000 m. Main Outcome Measures: Arterial oxygen pressure (PaO2) and arterial carbon dioxide pressure (PaCO2) before and 1 hour after consumption of alcohol or placebo. Results: At an altitude of 171 m, 50 g of alcohol caused no statistical change in PaO2 and PaCO2 (median PaO2, 91.5 compared with 90.5 mm Hg [P = 0.89]; median PaCO2, 37.5 compared with 36.0 mm Hg [P = 0.41]). At an altitude of 3000 m, the median PaO2 decreased from 69.0 to 64.0 mm Hg, a median decrease in the paired difference of 4.0 mm Hg (95.1% CI, 1.5 to 6.5 mm Hg; P < 0.01), and the median PaCO2 increased from 32.5 to 34.0 mm Hg, a median increase in the paired difference of 3.0 mm Hg (95.1% CI, 2.0 to 4.0 mm Hg; P < 0.01) 1 hour after drinking 50 g of alcohol. Placebo did not influence PaO2 or PaCO2 at either altitude. Conclusion: Alcohol inhibits the initial stages of adequate acute ventilatory adaptation to mild hypoxia at moderate altitude. Caution in the use of alcoholic beverages at moderate altitude is therefore necessary.			ROEGGLA, G (corresponding author), UNIV VIENNA, DEPT EMERGENCY MED, WAEHRINGER GUERTEL 18-20, VIENNA, AUSTRIA.							CAMPBELL MJ, 1988, BRIT MED J, V296, P1454, DOI 10.1136/bmj.296.6634.1454; ELLEHORN MJ, 1988, MED TOXICOL, P782; Hackett PH, 1989, MANAGEMENT WILDERNES, P1; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; HONIGMAN B, 1993, ANN INTERN MED, V118, P587, DOI 10.7326/0003-4819-118-8-199304150-00003; HOUSTON CS, 1987, GOING HIGHER STORY M; JOHNSON TS, 1988, NEW ENGL J MED, V319, P841, DOI 10.1056/NEJM198809293191306; KOSKINEN P, 1986, CLIN CARDIOL, V9, P479, DOI 10.1002/clc.4960091002; PITKIN AD, 1994, THORAX, V49, P364, DOI 10.1136/thx.49.4.364; ROEGGLA G, 1993, ANN INTERN MED, V119, P633, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00016; ROGGLA G, 1994, WIEN KLIN WOCHENSCHR, V106, P649; SPIRO SG, 1976, BRIT J DIS CHEST, V70, P263, DOI 10.1016/0007-0971(76)90042-5; WARD MP, 1989, HIGH ALTITUDE MED PH, P90	13	17	17	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					925	927		10.7326/0003-4819-122-12-199506150-00006	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755228				2022-12-28	WOS:A1995RC27000006
J	ISOMETSA, E; HENRIKSSON, M; MARTTUNEN, M; HEIKKINEN, M; ARO, H; KUOPPASALMI, K; LONNQVIST, J				ISOMETSA, E; HENRIKSSON, M; MARTTUNEN, M; HEIKKINEN, M; ARO, H; KUOPPASALMI, K; LONNQVIST, J			MENTAL-DISORDERS IN YOUNG AND MIDDLE-AGED MEN WHO COMMIT SUICIDE	BRITISH MEDICAL JOURNAL			English	Article							COMORBIDITY		HELSINKI UNIV,DEPT PSYCHIAT,HELSINKI,FINLAND	University of Helsinki	ISOMETSA, E (corresponding author), NATL PUBL HLTH INST,DEPT MENTAL HLTH,SF-00300 HELSINKI,FINLAND.							HENRIKSSON MM, 1993, AM J PSYCHIAT, V150, P935; LESAGE AD, 1994, AM J PSYCHIAT, V151, P1063; RICH CL, 1992, ACTA PSYCHIAT SCAND, V86, P335, DOI 10.1111/j.1600-0447.1992.tb03276.x; RICH CL, 1986, ARCH GEN PSYCHIAT, V43, P577; RUNESON B, 1989, ACTA PSYCHIAT SCAND, V79, P490, DOI 10.1111/j.1600-0447.1989.tb10292.x	5	53	55	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1366	1367		10.1136/bmj.310.6991.1366	http://dx.doi.org/10.1136/bmj.310.6991.1366			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB005	7787539	Green Published			2022-12-28	WOS:A1995RB00500022
J	MCLAREN, P; BALL, CJ				MCLAREN, P; BALL, CJ			TELEMEDICINE - LESSONS REMAIN UNHEEDED	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE	Telemedicine, the delivery of health care with the patient and health professional at different locations, has been around for over 30 years. Its driving force has been developments in communications technology, and as new communications systems are developed health applications are proposed such as supporting the delivery of primary health care to geographically remote areas or regions underserved through the maldistribution of professional expertise. Despite rapid technological advances, evaluations of such systems have been largely superficial, and more thorough evaluations have failed to show significant advantages for more advanced and expensive technology over older technology such as the telephone. Methods for evaluating the impact of particular technologies on the health care system need to be developed and clearer benefits shown in terms of improved standards of care.	LONDON HOSP,COLL MED,ACAD DEPT PSYCHIAT,LONDON E1 1BS,ENGLAND	University of London; Queen Mary University London	MCLAREN, P (corresponding author), UNITED MED & DENT SCH,LONDON SE1 9RT,ENGLAND.							BERGMAN R, 1993, HOSP HEALTH NETWORK, V10, P47; BRAUER GW, 1992, MED PROG TECHNOL, V18, P151; DUNNE V, 1977, HLTH SERVICES RES, V1, P19; GRUMET GW, 1979, AM J ORTHOPSYCHIAT, V49, P574, DOI 10.1111/j.1939-0025.1979.tb02643.x; HALLAM L, 1989, FAMILY PRACTITIONER, V6, P45; HOUSE AM, 1981, CAN MED ASSOC J, V124, P667; Ling R, 1993, J R Nav Med Serv, V79, P145; MARCUS AC, 1986, MED CARE, V24, P97, DOI 10.1097/00005650-198602000-00002; MOORE GR, 1975, NEW ENGL J MED, V13, P729; PRESTON J, 1992, HOSP COMMUNITY PSYCH, V43, P25; Rinde Eivind Vvar Nordrum, 1993, World Health Forum, V14, P71	11	42	42	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1390	1391		10.1136/bmj.310.6991.1390	http://dx.doi.org/10.1136/bmj.310.6991.1390			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB005	7787547	Green Published			2022-12-28	WOS:A1995RB00500032
J	STENTON, SC; SANDHU, PS; HENDRICK, DJ				STENTON, SC; SANDHU, PS; HENDRICK, DJ			INDUSTRIAL INJURY BENEFIT FOR OCCUPATIONAL ASTHMA IN NORTH-EAST OF ENGLAND	BRITISH MEDICAL JOURNAL			English	Article									NEWCASTLE GEN HOSP,REG UNIT OCCUPAT LUNG DIS,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND	Newcastle General Hospital	STENTON, SC (corresponding author), NEWCASTLE GEN HOSP,CHEST UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.							CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; LUCMALO J, 1991, AM REV RESPIR DIS, V143, P528; MEREDITH SK, 1994, OCCUP MED-OXFORD, V44, P183, DOI 10.1093/occmed/44.4.183; 1989, NI226 DEP HLTH SOC S	4	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 20	1995	310	6990					1299	1300		10.1136/bmj.310.6990.1299a	http://dx.doi.org/10.1136/bmj.310.6990.1299a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QZ860	7773044	Green Published			2022-12-28	WOS:A1995QZ86000022
J	TRAYNELIS, SF; HARTLEY, M; HEINEMANN, SF				TRAYNELIS, SF; HARTLEY, M; HEINEMANN, SF			CONTROL OF PROTON SENSITIVITY OF THE NMDA RECEPTOR BY RNA SPLICING AND POLYAMINES	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; EXCITATORY AMINO-ACIDS; PROTEIN-KINASE-C; HIPPOCAMPAL-NEURONS; SECONDARY-STRUCTURE; GLUCOSE DEPRIVATION; INDUCED CURRENTS; SINGLE-CHANNEL; RAT; GLUTAMATE	The function of the N-methyl-D-aspartate (NMDA)-preferring glutamate receptor can be regulated by extracellular pH, a process that may be important during ischemia in the brain or during seizures. Protons inhibit NMDA receptor function by 50 percent at pH 7.3 through interactions with the NR1 subunit, and both polyamines and NR1 exon 5 potentiate receptor function through relief of the tonic proton inhibition present at physiological pH. A single amino acid (lysine 211) was identified that mediates the effects of exon 5 in the rat brain. Electroneutral substitutions at this position restored pH sensitivity and, consequently, polyamine relief of tonic inhibition. This effect, together with the structural similarities between polyamines and the surface loop encoded by exon 5, suggest that exon 5 may act as a tethered pH-sensitive constitutive modulator of NMDA receptor function.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute	TRAYNELIS, SF (corresponding author), EMORY UNIV,DEPT PHARMACOL,ATLANTA,GA 30322, USA.				NINDS NIH HHS [NS28709, NS08549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028709] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANANTHARAM V, 1992, FEBS LETT, V305, P27, DOI 10.1016/0014-5793(92)80648-Z; ARANEDA RC, 1993, NEUROSCI LETT, V152, P107, DOI 10.1016/0304-3940(93)90495-7; BALESTRINO M, 1988, J PHYSIOL-LONDON, V396, P247, DOI 10.1113/jphysiol.1988.sp016961; BATES RG, 1978, ANAL CHEM, V50, P1295, DOI 10.1021/ac50031a026; BENVENISTE M, 1993, J PHYSIOL-LONDON, V464, P131, DOI 10.1113/jphysiol.1993.sp019627; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHRISTENSEN BN, 1990, NEURON, V5, P471, DOI 10.1016/0896-6273(90)90086-U; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; DINGLEDINE R, 1990, TRENDS PHARMACOL SCI, V11, P334, DOI 10.1016/0165-6147(90)90238-4; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; HIRSCHMAN SZ, 1967, BIOPOLYMERS, V5, P227, DOI 10.1002/bip.1967.360050209; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISHII T, 1993, J BIOL CHEM, V268, P2836; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MELDRUM BS, 1992, EPILEPSY RES, V12, P189, DOI 10.1016/0920-1211(92)90040-Z; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI N, 1992, P NATL ACAD SCI USA, V89, P8552, DOI 10.1073/pnas.89.18.8552; OBRENOVITCH TP, 1990, J NEUROPHYSIOL, V64, P1125, DOI 10.1152/jn.1990.64.4.1125; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS IJ, 1990, J PHARMACOL EXP THER, V255, P1001; ROCK DM, 1992, MOL PHARMACOL, V41, P83; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STANDAERT DG, 1993, NEUROSCI LETT, V152, P161, DOI 10.1016/0304-3940(93)90508-I; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TEMPLETON DM, 1985, CAN J CHEM, V63, P3122, DOI 10.1139/v85-515; TOMBAUGH GC, 1993, J NEUROCHEM, V61, P793, DOI 10.1111/j.1471-4159.1993.tb03589.x; TOMBAUGH GC, 1990, BRAIN RES, V506, P343, DOI 10.1016/0006-8993(90)91277-N; TRAYNELIS SF, 1991, J PHYSIOL-LONDON, V433, P727, DOI 10.1113/jphysiol.1991.sp018453; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; VYKLICKY L, 1990, J PHYSIOL-LONDON, V430, P497, DOI 10.1113/jphysiol.1990.sp018304; WILLIAMS K, 1994, MOL PHARMACOL, V46, P161; WILLIAMS K, 1990, NEURON, V5, P199, DOI 10.1016/0896-6273(90)90309-4; ZHANG L, 1994, P NATL ACAD SCI USA, V91, P10883, DOI 10.1073/pnas.91.23.10883; ZHENG X, 1994, NEURON, V12, P1	54	332	342	0	26	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 12	1995	268	5212					873	876		10.1126/science.7754371	http://dx.doi.org/10.1126/science.7754371			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX850	7754371				2022-12-28	WOS:A1995QX85000038
J	QUAGLIARELLO, VJ; VISCOLI, C; HORWITZ, RI				QUAGLIARELLO, VJ; VISCOLI, C; HORWITZ, RI			PRIMARY PREVENTION OF CRYPTOCOCCAL MENINGITIS BY FLUCONAZOLE IN HIV-INFECTED PATIENTS	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PRIMARY PROPHYLAXIS; AMPHOTERICIN-B; AIDS	To evaluate whether oral fluconazole reduces the risk of a first episode of cryptococcal meningitis in HIV-infected patients, we conducted a case-control study of patients cared for in a university teaching hospital and two urban HIV-outpatient clinics. Cases consisted of HIV-infected patients with CD4 cell counts less than 250/mu L who developed a first episode of cryptococcal meningitis between July 1, 1990, and June 30, 1993. For each case (n=18), 4 control subjects were chosen from HIV-infected patients (CD4 count < 250/mu L) whose cerebrospinal fluid was negative for cryptococcal antigen and culture, and who were matched by age, sex, and time of lumbar puncture. There were no significant differences between cases and controls in age, sex, insurance status, mean CD4 count, history of oral candidosis, presence of a previous AIDS-defining illness, the number of visits to the HIV-outpatient clinic, or use of antiretroviral therapy. In the 6 months before lumbar puncture, 2 of 18 cases (11%) and 26 of 72 controls (36%) were exposed to fluconazole, a finding that gives a matched odds ratio (adjusted for race, route of HIV infection, and CD4 count) of 0.08 (95% CI 0.01-0.84; p=0.035) and indicates a 92% protective efficacy. We conclude that fluconazole reduces the risk of a first episode of cryptococcal meningitis in HIV-infected patients with a CD4 count less than 250/mu L. Although the optimum dose and duration of fluconazole could not be determined, our results suggest that less than daily use was effective in the prevention of cryptococcal meningitis.			QUAGLIARELLO, VJ (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510, USA.							Breslow N, 1980, STAT METHODS CANC RE, P248; CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; Cotton D., 1992, AIDS Clinical Care, V4, P85; FEINSTEIN AR, 1988, J CLIN INVEST, V81, P1, DOI 10.1172/JCI113279; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P118; GALGIANI JN, 1990, ANN INTERN MED, V113, P177, DOI 10.7326/0003-4819-113-3-177; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; HAYDEN GF, 1982, JAMA-J AM MED ASSOC, V247, P326, DOI 10.1001/jama.247.3.326; IMPERIALE TF, 1990, AM J MED, V88, P131, DOI 10.1016/0002-9343(90)90461-L; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; NIGHTINGALE SD, 1992, AIDS, V6, P191, DOI 10.1097/00002030-199202000-00008; POWDERLY WG, 1992, NEW ENGL J MED, V326, P793, DOI 10.1056/NEJM199203193261203; POWDERLY WG, 1993, CLIN INFECT DIS, V17, P837, DOI 10.1093/clinids/17.5.837; SAAG MS, 1992, NEW ENGL J MED, V326, P83, DOI 10.1056/NEJM199201093260202; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; Wheat L. J., 1994, AIDS Clinical Care, V6, P27; 1992, MMWR-MORBID MORTAL W, V41, P1	18	42	43	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					548	552		10.1016/S0140-6736(95)90465-4	http://dx.doi.org/10.1016/S0140-6736(95)90465-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776774	hybrid			2022-12-28	WOS:A1995QK44400010
J	PETROS, AJ; MARSHALL, JC; VANSAENE, HKF				PETROS, AJ; MARSHALL, JC; VANSAENE, HKF			SHOULD MORBIDITY REPLACE MORTALITY AS AN END-POINT FOR CLINICAL-TRIALS IN INTENSIVE-CARE	LANCET			English	Editorial Material							HEALTH-STATUS; DISEASE; SEPSIS; FEVER		TORONTO GEN HOSP,DEPT CRIT CARE SURG,TORONTO,ON,CANADA; ROYAL LIVERPOOL CHILDRENS NHS TRUST,DEPT MICROBIOL,LIVERPOOL,MERSEYSIDE,ENGLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Alder Hey Children's NHS Foundation Trust; University of Liverpool	PETROS, AJ (corresponding author), ROYAL BROMPTON & NATL HEART HOSP,DEPT ANAESTHESIA & INTENS CARE,SYDNEY ST,LONDON SW3 6NP,ENGLAND.							ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; ATKINSON S, 1994, LANCET, V344, P1203, DOI 10.1016/S0140-6736(94)90514-2; BONE RC, 1987, NEW ENGL J MED, V317, P53; CROSS AS, 1994, ANN INTERN MED, V121, P58, DOI 10.7326/0003-4819-121-1-199407010-00011; DERKX B, 1993, LANCET, V342, P173, DOI 10.1016/0140-6736(93)91375-V; DEYO RA, 1983, MED CARE, V21, P180, DOI 10.1097/00005650-198302000-00006; EIDELMAN LA, 1994, CRIT CARE MED, V33, P1330; GUYATT G, 1989, GASTROENTEROLOGY, V96, P804, DOI 10.1016/0016-5085(89)90905-0; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; HEYLAND DK, 1993, INTENS CARE MED, V19, P435, DOI 10.1007/BF01711083; HOFFMAN SL, 1984, NEW ENGL J MED, V310, P82, DOI 10.1056/NEJM198401123100203; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KWIATKOWSKI D, 1993, Q J MED, V86, P91; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; NICHOLS RL, 1973, ANN SURG, V178, P453, DOI 10.1097/00000658-197310000-00008; NYSTROM B, 1994, INFECT CONT HOSP EP, V15, P435; ROMANI L, 1994, J IMMUNOL, V152, P3514; SHOEMAKER WC, 1990, CRIT CARE MED, V18, P1294; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; THOMPSON BT, 1994, LANCET, V344, P7, DOI 10.1016/S0140-6736(94)91044-8; VANDERMEER JTM, 1992, LANCET, V339, P135, DOI 10.1016/0140-6736(92)90207-J	22	85	86	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 11	1995	345	8946					369	371		10.1016/S0140-6736(95)90347-X	http://dx.doi.org/10.1016/S0140-6736(95)90347-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF722	7772121	Bronze			2022-12-28	WOS:A1995QF72200015
J	[Anonymous]				[Anonymous]			GOING PRIVATE - TIME FOR CHANGE	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1699	1700						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7772117				2022-12-28	WOS:A1994PY71700022
J	FREEMAN, EW; RICKELS, K; SONDHEIMER, SJ; POLANSKY, M				FREEMAN, EW; RICKELS, K; SONDHEIMER, SJ; POLANSKY, M			A DOUBLE-BLIND TRIAL OF ORAL PROGESTERONE, ALPRAZOLAM, AND PLACEBO IN TREATMENT OF SEVERE PREMENSTRUAL-SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIMENSTRUAL SYMPTOMS; MOOD; BIOAVAILABILITY; METABOLITES; PERFORMANCE; PREVALENCE; TENSION	Objective.-To determine the effectiveness of oral micronized progesterone, alprazolam, and placebo in premenstrual syndrome (PMS) treatment and the effect of clinical contact on treatment responses. Design.-Randomized, double-blind, placebo-controlled 3-month parallel treatment arms with flexible dosage and with the length of clinical contact randomized within each treatment group. Setting.-University hospital PMS medical treatment outpatient program in obstetrics/gynecology department. Subjects.-Among volunteers for PMS treatment, 444 were evaluated and 185 meeting defined PMS criteria were randomized to treatment; treatment data are available for 170. There were no medical withdrawals for adverse events. Intervention.-A double-blinded protocol in which 300 mg of oral micronized progesterone, 0.25 mg of alprazolam, or placebo was administered four times a day from day 18 of the menstrual cycle through day 2 of the next cycle, including taper. The mean daily dose at the third treatment was 1760 mg of progesterone or 1.5 mg of alprazolam. Subjects were randomized to brief (<20 minutes) or extended (50 minutes) visits. Main Outcome Measures.-Daily symptom report (DSR) scared for total DSR symptoms, four DSR factors. Results.-Alprazolam was significantly better than placebo or progesterone for total premenstrual symptoms and DSR factors of mental function, pain, and mood. Thirty-seven percent of the alprazolam group experienced a 50% reduction in total DSR scores. There were no clinically significant withdrawal symptoms when alprazolam administration was restricted to the luteal phase. Oral micronized progesterone therapy was no better than placebo. Brief vs extended visits had no effect on treatment outcome. Treatment response was associated with severity of premenstrual symptoms at baseline but with no other diagnostic variables. Conclusions.-Alprazolam has a role in PMS treatment and offers a therapy limited to the luteal phase. Oral micronized progesterone is ineffective for PMS.	UNIV PENN,SCH MED,DEPT PSYCHIAT,PHILADELPHIA,PA 19104; HAHNEMANN UNIV,DEPT BIOMETR & COMP,PHILADELPHIA,PA 19102	University of Pennsylvania; Drexel University	FREEMAN, EW (corresponding author), UNIV PENN,MED CTR,SCH MED,DEPT OBSTET & GYNECOL,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018633] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18633] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSCH B, 1985, J PSYCHOSOM RES, V29, P489, DOI 10.1016/0022-3999(85)90082-0; BANCROFT J, 1985, CLIN ENDOCRINOL, V22, P313, DOI 10.1111/j.1365-2265.1985.tb03244.x; CHAKMAKJIAN ZH, 1987, J REPROD MED, V32, P443; DALTON K, 1984, PREMENSTRUAL SYNDROM, P130; DENNERSTEIN L, 1986, HORM BEHAV, P175; DENNERSTEIN L, 1985, BRIT MED J, V290, P1017; FREEMAN E, 1990, JAMA-J AM MED ASSOC, V264, P349; FREEMAN EW, 1993, J CLIN PSYCHIAT, V54, P192; FREEMAN EW, 1992, BRIT J CLIN PHARMACO, V33, P293, DOI 10.1111/j.1365-2125.1992.tb04038.x; FREEMAN EW, 1993, NEUROENDOCRINOLOGY, V58, P478, DOI 10.1159/000126579; FREEMAN EW, 1994, J CLIN PSYCHOPHARM, V14, P180; HALBREICH U, 1982, ACTA PSYCHIAT SCAND, V65, P46, DOI 10.1111/j.1600-0447.1982.tb00820.x; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMMARBACK S, 1985, ACTA OBSTET GYN SCAN, V64, P393, DOI 10.3109/00016348509155154; HARGROVE JT, 1989, AM J OBSTET GYNECOL, V161, P948, DOI 10.1016/0002-9378(89)90759-X; HARRISON WM, 1990, ARCH GEN PSYCHIAT, V47, P270; LOGUE CM, 1986, PSYCHOSOM MED, V48, P388, DOI 10.1097/00006842-198607000-00002; MADDOCKS S, 1986, AM J OBSTET GYNECOL, V154, P573, DOI 10.1016/0002-9378(86)90604-6; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MAXSON WS, 1986, FERTIL STERIL, V44, P622; MOLINE ML, 1993, CLIN PHARMACY, V12, P181; MYERS ER, 1987, FERTIL STERIL, V47, P71; RICHTER MA, 1984, CURR THER RES CLIN E, V36, P840; RICKELS K, 1990, CURR THER RES CLIN E, V48, P161; SAMPSON GA, 1979, BRIT J PSYCHIAT, V135, P209, DOI 10.1192/bjp.135.3.209; SCHMIDT PJ, 1993, ARCH GEN PSYCHIAT, V50, P467; SCHMIDT PJ, 1991, NEW ENGL J MED, V324, P1174, DOI 10.1056/NEJM199104253241705; SITRUKWARE R, 1987, CONTRACEPTION, V36, P373, DOI 10.1016/0010-7824(87)90088-6; SMITH S, 1987, OBSTET GYNECOL, V70, P37; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; SPITZER RL, 1988, INSTRUCTION MANUAL S; VANDEGINSTE BGM, 1983, TRAC-TREND ANAL CHEM, V2, P220; WOODS NF, 1982, AM J PUBLIC HEALTH, V72, P1257, DOI 10.2105/AJPH.72.11.1257; YORK R, 1989, OBSTET GYNECOL, V73, P601; 1994, DIAGNOSTIC STATISTIC, P714; 1987, DIAGNOSTIC STATISTIC; 1989, SAS STAT GUIDE PERSO	37	143	145	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					51	57		10.1001/jama.274.1.51	http://dx.doi.org/10.1001/jama.274.1.51			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791258				2022-12-28	WOS:A1995RG23300030
J	SHIN, ES				SHIN, ES			OF LOCKER ROOMS AND LABOR PAINS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									NORTHWESTERN UNIV, SCH MED, CHICAGO, IL 60611 USA	Northwestern University								QUINDLEN A, 1994, NY TIMES A      0316, P21	1	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					71	72		10.7326/0003-4819-123-1-199507010-00012	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762919				2022-12-28	WOS:A1995RE66500013
J	CLARK, LR				CLARK, LR			TEEN SEX BLUES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 28	1995	273	24					1969	1970						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE354	7783311				2022-12-28	WOS:A1995RE35400040
J	STONE, RM; BERG, DT; GEORGE, SL; DODGE, RK; PACIUCCI, PA; SCHULMAN, P; LEE, EJ; MOORE, JO; POWELL, BL; SCHIFFER, CA				STONE, RM; BERG, DT; GEORGE, SL; DODGE, RK; PACIUCCI, PA; SCHULMAN, P; LEE, EJ; MOORE, JO; POWELL, BL; SCHIFFER, CA			GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER INITIAL CHEMOTHERAPY FOR ELDERLY PATIENTS WITH PRIMARY ACUTE MYELOGENOUS LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; CLINICAL-TRIALS; INDUCTION CHEMOTHERAPY; INTENSIVE CHEMOTHERAPY; REMISSION-INDUCTION; DOSE CYTARABINE; GROWTH-FACTORS; GM-CSF	Background. Elderly patients with primary acute myelogenous leukemia (AML) are less likely to enter remission than younger adults, in part because of a higher mortality rate related to severe myelosuppression. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been shown to shorten the duration of neutropenia and decrease infectious complications when administered after chemotherapy to patients with lymphomas and solid tumors. Methods. We randomly assigned 388 patients 60 years of age or older who had newly diagnosed primary AML to receive placebo or GM-CSF (5 mu g per kilogram of body weight per day intravenously) in a double-blind manner, beginning the day after the completion of three days of daunorubicin and seven days of cytarabine. If leukemic cells persisted in the marrow three weeks after the initiation of chemotherapy, further daunorubicin (two days) and cytarabine (five days) were administered. GM-CSF or placebo was given daily until the neutrophil count was at least 1000 per cubic millimeter, there was evidence of the regrowth of leukemia, or severe toxic effects attributable to the study infusion occurred. Patients who had a complete remission were then randomly assigned to receive one of two intensification regimens. Results. Of 388 patients (median age, 69 years), 193 were randomly assigned to receive GM-CSF and 195 to receive placebo. The rate of complete remission was 51 percent (95 percent confidence interval, 44 to 59 percent) among those assigned to GM-CSF and 54 percent (95 percent confidence interval, 47 to 61 percent) among those assigned to placebo (P = 0.61). The reasons for failure (early death, death during marrow hypoplasia, and persistent leukemia), the incidence of severe or lethal infection, and the incidence of the regrowth of leukemia (2 percent overall) were similar in the two groups. The median duration of neutropenia was slightly shorter (P = 0.02) in the patients who received GM-CSF (15 days) than in those who received placebo (17 days), but the clinical importance of this result was minimal because the growth factor failed to lower the treatment-related mortality rate or improve the rate of complete remission. Conclusions. GM-CSF, in the dose and schedule we used, does not stimulate the regrowth of leukemia, but it also does not decrease the severe myelosuppressive consequences of initial chemotherapy or improve the response rate in patients 60 years of age or older with primary AML. It should not be recommended for use in such patients.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; DUKE UNIV,MED CTR,DURHAM,NC; N SHORE UNIV HOSP,MANHASSET,NY; UNIV MARYLAND,CTR CANC,BALTIMORE,MD 21201; BOWMAN GRAY SCH MED,WINSTON SALEM,NC	Harvard University; Harvard Medical School; Duke University; Northwell Health; North Shore University Hospital; University System of Maryland; University of Maryland Baltimore; Wake Forest University; Wake Forest Baptist Medical Center	STONE, RM (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA.				NCI NIH HHS [CA31946, CA37055, CA33601] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037055, U10CA031946, U10CA033601] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman DG, 1991, PRACTICAL STAT MED R, P230; ARMITAGE P, 1971, STATISTICAL METHODS, P363; BEGG CB, 1994, SEMIN ONCOL, V21, P569; BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BETTELHEIM P, 1991, BLOOD, V77, P700; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; BUCHNER T, 1991, BLOOD, V78, P1190; BUCHNER T, 1993, P AN M AM SOC CLIN, V12, pA985; CANNISTRA S A, 1991, Current Opinion in Oncology, V3, P4, DOI 10.1097/00001622-199102000-00002; CASSILETH PA, 1992, BLOOD, V79, P1924; CHESON BD, 1990, J CLIN ONCOL, V8, P813, DOI 10.1200/JCO.1990.8.5.813; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; ESTEY EH, 1990, BLOOD, V75, P1766; ESTEY EH, 1994, BLOOD, V83, P2015; Fleiss JL, 1981, STAT METHODS RATES P; KANTARJIAN HM, 1992, BLOOD, V79, P876; KANTARJIAN HM, 1993, BLOOD, V81, P1146; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIST AF, 1993, J CLIN ONCOL, V11, P1652, DOI 10.1200/JCO.1993.11.9.1652; LOWENBERG B, 1989, J CLIN ONCOL, V7, P1268; LOWENBERG B, 1993, BLOOD, V81, P281; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MIYAUCHI J, 1987, BLOOD, V70, P657; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PEDERSENBJERGAA.J, 1990, BLOOD, V76, P1083; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pocock SJ., 2013, CLIN TRIALS PRACTICA; PREISLER HD, 1978, MED PEDIATR ONCOL, V4, P275, DOI 10.1002/mpo.2950040311; REES JKH, 1986, LANCET, V2, P1236; ROWE JM, 1993, BLOOD, V82, pA329; SCHILLER G, 1992, BLOOD, V80, P2977; STONE RM, 1993, HEMATOL ONCOL CLIN N, V7, P65, DOI 10.1016/S0889-8588(18)30258-2; SWANSBURY GJ, 1994, CANCER GENET CYTOGEN, V73, P1, DOI 10.1016/0165-4608(94)90174-0; TILLY H, 1990, J CLIN ONCOL, V8, P272, DOI 10.1200/JCO.1990.8.2.272; VELLENGA E, 1987, BLOOD, V69, P1771; WEISS RB, 1993, JAMA-J AM MED ASSOC, V270, P459, DOI 10.1001/jama.270.4.459; WITZ F, 1994, BLOOD S1, V84, P231; YUNIS JJ, 1986, BLOOD, V67, P1721; ZITTOUN R, 1994, BLOOD, V84, P231	42	369	375	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1671	1677		10.1056/NEJM199506223322503	http://dx.doi.org/10.1056/NEJM199506223322503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760868				2022-12-28	WOS:A1995RD99600003
J	EMMETT, PM; HEATON, KW				EMMETT, PM; HEATON, KW			IS EXTRINSIC SUGAR A VEHICLE FOR DIETARY-FAT	LANCET			English	Article							11-12-YEAR-OLD ENGLISH CHILDREN; ENERGY; QUESTIONNAIRE; WOMEN	Although many guidelines to healthy eating recommend restriction of the intake of extrinsic (refined) sugar, there are concerns that such restriction might result in an increase in the amount and the proportion of dietary fats with a consequent possible increase in the risk of cardiovascular disease. We used regression analysis to examine the determinants of fat intake in subjects from a population survey who had weighed their food for 4 days. In men (n=77) acid women (n=83), fat eaten was positively related to the intake of extrinsic sugar. When intakes were expressed as percent of calories the relation became negative. A survey in a semi-random sample of 739 men aged 40-69 yr and 976 women aged 25-69 yr showed that, in both sexes, an increase in extrinsic sugar was a linear increase in the intake of and hence of fat combined with carbohydrate. This was due mainly to a higher intake of cakes and biscuits. Foods containing sugar and fat provided an extra 12.0 g per day of fat in the men and 13.8 g per day in the women when the highest quartile of extrinsic sugar consumers were compared with the lowest quartile. We conclude that lowering the intake of extrinsic sugar is unlikely to be associated with higher fat intake. Instead extrinsic sugar may act as a vehicle for fat intake, encouraging consumption by making the fat more palatable.	UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary; University of Bristol			Emmett, Pauline/AAL-6815-2021	Emmett, Pauline/0000-0003-1076-4779				ADAMSON AJ, 1992, J HUM NUTR DIET, V5, P371, DOI 10.1111/j.1365-277X.1992.tb00177.x; BARKER M E, 1988, Journal of Human Nutrition and Dietetics, V1, P179, DOI 10.1111/j.1365-277X.1988.tb00187.x; BINGHAM S, 1991, P NUTR SOC, V50, pA32; BLACK AE, 1991, EUR J CLIN NUTR, V45, P583; EMMETT P, 1992, J HUM NUTR DIET, V5, P245, DOI 10.1111/j.1365-277X.1992.tb00159.x; EMMETT PM, 1993, EUR J CLIN NUTR, V47, P20; GIBNEY MJ, 1980, J HUM NUTR DIET, V3, P245; Gregory F., 1990, DIETARY NUTR SURVEY; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; MANN GV, 1994, LANCET, V343, P1268, DOI 10.1016/S0140-6736(94)92157-1; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRENTICE AM, 1986, BRIT MED J, V292, P983, DOI 10.1136/bmj.292.6526.983; Pryer J. A., 1994, Proceedings of the Nutrition Society, V53, p235A; RUGGGUNN AJ, 1993, J HUM NUTR DIET, V6, P419, DOI 10.1111/j.1365-277X.1993.tb00387.x; WILES SJ, 1980, J HUM NUTR, V34, P189; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103; 1992, GOOD DIETARY PRACTIC, V3, P1; 1992, HLTH NATION STRATEGY; 1991, REPORTS HLTH SOCIAL, V41; 1989, REPORTS HLTH SOCIAL, V37	21	46	46	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 17	1995	345	8964					1537	1540		10.1016/S0140-6736(95)91087-5	http://dx.doi.org/10.1016/S0140-6736(95)91087-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD790	7791439				2022-12-28	WOS:A1995RD79000009
J	RANGANATHAN, R; STEVENS, CF				RANGANATHAN, R; STEVENS, CF			ARRESTIN BINDING DETERMINES THE RATE OF INACTIVATION OF THE G-PROTEIN-COUPLED RECEPTOR RHODOPSIN IN-VIVO	CELL			English	Article							LIGHT-INDUCED PHOSPHORYLATION; 48-KDA PROTEIN; DROSOPHILA PHOTORECEPTOR; PHOTOEXCITED RHODOPSIN; RETINAL RODS; INVIVO; DESENSITIZATION; KINASE; DEACTIVATION; ACTIVATION	G protein-coupled receptor inactivation is a crucial feature of cellular signaling systems; this process determines the catalytic lifetime of the activated receptor and is necessary for response termination. Although previous work has indicated a class of models in which several sequential steps are required for receptor inactivation, the rate-limiting event is still unclear. In this paper, we develop a theory that describes the kinetics of inactivation of the G protein-coupled receptor rhodopsin based on the rate of arrestin binding and test the theory using a combination of genetic and electrophysiological techniques in Drosophila photoreceptors. The theory quantitatively describes the inactivation kinetics of activated rhodopsin in vivo and can be independently tested with molecular and spectroscopic data. The results demonstrate that the rate of arrestin binding determines the kinetics of receptor inactivation in vivo and thus is the event that controls signal amplification at the first step of this G protein-coupled transduction cascade.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; SALK INST BIOL STUDIES,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Salk Institute	RANGANATHAN, R (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.							BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; COLLINS S, 1990, BIOCHEM SOC T, V18, P541, DOI 10.1042/bst0180541; Dartnall H. J. A., 1972, HDB SENSORY PHYSIOLO, V7, P122; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; Goodeve CF, 1938, PROC R SOC LON SER-A, V166, P0342, DOI 10.1098/rspa.1938.0097; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KUHN H, 1987, J RECEPTOR RES, V7, P283, DOI 10.3109/10799898709054990; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LEVINE H, 1990, MECH DEVELOP, V33, P19, DOI 10.1016/0925-4773(90)90131-5; MAKINO CL, 1991, J PHYSIOL-LONDON, V442, P761, DOI 10.1113/jphysiol.1991.sp018818; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MATSUMOTO H, 1984, SCIENCE, V223, P184, DOI 10.1126/science.6419348; MCDOWELL JH, 1977, BIOCHEMISTRY-US, V16, P4054, DOI 10.1021/bi00637a018; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; RANGANATHAN R, 1991, ANN REV NEUROL, V18, P283; RICHARD EA, 1992, NATURE, V356, P336, DOI 10.1038/356336a0; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SCHWEMER J, 1984, J COMP PHYSIOL, V154, P535, DOI 10.1007/BF00610167; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; YAMAMOTO K, 1983, BIOPHYS STRUCT MECH, V9, P259, DOI 10.1007/BF00535661	29	50	51	0	2	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 16	1995	81	6					841	848		10.1016/0092-8674(95)90004-7	http://dx.doi.org/10.1016/0092-8674(95)90004-7			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RD768	7781061	Bronze			2022-12-28	WOS:A1995RD76800005
J	CORTES, J; WIESMANN, KEH; ROBERTS, GA; BROWN, MJB; STAUNTON, J; LEADLAY, PF				CORTES, J; WIESMANN, KEH; ROBERTS, GA; BROWN, MJB; STAUNTON, J; LEADLAY, PF			REPOSITIONING OF A DOMAIN IN A MODULAR POLYKETIDE SYNTHASE TO PROMOTE SPECIFIC CHAIN CLEAVAGE	SCIENCE			English	Article							SACCHAROPOLYSPORA-ERYTHRAEA; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; BIOSYNTHESIS; GENES; ORGANIZATION; EXPRESSION; CLUSTER	Macrocyclic polyketides exhibit an impressive range of medically useful activities, and there is great interest in manipulating the genes that govern their synthesis. The 6-deoxyerythronolide B synthase (DEBS) of Saccharopolyspora erythraea, which synthesizes the aglycone core of the antibiotic erythromycin A, has been modified by repositioning of a chain-terminating cyclase domain to the carboxyl-terminus of DEBS1, the multienzyme that catalyzes the first two rounds of polyketide chain extension. The resulting mutant markedly accelerates formation of the predicted triketide lactone, compared to a control in which the repositioned domain is inactive. Repositioning of the cyclase should be generally useful for redirecting polyketide synthesis to obtain polyketides of specified chain lengths.	UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT ORGAN CHEM,CAMBRIDGE CB2 1EW,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge				Leadlay, Peter/0000-0002-3247-509X; Roberts, Gareth/0000-0002-3726-390X; Cortes, Jesus/0000-0002-2475-6983				APARICIO JF, 1994, J BIOL CHEM, V269, P8524; BECK J, 1990, EUR J BIOCHEM, V192, P487, DOI 10.1111/j.1432-1033.1990.tb19252.x; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; CAFFREY P, 1991, EUR J BIOCHEM, V195, P823, DOI 10.1111/j.1432-1033.1991.tb15771.x; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CUTTER A, UNPUB; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; JOSHI AK, 1993, J BIOL CHEM, V268, P22508; KANEDA T, 1962, J BIOL CHEM, V237, P322; KAO CM, 1994, J AM CHEM SOC, V116, P11612, DOI 10.1021/ja00104a069; KAO CM, 1994, J BIOL CHEM, V265, P509; LEADLAY PF, 1993, BIOCHEM SOC T, V21, P218, DOI 10.1042/bst0210218; MACNEIL DJ, 1992, GENE, V115, P97; MARSDEN AFA, 1994, SCIENCE, V263, P378, DOI 10.1126/science.8278811; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; ROBERTS GB, UNPUB; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; STAUNTON J, 1991, ANGEW CHEM INT EDIT, V30, P1302, DOI 10.1002/anie.199113021; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; YE JS, 1994, J BACTERIOL, V176, P6270, DOI 10.1128/jb.176.20.6270-6280.1994	25	226	248	1	28	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1487	1489		10.1126/science.7770773	http://dx.doi.org/10.1126/science.7770773			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770773				2022-12-28	WOS:A1995RC19000037
J	KOENIG, HL; SCHUMACHER, M; FERZAZ, B; DOTHI, AN; RESSOUCHES, A; GUENNOUN, R; JUNGTESTAS, I; ROBEL, P; AKWA, Y; BAULIEU, EE				KOENIG, HL; SCHUMACHER, M; FERZAZ, B; DOTHI, AN; RESSOUCHES, A; GUENNOUN, R; JUNGTESTAS, I; ROBEL, P; AKWA, Y; BAULIEU, EE			PROGESTERONE SYNTHESIS AND MYELIN FORMATION BY SCHWANN-CELLS	SCIENCE			English	Article							NEUROACTIVE STEROIDS; SCIATIC-NERVES; TREMBLER MOUSE; BASAL LAMINA; NEUROSTEROIDS; BRAIN; PREGNENOLONE; DIFFERENTIATION; PHOSPHOLIPIDS; REGENERATION	Progesterone is shown here to be produced from pregnenolone by Schwann cells in peripheral nerves, After cryolesion of the sciatic nerve in male mice, axons regenerate and become myelinated. Blocking either the local synthesis or the receptor-mediated action of progesterone impaired remyelination. Administration of progesterone or its precursor, pregnenolone, to the lesion site increased the extent of myelin sheath formation. Myelination of axons was also increased when progesterone was added to cultures of rat dorsal root ganglia. These observations indicate a role for locally produced progesterone in myelination, demonstrate that progesterone is not simply a sex steroid, and suggest a new therapeutic approach to promote myelin repair.	INSERM,U33,HORMONES LAB,F-94276 LE KREMLIN BICETR,FRANCE; UNIV BORDEAUX 1,DEV NEUROBIOL LAB,F-33405 TALENCE,FRANCE; COLL FRANCE,CNRS,U1115,F-75231 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France			Schumacher, Michael/G-3581-2013; Messier, Claude/A-2322-2008; Guennoun, Rachida/F-2420-2011; Akwa, Yvette/I-5223-2018	Schumacher, Michael/0000-0001-6117-5371; Messier, Claude/0000-0002-4791-1763; Guennoun, Rachida/0000-0002-9219-7300; Akwa, Yvette/0000-0003-2181-4612				AKWA Y, 1993, CR ACAD SCI III-VIE, V316, P410; AKWA Y, 1993, J CELL BIOL, V121, P135, DOI 10.1083/jcb.121.1.135; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Baulieu E. -E., 1981, STEROID HORMONE REGU, P3; BAULIEU EE, 1991, BIOL CELL, V71, P3, DOI 10.1016/0248-4900(91)90045-O; BIZZOZERO OA, 1991, J BIOL CHEM, V266, P17092; BOLIN LM, 1993, J CELL BIOL, V123, P237, DOI 10.1083/jcb.123.1.237; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CHADWICK D, 1990, CIBA F S, V153; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; DROZ B, 1981, BRAIN RES, V219, P57, DOI 10.1016/0006-8993(81)90267-5; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FERZAZ B, 1989, CR ACAD SCI III-VIE, V309, P377; FUXE K, 1981, STEROID HORMONE REGU; GUENNOUN R, IN PRESS MOL BRAIN R; HILDEBRAND C, 1994, PROG NEUROBIOL, V43, P85, DOI 10.1016/0301-0082(94)90010-8; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JUNGTESTAS I, 1994, J STEROID BIOCHEM, V48, P145, DOI 10.1016/0960-0760(94)90261-5; JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083; Kleitman N, 1991, CULTURING NERVE CELL, P337; KOENIG H, UNPUB; LEGOASCOGNE C, 1987, SCIENCE, V237, P1212, DOI 10.1126/science.3306919; MAJEWSKA MD, 1986, SCIENCE, V232, P1004, DOI 10.1126/science.2422758; MCEWEN BS, 1991, TRENDS ENDOCRIN MET, V2, P62, DOI 10.1016/1043-2760(91)90042-L; MELLON SH, 1994, J CLIN ENDOCR METAB, V78, P1003, DOI 10.1210/jc.78.5.1003; MORFIN R, 1992, P NATL ACAD SCI USA, V89, P6790, DOI 10.1073/pnas.89.15.6790; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; RAISINGHANI KH, 1968, ACTA ENDOCRINOL-COP, V57, P393; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SCHUMACHER M, 1990, SCIENCE, V250, P691, DOI 10.1126/science.2173139; SUTER U, 1992, NATURE, V356, P241, DOI 10.1038/356241a0; TOEWS AD, 1988, J NEUROSCI, V8, P593; VERDI JM, 1990, J BIOL CHEM, V265, P20314	37	402	414	0	24	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1500	1503		10.1126/science.7770777	http://dx.doi.org/10.1126/science.7770777			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770777				2022-12-28	WOS:A1995RC19000041
J	FULLER, SD; BERRIMAN, JA; BUTCHER, SJ; GOWEN, BE				FULLER, SD; BERRIMAN, JA; BUTCHER, SJ; GOWEN, BE			LOW PH INDUCES SWIVELING OF THE GLYCOPROTEIN HETERODIMERS IN THE SEMLIKI-FOREST VIRUS SPIKE COMPLEX	CELL			English	Article							HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; SINDBIS VIRUS; ELECTRON-MICROGRAPHS; INFLUENZA-VIRUS; FUSION PROCESS; PROTEIN; ENVELOPE; RECONSTRUCTION; MECHANISM; CELLS	Time-resolved cryoelectron microscopy reveals the first step in the conformational changes that enable membrane fusion in Semliki Forest virus. The neutral pH structure reveals a central cavity within the spike complex, plate-like extensions forming a layer above the membrane, and the paths of the paired transmembrane domains connecting the trimeric spikes and pentamer-hexamer clustered capsid subunits. Low pH treatment results in centrifugal movement of E2, the receptor-binding subunit, centripetal movement of E1 to narrow the central cavity initiating the formation of an E1 trimer, and the extension of the E1 fusion sequence toward the target membrane.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	FULLER, SD (corresponding author), EUROPEAN MOLEC BIOL LAB,STRUCT BIOL PROGRAMME,MEYERHOFSTR 1,D-69012 HEIDELBERG,GERMANY.		Butcher, Sarah J/H-5579-2012	Butcher, Sarah/0000-0001-7060-5871	NIGMS NIH HHS [GM41449] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041449] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1994, STRUCTURE, V2, P907, DOI 10.1016/S0969-2126(94)00091-3; BERRIMAN J, 1994, ULTRAMICROSCOPY, V156, P241; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHENG RH, 1995, CELL, V80, P621; DUBUISSON J, 1993, J VIROL, V67, P3363, DOI 10.1128/JVI.67.6.3363-3374.1993; FULLER S, 1994, STRUCTURE, V2, P903, DOI 10.1016/S0969-2126(94)00090-5; FULLER SD, 1987, CELL, V48, P923, DOI 10.1016/0092-8674(87)90701-X; GAROFF H, 1980, NATURE, V288, P221; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; JAIN SK, 1991, J BIOL CHEM, V266, P5756; JUSTMAN J, 1993, J VIROL, V67, P7597, DOI 10.1128/JVI.67.12.7597-7607.1993; KENNEY JM, 1994, STRUCTURE, V2, P823, DOI 10.1016/S0969-2126(94)00083-2; Kielian M, 1986, TOGAVIRIDAE FLAVIVIR, P91; KIELIAN N, 1994, ADV VIRUS RES, V45, P113; LEVYMINTZ P, 1991, J VIROL, V65, P4292, DOI 10.1128/JVI.65.8.4292-4300.1991; LOBIGS M, 1990, J VIROL, V64, P4346, DOI 10.1128/JVI.64.9.4346-4355.1990; PAREDES AM, 1993, P NATL ACAD SCI USA, V90, P9095, DOI 10.1073/pnas.90.19.9095; SALMINEN A, 1992, J CELL BIOL, V116, P349, DOI 10.1083/jcb.116.2.349; SCHLESINGER MJ, 1986, TOGAVIRIDAE FLAVIVIR, P21; SIMONS K, 1980, J GEN VIROL, V50, P1, DOI 10.1099/0022-1317-50-1-1; Singh I., 1992, SEMIN VIROL, V3, P511; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; STEWART PL, 1993, EMBO J, V72, P2589; STUBBS MJ, 1991, J MOL BIOL, V221, P39, DOI 10.1016/0022-2836(91)80200-E; TUCKER PC, 1991, J VIROL, V65, P1551, DOI 10.1128/JVI.65.3.1551-1557.1991; VENIENBRYAN C, 1994, J MOL BIOL, V236, P572, DOI 10.1006/jmbi.1994.1166; VOGEL RH, 1986, NATURE, V320, P533, DOI 10.1038/320533a0; VOGEL RH, 1988, ULTRAMICROSCOPY, V25, P223, DOI 10.1016/0304-3991(88)90017-4; WAHLBERG JM, 1992, J CELL BIOL, V116, P339, DOI 10.1083/jcb.116.2.339; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WHITE J, 1980, J CELL BIOL, V87, P264, DOI 10.1083/jcb.87.1.264; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	36	119	119	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					715	725		10.1016/0092-8674(95)90533-2	http://dx.doi.org/10.1016/0092-8674(95)90533-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774013	Bronze			2022-12-28	WOS:A1995RB96100010
J	NICOLELIS, MAL; BACCALA, LA; LIN, RCS; CHAPIN, JK				NICOLELIS, MAL; BACCALA, LA; LIN, RCS; CHAPIN, JK			SENSORIMOTOR ENCODING BY SYNCHRONOUS NEURAL ENSEMBLE ACTIVITY AT MULTIPLE LEVELS OF THE SOMATOSENSORY SYSTEM	SCIENCE			English	Article							SOMATIC SENSORY TRANSMISSION; MOTOR CORTEX STIMULATION; AWAKE RATS; AFFERENT MODULATION; RECEPTIVE-FIELDS; PARIETAL RHYTHMS; DIRECT RESPONSES; SINGLE NEURONS; SI-CORTEX; MOVEMENT	Neural ensemble processing of sensorimotor information during behavior was investigated by simultaneously recording up to 48 single neurons at multiple relays of the rat trigeminal somatosensory system. Cortical, thalamic, and brainstem neurons exhibited widespread 7- to 12-hertz synchronous oscillations, which began during attentive immobility and reliably predicted the imminent onset of rhythmic whisker twitching. Each oscillatory cycle began as a traveling wave of neural activity in the cortex that then spread to the thalamus. Just before the onset of rhythmic whisker twitching, the oscillations spread to the spinal trigeminal brainstem complex. Thereafter, the oscillations at all levels were synchronous with whisker protraction. Neural structures manifesting these rhythms also exhibited distributed spatiotemporal patterns of neuronal ensemble activity in response to tactile stimulation, thus, multilevel synchronous activity in this system may encode not only sensory information but also the onset and temporal domain of tactile exploratory movements.	MED COLL PENN, DEPT ANAT & NEUROBIOL, PHILADELPHIA, PA 19102 USA; HAHNEMANN UNIV, PHILADELPHIA, PA 19102 USA; UNIV PENN, DEPT ELECT ENGN, PHILADELPHIA, PA 19104 USA; UNIV SAO PAULO, DEPT ELECTR ENGN, BR-05508 SAO PAULO, BRAZIL	Drexel University; Drexel University; University of Pennsylvania; Universidade de Sao Paulo			Baccala, Luiz Antonio/A-3370-2008	Baccala, Luiz Antonio/0000-0002-2668-6747	NIDCR NIH HHS [DE11121-01] Funding Source: Medline; NINDS NIH HHS [NS-29161, NS-26722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026722, R01NS029161] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONGJAMES M, 1991, J COMP NEUROL, V303, P211, DOI 10.1002/cne.903030204; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; BUZSAKI G, 1991, NEUROSCIENCE, V41, P351, DOI 10.1016/0306-4522(91)90332-I; CARVELL GE, 1990, J NEUROSCI, V10, P2638; CHAPIN JK, 1982, EXP NEUROL, V78, P654, DOI 10.1016/0014-4886(82)90082-6; CHAPIN JK, 1986, EXP BRAIN RES, V62, P549; CHAPIN JK, 1982, EXP NEUROL, V78, P670, DOI 10.1016/0014-4886(82)90083-8; CHAPIN JK, 1984, J COMP NEUROL, V229, P199, DOI 10.1002/cne.902290206; CHMIELOWSKA J, 1989, J COMP NEUROL, V285, P325, DOI 10.1002/cne.902850304; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; COULTER JD, 1974, J NEUROPHYSIOL, V37, P831, DOI 10.1152/jn.1974.37.5.831; DIAMOND IT, 1969, SCIENCE, V164, P251, DOI 10.1126/science.164.3877.251; ERICKSON RP, 1968, PSYCHOL REV, V75, P447, DOI 10.1037/h0026752; FREEMAN WJ, 1987, BEHAV NEUROSCI, V101, P393, DOI 10.1037/0735-7044.101.3.393; Freeman WJ, 1975, MASS ACTION NERVOUS; GASTAUT MH, 1952, REV NEUROL, V87, P176; HOPFIELD JJ, 1986, SCIENCE, V233, P625, DOI 10.1126/science.3755256; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; KAAS JH, 1990, HUMAN NERVOUS SYSTEM, P813; KRISTEVAFEIGE R, 1993, NEUROREPORT, V4, P1291, DOI 10.1097/00001756-199309150-00001; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; LIN RCS, 1993, SOC NEUR ABSTR, V19, P106; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NELSON RJ, 1984, BRAIN RES, V304, P143, DOI 10.1016/0006-8993(84)90870-9; Nicolelis M. A. L., 1994, Society for Neuroscience Abstracts, V20, P125; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; NICOLELIS MAL, 1993, P NATL ACAD SCI USA, V90, P2212, DOI 10.1073/pnas.90.6.2212; NICOLELIS MAL, 1994, J NEUROSCI, V14, P3511; ROUGEUL A, 1979, ELECTROEN CLIN NEURO, V46, P310, DOI 10.1016/0013-4694(79)90205-0; SALMELIN R, 1994, NEUROSCIENCE, V60, P537, DOI 10.1016/0306-4522(94)90263-1; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; SEMBA K, 1984, NEUROSCIENCE, V12, P761, DOI 10.1016/0306-4522(84)90168-4; SEMBA K, 1980, BRAIN RES, V195, P281, DOI 10.1016/0006-8993(80)90065-7; SHERMAN SM, 1990, SYNAPTIC ORG BRAIN, P246; SHIN HC, 1990, NEUROSCI LETT, V108, P116, DOI 10.1016/0304-3940(90)90716-M; SHIN HC, 1990, BRAIN RES BULL, V24, P257; SHIN HC, 1989, BRAIN RES BULL, V22, P245, DOI 10.1016/0361-9230(89)90049-X; SOMPOLINSKY H, 1991, PHYS REV A, V43, P6990, DOI 10.1103/PhysRevA.43.6990; Steriade M., 1990, THALAMIC OSCILLATION	39	450	464	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 2	1995	268	5215					1353	1358		10.1126/science.7761855	http://dx.doi.org/10.1126/science.7761855			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB198	7761855				2022-12-28	WOS:A1995RB19800040
J	MARRS, KA; ALFENITO, MR; LLOYD, AM; WALBOT, V				MARRS, KA; ALFENITO, MR; LLOYD, AM; WALBOT, V			A GLUTATHIONE-S-TRANSFERASE INVOLVED IN VACUOLAR TRANSFER ENCODED BY THE MAIZE GENE BRONZE-2	NATURE			English	Article							CONJUGATE EXPORT PUMP; STRUCTURAL-ANALYSIS; ZEA-MAYS; TOBACCO; PROTOPLASTS; ARABIDOPSIS; EXPRESSION; MEMBRANE; PROTEIN; FAMILY	GLUTATHIONE S-transferases (GSTs) are enzymes that detoxify heterocyclic compounds (xenobiotics) by covalently linking glutathione to the substrate, forming a glutathione S-conjugate(1,2). A glutathione pump in the vacuolar membrane of barley actively sequesters herbicide-glutathione S-conjugates; glutathionation allows recognition and entry of the conjugates into vacuoles(3). The protein encoded by the Bronze-2 gene in maize performs the last genetically defined step in anthocyanin biosynthesis, resulting in the deposition of red and purple pigments in the vacuoles of maize tissues(4). We show here that Bz2 encodes a GST with activity in maize, transformed Arabidopsis thaliana plants and Escherichia coli. We demonstrate that anthocyanins extracted from maize protoplasts expressing BZ2 are conjugated with glutathione, and that vanadate, a known inhibitor of the glutathione pump(3) in plant vacuolar membranes, inhibits the accumulation of anthocyanins in the vacuole. These results provide a biochemical function for BZ2, and suggest a common mechanism for the ability of plants to sequester structurally similar but functionally diverse molecules in the vacuole.			MARRS, KA (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.			Walbot, Virginia/0000-0002-1596-7279				BODEAU JP, 1992, MOL GEN GENET, V233, P379, DOI 10.1007/BF00265434; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Coe E. H. Jr., 1988, Corn and corn improvement. Third edition., P81; CZAMECKA E, 1988, MOL CELL BIOL, V8, P113; DROOG FNJ, 1993, PLANT MOL BIOL, V21, P965, DOI 10.1007/BF00023595; DUDLER R, 1991, MOL PLANT MICROBE IN, V4, P14, DOI 10.1094/MPMI-4-014; GOFF SA, 1990, EMBO J, V9, P2517, DOI 10.1002/j.1460-2075.1990.tb07431.x; GROVE G, 1988, NUCLEIC ACIDS RES, V16, P425, DOI 10.1093/nar/16.2.425; Harborne J. B. M. T. J. M. H., 1975, FLAVONOIDS; HARBORNE JB, 1986, PHYTOCHEMISTRY, V25, P1887, DOI 10.1016/S0031-9422(00)81168-1; HARBORNE JB, 1987, PHYTOCHEMISTRY, V26, P2417, DOI 10.1016/S0031-9422(00)84738-X; IRZYK GP, 1982, PLANT PHYSIOL, V102, P803; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; LAMOUREUX GL, 1983, PESTICIDE CHEM HUMAN, P295; LAMOUREUX GL, 1981, SULFUR PESTICIDE ACT, P133; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; Mannervik B, 1981, Methods Enzymol, V77, P231; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; NASH J, 1993, PLANT PHYSIOL, V100, P464; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PILUKA S, 1994, J BIOL CHEM, V269, P27566; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; SCHMITZ G, 1992, MOL GEN GENET, V233, P269, DOI 10.1007/BF00587588; SHAH DM, 1986, PLANT MOL BIOL, V6, P203, DOI 10.1007/BF00015226; TAKAHASHI Y, 1991, PLANT J, V1, P327, DOI 10.1046/j.1365-313X.1991.t01-2-00999.x; TAYLOR JL, 1990, MOL PLANT MICROBE IN, V3, P72; TIMMERMAN KP, 1989, PHYSIOL PLANTARUM, V77, P465, DOI 10.1111/j.1399-3054.1989.tb05668.x; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VANDERZAAL EJ, 1991, PLANT MOL BIOL, V16, P983, DOI 10.1007/BF00016071; WALBOT V, 1994, MAYDICA, V39, P19	30	447	504	5	92	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 1	1995	375	6530					397	400		10.1038/375397a0	http://dx.doi.org/10.1038/375397a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RB101	7760932				2022-12-28	WOS:A1995RB10100051
J	FAIRWEATHERTAIT, SJ; FOX, TE; MALLILLIN, A				FAIRWEATHERTAIT, SJ; FOX, TE; MALLILLIN, A			BALTI CURRIES AND IRON	BRITISH MEDICAL JOURNAL			English	Article							FOOD				FAIRWEATHERTAIT, SJ (corresponding author), INST FOOD RES,NORWICH LAB,NORWICH NR4 7UA,NORFOLK,ENGLAND.		Fairweather-Tait, Susan J/K-4251-2012	Fairweather-Tait, Susan/0000-0002-1413-5569				BRITTIN HC, 1986, J AM DIET ASSOC, V86, P897; FAIRWEATHERTAIT SJ, 1990, BRIT J NUTR, V64, P547, DOI 10.1079/BJN19900054; Gregory F., 1990, DIETARY NUTR SURVEY; MARTINEZ FE, 1986, NUTR RES, V6, P421, DOI 10.1016/S0271-5317(86)80183-X	4	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1368	1368		10.1136/bmj.310.6991.1368	http://dx.doi.org/10.1136/bmj.310.6991.1368			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787541	Green Published			2022-12-28	WOS:A1995RB00500024
J	JOOSSENS, L; RAW, M				JOOSSENS, L; RAW, M			SMUGGLING AND CROSS-BORDER SHOPPING OF TOBACCO IN EUROPE	BRITISH MEDICAL JOURNAL			English	Article								Governments have recently become concerned about cross border shopping and smuggling because it can decrease tax revenue. The tobacco industry predicted that, with the removal of border controls in the European Union, price differences between neighbouring countries would lead to a diversion of tobacco trade, legally and illegally, to countries with cheaper cigarettes. According to them this diversion would be through increased cross border shopping for personal consumption or through increased smuggling of cheap cigarettes from countries with low tax to countries with high tax, where cigarettes are more expensive. These arguments have been used to urge governments not to increase tax on tobacco products. The evidence suggests, however, that cross border shopping is not yet a problem in Europe and that smuggling is not of cheap cigarettes to expensive countries. Instead, more expensive ''international'' brands are smuggled into northern Europe and sold illegally on the streets of the cheaper countries of southern Europe.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT EPIDEMIOL & PUBL HLTH,LONDON SE5 9PJ,ENGLAND	University of London; King's College London	JOOSSENS, L (corresponding author), CTR RECH INFORMAT ORG CONSOMMATEURS,RUE CHEVALIERS 18,B-1050 BRUSSELS,BELGIUM.							BARFORD MF, 1994, TOBACCO J INT, V6, P41; Barford MF, 1993, TOBACCO J INT, V3, P16; BUCK D., 1994, SHOULD CROSS BORDER; WHITE D, 1994, FINANCIAL TIMES 0705; 1994, NEWSLETTER, V23; 1994, TOBACCO HLTH EUROPEA; 1976, USDA FT376 FOR AGR S; 1994, USDA FT294 FOR AGR S; 1994, EUROPE          1212; 1994, USDA FT894 FOR AGR S, P23; 1995, NEWSLETTER, V27; 1994, 1ST REPORT CROSS BOR, V1; 1995, CEC1994 COMM EUR COM; 1990, PROPOSED COUNCIL DIR; IN PRESS CHRONIC DIS; 1994, NOVEMBER 1994 BUDGET; 1994, SMUGGLING TOBACCO PR; 1994, NOVEMBER 1994 CHANCE; 1994, MAXWELL TOBACCO FACT	19	54	55	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1393	1397		10.1136/bmj.310.6991.1393	http://dx.doi.org/10.1136/bmj.310.6991.1393			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787549	Green Published			2022-12-28	WOS:A1995RB00500034
J	MICHIELS, F; HABETS, GGM; STAM, JC; VANDERKAMMEN, RA; COLLARD, JG				MICHIELS, F; HABETS, GGM; STAM, JC; VANDERKAMMEN, RA; COLLARD, JG			A ROLE FOR RAC IN TIAM1-INDUCED MEMBRANE RUFFLING AND INVASION	NATURE			English	Article							GTP-BINDING-PROTEIN; ONCOGENE PRODUCT; RHO GDI; EXCHANGE; TRANSFECTION; CELLS; GENE	RHO-LIKE GTPases have been implicated in the regulation of the actin cytoskeleton which controls the morphology, adhesion and motility of cells(1-3). Like Ras proteins, they become activated when bound GDP is exchanged for GTP, a process catalysed by GDP-dissociation stimulator (GDS) proteins(4). Several GDS proteins specific for Rho-like GTPases have been identified(5-8). Most of these contain a conserved catalytic domain, the DBL-homology (DH) domain(9), and activate Cdc42 or Rho but not Rac(5-8). We have isolated the invasion-inducing Tiam1 gene, which also encodes a protein with a DH domain(10). Here we show that Tiam1 is a GDS protein for Rho-like GTPases in vitro. In fibroblasts, Tiam1 induces a similar phenotype as constitutively activated (V12)Rac1, including membrane ruffling, and this is inhibited by dominant negative (N17)Rac1. Moreover, T-lymphoma cells expressing V12Rac1 become invasive, indicating that the Tiam1-Rac signalling pathway could be operating in the invasion and metastasis of tumour cells.	NETHERLANDS CANC INST, DIV CELL BIOL, 1066 CX AMSTERDAM, NETHERLANDS	Netherlands Cancer Institute								BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; CHUANG TH, 1994, BIOCHEM J, V303, P761, DOI 10.1042/bj3030761; COLLARD JG, 1987, CANCER RES, V47, P754; COOK S, 1994, NATURE, V369, P361, DOI 10.1038/369361a0; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; HORLI Y, 1994, EMBO J, V13, P4776; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	26	508	521	1	12	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 25	1995	375	6529					338	340		10.1038/375338a0	http://dx.doi.org/10.1038/375338a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA030	7753201				2022-12-28	WOS:A1995RA03000057
J	COLAMARINO, SA; TESSIERLAVIGNE, M				COLAMARINO, SA; TESSIERLAVIGNE, M			THE AXONAL CHEMOATTRACTANT NETRIN-1 IS ALSO A CHEMOREPELLENT FOR TROCHLEAR MOTOR AXONS	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD; C-ELEGANS; NEURITE OUTGROWTH; GUIDES CELL; NEURONS; RAT; OCULOMOTOR; EXPRESSION; GUIDANCE	Extending axons are guided in part by diffusible chemoattractants that lure them to their targets and by diffusible chemorepellents that keep them away from nontarget regions. Floor plate cells at the ventral midline of the neural tube express a diffusible chemoattractant, netrin-1, that attracts a group of ventrally directed axons. Here we report that floor plate cells also have a long-range repulsive effect on a set of axons, trochlear motor axons, that grow dorsally away from the floor plate in vivo. COS cells secreting recombinant netrin-1 mimic this effect, suggesting that netrin-1 is a bifunctional guidance cue that simultaneously attracts some axons to the floor plate while steering others away. This bifunctionality of netrin-1 in vertebrates mirrors the dual actions of UNC-6, a C. elegans homolog of netrin-1, which is involved in guiding both dorsal and ventral migrations in the nematode.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, DEV BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, NEUROSCI PROGRAM, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	COLAMARINO, SA (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA.							ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; ALTMAN J, 1981, J COMP NEUROL, V198, P677, DOI 10.1002/cne.901980409; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; CHEDOTAL A, 1995, EUR J NEUROSCI, V7, P198, DOI 10.1111/j.1460-9568.1995.tb01056.x; COWAN WM, 1967, J EXP ZOOL, V164, P267, DOI 10.1002/jez.1401640210; DEROUICHE A, 1994, J COMP NEUROL, V341, P340, DOI 10.1002/cne.903410305; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; FITZGERALD M, 1993, DEVELOPMENT, V117, P1377; FRITZSCH B, 1993, DEV BRAIN RES, V74, P122, DOI 10.1016/0165-3806(93)90091-N; FRITZSCH B, 1990, NEUROSCI LETT, V114, P129, DOI 10.1016/0304-3940(90)90060-M; FRITZSCH B, 1988, CELL TISSUE RES, V252, P223; FRITZSCH B, 1995, IN PRESS J NEUROBIOL; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GUTHRIE S, 1995, IN PRESS NEURON, V14; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATESZ C, 1990, NEUROSCI LETT, V116, P1, DOI 10.1016/0304-3940(90)90376-K; MATTHES D, 1985, CELL, V81, P631; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; MURPHY EH, 1990, J COMP NEUROL, V295, P685; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PRINCE JT, 1992, DEV BRAIN RES, V68, P193, DOI 10.1016/0165-3806(92)90061-Z; PUELLES L, 1977, ANAT EMBRYOL, V150, P187, DOI 10.1007/BF00316650; RAMONYCAJAL S, 1892, CELLULE, V9, P119; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SINCLAIR JOHN G., 1958, TEXAS REPTS BIOL AND MED, V16, P253; SOHAL GS, 1985, J COMP NEUROL, V239, P227, DOI 10.1002/cne.902390209; SOHAL GS, 1977, EXP NEUROL, V56, P227, DOI 10.1016/0014-4886(77)90152-2; SOHAL GS, 1991, J COMP NEUROL, V304, P187, DOI 10.1002/cne.903040204; SOHAL GS, 1991, J NEUROSCI, V23, P10; SONNTAG R, 1987, NEUROSCI LETT, V77, P143, DOI 10.1016/0304-3940(87)90576-3; Szekely G, 1993, Adv Anat Embryol Cell Biol, V128, P1; TAMADA A, 1995, IN PRESS NEURON, V14; TESSIERLAVIGNE M, 1994, CURR OPIN GENET DEV, V4, P596, DOI 10.1016/0959-437X(94)90078-H; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WEHRLE B, 1990, DEVELOPMENT, V110, P401; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V	50	492	505	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					621	629		10.1016/0092-8674(95)90083-7	http://dx.doi.org/10.1016/0092-8674(95)90083-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758116	Bronze			2022-12-28	WOS:A1995QZ71000019
J	JURGENS, G				JURGENS, G			AXIS FORMATION IN PLANT EMBRYOGENESIS - CUES AND CLUES	CELL			English	Review							ARABIDOPSIS-THALIANA; EMBRYO; GENE; ORGANIZATION; MERISTEM; ROOT				JURGENS, G (corresponding author), UNIV TUBINGEN, LEHRSTUHL ENTWICKLUNGSGENET, D-72076 TUBINGEN, GERMANY.							BARTON MK, 1993, DEVELOPMENT, V119, P823; BENFEY PN, 1993, DEVELOPMENT, V119, P57; BERGER F, 1994, SCIENCE, V263, P1421, DOI 10.1126/science.263.5152.1421; BERLETH T, 1993, DEVELOPMENT, V118, P575; CLARK SE, 1993, DEVELOPMENT, V119, P397; DOLAN L, 1994, DEVELOPMENT, V120, P2465; DOLAN L, 1993, DEVELOPMENT, V119, P71; DUCKETT CM, 1994, DEVELOPMENT, V120, P3247; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jurgens G., 1994, PLANT MOL BIOL MOL G, P95; Jurgens G, 1994, COLOUR ATLAS DEV EMB EMBRYOS COLOR ATLAS, P7; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MAYER U, 1993, DEVELOPMENT, V117, P149; QUATRANO RS, 1991, DEVELOPMENT, P11; RUIZ RAT, 1994, DEVELOPMENT, V120, P2967; SCHERES B, 1995, DEVELOPMENT, V121, P53; SCHERES B, 1994, DEVELOPMENT, V120, P2475; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SINHA NR, 1993, GENE DEV, V7, P787, DOI 10.1101/gad.7.5.787; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; SUNG ZR, 1992, SCIENCE, V258, P1645, DOI 10.1126/science.258.5088.1645; THOMA S, 1994, PLANT PHYSIOL, V105, P35, DOI 10.1104/pp.105.1.35; WEBB MC, 1991, PLANTA, V184, P187, DOI 10.1007/BF00197947; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7	26	90	91	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 19	1995	81	4					467	470		10.1016/0092-8674(95)90065-9	http://dx.doi.org/10.1016/0092-8674(95)90065-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QZ710	7758100	Bronze			2022-12-28	WOS:A1995QZ71000001
J	HATTON, MQF; ALLEN, MB; VATHENEN, AS; MELLOR, E; COOKE, NJ				HATTON, MQF; ALLEN, MB; VATHENEN, AS; MELLOR, E; COOKE, NJ			DOES SEDATION HELP IN FIBEROPTIC BRONCHOSCOPY	BRITISH MEDICAL JOURNAL			English	Article							FIBEROPTIC BRONCHOSCOPY; PREMEDICATION		UNIV LEEDS,GEN INFIRM,DEPT RESP MED,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND; UNIV LEEDS,GEN INFIRM,DEPT PHARM,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds; Leeds General Infirmary; University of Leeds								COLT HG, 1990, CHEST, V98, P1327, DOI 10.1378/chest.98.6.1327; CREDLE WF, 1974, AM REV RESPIR DIS, V109, P67; PEARCE SJ, 1980, BRIT MED J, V281, P779, DOI 10.1136/bmj.281.6243.779; REES PJ, 1983, THORAX, V38, P624, DOI 10.1136/thx.38.8.624; SIMPSON FG, 1986, THORAX, V41, P311, DOI 10.1136/thx.41.4.311	5	73	75	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1994	309	6963					1206	1207		10.1136/bmj.309.6963.1206	http://dx.doi.org/10.1136/bmj.309.6963.1206			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ662	7772114	Green Published			2022-12-28	WOS:A1994PQ66200021
J	BENNETT, SN; MCNEIL, MM; BLAND, LA; ARDUINO, MJ; VILLARINO, ME; PERROTTA, DM; BURWEN, DR; WELBEL, SF; PEGUES, DA; STROUD, L; ZEITZ, PS; JARVIS, WR				BENNETT, SN; MCNEIL, MM; BLAND, LA; ARDUINO, MJ; VILLARINO, ME; PERROTTA, DM; BURWEN, DR; WELBEL, SF; PEGUES, DA; STROUD, L; ZEITZ, PS; JARVIS, WR			POSTOPERATIVE INFECTIONS TRACED TO CONTAMINATION OF AN INTRAVENOUS ANESTHETIC, PROPOFOL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE UNITS; NOSOCOMIAL INFECTIONS; STAPHYLOCOCCUS-AUREUS; ENDOTOXIN PRODUCTION; CANDIDA-ALBICANS; MICROBIAL-GROWTH; BACTERIAL-GROWTH; SYRINGES; INFUSION; OUTBREAK	Background. Between June 1990 and February 1993, the Centers for Disease Control and Prevention conducted investigations at seven hospitals because of unusual outbreaks of bloodstream infections, surgical-site infections, and acute febrile episodes after surgical procedures. Methods. We conducted case-control or cohort studies, or both, to identify risk factors. A case patient was defined as any patient who had an organism-specific infection or acute febrile episode after a surgical procedure during the study period in that hospital. The investigations also included reviews of procedures, cultures, and microbiologic studies of infecting, contaminating, and colonizing strains. Results. Sixty-two case patients were identified, 49 (79 percent) of whom underwent surgery during an epidemic period. Postoperative complications were more frequent during the epidemic period than before it. Only exposure to propofol, a lipid-based anesthetic agent, was significantly associated with the postoperative complications at all seven hospitals. In six of the outbreaks, an etiologic agent (Staphylococcus aureus, Candida albicans, Moraxella osloensis, Enterobacter agglomerans, or Serratia marcescens) was identified, and the same strains were isolated from the case patients. Although cultures of unopened containers of propofol were negative, at two hospitals cultures of propofol from syringes currently in use were positive. At one hospital, the recovered organism was identical to the organism isolated from the case patients. Interviews with and observation of anesthesiology personnel documented a wide variety of lapses in aseptic techniques. Conclusions. With the increasing use of lipid-based medications, which support rapid bacterial growth at room temperature, strict aseptic techniques are essential during the handling of these agents to prevent extrinsic contamination and dangerous infectious complications.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, DIV BACTERIAL & MYCOT DIS, ATLANTA, GA 30333 USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA 30333 USA; TEXAS DEPT HLTH, AUSTIN, TX USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Texas Department of State Health Services			Arduino, Matthew/C-1461-2012	Arduino, Matthew/0000-0001-7072-538X; McNeil, Michael/0000-0003-0713-8312; Zeitz, Paul/0000-0002-0865-088X				ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; ARDUINO MJ, 1991, INFECT CONT HOSP EP, V12, P535; BERRY CB, 1993, ANAESTHESIA, V48, P30; BLAIR JE, 1961, B WORLD HEALTH ORGAN, V24, P771; CORBETT JJ, 1971, NEUROLOGY, V21, P946, DOI 10.1212/WNL.21.9.946; CROCKER KS, 1984, JPEN-PARENTER ENTER, V8, P391, DOI 10.1177/0148607184008004391; Dean A. G., 1990, EPI INFO VERSION 5 W; EDWARDS PR, 1986, IDENTIFICATION ENTER, P431; FROGGATT JW, 1991, 31ST INT C ANT AG CH; Garner J. S., 1985, GUIDELINE PREVENTION; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GREENE ES, 1990, ANESTHESIOLOGY, V73, pA1061; HARRISON CA, 1990, ANAESTHESIA, V45, P831, DOI 10.1111/j.1365-2044.1990.tb14564.x; JACKSON PG, 1981, TUBERCLE, V62, P277, DOI 10.1016/S0041-3879(81)80008-6; JARVIS WR, 1991, AM J MED, V91, pS185, DOI 10.1016/0002-9343(91)90367-7; JARVIS WR, 1984, J CLIN MICROBIOL, V19, P17, DOI 10.1128/JCM.19.1.17-20.1984; KANTOR RJ, 1983, AM J MED, V74, P449, DOI 10.1016/0002-9343(83)90978-6; KEMPEN P M, 1989, Anesthesiology (Hagerstown), V71, pA948, DOI 10.1097/00000542-198909001-00948; KEMPEN PM, 1989, CAN J ANAESTH, V36, P730, DOI 10.1007/BF03005435; KEMPEN PM, 1990, ANESTH ANALG       S, V70, pS199; KOEPKE JW, 1985, ANN ALLERGY, V55, P776; KOEPKE JW, 1984, NEW ENGL J MED, V311, P1188; LASKER BA, 1989, NUCLEIC ACIDS RES, V17, P3783, DOI 10.1093/nar/17.10.3783; LUTZ CT, 1984, NEW ENGL J MED, V310, P1335, DOI 10.1056/NEJM198405173102024; MAKI DG, 1974, APPL MICROBIOL, V28, P778, DOI 10.1128/AEM.28.5.778-784.1974; Maniatis T., 1982, MOL CLONING; MASON MM, 1987, J CLIN MICROBIOL, V25, P563, DOI 10.1128/JCM.25.3.563-566.1987; MASTRO TD, 1990, NEW ENGL J MED, V323, P968, DOI 10.1056/NEJM199010043231406; NORTH JB, 1979, AUST NZ J SURG, V49, P484, DOI 10.1111/j.1445-2197.1979.tb05847.x; ODONNELL NG, 1992, ANAESTHESIA, V47, P923, DOI 10.1111/j.1365-2044.1992.tb03191.x; PARLOW JL, 1989, CAN J ANAESTH, V36, pS61; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; REMILLARD JF, 1987, DETECTION BACTERIAL, V231, P197; ROSENBERG A D, 1989, Anesthesiology (Hagerstown), V71, pA949, DOI 10.1097/00000542-198909001-00949; ROSENBERG AD, 1991, ANESTH ANALG, V72, pS228; RUDNICK JR, 1992, 2ND ANN M SOC HOSP E; SCHAFFNER W, 1969, NEW ENGL J MED, V280, P1224, DOI 10.1056/NEJM196905292802209; SOSIS MB, 1993, ANESTH ANALG, V77, P766; STEERE AC, 1978, TRANSFUSION, V18, P102, DOI 10.1046/j.1537-2995.1978.18178118551.x; TESSLER M, 1992, CAN J ANAESTH, V39, P509, DOI 10.1007/BF03008718; THOMAS DV, 1991, BRIT J ANAESTH, V66, P274, DOI 10.1093/bja/66.2.274-a; TRAUB WH, 1977, J CLIN MICROBIOL, V5, P115; TREPANIER CA, 1990, CAN J ANAESTH, V37, P156, DOI 10.1007/BF03005462; WEINSTEIN RA, 1991, AM J MED, V91, pS179, DOI 10.1016/0002-9343(91)90366-6; ZACHER AN, 1991, ANESTHESIOLOGY, V75, P893, DOI 10.1097/00000542-199111000-00022; 1993, RECOMMENDATIONS INFE; 1985, US PHARMACOPEIA, P1165; 1976, MMWR-MORBID MORTAL W, V25, P141; 1990, MMWR-MORBID MORTAL W, V39, P426; 1993, INFECTION CONTROL GU; 1993, DIPRIVAN INJECTION; 1985, STANDARD METHODS EXA, P869	52	362	374	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 20	1995	333	3					147	154		10.1056/NEJM199507203330303	http://dx.doi.org/10.1056/NEJM199507203330303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK917	7791816				2022-12-28	WOS:A1995RK91700003
J	MEINKING, TL; TAPLIN, D; HERMIDA, JL; PARDO, R; KERDEL, FA				MEINKING, TL; TAPLIN, D; HERMIDA, JL; PARDO, R; KERDEL, FA			THE TREATMENT OF SCABIES WITH IVERMECTIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTESTINAL HELMINTHS; PERMETHRIN CREAM; INFECTION; COMMUNITY; EFFICACY	Background. Ivermectin is an anthelmintic agent that has been a safe, effective treatment for onchocerciasis (river blindness) when given in a single oral dose of 150 to 200 mu g per kilogram of body weight. Anecdotal reports of improvement in patients who suffered from infestation with the mite Sarcoptes scabiei suggest that the ectoparasitic disease scabies might be treated with ivermectin. Methods. We conducted an open-label study in which ivermectin was administered in a single oral dose of 200 mu g per kilogram to 11 otherwise healthy patients with scabies and to 11 patients with scabies who were also infected with the human immunodeficiency virus (HIV), 7 of whom had the acquired immunodeficiency syndrome. All patients received a full physical and dermatologic examination; scrapings from the skin of all patients tested positive for scabies. Patients were reexamined two and four weeks after treatment, when the scrapings for scabies were repeated. The patients used no other scabicides during the 30 days before ivermectin treatment or during the 4-week study period. Results. None of the 11 otherwise healthy patients had evidence of scabies four weeks after a single dose of ivermectin. Of the 11 HIV-infected patients, 2 had less than or equal to 10 scabies lesions before treatment, 3 had 11 to 49 lesions, 4 had greater than or equal to 50 lesions, and 2 had heavily crusted skin lesions. In eight of the patients the scabies was cured after a single dose of ivermectin. Two patients received a second dose two weeks after the first. Ten of the 11 patients with HIV infection (91 percent) had no evidence of scabies four weeks after their first treatment with ivermectin. Conclusions. The anthelmintic agent ivermectin, given in a single oral dose, is an effective treatment for scabies in otherwise healthy patients and in many patients with HIV infection.	UNIV MIAMI,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,MIAMI,FL	University of Miami	MEINKING, TL (corresponding author), UNIV MIAMI,SCH MED,DEPT DERMATOL & CUTANEOUS SURG,POB 016960,R-117,MIAMI,FL 33101, USA.							AUBIN F, 1995, NEW ENGL J MED, V332, P612, DOI 10.1056/NEJM199503023320917; BLAIR LS, 1980, AM J VET RES, V41, P2108; CAMPBELL W C, 1985, Parasitology Today, V1, P10, DOI 10.1016/0169-4758(85)90100-0; CAMPBELL WC, 1989, IVERMECTION ABAMECTI, V149, P215; CARTEL JL, 1992, T ROY SOC TROP MED H, V86, P537, DOI 10.1016/0035-9203(92)90098-W; COMMENS CA, 1994, MED J AUSTRALIA, V160, P317, DOI 10.5694/j.1326-5377.1994.tb138227.x; DUNNE CL, 1991, T ROY SOC TROP MED H, V85, P550, DOI 10.1016/0035-9203(91)90255-W; ENCARNACION CF, 1994, ARCH INTERN MED, V154, P1749, DOI 10.1001/archinte.154.15.1749; ESTES SA, 1993, SEMIN DERMATOL, V12, P26; FREEDMAN DO, 1990, J INFECT DIS, V159, P1151; GLAZIOU P, 1993, TROP MED PARASITOL, V44, P331; Greene B. M., 1989, Ivermectin and abamectin., P311; GREENE BM, 1985, NEW ENGL J MED, V313, P133, DOI 10.1056/NEJM198507183130301; Kar S. K., 1994, National Medical Journal of India, V7, P15; LAWRENCE GW, 1994, MED J AUSTRALIA, V161, P232, DOI 10.5694/j.1326-5377.1994.tb127407.x; Macotela-Ruiz E, 1993, Gac Med Mex, V129, P201; MARTINPREVEL Y, 1993, AM J TROP MED HYG, V48, P186, DOI 10.4269/ajtmh.1993.48.186; Meinking T L, 1990, Adv Dermatol, V5, P131; NAQUIRA C, 1989, AM J TROP MED HYG, V40, P304, DOI 10.4269/ajtmh.1989.40.304; SCHULTZ MW, 1990, ARCH DERMATOL, V126, P167, DOI 10.1001/archderm.126.2.167; TAPLIN D, 1991, LANCET, V337, P1016, DOI 10.1016/0140-6736(91)92669-S; TAPLIN D, 1986, J AM ACAD DERMATOL, V15, P995; TAPLIN D, 1990, ARCH DERMATOL, V126, P213, DOI 10.1001/archderm.126.2.213; TAPLIN D, 1990, PEDIATR DERMATOL, V7, P67, DOI 10.1111/j.1525-1470.1990.tb01078.x; WHITWORTH JAG, 1991, T ROY SOC TROP MED H, V85, P232, DOI 10.1016/0035-9203(91)90037-Y; 1992, MMWR-MORBID MORTAL W, V41, P1	26	233	243	1	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	1995	333	1					26	30		10.1056/NEJM199507063330105	http://dx.doi.org/10.1056/NEJM199507063330105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG735	7776990				2022-12-28	WOS:A1995RG73500005
J	RANDIN, D; VOLLENWEIDER, P; TAPPY, L; JEQUIER, E; NICOD, P; SCHERRER, U				RANDIN, D; VOLLENWEIDER, P; TAPPY, L; JEQUIER, E; NICOD, P; SCHERRER, U			SUPPRESSION OF ALCOHOL-INDUCED HYPERTENSION BY DEXAMETHASONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOTROPIN-RELEASING FACTOR; SYMPATHETIC EFFERENT DISCHARGE; BARORECEPTOR REFLEX CONTROL; NERVOUS-SYSTEM; BLOOD-PRESSURE; HEART-RATE; ETHANOL; CONSUMPTION; ACTIVATION; STROKE	Background. Alcohol consumption is associated with an increased incidence of hypertension and stroke, but the triggering mechanisms are unclear. In animals, alcohol causes activation of the sympathetic nervous system and also stimulates the release of corticotropin-releasing hormone (CRH), which has sympathoexcitatory effects when administered centrally. Methods. To determine whether alcohol evokes sympathetic activation and whether such activation is attenuated by the inhibition of CRH release, we measured blood pressure, heart rate, and sympathetic-nerve action potentials (using intraneural microelectrodes) in nine normal subjects before and during an intravenous infusion of alcohol (0.5 g per kilogram of body weight over a period of 45 minutes) and for 75 minutes after the infusion. Each subject received two infusions, one after the administration of dexamethasone (2 mg per day) and one after the administration of a placebo for 48 hours. Results. The infusion of alcohol alone evoked a marked (P<0.001) and progressive increase in the mean (+/-SD) rate of sympathetic discharge, from 16+/-3 bursts per minute at base line to 30+/-8 bursts per minute at the end of the two-hour period. This sympathetic activation was accompanied during the second hour by an increase in mean arterial pressure of 10+/-5 mm Hg (P<0.001). After the administration of dexamethasone, the alcohol infusion had no detectable sympathetic effect. The dexamethasone-induced suppression of sympathetic activation was associated with a decrease in mean arterial pressure of 7+/-6 mm Hg (P<0.001) during the alcohol infusion and with suppression of the presser effect during the second hour. Conclusions. Alcohol induces presser effects by sympathetic activation that appear to be centrally mediated. It is possible that these alcohol-induced hemodynamic and sympathetic actions could participate in triggering cardiovascular events.	UNIV LAUSANNE,INST PHYSIOL,LAUSANNE,SWITZERLAND	University of Lausanne	RANDIN, D (corresponding author), CHU VAUDOIS,DEPT INTERNAL MED B,BH 10642,CH-1011 LAUSANNE,SWITZERLAND.		Tappy, Luc/A-8911-2017	Tappy, Luc/0000-0001-8469-4692				ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; ARKWRIGHT PD, 1982, CIRCULATION, V66, P515, DOI 10.1161/01.CIR.66.3.515; BERNE C, 1989, J CLIN INVEST, V84, P1403, DOI 10.1172/JCI114313; BROWN MR, 1985, FED PROC, V44, P243; CLAYTON S, 1963, J PHYSIOL-LONDON, V169, pP82; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GRASSI GM, 1989, J HYPERTENS, V7, pS20, DOI 10.1097/00004872-198900076-00007; HILLBOM M, 1983, STROKE, V14, P694, DOI 10.1161/01.STR.14.5.694; HOWES LG, 1986, CLIN SCI, V71, P9, DOI 10.1042/cs0710009; JENKINS JS, 1968, BRIT MED J, V2, P804, DOI 10.1136/bmj.2.5608.804; KLAG MJ, 1993, HYPERTENSION, V22, P365, DOI 10.1161/01.HYP.22.3.365; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; KUROSAWA M, 1986, BRAIN RES, V367, P250, DOI 10.1016/0006-8993(86)91599-4; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; NAKANO J, 1972, ARCH INT PHARMACOD T, V196, P259; OVERTON JM, 1989, REGUL PEPTIDES, V25, P315, DOI 10.1016/0167-0115(89)90179-1; RIVIER C, 1990, BRAIN RES, V520, P1, DOI 10.1016/0006-8993(90)91685-A; RIVIER C, 1984, J PHARMACOL EXP THER, V229, P127; RUSS R, 1991, ALCOHOL, V8, P301, DOI 10.1016/0741-8329(91)90433-W; SCHERRER U, 1990, NEW ENGL J MED, V323, P693, DOI 10.1056/NEJM199009133231101; SCHERRER U, 1993, CIRCULATION, V88, P388, DOI 10.1161/01.CIR.88.2.388; SLOAND JA, 1989, AM J CARDIOL, V63, P1140, DOI 10.1016/0002-9149(89)90096-9; VALLBO AB, 1979, PHYSIOL REV, V59, P919, DOI 10.1152/physrev.1979.59.4.919; VOLLENWEIDER P, 1993, J CLIN INVEST, V92, P147, DOI 10.1172/JCI116542; ZHANG X, 1989, HYPERTENSION, V14, P282, DOI 10.1161/01.HYP.14.3.282; ZHANG X, 1988, P SOC EXP BIOL MED, V187, P14	27	127	127	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1733	1737		10.1056/NEJM199506293322601	http://dx.doi.org/10.1056/NEJM199506293322601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760888	Green Published			2022-12-28	WOS:A1995RE66700001
J	POLLOCK, AM				POLLOCK, AM			WHERE SHOULD HEALTH-SERVICES GO - LOCAL-AUTHORITIES VERSUS THE NHS	BRITISH MEDICAL JOURNAL			English	Article								The Association of Metropolitan Authorities has recently proposed that responsibility for the NHS should pass from health authorities to local authorities. One of the fiercest debates at the outset of the NHS was whether the hospitals should be run by local authorities. In the end the minister for health, Aneurin Bevan, decided against local democracy and in favour of a national health service. His arguments included the fact that equality of treatment could not be guaranteed if facilities varied with local finances and that even the largest authorities were not big enough to pool risks and expertise. Ah these arguments still apply today, and the recent changes in community care provide an insight into how a market model of local authority control might work. The changes have been accompanied by a shift from public to private sector provision and the introduction of charges for services that the NHS once provided free. As important, the willingness and ability of local authorities to raise extra revenue from local taxes and charges affect the service they can provide, so leading to inequalities of provision. Local authorities have yet to make the case that they can preserve the fundamental principles and benefits of the NHS, including its reliance on central taxation and unified funding formulas.			POLLOCK, AM (corresponding author), ST GEORGES MED SCH,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.			pollock, allyson/0000-0002-7388-3110				BRADSHAW J, 1988, PUBLIC SUPPORT PRIVA; CARPENTER M, 1994, NORMALITY IS HARD WO; CHALLIS L, 1994, BRIT MED J, V308, P1496, DOI 10.1136/bmj.308.6942.1496; CHARLTON BG, 1994, BRIT MED J, V308, P1019, DOI 10.1136/bmj.308.6935.1019; DAVIS H, 1994, GROWTH GOVT APPOINTM; DIXON J, 1991, BRIT MED J, V309, P30; DONALDSON LJ, 1992, HLTH ELDERLY PEOPLE; HARRISON S, 1991, HLTH HLTH CARE; HENWOOD M, 1992, GLASS DARKLY COMMUNI; JUDGE K, 1994, BRIT MED J, V308, P1363, DOI 10.1136/bmj.308.6940.1363; KLEIN R, 1989, MILBANK Q, V67, P1; Laing W., 1993, FINANCING LONG TERM; POLLOCK AM, 1992, BRIT MED J, V305, P535, DOI 10.1136/bmj.305.6853.535; STEWART J, 1993, DEMOS            WIN, P14; Webster C., 1988, HLTH SERVICES WAR; WEBSTER C, 1991, ANEURIN BEVAN NHS; WHITEHEAD M, 1994, BRIT MED J, V308, P1284, DOI 10.1136/bmj.308.6939.1284; 1994, NHSE HSG94 NHS EX; 1992, 1ST STEPS REPORT 1ST; 1994, PERSONAL SOCIAL SERV; 1994, ACCOUNTABILITY DEMOC; 1990, CARING PEOPLE COMMUN; 1994, SURVEY SOCIAL SERVIC; 1992, 1ST SPECIAL REPORT; 1994, LOCAL AUTHORITIES HL; 1991, FINANCING PRIVATE RE	26	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1580	1584		10.1136/bmj.310.6994.1580	http://dx.doi.org/10.1136/bmj.310.6994.1580			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787651	Green Published			2022-12-28	WOS:A1995RE35300026
J	MOULDING, T; DUTT, AK; REICHMAN, LB				MOULDING, T; DUTT, AK; REICHMAN, LB			FIXED-DOSE COMBINATIONS OF ANTITUBERCULOUS MEDICATIONS TO PREVENT DRUG-RESISTANCE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							TUBERCULOSIS; CHEMOTHERAPY	The treatment of tuberculosis requires at least two drugs to retard the development of drug resistance. Unfortunately, patients may take only one drug (monotherapy) when more than one is prescribed. Fixed-dose combinations with two or more antituberculous drugs in one capsule or tablet are available to prevent this. In the United States, these drugs are Rifamate (Marion Merrell Dow), which contains isoniazid plus rifampin, and Rifater (Marion Merrell Dow), which contains isoniazid plus rifampin and pyrazinamide. Because these preparations make monotherapy impossible, they are clearly preferable to individual drugs. In the United States in 1993, however, only 15% to 18% of rifampin was sold in the form of fixed-dose combinations. To correct this deficiency, fixed-dose combinations should be widely promoted and accepted as a primary way to prevent drug-resistant tuberculosis. There are two caveats regarding these preparations. First, many fixed-dose combinations, especially those in developing countries, achieve inadequate blood levels of one or more of the component drugs, especially rifampin. Our recommendations apply only to preparations with proven bioavailability. Second, because the name Rifamate is similar to the name rifampin, mistakes in prescribing and dispensing can result in the patient receiving rifampin alone when Rifamate is intended. A name change from Rifamate to a highly distinctive name such as Rif-Isoniazid is needed to prevent such occurrences.	ALVIN C YORK VET ADM MED CTR, MURFREESBORO, TN 37129 USA; UNIV MED & DENT NEW JERSEY, NATL TB CTR, NEWARK, NJ 07107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	MOULDING, T (corresponding author), UNIV CALIF LOS ANGELES, HARBOR MED CTR, DIV RESP & CRIT CARE PHYSIOL & MED, TORRANCE, CA 90501 USA.				PHS HHS [200-93-0690, 200-93-0636, K07-H103015-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Acocella G, 1989, Bull Int Union Tuberc Lung Dis, V64, P38; [Anonymous], 1993, MMWR Recomm Rep, V42, P1; [Anonymous], 1991, Am Rev Respir Dis, V143, P707; [Anonymous], 1974, Lancet, V2, P1100; [Anonymous], 1991, Am Rev Respir Dis, V143, P700; [Anonymous], 1994, Tuber Lung Dis, V75, P180; [Anonymous], 1960, TUBERCLE, V41, P83; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; DAVIES PDO, 1993, AM REV RESPIR DIS, V147, P497, DOI 10.1164/ajrccm/147.2.497; Geiter L J, 1987, Tubercle, V68, P41, DOI 10.1016/S0041-3879(87)80021-1; GLASSROTH J, 1993, AM REV RESPIR DIS, V147, P497, DOI 10.1164/ajrccm/147.2.497a; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MITCHISON DA, 1979, CHEST, V76, P771, DOI 10.1378/chest.76.6_Supplement.771; 1969, NEW ENGL J MED, V280, P1149; 1950, BRIT MED J, V2, P1073	17	65	67	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					951	954		10.7326/0003-4819-122-12-199506150-00010	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755232				2022-12-28	WOS:A1995RC27000010
J	HAMMOND, HA; RADMAN, JB; CASKEY, CT				HAMMOND, HA; RADMAN, JB; CASKEY, CT			IN-UTERO PATERNITY TESTING FOLLOWING ALLEGED SEXUAL ASSAULT - A COMPARISON OF DNA-BASED METHODS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VARIABLE NUMBER; TANDEM REPEATS; VNTR LOCI; MARKERS	Objective.-To compare DNA typing by both variable number of tandem repeats (VNTR) and polymerase chain reaction (PCR) methods to determine the utility of each for prenatal paternity testing following sexual assault. To consider ethical issues of limiting prenatal paternity studies. Design.-Criterion standard. Setting.-Prenatal diagnostic clinic after determination of pregnancy following an alleged sexual assault. Subjects.-Ten prenatal paternity cases accepted during a 5-year period. Main Outcome Measure.-Inclusion or exclusion of paternity by consensual partner. Results.-In all cases DNA typing using the PCR-based method provided the same conclusion as that from VNTR-based data. High probabilities of paternity were reported with both methods. Conclusions.-DNA typing with PCR using short tandem repeat loci provides a reliable method for quickly determining paternity in prenatal cases. The ethics of providing paternity testing in the context of sexual assault is discussed. The issue of providing prenatal paternity testing in consensual relationships is considered.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute	HAMMOND, HA (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.							ALFORD RL, 1994, AM J HUM GENET, V55, P190; [Anonymous], 1992, DNA TECHNOLOGY FOREN; BROCK DJ, 1992, LANCET, V338, P1151; BUDOWLE B, 1990, CLIN BIOCHEM, V23, P287, DOI 10.1016/0009-9120(90)80055-N; BUDOWLE B, 1991, AM J HUM GENET, V48, P841; BUDOWLE BF, 1990, DATA ACQUISITION STA, P103; CASKEY CT, 1992, ADV FORENSIC HAEMOGE, P12; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EDWARDS A, 1991, AM J HUM GENET, V49, P746; HAMMOND HA, 1994, AM J HUM GENET, V55, P175; Hardy GH, 1908, SCIENCE, V28, P49, DOI 10.1126/science.28.706.49; KANTER E, 1986, J FORENSIC SCI, V31, P403; LOBBIANI A, 1991, PRENATAL DIAG, V11, P343, DOI 10.1002/pd.1970110512; MACINTYRE S, 1992, LANCET, V338, P869; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; ODELBERG SJ, 1989, GENOMICS, V5, P915, DOI 10.1016/0888-7543(89)90134-1; WADHAMS M, 1992, J FORENSIC SCI, V44, P65; 1991, UNIFORM CRIME REPORT; 1990, GENETIC WITNESS FORE	19	7	7	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 14	1995	273	22					1774	1777		10.1001/jama.273.22.1774	http://dx.doi.org/10.1001/jama.273.22.1774			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB800	7769772				2022-12-28	WOS:A1995RB80000031
J	RAFFLE, AE; ALDEN, B; MACKENZIE, EFD				RAFFLE, AE; ALDEN, B; MACKENZIE, EFD			DETECTION RATES FOR ABNORMAL CERVICAL SMEARS - WHAT ARE WE SCREENING FOR	LANCET			English	Article							CARCINOMA INSITU; MORTALITY; CANCER; TRENDS; DNA	We analysed rates of detection for smear abnormalities in 255 000 women served by the Bristol screening programme. The programme began in 1966 with the aim of eradicating the 30-40 deaths each year in Bristol from cervical cancer. Organisation has been good and population uptake has been high for the past 15 years. Records were computerised in 1977. During the 1988 to 1993 screening round, 225 974 women were tested. New smear abnormalities were found in 15 551, of whom nearly 6000 were referred for colposcopy. These numbers are excessively high in comparison with the incidence of the malignancy we are trying to prevent. The effect of screening on death rates in Bristol is too small to detect. Our conclusion is that despite good organisation of the service, much of our effort in Bristol is devoted to limiting the harm done to healthy women and to protecting our staff from litigation as cases of serious disease continue to occur. The real lesson from 30 years' cervical screening is that no matter how obvious the predicted benefit may seem for any screening test, introduction should never take place without adequate prior evaluation of both positive and negative effects in controlled trials.	UNITED BRISTOL HEALTHCARE TRUST,DEPT INFORMAT TECHNOL,BRISTOL,AVON,ENGLAND; SOUTHMEAD HLTH SERV TRUST,BRISTOL,AVON,ENGLAND		RAFFLE, AE (corresponding author), BRISTOL & DIST HLTH AUTHOR,10 DIGHTON ST,BRISTOL BS2 8EE,AVON,ENGLAND.							ADELSTEIN AM, 1971, BRIT J PREV SOC MED, V25, P186; ANDERSON CM, 1994, BRIT MED J, V309, P953, DOI 10.1136/bmj.309.6959.953a; AUSTOKER J, 1994, CANCER CERVIX UTERI; BUCKLEY CH, 1994, J CLIN PATHOL, V47, P481; CREASMAN WT, 1972, OBSTET GYNECOL, V39, P373; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; DUNCAN ID, 1993, GUIDELINES CLIN PRAC; EVANS DMD, 1986, J CLIN PATHOL, V39, P933, DOI 10.1136/jcp.39.9.933; FLANNELLY G, 1994, BRIT MED J, V308, P1399, DOI 10.1136/bmj.308.6941.1399; KOLSTAD P, 1976, OBSTET GYNECOL, V48, P125; MACGREGOR JE, 1994, BMJ-BRIT MED J, V308, P1407, DOI 10.1136/bmj.308.6941.1407; MACGREGOR JE, 1978, LANCET, V2, P774; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; PARTINGTON CK, 1991, CANCER, V67, P3104, DOI 10.1002/1097-0142(19910615)67:12<3104::AID-CNCR2820671227>3.0.CO;2-L; SASIENI P, 1991, LANCET, V338, P818, DOI 10.1016/0140-6736(91)90701-P; SIGURDSSON K, 1991, INT J CANCER, V48, P523, DOI 10.1002/ijc.2910480408; 1965, REPORT MED OFFICER H; 1994, REPORT 1ST 5 YEARS N	18	111	111	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 10	1995	345	8963					1469	1473		10.1016/S0140-6736(95)91036-0	http://dx.doi.org/10.1016/S0140-6736(95)91036-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769901				2022-12-28	WOS:A1995RC18900008
J	MAINEN, ZF; SEJNOWSKI, TJ				MAINEN, ZF; SEJNOWSKI, TJ			RELIABILITY OF SPIKE TIMING IN NEOCORTICAL NEURONS	SCIENCE			English	Article							CAT VISUAL-CORTEX; SINGLE NEURONS; RESPONSES; MONKEY; VARIABILITY; STIMULUS; PATTERNS; CELLS; BRAIN; TRANSMISSION	It is not known whether the variability of neural activity in the cerebral cortex carries information or reflects noisy underlying mechanisms. In an examination of the reliability of spike generation using recordings from neurons in rat neocortical slices, the precision of spike timing was found to depend on stimulus transients. Constant stimuli led to imprecise spike trains, whereas stimuli with fluctuations resembling synaptic activity produced spike trains with timing reproducible to less than 1 millisecond. These data suggest a low intrinsic noise level in spike generation, which could allow cortical neurons to accurately transform synaptic input into spike sequences, supporting a possible role for spike timing in the processing of cortical information by the neocortex.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	MAINEN, ZF (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037, USA.		Sejnowski, Terrence/AAV-5558-2021	Mainen, Zachary/0000-0001-7913-9109				Abeles M., 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; ADRIAN ED, 1926, J PHYSIOL-LONDON, V61, P47; ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BAIR W, 1994, SOC NEUR ABSTR, V20, P1229; Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; BARLOW HB, 1963, KYBERNETIK, V2, P1, DOI 10.1007/BF00292103; BERGMAN H, 1993, J NEUROPHYSIOL, V70, P1629; BRYANT HL, 1976, J PHYSIOL-LONDON, V260, P279, DOI 10.1113/jphysiol.1976.sp011516; BULLOCK TH, 1970, J GEN PHYSIOL, V55, P565, DOI 10.1085/jgp.55.5.565; Burns BD, 1968, UNCERTAIN NERVOUS SY; CALVIN WH, 1968, J NEUROPHYSIOL, V31, P574, DOI 10.1152/jn.1968.31.4.574; CARR CE, 1990, J NEUROSCI, V10, P3227; CRONER LJ, 1993, P NATL ACAD SCI USA, V90, P8128, DOI 10.1073/pnas.90.17.8128; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; FERSTER D, 1992, J NEUROSCI, V12, P1262; Gray C M, 1994, J Comput Neurosci, V1, P11, DOI 10.1007/BF00962716; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Hines M, 1993, NEURAL SYSTEMS ANAL, P127; JAGADEESH B, 1992, SCIENCE, V257, P552, DOI 10.1126/science.1636094; KORENBERG MJ, 1989, J NEUROPHYSIOL, V61, P1110, DOI 10.1152/jn.1989.61.6.1110; KRUGER J, 1991, TRENDS NEUROSCI, V14, P282, DOI 10.1016/0166-2236(91)90138-K; LASS Y, 1975, BIOL CYBERN, V19, P61, DOI 10.1007/BF00364102; LESTIENNE R, 1987, BRAIN RES, V437, P214, DOI 10.1016/0006-8993(87)91638-6; LEVINE MW, 1988, VISUAL NEUROSCI, V1, P31, DOI 10.1017/S0952523800001000; MacKAY DONALD M., 1952, BULL MATH BIOPHYS, V14, P127, DOI 10.1007/BF02477711; MAINEN ZF, UNPUB; MALNEN ZF, UNPUB; Marmarelis P.Z., 1978, ANAL PHYSL SYSTEMS; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332, DOI 10.1152/jn.1992.68.4.1332; MCCLURKIN JW, 1991, SCIENCE, V253, P675, DOI 10.1126/science.1908118; MIDDLEBROOKS JC, 1994, SCIENCE, V264, P842, DOI 10.1126/science.8171339; NODA H, 1970, BRAIN RES, V18, P513, DOI 10.1016/0006-8993(70)90134-4; OTMAKHOV N, 1993, NEURON, V10, P1101, DOI 10.1016/0896-6273(93)90058-Y; PECHER C, 1939, ARCH INTERN PHYSIOL, V49, P129; PHILLIPS JR, 1992, J NEUROSCI, V12, P827; Rice SO, 1954, SELECTED PAPERS NOIS, P133; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P370, DOI 10.1152/jn.1990.64.2.370; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; SCHREINER RC, 1978, J NEUROPHYSIOL, V41, P338, DOI 10.1152/jn.1978.41.2.338; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SNOWDEN RJ, 1992, EXP BRAIN RES, V88, P389, DOI 10.1007/BF02259114; SOFTKY WR, 1993, J NEUROSCI, V13, P334; STEIN RB, 1967, BIOPHYS J, V7, P797, DOI 10.1016/S0006-3495(67)86623-2; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; SUGA N, 1990, COLD SPRING HARB SYM, V55, P585; THOMSON AM, 1993, J NEUROPHYSIOL, V70, P2354, DOI 10.1152/jn.1993.70.6.2354; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6; TOMKO GJ, 1974, BRAIN RES, V79, P405, DOI 10.1016/0006-8993(74)90438-7; TOVEE MJ, 1993, J NEUROPHYSIOL, V70, P640, DOI 10.1152/jn.1993.70.2.640; VANSTEVENINCK RD, 1988, PROC R SOC SER B-BIO, V234, P379; WERNER G, 1963, J NEUROPHYSIOL, V26, P958, DOI 10.1152/jn.1963.26.6.958; WHITSEL BL, 1977, J NEUROPHYSIOL, V40, P589, DOI 10.1152/jn.1977.40.3.589; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	55	1429	1442	2	51	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 9	1995	268	5216					1503	1506		10.1126/science.7770778	http://dx.doi.org/10.1126/science.7770778			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770778				2022-12-28	WOS:A1995RC19000042
J	STRATER, N; KLABUNDE, T; TUCKER, P; WITZEL, H; KREBS, B				STRATER, N; KLABUNDE, T; TUCKER, P; WITZEL, H; KREBS, B			CRYSTAL-STRUCTURE OF A PURPLE ACID-PHOSPHATASE CONTAINING A DINUCLEAR FE(III)-ZN(II) ACTIVE-SITE	SCIENCE			English	Article							REACTION-MECHANISM; BOVINE SPLEEN; PROTEIN; UTEROFERRIN; CATALYZES	Kidney bean purple acid phosphatase (KBPAP) is an Fe(III)-Zn(II) metalloenzyme resembling the mammalian Fe(III)-Fe(II) purple acid phosphatases. The structure of the homodimeric III-kilodalton KBPAP was determined at a resolution of 2.9 angstroms. The enzyme contains two domains in each subunit. The active site is located in the carboxyl-terminal terminal domain at the carboxy end of two sandwiched beta alpha beta alpha beta motifs. The two metal ions are 3.1 angstroms apart and bridged monodentately by Asp(164) The iron is further coordinated by Tyr(167), His(325), and Asp(135), and the zinc by His(286), His(323), and Asn(201). The active-site structure is consistent with previous proposals regarding the mechanism of phosphate ester hydrolysis involving nucleophilic attack on the phosphate group by an Fe(III)coordinated hydroxide ion.	EUROPEAN MOLEC BIOL LAB, D-69117 HEIDELBERG, GERMANY; UNIV MUNSTER, INST BIOCHEM, D-48149 MUNSTER, GERMANY	European Molecular Biology Laboratory (EMBL); University of Munster	STRATER, N (corresponding author), UNIV MUNSTER, INST ANORGAN CHEM, D-48149 MUNSTER, GERMANY.		Krebs, Bernt/B-9068-2011; Strater, Norbert/P-4856-2018	Strater, Norbert/0000-0002-2001-0500				AQUINO MAS, 1994, J CHEM SOC DALTON, P429, DOI 10.1039/dt9940000429; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BECK JL, 1986, BIOCHIM BIOPHYS ACTA, V869, P61, DOI 10.1016/0167-4838(86)90310-9; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER TA, 1993, XPLOR VERSION 3 1 MA; DIETRICH M, 1991, EUR J BIOCHEM, V199, P105, DOI 10.1111/j.1432-1033.1991.tb16097.x; Doi K., 1988, STRUCT BONDING BERLI, V70, P1; HAYMAN AR, 1994, J BIOL CHEM, V269, P1294; HOLMES MA, 1991, J MOL BIOL, V218, P583, DOI 10.1016/0022-2836(91)90703-9; HOLZ RC, 1992, J AM CHEM SOC, V114, P4434, DOI 10.1021/ja00037a079; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT; KAUZLARICH SM, 1986, INORG CHEM, V25, P2781, DOI 10.1021/ic00236a025; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KLABUNDE T, 1994, EUR J BIOCHEM, V226, P369, DOI 10.1111/j.1432-1033.1994.tb20061.x; KLEYWEGT GJ, IN PRESS ACTA CRYS D; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MUELLER EG, 1993, J AM CHEM SOC, V115, P2974, DOI 10.1021/ja00060a055; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PRIGGEMEYER S, 1995, INORG CHEM, V34, P1445, DOI 10.1021/ic00110a024; QUE L, 1990, PROG INORG CHEM, V38, P97; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; STAHL B, 1994, EUR J BIOCHEM, V220, P321, DOI 10.1111/j.1432-1033.1994.tb18628.x; STRATER N, 1992, J MOL BIOL, V224, P511, DOI 10.1016/0022-2836(92)91012-E; SUERBAUM H, 1993, EUR J BIOCHEM, V214, P313, DOI 10.1111/j.1432-1033.1993.tb17926.x; TRUE AE, 1993, J AM CHEM SOC, V115, P4246, DOI 10.1021/ja00063a047; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P5263, DOI 10.1021/bi00138a004	28	404	413	1	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 9	1995	268	5216					1489	1492		10.1126/science.7770774	http://dx.doi.org/10.1126/science.7770774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC190	7770774				2022-12-28	WOS:A1995RC19000038
J	CHIARA, MD; REED, R				CHIARA, MD; REED, R			A 2-STEP MECHANISM FOR 5' AND 3' SPLICE-SITE PAIRING	NATURE			English	Article							MESSENGER-RNA PRECURSORS; ACTIVE-SITE; U6 SNRNA; SELECTION; SEQUENCES; INVITRO	A FUNDAMENTAL question in the splicing of precursor messenger RNA is how the 5' and 3' splice sites are recognized and paired during the splicing reaction. It has been proposed that spliceosome assembly in metazoan pre-mRNAs can be initiated through interaction between the 3' splice site and specific sequence elements on the downstream exon (an exonic enhancer or a 5' splice site)(1). Pairing of the intronic 5' and 3' splice sites occurs subsequently. We report here that 5' and 3' splice sites located on separate synthetic pre-mRNA substrates can be efficiently trans-spliced if the 3' trans-splicing substrate contains these downstream sequence elements. Moreover, selection of the trans 5' splice site can occur after the second pre-spliceosomal complex A has assembled on the 3' trans-splicing substrate. Thus our data demonstrate that 5' and 3' splice-site pairing in metazoans can occur in two distinct steps.			CHIARA, MD (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Chiara, María Dolores/AAG-5765-2019	Chiara, María Dolores/0000-0002-1112-1583				DATTA B, 1993, MOL CELL BIOL, V13, P5377, DOI 10.1128/MCB.13.9.5377; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KONARSKA MM, 1985, CELL, V42, P165, DOI 10.1016/S0092-8674(85)80112-4; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KUO HC, 1992, SCIENCE, V251, P1045; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SOLNICK D, 1986, CELL, V44, P211, DOI 10.1016/0092-8674(86)90752-X; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WOLFF T, 1994, P NATL ACAD SCI USA, V91, P903, DOI 10.1073/pnas.91.3.903	17	93	97	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 8	1995	375	6531					510	513		10.1038/375510a0	http://dx.doi.org/10.1038/375510a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RC188	7777062				2022-12-28	WOS:A1995RC18800054
J	ERICSON, J; MUHR, J; PLACZEK, M; LINTS, T; JESSELL, TM; EDLUND, T				ERICSON, J; MUHR, J; PLACZEK, M; LINTS, T; JESSELL, TM; EDLUND, T			SONIC HEDGEHOG INDUCES THE DIFFERENTIATION OF VENTRAL FOREBRAIN NEURONS - A COMMON SIGNAL FOR VENTRAL PATTERNING WITHIN THE NEURAL-TUBE	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FLOOR PLATE; CELL PATTERN; PROTEIN ISL-1; CHICK-EMBRYO; EXPRESSION; NOTOCHORD; INDUCTION; HOMEODOMAIN; HOMEOBOX	The vertebrate hedgehog-related gene Sonic hedgehog (Shh) is expressed in ventral domains along the entire rostrocaudal length of the neural tube, including the forebrain. We show here that SHH induces the differentiation of ventral neuronal cell types in explants derived from prospective forebrain regions of the neural plate. Neurons induced in explants derived from both diencephalic and telencephalic levels of the neural plate express the LIM homeodomain protein Isl-1, and these neurons possess distinct identities that match those of the ventral neurons generated in these two subdivisions of the forebrain in vivo. A single inducing molecule, SHH, therefore appears to mediate the induction of distinct ventral neuronal cell types along the entire rostrocaudal extent of the embryonic central nervous system.	NATL INST MED RES, LONDON NW7 1AA, ENGLAND; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA; COLUMBIA UNIV, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	MRC National Institute for Medical Research; Columbia University; Howard Hughes Medical Institute; Columbia University	ERICSON, J (corresponding author), UMEA UNIV, DEPT MICROBIOL, S-90187 UMEA, SWEDEN.		Placzek, Marysia/E-6172-2010; Lints, Thierry/K-4408-2012	Ericson, Johan/0000-0002-8019-7127; Placzek, Marysia/0000-0002-4106-9229	NINDS NIH HHS [NS-33245, NS-30532] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033245, P01NS030532] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTABA ARI, 1992, DEVELOPMENT, V116, P67; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BARTH KA, 1995, IN PRESS DEVELOPMENT, V121; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; CHANG DT, 1994, DEVELOPMENT, V120, P3339; COULY GF, 1987, DEV BIOL, V120, P198, DOI 10.1016/0012-1606(87)90118-7; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HATTA K, 1994, P NATL ACAD SCI USA, V91, P2061, DOI 10.1073/pnas.91.6.2061; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HYNES M, 1995, CELL, V80, P95, DOI 10.1016/0092-8674(95)90454-9; INOUE A, 1994, DEV DYNAM, V199, P1, DOI 10.1002/aja.1001990102; JACOBSON CO, 1964, ZOOL BIDR UPPS, V36, P73; JESSELL TM, 1992, HARVEY LECT, V86, P87; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kingsbury BF, 1930, J COMP NEUROL, V50, P177, DOI 10.1002/cne.900500109; KORZH V, 1993, DEVELOPMENT, V118, P417; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; PLACZEK M, 1991, DEVELOPMENT, P105; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PUELLES L, 1987, J COMP NEUROL, V266, P247, DOI 10.1002/cne.902660210; PUELLES L, 1993, TRENDS NEUROSCI, V16, P472, DOI 10.1016/0166-2236(93)90080-6; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROACH FC, 1945, J EXP ZOOL, V99, P53, DOI 10.1002/jez.1400990203; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SIMON H, 1995, CURR BIOL, V5, P205, DOI 10.1016/S0960-9822(95)00041-8; SIMON H, 1994, J NEUROBIOL, V25, P1129, DOI 10.1002/neu.480250908; SMITH JC, 1993, CURR BIOL, V3, P582, DOI 10.1016/0960-9822(93)90003-7; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TANABE Y, 1995, IN PRESS CURR BIOL; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; THOR S, 1991, NEURON, V7, P881, DOI 10.1016/0896-6273(91)90334-V; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VANSTRAATEN HWM, 1988, ANAT EMBRYOL, V177, P317; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	51	454	476	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 2	1995	81	5					747	756		10.1016/0092-8674(95)90536-7	http://dx.doi.org/10.1016/0092-8674(95)90536-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774016	Bronze			2022-12-28	WOS:A1995RB96100013
J	TEWARI, M; QUAN, LT; OROURKE, K; DESNOYERS, S; ZENG, Z; BEIDLER, DR; POIRIER, GG; SALVESEN, GS; DIXIT, VM				TEWARI, M; QUAN, LT; OROURKE, K; DESNOYERS, S; ZENG, Z; BEIDLER, DR; POIRIER, GG; SALVESEN, GS; DIXIT, VM			YAMA/CPP32-BETA, A MAMMALIAN HOMOLOG OF CED-3, IS A CRMA-INHIBITABLE PROTEASE THAT CLEAVES THE DEATH SUBSTRATE POLY(ADP-RIBOSE) POLYMERASE	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; CELL-DEATH; C-ELEGANS; ALPHA-1-PROTEINASE INHIBITOR; GENE CED-3; INDUCTION; APOPTOSIS; ENCODES	Although the mechanism of mammalian apoptosis has not been elucidated, a protease of the CED-3/ICE family is anticipated to be a component of the death machinery. Several lines of evidence predict that this protease cleaves the death substrate poly(ADP-ribose) polymerase (PARP) to a specific 85 kDa form observed during apoptosis, is inhibitable by the CrmA protein, and is distinct from ICE, We cloned a ced-3/ICE-related gene, designated Yama, that encodes a protein identical to CPP32 beta. Purified Yama was a zymogen that, when activated, cleaved PARP to generate the 85 kDa apoptotic fragment. Cleavage of PARP by Yama was inhibited by CrmA but not by an inactive point mutant of CrmA. Furthermore, CrmA blocked cleavage of PARP in cells undergoing apoptosis. We propose that Yama may represent an effector component of the mammalian cell death pathway and suggest that CrmA blocks apoptosis by inhibiting Yama.	UNIV MICHIGAN,SCH MED,GRAD PROGRAM CELLULAR & MOLEC BIOL,ANN ARBOR,MI 48109; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; CHU LAVAL,RES CTR,MOLEC ENDOCRINOL LAB,POLY ADPRIBOSE METAB GRP,ST FOY,PQ G1V 4G2,CANADA; UNIV LAVAL,ST FOY,PQ G1V 4G2,CANADA	University of Michigan System; University of Michigan; Duke University; Laval University; Laval University	TEWARI, M (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109, USA.		dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Poirier, Guy/0000-0002-4869-1424	NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER; NCI NIH HHS [CA64803] Funding Source: Medline; NHLBI NIH HHS [HL07517] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; DESNOYERS S, 1994, ANAL BIOCHEM, V218, P470, DOI 10.1006/abio.1994.1212; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FERNANDESALNEMR.T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HU HM, 1994, J BIOL CHEM, V269, P30069; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOMIYAMA T, 1994, TECHNIQUES PROTEIN C, V5, P305; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RON D, 1992, BIOTECHNIQUES, V13, P866; SCHULZE AJ, 1991, EUR J BIOCHEM, V202, P1147, DOI 10.1111/j.1432-1033.1991.tb16483.x; SHAO HN, 1994, J BIOL CHEM, V269, P26606; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAHRADKA P, 1984, EUR J BIOCHEM, V142, P503, DOI 10.1111/j.1432-1033.1984.tb08314.x	38	2291	2361	1	32	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 2	1995	81	5					801	809		10.1016/0092-8674(95)90541-3	http://dx.doi.org/10.1016/0092-8674(95)90541-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	RB961	7774019	Bronze			2022-12-28	WOS:A1995RB96100018
J	KANG, CH; CHAN, R; BERGER, I; LOCKSHIN, C; GREEN, L; GOLD, L; RICH, A				KANG, CH; CHAN, R; BERGER, I; LOCKSHIN, C; GREEN, L; GOLD, L; RICH, A			CRYSTAL-STRUCTURE OF THE T4 REGA TRANSLATIONAL REGULATOR PROTEIN AT 1.9-ANGSTROM RESOLUTION	SCIENCE			English	Article							BACTERIOPHAGE-T4; REPRESSOR; BINDING	The translational regulator protein regA is encoded by the T4 bacteriophage and binds to a region of messenger RNA (mRNA) that includes the initiator codon, RegA is unusual in that it represses the translation of about 35 early T4 mRNAs but does not affect nearly 200 other mRNAs. The crystal structure of regA was determined at 1.9 Angstrom resolution; the protein was shown to have an alpha-helical core and two regions with antiparallel beta sheets. One of these beta sheets has four antiparallel strands and has some sequence homology to RNP-1 and RNP-2, which are believed to be RNA-binding motifs and are found in a number of known RNA-binding proteins. Structurally guided mutants may help to uncover the basis for this variety of RNA interaction.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HANNOVER MED SCH,DEPT BIOPHYS CHEM,D-30623 HANNOVER,GERMANY; NEXAGEN INC,BOULDER,CO 80302; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80302	Massachusetts Institute of Technology (MIT); Hannover Medical School; University of Colorado System; University of Colorado Boulder				Berger, Imre/0000-0001-7518-9045				BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNGER AT, XPLOR; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAVARELLI J, 1991, NATURE, V352, P181; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; JOZWIK CE, 1992, P NATL ACAD SCI USA, V89, P5053, DOI 10.1073/pnas.89.11.5053; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILLER ES, 1985, J BIOL CHEM, V260, P3053; MILLER ES, 1994, MOL BIOL BACTERIOP T, V4, P193; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pflugrath J. W., 1984, Methods and Applications in Crystallographic Computing. International Summer School on Crystallographic Computing, P404; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; STEIGMANN W, 1982, PROTEIN PACKAGE CRYS; TROJANOWSKA M, 1984, NUCLEIC ACIDS RES, V12, P5979, DOI 10.1093/nar/12.15.5979; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEBSTER KR, 1990, J BIOL CHEM, V265, P19007; WEBSTERKR, 1992, J BIOL CHEM, V267, P26097; WINTER RB, 1987, P NATL ACAD SCI USA, V84, P7822, DOI 10.1073/pnas.84.22.7822	21	21	22	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 26	1995	268	5214					1170	1173		10.1126/science.7761833	http://dx.doi.org/10.1126/science.7761833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RA604	7761833				2022-12-28	WOS:A1995RA60400035
J	KALE, R				KALE, R			SOUTH-AFRICA HEALTH - TRADITIONAL HEALERS IN SOUTH-AFRICA - A PARALLEL HEALTH-CARE SYSTEM	BRITISH MEDICAL JOURNAL			English	Article							MEDICINES											FREEMAN M, 1992, SOC SCI MED, V34, P1183, DOI 10.1016/0277-9536(92)90311-D; GRAHAM R, 1993, WHITE WOMAN WITCH DO, V229, P234; KARIM SSA, 1992, BRINDGING GAP PROJEC; MCVANN A, 1992, S AFR MED J, V81, P139; SEGAL I, 1994, BARAGWANATH HOSPITAL, P17; VANRENSBURG HCJ, 1982, PROFILE DISEASE HLTH, P180; VEALE DJH, 1992, J ETHNOPHARMACOL, V36, P185, DOI 10.1016/0378-8741(92)90043-Q; WOOD R, 1990, S AFR MED J, V77, P640	8	116	119	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1182	1185		10.1136/bmj.310.6988.1182	http://dx.doi.org/10.1136/bmj.310.6988.1182			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX566	7767156	Green Published			2022-12-28	WOS:A1995QX56600030
J	CHESTER, MR; BARNETT, DB				CHESTER, MR; BARNETT, DB			CARDIAC CHAMBER-SPECIFIC BETA-ADRENOCEPTOR REGULATION AND SYMPATHETIC INNERVATION	LANCET			English	Note							HEART-FAILURE; DOWN-REGULATION; BETA-1-ADRENOCEPTOR; BETA-2-ADRENOCEPTOR; CARDIOMYOPATHY	We assessed by radioligand binding techniques the effect of cardiac failure on beta-adrenoceptor density in 5 hearts from patients undergoing repeat transplantation and 5 normal (unused donor) hearts. Right ventricular total and subtype beta-adrenoceptors in the denervated repeat-transplant hearts were down-regulated compared with the normally innervated controls. Within the denervated hearts, beta(1)-adrenoceptors were selectively down-regulated in the right ventricle compared with the left ventricle. Tissue noradrenaline content confirmed sympathetic denervation in the transplantd hearts. Thus, regional sympathetic innervation is not necessary for chamber-specific beta-adrenoceptor down-regulation; other mechanisms for this process should be sought.	NATL HEART & LUNG INST, LONDON, ENGLAND; LEICESTER ROYAL INFIRM, DEPT PHARMACOL, LEICESTER LE2 7LX, LEICS, ENGLAND	Imperial College London; University of Leicester								BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; BRODDE OE, 1989, J AM COLL CARDIOL, V14, P323, DOI 10.1016/0735-1097(89)90181-2; CHESTER MR, 1992, BRIT J CLIN PHARMACO, V33, P417, DOI 10.1111/j.1365-2125.1992.tb04061.x; GILBERT EM, 1989, CIRCULATION, V79, P344, DOI 10.1161/01.CIR.79.2.344; KAWAI C, 1983, J AM COLL CARDIOL, V2, P834, DOI 10.1016/S0735-1097(83)80229-0; LIANG CS, 1989, J CLIN INVEST, V84, P1267, DOI 10.1172/JCI114294; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; WAAGSTEIN F, 1989, CIRCULATION, V80, P551, DOI 10.1161/01.CIR.80.3.551; YOSHIKAWA T, 1994, J AM COLL CARDIOL, V24, P210, DOI 10.1016/0735-1097(94)90565-7	10	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 4	1995	345	8949					553	555		10.1016/S0140-6736(95)90467-0	http://dx.doi.org/10.1016/S0140-6736(95)90467-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776776				2022-12-28	WOS:A1995QK44400012
J	BAKER, EL; MELTON, RJ; STANGE, PV; FIELDS, ML; KOPLAN, JP; GUERRA, FA; SATCHER, D				BAKER, EL; MELTON, RJ; STANGE, PV; FIELDS, ML; KOPLAN, JP; GUERRA, FA; SATCHER, D			HEALTH REFORM AND THE HEALTH OF THE PUBLIC - FORGING COMMUNITY-HEALTH PARTNERSHIPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE SYSTEM; PERSPECTIVE		CTR DIS CONTROL & PREVENT,OFF DIRECTOR,ATLANTA,GA; DEPT HLTH MONTEREY CTY,SALINAS,CA; ASSOC SCH PUBL HLTH,ATLANTA,GA; WASHINGTON STATE DEPT HLTH,OLYMPIA,WA; PRUDENTIAL CTR HLTH CARE RES,ATLANTA,GA; METROPOLITAN HLTH DIST,SAN ANTONIO,TX	Centers for Disease Control & Prevention - USA	BAKER, EL (corresponding author), CTR DIS CONTROL & PREVENT,PUBL HLTH PRACTICE PROGRAM OFF,1600 CLIFTON RD,MAILSTOP E20,ATLANTA,GA 30333, USA.							ABELSON PH, 1993, SCIENCE, V261, P407, DOI 10.1126/science.8305008; ADAY L, 1993, RISK AM HLTH HLTH CA; ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; [Anonymous], 1988, FUTURE PUBLIC HLTH; [Anonymous], 1989, GUIDE CLIN PREVENTIV; Beauchamp D E, 1976, Inquiry, V13, P3; Bellah R. N., 1985, HABITS OF THE HEART; Bellah RN, 1992, GOOD SOC; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; BOROW W, 1993, JAMA-J AM MED ASSOC, V270, P1601, DOI 10.1001/jama.270.13.1601; CLEVELAND H, 1989, KNOWLEDGE EXECUTIVE; CRAWSHAW R, 1994, ANN INTERN MED, V120, P677, DOI 10.7326/0003-4819-120-8-199404150-00009; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P817, DOI 10.1001/jama.272.10.817; FIELDING J, 1994, JAMA-J AM MED ASSOC, V272, P1292, DOI 10.1001/jama.272.16.1292; Flynn B C, 1994, Healthc Forum J, V37, P55; FLYNN BC, 1994, HEALTHCARE FORUM J, V37, P73; FOEGE WH, 1993, JAMA-J AM MED ASSOC, V270, P251, DOI 10.1001/jama.270.2.251; GORDON BR, 1993, TRANSFUS SCI, V14, P261, DOI 10.1016/0955-3886(93)90006-G; GREENSPAN B, 1994, APR NAT C MOD MAN HL; HURWITZ JC, 1993, NEW ENGL J MED, V329, P130; IGLEHART JK, 1993, NEW ENGL J MED, V329, P372, DOI 10.1056/NEJM199307293290528; IGLEHART JK, 1994, NEW ENGL J MED, V330, P78; KATZ MF, IN PRESS PRINCIPLES; KECK CW, 1992, AM J PUBLIC HEALTH, V82, P1206, DOI 10.2105/AJPH.82.9.1206; KEENEY RL, 1994, NEW ENGL J MED, V331, P193, DOI 10.1056/NEJM199407213310311; LEE PR, 1993, JAMA-J AM MED ASSOC, V270, P2670, DOI 10.1001/jama.270.22.2670; LUNDBERG GD, 1993, JAMA-J AM MED ASSOC, V269, P2554, DOI 10.1001/jama.269.19.2554; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; OBERLE MW, 1994, ANNU REV PUBL HEALTH, V15, P259; OSBORNE O, 1992, REINVENTING GOVT ENT; PICKETT G, 1980, ANNU REV PUBL HEALTH, V1, P297, DOI 10.1146/annurev.pu.01.050180.001501; RICE JA, 1993, COMMUNITY HLTH ASSES; SCHILLING R, 1993, JUL CTR DIS CONTR PR; SHOEMAKER WC, 1993, JAMA-J AM MED ASSOC, V270, P2833, DOI 10.1001/jama.270.23.2833; Smith Steven Rathgeb, 1993, NONPROFITS HIRE WELF; SUSSER M, 1993, AM J PUBLIC HEALTH, V83, P418, DOI 10.2105/AJPH.83.3.418; ZABLOCKI E, 1994, HMO MAGAZINE     MAR, V33, P27; [No title captured]; 1990, DHHS PHS9150212 PUBL; 1992, AM PUBLIC HLTH REPOR; 1994, HLTH DATA INFORMATIO; 1993, MINNESOTA INTEGRATED; 1993, HEDIS 2 0 EXECUTIVE; 1992, WASHINGTON HLTH CARE; 1991, HLTH COMMUNITIES 200; 1991, ASSESSMENT PROTOCOL	47	115	116	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1276	1282		10.1001/jama.272.16.1276	http://dx.doi.org/10.1001/jama.272.16.1276			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PN068	7772104				2022-12-28	WOS:A1994PN06800034
